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Abstract 
Oral cancer may be proceeded by dysplastic PMDs mainly presenting as leukoplakia or 
erythroplakia and which can carry an increased risk of malignant transformation. Therefore, 
early recognition of PMDs with a high potential for cancer development is important to 
improve patient outcome. 
100 patients with dysplastic PMDs presenting in Newcastle underwent a standardised 
interventional management protocol based on risk factor assessment, laser excision of 
dysplastic lesions and long-term clinical follow-up at regular intervals. This patient cohort 
was studied in detail to examine the clinicopathological features that may influence disease 
progression. Single dysplastic PMDs were mainly observed in the floor of mouth, with 92% 
presenting as leukoplakia and 8% as erythroplakia. Follow-up revealed that 62% of patients 
remained disease-free following laser surgery, 17% showed recurrent-disease, 14% new-site 
dysplasia, with 5% malignant transformation and 2% developed OSCC at a site distant from 
the primary dysplasia. 
Clinical appearance, high grade dysplasia, larger sized PMDs, high risk sites and positive 
excision margins were shown to increase the risk of unfavourable clinical outcome. 
Malignant transformation was mainly seen in non-smokers and non-alcohol users, whilst 
new-site OSCC was only seen in non-smokers and light drinkers. 
The use of Raman spectroscopy in the detection and classification of dysplasia within the 
human oral tissue was investigated. Currently, histopathology is considered the diagnostic 
gold standard. Consensus opinion on dysplasia grading of individual PMD lesions using two 
classification systems (WHO and binary grading) was obtained and a spectral diagnostic 
model then correlated with the results. The ability of Raman spectroscopy to differentiate 
between dysplasia and morphologically normal tissue was shown, with an 81% sensitivity 
and specificity. This supports the suitability of the Raman system in clinical use to 
distinguish morphologically normal from dysplastic tissue. This work has also shown the 
efficacy of Raman spectroscopy in identifying early biochemical changes in epithelial 
dysplastic tissue before morphological/histological change becomes apparent. 
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General Introduction 
Oral cancer is a potentially fatal disease that usually presents late and has a poor prognosis. In 
the UK in 2009, 6236 persons were diagnosed with oral cancer and there were approximately 
1985 deaths in 2010 (Oral cancer statistics - UK, 2012). The most common oral cancer is 
squamous cell carcinoma (OSCC) (Chen and Hunter, 2005; Lee et al., 2006; Epstein et al., 
2008; Rapidis et al., 2009). 
OSCC affects significant numbers of people around the world and represents more than 90% 
of head and neck cancers (Arduino et al., 2008; Warnakulasuriya, 2009). Recently, 4-10% of 
cases have been reported in patients below the age of 40 years (Bachar et al., 2011); however, 
other studies suggest that the incidence in this age group may actually be higher (Myers et al., 
2000; Gillison, 2007). Approximately two thirds of OSCCs are diagnosed at advanced stages 
(Epstein et al., 2007; Ahmed et al., 2009). The late diagnosis of a significant number of 
OSCCs is mostly attributable to delays in patients seeking treatment, insufficient patient 
awareness, asymptomatic clinical states and/or inappropriate investigation (Mehrotra et al., 
2006; Morse et al., 2009).  
Despite the different treatment modalities for OSCCs, such as surgery, radiotherapy, 
chemotherapy, chemo-radiation and immunotherapy (Bagan and Scully, 2008), the five-year 
survival rate has not improved in recent years (Chen and Hunter, 2005). There is thus a vital 
need for an effective and reliable diagnostic procedure for early detection and subsequent 
effective management and eventually improvement in quality of life for patients. 
 
OSCCs may arise from Potentially Malignant Disorders (PMDs), a term that has been 
recently introduced by the WHO to be used instead of premalignant or precancerous 
lesions/conditions (van der Waal, 2009), which incorrectly imply cancer development is a 
simple two-step process (Reibel, 2003). PMDs are mainly leukoplakia, erythroplakia, 
erythroleukoplakia, lichen planus, submucous fibrosis and actinic cheilitis as well as inherited 
cancer syndromes (van der Waal, 2009). Most oral PMDs are asymptomatic or present with 
few symptoms and they are regarded as an intermediate stage between normal and malignant 
tissues (Kujan et al., 2006).  
 
PMDs may exhibit epithelial dysplasia, a histological term that has no specific clinical 
association, but tends to increase the risk of malignant transformation (MT) of these disorders 
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(Reibel, 2003; Hsue et al., 2007). Histologically, epithelial dysplasia is characterised by 
cellular atypia and tissue dysmaturation and it ranges from hyperplasia to intraepithelial 
dysplasia (Kujan et al., 2007). MT of normal oral epithelium into a carcinoma may be caused 
by carcinogens and this includes changes in genes regulating cell division, cell cycle 
progression, DNA synthesis and repair (Bettendorf et al., 2004; Thomson et al., 2006). 
 
There are several classification systems for epithelial dysplasia and this causes difficulties in 
routine application (Kujan et al., 2007). As a result, the WHO Consensus Group made efforts 
to establish a universal classification of oral epithelial dysplasia. This classification depends 
on architectural and cellular features as well as the dysplastic layer thickness in relation to 
full epithelial thickness (Gale et al., 2005). Five histological grades have been identified: 
hyperplasia, mild, moderate or severe dysplasia, and carcinoma in situ. Using the same WHO 
cellular and architectural criteria, a binary grading system of ‘high risk’ and ‘low risk’ 
classification has been suggested and evaluated by Kujan et al. (2006) who indicated that a 
two-tier classification may produce an improvement in observer agreement compared with 
the five-point WHO classification system.  
 
Early diagnosis and treatment of oral cancer and PMDs requires assessment of potential 
predisposing risk factors (Mawardi et al., 2011) and necessitates a partnership between 
clinicians, pathologists and surgeons. Taking a biopsy from a PMD at the first visit is 
preferable to delaying biopsy until after elimination of possible causative factors and 
observation for possible regression (van der Waal, 2009). However, an observation period of 
2-4 weeks for regression has been suggested and if no regression occurs, a biopsy for 
histopathological diagnosis should then be carried out to confirm the presence and also the 
degree of epithelial dysplasia (van der Waal, 2009). 
 
Surgical biopsy is the conventional method of diagnosis for PMDs and suspected cancers. 
Although histopathological examination is the gold standard in the diagnosis of dysplastic 
and malignant tissues (Bremmer et al., 2009), it suffers from inter- and intra-pathological 
observer variation. Hence, there is a vital need for an objective tool which is able to detect 
early dysplastic tissue changes in a standardised and universal way.  
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Recently, optical spectroscopy has been employed to analyse different aspects of clinical 
disease and has been used for PMD diagnosis (Malini et al., 2006; Sharwani et al., 2006). 
Optical spectroscopy is a general term encompassing three methods: fluorescence, Raman 
and infra-red spectroscopy (Swinson et al., 2006). These techniques have different principles 
but they are all sensitive to changes in biochemical tissue structure which has been found to 
play a role in differentiating between normal and dysplastic tissues (de Veld et al., 2005b; 
Krishna et al., 2005b) potentially aiding early, objective diagnosis and targeting 
interventional treatments.  
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Potentially Malignant Disorders 
PMD is the latest WHO recommend term for a group of disorders that carry an unpredictable 
risk of MT; leukoplakia and erythroplakia are the most common lesions (van der Waal, 
2009). PMDs have been defined as a morphologically altered tissue in which cancer is more 
likely to develop than apparently normal counterpart (Kramer et al., 1978a; Pindborg et al., 
1997). They vary from a small well-defined white or red mucosal patch to a widespread and 
extensive involvement of oral mucosa (van der Waal and Axell, 2002; Sloan, 2011). 
Examples of white, predominantly white and/or red disorders of the oral mucosa that carry an 
increased risk for oral cancer development are listed in Table 1.1. 
 
 
 
Table 1.1: Potentially malignant disorders. 
(Pindborg et al., 1997; Napier and Speight, 2008; Scully and Bagan, 2009; van der Waal, 2009) 
Disorders 
Leukoplakia 
Erythroplakia 
Erythroleukoplakia 
Lichen planus 
Submucous fibrosis 
Actinic cheilitis 
Dyskeratosis congenita 
Xeroderma pigmentosum  
Epidermolysis bullosa 
Discoid lupus erythematousus 
Fanconi syndrome 
Paterson–Kelly-Brown syndrome (sideropenic dysphasia; Plummer–Vinson syndrome) 
Immunosuppression 
Chronic candidiasis 
Scleroderma 
Palatal lesion of reverse cigar smoking 
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1.1. Oral Leukoplakia 
Oral leukoplakia (OL) is defined as ‘‘a white plaque of questionable risk having excluded 
(other) known diseases or disorders that carry no increased risk for cancer” (Warnakulasuriya 
et al., 2007). OL is the most common PMD (Axell et al., 1996; Pindborg et al., 1997; Dietrich 
et al., 2004; Mithani et al., 2007) affecting 0.2- 4.9% of the world population (Gupta et al., 
1980; van der Waal et al., 1997), depending on country, population, associated risk factors 
and clinical definition (Napier and Speight, 2008). Epidemiological data over the past 30 
years showed a prevalence of OL ranging from 1.1% to 11.7% depending on age and sex 
(Campo-Trapero et al., 2008a). In a systematic review of 23 studies from 17 countries, an 
overall 2.6% prevalence of OL was calculated in spite of considerable differences noted 
between studies (Petti, 2003). 
 
Generally, OL is more common in males than females with a ratio of 5: 3 (Petti, 2003). 
However, the sex distribution may vary greatly depending on geographical variations and 
lifestyle habits (Reichart, 2001). Usually OL is not diagnosed before the age of 30 years, the 
highest prevalence is in the fifth decade (van der Waal et al., 1997). In developed countries, 
leukoplakias are more common in middle age and elderly patients with the majority seen in 
patients aged between forty and seventy, whilst in developing countries it may appear five to 
ten years earlier (Napier and Speight, 2008). 
 
The most common site affected by OLs varies in different studies and this variation may 
similarly be related to geographical differences, race, and individual habits (Ishii et al., 2004). 
For example, the buccal mucosa, alveolar mucosa and lower lip were the common sites 
observed in a study conducted by Waldron and Shafer (1975), whilst buccal mucosa and the 
floor of mouth (FOM) were the most commonly affected oral sites, followed by lateral border 
of tongue, with gingiva and labial commissures least affected in a study carried out by Jaber 
et al. (2003). Ishii et al. (2004) showed that OL is mainly observed on gingiva, followed by 
tongue, and palatal mucosa. Another study, performed by Holmstrup et al. (2006), showed 
that the FOM and the buccal mucosa were the most common sites. A retrospective hospital-
based study demonstrated that the lateral border of the tongue was the commonest affected 
site, followed by the buccal mucosae (Arduino et al., 2009). 
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In the same year, (Hamadah and Thomson, 2009) reported that the FOM and the ventro-
lateral surface of the tongue, followed by the buccal mucosae were the most common 
involved sites. In more recent studies, Lim et al. (2010) reported that the FOM, lip, tongue 
and buccal mucosa were the most common oral subsites affected by OL, whereas the palate 
and alveolus were less commonly affected. Jerjes et al. (2012) showed that primary affected 
sites were mainly the ventro-lateral tongue and FOM, followed by buccal mucosa. 
 
 
1.1.1. Oral Leukoplakia: Clinical Presentation 
OL is a predominantly white lesion of the oral mucosa that cannot be characterized as any 
other definable lesion (Axell et al., 1996) and may be seen in any part of the oral cavity and 
oropharynx. Clinically, OL is of two main types: homogenous and non-homogenous. The 
differentiation between them is entirely clinical, based upon surface, colour and 
morphological features (Warnakulasuriya et al., 2007; Winter et al., 2011).  
 
Homogenous leukoplakia, which represents approximately 90% of all leukoplakia cases, is 
predominantly white in colour, flat, thin, with shallow cracks, wrinkled or corrugated surface 
keratin with a uniform texture throughout (Axell et al., 1996; Warnakulasuriya et al., 2007; 
van der Waal, 2009). 
 
Non-homogenous leukoplakia is predominantly white or mixed white and red. It is either 
irregular flat, nodular with small polypoid outgrowths or excrescences, speckled 
(erythroleukoplakia) which is mixed white and red, ulcerated or verrucous leukoplakia 
(Pindborg et al., 1997; Warnakulasuriya et al., 2007). However, individual leukoplakias may 
have a varied clinical appearance which can change over time (Neville et al., 1995). 
 
OL may present as single localized lesion, or as multiple widespread areas with diffuse 
outlines (van der Waal and Axell, 2002). Classification and/or staging of OL recommend 
recording the size of a single leukoplakic lesion and to add together sizes of multiple 
leukoplakias (van der Waal and Axell, 2002).  
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Also, the oral subsite should be specified according to the International Classification of 
Disease (ICD) topographical codes for localization in the oral cavity (van der Waal and 
Axell, 2002); Table 1.2. 
 
 
 
Table 1.2: Topographical codes of disease localization in the oral cavity. 
International Classification of Disease (ICD-10) 
Oral subsites Topographical code 
Lips C00.3, C00.4, C00.5, C006 
Tongue C02.0, C02.1, C02.2 
Gum C03.0, C03.9 
FOM C04.0, C04.1 
Hard palate C05.0 
Soft palate C05.1 
Cheek mucosa C06.0 
Retromolar area C06.2 
Mouth unspecified C06.9 
Tonsillar pillar C09.1 
 
 
 
Proliferative verrucous leukoplakia (PVL), which was first described by Hansen et al. (1985), 
is more prevalent among elderly women with or without history of tobacco use (van der 
Waal, 2009). It is four times more common in women than men and is typically diagnosed 
after the sixth decade of life (Hansen et al., 1985; Silverman and Gorsky, 1997; Bagan et al., 
2011). Tobacco use, the presence of candida or immunodeficiency are not associated with 
PVL (Suarez et al., 1998) and the majority (63%) of PVL patients do not use tobacco 
products according to a study conducted by Cabay et al. (2007). 
PVL is of uncertain aetiology, although some authors have reported an association with HPV 
(Eversole, 2000), whilst others have found no association (Bagan et al., 2007; Stokes et al., 
2012). The verrucous texture of PVL is a distinguishing feature from homogeneous 
leukoplakia; however, verrucous leukoplakia may be indistinguishable from verrucous 
carcinoma (Cabay et al., 2007). 
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PVL may develop on any soft tissue surface of the oral cavity and may be either a single, 
discrete lesion or less commonly scattered, multifocal growths involving multiple oral sites 
(Morton et al., 2007). Buccal mucosa and tongue are the most common sites associated with 
PVL, with palatal mucosa, alveolar mucosa, gingiva, FOM and lip showing a much lower 
incidence (Hansen et al., 1985; Batsakis et al., 1999). According to Silverman and Gorsky 
(1997), buccal mucosa is the most common site for PVL in women, whilst in men it is the 
tongue. 
Clinically, PVL mostly appears as a flat white keratotic lesion with a verrucous surface and 
may be associated with an erythematous component. As the lesion progresses it becomes 
more exophytic, granular and verruciform ultimately becoming multifocal and developing a 
warty-type appearance (Hansen et al., 1985). 
 
 
1.1.2. Leukoplakia and Level of Certainty 
The term leukoplakia can be used at different levels of certainty (C-factor). According to van 
der Waal (2009), four steps of certainty may be useful in the diagnosis of OL: C1 and C2 
which are clinical terms and C3 and C4 which are clinicopathological terms. 
 
1) C1:  a single visit, provisional clinical diagnosis involving inspection and palpation. 
2) C2: a definitive clinical diagnosis when there is no evidence of resolution following 
elimination of etiological factors (mechanical irritation) over 2-4 weeks of follow-up or in the 
absence of any other etiological factors. 
3) C3:  a provisional histopathological diagnosis similar to C2 but with incisional biopsy data. 
4) C4: the definitive histopathological diagnosis with evidence from histopathological 
examination of completely excised lesions.  
 
Leukoplakia is mostly used as a clinical term and a provisional diagnosis is made when a 
predominantly white area at clinical examination cannot be clearly diagnosed as any other 
disease in the oral mucosa (Axell et al., 1996; Pindborg et al., 1997).  
The diagnosis of OL is thus made after exclusion of other disorders and biopsy is 
recommended when other disorders cannot be identified. The disorder is diagnosed as an OL 
with or without epithelial dysplasia.  
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Table 1.3 shows the ‘excluded disorders’ with their diagnostic criteria and whether there is a 
need for biopsy or not. 
 
Figure 1.1 demonstrates a schematic diagram of the most common steps of OL diagnosis. 
 
All leukoplakias should be viewed with suspicion because even small leukoplakia can 
manifest significant dysplasia or unexpected carcinoma; therefore conventional biopsy is 
recommended for any true leukoplakia. 
 
 
 
Table 1.3: The “excluded disorders” in relation to diagnosing of oral leukoplakia.  
(Warnakulasuriya et al., 2008; van der Waal, 2009) 
Disorders Diagnostic criteria Biopsy need 
White spongy nevus 
Seen in early life, family history, larger area, may affect 
genital mucosa as well as oral mucosa 
Not required 
Lichen planus plaque type or reticular form  Yes 
Discoid lupus 
erythematousus 
Circumscribed central erythema with white radiating striae 
Yes, with 
Immunofluorescence 
Frictional keratosis 
Associated with trauma, along the occlusal line, mostly 
reversible by removing the cause 
Yes 
Morsicatio buccarum Irregular white scale due to habitual biting of lip and cheek Not required 
Chemical injury Related to chemical substance,  painful,  rapidly reversible  Not required 
Acute pseudomembranous 
candidiasis 
The membrane can be removed by scraping, resulting in an 
erythematous bleeding surface  
Swab for culture 
Leukoedema Bilateral on buccal mucosa Not required 
Hairy leukoplakia Hyperkeratosis of lateral  tongue bilaterally Yes 
Skin graft From the history Not required 
leukokeratosis nicotina 
palate 
Related to smoking history, greyish, white palate  Not required 
Lichenoid reaction Related to drug history or sited near amalgam restoration Yes 
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Figure 1.1: Steps in diagnosis of oral leukoplakia. 
(Warnakulasuriya et al., 2007; van der Waal, 2009) 
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1.1.3. Histopathology of Oral Leukoplakia 
OL is entirely a clinical term and has no definitive histopathological connection (Reibel, 
2003), it may present with atrophy or hyperplasia and may or may not show epithelial 
dysplasia (Warnakulasuriya et al., 2007). Microscopically, differentiation can be made 
between dysplastic and non-dysplastic OLs and a pathological report should always include a 
statement of the presence or absence of epithelial dysplasia (Pindborg et al., 1997).  
The histopathological changes observed in leukoplakia range from hyperkeratosis, 
hyperplasia, mild to severe dysplasia or carcinoma in situ (CIS) (Chattopadhyay and Ray, 
2008). According to Speight (2007), histological assessment shows approximately 50% of 
leukoplakias display epithelial dysplasia, whilst the other 50% shows hyperplasia and/or 
hyperkeratosis. In dysplastic leukoplakias, 50% of severe, 30% of moderate and less than 5% 
of mild dysplasias transform to oral cancer (Speight, 2007). 
 
The rates of MT vary in different parts of the world, probably due to differences in ethnic and 
environmental factors, particularly oral and dietary habits (Gupta et al., 1989; van der Waal et 
al., 1997; Shiu et al., 2000; Reibel, 2003). The MT rate of leukoplakia has been reported to 
range from 0.13 to 17.5% (Reibel, 2003; Amagasa et al., 2006). According to 
epidemiological data from European patients, the annual rate of MT probably does not 
exceed 1% (Scheifele and Reichart, 2003). 
Regarding the risk of MT, it is generally accepted that the non-homogeneous subtypes of 
leukoplakia carry an increased risk of transformation compared to homogenous leukoplakia 
(Silverman et al., 1984; Pindborg et al., 1997; Reibel, 2003; Warnakulasuriya et al., 2007; 
van der Waal, 2009). 
Data have also shown that speckled leukoplakias are more often associated with high 
histological grade of dysplasia or CIS (Arduino et al., 2009) and have a high potential for MT 
(Hosni et al., 2009).  
 
Regarding PVL, it is characterized by both a resistance to treatment with a high recurrence 
rate and a high rate of MT into verrucous carcinoma or OSCC (Cabay et al., 2007; van der 
Waal and Reichart, 2008; Bagan et al., 2010). It has been reported that PVL lesions may 
undergo MT to OSCC in 40-100% of cases (Hansen et al., 1985; Silverman and Gorsky, 
1997; Cabay et al., 2007; Gandolfo et al., 2009). 
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Histologically, PVL has been reported to show progressive histological features over time 
with lymphocytic infiltrate within the superficial lamina propria that can be mistaken for 
lichen planus. This lymphocytic infiltrate may be intense and can mask visualization of the 
basement membrane (Cabay et al., 2007). In advanced cases, the deeply folded tissue may 
erode and infiltrate the underlying bone developing pseudocysts that may be mistaken for 
odontogenic cysts (Morton et al., 2007). In spite of the initially benign histological features, 
PVL has a poor clinical outcome with high rates of recurrence and a high risk MT reflecting 
both under-treatment and ineffective management (Cabay et al., 2007). It probably requires, 
therefore early and aggressive treatment. 
 
 
1.1.4. Staging and Classification of Oral Leukoplakia 
For the purpose of a standardised reporting system of OL management, staging and 
classification is highly recommended. The size, histopathology and localization of OL should 
be taken in consideration as should, sex, age and possible causative factors at the time of 
diagnosis (van der Waal et al., 2000; van der Waal and Axell, 2002; van der Waal, 2009). 
Depending on the treatment plan, if the decision to manage leukoplakia is by clinical 
observation alone, then the important feature to be evaluated is the size, colour and/or texture 
of the individual lesions. However, because the clinical appearance of OL may be variable 
and does not always allow clear classifications, clinical subtyping may be not useful (van der 
Waal and Axell, 2002). 
Considering assessment after surgical intervention, biopsy reveals that the staging system is 
an important consideration. Van der Waal (2009) indicated that the staging system of OL is 
mainly dependent on size and pathology. The system takes into account the highest 
pathological score in case of multiple biopsies of single or multiple leukoplakias and the 
lowest size if there is any uncertainty in considering size category. 
For classification and staging purposes it is recommended to record the size of a single 
leukoplakia, and to add together the sizes of multiple leukoplakias. The oral subsite should be 
specified according to the International Classification of Diseases Application to Dentistry 
and Stomatology (ICD-DA) codes for the oral cavity (van der Waal and Axell, 2002). 
In this system, three size categories have been proposed, analogous to the TNM system of 
oral cancer. L represents the size of single or multiple leukoplakias as follows: 
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L1 < 2 cm 
L2 =2-4 cm 
L3 > 4 cm 
Lx size not specified.  
P represents the pathology of leukoplakias as follows: 
P0 No epithelial dysplasia 
P1 Mild or moderate dysplasia 
P2 Severe dysplasia 
Px Absence or presence of dysplasia not specified  
Accordingly, four stages have been proposed in this system which includes: 
Stage 1            L1 P0  
Stage 11          L2 P0  
Stage 111        L3 P0 or L1 L2 P1 
Stage 1V         L3 P1 or any L P2  
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1.2. Oral Erythroplakia 
The current widely accepted WHO definition of oral erythroplakia (OE) is: “a fiery red patch 
that cannot be characterized clinically or pathologically as any other definable disease” 
(Kramer et al., 1978b; Pindborg et al., 1997).  
Research on the incidence and prevalence of OE is limited and depends on retrospective 
analysis. Previous studies have shown a prevalence range between 0.02% and 0.83% (Shafer 
and Waldron, 1975; Lay et al., 1982; Zain et al., 1997; Hashibe et al., 2000b). These data 
were only derived from research performed in South and Southeast Asia, however, and no 
published studies were reported from other geographical areas (Reichart and Philipsen, 
2005). 
OE is a rare disorder (Hosni et al., 2009) and is much less common than leukoplakia (Neville 
and Day, 2002). It is a disease of middle age and elderly and more common in men (Scully, 
2004). However, previous studies showed no sex predilection; female to male ratio was  
1: 1.15 and 1: 1.04 in studies conducted by Shafer and Waldron (1975) and Hashibe et al. 
(2000b), respectively. 
 
 
1.2.1. Oral Erythroplakia: Clinical Presentation  
Clinically, erythroplakias may have flat or depressed surfaces which may be smooth, granular 
or nodular with a well-defined demarcation adjacent to mucosa of normal appearance 
(Pindborg et al., 1997; Reichart and Philipsen, 2005). OE tends to present as solitary lesions 
and rarely affects widespread areas (Reichart and Philipsen, 2005). These features are quite 
useful clinically in discrimination OE from other multicentre, bilateral or symmetrical oral 
disorders, such as erosive lichen planus, erythematous candidiasis and lupus erythematous 
(Reichart and Philipsen, 2005; van der Waal, 2009). 
 
Erythroplakias may affect any part of the oral mucosa and different localizations have been 
reported. The soft palate, ventral tongue surfaces and the FOM (Pindborg et al., 1997; Scully, 
2004) together with buccal mucosa (Scully, 2004) are the most commonly OE affected sites. 
Regarding size of OE, it is typically less than 1.5 cm in diameter, but lesions larger than 4 cm 
have been reported (Bouquot and Ephros, 1995). 
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1.2.2. Oral Erythroplakia: Histopathology  
Erythroplakia as a clinical term does not carry any histological connotation; however, 
histological biopsy of OE may show epithelial dysplasia, CIS or invasive carcinoma (Shafer 
and Waldron, 1975). According to Reichart and Philipsen (2005), all erythroplakias showed 
some degree of epithelial dysplasia: 51% showed invasive squamous cell carcinoma, 40% 
CIS or severe dysplasia and the remaining 9% demonstrated mild to moderate dysplasia. 
Interestingly, since all OEs are therefore high risk, there is no need for high risk and low risk 
site classification, contrary to OL. 
 
Although OE is rare, its MT rate is the highest among all of the oral PMDs (Shafer and 
Waldron, 1975; Bouquot and Whitaker, 1994; Reichart and Philipsen, 2005). Dysplasia and 
CIS or invasive carcinoma may be seen in more than 90% of OE cases (Shafer and Waldron, 
1975; Mashberg, 2000). However, no annual transformation rate is available due to a lack of 
clinical case series which allow calculation of this rate (van der Waal, 2009). 
 
 
1.2.3. Oral Erythroplakia: Diagnosis and Management. 
Similar to leukoplakia, OE diagnosis is based on the principle of exclusion of numerous other 
red patches on the oral mucosa that may be confused with erythroplakia and should thus be 
excluded to confirmed the diagnosis (Pindborg et al., 1997). 
Table 1.4 lists a number of erythematous disorders which have a similar appearance to OE 
and need to be excluded when making a diagnosis of OE (Reichart and Philipsen, 2005).  
 
There is no specific study that considers the treatment of erythroplakia in the literature. Since 
OE may be symptomatic and biopsy may show severe dysplasia, CIS or microinvasive 
carcinoma (Reichart and Philipsen, 2005) and since erythroplakia is characterized by a high 
rate of MT, surgical removal is highly recommended either by conventional scalpel or by 
laser surgery (van der Waal, 2009).  
However, no guidelines are available for the width of resection margins and data on 
recurrence rate after surgical treatment are limited. OE recurrence rate seems to be high and 
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this may be due to the high rate of MT and the presence of epithelial dysplasia (Reichart and 
Philipsen, 2005). 
 
One can conclude that studies demonstrating that OE are the most dangerous PMDs are 
limited and further wider studies are needed to answers many question that are related to its 
behaviour, clinical outcome and treatment modalities. This will require either a meta-analysis 
of published series or longitudinal multicentre studies. 
 
 
 
Table 1.4: Disorders that should be excluded to diagnose oral erythroplakia. 
(Reichart and Philipsen, 2005) 
Red lesions resembling oral erythroplakia 
Infections 
Erythematous candidiasis  
Denture-induced stomatitis 
Histoplasmosis 
Tuberculosis 
Inflammatory-Immune disorders 
Erosive / Atrophic oral lichen planus  
Discoid Lupus Erythematosis 
Pemphigus 
Pemphigoid 
Others 
Haemangioma 
Telangiectasia 
Lingual varices 
Oral purpura 
Amelanotic melanoma  
Kaposi’s sarcoma 
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1.3. Oral Lichen Planus  
Oral lichen planus (OLP) is a chronic inflammatory disorder of unknown aetiology affection 
up to 2% of the middle aged and elderly (Axell and Rundquist, 1987). The pathogenesis of 
OLP is not fully understood; however, it is a cell mediated autoimmune condition associated 
with accumulation of an inflammatory infiltrate composed predominantly of T-lymphocytes 
beneath the epithelium of the oral mucosa resulting in cell-mediated damage to basal 
keratinocytes (Pindborg et al., 1997; Thornhill et al., 2006; Warnakulasuriya et al., 2007; 
Danielsson et al., 2011), which can be recognized by the immune system as antigenically 
foreign, causing the release of cytokines, chemokines and other proinflammatory mediators 
(Thornhill et al., 2006). 
There is an increased rate of differentiation of stratified squamous epithelium, resulting in 
hyperkeratosis and erythema with or without ulceration (Epstein et al., 2003).  
OLP has six clinical types: papular, reticular, plaque-like, atrophic, erosive (ulcerative) and 
bullous (Pindborg et al., 1997). It has characteristic clinical and histological appearance 
which usually allows distinction from OL. However, the plaque type of lichen planus may 
often resemble leukoplakia, emphasising the importance of biopsy in diagnosis 
(Warnakulasuriya et al., 2007). 
There is considerable debate in the literature about the potential malignant nature of OLP 
(van der Meij et al., 2003). However, previous studies have stated and accepted that OLP 
carries a risk of MT (Thornhill et al., 2006; Hsue et al., 2007; van der Meij et al., 2007). 
Although MT in lichen planus is distorted by the lack of clinicopathologic correlation in the 
diagnosis (van der Meij and van der Waal, 2003), in all clinical types of lichen planus, the 
reported annual MT rate is usually below 1% (Gandolfo et al., 2004). However, there are no 
possibilities to truly prevent MT of OLP and regular follow-up of patients has thus been 
recommended by many authors (Eisen, 2002; Al-Hashimi et al., 2007). 
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1.4. Oral Submucous Fibrosis (OSF) 
OSF is a chronic disorder characterized by fibrosis of the lining mucosa of the upper 
aerodigestive tract and frequently the upper third of the oesophagus (Warnakulasuriya et al., 
2007). It is limited to Southeast Asia, but a number of cases have been reported in other parts 
of the world including South Africa, Greece and the United Kingdom (van der Waal, 2009). 
The main aetiological factor of OSF is chewing areca and betel quid (Tilakaratne et al., 
2006), however, in some cases genetic traits may be implemented as predisposing factors 
(Pindborg et al., 1997). 
 
Within the oral cavity, different sites may be affected in different populations 
(Warnakulasuriya et al., 2007). Clinically, with the exception of early stage disease, OSF has 
characteristic clinical features due to fibrosis of the lamina propria and submucosa with an 
increasing loss of tissue mobility (Warnakulasuriya et al., 2007). 
Early stages of OSF are characterized by burning sensations, blanching of mucosa, 
vesiculation, and leathery mucosa, while fibrous bands within the mucosa appear in the 
cheeks, faucial of pillars, and encircle the lips resulting in stiffening of the affected mucosa 
and trismus in advanced stages (Warnakulasuriya et al., 2007; van der Waal, 2009). 
 
Histologically, fibrosis and hyalinization occur in the lamina propria, causing severe 
epithelial atrophy with underlying dense collagenous tissue fibre formation associated with 
varying degree of hyperkeratosis and epithelial dysplasia (Pindborg et al., 1997). 
The epithelial atrophy may predispose to cancer development in the presence of carcinogens. 
According to Murti et al. (1985), the MT rate of OSF was 4.5% over a 15-year observation 
period with an approximately 0.5% annual MT rate. 
Since OSF has a tendency to develop to oral cancer (Pindborg et al., 1997) regular follow-up 
of affected patients should be considered. 
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1.5. Actinic Cheilitis 
Actinic cheilitis is a clinical term for an ulcerative lesion, sometimes with crust formation on 
the mucosa of part of or the entire vermilion border of the lip (van der Waal, 2009). This 
PMD of the lip is mainly seen in men, although no figures for incidence rate are available in 
the literature (van der Waal, 2009). 
Histologically, the squamous epithelium of the lip vermilion may show hyperplastic or 
atrophic changes with disordered maturation, varying degrees of keratinization, cytological 
atypia and increased mitotic activity with the underlying connective tissue showing 
basophilic degeneration of collagen and elastosis (Pindborg et al., 1997). 
 
Depending on the histology and clinical signs and symptoms, the treatment of this disorder is 
usually by superficial surgical excision (lip shave) or laser ablation (Satorres Nieto et al., 
2001). Photodynamic therapy may be also used but it is less effective (Berking et al., 2007). 
 
Squamous cell carcinoma often develops in untreated patients. There are, however no follow-
up studies of untreated actinic cheilitis that allow calculation of annual MT rates (van der 
Waal, 2009). 
 
1.6. Hereditary Disorders 
There are a few known inherited disorders associated with an increased risk of malignancy in 
the oral cavity, such as Fanconi’s anemia, Dyskeratosis congenita, Epidermolysis bullosa, 
Xeroderma pigmentosum and Bloom’s syndrome (Prime et al., 2001). 
 
1.6.1. Fanconi’s anaemia  
Fanconi’s anaemia is a rare autosomal recessive syndrome caused by defects in 
approximately 11 genes involved in the detection and repair of DNA (Thompson, 2005). The 
incidence of the disease is unusually high in the Afrikaner population of South Africa (Saleh 
and Stephen, 2008). Those types of patients are characterized by aplastic anaemia with 
progressive bone marrow failure, congenital abnormalities, and a high tendency to 
malignancies including head and neck cancer (Otan et al., 2004; Masserot et al., 2008; Saleh 
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and Stephen, 2008). In the absence of alcohol and tobacco exposure, 14% of anaemic patients 
develop head and neck squamous cell carcinomas by the age of 40s (Kutler et al., 2003). 
Of the 800 cases of Fanconi’s anaemia available for a study conducted by Lustig et al. 
(1995), 17 cases with head and neck cancer arose in young patients less than 30 years and 
were seen equally in females and males mainly affecting the tongue, followed by the 
gingivae. 
Orally, there is a manifestation of generalized black hyperpigmentation on the buccal 
mucosa, tongue and palate associated with severe generalized periodontitis reported in 
patients with Fanconi’s anaemia (Saleh and Stephen, 2008). 
 
1.6.2. Dyskeratosis Congenita 
Dyskeratosis congenita is a rare inherited syndrome exhibiting marked clinical and genetic 
heterogeneity. It is characterised by mucocutaneous abnormalities, bone marrow failure and a 
predisposition to cancer (Walne and Dokal, 2009). 
Most cases of dyskeratosis congenita are X-linked and affect males (Handley et al., 2006). 
Leukoplakia has been reported in 80% of dyskeratosis congenita patients (Dokal, 2000) and it 
may affect any mucosal surface, but the oral mucosa is most commonly affected with the 
tongue the most frequently affected site (Ling et al., 1985). Patients with dyskeratosis 
congenita often develop white plaques on the dorsal surface of the tongue which may be 
confused with OL, but the absence of habits and the young age of patients indicate the 
hereditary nature of this disorder (Handley et al., 2006). 
 
Diagnosis of dyskeratosis congenita is relatively straight forward when all the classical 
mucocutaneous features of the disease exist. However, genetic analysis can confirm the 
diagnosis in the majority of dyskeratosis congenita patients (Handley et al., 2006). 
 
Patients with dyskeratosis congenita have a recognised increased risk of malignancy from 
pre-existing mucosal leukoplakia (Drachtman and Alter, 1995), with an incidence of 
approximately 35% with a peak in the third decade of life (Sirinavin and Trowbridge, 1975). 
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1.6.3. Epidermolysis Bullosa 
Epidermolysis bullosa is a hereditary disorder of skin and oral mucosa which is either 
autosomal dominant or recessive (Das and Sahoo, 2004). Clinically, epidermolysis bullosa is 
characterized by an exceptional tendency of the skin and mucosae to form bullae and vesicles 
after minor friction and trauma (Sedano and Gorlin, 1989), such as routine dental care or 
even normal tooth brushing. 
Oral features include repeated blistering and oral tissue scarring leading to limited oral 
opening, ankyloglossia, obliteration of the oral vestibule, perioral stricture (microstomia), 
severe periodontal disease and alveolar bone resorption, atrophy of the maxilla with 
mandibular prognathism and an increased mandibular angle. Patients with epidermolysis 
bullosa have an increased risk for squamous cell carcinoma (Wright and Fine, 1994; Pindborg 
et al., 1997; Das and Sahoo, 2004). 
 
1.6.4. Xeroderma Pigmentosum  
Xeroderma pigmentosum is a rare neurocutaneous disease with a recessive mode of 
inheritance which may affect all races worldwide and has an equal sex incidence (Mehta et 
al., 1996). It is characterized by skin changes and neoplasia in exposed parts of the body due 
to UV radiation. The lips are the most frequently affected and show epithelia atrophy, 
telangiectasia and hyperpigmentation and this may occasionally be seen in oral mucosa 
(Pindborg et al., 1997). 
Most cases of Xeroderma pigmentosum start in early childhood and are fatal by 20 years of 
age due to multiple metastasis of squamous cell carcinoma and melanoma, infection or 
neurological complications (Mehta et al., 1996). There is an increased incidence of 
malignancies including oral cancer (Prime et al., 2001). 
 
1.6.5. Bloom’s Syndrome 
Bloom’s syndrome is an autosomal recessive chromosomal disorder. Patients with Bloom’s 
syndrome are hypersensitive to UV radiation, suffering from sun-sensitive, facial erythema, 
and show predisposition to solid tumour development in a wide variety of anatomical sites; 
8% of these tumours are seen in the tongue (Prime et al., 2001). 
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1.7. Oral Epithelial Dysplasia (OED) 
Dysplasia as a term has been used for many years and has been implemented again in the 
latest version of WHO Classification of Tumour in the Oral Cavity and Oropharynx (Barnes 
et al., 2005). Dysplastic features of a stratified squamous epithelium are characterized by 
cellular atypia and loss of normal maturation and stratification; a combination of architectural 
and cytological changes that are associated with an increased risk of MT compared to normal 
mucosa (Pindborg et al., 1997; Reibel, 2003; Warnakulasuriya et al., 2008). 
Epithelial dysplasia represents a spectrum of changes and does not refer to a precise 
diagnostic category (Kujan et al., 2007). No existing criteria can precisely divide this 
spectrum definitively into mild, moderate or severe dysplasia (Gale et al., 2005). Therefore, 
pathologists frequently face difficulties in the accurate assessment of dysplasia grade, mainly 
due to a lack of specific classification criteria, limited objectivity for evaluation of the 
diagnostic criteria and insufficient information about the important criteria that may be used 
to predict MT (Kujan et al., 2006). 
 
Although some cancers may develop from non-dysplastic tissue (Warnakulasuriya et al., 
2008), there is support for the view of greater risk of cancer development in more severe 
dysplasias (Reibel, 2003). This is possibly because of the greater accumulation of 
chromosomal, genomic and molecular alterations (Warnakulasuriya et al., 2008). 
Approximately 50% of OL biopsies demonstrate OED, although not all of them progress to 
oral cancer (Speight, 2007). 
 
Since OED is considered a precursor for MT, pathologists need to evaluate accurately the 
dysplastic changes of the PMD for accurate (error-free) prediction and effective management 
(Kujan et al., 2006). 
It is well-recognized that the classification system is not perfect, however it is highly 
recommended for the selection of treatment options to help and improve clinical outcomes. 
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1.7.1. Classification Systems 
Different classification schemes have been proposed to detail OED: Squamous Intraepithelial 
Neoplasia (SIN), Ljubljana classification/squamous intraepithelial lesions (SIL) and WHO 
epithelial dysplasia grading (Warnakulasuriya et al., 2008).  
Table 1.5 displays the three classification systems for the purpose of evaluation and relation. 
 
 
 
Table 1.5: Classification systems for epithelial dysplasia. 
(Gale et al., 2005) 
Oral Epithelial Dysplasia 
2005 WHO 
Classification 
(OED) 
Squamous 
Intraepithelial 
Neoplasia (SIN) 
Ljubljana Classification 
Squamous Intraepithelial 
Lesions 
(SIL)  
Epithelial hyperplasia - Simple hyperplasia (squamous cell) 
Mild dysplasia SIN 1 Basal/parabasal hyperplasia 
Moderate dysplasia SIN 2 Atypical hyperplasia 
Severe dysplasia SIN 3 Atypical hyperplasia 
Carcinoma in situ SIN 3 Carcinoma in situ 
 
 
Squamous Intraepithelial Neoplasia (SIN) 
Squamous intraepithelial neoplasia (SIN) or oral intraepithelial neoplasia (OEN) is a 
modification of a classification of cervical pre-malignant lesions which has been suggested 
previously by Richard in 1968 (Warnakulasuriya et al., 2008). This system was not accepted 
by the WHO consensus group because it is unable to explain the concept of epithelial 
dysplasia internationally (Warnakulasuriya et al., 2008) and also there is no evidence to 
suggest that all PMDs will transfer to malignancy (Warnakulasuriya et al., 2007; Napier and 
Speight, 2008).  
Squamous intraepithelial neoplasia (SIN) is of three grades: SIN1, SIN2 and SIN3, where the 
first grade corresponds to mild dysplasia and the second grade corresponds to moderate 
dysplasia, while SIN3 refers to a combination of severe dysplasia and CIS in the WHO 
classification system; Table 1.5. 
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Ljubljana Classification-Squamous Intraepithelial Lesions (SIL) 
The Ljubljana classification was developed to be used for special clinical and histological 
laryngeal abnormalities (Hellquist et al., 1999; Gale et al., 2000). This system is more 
complicated even for the experience pathologist to use when compared to the WHO concept 
of dysplasia (Warnakulasuriya et al., 2008). 
The Ljubljana grading system identifies four categories: simple and abnormal hyperplasia 
both of which are regarded as benign, atypical hyperplasia which is pre-malignant, and CIS 
which is malignant without detectable invasion (Hellquist et al., 1999; Zerdoner, 2003). 
Table 1.5 demonstrates Ljubljana grading system in relation to WHO and SIN. 
 
1) Simple hyperplasia is characterized by increased thickness of the spinosum (prickle) 
cells layer without cellular atypia. 
2) Abnormal hyperplasia shows hyperplasia of basal and parabasal cell layers which 
constitutes up to one- half of full epithelial thickness. 
3) Atypical hyperplasia or risky hyperplasia is characterized by recognizable changes 
toward malignancy but epithelial stratification is unchanged. 
4) Carcinoma in situ shows marked cellular atypia, abnormal mitotic figures and complete 
loss of epithelial stratification. 
Although this system is quite difficult even for well-trained pathologists, it focuses on clinical 
decision though its scores. Simple and abnormal hyperplasia does not require close follow-
up, while close follow-up is required for risky hyperplasia, and CIS needs intervention 
(Zerdoner, 2003).  
 
A classification system with an easy routine daily application is required for an accurate 
diagnosis and subsequent successful management, with a universal grading system requires a 
high level of agreement between pathologists (Warnakulasuriya et al., 2008). 
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Epithelial Dysplasia /WHO Classification System (2005) 
The WHO Consensus Group made great efforts to establish a universal classification of OED 
by updating and improving the grading system used for OED (Kujan et al., 2007). 
The WHO classification system is mainly based on two main characteristic features: cellular 
atypia and architectural deregulation of epithelial tissue as well as the dysplastic layer 
thickness in relation to full epithelial thickness (Gale et al., 2005). 
 
WHO Five-Grade System 
The 5-score grading system has been proposed in the latest WHO Working Group (Gale et 
al., 2005). This classification system recognizes five-point ordinal scale grading system 
depending on nine-cellular and seven-architectural criteria, listed in Table 1.6. 
 
 
Table 1.6: Architectural and cytological features used in grading of OED in 2005 WHO 
classification system. 
Architecture Cytology 
1. Irregular epithelial  stratification 
2. Loss of polarity of basal cells 
3. Drop- shaped rete ridges 
4. Increased number of mitotic figures 
5. Abnormal superficial mitoses 
6. Premature keratinisation in single cell 
(dyskeratosis) 
7. Keratin pearls within rete pegs 
 
1. Abnormal variation in nuclear size (anisonucleosis)  
2. Abnormal variation in nuclear shape (nuclear pleomorphism) 
3. Abnormal variation in cell size (anisocytosis) 
4. Abnormal variation in cell shape (cellular pleomorphism) 
5. Increased nuclear- cytoplasm ratio 
6. Increased nuclear size  
7. Atypical mitotic figures 
8. Increased number and size of nucleoli  
9. Hyperchromasia 
 
 
The 5 grades of the 2005 classification system include: hyperplasia, mild dysplasia, moderate 
dysplasia, severe dysplasia and CIS (Gale et al., 2005). 
1) Squamous hyperplasia is characterized by increased cell numbers in the spinous layer 
without cellular atypia and with a regular stratification. The hyperplasia may also be seen in 
the basal or parabasal cell layers.  
2) Mild dysplasia: the architectural disturbances are limited to the lower third of the 
epithelium associated with minimum cellular atypia. 
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3) Moderate dysplasia shows a considerable degree of atypia with architectural 
disturbances extending to the middle third of the epithelium.  
4) Severe dysplasia shows a significant degree of atypia with architectural disturbances 
affecting more than two-thirds of the epithelium. 
5) Carcinoma in situ: the architectural disturbances involve the full or almost the full 
epithelial thickness, with marked cytological atypia. 
 
Binary Grading System 
It should be emphasised that using five point system is found to be associated with inter- and 
intra-examiner variability in the assessment of OED and a better agreement may be achieved 
by reducing this number into a two-point classification system (Kujan et al., 2007).  
Kujan and co-workers (2006) evaluated the scheme of a “high-risk” and “low-risk” binary 
grading system based on the same architecture and cytology criteria used by the WHO 
classification 2005 for grading epithelial dysplasia. The high-risk grade which has the 
potential for MT is assigned using a minimum of four architectural changes and five cellular 
alterations, whilst the low-risk grade which has low tendency for MT was assessed using less 
than four architectural changes and less than five cellular alterations (Kujan et al., 2006). 
According to this system all hyperplasias and mild dysplasias are classified as low-risk, 
whereas, all cases with severe dysplasia and CIS are considered as high-risk. With respect to 
moderate dysplasia, the binary grading system can classify moderate dysplasia cases into 
either low-risk or high-risk grade.  
The evaluation of this system suggested that a binary scoring system reduced observer 
variability and increased agreement between pathologists, compared with the five-point 
system and that it may be easier to use, less subjective and have better discriminatory powers. 
Kujan et al.’s (2006) study demonstrated reasonable values of sensitivity and specificity 
(85% and 80%, respectively) with a test accuracy of 82% for predicting MT. 
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1.7.2. Pathologists’ Observer Variability in Grading Oral Epithelial Dysplasia 
The histopathological grading of epithelial dysplasia remains the most clinically applicable 
predictor of potential MT (Lumerman et al., 1995; Cowan et al., 2001; Reibel, 2003). 
According to Guillaud et al. (2008), the significance of dysplasia phenotypes as cancer risk 
prognosticators is well documented and the strong association of higher grade dysplasia with 
increased risk of cancer progression has been observed and confirmed in multiple body sites; 
this is why histopathologic diagnosis of dysplasia remains the current gold standard. 
However, this standard is subjective with low intra-and inter-observer agreement in grading 
epithelial dysplasia, lack of knowledge of the weight characteristics used to assess 
histopathologic grades and the problem of reactive changes in oral epithelial term which can 
cause changes similar to low-grade dysplasia, making differential diagnosis in early disease 
problematic. 
So, assessment of epithelial dysplasia by histological examination remains subjective and is 
greatly dependent upon individual pathologist’s experience. Therefore, disagreement on 
grading between pathologists is not uncommon.  
 
The degree of agreement between pathologists is measured by kappa statistics (weighted and 
un-weighted) which takes the value zero when there is no agreement or the value one for 
perfect agreement. A kappa value lower than 0.4 represents fair agreement, between 0.4 and 
0.6 moderate agreement, between 0.6- 0.8 substantial agreement and between 0.8-1.0 almost 
perfect or excellent agreements (Thomsen et al., 2002; Malpica et al., 2005). 
 
Several studies on inter-and intra-observer variability have demonstrated considerable 
variations in the assessment of the presence, absence and degree of OED using different 
scoring systems (Kujan et al., 2006). These variations may be due to the lack of objectivity in 
the evaluation of established criteria, arbitrary division of the grading, lack of calibration of 
criteria and grading, and lack of sufficient knowledge of which criteria are important for the 
prediction of MT (Pindborg et al., 1985; Warnakulasuriya, 2001). 
Abbey et al. (1995) used six American board-certified oral pathologists to evaluate 120 oral 
biopsies, with pathologies ranging from simple hyperkeratosis to severe dysplasia. The 
agreement range amongst the pathologists was from 35.8- 55.8%; however, the kappa values 
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improved from 0.70 to 0.88 for inter-observers comparisons when the grading was considered 
to within one histological grade. 
A more recent study conducted by Brothwell et al. (2003) described a higher inter-observer 
agreement and showed substantial agreement using a 5-point ordinal scale with a group-
weighted kappa of 0.74. However, similar to the other studies, the group un-weighted kappa 
showed a fair to moderate agreement of 0.37. 
Equally, Fischer et al. (2004) reported an overall kappa weighted value of 0.59 and an 
improvement in the kappa measure agreement of 0.70 was observed when the histological 
diagnosis was simplified into three general classes of no abnormality- hyperplasia, mild- 
moderate- severe dysplasia and CIS. 
 
In a study conducted by Kujan et al. (2006), all pathologists demonstrated satisfactory 
agreement on discriminating mild from severe dysplasia or from CIS using the WHO 
classification. Nonetheless, evaluation of moderate dysplasia remained problematic. The 
same group showed that 46.7% of moderate dysplasia cases (WHO grading) showed 
malignant changes, whilst the binary grading system distinguished between two subtypes of 
moderate dysplasia (high/low risk) according to the clinical outcomes, showed 87.5% of 
high-risk moderate dysplasia progressed to OSCC. 
 
Kujan et al. (2006) showed better agreement in the histological assessment of the presence or 
absence and the degree of OED between inter-and intra-observer variation of a novel binary 
grading system compared with the 2005 WHO system. This improvement was mainly due to 
the reduction in the number of grading points from five grades in the WHO to two grades in 
the binary system making decisions simpler (Kujan et al., 2007). 
Although reducing the points for a grading system may improve the agreement among 
pathologists, the subjectivity in evaluation the histopathological criteria remains the main 
cause of observer variability.  
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1.7.3. Factors Influencing the Epithelial Dysplasia Status  
Studies have shown that many variables may affect the status of epithelial dysplasia, and that 
these variables are often seen in PMDs which have a higher tendency for MT. However, the 
majority of these variables are not researched sufficiently but include patient age, sex, lesion 
duration, site, size, clinical appearance and the presence of associated risk factors. 
 
1) Age of Patient  
There is some evidence that the prevalence of OL closely follows the incidence of oral cancer 
(Napier and Speight, 2008). Usually leukoplakia is not diagnosed before the age of 30-years 
with the highest prevalence in the fifth decade (van der Waal et al., 1997). OED commonly 
affects old-age patients with a peak incidence in their 50s and 60s (Lumerman et al., 1995; 
Arduino et al., 2009), with the higher risk for OSCC reported in individuals over 45-years 
(Hay et al., 2002). An important relation between age of patients and MT rates has also been 
reported, with a higher MT rate in patients over 50-years old compared to those under 50 
(Amagasa et al., 2006). This is supported by the findings of Chiesa et al. (1993) and Banoczy 
(1977) who reported a higher risk of MT among 60-70 year old patients. 
 
2) Sex 
The sex distribution of PMDs is variable depending on geographical variations and lifestyle 
habits (Reichart, 2001). An earlier study conducted by Lind (1987) showed that dysplasia 
was more frequent in females and that females were more prone to undergo MT than males. 
Also, previous reports showed an increased risk of MT of oral PMDs in women without 
smoking habits (Silverman et al., 1984; Schepman et al., 1998). Silverman et al. (1984) 
showed an equal sex ratio in leukoplakias (125 males: 132 females), but slightly more 
females developed cancer (19 males: 26 females). Schepman et al. (1998) studied 76 male 
and 90 female patients with leukoplakia, but found oral squamous cell carcinoma (OSCC) 
developed in 4 males and 16 females. This is also supported by the finding of Amagasa et al. 
(2006) who reported a MT rate of 11.2% in females with leukoplakia, which was higher than 
the 6.2% observed in males. However, the reason for a higher risk of MT in females remains 
unclear. 
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3) Duration  
All studies emphasize that when PMD disorder is present for years, there is a chance to 
develop dysplasia and subsequently transform to malignancy (Napier and Speight, 2008; 
Warnakulasuriya et al., 2008). The chronicity of the oral PMD increases the tendency for 
malignant changes in the first five year, after that, the rate may decrease but the risk may not 
completely disappear (Napier and Speight, 2008). It was noted that the longer the time of 
follow-up, the higher the number of cases which undergo MT (Schepman et al., 1998); 
Kaplan-Meier survival curves in a group of 166 patients showed that 50% of patients with 
leukoplakia develop cancer with 200 months. 
Evidence suggests that large percentage of OSCCs are associated with or preceded by pre-
existent, long-standing OL (Gupta et al., 1989; Bouquot, 1994; Reibel, 2003). 
 
4) Site-Intraoral Location 
The localization of PMDs, mainly OLs, may have a profound influence on the risk of MT 
(Napier and Speight, 2008). Most pathologists take oral sites into consideration during their 
pathological reporting and may thus adjust the degree of risk (Warnakulasuriya et al., 2008). 
For example, the FOM, ventral and lateral borders of the tongue with thin or atrophic lesions 
may show a higher rate of malignancy, thus pathologists may enhance basic histological 
features with known clinical high risk behaviour in their reports. 
 
Leukoplakias located in the anatomic oral subsites such as FOM, ventral and lateral surfaces 
of the tongue, soft palate, and tonsillar pillar are considered high-risk sites, with an increased 
risk of cancer development compared to other oral subsites which are considered to be at 
lower risk of transformation (Mashberg and Meyers, 1976; Boffetta et al., 1992; Zhang et al., 
2001a; Neville and Day, 2002). 
In one recent study, for example, the chance of exhibiting a carcinoma and OED were 2.72-
fold and 1.84-fold higher, respectively, in leukoplakias on the tongue or FOM, compared to 
buccal mucosa (Lee et al., 2006). Similar to the previous study, which showed that OED 
especially severe dysplasia was more liable to occur on the lateral surface of tongue and 
FOM (Jaber et al., 1999), leukoplakias in these oral sites also have an increased rate of MT 
(Mashberg and Meyers, 1976; Kramer et al., 1978b; Silverman et al., 1984; Gupta et al., 
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1989; Zhang et al., 2001b). According to Reibel (2003), 24% of patients with FOM and/or 
ventral surface of the tongue followed-up from 1 to 19 years developed carcinoma. In a cross-
sectional study of OED and OSCC, the highest prevalence of severe dysplasia or CIS was 
found in the FOM and tongue, 13.5% and 5% respectively, emphasising the high-risk at these 
sites (Waldron and Shafer, 1975). 
 
Although the majority of OLs (63%) were seen on the buccal mucosa or buccal commissures 
in another study, only 2.9% and 1.1% respectively, progressed to OSCC, whilst 13% of FOM 
leukoplakias developed OSCC again emphasising that the FOM is a high-risk site for MT 
(Banoczy, 1977).  
Similarly, a study from England showed that the FOM was particularly at risk because 24% 
of leukoplakias eventually became malignant (Kramer et al., 1978b). Furthermore, in a study 
conducted by Ishii et al. (2004) whilst OL was mainly observed on the gingiva, followed by 
the tongue and palatal mucosa, MT was observed in 13.6% of tongue but only 1.8% of 
gingival cases. 
 
In contrast, however, Holmstrup et al. (2006) showed in a follow-up study of 166 
leukoplakias that although the majority of OLs were situated in the FOM and in the buccal 
mucosa, which were considered high-risk sites, these sites exhibited no increased risk of 
malignant development as compared with other oral sites.  
This is also supported by Schepman et al.’s (1998) findings which showed that no specific 
oral subsites were associated with an increased risk of malignant conversion. 
 
Different studies have thus shown differences in the most common affected oral site by OLs 
and variable rates of MT. These differences in the most common oral subsites among 
different studies may be related to geographical differences, race and associated oral habits 
(Ishii et al., 2004). In a study conducted by Lim et al. (2010) the FOM, lip, tongue, and 
buccal mucosa were the most common sites affected by leukoplakia, while the palate and 
alveolus were less commonly affected.  
A retrospective hospital-based study conducted by Arduino et al. (2009) demonstrated that 
the lateral border of the tongue was the most commonly affected site followed by the buccal 
mucosa. A further study showed that the buccal mucosa and the FOM were the most 
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commonly affected oral sites, followed by the lateral border of tongue with the gingiva and 
commissure the least commonly affected (Jaber et al., 2003). 
 
5) Clinical Appearance 
Although OED is not associated with any specific clinical appearance (Arduino et al., 2009; 
Jaber, 2010), leukoplakia and erythroplakia are classically associated with dysplastic changes 
(Reibel, 2003). 
OL can show a variety of clinical appearances with some containing nodular or red area. 
Speckled leukoplakias have been shown to carry a greater risk of MT than uniformly white 
types (Napier and Speight, 2008). Therefore, the clinical appearance of OL may be 
considered as one of the major indicators for malignant transformation; non-homogeneous 
lesions are considered at a more significant risk for MT compared to homogeneous 
leukoplakias (Lee et al., 2006).  
This is in agreement with a study conducted by Holmstrup et al. (2006) in which 73% of non-
homogeneous lesions exhibited dysplasia, compared to 33% for homogeneous leukoplakia; 
non-homogenous leukoplakia showed a seven-fold increased risk of developing OSCC 
compared with homogenous types. Also, this is supported by another study conducted by 
Arduino et al. (2009) in which mild dysplasias present clinically as homogenous or verrucous 
leukoplakias, whilst speckled leukoplakias are more often associated with increased degrees 
of OED. In a previous study conducted by Kramer et al. (1978a), 57% of 63 FOM nodular 
leukoplakias eventually transformed to OSCC compared to only 13.6% of other clinical 
subtypes. This is also consistent with a study of 157 leukoplakias conducted by Lind (1987) 
in which leukoplakias were divided into homogenous, verrucous, erosive and nodular; OSCC 
developed in a single homogenous, two verrucous, three erosive and eight nodular 
leukoplakia subtypes. Moreover, an earlier study showed that OSCC eventually developed in 
74% of erosive leukoplakias and 26% of verrucous types (Banoczy and Sugar, 1972). 
 
In contrary to the aforementioned studies, Jaber et al. (2003) in their study found that 50% of 
OED manifested as homogeneous white patches, 45% as speckled, 2.4% as ulcers and 2% as 
erythroplakia. They suggested that clinical appearance was not a significant predictor of the 
degree of dysplasia; erythroplakia showed more moderate dysplasia than leukoplakia, but 
both had the same frequency of severe dysplasia.  
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These findings contrast totally with previous studies which demonstrated that speckled 
leukoplakias and erythroplakias are predominantly severely dysplastic or carcinomas (Axell 
et al., 1996) and carry a higher risk of both severe dysplasia and malignancy. 
 
In spite of some conflicting results, it is clear that non-homogenous leukoplakias, nodular, 
speckled and erosive subtypes show a higher tendency for higher grade OED and are more 
liable for MT compared to homogenous and other non- homogenous subtypes. 
 
6) Size  
Although very few studies have investigated the size of PMDs and its significance in cancer 
development, the individual size of a PMD may be relevant in oral carcinogenesis. 
Previously, it was reported by Saito et al. (1999) that widespread, multiple leukoplakias have 
a higher potential for developing carcinoma compared to localized lesions, regardless of their 
dysplastic status. Saito et al. investigated series of 111 patients with OLs, 12 patients had 
large and widely spread leukoplakias with three of them (25%) developed OSCC compared 
with 5% (5/99) of localized leukoplakias. 
More recently, Holmstrup et al. (2006) reported a 5.4 odds ratio for cancer to occur in oral 
lesions exceeding 200 mm
2
 in size compared with smaller ones. In Holmstrup et al.’s study, 
the size was recorded by multiplying the length by the width of the excised specimens taking 
from the pathological reports.  
In a retrospective study to investigate the clinicopathological features of OL in smokers and 
non-smokers, Freitas et al. (2006) reported that the size of OLs in smokers at the time of 
diagnosis was 2 cm in 62%, 2-4 cm in 31%, and 4 cm in 8%, while leukoplakia in non-
smokers showed 55% with 2 cm and 45% with 2-4 cm.  
 
In another study of 50 patients conducted by Napier et al. (2003), multivariate survival 
analysis highlighted the link between the clinical extent of PMD and the risk of OSCC 
development, with the risk of malignant progression approximately six-times greater in 
patients with large, confluent PMDs. Also, the same group found that the risk of OSCC was 
approximately four-times greater in patients affecting with a single anatomical site lesion 
than those with multiple sites lesions. 
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According to Napier et al. (2003), the high risk of larger size PMDs may be explained on the 
basis that PMDs with a larger size may have been present for a longer time compared to 
smaller lesions, so the transformation of these PMDs may be seen sooner compared to small 
sizes. Also, larger PMDs may be at higher risk of acquiring the critical genetic hits from 
oncogenic agents, or they may be biologically different with clonal expansion replacing the 
surrounded normal epithelial tissue. In addition, there may be a greater chance of sampling 
errors with non-representative incisional biopsies in large PMDs, resulting in underestimates 
of the severity of dysplasia. 
 
One can conclude that the size of PMDs should be taken into consideration as an important 
clinical parameter in patients’ follow-up, due to its potential importance in MT. 
 
7) Idiopathic Leukoplakias 
While tobacco use is the most important risk factor in developing OL, so-called “idiopathic 
leukoplakias” in non-tobacco users seem to be at increased risk of MT (Banoczy, 1977; 
Silverman et al., 1984; Schepman et al., 1998; Napier and Speight, 2008). Studies showed 
that idiopathic leukoplakias, where no associated aetiological factors have been identified, 
have a significantly increased risk of MT compared with leukoplakias that where associated 
with obvious causative agents (Napier and Speight, 2008). 
According to Silverman et al. (1984), out of 74 non-smokers in a group of 257 leukoplakia 
patients, 18 (24%) developed OSCC, whilst in contrast 21 carcinomas (16%) arose in the 133 
individuals who continued to smoke after diagnosis and only 6 (12%) arose in the 50 
individuals who stopped smoking after diagnosis of leukoplakia.  
In a study conducted by Schepman et al. (1998), three patients who developed OSCC were 
non-smokers. Also, the same study found that non-smoking female patients with leukoplakia 
were at higher risk of MT compared with female smokers, although no such relationship 
could be identified for men. 
This is supported by the results of a multifactorial statistical analysis which was unable to 
determine an association between tobacco use and MT of PMD (Holmstrup et al., 2006). 
 
To conclude, the factors associated with the development of PMDs and dysplasia are more or 
less the same that are associated with increased risk of MT. Female-sex, widespread and 
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long-standing disease, anatomical site, clinical appearance, idiopathic leukoplakia and 
associated risk factors have been demonstrated in several studies as important factors in OED 
development and potential malignant changes (Silverman et al., 1984; Gupta et al., 1989; van 
der Waal et al., 1997; Jaber et al., 1999; Reibel, 2003; Napier and Speight, 2008). 
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1.8. Aetiology-Risk Factors  
Table 1.7 demonstrates 14 risk factors associated with oral cancer and PMDs, which will be 
discussed in this section. 
 
 
 
Table 1.7: Risk factors of oral cancer and PMDs identified from the literature. 
Risk Factors 
1. Tobacco smoking 
2. Smokeless tobacco 
3. Alcohol drinking and alcoholic mouthwash 
4. Betel quid and Areca nut 
5. Marijuana 
6. Family cancer history/ Genetic factors 
7. Old age 
8. Dietary factors 
9. Immunodeficiency 
10. Oral health 
11. Socioeconomic factors 
12. Human Papilloma Virus (HPV) 
13. Oral candida infection 
14. Diabetes mellitus 
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1.8.1. Tobacco Smoking 
Tobacco use has been identified as probably the most important risk factor for oral cancer 
(Llewellyn et al., 2004b) and PMDs (Dietrich et al., 2004), particularly OLs (Gupta, 1984; 
Evstifeeva and Zaridze, 1992; Dietrich et al., 2004), in a strong dose- response relationship 
(Reichart, 2001). A linear relation between the number of cigarettes smoked per day and the 
risk of oral cancer has been observed. However, quitting cigarette smoking considerably 
reduces oral cancer risk after 1-3 years but patients may need 17 years or more to be at the 
same risk of never smokers (Castellsague et al., 2004). 
It is evident that heavy smokers who smoke more than 20 cigarettes daily and with more than 
20 years smoking history are at higher risk of oral cancer, whereas mild smokers do not show 
such an enhanced risk for oral cancer compared with non-smokers (Applebaum et al., 2007). 
Also, in a follow-up study on smokers, Khuri et al. (2001) found that treated cancer patients 
who continued smoking had a 2 to 6-times greater risk of developing a second primary 
tumour than those who stopped smoking. 
 
Regarding sex predisposition, it has been reported by Muscat et al. (1996) that the risk of oral 
cancer is higher for women than for men after adjustment for alcohol and other confounding 
variables; 40 pack-years of smoking approximately increased the risk of oral cancer 2-fold in 
men and 5-fold in women relative to non-smokers. The possible biological explanations for 
females higher susceptibility to tobacco carcinogens with a higher risk of oral cancer 
compared with men, include nutritional deficiencies and metabolism (Muscat et al., 1996). 
 
It has been reported that approximately two-thirds of oral cancer patients use tobacco 
regularly (Khuri et al., 2001; Williams et al., 2008). This is supported by findings from a 
cohort study conducted by Lee et al. (2007b) who showed that heavy smoking tends to 
increase the rate of leukoplakia development to five-times compared with non-smokers.  
It has been found that both the type and amount of tobacco consumption have an influence on 
the location, size and number of PMDs (Schepman et al., 2001; Freitas et al., 2006; Napier 
and Speight, 2008). Tobacco smoking is associated with an increased risk of oral epithelial 
dysplasia (Morse et al., 2007) an important key stage in oral carcinogenesis preceding MT 
(Morse et al., 2007) and is considered as one of the most important predictors of MT in 
PMDs (Reibel, 2003). 
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Although cigarette smoking is the commonest form of tobacco use, tobacco may be chewed 
or snuffed (Gupta et al., 1996). Smoking products are mainly prepared from Nicotiana 
tabacum, while smokeless or chewing tobacco is prepared from Nicotiana rustica (Reichart, 
2001). Processed tobacco contains approximately 3050 different compounds (Hoffmann and 
Hoffmann, 1998) and many of these compounds have been recognized as toxic, tumorigenic 
and carcinogenic (Reichart, 2001).  
Smoked tobacco releases a complicated mixture of thousands of chemicals; of these, more 
than 60 known chemical carcinogens, and a further 16 chemicals in unburned tobacco, have 
been identified by the International Agency for Research on Cancer (IARC) (IARC, 2004b; 
IARC, 2007). Polycyclic aromatic hydrocarbons such as benzo(a)pyrene together with 
tobacco-specific nitrosamines and aromatic amines are the most important tobacco related 
carcinogens (Hecht, 2003). These carcinogens may be considered as the causative agents for 
PMDs in both smoking and chewing tobacco products (Reichart, 2001). 
 
Tobacco use is suggested to play an important role during oral carcinogenesis which precedes 
MT of oral epithelial dysplasia to oral cancer (Morse et al., 2007). Tobacco specific 
nitrosamines have been regarded by IARC as carcinogenic to humans (IARC, 2007) because 
of their direct mutagenic effect on the exposed epithelia of the upper aerodigestive tract. This 
nitrosamines react with DNA forming DNA adducts which subsequently cause mutational 
effect on important oncogenes and tumour suppressor genes (P53) resulting in cancer 
development (Pfeifer et al., 2002). 
 
Nearly all carcinogens and procarcinogens require activation by metabolizing enzymes 
named xenobiotic-metabolizing enzymes which are found in the liver and mucosa of the 
upper aerodigestive tract (Ho et al., 2007). Similarly, detoxifying enzymes exist to deactivate 
carcinogens as well as their intermediate by-products (Ho et al., 2007). Both 
biotransformation and detoxification processes are essential for the metabolism and 
subsequent excretion of chemical carcinogens of tobacco smoke and these take place in two 
phases: phase I oxidative enzymes such as cytochrome P450 transform lipophilic compounds 
into more polar molecules and phase II xenobiotic-metabolizing enzymes such as 
glutathione-S-transferases (Ho et al., 2007) then convert them into water-soluble compounds 
making them less biologically active and facilitating the excretion of the toxins and 
carcinogens from the body (Pelkonen and Nebert, 1982).  
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Genetic polymorphisms of these enzymes may play an important role in individual’s response 
to carcinogens and also determine inter-individual differences in the metabolism and 
excretion of tobacco smoke carcinogens (Ho et al., 2007). 
 
It has been suggested that OLs in tobacco smokers occur preferentially in particular locations 
in the oral cavity (Schepman et al., 2001). The buccal mucosa and FOM were the most 
frequent locations among smokers whereas; leukoplakias at the borders of the tongue are 
more common among non-smokers (Schepman et al., 2001; Freitas et al., 2006). This is in 
agreement with a pervious study investigated the role of tobacco in relation to the anatomical 
subsites for the development of OSCC, with a highest relative risk associated with tobacco 
smoking in the retromolar area followed by the FOM (Jovanovic et al., 1993).  
These findings are remarkable, since smoking is the most important etiologic factor for 
carcinoma of oral mucosa with possibility of accumulation of tobacco-smoke toxins in saliva 
(Lederman, 1964). Also, spatial variations in the degree of keratinization and permeability of 
oral mucosa may modulate the local effect of tobacco-smoke toxins (Mashberg and Meyers, 
1976; Lesch et al., 1989). 
 
With respect to the site predilection for leukoplakia in male and female smokers, it has been 
reported that leukoplakia in the cheek mucosa in men and in the FOM in women were the 
most commonly affected site (Schepman et al., 2001). However, there is no explanation for 
the sex differences in site for leukoplakia and it may be that men and women use a different 
way of placing cigarettes between their lips; men keep their cigarette perhaps more to the side 
of their lips, whilst women might keep the cigarette more centered (Schepman et al., 2001). 
 
One can conclude that tobacco is the principle risk factor for oral carcinogenesis associated 
with a site preferential localisation and inter-individual variation in the activity of enzymes 
involved in the detoxification of tobacco smoke. 
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1.8.2. Smokeless Tobacco 
According to Warnakulasuriya and Ralhan (2007), there are two main types of smokeless 
tobacco: chewing tobacco and snuff. Chewing tobacco is either loose leaf, cut or shredded, 
while snuff is for applying, dipping or sucking. Worldwide, several names are used to 
represent different products of smokeless tobacco: shamma, toombak, plug, gutkha, khiwam, 
khaini, iq’milk, zarda, naswar, nass, chimo, gudhaku, gul, mishri, maras and moist snus 
(Warnakulasuriya and Ralhan, 2007).  
 
Smokeless tobacco is widely used in south and Southeast Asia, the USA and Scandinavia 
(Axell, 1993; Warnakulasuriya, 2004). It is more commonly used by males and it is mainly 
placed in the buccal or labial vestibule (Idris et al., 1994; Warnakulasuriya, 2004). 
Oral mucosal disorders are mainly developed at the site where smokeless tobacco is usually 
placed, and mostly appeared as white plaque with wrinkled surface (Warnakulasuriya et al., 
2010). There is clear site-specific involvement connected to the pattern of use, chewing and 
dipping and placement of smokeless tobacco in different oral sites, which may be different 
from tobacco smoking associated leukoplakia. For example, in India, buccal site is more 
common in tobacco chewers (Warnakulasuriya and Ralhan, 2007). 
 
Although various commercial products may cause population differences, epidemiological 
studies have shown a significant risk from chronic daily use of smokeless tobacco 
(Warnakulasuriya and Ralhan, 2007), with the length and frequency of used were highly 
significant for leukoplakia (Wolfe and Carlos, 1987). In the United States studies that were 
reviewed by the Surgeon Advisory Committee on the health consequences of using 
smokeless tobacco, between 8-59% of smokeless tobacco consumers were found to have OL 
(Cullen et al., 1986), and the wide range may be due to different products, duration of use, 
and inconsistent terminology used for OL in some studies. 
Also, in an earlier study on 280 English coal miners who were tobacco chewers, leukoplakia 
were reported in 10 (3.6%) (Tyldesley, 1971). 
 
The IARC working group on smokeless tobacco has reported that there is sufficient evidence 
of the oral carcinogenicity of smokeless tobacco (Cogliano et al., 2004). This carcinogenesis 
may be due to direct contact with the lower lip, lower vestibule and the FOM (Allard et al., 
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1999), with histopathological appearance of smokeless-tobacco induced disorder may include 
epithelial hyperplasia, dysplasia, and CIS (Salem et al., 1984; Zhang et al., 2001c). Further, 
multiple oral PMDs associated with leukoplakia, notably erythroplakia, and submucous 
fibrosis were described in a cohort of tobacco chewers in Kerala, India. The presence of such 
multiple oral lesions is consistent with the concept of field cancerization due to prolonged 
chewing tobacco (Thomas et al., 2003). 
 
Smokeless tobacco products contain a large number of carcinogens (Hoffmann and 
Djordjevic, 1997) although it is fewer than in cigarette smoke (Hecht, 2003). Benzo(a) pyrene 
and other polycyclic aromatic carcinogens are the most important carcinogenic agents in 
tobacco smoke but in unburnt tobacco, nitrosamines are the strongest carcinogens (Cogliano 
et al., 2004). These carcinogens in experimental in vitro systems affect oral keratinocytes and 
cause alterations in cell proliferation, apoptosis and activation of inflammatory mediators 
(Warnakulasuriya and Ralhan, 2007). 
 
1.8.3. Alcohol Use 
It is well established that alcohol consumption is the second major risk factor for oral cancer 
(IARC, 1988) and oral PMDs (Maserejian et al., 2006a) including leukoplakia (Hashibe et al., 
2000a) and erythroplakia (Hashibe et al., 2000b). In a prospective study on men, Maserejian 
et al. (2006a) demonstrated that alcohol is an independent risk factor for oral precancer in 
non-tobacco users regardless of the type, pattern and frequency of drinking status. Also, 
according to the same group, one additional drink per day (12.5 g) is associated with a 22% 
increase in risk of oral cancer. Recently, Rooban and co-workers (2009) reported a higher 
prevalence of oral mucosal disorders among alcohol misusers. 
The risk for oral precancer increases with increased ethanol content of each type of drink 
therefore, drinking of spirits may increase the risk compared with wine or beer drinking 
(Castellsague et al., 2004). According to the same group, drinking alcohol only at meals is 
associated with a reduction of risk compared to drinking between or without food. This may 
be due to the washing effect of a meal minimizing alcohol effects on the oral mucosa or 
mixing with food may diminish its topical effect on oral epithelia. The extended analysis of 
the same group demonstrated that the risk progressively and significantly increased with a 
longer history of drinking, for example after 20 years, while stopping the consumption of 
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alcohol may considerably reduce that risk after at least 3 years of cessation. However, the 
overall risk may need 14 years of cessation to be close to that of non-drinkers (Castellsague et 
al., 2004). 
 
Alcohol can induce carcinogenesis in different organs either by local or systemic effects 
(Toriola et al., 2010). The metabolism of alcohol is carried out in the liver, although some 
metabolism takes place in the stomach and upper digestive tract and gut (Homann et al., 
1997). Ethanol is a general component for all kinds of alcoholic beverages (Castellsague et al., 
2004), but by itself ethanol is not carcinogenic and there is no clear experimental evidence of 
pure ethanol carcinogenicity (Wight and Ogden, 1998). However, there is strong 
epidemiological evidence supporting the role of the first metabolite of alcohol oxidation, 
acetaldehyde, in oral carcinogenesis (Kurkivuori et al., 2007; Salaspuro, 2007; Meurman and 
Uittamo, 2008).  
 
Whilst the exact carcinogenic effect of alcohol is not fully understood, there are many 
possible hypothetical explanations of alcohol’s effect on oral mucosa. Firstly, in the oral 
cavity, alcohol is metabolized in saliva either by oral microflora via bacterial alcohol 
dehydrogenase (Jokelainen et al., 1996b) or by alcohol dehydrogenase of oral and 
oesophageal mucosa. (Homann et al., 1997), into its main carcinogenic substances 
‘acetaldehydes’ (Harris, 1997; Burton, 2005) which act directly to damage the mucosa 
(Castellsague et al., 2004).  
 
Acetaldehydes are unstable substances which produce free toxic radicals damaging the DNA 
or they may covalently bond to DNA forming DNA adducts (Baez, 2008). This may interfere 
with DNA synthesis and repair (Poschl and Seitz, 2004; Brooks and Theruvathu, 2005), thus 
initiating carcinogenesis. It is believed that ethanol may exert a direct effect on the bilayer 
phospholipid cell membrane (Axford et al., 1999) by dissolving some of the lipid content of 
cell membrane in the superficial regions of the epithelium, thus increasing oral mucosal 
permeability. Increased oral mucosal permeability may play a role in carcinogenesis (Hindle 
et al., 2000) by affecting intercellular mucosal transport, and enhancing the penetration of 
carcinogens through oral epithelia (Squier et al., 1986; Castellsague et al., 2004) for example, 
solvent effects on tobacco (Riedel et al., 2003; Poschl et al., 2004) and this may explain the 
greater risk in heavy drinkers (Kato and Nomura, 1994). Furthermore, Ogden (2005) studied 
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the intracellular mucosal transport and found a significant reduction in endocytosis 
(membrane transport) of oral cells in patients with heavy alcohol consumption. This may 
reflect a reduction in their ability to eliminate local carcinogens leading to an increased 
exposure time to a particular carcinogen and this may explain the interaction between alcohol 
and tobacco use (Axford et al., 1999). 
 
Interestingly, dilute ethanol (15%) was found to be more effective than higher concentrations 
of ethanol (40%) which might be because higher ethanol concentrations act as chemical 
fixatives reducing tissue permeability (Squier, 1991) and eliminating the subsequent 
reduction of local carcinogens, exposing the oral tissue to long term effects of possible 
carcinogens. 
 
Secondly, in addition to ethanol, alcoholic beverages contain other possible carcinogens such 
as volatile and non-volatile flavour components and additives; of these components 
nitrosamines, acrylamide and oxidized polyphenols have been classified as possible 
carcinogens in humans, and animal experiments have shown mutagenic activity on oral 
epithelial cells (Jagerstad and Skog, 2005). 
 
The third possibility of alcohol carcinogenicity is interference with detoxifying enzymes. 
Normally alcohol oxidized to acetaldehyde by alcohol dehydrogenase enzyme which then 
converted to acetate by the catalysing action of aldehyde-dehydrogenase. Acetate is oxidized 
into carbon dioxide, fatty acids, and water as a final step in ethanol metabolization (Wight 
and Ogden, 1998; Ho et al., 2007). 
 
The fourth possible mechanism is interference with diet bioavailability (Wight and Ogden, 
1998; Blot, 1999) by impairment of nutrient metabolism causing nutritional deficiency 
(Homann et al., 1997; Riedel et al., 2003). Fifthly, reduce the immune function (Wight and 
Ogden, 1998; Blot, 1999; Riedel et al., 2003) potentiating the genotoxicity or activate 
carcinogenic agents, interfering with DNA repair (Wight and Ogden, 1998; Blot, 1999).  
 
According to Gillison (2007), the solvent effects of alcohol may be the most important factor 
of its carcinogenicity rather than acetaldehyde genotoxicity influenced by local habits such as 
diet and presence of other risk factors. 
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Considering the use of alcohol containing mouthwashes, many commercial products contain 
alcohol in the range of 10-25% (Bhatti et al., 1994) or even more. Frequent alcohol 
mouthwash users may expose their oral mucosal tissues to levels of alcohol equivalent to 
alcoholic beverages, which have been implicated in oral cancer development (Winn et al., 
2001).  
 
The potential relationship between mouthwash use and the risk of oropharyngeal cancers has 
been considered by a number of epidemiological studies which have been reviewed by La 
Vecchia (2009) who concluded that the majority of these studies have shown inconsistent 
results or negative relations. This may either suggest no significant risk associated with the 
use of alcohol containing mouth wash or small sample size, differences in the methodologies, 
difficulties in measuring exposures or individual variations, difficulties in separating the 
independent effects of mouthwash from smoking, drinking effects and also to the exact 
effects of other mouthwash constituents (Winn et al., 2001). Furthermore, these studies suffer 
from limitations such as underreporting of mouthwash use by individuals and the use of 
different mouthwash types, varying alcohol content, duration of use and time retained in the 
mouth leading to inaccurate results. The role of alcoholic mouthwash in oral carcinogenicity 
requires more accurate longitudinal studies with larger sample sizes and more detailed 
parameters to investigate the potential mechanisms of oral carcinogenesis with and without 
alcohol. 
 
Alcohol consumption often coexists with tobacco use, thus a combination of tobacco 
smoking and alcohol drinking are considered as a major risk factors for oral cancer and 
PMDs (Harris et al., 2004) in a dose-response and 
 
synergistic manner rather
 
than in an 
additive mode (Castellsague et al., 2004). To date, numerous studies have shown that a 
combination
 
of tobacco smoking and alcohol drinking increase the risk of oral cancer and 
together they are associated with approximately 75% of upper aerodigestive tract cancers 
(Llewellyn et al., 2003; Dobrossy, 2005; Ogden, 2005). According to Warnakulasuriya et al. 
(2008) this combination is a strong intensifying risk factor for PMDs and subsequent MT. 
The possibility of strong combined effects of alcohol and tobacco may be explained on the 
basis of high levels of acetaldehyde production from both in a synergistic and multiplicative 
risk effect (Salaspuro and Salaspuro, 2004; Salaspuro, 2007). After a dose of ethanol, salivary 
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acetaldehyde was 2 times higher in smokers without smoking and 7-times higher with active 
smoking (Salaspuro and Salaspuro, 2004). 
 
1.8.4. Betel Quid and Areca Nut 
Betel quid with or without tobacco has been identified as an oral carcinogen in humans by the 
IARC with evidence of a dose-response relationship (IARC, 2004a; Jacob et al., 2004; 
Secretan et al., 2009). It has been estimated that between 10-20% of the world’s population 
chew betel quid or areca nut in some form (Gupta and Warnakulasuriya, 2002). Betel quid is 
regarded as the fourth most frequently consumed psychoactive substance after nicotine, 
ethanol, and caffeine (Gupta and Ray, 2004). It is mostly used by people in the developing 
countries as dried husks or fresh nut (Bagan and Scully, 2008), chewed alone as in China and 
Taiwan, or used with tobacco as in India and Pakistan (Reichart and Zhang, 2007). 
 
Betel quid, with or without tobacco has been found to increase the risk of oral PMDs, 
although this relation is not as significant as with cigarette smoking or alcohol drinking (Yen 
et al., 2007). A significant association has been found between the frequency and duration of 
chewing betel quid and the risk of PMDs (Yen et al., 2007), such as OL (Hashibe et al., 
2000a; Lee et al., 2003; Jacob et al., 2004), submucous fibrosis (Hashibe et al., 2002a; Lee et 
al., 2003; Jacob et al., 2004), erythroplakia (Hashibe et al., 2000b; Jacob et al., 2004) and 
multiple PMDs (Thomas et al., 2003). However, the most significant association is with oral 
submucous fibrosis (Jacob et al., 2004). According to Reichart and Nguyen (2008), oral 
submucous fibrosis in betel quid chewers in Vietnam was observed in 13%, OL in 3.8% with 
lichen planus in 5.2%. 
 
Betel quid ingredients have been shown to exert cytotoxicity, mutagenicity and genotoxicity 
toward different types of cells including oral epithelial cells, bone marrow cells and 
peripheral blood mononuclear cells (Jeng et al., 2001; Kumpawat et al., 2003). The 
carcinogenicity of both betel quid and areca nut may refer to nitrosation with consequent 
production of potentially carcinogenic nitrosamines such as 3-methylnitrosopropionitrile and 
also to the generation of reactive oxygen species in the oral cavity due to auto-oxidation of 
polyphenols contained in areca nut enhanced by the alkaline pH from slaked lime (IARC, 
2004a; Nair et al., 2004; Subapriya et al., 2007). 
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With respect to the affected oral sites, in betel quid chewing, the buccal mucosa, followed by 
tongue and lips are the most commonly affected sites (Reichart and Nguyen, 2008), reflecting 
the effect of direct contact with these locations. 
 
1.8.5. Marijuana (Marihuana/Cannabis) 
Marijuana is one of the most commonly misused psychoactive unlicensed drugs (Scully, 
2007) which is mainly smoked or may be taken orally either directly or mixed with food 
(Hall et al., 2005). However, smoked marijuana is the predominant form of cannabis used 
(Agrawal and Lynskey, 2009). Marijuana preparations, which contains more than 60 types of 
cannabinoids, are derived from the plant Cannabis sativa particularly from small glands on 
the surface of the plant (ElSohly, 2007). Delta-9-tetrahydrocannabioid (THC) is the principle 
psychoactive chemical ingredient which is found in all types of cannabis (Ashton, 2001; Cho 
et al., 2005; Scully, 2007). 
Due to the similarity in carcinogens and co-carcinogens between marijuana and tobacco 
smoke, except for nicotine (Tashkin et al., 2002), it is important to include marijuana use in 
the medical history of patients and it should be included within risk factor assessment for oral 
PMDs (Hashibe et al., 2005). Smoking a low number of marijuana cigarettes per day has 
been described to have similar histopathological effects on tracheobronchial epithelium as 
smoking more than 20 tobacco cigarettes (Fligiel et al., 1997). This might be due to a 
different smoking pattern with deep inhalation and more tar retention in the respiratory tract 
from marijuana compared with tobacco smoke (Tashkin et al., 2002). 
 
Patients using marijuana may develop PMDs, such as OL, erythroplakia and oral submucous 
fibrosis which are found to have higher prevalence rates in marijuana users compared with 
the general population (Thavarajah et al., 2006). The higher prevalence of PMDs in 
marijuana users necessitates periodic oral examination of such patients for early identification 
of PMDs.  
 
Within the oral cavity, cannabis smoking and/or chewing are associated with changes in the 
oral epithelia forming cannabis stomatitis (Cho et al., 2005) which results in chronic 
inflammation and leukoplakia, with the possibility of progression to neoplasia (Darling and 
Arendorf, 1992). Epidemiological studies have shown that marijuana smoking raises the risk 
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of oral and head and neck cancers by 2.6-fold compared with non-users (Zhang et al., 1999) 
and in a dose-response relationship for both frequency of use per day and duration (Hashibe 
et al., 2002b). However, other studies have shown a conflicting results; Llewellyn et al. 
(2004a) in a small case-control study and a community-based study conducted by Rosenblatt 
et al. (2004) showed no association between regular cannabis use and OSCC. The absence of 
association may be due to a small sample size (small number of heavy cannabis users) or due 
to differences in marijuana consumption. 
 
Recently, cannabis and other derivatives have been suggested to have various therapeutic 
uses and efforts have been made to provide non-smokable, safe therapeutic agents without 
psychoactive effects.  
 
Regarding such medicinal use which is under intensive investigation (Ware et al., 2005), 
delta-9-tetrahydrocannabioid (THC) may be used in cancer care to improve appetite, reduce 
nausea and vomiting and to relieve moderate neuropathic pain (Hall et al., 2005). It is 
designed as a spray under the tongue or on the buccal mucosa in alcohol with a peppermint 
flavouring to relieve chronic pain in multiple sclerosis, arthritis and neuropathy (Scully, 
2007). Although it is efficient in pain relief, patients may develop white lesions, an oral 
burning sensation and stinging which might be due to the high alcohol concentration in 
addition to peppermint (Scully, 2007); this increases the concern in chronic oral users. 
 
The interactions between different risk factors may increase the risk of developing potentially 
malignant disorders such as leukoplakia, erythroplakia and oral submucous fibrosis which are 
found to be higher in psychoactive substances users who smoked tobacco, chewed areca nut, 
drank alcohol and smoked cannabis (Thavarajah et al., 2006). The synergistic effect between 
tobacco and marijuana smoke has been observed, suggesting that tobacco and cannabis 
smoking may enhance the inflammatory responses possibly promoting their carcinogenicities 
(Melamede, 2005). 
 
1.8.6. Family Cancer History/Individual Susceptibility 
A positive family history is usually defined as one or more first degree relatives with a 
history of cancer (Brown et al., 2001). In families with known inheritance syndromes, first-
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degree relatives have a 50% chance of inheriting gene mutations which increases the risk of 
developing associated cancers and passing the causative gene to their offspring compared 
with families with no familial mutations (Trepanier et al., 2004). 
 
The genetic factors may include chromosomal aberrations, single nucleotide polymorphisms, 
matrix metalloproteinase-1 and TP53 (Vairaktaris et al., 2006; Kuroda et al., 2007). In 
addition to a germline mutation in the p16 gene, all of these may affect the normal function of 
genes, regulation of cell growth and DNA integrity (Yu et al., 2002). 
 
Although few epidemiologic studies have assessed the importance of familial hereditary 
factors in oral carcinogenicity, there is growing evidence from case control studies that 
consider family history as a risk factor for oral cancer (Jefferies et al., 2008). The evidence is 
mainly based on the fact that more than 50% of oral cancer patients have not been exposed to 
any major identifiable risk factors such as tobacco and alcohol or other risk factors (Campo-
Trapero et al., 2008b). Also, a young age of onset of oral cancer is more likely to support the 
concept of inherited disorders associated with an increased risk of cancer (Jefferies et al., 
2008; Scully and Bagan, 2008). 
 
It has been found that the risk of cancer for patients with a positive family history increased 
after adjustment for the age, sex, alcohol and tobacco exposure (Brown et al., 2001). 
However, it is difficult to differentiate between the effects of genetic susceptibility, 
associated lifestyle exposures or a combination of these factors. 
 
In a multicentre case-control study conducted in Italy and Switzerland it was found that first-
degree relatives’ family history of oral and pharyngeal cancer is directly and significantly 
associated with the risk of oral and pharyngeal cancer independent of tobacco smoking and 
alcohol consumption (Garavello et al., 2008b). Also, Garavello et al. indicated that the risk is 
increased in subjects with a family history of lung cancer or skin melanoma and it is higher in 
families with two or more affected relatives. 
 
Furthermore, considering individual genetic variations in the development of oral cancer, one 
needs to understand that exogenous carcinogens usually require activation by metabolic 
enzymes, whilst deactivation of carcinogens or their by-products is by detoxifying enzymes 
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(Gillison, 2007). Hereditary polymorphisms in these enzymes may affect the balance between 
both metabolic activation and detoxification of carcinogens leading to an increase or decrease 
in carcinogenic potential (Chen and Hunter, 2005). Therefore, polymorphisms of carcinogen-
metabolizing enzymes may affect an individual’s susceptibility to risk factors and subsequent 
progression to cancer (Baez, 2008). It is believed that the influence of a positive family 
history is also due to an increased sensitivity to the genotoxic effects of mutagens in tobacco 
smoke and metabolites of alcohol which represent an inherited sensitivity (Gillison, 2007). 
However, the majority of hereditary cancer syndromes are characterized by variable 
expressivity in cancer development, age of onset, site and number of tumours (Trepanier et 
al., 2004). 
 
Recently, there is increasing interest in “Genetic Risk Assessment” which involves a 
multistep process commencing with a detailed personal medical and family history and 
ending with hereditary cancer risk assessment by Genetic Counselling (Trepanier et al., 2004). 
This risk assessment requires an accurate and comprehensive family history “genetic 
pedigree” or family tree which is useful in the management plan including prevention, risk 
reduction and cancer screening. 
 
1.8.7. Old Age  
Ageing is a complex physiological and biochemical process with molecular changes 
manifested at a cellular level as well as in the organism as a whole (Malaguarnera et al., 
2010). A considerable body of data suggest that the human lifespan is continuously growing 
with an increased prevalence of many diseases including oral cancers and PMDs. The 
majority of OSCCs and PMDs are observed in patients between 50 and 80 years old (Jemal et 
al., 2006; Hirota et al., 2008; Goldenberg et al., 2009) with a peak in the 70s (Kurtz et al., 
2010) and less common in patients under the age of 50s (Goldenberg et al., 2009). 
Investigating the risk factors for OL, Dietrich et al. (2004) demonstrated that age is one of the 
independent predictors for this most common PMD.  
 
The relation between cancer and age may be explained as a result of long periods of 
carcinogenic exposure with mixed genetic and environmental components (Finkel et al., 
2007); long cumulative exposure to different carcinogens mainly smoking and alcohol misuse 
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in old individuals compared to younger subjects with relatively less exposure time (Hirota et 
al., 2008).  
 
Furthermore, increasing knowledge regarding telomeres which are defined as “DNA protein 
complexes that cap the chromosomal ends promoting chromosomal stability” (Epel et al., 
2004) may help to understand and explain the relation between ageing and risk of tumour 
development (Malaguarnera et al., 2010). Normally with ageing, telomere length gradually 
decreases in dividing somatic cells and this may contribute to neoplastic transformation, 
replicative senescence or apoptosis resulting in early death and early onset of disease 
(Cawthon et al., 2003). It has been documented that the mortality rate for patients with short 
telomeres is two-fold more than those with long telomeres (Cawthon et al., 2003) and this is 
also supported by a study performed by Warnakulasuriya et al. (2007) to compare the 
survival rate of patients less than 45 years with patients who had been 45 years and older who 
when diagnosed with oral cancer; they showed a higher 5-year survival rate in young patients 
who have long telomeres. 
 
Due to many changes associated with the ageing process, one may conclude that age is one of 
the risk factors for oral cancer and PMDs and a periodic screening for all adult patients over 
the age of 40-years is recommended every 6 months for early detection and diagnosis of oral 
cancer and PMDs.  
 
1.8.8. Dietary Factors 
Dietary factors play a substantial role in the aetiology of many chronic diseases and cancers 
including oral cancer (Ronco et al., 2006; Gillison, 2007). In the United Kingdom, evidence 
has shown that the consumption of fat and refined carbohydrates have increased by 5 to 10-
fold, whilst there has been a reduction in fibre-rich grain intake (Petti, 2009). 
Epidemiological studies have shown that an unhealthy diet rich in saturated fats, sugar, with 
less dietary fibre, lack of physical activity and resultant obesity are responsible for 30-40% of 
cancer cases worldwide (Petti, 2009).  
 
Food diversity has a protective effect on health due to variation in dietary components and is 
often associated with a favourable lifestyle (Garavello et al., 2008a). Fruit and vegetable 
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intake appears to be the most consistent dietary component influencing the risk of 
oropharyngeal cancer, with most studies highlighting the protective effects of fruit and 
vegetables compared with other factors such as cereals, meat, fish, milk and dairy product 
(Amtha et al., 2009). These latter products have been investigated in many case-control and 
cohort studies, but results are inconsistent and may be due to variations in food preparation in 
different populations (Amtha et al., 2009). 
 
In chemoprevention studies, supplements of nutrients commonly obtained from fruit and 
vegetables, such as beta-carotene and lycopene have been shown to encourage regression of 
OLs (Singh et al., 2004). In a study to investigate the risk of oral PMDs, Maserejian and co-
workers (2006b) showed that increased consumption of fruit, particularly citrus fruits in men 
reduced the risk of oral PMDs even with the presence of tobacco smoking, whilst the results 
for vegetable consumption were inconsistent. Similarly, Boccia et al. (2008) found that even 
in presence of high alcohol consumption or cigarette smoking, a higher intake of fruit and 
vegetables might prevent the development of approximately one quarter of head and neck 
cancer cases. Llewellyn et al. (2004a) in a case-control study in Southern England showed 
that daily consumption of three or more portions of fresh fruit and vegetables showed a 
considerable risk reduction compared with two portions or less. 
 
Studies have also shown that deficiencies in fruit, non-starchy vegetables and carotenoid food 
may be associated with 10-15% of oral cancer cases (Popkin, 2007). This is in agreement 
with a previous study conducted by Levi et al. (1998) who showed higher percentages of oral 
and pharyngeal cancers with low fruit and vegetables intake. Furthermore, fast, fermented 
and canned processed food have been found to double the risk for oral cancer, PMDs and 
other diseases due to their high fat content that generates polycyclic aromatic hydrocarbons 
during high temperature cooking; these hydrocarbons have been shown to cause cancer in 
laboratory animals (Grosvenor and Smolin, 2002). Moreover, an association between the risk 
of oral cancer and heterocyclic amines, such as benzopyrene generated from burned amino 
acids and other substance in meat, has been reported by the same group. 
 
Neither the mechanism of action nor the relation between diet and the risk of oral cancer and 
PMDs is fully understood and this is partly due to the fact that not all chemical compounds of 
food are well known or measured. Also, the role of different micronutrients are not 
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completely clear (Petti, 2009). Nevertheless, this may be explained on the basis that raw fruit 
and vegetables provide a mechanical cleansing effect for the oral cavity with the benefit of 
many properties in plant food such as a dilution action, anti–oxidant and anti-carcinogenic 
properties of micronutrients such as vitamins A, C, E, carotenoid, flavonoids, phytosterol, 
folates and fibres which are crucial for neutralizing the carcinogenic effects of tobacco, 
alcohol, and betel quid (Potter and Steinmetz, 1996; Kane, 2005; Rossi et al., 2007; Boccia et 
al., 2008; Lucenteforte et al., 2009). 
 
Further research is required to investigate the relationship between oral cancer and PMDs 
with micro/macro-nutrients and ultimately a dietary pattern may be established for a better 
dietary cancer protection.  
 
1.8.9. Immunodeficiency 
Immunodeficiency is a condition in which the immune system is either compromised or 
absent. It may be either a primary (genetic) or secondary (acquired) immunodeficiency 
resulting from disease or external influence such as drugs, environmental or iatrogenic factors 
(Rosen et al., 1995). Anti-tumour immune responses by both innate and adaptive immunity 
are essential for clearance and elimination of malignancies. However, accumulated evidence 
reveals that these responses may themselves be suppressed by the properties and function of 
cancer cells (Jewett et al., 2006). 
 
Genetic immunodeficiency has been implicated in the aetiology of oral cancer and PMDs in 
young individuals. Inherited cancer syndromes such as xeroderma pigmentosum, Fanconi's 
anaemia and Bloom’s syndrome are associated with an increased incidence of oral cancer 
(Prime et al., 2001).  
 
Acquired, induced immunodeficiency such as in organ transplant patients where the drugs are 
used to prevent organ rejection is greatly improving the quality of life and survival rate of 
many patients. This improvement is partly due to the use of modern immunosuppressive 
regimens to control rejection after transplantations. However, an increased incidence of both 
benign and malignant post-transplantation tumours as side effects of long-term 
immunosuppression is recognised. Azathioprine, cyclosporine and steroids are the main 
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immunosuppressive agents that are used to avoid tissue rejection in transplanted patients 
(Curtis et al., 2005).  
 
Several studies have shown an increased incidence of post-organ transplantation tumours 
involving head and neck cancers by 2 to 4-fold compared with non-transplanted populations 
(Vajdic et al., 2006; Vegso and Jaray, 2007). In kidney transplantation patients, lip and skin 
cancers increase by 35-fold and head and neck cancers by 4-fold (Makitie et al., 2008). Also, 
OL has been found to be the third most commonly diagnosed disorder in patients who 
underwent solid organ transplantation with prevalence of 10.7% (King et al., 1994). 
According to the same group, in renal transplant recipients, leukoplakia of the lip occurred 22 
times more often than in normal subjects. Furthermore, the presence of leukoplakia in normal 
patients increases the risk of oral cancer development by 5-fold compared with a 50-fold 
higher risk in immunosuppressed transplant patients (Hernandez et al., 2003). 
 
In Human Immunodeficiency Virus (HIV) infection in AIDS patients, Human Papillomavirus 
(HPV), Epstein-Barr virus (EBV) and Human Herpes Virus-8 in which the precursors of the 
associated tumours are usually removed in immune competent individuals, but grow into 
tumours in congenitally or immunodefective individuals with immune impairment (Klein and 
Klein, 2005).  
 
The main role of the immune system is to protect the body’s integrity; however, our genome 
contains a number of proto-oncogenes continuously exposed to mutagens and this may 
explain why cancer increased following organ transplantation. Impaired or lack 
immunosurveillance due to prolonged immunosuppression resulting from several years 
treatment for chronic graft versus host disease, emerges as a major factor in the elevated 
incidence of tumours in transplanted patients (Gourin and Terris, 2004; Giese et al., 2009). 
Further, a rapid transformation of OL in liver transplant recipient four months after the 
transplantation (Hernandez et al., 2003), the diagnosis of OSCCs in organ transplant patients 
on immunosuppressive therapy in the absence of other risk factors, such as tobacco and 
alcohol (Meng and Jiamei, 2000). These are clearly assigned to the carcinogenic effect of 
immunosuppressive drugs (Hernandez et al., 2003).  
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A study performed by Gourin and Terris (2004) showed that patients post-liver transplant due 
to alcoholic liver cirrhosis suffer from more malignancies compared with patients who 
underwent liver transplant for other causes. This is probably due to the fact that both alcohol 
and tobacco, as well documented risk factors for oral cancer, synergies with the effect of 
immunosuppressive in this group. This is also agreeing with Scheifele et al. (2005) who 
found that the incidence of oral, pharyngeal and laryngeal carcinomas as late complications 
of liver transplantation is 3.6% in patients with alcoholic liver transplants compared with only 
0.17% incidence in patients with non-alcoholic liver transplants.  
 
Immunosuppression must be considered as an important risk factor for oral cancer and 
PMDs. Therefore, controlling or reduction of carcinogenic agents such as tobacco, alcohol, 
sun exposure and viral infections along with early detection and treatment of PMDs with low 
and efficient dose of anti-proliferative action of immunosuppressive therapy are more likely 
to reduce the risk of post-transplant tumour formation (Vegso and Jaray, 2007). 
 
1.8.10. Oral Health  
In the oral cavity, one milligram of dental plaque contains approximately 10
11
 bacteria, and 
between 750 to 1000 bacterial species (Aas et al., 2005; Jenkinson and Lamont, 2005). Oral 
streptococci, a gram-positive bacteria, forms the largest proportion of normal oral microflora 
(Jenkinson and Lamont, 2005). In high density plaques, these microbial species adhere to 
tooth surfaces and to other surfaces in the mouth such as oral epithelia, restorative and 
prosthetic dental materials (Meurman and Uittamo, 2008). 
 
Patients with poor oral hygiene show higher numbers of microorganisms from supragingival 
dental plaque which may increase carcinogenic acetaldehyde production in saliva (Bloching 
et al., 2007; Meurman and Uittamo, 2008) compared to those with better oral health (Homann 
et al., 1997). In saliva, several oral streptococci have alcohol dehydrogenase enzymes which 
enable these micro-organisms to oxidize ethanol into acetaldehyde (Meurman and Uittamo, 
2008). It is therefore understandable that such micro-organisms in the mouth may increase 
the production of carcinogenic acetaldehyde with a consequent increased potential for oral 
cancer (Meurman and Uittamo, 2008). 
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Bacterial production of acetaldehyde from ethanol depends on the activity and characteristics 
of alcohol dehydrogenase enzymes (Kurkivuori et al., 2007). This may contribute to the 
individual variation of acetaldehyde salivary level seen after alcoholic drinks, with 
subsequent variation in risk of oral PMD and cancer formation (Kurkivuori et al., 2007). 
 
In patients with poor oral health, higher salivary acetaldehyde concentrations during and 
immediately after drinking alcoholic beverages and smoking has been observed probably due 
to direct dissolution into saliva (Kurkivuori et al., 2007). The derived acetaldehyde appears to 
act as a local carcinogen and in a dose-dependent and synergistic way (Salaspuro, 2007). 
In a case control study, Macigo et al. (2006) investigated the influence of oral hygiene and 
development of OL and they found that failure to brush teeth and non-use of toothpastes was 
significantly associated with the development of OL, emphasising the need for proper daily 
oral hygiene in patients, particularly those who are using alcohol. 
 
Regarding carcinogenicity, acetaldehyde may cause point mutations in human lymphocytes, 
sister chromatid exchanges and cross chromosomal aberration and interference with DNA 
repair (Dellarco, 1988). Also, acetaldehyde may interact with DNA forming adducts which 
can lead to mutation (Brooks and Theruvathu, 2005). Furthermore, formation of endogenous 
nitrosamines in the oral cavity by nitrate-reducing bacteria in patients with poor oral health 
may enhance carcinogenicity (Shapiro et al., 1991). 
 
Interestingly, researchers have observed that the alcohol dehydrogenase enzyme can be 
inhibited by 4-methylpyrazole which subsequently reduces the acetaldehyde production. 
Also, using antiplaque, antimicrobial mouthwashes such as chlorhexidine may reduce oral 
microbiota responsible for acetaldehyde production and thus reduce local acetaldehyde 
production, subsequently protecting the subjects from acetaldehyde carcinogenesis (Meurman 
and Uittamo, 2008). However, there is no clinical study in that field due to chlorhexidine side 
effects (Muller and Kramer, 2008).  
 
Meurman and Uittamo (2008) suggested future studies for elimination of acetaldehyde 
production in the oral cavity either by using cysteine (α-amino acid), which supports the 
second step in acetaldehyde metabolism into relatively harmless acetic acid, or by using 
57 
 
probiotics (live naturally occurring microorganisms) which have an inhibitory effect on 
acetaldehyde production from oral flora. 
 
It is clear that routine dental care with regular dental visits as an indicator of a good oral 
health may reduce or prevent the exposure to some carcinogens, in addition to regular 
screening programs for prevention (Guha et al., 2007) and treatment as a part of the long-
term standardised care (Rooban et al., 2009). 
Oral hygiene status should be involved among the strategies of oral PMDs preventive and 
control programmes. 
 
1.8.11. Socioeconomic Factors 
Socioeconomic status is mainly based on the three important parameters of income, education 
and occupation and comprises three classes: high, middle and low level (Greenwood et al., 
2003).  
Although socioeconomic factors have been regarded of importance in the aetiology of oral 
cancer and PMDs, they are time changeable factors (Conway et al., 2008). The relation 
between socioeconomic status and oral cancer is complex and has received little attention. 
Lifestyle risk factors, particularly tobacco smoking and alcohol consumption, are directly 
affected by socioeconomic circumstances which influence the effects of these factors 
(Hashibe et al., 2003). These risk factors have been described as coping mechanisms for 
stress, which is associated with a variety of factors including deprivation, unemployment, low 
income and insecurity of work (Marmot, 1997; Stead et al., 2001). 
 
However, the biological basis for the stresses associated with low socioeconomic status and 
cancer development is not entirely clear. However, emerging hypotheses from “biological 
ageing” demonstrate that psychological stresses are associated with significant increased 
oxidative stress which can shorten telomeres, a known determinants of cell senescence and 
longevity, leading to premature ageing and earlier onset of disease with early death (Epel et 
al., 2004). Gradual loss of telomeric DNA (telomere shortening) in dividing somatic cells 
contributes to replicative senescence, apoptosis and neoplastic transformation (Cawthon et al., 
2003) and may all result from low socioeconomic circumstances (Adams and White, 2004). 
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Individuals in low socioeconomic groups with low income are almost always under stress 
which may require coping mechanisms such as tobacco chewing and/or smoking and alcohol 
drinking (Conway et al., 2008). So, those individuals are subjected to potential lifestyle risk 
factors besides a low consumption of fruit, vegetable and vitamins (protective agents) and 
their resultant low body mass index and less access to medical care may lead to a higher 
prevalence of oral PMDs (Brennan et al., 2004); they can be regarded as high risk patients.  
 
Furthermore, low socioeconomic status may lead a person to detrimental environmental and 
housing conditions, with physical, social and psychological effects in turn affecting overall 
human health (Conway et al., 2008). Large numbers of household residents increase human 
contact affecting hygienic living conditions, which may increase the possibility of fungal, 
bacterial or viral infections predisposing to the development of oral PMDs (Hashibe et al., 
2003). 
 
Analytical studies have shown that oral cancer is more common in the most deprived people 
in society (Greenwood et al., 2003; Conway et al., 2007; Conway et al., 2010) and low 
income may also contribute to cancer diagnosis delay (Hansen et al., 2008) which may have 
direct effects on the prognosis and survival rate for patients. Speight et al. (2006) proposed 
that patients at higher risk may be determined by their sex, age, smoking and drinking status 
and Conway et al. (2007) suggested that socioeconomic status should be considered as key 
for ‘priority risk grouping’. 
 
In contrast, individuals from high socioeconomic groups having higher incomes may be 
protected from oral cancer and PMDs through their higher consumption of vitamins from 
fruit and vegetables. In addition, they have more access to medical care at early stages of 
their diseases, such as treatment of oral PMDs before transformation to oral cancer. Indeed, 
such groups of people are more likely to be classified as low risk patients (Hashibe et al., 
2003). 
 
As preventive measures, all the socioeconomic factors that can be identified as real risks for 
oral cancer and PMDs need to be improved by effective measures to reduce inequalities 
between people in society through either local or national authorities or the WHO 
commission.  
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True prevention and early detection of oral cancer and PMDs requires addressing the 
underlying poverty and inequalities that affect the socioeconomic status of all peoples. 
 
1.8.12. Human Papillomavirus  
It has been reported that even in the absence of well-known risk factors or predisposing 
genetic factors, between 15–20% of patients may develop OSCCs (Gillison and Shah, 2001). 
This suggests the presence of other aetiological risk factors, such as viral infectious agents 
(Scully 2002). 
 
HPV is a small epitheliotropic DNA virus which may be considered as either an independent 
risk factor or as an intensifier to tobacco and alcohol effects in oral carcinogenesis (Nair and 
Pillai, 2005). More than 118 HPVs have been identified which can infect various human 
epithelial tissues (de Villiers et al., 2004); the mucosal type can infect human genital and oral 
epithelial cells and may cause disorders ranging in severity from benign growth to malignant 
features (Wise-Draper and Wells, 2008).  
 
HPVs are divided into low risk and high risk subtypes according to their clinical association. 
Low-risk subtypes include HPV 6 and 11 and are mostly associated with benign or mildly 
dysplastic disorders, whereas high-risk subtypes such as HPV 16 and 18 are mainly identified 
during MT and in established cancers (Munger and Howley, 2002; Slebos et al., 2006; Acay 
et al., 2008; Wise-Draper and Wells, 2008). HPV 16 is the most commonly recognized HPV 
in OSCCs and both HPV 16 and 18 play very important roles in MT (Boulet et al., 2007). 
 
It is well documented that HPVs are implicated in the pathogenesis of cervical cancer and 
although more than 95% of human cervical cancers are associated with HPV 16 and 18 
(Yuan et al., 2005); the association with the head and neck cancer remains controversial.  
 
Some studies could not demonstrate an association between HPV infection and oral PMDs or 
oral cancer and suggest HPV may represent a transient infection rather than an essential 
prerequisite during the step-wise carcinogenesis of OSCCs (Ha and Califano, 2004). 
However, more recently HPV infection as a possible etiologic factor for head and neck 
cancer has emerged indicating that HPV positive tumours may represent a distinct subset and 
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this is supported by the similarity between the HPV oncogenic types detected in cervical 
carcinomas and those seen in head and neck cancers (Khovidhunkit et al., 2008; 
Chocolatewala and Chaturvedi, 2009).  
 
According to a study conducted by D'Souza et al. (2007), oral HPV infection is strongly 
associated with oropharyngeal cancer with or without the established risk factors of tobacco 
and alcohol use. From different studies, a wide variation in prevalence of between 20-75% 
for HPVs in OSCCs has been reported (Smith et al., 2004; Kreimer et al., 2005; Syrjanen, 
2005; Chocolatewala and Chaturvedi, 2009). 
 
Furthermore, in a meta-analysis, high-risk HPV genotypes have been detected in normal oral 
mucosa, precancerous oral mucosal tissue and oral carcinoma, with increased frequency in 
oral epithelial dysplasia and carcinoma compared with normal oral mucosa (Miller and 
Johnstone, 2001). The virus was identified in precancerous oral mucosa at levels 2-3 times 
higher than in normal mucosa. Such findings may provide evidence for including HPV in the 
risk factors for oral PMDs. HPV has been identified in primary tumours of the tonsil, larynx, 
hypopharynx, oral cavity, tongue, and nasopharynx; however, the highest rates were found in 
tonsillar cancer followed by tongue and buccal mucosa (D'Souza et al., 2007; Chocolatewala 
and Chaturvedi, 2009). 
 
Molecular research has shown that carcinogenesis involving high risk HPVs acts mainly 
through two viral oncogenes E6 and E7 which are both regarded as indicators of HPV 
positive cancers, affecting apoptosis which is essential for HPV infection to avoid the 
immunological response (Mantovani and Banks, 2001). These two proteins have no intrinsic 
activities of enzymes, but they are able to interact directly and indirectly with two-key 
tumour suppresser proteins p53 and retinoblastoma. This may affect their ability to stimulate 
DNA repair or apoptosis interfering with the cell cycle control and promote carcinogenic 
processes (Wise-Draper and Wells, 2008). 
 
The knowledge of the detection of HPV in a patient with oral dysplastic disorders may be of 
benefit for deciding upon treatment plans and selection of treatment modalities which may be 
different for HPV associated disorders compared with non-HPV associated dysplastic 
disorders. According to Tomson et al. (2004), the identification of HPV as a cause of cervical 
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cancer indicates that HPV vaccines can potentially be used to prevent or treat cervical cancer 
and other HPV-associated malignancies and if these prophylactic and therapeutic vaccines 
prove as successful in patients as they have in animal models, HPV vaccines may play a role 
in the control of HPV infection and HPV-associated disease. 
 
1.8.13. Candida Infection 
Candida albicans is a normal flora of the aerodigestive and vaginal tracts but it may become 
pathogenic and produce dermatological, mucous membrane and internal infections in certain 
circumstances such as pregnancy, oral contraception, antibiotic therapy, diabetes, skin 
maceration, topical steroid therapy, certain endocrinopathies, and factors related to 
depression of cell-mediated immunity (Vuckovic et al., 2004).  
 
There is an increasing interest to investigate oral Candida infection, not only because of the 
association with Human Immunodeficiency Virus (HIV) but also because of an important 
association with oral PMDs (Vuckovic et al., 2004). Within the oral cavity, Candida 
infections are regarded by many studies as a significant risk factor enhancing epithelial 
dysplasia and subsequent MT of OL. In a study conducted by Cao and co-workers (2007) to 
estimate the rate of Candida infection in different oral epithelial disorders using human 
salivary samples, they found that Candida infection is one of the important factors inducing 
epithelial dysplasia and MT of OL. Also, the same group suggested using salivary cultures as 
routine tests for patients exhibiting OL with Candida infection and regular follow-up was 
encouraged for such patients. 
 
Vuckovic et al. (2004) isolated Candida from PMDs, mainly OL and lichen planus, with an 
apparent increased incidence in lesions with marked epithelial dysplasia. This is supported by 
a study performed by McCullough et al. (2002) who found significantly higher number of 
oral yeast in histopathologically confirmed oral epithelial dysplasia with more isolated yeast 
in advanced levels of dysplasia. These results are in agreement with the previous study 
performed on 223 oral mucosal biopsies to investigate the prevalence of fungal infection 
using periodic acid-Schiff stain; the study showed a significant positive association between 
fungal infection with both moderate and severe epithelial dysplasias (Barrett et al., 1998). 
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The same group suggested the use of anti-fungal therapy as a part of treatment plan in these 
types of disorders. 
 
However, it could be argued that the high numbers of oral yeast associated with dysplasia are 
completely coincidental with environmental changes contributing to the proliferation of these 
microorganisms, otherwise many more patients with chronic candidiasis should develop oral 
carcinomas (Sitheeque and Samaranayake, 2003). 
 
More recently, a study was carried out to test the ability of Candida albicans to promote 
epithelial dysplasia using 4 Nitroquinoline 1-oxide (4NQO) as an initiator of neoplasia in a 
mouse model. Candida albicans was found to play a promotion role in oral dysplasia in this 
model (Dwivedi et al., 2009) and this may provide more evidence of an association between 
Candida albicans and oral epithelial dysplasia. This is also supported by a previous study 
conducted by Field et al. (1989) who proposed that nitrosamine compounds produced by 
Candida species may act directly on oral mucosa, or interact with other chemical carcinogens 
to activate specific proto-oncogenes which initiate the development of oral neoplasia. 
 
In spite of the general acceptance of an association between Candida infection and the 
occurrence of oral epithelial dysplasia, the possible role of yeast in oral carcinogenesis is still 
unclear and further studies in this area of research are warranted. 
 
1.8.14. Diabetes Mellitus 
Diabetes mellitus (DM) is a rapidly growing metabolic disorder that parallels obesity and 
poor lifestyle behaviours (Auluck, 2007; Skamagas et al., 2008). It accounts for 
approximately 5% of world-wide deaths (Roglic et al., 2005). DM is a group of metabolic 
diseases characterized by hyperglycaemia resulting from a defect either in insulin secretion, 
action or both (American Diabetes Association, 2009). It is mainly of 2 types: type I or 
insulin dependent because of its clinical need for insulin or Juvenile onset diabetes due to its 
early age of onset (Jahromi and Eisenbarth, 2007). Type II or non-insulin dependent forms 
85-90% of DM cases (Skamagas et al., 2008). 
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Research has shown that DM increases the risk of oral pathologies, such as acute infections, 
periodontitis, candidiasis, PMD (lichen planus) and malignancies (Ujpal et al., 2004; Dikshit 
et al., 2006; Goutzanis et al., 2007; Skamagas et al., 2008). Recently, epidemiological studies 
have involved DM in the aetiopathogenesis of OSCCs and PMDs (Ujpal et al., 2002; Dietrich 
et al., 2004; Ujpal et al., 2004; Dikshit et al., 2006). However, more recent studies have 
shown no association between DM and oral PMDs (Saini et al., 2010). According to the same 
group, this contradictory result may be related to the sample size and adjustment of the 
confounding factors, and a relation between PMD and DM may still be possible. Although a 
more recent study conducted by de Souza Bastos et al. (2011) also found no significant 
association between OL and DM type II possibly due to a reduced number of smokers in this 
study group. 
 
A significant association between the development of OL and DM has been reported in a 
study conducted by Dietrich et al. (2004) who found that diabetic patients were 3-times more 
likely to develop OL compared to non-diabetics. Similar relations have been previously 
reported between DM and OL (Albrecht et al., 1992; Ujpal et al., 2002). Albrecht et al. (1992) 
reported a prevalence of 6.2% among diabetics compared with 2.2% in a control group. Also, 
Dikshit et al. (2006) reported that the odds ratio of OL in women with a history of DM was 2 
and 3.2 for erythroplakia after adjusting for potential confounders. The association is stronger 
in females with a history of diabetes compared with males which may relate to poorer 
metabolic control and higher levels of insulin in females with DM leading to more oxidative 
damage to DNA (Dikshit et al., 2006). 
 
Normally, oral epithelial tissue provides a protective barrier against external carcinogens. In 
diabetic patients, and as part of the disease process, a progressive atrophy of oral mucosa may 
occur due to reduction in both salivary secretion and pH (Taylor et al., 1996). This may 
increase oral disorders, such as glossitis and cheilitis (Ujpal et al., 2004) as well as increasing 
the permeability of oral mucosa to different carcinogens as a result of loss of the normal 
protective barrier of oral epithelium (Auluck, 2007). 
 
There are several explanations for the potential tumorigenic effects of DM. This 
tumorigenicity may be directly mediated by insulin receptors in target cells or might be due 
to related changes in endogenous hormone metabolism (Auluck, 2007). Insulin deficiency 
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results in reduction of insulin receptor substrate-1 (Goutzanis et al., 2007) and changes in the 
cytoskeleton leading to reduction in cell adhesion by affecting focal adhesion kinase 
pathways (Vairaktaris et al., 2007). This is probably a starting step towards neoplastic or 
dysplastic change (Goutzanis et al., 2007). Further, insulin can stimulate the synthesis and 
biologic activity of insulin-like growth factor-1 which promotes cell proliferation and inhibits 
apoptosis (Calle and Kaaks, 2004). 
 
However, limited evidence indicates that the effect of insulin-like growth factor-1 might be 
connected to p53 mutations, which are frequently seen in head and neck tumours (Dikshit et 
al., 2006). Also, elevated blood glucose levels and protein breakdown may lead to excessive 
formation of free radicals (Ujpal et al., 2004) causing imbalance between production of free 
toxic radicals and biological systems due to reduction of antioxidant activity of enzymes 
(Auluck, 2007). This may cause DNA damage and subsequent promotion of carcinogenesis 
(Seril et al., 2003). 
 
From the aforementioned points, the role of DM in the aetiopathogenesis of PMDs needs 
more accurate study to determine if the association is related to characteristics of the diabetic 
state or to the treatment agents or to other associated risk factors. To explain the exact 
associated mechanisms, future studies should take in consideration information such as the 
type of diabetes, type of treatment, age of onset of diabetes, duration between the onset of 
diabetes and the development of PMDs (Dikshit et al., 2006). 
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1.9. Management of Patients with Oral PMDs 
Management of PMDs includes both diagnostic and treatment processes (Marley et al., 1996). 
The intention of clinical management of oral PMDs is early detection, treatment, and 
prevention of MT by initiating an adequate intervention (Holmstrup et al., 2006). 
Since treatment of patients with advanced stages of disease is often associated with more 
damaging interventions, more cost and are more liable to failure (Heintzelman et al., 2000), 
early detection of oral PMDs is essential. However, there is no universally reliable method for 
early detection of PMD tissue changes (Heintzelman et al., 2000). This may be due to 
inexperienced practitioners who are unable to detect early dysplastic tissue changes or 
discriminate them from benign tissue changes or the whole mouth lining may be unstable and 
it is difficult even for experienced clinicians to decide the location and the time for biopsy. 
Also, performing repeated surgical and follow-up biopsies are often unpopular for both 
patients and practitioners (Heintzelman et al., 2000). 
 
At the present time, there are no molecular markers which enable a researcher to distinguish 
disorders that progress to cancer from those that will not (Napier and Speight, 2008; 
Warnakulasuriya et al., 2008). Therefore, the major challenge for the early diagnosis and 
treatment of patients with PMDs is the limited ability to discriminate between disorders at 
risk of progressing into OSCC and those at low-risk of such progression (Scully et al., 2003; 
Guillaud et al., 2008). However, currently, the most valuable prognostic indicators for the 
potential progression is the severity of oral epithelial dysplasia, with the most severe 
dysplasia at higher-risk of MT (Gupta et al., 1980; Silverman et al., 1984; Lumerman et al., 
1995; van der Waal et al., 1997; Schepman et al., 1998; Reibel, 2003). 
Epithelial dysplasia, however, is not always a reliable predictor in individual patient 
management. 
 
Currently, there is no consensus on the most effective treatment for complete cure, or 
prevention of recurrence or MT (Tradati et al., 1997; Zhang et al., 2001a; Schaaij-Visser et 
al., 2010). Also, there have been no large trials to show an ultimate, reliable intervention 
(Jerjes et al., 2012) nor any meaningful randomized controlled trials, leaving the management 
of oral PMDs controversial (Goodson and Thomson, 2011). 
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Several management modalities for the treatment of oral PMDs have been suggested, which 
include a change of patient lifestyle factors, such as tobacco use and alcohol consumption 
(Silverman et al., 1984; Gupta et al., 1995), medical management with vitamin A, retinoids or 
antimycotics (Boisnic et al., 1994; Tradati et al., 1994; Scully, 1995), surgical excision (Sako 
et al., 1972; Vedtofte et al., 1987; Lumerman et al., 1995; van der Waal et al., 1997; Neville 
and Day, 2002), cryosurgery (Sako et al., 1972; Tal et al., 1982; Saito et al., 2001), laser 
vaporization (Gooris et al., 1999; Ishii et al., 2004; van der Hem et al., 2005) or laser excision 
(Frame, 1985; Thomson and Wylie, 2002; Ishii et al., 2004). Although there are numerous 
treatment regimens, no strong scientific evidence base exists. 
 
Modification of lifestyle risk factors such as elimination of tobacco and alcohol intake and 
correction of local irritation are considered as essential first steps in the management of 
PMDs patients. However, risk factor assessment in individual patients is frequently based on 
subjective self-reporting of tobacco smoking or alcohol consumption. Patients may 
inaccurately report tobacco and alcohol intake, making both the assessment and the 
modification of risk factors of limited benefit which may affect the accurate identification of 
patients at high-risk of MT (Goodson et al., 2010). 
 
Generally, the clinical management of OL consists of initial biopsy to assess the grade of 
epithelial dysplasia followed by either excision or laser treatment, or observation (Schaaij-
Visser et al., 2010). Surgical intervention is predominantly recommended in the presence of 
moderate or severe epithelial dysplasia (Reibel, 2003). However, mild to moderate dysplastic 
leukoplakia may be either completely excised or left in situ depending on other factors that 
influence the treatment decision, such as site and size of OL, smoking habits and if the patient 
is engaged in a smoking cessation program or not (van der Waal et al., 1997; van der Waal 
and Axell, 2002; Reibel, 2003). Recently, Goodson and Thomson (2011) recommended the 
excision of mild oral epithelial dysplastic tissue at high-risk sites and in young patients 
mostly for those who continue to smoke or who are unlikely to attend the follow-up 
appointments on a regular basis. 
 
Surgical excision seems to decrease the risk of MT by more than a half, but does not 
eliminate it. Hence, continuous surveillance, especially for high-grade dysplasia cases, even 
after surgical excision is required (Mehanna et al., 2009). Also, van der Waal (2010) 
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recommended excision or laser intervention of any oropharyngeal leukoplakia or 
erythroplakia, irrespective of the presence or absence of dysplasia. However, it is unknown 
whether such removal truly prevents the potential MT, thus lifelong follow-up is 
recommended at intervals of no more than 6 months. 
 
Regarding non-surgical treatment of OL, randomized controlled trials have shown no 
evidence of effective treatment in preventing MT or lesion recurrence and this also 
necessitates close and regular follow-up of patients after any clinical resolution (Ribeiro et al., 
2010). 
 
Both treated and untreated patients may be followed-up every 3 months or less frequently at 
6-month intervals depending on the presence of epithelial dysplasia in the biopsy (Brennan et 
al., 2007; van der Waal, 2009). Histological grading of epithelial dysplasia is the gold 
standard to predict MT, but it remains somewhat subjective and has a limited value when 
applied in the assessment of individual patients and lesions. 
 
Management of PMDs is mostly dependent upon both clinical and histological features 
(Marley et al., 1996). However, at the present time there is no consensus on the treatment of 
patients with OED and the management plan may vary from initial incisional biopsy to 
exclude oral cancer to complete excision with an adequate margin resection (Epstein et al., 
2007). Therefore, the development of an evidence-based management and surveillance 
strategy is urgently required. 
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1.10. Treatment Outcome 
Reporting the treatment outcome requires standardisation of parameters as much as possible 
such as the length of the follow-up time and the type of study population, such as a hospital-
based population or a community-based study (van der Waal and Axell, 2002; Holmstrup et 
al., 2006; Jaber, 2010). 
 
The outcome after treatment is conventionally recorded at the last documented contact with 
patients and it is either successful in which the patient is noted to be a disease-free with 
complete resolution or as disease active. Disease active may be recurrence at the same site of 
primary disease after surgical intervention, or new disease formation at new-sites or indeed 
cancer development. The former is either MT of the disease at the same site of primary 
disease or development of cancer at new and distinct oral subsites. 
 
 
1.10.1. Malignant Transformation 
The clinical significance of PMDs is their unpredictable ability to transform to oral cancer. 
MT may be defined as the appearance of OSCC at the same site of the pre-existing PMD 
(Amagasa et al., 2006; Lim et al., 2010). The time to MT is the time between the onset of 
initial diagnosis and the progression to oral cancer confirmed by histological diagnosis (Hsue 
et al., 2007).  
 
It has been suggested that two important factors should be considered to diagnose a 
progression of PMD to oral cancer: the same primary site cancer progression and the time to 
MT (Hsue et al., 2007). The same group suggested at least 6 months latency time for the 
transformation to be considered to exclude the possibility of concomitant presentations; 
however, a rapid MT of OL may occur in a shorter time. 
 
The concept of the multistep process of oral cancer development, in which an initial precursor 
lesion consequently develops into oral cancer, is well-accepted. OL is the best known 
precursor of OSCC (Reibel, 2003), with progression from hyperplasia, through the increasing 
grades of dysplasia to CIS and finally OSCC the postulated pathway (Guillaud et al., 2008).  
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Although cases of oral cancer may derive from clinically identifiable oral PMDs with 
dysplasia, some cases may also arise from clinically normal appearing mucosa or progress so 
rapidly they escape the detection of dysplasia (Cowan et al., 2001). It remains uncertain how 
many OSCCs arise from precursors and how many develop from apparently normal oral 
mucosa (Reibel, 2003; Hsue et al., 2007). Previous studies have shown that between 16% and 
62% of OSCCs are associated with or preceded by clinically detectable PMDs such as OL 
(Schepman et al., 1998; Lee et al., 2000; Reibel, 2003) providing a rationale for both 
localization and systemic causes (Lee et al., 2000). 
 
The annual MT rate of OL is between 0.1 to 17% (Johnson et al., 1996; Schepman et al., 
1998; Saito et al., 2001; Reibel, 2003; Lodi and Porter, 2008). It is believed that the 
differences in MT in different parts of the world are probably due to differences in ethnic, 
environmental factors and lifestyle risk factors, such as different tobacco and dietary habits 
(Gupta et al., 1989; van der Waal et al., 1997; Shiu et al., 2000; Reibel, 2003). The majority 
of variations in the assessments of MT rates may well be related to different inclusion criteria 
used in individual studies, geographical variation, habits, genetic variations and the varied 
follow-up times (Reibel, 2003) as well as clinical definitions that have been used in different 
studies (Lee et al., 2000). Therefore, future studies on oral PMDs should state in detail the 
clinical definition, inclusion criteria, diagnostic criteria, type of biopsy specimen, exclusion of 
possible etiologic factors, study population and the length of follow-up. 
 
Follow-up studies have shown that between 0.13% and 36.4% of OLs may transform into oral 
cancer after a follow-up period of 1 to 11 years (Pindborg et al., 1977; Gupta et al., 1980; 
Silverman et al., 1984; Gupta et al., 1989; Gregg et al., 1992; Bouquot and Whitaker, 1994; 
Lumerman et al., 1995; Schepman et al., 1998; Shiu et al., 2000; Cowan et al., 2001; 
Thomson and Wylie, 2002; Reibel, 2003; Shiu and Chen, 2003; Ishii et al., 2004; Chandu and 
Smith, 2005; Arduino et al., 2009). 
 
MT is thought to be time dependent and the overall risk of MT is dependent on the length of 
follow-up (Silverman et al., 1984), the longer the follow-up time a higher rate of MT may be 
detected. A retrospective study on the incidence of MT in OL performed by Lind (1987) 
showed that carcinoma developed in 11 out of the 157 patients but this 7% incidence 
increased to 8.9% when the same patients were followed prospectively for 6 more years. 
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In spite of different treatment modalities, the risk of MT is not completely eliminated and the 
number of disorders that are prevented from progressing to malignant development is 
unknown (Scully, 1995; Tradati et al., 1997; Lodi et al., 2002). 
 
Many factors have been found to be associated with an increased risk of MT. These factors 
were reported in several previous studies, and include the presence and grade of epithelial 
dysplasia (Banoczy, 1977; Pindborg et al., 1977; Kramer et al., 1978a; Gupta et al., 1980; 
Silverman et al., 1984; Karabulut et al., 1995; Lumerman et al., 1995; Schepman et al., 1998; 
Lee et al., 2000). Nevertheless, some dysplastic areas may remain clinically unchanged or 
may be even regress completely (Gupta et al., 1980) and MT may also take place in non-
dysplastic leukoplakia (Holmstrup et al., 2006). 
 
Clinical appearance of PMDs (Mashberg and Meyers, 1976; Banoczy, 1977; Kramer et al., 
1978b; Silverman et al., 1984; Lind, 1987; Gupta et al., 1989; van der Waal et al., 1997; 
Schepman et al., 1998; Reibel, 2003; Holmstrup et al., 2006), location at high-risk anatomical 
site such as tongue or the FOM (Mashberg and Meyers, 1976; Kramer et al., 1978b; 
Silverman et al., 1984; Gupta et al., 1989; Lesch et al., 1989; van der Waal et al., 1997; 
Schepman et al., 1998; Reibel, 2003) and size (Saito et al., 1999; van der Waal and Axell, 
2002; Holmstrup et al., 2006) were all found to play a role in MT of PMDs. 
 
Furthermore, female-sex, clinical extent and long standing disease, idiopathic leukoplakia 
(non-smokers leukoplakia), viral infection, and the presence of candida albicans have also 
been reported as predisposing factors (Gupta et al., 1980; Silverman et al., 1984; Gupta et al., 
1989; Bouquot and Whitaker, 1994; van der Waal et al., 1997; Schepman et al., 1998; Jaber et 
al., 1999; Reibel, 2003; Napier and Speight, 2008; Jaber, 2010). 
 
Factors that, statistically, carry an increased risk for MT are listed in Table 1.8. 
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Table 1.8: Factors predisposing to malignant transformation of oral leukoplakias. 
Factors Reference 
Dysplastic leukoplakia (mostly high grade 
dysplasia)  
(Schepman et al., 1998; van der Waal, 2009) 
Persistent long standing leukoplakia (van der Waal, 2009) 
Idiopathic leukoplakia; non-smoker leukoplakia (Napier and Speight, 2008; van der Waal, 2009) 
Non-homogenous leukoplakia (van der Waal et al., 1997; van der Waal, 2009) 
Leukoplakia in high risk sites; FOM, 
ventral/lateral tongue and soft palate 
(Zhang et al., 2001b; van der Waal, 2009) 
Female sex (Napier and Speight, 2008; van der Waal, 2009) 
Leukoplakia size more than 200 mm
2
 (Holmstrup et al., 2006) 
 
 
 
MT can be explained on the basis of field cancerization or field change theory. This concept 
was proposed by Slaughter in 1953 based on extensive histologic examination of dysplastic 
epithelium adjacent to invasive oral cancer. Such dysplasia may account for the relatively 
high incidence of second primary tumours in patients treated for OSCC (Slaughter et al., 
1953) and this has been cited to explain both the occurrence of multiple primary diseases and 
recurrence after complete surgical excision (Thomson and Wylie, 2002).  
The concept of cancerization is supported by various clinical, histopathological and molecular 
evidences, in which clinically normal control epithelium was compared with adjacent tumour 
tissue and demonstrated similar subcellular or biochemical changes (Ogden et al., 1993; 
Thomson, 2002). 
 
Carcinogenesis theories suggest that dysplastic change may occur in any area of mucous 
membrane exposed to a carcinogen, so patients with oral cancer and PMDs are at risk of 
developing multiple primary disease within the upper aerodigestive tract from the 
accumulation of genetic alterations of oncogenes and tumour suppressor genes (Choi and 
Myers, 2008). While some researchers have suggested that each tumour arises as biologically 
unrelated and clonally independent genetic mutations, others believe that multiple diseases 
arise due to widespread migration of clonally related cells (transformed cells) throughout the 
mucosa (Ogden et al., 1993; Jang et al., 2001; Tabor et al., 2002; Thomas et al., 2003). 
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The hypothesis of independent cell clones has been supported by data from microsatellite 
analysis, and p53 mutational analysis (Bedi et al., 1996; Lydiatt et al., 1998; Tabor et al., 
2002). However, other genetic analyses have shown that second or multiple cancers even if 
distant from the abnormal fields can be clonally related and derived from expansion of an 
original clone (Braakhuis et al., 2002). 
Field change can thus explain both recurrence and MT at the same site or new OED and 
cancer development at new oral subsites based on both clonally related and unrelated 
mutagenic cells.  
 
Malignant Transformation and Clinical Appearance of PMDs 
It has been shown that the clinical appearance of PMDs is an important predictor of MT 
(McCullough et al., 2010). Non-homogenous leukoplakia, in particular speckled and nodular 
subtypes showed an increase risk for MT. Studies have shown that 26% of carcinomas 
developed from sites of specked leukoplakia, while only 2% developed from other types of 
leukoplakia (Banoczy and Csiba, 1976; Banoczy, 1977). This has been supported by an 
earlier study conducted by Pindborg (1968) who investigated mouth carcinoma and found 
64% of cases arose from areas of speckled leukoplakia. Similarly, the nodular leukoplakia 
subtype showed a higher incidence of MT (Lind, 1987) and a 16% MT was demonstrated in a 
series of nodular leukoplakias followed-up over 8 years in India (Gupta et al., 1989). 
 
A study performed by Holmstrup et al. (2006) showed that 12% of surgically treated cases 
developed carcinoma after a mean follow-up period of 7.5 years (range 2.7–15.1 years) in 
which non-homogenous leukoplakia accounted for the majority compared with homogenous 
leukoplakias (20% vs. 3% ). This finding is consistent with previous results demonstrating a 
higher potential for malignant development of non-homogenous leukoplakias (Banoczy, 
1977; Silverman et al., 1984; Lind, 1987; Gupta et al., 1989; Schepman et al., 1998). 
 
It is well accepted that homogenous leukoplakias carry a lower risk for MT (Axell et al., 
1996); however, in a study to assess the clinical usefulness of laser surgery for OL conducted 
by Ishii et al. (2004), all cases of MT (4.12%) were seen in a flat white-spotted type 
leukoplakias (homogenous type), as they classified leukoplakias into flat type (white-spotted 
and erythroleukoplakia types) and a bulging type (hillock and verrucous type). 
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It is generally accepted that the non-homogeneous subtype of OLs, and those located on the 
tongue and FOM carry an increased risk of MT (Silverman et al., 1984; Gupta et al., 1989; 
van der Waal et al., 1997; Reibel, 2003). 
 
Malignant Transformation and Site Localization 
The lateral tongue and FOM, extending back to the lateral soft palate and tonsillar area 
combine to form a horseshoe-shaped region of the oral mucosa considered as a high-risk sites 
with an increased risk of cancer development compared to the remaining low-risk oral 
subsites (Mashberg and Meyers, 1976; Kramer et al., 1978b; Silverman et al., 1984; Gupta et 
al., 1989; Boffetta et al., 1992; Zhang et al., 2001b). The possible explanation for higher risk 
at these subsites may be due to the fact that these sites are lined by thinner non-keratinized 
epithelial mucosa with a higher permeability as indicated by experimental human studies on 
oral mucosa (Lesch et al., 1989) and less of a protective barrier against carcinogens pooled in 
saliva when compared to other areas of the oral cavity. 
 
The lateral tongue and FOM are characterized by a significant proportion of dysplastic 
changes mainly severe dysplasia compared to the other low-risk subsites (Flynn et al., 1988; 
Jaber et al., 1999). A reported MT of 13.6% of tongue lesions compared to 1.8% of gingiva 
has been reported in a hospital-based population study conducted by Ishii et al. (2004). 
 
Interestingly, it has been found that dysplasia in high-risk sites for MT, such as the FOM, 
ventro-lateral tongue and soft palate contain significantly higher frequencies of loss of 
heterozygosity at chromosomes 3p, 9p, and 17p, compared with other low-risk regions and 
that this pattern of loss is associated with an increased risk of progression to malignancy 
(Zhang et al., 2001b). 
The use of these markers, together with conventional histopathological examination, may be 
important for accurate prediction and effective management (Scully et al., 2003). 
 
Malignant Transformation and Risk Factors 
It is well documented that tobacco and alcohol are the principal etiological factors in the 
development of PMDs and oral cancer. However, results of studies have shown that OL 
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associated with non-smokers are more likely to undergo MT than OL of smokers (Pindborg et 
al., 1977; Gupta et al., 1980; Silverman et al., 1984; Lind, 1987; Hogewind and van der Waal, 
1988; Schepman et al., 1998; Reibel, 2003). 
 
In a study conducted by Silverman et al. (1984) of 257 patients with OL, 12% from the 183 
smokers developed carcinoma, whereas 32% from 74 non-smokers developed carcinoma. 
Schepman et al. (1998) investigated 166 patients with OL and found a statistically significant 
increased risk of transformation among female non-smokers compared to smokers. In a recent 
study performed by Jaber (2010), 4% of tobacco users and 10.8% of non-users transformed to 
malignancy after a 2-96 month follow-up period. 
 
The reasons for a lower rate of MT of leukoplakias associated with smoking are not clear. 
Since tobacco as a stimulating factor is absent in non-users, other strong carcinogenic agents 
may exist (Lee et al., 2006). However, a more likely explanation is that the multistage 
carcinogenesis pathway factors affecting the development of leukoplakias may be different 
from those responsible for MT (Lee, 2006). Also, non-tobacco users exhibiting leukoplakias 
may have intrinsically more unstable mucosa due to pre-existing genetic abnormalities, 
resulting in higher MT rate. 
 
However, Morse et al. (2007) reported that the association between tobacco smoking and 
dysplasia is at least as strong as the association between smoking and oral cancer, suggesting 
that smoking may influence oral carcinogenesis in stages prior to the MT of dysplasia to 
cancer. 
 
Although the role of alcohol in MT of OL has received little attention (Banoczy and Sugar, 
1972) a more recent hospital-based case-control study from Taiwan determined that alcohol 
intake, but not smoking, was strongly associated with the MT of OL to OSCC (Shiu and 
Chen, 2004). They concluded that smoking and betel quid were two significant risk factors 
for the occurrence of leukoplakia, whereas alcohol was significantly responsible for MT. In 
contrast, a study conducted in the Netherlands found no association between alcohol 
consumption and the MT of OL, but a statistically significant increased risk of transformation 
among female non-smokers compared to smokers (Schepman et al., 1998). 
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Malignant Transformation and Oral Epithelia Dysplasia  
It is generally accepted that OEDs have a greater tendency for MT (Silverman et al., 1984) 
and the more severe the dysplasia the greater the risk of progression (Banoczy and Csiba, 
1976; Silverman et al., 1984; van der Waal et al., 1997; Reibel, 2003). However, the grade of 
dysplasia alone is not a reliable predictor of prognosis (Lind, 1987), because not all cases in 
which dysplastic epithelium are present will progress to malignancy and some may even 
regress (Pindborg et al., 1977). It has been found that 6% of all OLs may transform over a 10 
year period, while histologically confirmed dysplasia may transform in 16–36% of cases 
(Lumerman et al., 1995). They may also regress at a rate between 10-30% (Hong et al., 1986; 
Papadimitrakopoulou et al., 2008). 
 
Epithelial dysplasia is an essential factor in determining the malignant potential of OLs (Hsue 
et al., 2007; Schaaij-Visser et al., 2010). Leukoplakias with dysplasia are more likely to 
progress to OSCC than those without dysplasia. Studies reported progression of OED to 
OSCC at rate from 6.6%-36.4% after mean follow-up period of 8.5 years (Pindborg et al., 
1977; Silverman et al., 1984; Gregg et al., 1992; Lumerman et al., 1995). 
 
It is generally accepted that the higher grade of OED is associated with higher rate of MT 
(Hsue et al., 2007). This is supported by a meta-analysis study conducted by Mehanna et al. 
(2009) who found that MT rate for mild to moderate dysplasia was 10.3% compared with 
24.1% for severe dysplasia and CIS. According to Lee et al. (2000), the risk in moderate or 
severe dysplasia appears to be at least double (2.3 times) that seen in mild dysplasia or 
hyperplasia. 
 
The current gold standard of histopathology is reasonably efficient in identifying malignant 
risk for severe dysplasia and CIS, of which 30 to 40% may undergo recurrence or MT even 
with aggressive surgical treatment (Vedtofte et al., 1987; Thomson and Wylie, 2002). 
Furthermore, a hospital-based study conducted by Holmstrup et al. (2006) showed that CIS 
was associated with the highest percentage of MT after surgical intervention (33%) compared 
to 9% in moderate or severe and 11% in mild dysplasia. 
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A further study conducted by Kujan et al. (2006) demonstrated that high-risk grades of OED 
tend to have higher rates of MT compared to low-risk OED grades; 84.2% of cases with 
either severe dysplasia or CIS developed an OSCC, while 15.8% of cases diagnosed with 
hyperplasia or mild dysplasia showed MT. 
 
According to Guillaud et al. (2008), however, the gold standard histopathology may be 
considered as a poor predictor for the majority of PMDs, particularly hyperplasia or mild-
moderate dysplasia in which most do not progress to cancer. Some authors do not attach 
much significance to mild dysplastic changes (Cruz et al., 1998; Lee et al., 2000); however, 
mild epithelial dysplasia demonstrated MT rates similar to severe dysplasia in a study 
conducted by Holmstrup et al. (2006) and this may challenge previous assumptions that mild 
dysplasias can be considered as harmless. 
 
Moderate or severe dysplasia and CIS are accepted to have the highest potential for MT, 
although, progression to cancer is not predictable (Banoczy and Sugar, 1972; Gupta et al., 
1980). This is discordant with the results reported by Holmstrup et al. (2006) who did not 
find a significant relationship between epithelial dysplasia and progression to oral cancer in a 
cohort of 269 leukoplakias. Similarly, Arduino et al. (2009) reported that histological grading 
had no significant value in predicting malignant development; OSCC may arise without a 
preceding dysplasia (Schoelch et al., 1999) and no significant tendency to increased MT with 
increased degree of dysplasia was seen. According to Holmstrup et al. (2006) the absence of 
accurate correlation between histological features of biopsy and the clinical outcome could be 
related to unrepresentative features of incisional biopsy specimens. 
 
Furthermore, MT rates by grade of dysplasia are difficult to establish (Brennan et al., 2007), 
because of the inherent subjectivity of the histopathological grading system which is a 
disadvantage of using existing histological criteria of dysplasia to predict transformation.  
Several studies have revealed low-to-moderate inter-observer agreement for the grade of 
dysplasia diagnosis amongst experienced oral pathologists (Abbey et al., 1995; Karabulut et 
al., 1995; Brothwell et al., 2003). In a study conducted by Hsue et al. (2007), only eight of the 
166 patients with OED (4.82%) underwent MT, and none of the severe dysplasias 
transformed during the follow-up study.  
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A study with CO2 laser surgery reported only 1% developing cancer over a mean one year 
period (van der Hem et al., 2005). The low figure for MT as compared with a similar study in 
an Irish population which quoted a 14% MT (Cowan et al., 2001) is mainly due to the short 
follow-up time (1 year) and a higher percentage of low grade dysplasia (83.13%) in the first 
study which is believed to be at low-risk of MT. 
 
From these data, one can understand that oral carcinogenesis is multifactorial and this may 
cause treatment failure. In spite of complete removal of clinically evident disease, the altered 
field may remain and the patient can develop recurrence, second primary disease or undergo 
MT. 
 
 
1.10.2. Recurrence 
Local recurrence is defined as the reappearance of PMD in the same site of the primary 
disease which was previously treated and which is confirmed by follow-up biopsy (Lim et al., 
2010).  
After surgical excision, recurrences are not uncommon irrespective of the time span between 
the excision and the recurrence event (van der Waal and Axell, 2002). Although there is some 
difficulty in comparing recurrence rates in different studies, the rate of recurrence is found to 
vary significantly between different types of surgical treatment, with the highest rate of 
recurrence associated with cryosurgery 71.4%, followed by laser vaporization 30.1%, 
excision surgery 25% and laser excision 22.2% (Ishii et al., 2004). 
 
According to Frame (1985), different surgical techniques, patient factors, and different patient 
follow-up periods may all be responsible for different recurrence rates. Previous reported 
recurrence rates for OL in laser surgery range from 7.7 to 38.1% (Frame et al., 1984; Vedtofte 
et al., 1987; Chu et al., 1988; Chiesa et al., 1990; Roodenburg et al., 1991; Chiesa et al., 1993; 
Schoelch et al., 1999; Thomson and Wylie, 2002; Ishii et al., 2003). This wide range variation 
of recurrence rates may be attributed to differences in the variety and conditions of the laser 
surgery, the follow-up time, geographical and racial variations (Ishii et al., 2004). 
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In one of the earliest studies of the CO2 laser being used to treat leukoplakia by ablation and 
excision, Frame et al. (1984) reported recurrent or new lesions in 13.6% of cases after 10 
months. Reported recurrence rates for PMDs were as high as 34.4% in a study conducted by 
Silverman et al. (1984). Also, one study found an 18% recurrence rate in cases of severe 
dysplasia or CIS which were all excised with 3-5 mm margins of normal tissue (Vedtofte et 
al., 1987). Chu et al. (1988) reported an initial recurrence rate of 10.8% with a 3-year local 
control rate of 97% after one to two laser excisions. A later study with CO2 laser surgery 
reported good prophylaxis with 10% local recurrence and 1% developing cancer over a mean 
one year follow-up period (van der Hem et al., 2005). 
 
It has been reported previously by Chiesa et al. (1990) that the recurrence rate of leukoplakia 
increases over time. In a study performed by Chandu and Smith (2005) the mean time to first 
recurrence/new lesion was 19.1 months, while the mean time to second recurrence was 22.5 
months. The median time to recurrence in a study conducted by Guntinas-Lichius et al. 
(2010) was 27 months (range 15–56 months). According to Thomson et al. (2008), most 
episodes of further disease occurred during the first 18 months following treatment. 
 
Removing all local diseased tissue and establishing clear resection margins is the ultimate aim 
of surgery. This may facilitate disease free recurrence and improve patient survival rates. 
Regarding resection margins, these are highly dependent on the biological and anatomical 
situation of the affected region and determined by both functional and aesthetic factors. 
However, there is no accepted standard for the amount of normal tissue to be removed and the 
effect of positive margins on local recurrence rates appears to be considerably dependent on 
the site of the disease. 
 
In spite of complete removal or laser vaporization, adjacent or peripheral dysplastic epithelial 
tissue may proliferate as a recurrence phenomenon, and such epithelial tissues which may 
show clinically normal features but consist of highly active cells are probably abundant 
within the oral mucosa of PMD patients (Ishii et al., 2004). Also, Frame et al. (1984) 
hypothesized that recurrence of leukoplakia might be due to migration of new epithelium 
from surrounding unstable oral mucosa. 
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A different explanation of recurrence has been proposed that deep nests of dysplasia may be 
left in situ after any surgical treatment (Lim et al., 2010) and it is therefore important to 
remove the full thickness of epithelium during ablative laser surgery (Cantarelli Morosolli et 
al., 2006).  
 
The recurrence of leukoplakia could also be related to the concept of field change or 
cancerization (Lim et al., 2010) in which the oral epithelial tissue within the area of field 
change could appear clinically normal. Thus, in such patients, recurrence may be 
unavoidable, regardless of the type of treatment because all surgical margins might be within 
an area of field change (Thomson and Wylie, 2002; Chandu and Smith, 2005). 
 
Moreover, the risk of recurrence may be also related to continue exposure to risk factors after 
treatment (Arduino et al., 2009) and reducing the alcohol intake and cessation of smoking 
could have the potential to reduce the incidence of recurrence (Poate and Warnakulasuriya, 
2006). However, it is estimated that it may take 10-15 years before the risk lessens 
significantly (Jaber et al., 1999). 
 
Whether recurrence is primarily related to continued exposure to risk factors or to the 
underlying mechanism that initiated the disease remains unclear, but all patients should be 
closely monitored for recurrence regardless (Jaber, 2010). 
 
 
1.11. Follow-up of PMD Patients 
Since oral PMDs have a definite but unpredictable tendency for transformation to oral cancer, 
close and regular follow-up of PMD patients, both treated and untreated cases, is warranted 
irrespective of clinical or histological characterisations. To date, there are no available 
universally accepted guidelines in the literature with regard to the intervals and frequency of 
follow-up examinations (van der Waal and Axell, 2002; Weijers et al., 2008) with follow-up 
strategies varying from immediate discharge to life-time recall (Epstein et al., 2007). Also, 
the true advantage of such follow-up appointments remains unproven (Weijers et al., 2008). 
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Follow-up time is measured from the date of diagnosis to the most recent follow-up or last 
contact with patients. It is generally accepted that the length and the duration of follow-up for 
PMD patients is greatly dependent upon both the clinical and histopathology features. 
 
In general, life-long follow-up examination is advised at 6–12 months intervals for both 
treated and untreated patients; although occasionally a non-treated patient with a dysplastic 
leukoplakia may need follow-up visits at 3-month intervals (van der Waal and Axell, 2002; 
Jaber, 2010). The recommended shorter follow-up interval for patients with non-treated 
dysplastic lesions is mainly due to the potential risk for MT as well as the possibility of 
developing secondary dysplasia from field change phenomenon. 
 
Different follow-up schedules have been reported by many research groups; Holmstrup et al. 
(2006) reported a follow-up schedule after the immediate postoperative period every 3 
months for the first 2 years and thereafter every 6 months during the following years and in 
case of recurrence, new biopsies were taken. In a study conducted by Arduino et al. (2009), 
patients were followed-up with varying intervals at 3, 6 or 8-months based upon clinical or 
histopathological features unless death of the patient occurred; new biopsies were taken in 
case of recurrence or any oncological event. 
 
According to Arduino et al. (2009), patients suffering from speckled leukoplakia and/or 
severe dysplasia were seen every 3 months, whereas those with homogeneous leukoplakia 
and/or mild-moderate dysplasia every 6 months. Li et al. (2011) followed patients for 5 years 
reviewing postoperatively every month for the first year, every two months during the second 
year, four-monthly during the third and fourth years and six-monthly thereafter.  
 
Longer follow-up time for patients with PMDs is recommended due to their potential MT and 
possibility of further disease events (Merkx et al., 2005). This is supported by a study 
conducted by Chandu and Smith (2005) who observed a fall in disease-free survival after 5 
years compared with 3 years post-interventions (33.9% vs. 55.4%). This gives a strong 
indication that disease active state such as recurrence, new disease or MT may occur 3 years 
after intervention.  
 
81 
 
Clearly, the main objective of follow-up is the early detection of recurrence, new disease 
formation or cancer development to offer patients a rapid, second curative therapy (Merkx et 
al., 2006). Also, follow-up can provide important information about the efficacy and the 
scientific value of treatment regimens for the benefit of patients in the future. In addition, 
psychological support of patients with functional or cosmetic problems as a result of 
destructive treatments may be facilitated (Merkx et al., 2006). 
 
The effective clinical surveillance of patients with PMDs requires careful oral examination 
which may be supported by clinical aids and recording of the clinical appearance and size of 
lesions with photography. However, the duration of follow-up and the frequency of routine 
visits after treatment are based on anecdotal regions rather than evidence-based practice.  
 
 
1.12. High risk / Low Risk Patients 
It is well accepted that higher-grade OEDs including moderate, severe dysplasia, and CIS 
have a greater chance of progression to OSCC (Neville and Day, 2002; Rosin et al., 2007), 
whereas mild dysplasia is a low-risk grade, with a lower risk of progress to cancer. The 
significance of dysplasia phenotypes as cancer risk prognosticators is well documented 
(Guillaud et al., 2008) and the strong association of marked dysplasia with increased risk of 
cancer progression has been observed and confirmed in multiple body sites such as lung, 
esophagus, breast, cervix, and skin; that is why histopathologic diagnosis of dysplasia is the 
current gold standard. 
 
PMDs in certain anatomic subsites such as the FOM, ventral and lateral tongue, soft palate 
and tonsillar pillar have been associated with a greater risk of cancer development (Mashberg 
and Meyers, 1976; Boffetta et al., 1992; Zhang et al., 2001b) and these locations were 
classified as high-risk sites whilst the remaining subsites were classified as low-risk 
(Jayaprakash et al., 2009). A greater proportion of high grade dysplasia was seen on the high-
risk anatomical sites (65%) compared with low-risk ones (35%) (Jayaprakash et al., 2009). 
In addition to dysplasia grade and localization of PMDs, lifestyle risk factors are also 
important parameters in the classification of the patient at high-risk or low-risk. 
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Assessment of the risk factors in PMDs patients may help to identify patients at higher risk of 
unfavourable clinical outcomes who require more extended care and surveillance. Also, 
stratification of patients may facilitate treatment planning for each group of patients which 
may subsequently minimize treatment failure by considering their demography, 
clinicopathological features and pre-existing or associated risk factors. 
 
Tobacco smoking and alcohol consumption are the two major confirmed risk factors for 
PMDs. However, according to Ho et al. (2007) not all individuals who smoke or drink 
develop OSCC; individual genetic susceptibility, differences in carcinogen-metabolizing 
enzyme function, mutagen sensitivity, apoptosis, and chromosomal aberrations either alone or 
in combination have been hypothesized to modify the risk of OSCC. 
Nearly all carcinogens and pro-carcinogens require activation by metabolizing enzymes. 
Similarly, detoxifying enzymes exist and deactivate carcinogens as well as their intermediate 
by-products; together these enzymes are termed xenobiotic-metabolizing enzymes. Genetic 
polymorphisms of these enzymes can modify an individual’s response to carcinogens and 
hence the carcinogenic potential of such exposures (Ho et al., 2007). 
 
One can understand that, patients with PMDs may be classified as either high-risk or low-risk 
based on the severity, location of dysplasia, the associated risk factors and individual genetic 
susceptibility. Clinical staging or classification of patients may allow clinicians to design 
treatment plans, compare results, and assess the likelihood of treatment success or determine 
the progress of individual disease. 
 
High-risk dysplasia in a high risk individual may be excised with wider surgical margins, 
while for patients with low-risk dysplasia observational treatment, perhaps with less frequent 
follow-up would suffice (Schaaij-Visser et al., 2010). The main challenge for early diagnosis 
of high-risk tissue is the limited ability to differentiate those at risk of progressing into 
invasive OSCC from those at low-risk (Guillaud et al., 2008). It is as so important to 
remember that some mild dysplasia cases may transform to oral cancer. 
 
The results of a randomized trial recommended periodic screening with regular surveillance 
of high-risk patient populations for early identification of PMDs and detection of the early 
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symptoms of malignancy (Sankaranarayanan et al., 2005). However, early malignant changes 
are often subtle with late clinical presentation of established tumours remains the norm.  
There is thus a real need for the development of a tool with a complementary diagnostic 
ability, objective, quantitative, and sensitive enough to differentiate between oral tissues at 
high tendency to progress to malignancy from non-progressing, low-risk ones. 
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Chapter Two: Study Aims, Objectives and Hypotheses 
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2.1. Study Aims 
The aims of this study were: 
1. To determine the socio-demographic and clinicopathological features of a cohort of 
patients with a single potentially malignant disorder (PMD), diagnosed and treated in the 
North-East of England in the Oncology/Dysplasia clinic in the Maxillofacial Unit at 
Newcastle General Hospital. 
 
2. To investigate the risk factors that influence the development and progression of PMDs, 
that may affect patient treatment outcomes. 
 
3. To determine the outcome of laser treated oral epithelial dysplasia and to identify the 
significant risk factors for recurrence, development of new-site dysplasia and cancer 
development of a long term follow-up cohort of patients with oral dysplastic PMDs. 
 
4. To investigate the suitability of the Raman spectroscopy (RS) for distinguishing 
dysplastic PMDs from morphologically normal tissue and whether RS is able to identify 
dysplastic tissue changes at early stages. 
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2.2. Study Objectives 
1. To build-up a database of clinical outcomes and histopathological features for patients 
treated in the North-East of England for PMDs of oral mucosa, using a retrospective patient 
record.  
 
2. Using archived tissue specimens, assess whether RS is an objective diagnostic tool by 
trying to detect changes in biochemical tissue structure of diseased tissues and comparing 
these changes with morphologically normal oral tissue, with the objective of trying to find 
biochemical tissue markers for early diagnosis of PMDs. 
 
 
 
 
87 
 
2.3. Study Hypotheses 
The null hypotheses behind the present study were: 
 
1. Analysis of clinicopathological findings from PMDs does not aid in the development of 
“high-risk”/”low-risk” classification systems to predict clinical outcome and direct clinical 
management protocols. 
 
2. The clinical outcome following PMD treatment is independent of patient demography, 
PMD clinical type, size, site, grade of oral epithelial dysplasia and risk factor assessment. 
 
3. Residual dysplasia found at resection margins of excisional specimens does not affect 
clinical outcome following laser excision of individual PMDs. 
 
4. Raman spectroscopy is unable to discriminate morphologically normal tissue from 
dysplastic tissue. 
 
5. Raman spectroscopy is unable to identify biochemical tissue changes associated with early 
dysplastic changes seen in PMDs. 
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Chapter Three: Potentially Malignant Disorders (PMDs): 
Demographic, clinical and histopathological features of a cohort 
of 100 patients, who were diagnosed, treated and reviewed at 
Newcastle General Hospital 
 
Study 1 
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3.1. Introduction 
Oral PMDs are mainly leukoplakias, erythroplakias, erythroleukoplakia, submucous 
fibrosis, lichen planus and actinic cheilitis as well as inherited cancer disorders (Napier and 
Speight, 2008; Rapidis et al., 2009; van der Waal, 2009). However, leukoplakia is the most 
common oral PMD (Gupta et al., 1980; Axell et al., 1996; Pindborg et al., 1997; van der 
Waal et al., 1997; Lee et al., 2006). PMDs convey that not all the disorders will transform to 
cancer and reflect a widespread anatomical distribution (Warnakulasuriya et al., 2007). 
PMD is able to correct the misunderstanding that the disease is associated with either a 
lesion or a condition; lesions imply cancer is more likely to occur in the same site, whilst 
conditions correspond to cancer development in any anatomical site (Warnakulasuriya et al., 
2007). Moreover, it is unknown precisely which lesions or conditions will undergo MT; 
therefore, PMD is the best clinical term to describe a group of disorders of morphologically 
altered tissues that have a higher tendency for MT than apparently normal tissue (Speight 
and Morgan, 1993; Axell et al., 1996; Warnakulasuriya et al., 2007; van der Waal, 2009). 
 
PMDs may exhibit variable degrees of epithelial dysplasia, which is the most important 
feature of PMDs (Reibel, 2003). Histologically, it is characterised by cellular atypia and loss 
of normal maturation and stratification (Pindborg et al., 1997; Gale et al., 2005). The 
diagnosis and grading of oral epithelial dysplasia is based on a combination of architectural 
and cytological criteria, but the evaluation of these features is subjective and depends on the 
pathologist’s experience. Thus, there is considerable inter-and intra-observer variations in 
grading (Abbey et al., 1995; Kujan et al., 2007) with Kappa values showing low to moderate 
agreement among even experienced oral pathologists (Pindborg et al., 1985; Abbey et al., 
1995; Karabulut et al., 1995; Brothwell et al., 2003; Kujan et al., 2007; Arduino et al., 
2009). 
 
At present, epithelial dysplasia is considered the most important predictor of MT in PMDs 
(Lumerman et al., 1995; Cowan et al., 2001; Reibel, 2003; Brennan et al., 2007); however, 
accurate prediction of clinical outcome for an individual patient is not possible (Napier and 
Speight, 2008), because not all dysplasia will undergo transformation to malignancy and 
some may be even regress or disappear. Also, malignancy may develop from non-dysplastic 
tissue (Pindborg et al., 1977; Silverman et al., 1984; Schepman et al., 1998; 
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Warnakulasuriya et al., 2008). The presence of dysplasia in oral epithelial tissue is believed 
to be associated with an expected progression to malignancy and there is a widely accepted 
concept that the more severe the dysplasia the greater the tendency for MT (Reibel, 2003). 
This may be related to the accumulation of chromosomal, genomic and molecular 
alterations within the affected tissues (Warnakulasuriya et al., 2008) associated with 
exposure to risk factors.  
 
Thus, understanding of the process of carcinogenesis and the associated risk factors is of 
great benefit to identify high-risk PMDs (Lee et al., 2006) and also to identify patients at 
increased risk. The carcinogenesis process may be initiated by carcinogens from lifestyle 
habits. The major risk factors of oral PMDs are generally believed to correspond to those of 
OSCC such as tobacco and alcohol use (Johnson et al., 1996; van der Waal et al., 1997; 
Lodi et al., 2002; Neville and Day, 2002). 
 
Tobacco smoking and excessive alcohol consumption are the major risk factors for OL, 
epithelial dysplasia and OSCC (Blot et al., 1988; Jaber et al., 1999). Approximately 75% of 
all oral cancers arise in association with tobacco and alcohol use (Llewellyn et al., 2003; La 
Vecchia et al., 2004) and OLs have been shown to occur up to six times more frequently in 
smokers than in non-smokers (Hogewind and van der Waal, 1988; Franceschi et al., 1992) 
in a dose-response relationship; increased risk is associated with an increased number of 
cigarettes smoked per day in leukoplakia (Roed-Petersen, 1982; Gupta, 1984; Evstifeeva 
and Zaridze, 1992) and epithelial dysplasia (Kulasegaram et al., 1995; Morse et al., 1996; 
Jaber et al., 1998; Jaber et al., 1999). Approximately 60% of OLs may disappear if patients 
stop smoking (Banoczy and Rigo, 1991), whilst continued exposure to risk factors may 
result in persistent disease (Arduino et al., 2009) and the possibility of developing 
carcinoma which is 50 to 100 times greater in smokers than in the general population 
(Cawson, 1975). 
 
The intention of clinical management is early diagnosis and treatment of PMDs which is 
crucial to prevent MT or recurrence after removal (Dietrich et al., 2004). In addition, it 
allows effective, less aggressive treatment with lower morbidity and reduced cost 
(Holmstrup et al., 2006; Epstein et al., 2007) as well as better prognosis and better quality of 
life (Warnakulasuriya et al., 2008). 
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Although various treatments modalities have been developed, currently, there is no 
consensus on the most successful and reliable one (Tradati et al., 1997; Zhang et al., 2001a; 
Jerjes et al., 2012) and treatment remains controversial, polarized between surgical removal 
or medical treatment with clinical observation. These modalities include change in patient 
lifestyle factors, such as tobacco use and alcohol consumption (Silverman et al., 1984; 
Gupta et al., 1995), medication with retinoids or antifungal agents (Boisnic et al., 1994; 
Tradati et al., 1994; Scully, 1995), surgical excision (Sako et al., 1972; Vedtofte et al., 1987; 
Lumerman et al., 1995), cryosurgery (Sako et al., 1972; Tal et al., 1982; Saito et al., 2001), 
laser vaporisation (Gooris et al., 1999; Ishii et al., 2004; van der Hem et al., 2005) or laser 
excision (Frame, 1985; Thomson and Wylie, 2002; Ishii et al., 2004). However, the outcome 
of these interventions appears to vary and long-term follow-up studies are warranted 
(Holmstrup et al., 2006). 
 
After surgical intervention, recurrences and development of cancer in the same sites have 
been previously reported in 10-20% and 2-9%, respectively (Vedtofte et al., 1987; Chiesa et 
al., 1993; Schoelch et al., 1999); however, no randomized clinical trials have been reported 
(Lodi et al., 2004). Identification of PMDs with high risk of recurrence or MT rate is 
essential in rationalisation of management of PMDs (Thomson et al., 2008). 
However, development of new disease at new sites remains a major problem within oral 
epithelium and is consistent with the field cancerization theory first described by Slaughter 
et al. (1953). The development of multiple disease sites due to carcinogenic exposure can 
cause simultaneous genetic defects in the upper aerodigestive tract epithelium putting the 
whole epithelium at high risk for multicentric disease which may develop synchronously or 
metachronously, resulting in complicated clinical management situations (Thomson and 
Wylie, 2002; Thomas et al., 2003; Thomson et al., 2006). 
 
This study investigates the demographic, clinical and histopathological features of a cohort 
of 100 patients with a single PMD with known clinical outcomes and was carried out to 
assess which patients are at high risk of further disease or MT. 
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3.2. Aim  
The aim of this study was to develop a new method to assess prognostic factors for patients 
with oral PMDs in the North-East of England after long term follow-up of laser intervention 
based upon demographical, clinical and histopathological features and utilizing known 
clinical outcome data. 
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3.3. Methods 
3.3.1. Study Design 
A retrospective cohort study was conducted after obtaining ethical approval from County 
Durham &Tees Valley 1 Research Ethics Committee on the 9
th
 of July 2009 (Appendix 1-
A). Patients with PMDs (leukoplakia, erythroplakia and erythroleukoplakia) and a 
histological confirmed diagnosis of oral epithelial dysplasia (OED) attending the Oral 
Oncology/Dysplasia clinics at the Maxillofacial Unit at Newcastle General Hospital were 
invited to take part in this study. After receiving a patient information sheet (Appendix 1-B) 
and explaining the study aims, patients signed a consent form (Appendix 1-C) and were 
enrolled into the study. Patients consented to use their medical records along with biopsy 
specimens previously used for diagnosis and routinely stored in the Pathology Department 
at the Royal Victoria Infirmary (RVI). Also, letters have been sent to general practitioners of 
patients who participated in this study (Appendix 1-D). 
 
All patients in this study underwent a standardised treatment plan by the same clinical team 
led by Professor Peter Thomson. Patients received an initial clinical oral examination, 
education about risk factor behaviour; an explanation of the role of MT of unstable mouth 
lining and all patients underwent laser interventional surgery to excise PMD lesions. 
 
Patients were followed-up post-laser intervention at Newcastle General Hospital, by regular 
appointments every month, 2 months, 3 months, 4 months, 6 months or every year 
depending on the need of each individual case. 
 
In this study, all patients at their initial examination and during follow up visits were 
provided risk factor advice, for example they were encouraged to stop tobacco smoking and 
reduce alcohol consumption. Candida infections identified by the presence of hyphae or 
pseudohyphae in periodic acid-Schiff-stained histological sections were treated with 
antifungal therapy. 
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3.3.2. Study Criteria 
Clinicopathological data were collected from both medical records and pathological reports 
of patients with PMDs treated and followed-up in the Oral Oncology/Dysplasia clinics at 
Newcastle General Hospital. 
 
The clinical diagnosis of the PMDs was based on the criteria adopted by the WHO and 
provided by Pindborg et al. (1997); van der Waal and Axell (2002). The histopathological 
diagnosis of oral epithelial dysplasia of laser excised tissue specimens was made using two 
classification systems: the WHO system (Gale et al., 2005): 
 Mild dysplasia, in which architectural disturbances are limited to the lower third of 
the epithelium accompanied with cytological atypia. 
 Moderate dysplasia, where the architectural disturbance extending into the middle 
third of the epithelium with a considerable degree of cytological atypia. 
 Severe dysplasia, in which architectural disturbance starts with greater than two-
thirds of the epithelium associated with significant cytological atypia. 
 Carcinoma in situ, which comprised full or almost full epithelial thickness 
architectural abnormalities in the cellular layers accompanied with marked 
cytological atypia. 
And the binary grading system, which comprised the categories of high and low grade 
dysplasia (Kujan et al., 2006). 
 
Primarily, pathological slides of the selected cases were collected from the pathological 
archive, reviewed and suitable paraffin blocks were selected. In the pathology department of 
the RVI, 10-micrometer-thick tissue sections were cut from the formalin fixed paraffin 
embedded tissue samples using a microtome, mounted onto a glass slide and stained with 
haematoxylin and eosin (H&E). The histopathological verification of the stained tissue 
sections were independently assessed by two experienced oral pathologists and then a 
consensus diagnosis of the grade of epithelial dysplasia was assigned and used in this study. 
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Selection of Patients 
100 patients with PMDs of the oral mucosa were recruited for the current study. 
 
Inclusion Criteria 
1) Patients with single oral PMD: leukoplakia, erythroplakia or erythroleukoplakia. 
2) Histopathologically confirmed OED. 
3) First presentation of oral PMD. 
4) No previous treatment for oral PMD. 
5) Known clinical outcome. 
 
Exclusion Criteria  
1) Patients with multiple PMDs. 
2) Patients with non-dysplastic lesions. 
3) Patients who did not undergo laser surgery. 
4) Previously treated patients. 
5) Patients with oral cancer.  
6) Patients who had previously undergone head and neck surgery, radiotherapy or 
chemotherapy.  
7) Patients who could not consent for themselves or patients with special communication 
needs or difficulties in understanding verbal or written information. 
 
3.3.3. Data Collection 
Demographical, clinical and histopathological data were collected at various time points 
starting from the first presentation as a baseline, during treatment, and at each follow-up 
point. 
The data collection, retention and management were all carried out according to Data 
Protection Act 1998 and Caldicott Principles. Data were stored in a university-based 
computer secured with password access. 
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For each patient, data were recorded in a standardised case sheet (Appendix 1-E) which 
included the following variables: 
 
1. Patient’s study number  
2. Age  
3. Sex 
4. Occupation; classified according to the International Standard Classification of 
Occupations (ISCO-08); Appendix (1-F). 
5. Civil status (married, single, divorced and widowed). 
6. Patient medical history.  
 Immunodeficiency 
 Diabetes mellitus 
 Anaemia 
 Candida infection 
 Hypertension 
 Familial cancer history  
 Other medical problems 
7. Clinical types of PMDs (Pindborg et al., 1997). 
 Leukoplakia  
 Homogenous leukoplakia 
 Non- Homogenous leukoplakia 
o Speckled  
o Nodular  
o Exophytic  
o Ulcerated 
 Erythroplakia 
8. Size of PMD in (mm2) (length x width) depending on excision biopsy report. 
9. Anatomical location of the PMDs according to the topographical code (ICD-10). 
1) Floor of the mouth (C04.0, C04.1) 
2) Tongue (C02.0, C02.1, C02.2) 
 Ventral tongue  
 Lateral tongue 
 Dorsal tongue 
3) Buccal (cheek) mucosa(C06.0) 
4) Soft palate (C05.1) 
5) Fauces (C09.1) 
6) Hard palate(C05.0) 
7) Retromolar area (C06.2) 
8) Gum(C03.0, C03.9) 
9) Alveolar mucosa 
10) Lips (C00.3, C00.4, C00.5, C006) 
 Lower lip 
 Upper Lip 
10. Risk factors assessment 
1) Tobacco smoking 
 Non-smoker 
(If the patient never smoked tobacco) 
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 Ex-smoker 
(If the patient stopped smoking for at least 1 year before initial presentation) 
o Length of smoking history  
o Number of cigarettes smoked per day  
 Current smoker (Regular smoker) 
o Length of smoking history 
o Number of cigarettes smoked per day 
2) Alcohol consumption 
 Non-drinker  
(Never drink alcohol)  
 Ex-drinker  
(If the patient stopped drinking for at least 1 year before initial presentation) 
o Length of drinking history 
o Number of units per week 
 Current drinker (Regular drinker) 
o Length of drinking history 
o  Number of units per week  
3) Type of diet  
 Processed, prepared food 
 Fresh fruit and vegetables. 
4) Oral hygiene 
 Good  
 Bad 
5) Mouth wash use 
 User 
 Non-user 
6) Oral prosthesis use 
 None 
 Full denture 
 Crowns and bridges 
 Upper or lower denture 
11. Initial diagnostic biopsy (incisional biopsy) 
 Pathology reference number 
 Time of biopsy 
 Histopathological diagnosis  
WHO classification system (2005) 
o Mild dysplasia (disorganisation affecting the lower third of the epithelium) 
o Moderate dysplasia (disorganisation affecting up to two- third) 
o Severe dysplasia (disorganisation affecting greater than two- third) 
o Carcinoma in situ (disorganisation affecting the whole epithelial thickness) 
12. Observational biopsy (incisional biopsy before any laser excision) 
 Number of biopsies carried out and pathology reference number 
 Date 
 Histopathological diagnosis 
13. Laser excision specimen 
 Pathology reference number 
 Date of laser surgery 
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 Histopathological diagnosis 
14. Surgical margin status  
 Free margins 
 Dysplastic margins 
o Mild dysplasia 
o Moderate dysplasia 
o Severe dysplasia 
o Carcinoma in situ 
15. Follow-up biopsies (incisional biopsies post-laser treatment for patient monitoring) 
 Number of biopsies carried out and pathology reference number  
 Date 
 Histopathological diagnosis 
16. Treatment after recurrence  
 Further laser intervention 
 Observation  
17. Clinical outcome 
 Clinical resolution (Disease-free) 
 Persistent (same site, same disorder) 
 Recurrence after treatment (same site of primary disease) 
o Time of recurrence 
o Number of recurrences 
 Development of new disease (new-site) 
o Time 
o New site 
 Malignant transformation (same site OSCC) 
o Time 
 OSCC development (new-site, new disease)  
o Time  
o location 
 Malignant events outside the oral cavity 
o Time  
o Location 
18. Follow-up after laser intervention 
o Length of follow-up 
o Frequency  
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3.3.4. Statistical Analysis 
Statistical analysis was performed with SPSS (Statistical Package for Social Sciences) 
version 17.0 and 19.0 software package (SPSS Inc; Chicago, IL, USA). Descriptive 
statistical analysis, the Chi-Square, Fisher’s Exact, Independent Paired Student T-test, 
analysis of variance (ANOVA) and bivariate correlation were used to compare the variables 
and find correlations. Non-parametric tests included the Mann-Whitney U and Kruskal-
Wills tests were also used when the data were not assuming a normal distribution. In 
addition, Kappa statistics to assess inter-observer variability in histopathological diagnosis 
and Kaplan-Meier analysis for cumulative survival were used. A p-value of less than 0.05 
was considered to indicate statistical significance. 
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3.4. Results 
A total of 157 medical records were reviewed in this study. However, according to study 
inclusion criteria, 57 patients were excluded due to the presence of multiple PMDs (n=20), 
development of oral cancer, or having undergone head and neck surgery, radiotherapy or 
chemotherapy (n=24), incomplete clinical outcome data (n=3) or lack of dysplasia in 
pathological reports (n=9) and one observational treatment case, leaving 100 patients 
available for the clinicopathological dataset analysis. 
 
100 patients with single dysplastic PMD were thus enrolled in this study. The age at first 
presentation ranged from 30-94 years with an overall mean age of 57.72 years (SD: 12.89). 
The cohort comprised mostly men, with a male to female ratio of 2: 1. The majority of our 
study population were retired followed by unemployed, while the remaining was classified 
according to the International Standard Classification of Occupations (ISCO-08); Appendix 
(1-F). 
 
Married patients formed the main civil group (62%), followed by single (19%), divorced 
(10%) and widowed (9%). 
The majority of the study population were current smokers (63%) followed by ex-smokers 
(22%) and non-smokers (15%). The majority of patients in this study were current drinkers 
(83%), followed by non-drinkers (14%) with the remaining 3% ex-drinkers. 
 
In relation to patients’ medical histories in our study population, hypertension occurred in 
60% followed by diabetes mellitus 14%, Candida infection 8%, anaemia 4% and 
immunodeficiency 1%. Also, a variety of other chronic medical conditions were observed in 
70% of our PMD patients, such as cardiovascular (28%), respiratory (19%), musculoskeletal 
(18%), liver (15%), psychological disorders (10%), nervous system disorders (8%), digestive 
system (7%), endocrine (6%), skin (4%) and renal related problems (3%) which is accounted 
for the least frequent conditions. 
 
The FOM was the most commonly affected anatomical site (46) followed by lateral (19) and 
ventral surfaces of the tongue (14), the soft palate (9), buccal mucosa (5), fauces (4), alveolar 
mucosa (2) and retromolar areas (1). 
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Clinically, 92% of PMDs presented as leukoplakia, while only 8% manifested as 
erythroplakia. Homogenous leukoplakia was the main clinical type of PMDs, followed by 
non-homogenous leukoplakia in which the speckled subtype was the most common. 
 
Histologically, in both incisional and excisional biopsies, the majority of PMDs were 
diagnosed as mild dysplasia (37%, 43%), followed by moderate (26%, 24%), severe (19%, 
10%) and CIS (18%, 10%). Males were more likely to have higher dysplastic features in their 
PMDs compared with females (55% vs. 48%).  
 
PMDs sizes were classified into 3 categories: minor (< 200 mm
2
), intermediate (200-600 
mm
2
) and major sizes (> 600 mm
2
); intermediate (45/97) and minor sized (42/97) were the 
most common, followed by major size group (10/97). 
 
 
3.4.1. Sex and Age 
Men were the most common in the study population. There were 66 males with a mean age of 
56.71 years (SD: 12.01), age range 30-81 years and 34 females with a mean of 59.68 years 
(SD: 14.45) and age range 33-94 years. 
 
Females tended to be older than male patients at initial presentation, however the difference 
was not statistically significant (p=0.279; Independent t-test). 
 
Patients were classified into 4 age categories: young, middle aged, old and elderly; (≤ 40), 
(41-62), (63-84) and (> 85) years, respectively; Figure 3.1. The majority of patients were 
found within the middle age group 56% (41 males and 15 females), followed by old 33% (19 
males and 14 females), young 10% (6 males, 4 females) and only one female was observed in 
the elderly age group. In this study, 90% of the PMD patients were older than 40 years. 
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Figure 3.1: Sex distribution according to age group. 
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3.4.2. Occupation and Marital Status of PMD Patients  
Data showed that out of 100 patients, 41 were retired, followed by 25 unemployed, while the 
remaining 34 of patients were classified according to the International Standard Classification 
of Occupations (ISCO-08). Service and sale workers represented 13, followed by craft and 
related trades workers (5); Figure 3.2. 
 
Males were the most common in retired, unemployed, service and sale workers, whilst no 
females were seen in craft and related trades, machine operators, professional and manager 
categories; Figure 3.3. An equal distribution of males and females in both clerical support 
workers and technician/associate professionals was observed. Females were more frequently 
seen in elementary work compared to males. 
 
Considering civil status, married patients formed the main group (62), followed by single 
(19), divorced (10) and widowed (9); Figure 3.4. 
Males represented the most common in married, single and divorced groups, whilst females 
showed the higher frequency in widowed group; Figure 3.5. 
Using Chi-Square test, a significant relation was found between sex and civil status; 78% 
(7/9) of widowed were females compared to 22% of males, while 71% (44/62) of married, 
70% (7/10) of divorced and 68% (13/19) of single were males compared to 29%, 30% and 
32% of females, respectively (p=0.001). 
Married patients were the most common in both middle and old age group; Figure 3.6. 
A significant relation was found between marital status and age groups; 65% (40/62) of 
married and 60% (6/10) of divorced were middle age, while 56% (5/9) of widowed were old 
age (p=0.002; Chi-Square test). 
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Figure 3.2: Distribution of 100 patients according to occupations. 
 
 
Figure 3.3: Sex distribution according to occupations. 
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Figure 3.4: Distribution of civil status of 100 PMD patients. 
 
 
Figure 3.5: Sex distribution according to civil status. 
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Figure 3.6: Age groups and civil status. 
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3.4.3. Anatomical Sites of PMDs 
In this study, single dysplastic PMDs within the oral cavity were mainly observed in the 
FOM, lateral tongue, ventral tongue, soft palate, buccal mucosa, fauces, alveolar mucosa 
and retromolar area. 
The data showed that FOM (46) was the most commonly affected site, followed by lateral 
tongue (19), ventral tongue (14%), soft palate (9), buccal mucosa (5), and fauces (4). 
Alveolar mucosa (2) and the retromolar area (1) were the least commonly affected oral 
subsites; Figure 3.7. 
For statistical analysis, anatomical subsites were combined to form five groups: FOM, 
tongue, buccal mucosa, soft palate and other sites (fauces, alveolar mucosa and retromolar 
area). Accordingly, PMDs were thus most frequently identified in FOM (46), followed by 
tongue (33), soft palate (9), buccal mucosa (5) and other sites (7). 
The sites were then combined to form two groups: high-risk sites (FOM and tongue) and 
low-risk sites (the remaining oral sites), accordingly the majority of PMDs were distributed 
among the higher-risk sites (79/100) compared with lower-risk sites (21/100); Figure 3.8. 
 
 
Anatomical Sites, Sex and Age  
Table 3.1 shows sex distribution according to the anatomical oral locations of dysplastic 
PMDs. FOM, ventral and lateral tongue surface were the main affected sites in both males 
and females. 
Males (66/100) were the predominant in all oral subsites compared with females (34/100). 
Ventral tongue and soft palate showed equal distribution in males; whilst buccal mucosa and 
fauces were equally distributed in females. In female patients, dysplastic PMDs were not 
observed in the soft palate, retromolar area or alveolar mucosa. 
 
Using Chi-Square test, a significant relation between sex and anatomical oral sites was 
found (p=0.0001); females showed a higher percentage of dysplastic PMD in FOM and 
lateral tongue compared to males (53%; 18/34 vs. 42%; 28/66) and (26%; 9/34 vs.15%; 
10/66), respectively. 
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Similarly, a statistical significant association between oral sites classified as high and low-
risk groups and sex was observed; dysplastic PMDs were more frequently recorded in males 
in both high-risk (47 vs. 32) and low-risk sites (19 vs. 2) compared with females (p=0.009; 
Fisher’s Exact test); Figure 3.8. 
 
Figure 3.9 demonstrates the distribution of age groups (young, middle and old age) 
according to the anatomical sites of single dysplastic PMDs. 
The FOM was the main affected anatomical site in all age groups; a significant relation 
between age and the anatomical sites was found; 80% (8/10) of patients younger than 40 
years old were observed with FOM compared to 46% (26/56) of middle age and 36% 
(12/33) of older age (p=0.010; Chi-Square test). 
 
Figure 3.10 shows the relationship between the anatomical sites of PMDs and age group 
classified as younger than 40 and older than 41 years. 
Patients ≤ 40 years showed mainly FOM dysplastic PMDs (80%), followed by buccal 
mucosa and soft palate (10% for each). Similarly, patients > 41 years showed mainly FOM 
dysplastic PMDs (42%), followed by tongue (37%), soft palate 9%, buccal mucosa and 
fauces equally 4%, alveolar mucosa 2% and retromolar area 1%. 
 
Although FOM was the commonest site of occurrence of PMDs in both ≤ 40 and > 41 years 
age group, the frequency was higher in younger patients (80% vs. 42%). Chi-Square test 
showed no significant association between PMD sites and age group (≤ 40 and > 41 years) 
(p=0.101). 
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Figure 3.7: Anatomical site distribution of PMDs. 
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Figure 3.8: Sex distribution according to high/low risk sites. 
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Table 3.1: Sex distribution according to PMD anatomical site. 
PMD anatomical site 
Sex 
Total 
Male Female 
 
FOM 
28 
61% 
18 
39% 
46 
100% 
Lateral tongue 
10 
53% 
9 
47% 
19 
100% 
Ventral tongue 
9 
64% 
5 
36% 
14 
100% 
Soft palate 9 - 
9 
100% 
Buccal mucosa 
4 
80% 
1 
20% 
5 
100% 
Fauces 
3 
75% 
1 
25% 
4 
100% 
Alveolar mucosa 2 - 
2 
100% 
Retromolar area 1 - 
1 
100% 
Total 66 34 100 
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Figure 3.9: Age group according to PMD anatomical sites. 
 
 
 
Figure 3.10: Site distribution of PMDs according to two age groups. 
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3.4.4. Clinical Appearance of PMDs 
In this study, as can be seen in Figure 3.11, dysplastic PMDs presented mainly as 
leukoplakias (92%) with only 8% as erythroplakia. Homogenous leukoplakias formed 67% 
and non-homogenous 25%, with males showed a higher percentage of non-homogenous 
leukoplakia compared to females (31%; 18/59 vs. 21%; 7/33), however, Fisher’s exact test 
was not significant (p=0.464); Table 3.2. 
 
Considering non-homogenous leukoplakias, speckled was the most common (16/25), 
followed by exophytic (5/25), nodular (2/25) and ulcerated (2/25) appearance.  
In general, all clinical types of PMDs were seen more frequently in males compared with 
females; Table 3.3. In females, 97% of PMDs were leukoplakias and only 3% were 
erythroplakias; whereas, in males, 89% were leukoplakias and 11% were erythroplakias. 
Comparing males to females, a higher percentage of speckled subtypes were seen in females 
(18% compared to 15%). 
Overall, all erythroplakia cases were observed in patients over 40 years old with 88% (7/8) 
identified in males compared to only 12% (1/8) in females. 
 
 
Clinical Appearance and Site Distribution of PMDs  
Table 3.4 shows that the FOM represented the most common site for homogenous 
leukoplakia (37/67), followed by equal distribution in both lateral and ventral surfaces of the 
tongue (11/67) and soft palate (5/67). 
 
In the FOM, the speckled subtype was the most common amongst non-homogenous 
subtypes (6/16), followed by pillar of fauces (3/16), whereas an equal distribution was seen 
in the lateral and ventral surfaces of the tongue and the soft palate (2/16). 
 
The nodular subtype was only seen in the ventral tongue and the buccal mucosa and in an 
equal distribution. The exophytic subtype was more frequently seen in buccal mucosa (2/5) 
but was also observed in FOM, lateral tongue and alveolar mucosa (1/4). Ulcerated PMDs 
were only seen on the lateral surface of the tongue (2/2). 
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Erythroplakia was seen most on the lateral tongue surface (3/8), followed by the FOM and 
soft palate (2/8) with retromolar area (1/8) the least affected site. 
 
Regarding high-risk and low-risk oral sites, homogenous leukoplakia was the commonest 
clinical appearance, followed by speckled leukoplakia and erythroplakia with higher 
percentage in high-risk sites. Although ulcerated PMDs were only identified in high-risk site 
(2/2), 60% of exophytic leukoplakias were seen in low-risk oral sites. Nodular lesions were 
equally seen in both high/low-risk regions; Figure 3.12 and Table 3.5. 
Using Chi-square test, a highly significant relation was found between clinical types of 
dysplastic PMDs and anatomical oral sites (p=0.0001); 55% (37/67) of homogenous 
leukoplakia and 38% (6/16) of speckled subtype were reported in the FOM. While 38% 
(3/8) of erythroplakia and all ulcerated cases (2/2) were seen in lateral tongue. 
 
Likewise, a significant association between clinical appearance and anatomical site as 
high/low-risk sites was found (p=0.002); 88% (59/67) of homogenous leukoplakia, 63% 
(10/16) of speckled and 63% (5/8) of erythroplakia and all ulcerated cases (2/2) were 
observed in high-risk sites. 
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Figure 3.11: Clinical appearance of PMDs at first presentation. 
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Table 3.2: Sex distribution according to type of leukoplakia. 
Types of leukoplakia 
Sex 
Total 
Male Female 
 
Homogenous 
41 26 67 
69% 79% 73% 
Non-homogenous 
18 7 25 
31% 21% 27% 
Total 
59 33 92 
100% 100% 100% 
 
 
 
 
Table 3.3: Sex distribution according to clinical appearance of PMDs. 
Clinical type of PMDs 
Sex 
Total 
Male Female 
 
Homogenous leukoplakia 41 26 67 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 10 6 16 
Nodular 2 - 2 
Exophytic 4 1 5 
Ulcerated 2 - 2 
Erythroplakia 7 1 8 
Total 66 34 100 
 
  
 
 
1
1
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Table 3.4: Distribution of clinical types of PMDs according to the anatomical sites. 
 
 Clinical type of PMDs 
Anatomical sites of PMDS 
Total 
FOM 
Lateral 
tongue 
Ventral 
tongue 
Buccal 
mucosa 
Soft 
palate 
Fauces 
Retromolar 
area 
Alveolar 
mucosa 
 
Homogenous 
leukoplakia 
37 11 11 1 5 1 - 1 67 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 6 2 2 1 2 3 - - 16 
Nodular - - 1 1 - - - - 2 
Exophytic 1 1 - 2 - - - 1 5 
Ulcerated - 2 - - - - - - 2 
Erythroplakia 2 3 - - 2 - 1 - 8 
Total 46 19 14 5 9 4 1 2 100 
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Figure 3.12: Clinical type of PMDs according to high and low risk sites. 
 
 
Table 3.5: Clinical type of PMDs according to high and low risk sites. 
PMD 
site 
Clinical appearance of PMDs 
Total Homogenous 
leukoplakia 
Non-homogenous leukoplakia 
Erythroplakia 
Speckled Nodular Exophytic Ulcerated 
High risk 
59 10 1 2 2 5 79 
88% 63% 50% 40% 100% 63% 79% 
Low risk 
8 6 1 3 - 3 21 
12% 38% 50% 60%  38% 21% 
Total 
67 16 2 5 2 8 100 
100% 100% 100% 100% 100% 100% 100% 
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3.4.5. Size of a Single Dysplastic PMD 
The size of a single PMD was recorded in mm
2
 by multiplying the length by the width, taken 
from the pathological report of the laser excised specimen. The data were recorded for 97/100 
(with 3 cases of laser vaporization). 
The size range was 21-1,800 mm
2
, with a mean of 299.97 mm
2
 (SD: 279.16). PMDs sizes 
were classified into 3 categories; minor (< 200 mm
2
), intermediate (200-600 mm
2
) and major 
sizes (> 600 mm
2
) with the intermediate (45/97) and minor size (42/97) were the most 
common, followed by the major size group (10/97); Figure 3.13. 
 
For statistical analysis, sizes were further classified according to the 75th percentile (third 
quartile) into 2 groups: < 425 mm
2
 and ≥ 425 mm2; 75% (73/97) of cases were found to be 
less than 425 mm
2 
in size and 25% (24/97) were more than 425 mm
2 
in size. 
 
 
Age and Size 
In all age groups, the majority of PMDs were intermediate and minor, followed by major 
sizes; 46%, 44% and 10%, respectively; Table 3.6. 
In the young age group, the majority of PMDs were minor (6/10), followed by intermediate 
(4/10), while no major sized PMD was observed. The old age groups demonstrated minor and 
intermediate sized PMDs equally (13/30), followed by major sized (4/30). Whilst in middle 
age patients, intermediate sized PMDs were the most common (27/56), followed by minor 
(23/56) and major sized (6/56). 
 
Although the mean size of PMDs was found to increase with increasing age, the correlation 
was not significant when considering the 4 age groups (r=0.151, n=98, p=0.137; Spearman 
Correlation); Table 3.7. However, the correlation was found to be significant between PMDs 
size and age when the 4 groups were compressed into 2 groups: > 41 and ≤ 40 years (r=0.222, 
n=98, p<0.01); Table 3.8. 
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Sex and Size  
Male patients were most commonly seen in all the size groups, with highest frequency in 
intermediate, minor and then major size categories; Figure 3.14. 
No significant association was found between sex and size groups (p=0.096, Chi-Square test). 
Consequently, a Mann-Whitney U test was performed which revealed no significant 
differences between males and females in their average size of PMDs (p=0.089); however, 
the mean size of PMDs in males (344.50 mm
2
, range 21-1,800 mm
2
) was greater compared to 
that of females (216.15 mm
2
, range 32-682 mm
2
). 
 
 
Site and Size  
Figure 3.15 and Table 3.9 show that the FOM was the main site for minor sized PMDs 
(23/46), followed by intermediate (22/46) and major sized (1/46). 
The lateral surface of the tongue was the main site for major sized PMDs (6/10), followed by 
the ventral tongue (3/10). The buccal mucosa and fauces showed an equal distribution of 
minor sized PMDs, similar to ventral tongue and soft palate. 
Using Chi-Square test, a significant association was found between size and PMDs oral sites 
(p=0.0001).  
 
Table 3.10 shows the average sizes of PMDs according to their oral subsites. Investigation 
the differences in the average size of PMDs among different oral locations showed a highly 
significant differences (p=0.0001; Kruskal-Wallis test). Subsequently, pair-wise comparisons 
were performed using Mann-Whitney U test which revealed a significantly smaller mean 
sized PMDs in the FOM (200.78 mm
2
) compared with the lateral tongue (591.63 mm
2
) 
(p=0.001) and to the ventral tongue (369.39 mm
2
) (p=0.034). 
 
Table 3.11 shows that major sized PMDs were only seen at high-risk sites (10/10), followed 
in frequency by intermediate (36/45) and minor sized PMDs (32/42). 
Low-risk sites exhibited minor (10/19) and intermediate sized PMDs (9/19), with no major 
sized PMDs were observed. However, no significant relation was seen between high/low-risk 
sites and size categories (p=0.301; Chi-Square test). 
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Using Fisher’s Exact test, a significant relation was found between high/low-risk sites and the 
size of PMDs as smaller than the third quartile (< 425 mm
2
), and bigger than the third 
quartile (≥ 425 mm2) (p=0.036). Whilst ninety-six percent (23/24) of PMDs larger than the 
third quartile were seen in the high risk-sites, 95% (18/19) of PMDs located in low-risk sites 
showed a smaller size than the third quartile (< 425 mm
2
); Table 3.12. 
 
 
Clinical Appearance and Size 
As can be seen in Table 3.13 and Figure 3.16, leukoplakia was the most prevalent type of 
PMD (89/97) in all size categories. 
Erythroplakia was only seen in 8 cases mainly in the minor sized group (5/8), followed by 
intermediate (2/8) and major (1/8). 
Considering the non-homogenous subtypes, speckled leukoplakia (13/16) was the most 
common type identified within the intermediate sized group. An equal distribution of 
speckled and exophytic subtypes was seen in the minor size category (3/42). Ulcerated PMDs 
(2) were only seen within the major size category (> 600 mm
2
). An equal number of nodular 
PMD was seen in intermediate and major size categories (1 for each). 
 
Forty-nine percent (31/64) of homogenous leukoplakia and 60% (3/5) of exophytic exhibited 
minor size PMDs, with 81% (13/16) of speckled intermediate and all ulcerated cases were 
major size PMDs.  
Using Chi-Square test, a significant relation was found between size and clinical appearance 
of PMDs (p=0.001). 
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Figure 3.13: Distribution of PMDs according to size categories (mm
2
). 
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Table 3.6: Distribution of PMD size according to age group. 
Age group 
(years) 
Size category of PMDs (mm
2
) 
Total 
Minor 
< 200 
Intermediate 
(200-600) 
Major 
> 600 
 
≤ 40 6 4 - 10 
41-62 23 27 6 56 
63-84 13 13 4 30 
≥ 85 - 1 - 1 
Total 
42 45 10 97 
44% 46% 10% 100% 
 
 
 
Table 3.7: Mean size of PMDs according to four age groups. 
Age group 
(years) 
Size of PMDs (mm
2
) 
Mean N Minimum Maximum SD 
≤ 40 160.90 10 32 450 156.425 
41-62 298.45 56 21 1,050 234.212 
63-84 345.16 30 36 1,800 367.870 
≥ 85 375.00 1 375 375 . 
Total 299.97 97 21 1,800 279.166 
 
 
Table 3.8: Mean size of PMDs according to two age groups. 
Age group 
(years) Mean N Maximum Minimum SD 
≤ 40 160.90 10 450 32 156.425 
> 41 315.77 87 1,800 21 286.155 
Total 299.97 97 1,800 21 279.166 
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Figure 3.14: Sex distribution according to size category. 
 
 
 
 
 
 
 
 
  
125 
 
 
Figure 3.15: PMD anatomical sites according to size (mm
2
). 
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Table 3.9: Size category of PMDs according to anatomical sites. 
PMD 
 anatomical sites 
Size category (mm
2
) 
Total 
Minor < 200 
Intermediate 
(200-600) 
Major > 600 
  
FOM 
23 22 1 46 
50% 48% 2% 100% 
Lateral tongue 
3 9 6 18 
17% 50% 33% 100% 
Ventral tongue 
6 5 3 14 
43% 36% 21% 100% 
Buccal mucosa 
1 4 - 5 
20% 80%  100% 
Soft palate 
6 2 - 8 
75% 25%  100% 
Fauces 
1 3 - 4 
25% 75%  100% 
Retromolar 
area 
1 - - 1 
100%   100% 
Alveolar 
mucosa 
1 - - 1 
100%   100% 
Total 
42 45 10 97 
44% 46% 10% 100% 
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Table 3.10: Mean size of PMDs according to anatomical sites. 
PMD  
anatomical site 
Size of PMD (mm
2
) 
N Mean Minimum Maximum SD 
Lateral tongue 18 591.63 105 1,800 403.115 
Ventral tongue 14 369.36 66 884 270.436 
Buccal mucosa 5 344.20 150 450 128.290 
Fauces 4 243.75 160 351 83.348 
FOM 46 200.78 32 620 146.324 
Soft palate 8 112.62 21 377 115.489 
Alveolar mucosa 1 92.00 92 92 - 
Retromolar area 1 60.00 60 60 - 
Total 97 299.97 21 1,800 279.166 
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Table 3.11: Distribution of high/low-risk sites according to three PMDs size groups. 
Size category  
(mm
2
) 
Anatomical site 
Total 
High risk Low risk 
 
Minor < 200 32 10 42 
Intermediate  
(200-600) 
36 9 45 
Major > 600 10 - 10 
Total 
78 19 97 
80% 20% 100% 
 
 
 
 
Table 3.12: Distribution of high/low-risk sites according to two PMDs size groups. 
Size category  
(mm
2
) 
Anatomical sites 
Total 
High risk Low risk 
 
≥ 425 
23 1 24 
96%  100% 
< 425 
55 18 73 
 95%  
Total 
79 19 97 
 100% 100% 
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Table 3.13: Clinical appearance of PMDs according to size category. 
Clinical appearance  
of PMDs 
PMD size category (mm
2
) 
Total 
Minor < 200 
Intermediate 
(200-600) 
Major > 600 
  
Homogenous leukoplakia 
31 27 6 64 
49% 42% 9% 100% 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 
3 13 - 16 
19% 81%  100% 
Nodular 
- 1 1 2 
 50% 50% 100% 
Exophytic 
3 2 - 5 
60% 40%  100% 
Ulcerated 
- - 2 2 
  100% 100% 
Erythroplakia 
5 2 1 8 
63% 25% 13% 100% 
Total 
42 45 10 97 
44% 46% 10% 100% 
 
 
 
Figure 3.16: Clinical appearance of PMD in relation to size (mm
2
). 
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3.4.6. Histopathological Features of PMDs  
Overall, the majority of excised dysplastic PMD specimens were diagnosed 
histopathologically as mild dysplasia 43% (42), followed by moderate 24% (23), severe 23% 
(22) and CIS 10% (10). Table 3.14 shows the histopathological diagnosis of both incisional 
and excisional biopsies according to the WHO classification system. 
According to the binary grading system, 54% of the PMDs were diagnosed as high-grade 
dysplasia and the remaining 46% were diagnosed as low-grade dysplasia as consensus 
diagnosis of two oral pathologists; Table 3.15. 
 
 
Table 3.14: Oral epithelial dysplasia: Incisional vs. Excisional. 
Oral epithelial dysplasia 
WHO grading 
Incisional  
Biopsy 
Excisional  
Biopsy 
 
Mild 
37 
37% 
42 
43% 
Moderate 
26 
26% 
23 
24% 
Severe 
19 
19% 
22 
23% 
CIS 
18 
18% 
10 
10% 
Total 
100 
100% 
97 
100% 
 
 
Table 3.15: Oral epithelial dysplasia: Binary grading system. 
Oral epithelial dysplasia 
Total The WHO grading  
system 
Binary grading system 
Low grade High grade 
 
Mild 42 - 42 
Moderate 3 20 23 
Severe - 22 22 
CIS - 10 10 
Total 45 52 97 
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Sex, Age and Oral Epithelial Dysplasia 
Generally, males were more frequently seen in all dysplastic groups compared with females; 
however, Chi-Square test showed no significant relation between sex and WHO 
histopathology consensus diagnosis of excisional specimens (p=0.502); Figure 3.17. 
 
Fifty–two percent of females (17/33) exhibited mild dysplasia compared to 39% (25/64) of 
males. Females showed higher percentage of severe dysplasia compared to males (24% vs. 
21%); whereas higher degree of moderate dysplasia and CIS were seen in males compared 
with females (27% vs.18%), (13% vs. 6%), respectively; Table 3.16. 
 
Regarding the binary grading system, 55% (35/64) of males were diagnosed with high grade 
dysplasia, while 52% (17/33) of females were diagnosed with low grade dysplasia; Table 
3.17. 
Fisher’s Exact test showed no significant association between sex and epithelial dysplasia 
classified as high/low grade dysplasia. 
 
Risk estimate showed that males were 1.13 times more likely to develop higher dysplastic 
features compared to females (95% CI, 0.744-1.711). 
 
A higher grade of dysplasia was seen in patients within the middle age group (41-62 years), 
but no significant relation was found between degree of oral epithelial dysplasia and age 
(p=0.643, Chi-Square test); Figure 3.18. 
 
Table 3.18 shows the mean age of patients with different degrees of oral epithelia dysplasia. 
Comparing the mean age of patients with different degrees of epithelia dysplasia, higher 
dysplastic features were observed with advancing age; however ANOVA test was not 
significant regarding WHO grading (p=0.393). Also, the correlation was not significant 
between age and oral epithelial dysplasia (r=0.179, n=97, p=0.080, Spearman Correlation); 
Figure 3.19. 
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Similarly with low grade and high grade dysplasia, higher grade dysplasia was seen with 
advancing age, but the differences between the mean age of patients with high and low grade 
dysplasia was not significant (p=0.323, Independent t-test). 
Seventy-percent (7/10) of mild dysplasia was seen in patients less than 40 years compared to 
only 40% (35/87) in patients older than 41 years; Table 3.19. 
 
Considering the binary grading system, 94% (48/51) of high grade dysplasia was recognized 
in patients older than 41 years compared to just 6% (3/51) in young age (≤ 40). While 70% 
(7/10) of patients younger than 40 years were affected with low-grade dysplasia; Table 3.20. 
However, no significant association between age group and binary grading system (p=0.184; 
Fisher’s Exact test). 
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Figure 3.17: Sex distribution according to degree of dysplasia. 
 
 
 
Table 3.16: Oral epithelial dysplasia (WHO grading) and sex. 
Sex 
Oral epithelial dysplasia 
(consensus grade) Total 
Mild Moderate Severe CIS 
 
Male 
25 17 14 8 64 
39% 27% 21% 13% 100% 
Female 
17 6 8 2 33 
52% 18% 24% 6% 100% 
Total 
42 23 22 10 97 
43% 24% 23% 10% 100% 
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Table 3.17: Oral epithelial dysplasia (binary grading) and sex. 
Sex 
Binary grading system 
Total 
High grade Low grade 
 
Male 
35 
55% 
29 64 
45% 100% 
Female 
16 17 
52% 
33 
48% 100% 
Total 
51 46 97 
53% 47% 100% 
 
 
 
 
Figure 3.18: Degree of dysplasia in relation to age group. 
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Figure 3.19: Mean age of patients in relation to degree of dysplasia. 
 
 
 
Table 3.18: Mean age of patients in relation to degree of dysplasia. 
Histopathology 
(WHO grading) 
Mean age 
(years) 
N Minimum Maximum SD 
Mild 55.12 42 30 94 13.978 
Moderate 57.96 23 39 81 12.568 
Severe 59 22 39 81 12.122 
CIS 62.1 10 47 76 9.938 
Binary grading 
Low grade 56.02 46 30 94 14.177 
High grade 58.63 51 39 81 11.622 
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Table 3.19: The WHO histopathological diagnosis and age group. 
Age group 
(years) 
Degree of dysplasia (WHO) 
Total 
Mild Moderate Severe CIS 
 
≤ 40 
7 2 1 - 10 
70% 20% 10%  100% 
> 41 
35 21 21 10 87 
40% 24% 24% 12% 100% 
Total 
42 23 22 10 97 
43% 24% 23% 10% 100% 
 
 
 
 
Table 3.20: Binary grading dysplasia and age group. 
Age group 
(years) 
Binary grading system 
Total 
Low grade High grade 
 
≤ 40 
7 3 10 
15% 6%  
> 41 
39 48 87 
85% 94%  
Total 
46 51 97 
100% 100% 100% 
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Anatomical Site and Oral Epithelial Dysplasia 
Table 3.21 shows histopathological diagnosis of dysplastic PMDs according to oral 
anatomical sites. 
Fifty-seven percent (24/42) of mild dysplasia was diagnosed in the FOM, followed by lateral 
tongue 21% (9/42) and ventral tongue 7% (3/42). Similarly moderate dysplasia was mostly 
seen in the FOM, followed by lateral and ventral tongue (35%, 22% and 9%, respectively).  
 
Severe dysplasia was seen more frequently in FOM 41% (9/22), followed by ventral tongue 
23% (5/22) and lateral tongue 18% (4/22). 50% (5/10) of CIS cases were identified in the 
FOM, with 30% (3/10) of CIS cases were seen in the ventral tongue. 
 
Severe dysplasia was the main dysplastic feature diagnosed in ventral tongue surface 23% 
(3/13). Moderate dysplasia was the main dysplastic feature in soft palate 22% (5/23) and mild 
dysplasia was the most commonly seen dysplasia in the FOM and lateral tongue. Using Chi-
Square test, a significant relation was found between degree of epithelial dysplasia and sites 
of PMDs (p=0.010). 
 
Table 3.22 shows the relation between high/low-grade dysplasia and PMD oral site. A 
significant association was seen between anatomical site and the binary grading dysplasia 
(p=0.010; Chi-Square test). The high grade dysplasias were mainly diagnosed in high-risk 
sites; 41% in FOM, 20% in both lateral and ventral tongue surface, 8% in soft palate and 6% 
in both buccal mucosa and fauces. All alveolar mucosa cases (2/2) were diagnosed as low-
grade dysplasia. High and low-grade dysplasias were equally observed in soft palate.  
 
Similarly, although 80% (41/51) of high-grade dysplasia was diagnosed in the FOM and 
tongue compared to 20% (10/51) at remaining oral sites, this did not reach statistical 
significance (p=0.342; Chi-Square test). 
 
Regarding high/low-risk sites in relation to dysplastic features, it is clear that all dysplastic 
features were more commonly seen in high-risk sites (FOM and tongue) compared to low-
risk sites (remaining oral sites), Chi-Square test was significant (p=0.026); Table 3.23. 
  
 
 
1
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Table 3.21: Anatomical site of PMD in relation to histopathological diagnosis. 
Histopathology 
(WHO grading) 
Anatomical site of PMDs 
Total 
FOM 
Lateral 
tongue 
Ventral 
tongue 
Buccal 
mucosa 
Soft 
palate 
Fauces 
Alveolar 
mucosa 
 
Mild 
24 9 3 2 2 1 1 42 
57% 21% 7% 5% 5% 2% 2% 100% 
Moderate 
8 5 2 1 5 1 1 23 
35% 22% 9% 4% 22% 4% 4% 100% 
Severe 
9 4 5 2 1 1 - 22 
41% 18% 23% 9% 5% 5%  100% 
CIS 
5 1 3 - - 1 - 10 
50% 10% 30%   10%  100% 
Total 
46 19 13 5 8 4 2 97 
47% 20% 13% 5% 8% 4% 2% 100% 
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Table 3.22: Anatomical site of PMDs according to high/low grade dysplasia. 
Histopathology  
(binary grading) 
Anatomical site of PMDs 
Total 
FOM 
Lateral 
tongue 
Ventral 
tongue 
Buccal 
mucosa 
Soft 
palate 
Fauces 
Alveolar 
mucosa 
Low grade 
dysplasia 
25 9 3 2 4 1 2 46 
54% 20% 7% 4% 9% 2% 4% 100% 
High grade 
dysplasia 
21 10 10 3 4 3 - 51 
41% 20% 20% 6% 8% 6%  100% 
Total 
46 19 13 5 8 4 2 97 
47% 20% 13% 5% 8% 4% 2% 100% 
 
 
Table 3.23: Degree of dysplasia in relation to high/low risk sites. 
Anatomical site of 
PMDs 
Histopathological diagnosis 
Total 
Mild Moderate Severe CIS 
 
High risk  
36 15 18 9 78 
86% 65% 82% 90% 80% 
Low risk  
6 8 4 1 19 
14% 35% 18% 10% 20% 
Total 
42 23 22 10 97 
100% 100% 100% 100% 100% 
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Clinical Types of PMDs and Oral Epithelial Dysplasia 
Overall, 98% (41/42) of mild, 91% (21/23) of moderate, 86% (19/22) of severe dysplasia and 
90% (9/10) of CIS appeared as leukoplakia. Erythroplakia manifested mainly in severe 
dysplasia 43% (3/7) and moderate 29% (2/7) and equally demonstrated in both mild and CIS 
14% (1/7); Figure 3.20. 
Using Chi-Square test, a significant association was found between the clinical appearance of 
PMDs (leukoplakia and erythroplakia) and the grade of oral epithelial dysplasia (p=0.035). 
 
As can be seen in Figure 3.21, leukoplakia was equally seen in both low and high grade 
dysplasia (45/90); whereas 86% (6/7) of erythroplakias were observed within high grade 
dysplasia compared to 14% (1/7) in low grade dysplasia. However, the association was not 
significant (p=0.115; Fisher’s Exact test). 
 
Considering homogenous and non-homogenous leukoplakia subtypes, the majority of 
homogenous lesions were diagnosed as mild dysplasia 53% (35/66), whilst the majority of 
non-homogenous were diagnosed as severe dysplasia 38% (9/24); Table 3.24. 
The relation between the grade of dysplasia and types of leukoplakia (homogenous and non-
homogenous) approached statistical significance (p=0.051; Chi-Square test). 
 
The majority of homogenous leukoplakias 58% (38/66) were diagnosed as low grade 
dysplasia, whereas the majority of non-homogenous leukoplakias were diagnosed as high 
grade dysplasia 71% (17/24); Figure 3.22. 
 
There was a significant association between high/low grade dysplasia and clinical types of 
leukoplakia (homogenous and non-homogenous) (p=0.031; Fisher’s Exact test). 
Also, risk estimate showed that non-homogenous leukoplakia was 1.67 times higher risk for 
high grade dysplasia compared to homogenous leukoplakia. 
 
Considering subtypes of non-homogenous leukoplakia, the speckled subtype showed mainly 
severe dysplasia 47% (7/15), followed by moderate dysplasia 27% (4/15). Ulcerated cases 
were equally observed in moderate and severe dysplasia (1/2); Table 3.25. However, no 
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significant association was found between the non-homogenous subtypes (speckled, 
exophytic, nodular and ulcerated) and the degree of dysplasia (WHO system) (p=0.792; Chi-
Square test). 
 
For the binary grading system, 80% (12/15) of the speckled subtype was diagnosed as high-
grade dysplasia. Similarly, ulcerated PMDs were only diagnosed as high-grade dysplasia 
(2/2); while exophytic non-homogenous leukoplakia was more commonly seen as low-grade 
dysplasia 60% (3/5). The nodular subtype was equally observed in low and high grade 
dysplasia (1/2); however, Chi-Square test showed no statistical significance (p=0.304); 
Figure 3.23. 
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Figure 3.20: Distribution of leukoplakia and erythroplakia according to degree of 
dysplasia. 
 
 
 
Figure 3.21: Distribution of leukoplakia and erythroplakia according to high/low grade 
dysplasia. 
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Table 3.24: Homogenous/non-homogenous leukoplakia in relation to degree of 
dysplasia. 
Histopathology 
(WHO) 
Leukoplakia type 
Total 
Homogenous Non-homogenous 
 Mild 
35 
53% 
6 
25% 
41 
 
 
Moderate 
14 
21% 
7 
29% 
21 
 
Severe 
10 
15% 
9 
38% 
19 
 
CIS 
7 
11% 
2 
8% 
9 
 
Total 
66 
100% 
24 
100% 
90 
100% 
 
 
 
Figure 3.22: High/low grade dysplasia in relation to type of leukoplakia. 
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Table 3.25: Degree of dysplasia and non-homogenous leukoplakia subtypes. 
Histopathology 
(WHO) 
Non-homogenous leukoplakia subtypes 
Total 
Speckled Nodular Exophytic Ulcerated 
Mild 
3 1 2 - 6 
20% 50% 40%  25% 
Moderate 
4 - 2 1 7 
27%  40% 50% 29% 
Severe 
7 1 - 1 9 
47% 50%  50% 38% 
CIS 
1 - 1 - 2 
7%  20%  8% 
Total 
15 2 5 2 24 
100% 100% 100% 100% 100% 
 
 
 
Figure 3.23: High/low-grade dysplasia and non-homogenous leukoplakia subtypes. 
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Sex, Clinical Types and Degree of Oral Epithelial Dysplasia 
Generally, a higher proportion of leukoplakia was found in both males (59/66) and females 
(33/34). However, erythroplakia presented as high as 88% (7/8) in males compared to 12% 
(1/8) in females; Table 3.26. 
However, the relation was not significant between sex and clinical appearance of PMDs 
(leukoplakia and erythroplakia) (p=0.259; Fisher’s Exact test). 
Homogenous and non- homogenous leukoplakias were more predominant in males compared 
to females. 72% of non-homogenous and 61% of homogenous leukoplakia was observed in 
males, whilst 28% of non-homogenous and 39% of homogenous leukoplakia was seen in 
females; Table 3.27. 
 
In female patients, homogenous and non-homogenous PMDs showed mainly mild dysplasia;  
54% of homogenous leukoplakia showed mild dysplasia, 8% CIS and the remaining 38% was 
divided equally between moderate and severe dysplasia. Similarly, 50% of non-homogenous 
leukoplakia was diagnosed as mild dysplasia, followed by 33% severe and 17% moderate 
dysplasia; Table 3.28. 
Using Chi-Square test, no significant relation was seen between homogenous/non-
homogenous leukoplakia and the degree of epithelial dysplasia in females (p=0.439). 
 
In males, 53% (21/40) of homogenous leukoplakia showed mild dysplasia; followed by 23% 
(9/15) moderate dysplasia, while severe dysplasia and CIS were equally diagnosed (13%; 
5/40 for each). Non-homogenous leukoplakia mainly exhibited severe (39%; 7/18) and 
moderate dysplasia (33%; 6/18); Table 3.29. 
A significant association was seen between homogenous/non-homogenous leukoplakia and 
the degree of epithelial dysplasia in males (p=0.003; Chi-Square test). 
 
Both males and females presented with higher proportion of speckled leukoplakia; 56% 
(10/18) of male patients and 86% (6/7) of females affected by speckled leukoplakia. While 
exophytic was more commonly seen in males 22% (4/18) compared to 14% (1/7) in females; 
nodular and ulcerated subtypes were only seen in males and in equal frequency (2/18); Table 
3.30. 
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Taking into consideration the binary grading system in male patients, as can be seen in Figure 
3.24 and Table 3.31; 83% (5/6) of erythroplakias in men were diagnosed as high grade 
dysplasia. Also, the majority of leukoplakia (52%) was identified as high grade dysplasia, 
although the relation was not significant (p=0.209; Fisher’s Exact test). 
Furthermore, in males 78% (14/18) of non-homogenous leukoplakias were diagnosed with 
high grade dysplasia, whilst the majority of homogenous was low grade 60% (24/40); Figure 
3.25 and Table 3.32. 
Using Fisher’s Exact test, a significant association between leukoplakia types (homogenous 
and non-homogenous) and binary grading dysplasia was found in males (p=0.011; Chi-
Square test). All ulcerated and 90% of speckled non-homogenous leukoplakia in males was 
identified as high-grade dysplasia; Figure 3.26 and Table 3.33. 
However, the relation between binary dysplasia and non-homogenous subtypes was not 
significant (p=0.078; Chi-Square test). 
 
In females, the majority of leukoplakias 53% were low grade dysplasia with one case of 
erythroplakia diagnosed as high-grade dysplasia; Figure 3.27 and Table 3.34. 
Fisher’s Exact test showed no significant relation between clinical type of PMD 
(leukoplakia/erythroplakia) and binary grading diagnosis in females (p=0.485). 
Female non-homogenous leukoplakia was equally distributed in both high and low-grade 
dysplasia, but the majority of homogenous leukoplakia (54%) was low grade dysplasia; 
Figure 3.28 and Table 3.35. Statistically, Fisher’s Exact test was not significant (p=1.000). 
 
Regarding the non-homogenous subtypes, 60% of speckled subtypes in females exhibited 
high grade dysplasia with only one exophytic subtype which showed low-grade dysplasia; 
Figure 3.29 and Table 3.36. Statistically, Fisher’s Exact test was not significant (p=1.000). 
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Table 3.26: Sex and clinical appearance of PMDs. 
Sex Leukoplakia Erythroplakia Total 
 
Male 
59 7 66 
64% 88% 66% 
Female 
33 1 34 
36% 12% 34% 
Total 
92 8 100 
100% 100% 100% 
 
 
Table 3.27: Sex and type of leukoplakia. 
Sex 
Leukoplakia clinical type 
Total 
Non-homogenous Homogenous 
 
Male 
18 41 59 
72% 61% 64% 
Female 
7 26 33 
28% 39% 36% 
Total 
25 67 92 
100% 100% 100% 
 
 
Table 3.28: Clinical type of leukoplakia and degree of dysplasia in females. 
Degree of dysplasia 
Leukoplakia clinical type 
Total 
Homogenous Non-homogenous 
  
Mild 
14 3 17 
54% 50% 53% 
Moderate 
5 1 6 
19% 17% 19% 
Severe 
5 2 7 
19% 33% 22% 
CIS 
2 - 2 
8%  6% 
Total 
26 6 32 
100% 100% 100% 
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Table 3.29: Clinical type of leukoplakia and degree of dysplasia in males. 
Degree of dysplasia 
Leukoplakia clinical type 
Total 
Homogenous Non-homogenous 
  
Mild 
21 3 24 
53% 17% 41% 
Moderate 
9 6 15 
23% 33% 26% 
Severe 
5 7 12 
13% 39% 21% 
CIS 
5 2 7 
13% 11% 12% 
Total 
40 18 58 
100% 100% 100% 
 
 
 
Table 3.30: Sex and non-homogenous leukoplakia subtypes. 
Sex 
Non-homogenous leukoplakia subtype 
Total 
Speckled Nodular Exophytic Ulcerated 
 
Male 
10 2 4 2 18 
56% 11% 22% 11% 100% 
Female 
6 - 1 - 7 
86%  14%  100% 
Total 
16 2 5 2 25 
64% 8% 20% 8% 100% 
  
149 
 
 
Figure 3.24: Leukoplakia and erythroplakia in relation to high/low grade dysplasia in 
males. 
 
 
 
Table 3.31: Leukoplakia and erythroplakia in relation to high/low grade dysplasia in 
males. 
Binary grading 
dysplasia 
Leukoplakia Erythroplakia Total 
 
Low grade  
 28 1 29 
 48% 17% 45% 
High grade  
 30 5 35 
 52% 83% 55% 
Total 
 58 6 64 
 100% 100% 100% 
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Figure 3.25: Types of leukoplakia and high/low grade dysplasia in males. 
 
 
 
Table 3.32: Types of leukoplakia and high/low grade dysplasia in males. 
Binary grading 
Leukoplakia clinical type 
Total 
Non-homogenous Homogenous 
 
Low grade 
4 24 28 
22% 60% 48% 
High grade 
14 16 30 
78% 40% 52% 
Total 
18 40 58 
100% 100% 100% 
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Figure 3.26: Non-homogenous leukoplakia subtypes according to high/low grade 
dysplasia in males. 
 
 
Table 3.33: Non-homogenous leukoplakia according to high/low grade dysplasia in 
males. 
Binary grading 
dysplasia 
Non-homogenous leukoplakia 
Total 
Speckled Nodular Exophytic Ulcerated 
 
Low grade 
1 1 2 - 4 
10% 50% 50%  22% 
High grade 
9 1 2 2 14 
90% 50% 50% 100% 78% 
Total 
10 2 4 2 18 
100% 100% 100% 100% 100% 
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Figure 3.27: Leukoplakia and eythroplakia according to high/low grade dysplasia in 
females. 
 
 
 
Table 3.34: Leukoplakia and eythroplakia according to high/low grade dysplasia in 
females. 
Binary grading 
dysplasia 
Leukoplakia Erythroplakia Total 
  
Low grade  
17 - 17 
53%  52% 
High grade  
15 1 16 
47% 100% 48% 
Total 
32 1 33 
100% 100% 100% 
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Figure 3.28: Leukoplakia types according to high/low grade dysplasia in females. 
 
 
 
Table 3.35: Leukoplakia types according to high/low grade dysplasia in females. 
Binary grading 
dysplasia 
Leukoplakia clinical type 
Total 
Non-homogenous Homogenous 
 
Low grade  
3 14 17 
50% 54% 53% 
High grade  
3 12 15 
50% 46% 47% 
Total 
6 26 32 
100% 100% 100% 
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Figure 3.29: Non-homogenous leukoplakia subtypes according to high/low grade 
dysplasia in females. 
 
 
 
Table 3.36: Non-homogenous leukoplakia subtypes according to high/low grade 
dysplasia in females. 
Binary grading 
dysplasia 
Non-homogenous subtypes 
Total 
Speckled Exophytic 
  
Low grade  
2 1 3 
40% 100% 50% 
High grade  
3 - 3 
60%  50% 
Total 
5 1 6 
100% 100% 100% 
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Size of PMDs and Oral Epithelial Dysplasia 
Figure 3.30 shows that the majority of minor sized PMDs 49% (20/41) and 44% (20/45) of 
intermediate sized PMDs were diagnosed with mild dysplasia. 50% (5/10) of major sized 
PMDs were diagnosed with severe dysplasia with only one case of mild dysplasia seen in the 
major size group. 
Chi-Square test indicated a significant relation between oral epithelial dysplasia (mild, 
moderate, severe and CIS) and size (minor, moderate and major) (p=0.029). 
Subsequently, Spearman correlation revealed a positive significant correlation between the 
degree of dysplasia and size of PMDs (r=0.272; n=96; p< 0.01), whereby increased size of 
PMD was associated with increased severity of epithelial dysplasia; Figure 3.31. 
 
Considering the mean size of PMDs, significant differences were observed among oral 
dysplasia groups (p=0.044; Kruskal-Wallis). Subsequently, Mann-Whitney U test was 
performed for pair-wise comparison and showed a significant difference between mild and 
severe dysplasia (239.44 vs. 375.70 mm
2
) (p=0.026) and between mild and CIS (239.44 vs. 
481.50 mm
2
) (p=0.027). 
 
Although there were clear differences in the mean size between mild/moderate, moderate 
/CIS, severe/CIS and moderate/severe, statistically Mann-Whitney U test showed no 
significance differences (p=0.796) (p=0.092) (p=0.477) (p=0.137), respectively. 
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Figure 3.30: Degree of dysplasia in relation to PMD size category (mm
2
). 
 
 
 
 
Figure 3.31: Mean size of PMDs in relation to degree of dysplasia.  
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3.4.7. Resection Margins  
The status of resection margins was recorded for 87 patients, whilst no data were reported for 
the remaining 13 patients of the study population. 
 
Surgical margins were clear in 44% (38). Residual dysplasia was reported in 56% (49) of the 
margins, distributed as 23% (20) mild, 15% (13) moderate and severe equally, and 3% (3) 
CIS; Figure 3.32. 
As shown in Figure 3.33, clear margins were commonly seen in mildly dysplastic PMDs, 
while margins with residual dysplasia were more frequently seen in PMDs with higher 
dysplastic features (moderate, severe and CIS). 
Figure 3.34 shows that mild dysplasia at the surgical margins was mainly seen in cases of 
mild dysplasia 60% (12/20), moderate dysplasia at the margin was mainly seen in moderate 
dysplasia cases 54% (7/13), severe dysplasia at the margin was usually seen in severe 
dysplasia cases 54% (7/13) and CIS at the resection margins was mainly seen in CIS cases 
68% (2/3). 
A highly significant association was found between histopathology of surgical margins and 
histopathology of laser excised tissue specimens (p=0.0001; Chi-Square test). Clear margins 
were mainly observed in mild dysplasia cases and decreased in frequency with increased 
dysplasia severity, whilst dysplasia at the resection margins was mostly the same grade of the 
excised lesion. 
 
Furthermore, 58% (21/36) of free-margins and 65% (13/20) of mildly dysplastic margins 
were seen in low grade dysplasia cases, while 77% (10/13) of moderately dysplastic margins, 
83% (10/12) of severely dysplastic margins and all margins with CIS (3/3) were observed in 
high grade dysplasia cases; Figure 3.35. 
 
Using Kaplan-Meier analysis, a clear fall in the overall disease-free survival rates of patients 
with dysplastic margins can be seen in the Kaplan-Meier curve showing in Figure 3.36. The 
disease-free survival rates 1-year, 2-years, 3-years and 5-years post-laser surgery for patients 
with dysplastic margins were 87%, 70%, 59% and 43%, respectively. Comparing the disease-
free survival rates of patients with free and dysplastic margins, Figure 3.37 shows lower rates 
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in cases with dysplastic margins than free-margins, 1-year (83% vs. 94%), 2-years (75% vs. 
81%) and 4-years (55% vs. 61%) postoperatively; however, Log-Rank test was not 
significant (p=0.337). 
 
A significant relationship was seen between the clinical extent of dysplasia and resection 
margin status (p=0.010; Chi-Square test); Table 3.37. Clear margins (23/40; 57%) were 
mainly observed in minor sized dysplasias compared with dysplastic margins (17/40; 43%). 
The majority of margins with residual dysplasia (6/9; 67%) were seen in major sized 
dysplasia compared to 33% (3/9) cases with clear margins. Similarly, for cases of 
intermediate size, 72% (26/36) showed dysplasia in the margins compared to 28% (10/36) 
with clear margins. 
 
Table 3.38 shows the relationship between the histopathology of resection margins and the 
size of the excised dysplasia; a highly significant association was found (p=0.005; Chi-
Square test). The majority of residual dysplasia in margins of minor sized cases (10/46) were 
mild dysplasia, followed by moderate and then severe dysplasia–CIS. Major sized cases were 
associated with higher grades dysplasia in the margins; 33% (3/9) severe dysplasia-CIS, 
followed by 22% (2/9) moderate dysplasia, whilst mild dysplasia was least common (11%; 
1/9). 
 
Four groups were defined according to the number of margins involved by residual dysplasia: 
one, two, three or four. The majority of cases only showed one margin involvement (61%; 
30/49), followed by four margins (17%; 8/49), three (10%; 5/49) and then two (12%; 6/49); 
Figure 3.38. 
 
Out of the 49 cases with dysplasia in the margins, 65% were male (32/49) and 35% (17/49) 
female. A significant relation was found between sex and degree of dysplasia in the margins 
(p=0.012; Chi-Square test); higher grades of dysplasia in the margins were mainly associated 
with male patients, whilst residual mild dysplasia was most commonly seen in females; 
Figure 3.39.  
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The extent of resection margin involvement was higher in males compared to females; Figure 
3.40. All three margin involvement cases, 75% of four margin, 67% of two margin and 57% 
of one margin involvement were all observed in males. However, the relation between sex 
and extent of dysplasia in the margins (number of margins involved) was only marginally 
significant (p=0.051; Chi-Square test). 
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Figure 3.32: Histopathological diagnosis of surgical margins of PMD patients. 
 
 
Figure 3.33: Resection margin status and PMD histopathology diagnosis. 
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Figure 3.34: Histopathological diagnosis of PMDs in relation to histopathological 
diagnosis of resection margins. 
 
 
Figure 3.35: Distribution of high/low grade dysplasia according to histopathology of 
resection margins. 
  
162 
 
 
Figure 3.36: Overall disease-free survival rate of dysplastic margins by Kaplan-Meier 
analysis. 
 
 
Figure 3.37: Kaplan-Meier analysis of patients with free and dysplastic margins.
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Table 3.37: Resection margin status in relation to PMD size category. 
Size of PMD 
(mm
2
) 
Resection margin status 
Total 
Free-margin Dysplastic 
  
Minor < 200 
23 17 40 
57% 43% 100% 
Intermediate 
(200-600) 
10 26 36 
28% 72% 100% 
Major > 600 
3 6 9 
33% 67% 100% 
Total 
36 49 85 
42% 58% 100% 
 
 
 
Table 3.38: Histopathology of resection margins in relation to PMD size category. 
Size of PMD 
(mm
2
) 
Histopathology of resection margins 
Total 
Free-margin  Mild Moderate Severe 
  
Minor < 200 
23 10 4 3 40 
57% 25% 10% 8% 100% 
Intermediate 
(200-600) 
10 9 7 10 36 
28% 25% 19% 28% 100% 
Major > 600 
3 1 2 3 9 
33% 11% 22% 33% 100% 
Total 
36 20 13 16 85 
42% 24% 15% 19% 100% 
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Figure 3.38: Distribution of margin involvement in dysplastic resection margins. 
 
 
Figure 3.39: Sex and resection margin histopathology. 
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Figure 3.40: Sex and the number of involved margins. 
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3.4.8. Inter-observer Variation between Pathologists 
To assess the variability between pathologists in grading oral epithelial dysplasia, a total of 
106 post-laser specimens were independently scored by 2 oral pathologists using both the 
WHO scoring system of mild, moderate, severe dysplasia, CIS and the binary grading system 
as high/low-grade dysplasia. 
 
The degree of agreement between the pathologists was characterized by Kappa statistics.  
For the WHO scoring, Kappa statistics showed a substantial agreement between the two 
pathologists (Kappa value=0.644, p< 0.001). 
As shown in Table 3.39, although a complete agreement between the 2 pathologists in 
grading CIS, the disagreement between the two oral pathologists was mainly seen in 10 
cases; 5 moderate, 4 severe cases with only 1 mild dysplasia. 
 
Considering the binary grading system, Kappa analysis showed also a substantial agreement 
between the two pathologists (Kappa value=0.756, p< 0.001); however, the Kappa value was 
higher compared with the WHO scoring system which indicates a higher agreement between 
pathologists using the two grading system. 
Table 3.40 shows that the 2 pathologists disagreed in 9 cases in high grade dysplasia which 
were scored as low grade dysplasia with similar number of cases in low grade dysplasia 
which were graded as high grade dysplasia. 
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Table 3.39: Crosstabulation of the WHO scoring of oral epithelial dysplasia of two oral 
pathologists. 
1
st
 pathologist 
(WHO scoring) 
2
nd
 pathologist (WHO scoring) 
Total 
Mild Moderate Severe CIS 
Mild 
42 5 - - 47 
89% 11%   100% 
Moderate 
4 17 4 - 25 
16% 68% 16%  100% 
Severe 
- 7 14 3 24 
 29% 58% 13% 100% 
CIS 
- 1 2 7 10 
 10% 20% 70% 100% 
Total 
46 
43% 
30 
28% 
20 
19% 
10 
9% 
106 
100% 
 
 
 
 
Table 3.40: Crosstabulation of binary scoring system of two oral pathologists. 
1
st 
pathologist 
(binary scoring) 
2
nd
 pathologist 
(binary scoring) 
Total 
Low grade High grade 
Low grade 
47 11 58 
81% 19% 100% 
High grade 
2 46 48 
4% 96% 100% 
Total 
49 57 106 
46% 54% 100% 
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3.5. Discussion 
Establishing an accurate and accessible dataset for oral PMD patients in the North East of 
England was an important aim of this study as it is vital for patients’ management by 
providing a baseline for comparison at follow-up appointments and comprises a unique data 
set for further investigations. 
 
The patient cohort in this study comprised more males (66%) than females (34%) (ratio 2: 1) 
which is in line with most previous studies (Silverman et al., 1976; Gupta et al., 1980; Axell, 
1987; Jaber et al., 2003; Jaber, 2010). 
The International Standard Classification of Occupations (ISCO-08) was used to classify the 
occupation of the study population, although the majority of patients were either retired 
(41%) or unemployed (25%). As expected, females were predominant in elementary work 
with males and females equally seen in clerical and technical work. Assessing the influence 
of different occupations on the clinicopathological features of PMDs was not feasible because 
of the small number of patients in each group. 
 
The study demonstrated that 90% of patients with dysplastic PMDs were over the age of 40 
years and 56% of patients were between 41-62 years, regardless of sex, which agrees with the 
results of other studies (Waldron and Shafer, 1975; Schepman et al., 1998; Jaber et al., 2003). 
This also supports a view that leukoplakia, the most common PMD, is not usually diagnosed 
before the age of 30-years, with it’s highest prevalence in the fifth decade (van der Waal et 
al., 1997). 
 
Excisional specimens are able to provide a much more representative tissue sample for the 
assessment of the degree of dysplasia compared to incisional specimens, which may be 
inadequate for definitive diagnostic purposes due to sampling errors (Goodson and Thomson, 
2011). Thus, in the present study, excisional specimens were used, with the highest dysplasia 
score recorded. 
Overall, mild dysplasia was the predominant dysplastic feature seen in our study sample 
(43/100) which is quite similar to the findings recognized in a study of Western European 
residents conducted by Jaber et al. (2003) (47%; 297/630). However, a lower proportion of 
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mild dysplasia 37% (167/456) was reported in a study of 456 patient hospital records with 
oral epithelial dysplasia (Jaber, 2010). Whereas a higher percentage of mild dysplasia (65%; 
135/207), was reported in a retrospective hospital-based study conducted by Arduino et al. 
(2009). Using incisional biopsies instead of excisional specimens in Arduino et al.’s study 
may explain the higher percentage of mild dysplasia compared to other studies. 
 
In this study, a higher grade dysplasia was observed with advancing age, but ANOVA test 
was not significant; 70% of mild dysplasias were identified in patients less than 40 years, 
whilst 60% of severe dysplastic features were recognized in patient older than 40 years. 
Likewise, 94% of high grade dysplasia was reported in patient older than 40 years and 70% 
of young patients were associated with low grade dysplasia. This is consistent with previous 
studies that showed higher dysplastic features affecting patients in their 50s and 60s 
(Lumerman et al., 1995; Arduino et al., 2009). 
 
Mild and severe dysplasia was more predominant in females, whilst moderate dysplasia and 
CIS was more commonly seen in males; however, the relation was not significant between 
sex, age and the degree of epithelial dysplasia which agrees with other studies (Jaber et al., 
2003; Arduino et al., 2009). The non-significant relation may be due to the small sample size 
in some dysplastic groups. 
 
In the current study, the majority of high grade dysplasia (81%) was identified at high-risk 
sites (FOM and tongue) compared to 19% in low-risk sites (all other remaining oral sites). 
 
In the present study, the FOM and lateral tongue surfaces were the most frequent sites for 
oral dysplastic PMDs. This is similar to the findings of Mincer et al. (1972), Thomson and 
Wylie (2002), and Hamadah (2007). Others have reported that buccal mucosa, FOM (Jaber et 
al., 2003); gingiva, tongue and palatal mucosa (Ishii et al., 2004); FOM, lip, tongue, and 
buccal mucosa (Lim et al., 2010) and lateral border of the tongue followed by the buccal 
mucosae (Arduino et al., 2009) are the most common sites for PMDs. The differences in the 
most common oral subsites may be related to geographical differences, race, and social habits 
(Ishii et al., 2004).  
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Male patients were common in all affected oral sites, although females showed a higher 
percentage of FOM and lateral tongue sites compared to males, whilst the soft palate, 
retromolar area and alveolar mucosa were not affected in female patients. In this study, a 
statistically significant relation between patient sex and site of dysplastic PMDs was found 
which is inconsistent with a study conducted by Jaber et al. (2003) who investigated the 
clinical characteristics of patients with oral epithelial dysplasia attended the oral medicine 
clinics in London and Bristol between 1972 and 1996. 
 
Considering site-distribution and the age of patients, 80% (8/10) of FOM cases were reported 
in patients ≤ 40 years compared to 42% (38/90) in patients > 41 years. This may support the 
view that all patients younger than 40 years were tobacco users, whilst patients > 40 years 
were a mixture of user and non-users. Similar to what has been reported by Schepman et al. 
(2001), that FOM leukoplakia was the most common lesion in tobacco smokers. 
 
In this study, the majority of cases presented as leukoplakias (92%) which agrees with Chadu 
and Smith’s study (2005). Most leukoplakias were homogenous (67%) with a smaller 
proportion of non-homogenous leukoplakias (25%) and erythroplakias (8%) which is in 
agreement with other studies (Jaber et al., 2003; Amagasa et al., 2006). However, Jaber et al. 
(2003) showed a higher incidence of non-homogenous leukoplakias and lower erythroplakias 
compared to this study, at 45% and 2% respectively. Holmstrup et al. (2006) reported a 
higher percentage of non-homogenous leukoplakias (49%) than homogenous type, with 
erythroplakia (9%) in accordance with this present study. 
 
Clinical appearance and localisation of PMDs was significantly associated in the present 
study. Ulcerated PMDs were only seen in the lateral tongue as a high-risk site, speckled 
leukoplakias and erythroplakias were more frequently reported in the FOM and lateral tongue 
as a high risk site, and 60% of exophytic subtypes were seen in low-risk sites, such as buccal 
mucosa, whilst nodular subtypes were only seen in ventral tongue and buccal mucosa. There 
is no clear explanation for the site predilection for specific clinical appearance of PMDs, but 
this may be due to the biology of each particular clinical type which favours a specific 
anatomical site. 
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In the present study, all erythroplakia cases (8/8) were reported in patients over 41 years old, 
with 88% (7/8) reported in males, 83% of which exhibited severe dysplasia (high grade 
dysplasia) compared to 12% (1/8) in female patients. Similar findings were reported by 
Scully (2004), although other studies have demonstrated no sex predilection (Shafer and 
Waldron, 1975; Hashibe et al., 2000a). There is no obvious reason why erythroplakia is more 
predominant in males and in patients over 41 years. 
 
Also, 72% of non-homogenous leukoplakia and 61% of homogenous leukoplakia were 
reported in male patients with 39% of non-homogenous leukoplakia exhibiting severe 
dysplasia (high grade dysplasia), whereas 53% of homogenous showed mild dysplasia (low 
grade dysplasia). 
 
Regarding the clinical appearance of PMDs and their degree of dysplasia, erythroplakia 
primarily showed severe dysplasia, with 86% of it observed in high-risk sites. 
In the current study, the relation between the degree of dysplasia and leukoplakia types was 
significant (p=0.031; Fisher’s Exact test). The majority of homogenous leukoplakia (58%) 
was identified as a low grade dysplasia in which mild dysplasia was most frequent (53%). 
The majority of non-homogenous leukoplakia (71%) was recognized as high grade dysplasia 
of which severe dysplasia was the most common (38%). 
 
This study has demonstrated that non-homogenous leukoplakia displayed a 1.7 times 
increased risk for high grade dysplasia compared to homogenous lesions. 80% of speckled 
non-homogenous subtypes were mainly diagnosed as high grade dysplasia, in which severe 
dysplasia formed the most frequent grade (47%). All ulcerated cases showed high grade 
dysplasia and 60% of exophytic subtypes were low grade dysplasia. These associations in our 
study were statistically significant and agree with a recent study conducted by Vazquez-
Alvarez et al. (2010) on the correlation between clinical and pathological diagnoses for OL in 
54 patients. 
 
Considering non-homogenous subtypes and sex, this study showed that all ulcerated and 
nodular cases, 80% of exophytic and 63% of speckled subtypes were seen in male patients, 
with all ulcerated and 90% of speckled showing high grade dysplasia. In females, no nodular 
  
172 
 
or ulcerated subtypes were seen, with the majority of speckled subtypes (60%) exhibiting 
high grade dysplasia. 
 
In the current study, the size of dysplastic PMDs was recorded by multiplying the length by 
the width of the laser excised specimens obtained from the pathological reports, which is 
similar to Holmstrup et al. (2006). It is worth noting that obtaining a precise measurement of 
microscopic specimens is problematic and shrinkage by 1 mm of specimens after formalin 
fixation is a general consensus amongst surgeons and pathologists (Huang et al., 2010). This 
shrinkage will affect all samples equally. However, taking the measurement from the 
histopathological report remains the most accurate method because recorded measurements in 
the medical records of patients are not always appropriately standardised. 
 
A positive correlation between lesion size and patient age was found in this study (r=0.222, 
n=98, p<0.01; Pearson correlation). The mean size increased with increasing age of patients; 
however, this correlation was is not significant when considering the four age groups, but was 
significant when the 4 age groups were compressed into two. Larger sized PMDs may have 
been present for a longer time compared to small size lesions (Napier et al., 2003) and this 
may explain the chronicity of the disorder with age. Male patients presented with greater 
mean sized PMDs compared to female patients (344.5 vs. 216.2 mm
2
), but this did not reach 
statistical significance. The bigger size of PMDs in males and with increased age has no 
obvious cause, but may reflect a general neglect of oral health by males compared to females. 
 
In the present study, the FOM was the main site for minor sized PMDs (50%), whilst lateral 
tongue was the principal site for major sized PMDs (55%). While no major sized PMDs were 
seen in low-risk sites, major sized PMDs were observed only at high-risk sites (10/10).  
A lower statistically significant mean size of PMDs in the FOM was seen compared to lateral 
and ventral tongue surfaces (200.8 vs. 591.6, 369.4 mm
2
), respectively. There is no clear 
explanation for the differences in the size of dysplasia affecting the tongue and the FOM. 
 
Considering the relation between clinical appearance and size, whilst 63% of erythroplakias 
were minor in size, a significant relation was found between size and non-homogenous 
subtypes, with 60% of exophytic minor sized, 81% of speckled subtypes intermediate in size, 
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and all ulcerated PMDs major sized. There is no clear reason for the differences in the sizes 
among the non-homogenous subtypes. 
 
The current study showed a positive significant correlation between the size of PMDs and the 
degree of oral epithelial dysplasia present, with an increased severity of dysplasia associated 
with larger sized PMDs. Histopathologically, 49% of minor sized and 44% of intermediate 
sized PMDs were associated with mild dysplasia, whilst 50% of major sized lesions showed 
severe dysplasia. A significant difference in the mean size of mild dysplasia from both severe 
dysplasia and CIS was observed; mild dysplasia was significantly smaller in size than severe 
dysplasia and CIS. However, differences in the mean size between mild-moderate, moderate-
severe, moderate-CIS and severe-CIS did not reach level of significance. Dysplasia severity 
may be related to a longer time of presentation and larger sized PMDs may be related to the 
chronicity of the PMD, perhaps explaining the observed relation between higher grade of 
dysplasia and larger sized PMDs. 
 
In this study, both the WHO (2005) and binary systems were used for grading oral epithelial 
dysplasia by two expert oral pathologists using a consensus diagnosis for both grading 
systems. A substantial agreement using Kappa statistics for both WHO and binary grading 
systems was seen; with an improvement in the pathologists’ agreement using the binary 
scoring system compared to the WHO system. This is clearly reflected by the higher kappa 
value for the binary system compared to the WHO (Kappa=0.756 compared to 0.644). 
 
The improvement in the pathologists’ agreement for the binary scoring system is consistent 
with a previous study (Kujan et al., 2006). The two-scoring scheme combines severe 
dysplasia, CIS and the majority of moderate dysplasia into high grade dysplasia, with mild 
dysplasia categorised as low grade dysplasia, providing an easier, less subjective system with 
better discriminatory powers than the WHO scoring system (Kujan et al., 2006). 
However, it is worth noting that poor to moderate inter-observer agreement, which can be 
related to subjective judgments and varied individual pathologist experience and which has 
been reported in several previous studies (Pindborg et al., 1985; Karabulut et al., 1995; Kujan 
et al., 2007), was not found in the current study and this is probably due to the highly expert 
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oral pathology team who assessed the grade of oral epithelial dysplasia in our study 
specimens. 
 
Microscopically, the resection margin was defined as the distance between the outer edge of 
the dysplastic tissue and the cut edge of the tissue specimen. In this study the resection 
margin status of 87 excisional specimens were obtained from histopathological reports but no 
data on margins were available for the rest of the cases. This was either due to the thermal 
damage of margins due to heating effect from laser intervention making the pathological 
reporting difficult (Jerjes et al., 2012) or the margin status was not recorded in the pathology 
report. 
 
The study showed that clear margins were reported in 44% of cases (38/87), while the 
remaining 56% (49/87) showed different grades of residual dysplasia. A significant 
association was found between margin status and the degree of dysplasia, with clear margins 
primarily seen in mild dysplasia cases. Interestingly, margins showing mild dysplasia were 
more frequently observed in mild dysplasia cases which were similar for moderate, severe 
and CIS margins which were all more commonly reported in lesions with the same grade of 
dysplasia. 
 
The clinical extent of dysplastic PMDs was significantly associated with resection margin 
status; clear resection margins were mainly seen in minor sized lesions whilst dysplastic 
margins were more frequently observed in major and intermediate sized PMDs. Similarly, a 
significant relation was found between the size of PMDs and the degree of dysplasia in the 
margin; major sized dysplasias primarily showed higher grades of dysplasias in their margins, 
whereas minor sized dysplasia frequently exhibited only mild dysplasia in the margins. These 
observations clearly reflect an association between the clinical extent of dysplasia and the 
risk of residual foci of dysplasia occurring in surgical margins. Since large size dysplasias 
may have been present for a long time, with subsequently more extensive dysplastic changes 
arising in the mucosa, removal of the entire disease becomes more difficult with an increased 
likelihood of incomplete surgical excision due to biological and anatomical restriction. 
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In this study, the extent of dysplasia in margins was also investigated; one margin 
involvement was the most common, followed by 4 margins, three margins and 2 margins 
involvement. Males were more frequently affected with dysplastic margins and more margin 
involvement with significantly higher grade dysplasia in their resection margins compared to 
females. This may be related to the fact that male patients had larger sized PMDs (344.5 vs. 
216 mm
2
) and exhibited more severely dysplastic features in their PMDs compared to 
females; however, this was not significant. 
 
In the present study, Kaplan-Meier analysis showed lower cumulative disease-free survival 
rates for patients with dysplastic margins compared to patients with free resection margins; 
the disease-free survival rate of patients with dysplastic margins dropped from 87% 1-year 
after laser intervention to 75% at 2-years, 65% at 3-years and 44% 5-years post-laser 
treatment. While disease-free survival rates of patients with non-dysplastic margins 1-year, 2-
years, 3-years and 5-years post-laser surgery, were 97%, 81%, 81% and 49%, respectively. 
This may suggest that the status of the resection margins is an important prognostication 
parameter and any dysplastic margin may require re-intervention or very close follow-up 
taking in consideration other clinicopathological and associated risk factors. 
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3.6. Conclusions 
1. Males were most common in our cohort, with a male to female ratio was 2: 1. 
2. Ninety-percent of our PMDs patients were over the age of 41 years. 
3. The majority of this study population were retired and married. 
4. The most common PMD sites in these patients were the FOM and lateral tongue surface. 
5. Females had the highest percentage of FOM PMDs (53%) and lateral tongue (26%) 
compared to males, at 42% and 15%, respectively. 
6. The soft palate, retromolar area and alveolar mucosa were not affected in female patients. 
7. Patients younger than 40 years exhibited the highest percentage of FOM PMDs compared 
to older age groups (80% vs. 42%). 
8. Patients younger than 40 years were mainly diagnosed with low grade dysplasia (70%). 
9. Patients older than 41 years were mainly affected by high grade dysplasia (94%).  
10. Higher dysplastic features were associated with advancing age.  
11. Erythroplakia is more predominant in males (88%; 7/8) and in patients over the age of 41 
years. 
12. Homogenous leukoplakias were the most common clinical presentation (67%). 
13. The majority of homogenous leukoplakias were identified as low grade dysplasias (58%). 
14. The majority of non-homogenous leukoplakias were diagnosed as high grade dysplasias 
(71%). 
15. Ulcerated PMDs were only seen in the lateral tongue (2/2), the site which was previously 
classified as a high-risk site. 
16. Erythroplakias and speckled leukoplakias were more frequently reported in the FOM and 
lateral tongue, the sites which were previously classified as high-risk sites. 
17. Exophytic subtypes were mainly seen in buccal mucosa (2/5), the site which was 
previously classified as a low-risk site. 
18. Nodular subtypes were only seen in ventral tongue and buccal mucosae. 
19. No nodular or ulcerated subtypes were seen in female patients. 
20.  All ulcerated and nodular cases were seen in male patients. 
21. The size of PMDs increased with increasing age of patients. 
22. The severity of dysplasia is associated with larger sized PMDs. 
23. Clear surgical margins were primarily seen in mildly dysplastic PMDs (60%). 
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24. Dysplastic margins were more frequently seen in PMDs with higher dysplastic features. 
25. Clear surgical margins were significantly observed in minor sized lesions. 
26. Major sized PMDs were significantly associated with higher dysplastic features in the 
margins. 
27. Mild dysplasia in the margins was mainly seen in minor sized PMDs. 
28. Males exhibited a higher number of margin involvement compared to females. 
29. Significantly, males showed higher dysplastic features in their dysplastic margins. 
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Chapter Four: Risk Factors of Patients with PMD in the North-East of 
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4.1. Introduction 
Oral squamous cell carcinomas may be preceded by PMDs which can be detected 
morphologically as leukoplakia, erythroplakia or erythroleukoplakia, reflecting the multi-step 
process of oral cancer development (Melrose, 2001; Brinkman and Wong, 2006; Williams et 
al., 2008). 
It has been estimated that one-third of oral PMDs progress to cancer (Saran et al., 2008). 
Thus, it is important to identify patients at risk of developing PMDs and to detect these 
disorders as early as possible. Current research efforts are aimed towards early identification 
of risk factor(s) associated with oral carcinogenesis and to recognize those patients at 
increased risk (Bloching et al., 2007). 
 
A risk factor is a variable that might be associated with an increased risk of a disease and it 
either acts as a disease initiator or promoter (Binnie, 1991). Risk factors for PMDs generally 
correspond to those of OSCCs (Dietrich et al., 2004). Assessment of potential risk factors is 
essential for early diagnosis and treatment of oral cancer and PMDs (Mawardi et al., 2011), 
and to help identify patients at risk of unfavourable clinical outcome and treatment failures 
such as recurrence or malignant transformation and who require extended surveillance.  
 
Several risk factors have been associated with the aetiology of PMDs and OSCCs, but 
tobacco smoking and alcohol use (Reichart, 2001) are the most important. They are 
independently and synergistically associated with high risk in a dose-dependent pattern (Blot 
et al., 1988; Castellsague et al., 2004).  
 
It has been suggested that the association between tobacco smoking and oral epithelial 
dysplasia is at least as strong as the association between smoking and oral cancer (Morse et 
al., 2007). However, the risk association for these preventable aetiological factors is not 
necessarily constant over the multi-step pathway of oral carcinogenesis (Morse et al., 2007). 
 
In the current study, the exposure profile of smoking and drinking behaviour including 
number of cigarettes smoked per day and the units of alcohol consumed per week, history of 
use and total lifetime accumulation (pack-year score) for tobacco smoking were all 
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considered. These exposure parameters were studied in relation to patient demography and 
clinicopathological features of PMDs such as oral anatomical site, clinical appearance, size 
and the presence of epithelial dysplasia. In addition, local factors (intraoral dental prosthesis 
wear) and the presence of systemic disease such as immunodeficiency, anaemia, diabetes 
mellitus, hypertension, a familial cancer history and oral candida infection were also 
investigated. 
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4.2. Aims 
The aim of this study was to identify the associated risk factors in patients presenting 
with new, single dysplastic PMDs and to investigate the possible relation and correlation 
with their clinicopathological behaviour in order to classify patients into high and low-
risk groups to aid future management protocols. 
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4.3. Methods 
Utilising the records of the 100 PMD patients, the presence of aetiological risk factors such as 
tobacco smoking, alcohol consumption, history of systemic disease and oral health status 
were identified. Data regarding risk factor assessment were collected from patients’ medical 
records at initial presentation and at each follow-up appointment up to the most recent clinic 
review. 
 
Patients were classified as non-smokers (if they had never smoked tobacco), ex-smokers (if 
the patient stopped tobacco smoking for at least 1 year before initial presentation) and current 
smokers (regular smokers). Data collected included the number of cigarettes or grams of 
tobacco smoked per day and the length of smoking history in terms of years.  
 
Regarding alcohol behaviour, patients were classified as non-drinkers (if they had never 
drunk alcohol), ex-drinkers (if the patient stopped drinking for at least 1 year before initial 
presentation) and current drinkers (regular drinkers). Data including the number of alcohol 
units consumed per week and the length of drinking history were recorded. 
 
For each patient in this study, the history of any concurrent medical problems, oral health 
status such as mouthwash use, the presence of dental prostheses (dentures, crowns and 
bridges) and a family cancer history were all recorded. 
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4.3.1. Statistical Analysis 
Statistical analysis was performed with SPSS (Statistical Package for Social Sciences) 
version 17.0 and 19.0 software package (SPSS Inc; Chicago, IL, USA). Descriptive statistical 
analysis, the Chi-Square, Fisher’s Exact, Independent/Paired Student T-test, ANOVA and 
bivariate correlation were used to compare the variables and find correlations. Non-
parametric tests including Mann-Whitney U and Kruskal-Wills tests were also used when 
data did not assume a normal distribution. In addition, logistic regression analysis with the -2 
log likelihood ratio test statistic was performed to identify the significant predictor(s) for non-
homogenous leukoplakia and for high grade dysplasia to develop. A p-value of less than 0.05 
was considered to indicate statistical significance. 
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4.4. Results 
4.4.1. Tobacco Smoking Behaviour in PMD patients 
At initial presentation, 63 out of the 100 patients (46 males and 17 females) were current 
smokers, followed by 22 ex-smokers (15 males and 7 females); only 15 were non-smokers (5 
males and 10 females); Figure 4.1. 
 
Current smokers were divided into 3 groups according to the number of cigarettes smoked 
per day: light (< 10), intermediate (10-20) and heavy smokers (> 20). Overall, intermediate 
smokers were most common (60%; 38/63), followed by heavy smokers (37%; 23/63) and 
light smokers (3%; 2/63); Figure 4.2. 
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Figure 4.1: Distribution of 100 PMD patients according to smoking status. 
 
 
 
Figure 4.2: Current smoker categories according to the number of cigarettes. 
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Age, Sex, Occupation and Smoking Status  
Overall, significant differences were found in mean age between current smokers and both 
non-smokers and ex-smokers (p=0.0001, One way ANOVA), whilst no significant 
differences were found between non-smokers and ex-smokers (p=0.998). Current smokers 
(mean age, 52.27 years; SD: 9.73) were younger than both non-smokers (66.87 years; SD: 
15.53) and ex-smokers (67.09 years; SD: 10.14). 
 
All patients ≤ 40 years were tobacco users, with 90% current smokers and 10% ex-smokers. 
In middle age (41-62 years), the majority of patients were current smokers (80%), followed 
by 11% ex-smokers and 9% non-smokers. In old age (63-85 years), ex-smokers were most 
common (46%), followed equally by current and non-smokers (27% for each). In this study, 
there was only one elderly patient (> 85 years) who was a non-smoker; Figure 4.3.  
 
A significant relation was also found between smoking status and sex (p=0.014; Chi-Square 
test). Current smokers were predominantly males 73% (46/63) with the remaining 27% 
(17/63) females. Similarly, the majority of ex-smokers 68% (15/22) were males compared to 
32% (7/22) females, whilst non-smokers were mainly females 67% (10/15) compared to 
males (33%; 5/15); Figure 4.4. 
 
Female current smokers were significantly younger than both non-smokers and ex-smokers 
(mean age 52.47 years vs. 68.20 years, 65 years), (p=0.004, p=0.021, respectively). No 
significant differences were observed in mean age between non-smokers and ex-smokers 
(p=0.740; Independent t-test). 
Similarly, male current smokers had a significantly lower mean age compared to ex-smokers 
(52.20 years vs. 68.07 years) (p=0.0001), whereas the differences between current smokers 
and non-smokers (52.20 years vs. 64.20 years) (p=1.000) and between non-smokers and ex-
smokers were not significant (64.20 years vs. 68.07 years) (p=0.624). 
 
A highly significant association was found between smoking status and employment status 
(employed, unemployed or retired) (p=0.0001; Chi-Square test). The majority of employed 
and unemployed patients were current smokers, whilst the majority of retired patients were 
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ex-smokers. Eighty-eight percent (22/25) of unemployed patients were current smokers, 
compared to 74% (25/34) of employed and 44% (18/41) of retired patients; Figure 4.5. 
 
Table 4.1 shows the relation between occupation status and number of cigarettes smoked per 
day. Using Chi-Square test, a significant relation was found between occupational status and 
the intensity of smoking (p=0.032). Employed patients were mainly heavy smokers 44% 
(11/25), unemployed often intermediate smokers (68%; 15/22), and retired patients only light 
smokers (2/2). Retired patients smoked the least number of cigarettes per day (mean 18, 
range 7-30) compared to both unemployed (mean 25, range 10-60) and employed patients 
(mean 25, range 10-50). 
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Figure 4.3: Age group according to smoking status. 
 
 
 
Figure 4.4: Sex distribution according to smoking status. 
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Figure 4.5: Smoking status according to occupation of PMD patients. 
 
 
 
Table 4.1: Occupational status according to the number of cigarettes. 
Tobacco smoking 
(cigarettes/day) 
Occupational status 
Total 
Employed Unemployed Retired 
 
< 10 
- - 2 2 
  100% 100% 
10-20 
14 15 9 38 
37% 39% 24% 100% 
> 20 
11 7 5 23 
48% 30% 22% 100% 
Total 
25 22 16 63 
40% 35% 25% 100% 
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Smoking Status and Anatomical Site 
Figure 4.6 and Table 4.2 summarise the relation between smoking status and PMD 
anatomical sites. Using Chi-Square testing, a significant relationship was found between 
smoking status and anatomical site (p=0.0001). 
Out of 63 current smokers, 38 (60%) displayed FOM PMDs, followed by soft palate (7/63) 
and ventral tongue (6/63); whereas an equal distribution of PMDs were observed in lateral 
tongue, buccal mucosa and faucial pillars (4/63 for each). 
 
In non-smokers, 93% (14/15) of PMDs were seen in the tongue (9 lateral and 5 ventral 
surfaces); with the remaining one non-smoker case seen in buccal mucosa. 
PMDs in ex-smokers were mainly observed in the tongue (9/22; 6 lateral and 3 ventral 
surfaces), followed by the FOM (8/22). No PMDs were seen in the buccal mucosa and fauces; 
PMDs in the retromolar area and alveolar mucosa were only seen in ex-smokers.  
PMDs in the soft palate were seen in tobacco users: current smokers (78%; 7/9), followed by 
ex-smokers (22%; 2/9), but not in non-smokers. 
 
Considering high-risk (FOM and tongue) versus low-risk sites (all remaining other sites), 
there was no significant difference (p=0.104; Chi-Square test), although high-risk sites were 
predominant in all smoking groups; Figure 4.7. 
 
Different site predilections in smokers and non-smokers were seen, with FOM most 
frequently affected in current smokers, and tongue more common in non-smokers. However, 
both FOM and tongue were similarly affected in ex-smokers (8/22) and (9/22), respectively; 
Table 4.3. 
 
Figure 4.8 and Figure 4.9 demonstrate sex-site distribution in relation to smoking status. A 
significant association was found between smoking status and sex (p=0.014; Chi-Square test). 
Both male and female non-smokers showed no FOM PMDs, with the tongue the only 
affected site in non-smoker females and 80% of non-smoking males. The FOM was mainly 
affected in current smokers in both females and males (82%; 14/17 and 52%; 24/46, 
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respectively). The tongue was the main affected site in male ex-smokers (6/15), whereas 
FOM was the most commonly affected site in female ex-smokers (4/7).  
Current smokers younger than 40 years more frequently developed FOM PMDs (7/9), but 
with no tongue lesions, whilst patients older than 41 years showed PMDs in both FOM 
(31/54) and tongue (10/54). 
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Figure 4.6: PMD anatomical site in relation to smoking status. 
 
Table 4.2: PMD anatomical site in relation to smoking status. 
PMD anatomical sites 
Smoking status at first presentation 
Total 
Non-smoker 
Current 
smoker 
Ex-smoker 
 FOM - 38 8 46 
Lateral tongue 9 4 6 19 
Ventral tongue 5 6 3 14 
Buccal mucosa 1 4 - 5 
Soft palate - 7 2 9 
Fauces - 4 - 4 
Retromolar area - - 1 1 
Alveolar mucosa - - 2 2 
Total 15 63 22 100 
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Figure 4.7: Smoking status in relation to high/low-risk anatomical sites. 
 
 
 
Table 4.3: Smoking status in relation to five anatomical sites. 
Smoking status 
PMD anatomical sites 
Total 
FOM Tongue 
Soft 
palate 
Buccal 
mucosa 
The remaining 
sites 
 
Non-smoker - 14 - 1 - 15 
Current smoker 38 10 7 4 4 63 
Ex-smoker 8 9 2 - 3 22 
Total 46 33 9 5 7 100 
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Figure 4.8: Smoking status and PMD oral sites in males. 
 
 
Figure 4.9: Smoking status and PMD oral sites in females. 
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Smoking Status and Clinical Appearance 
In all groups (Figure 4.10), homogenous leukoplakia was the main clinical type (67/100), 
followed by speckled non-homogenous leukoplakia (16/100), erythroplakia (8/100) and 
exophytic non-homogenous subtypes (5/100). Ulcerated PMDs were observed equally in 
current and ex-smokers (1/2), but were not seen in non-smokers. Nodular and exophytic 
subtypes were seen equally in non-smokers (1/15 for each), with nodular also seen equally 
in current and non-smokers (1/2), but not in ex-smokers. 
 
In current smokers, higher frequencies of exophytic lesions (3/5) were seen with an equal 
distribution between non-smokers and ex-smokers (1/5). No significant relation was found 
between smoking status and PMD clinical appearance (p=0.068; Chi-Square test). 
 
 
 
 
Figure 4.10: PMD clinical appearance according to smoking status. 
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Smoking Status and Size of PMD 
Three size categories were defined in this study: minor < 200 mm
2
, intermediate 200-600 
mm
2
 and major > 600 mm
2
. 
In current smokers, the majority of PMDs were intermediate (49%; 31/63), followed by 
minor (44%; 28/63) and major (6%; 4/63). In ex-smokers, minor size PMDs were most 
common (10/20), followed by intermediate (8/20) and major (2/20). 
Non-smokers exhibited mainly intermediate sized PMDs (6/15), followed by minor (5/15) 
and major (4/15); Figure 4.11. 
 
Kruskal-Wallis testing showed significant differences in mean size between smoking groups 
(p=0.026). Subsequently, a Mann-Whitney U test was performed which revealed a highly 
significant difference between current and non-smokers (p=0.006). Whereas the differences 
between ex-smokers and both current and non-smokers were non-significant (p=0.594 and 
p=0.093, respectively).  
 
Figure 4.12 shows the association between PMDs mean size and smoking status. Non-
smokers showed the highest mean size (473.20 mm
2
), followed by ex-smokers (354.25 mm
2
) 
with current smokers showing smallest mean size (241.49 mm
2
). 
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Figure 4.11: Distribution of PMD size (mm
2
) according to smoking status. 
 
 
 
 
Figure 4.12: Mean size of PMD (mm
2
) according to smoking status. 
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Smoking Status and Dysplasia Grading 
Generally, a higher presentation of dysplastic features were seen in current smokers (63/97), 
compared to 19/97 for ex-smokers and 15/97 in non-smokers; Table 4.4. 
No significant relation was found between smoking status and grade of epithelial dysplasia, 
however (p=0.105; Chi-Square test). 
 
 
 
Table 4.4: Degree of epithelial dysplasia in relation to smoking status. 
Smoking status 
(at first presentation) 
Oral epithelial dysplasia 
(consensus diagnosis WHO system) Total 
Mild Moderate Severe CIS 
 
Non-smoker 
6 2 5 2 15 
40% 13% 33% 13% 100% 
Current smoker 
27 16 15 5 63 
43% 25% 24% 8% 100% 
Ex-smoker 
9 5 2 3 19 
47% 26% 11% 16% 100% 
Total 
42 23 22 10 97 
43% 24% 23% 10% 100% 
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Number of Cigarettes per day, Tobacco Grams per week and Sex 
Overall, the average number of cigarettes smoked per day was 23, and the range 7 to 60. No 
significant differences were found between males and females in mean number of cigarettes 
smoked per day (p=0.345; Independent t- test); males showed a slightly higher mean number 
(24) compared to females (21). 
The number of cigarettes smoked/day was converted into grams/week (1 cigarette contains 
approximately 1 gram of tobacco), providing a range of 49-420 grams/week with a mean of 
164 (SD: 73.67). 
 
To assess the influence of smoking intensity, smokers were classified according to the 
number of cigarettes smoked per day into 3 groups: light (< 10), intermediate (10-20) and 
heavy smokers (> 20). Males consumed more tobacco than females, 78% (18/23) of heavy 
smokers were males compared to only 22% (5/23) of females. Similarly, 68% (26/38) of 
intermediate smokers were males compared to 32% (12/38) females; Figure 4.13. 
No significant relationship was found between sex and intensity of smoking in terms of 
cigarettes/day (p=0.160; Chi-Square test). 
 
 
Figure 4.13: Number of cigarettes smoked per day in males and females. 
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Number of Cigarettes and Age of Patient 
Figure 4.14 and Table 4.5 summarise the number of cigarettes smoked per day in relation to 
age. Higher frequencies of intermediate, followed by heavy smoking were seen in all age 
groups. Eighty-two percent (19/23) of heavy and 66% (25/38) of intermediate smokers were 
middle age; 16% (6/38) of intermediate and 9% (2/23) of heavy smokers were old age. Whilst 
Chi-Square test showed no significant relation between number of cigarettes smoked per day 
(light, intermediate, heavy) and age groups (p=0.137), Kruskal-Wallis testing showed a 
significant difference in average tobacco intake (cigarettes/day) between age groups 
(p=0.026). Subsequently, a Mann-Whitney U test was performed and revealed a significant 
difference in mean tobacco intake between middle and old age (p=0.009), whilst no 
significant differences were observed regarding other age groups. Middle age patients 
consumed the highest average number of cigarettes per day (25), followed by young (22) and 
then old (16); Figure 4.15.  
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Figure 4.14: Number of cigarettes smoked per day according to age group. 
 
 
 
Table 4.5: Number of cigarettes smoked per day according to age group. 
Smoking intensity 
(cigarettes/day) 
Age group (years) 
Total 
≤ 40 41-62 63-84 
 
< 10 
- 1 1 2 
 50% 50% 100% 
10-20 
7 25 6 38 
18% 66% 16% 100% 
> 20 
2 19 2 23 
9% 82% 9% 100% 
Total 
9 
14% 
45 
72% 
9 
14% 
63 
100% 
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Figure 4.15: Mean cigarettes smoked per day in relation to age group. 
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Number of Cigarettes per day and PMD Anatomical Site  
The FOM was the main site affected by PMDs in intermediate smokers 61% (23/38) and 
heavy smokers 37% (14/38); Figure 4.16. 
The intensity of smoking in term of cigarettes smoked per day did not influence PMD site 
distribution; Chi-Square test was not significant considering all sites (p=0.085), 5 anatomical 
sites (FOM, tongue, soft palate, buccal mucosa and other sites) (p=0.086) or high/low-risk 
sites (p=0.144). 
Mann-Whitney U test also showed no significant relation between amount of tobacco smoked 
per day and PMDs in high or low-risk oral sites (p=0.960). 
 
 
 
 
Figure 4.16: Number of cigarettes smoked per day in relation to PMD anatomical site. 
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Number of Cigarettes per day and Clinical Appearance of PMD 
Figure 4.17 shows the distribution of clinical type of PMD in relation to number of cigarettes 
smoked per day. 
Erythroplakia was only seen in heavy smokers (3/3), whilst light smokers exhibited only 
exophytic non-homogenous leukoplakia (2/2). Homogenous and specked non-homogenous 
leukoplakias were both more frequently seen in heavy and intermediate smokers. 
Whilst Chi-Square test was significant (p=0.001); Kruskal-Wallis testing showed no 
significant difference in the average number of cigarettes smoked per day and clinical type of 
PMD (p=0.274). 
 
 
 
 
Figure 4.17: Clinical appearance of PMDs according to number of cigarettes/day. 
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Number of Cigarettes and Size of Dysplastic PMD 
Patients who smoked more than 20 cigarettes/day demonstrated the highest frequency of 
minor sized PMDs (48%; 11/23), followed by intermediate (39%; 9/23) and major size (13%; 
3/23). 
 
Fifty-percent (19/38) of intermediate smokers showed intermediate sized PMDs (200-600 
mm
2
), followed by minor (45%; 17/38) and major size (5%; 2/38). Light smokers showed 
only intermediate size PMDs (2/2); Table 4.6. 
Chi-Square testing showed no significant association between intensity of smoking and size 
of PMD (p=0.392).  
 
A weak negative, albeit non-significant, correlation was observed between the number of 
cigarettes smoked per day and PMD size (r=-0.50, n=63, p>0.01). Heavy smokers showed the 
smallest mean size compared with light smokers (247.48 mm
2
 vs. 316 mm
2
). 
 
 
 
Table 4.6: Association between size of PMDs and the number of cigarettes/day. 
Number of cigarettes/day 
PMD size (mm
2
) 
Total 
Minor 
< 200 
Intermediate 
(200-600) 
Major 
> 600 
 
< 10 
Light smoker 
- 
 
2 
100% 
- 
 
2 
100% 
10-20 
Intermediate 
17 
45% 
19 
50% 
2 
5% 
38 
100% 
> 20 
Heavy smoker 
11 
48% 
9 
39% 
3 
13% 
23 
100% 
Total 
28 
44% 
30 
48% 
5 
8% 
63 
100% 
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Number of Cigarettes and Dysplasia Grading 
Patients smoking 10-20 cigarettes per day, which was the largest group in this study, 
exhibited a higher number of dysplasia cases (38/63), compared to heavy smokers (23/63). 
Severe dysplasia (9/23) was the main dysplastic feature in heavy smokers (> 20), followed by 
moderate (7/23) and mild dysplasia (6/23). Light smokers (< 10) showed the least dysplastic 
features (1 mild and 1 CIS), whereas intermediate smokers were more frequently diagnosed 
with mild dysplasia (20/38); Table 4.7 and Figure 4.18.  
 
Using Chi-Square testing, a significant association was found between number of cigarettes 
smoked per day and degree of dysplasia (p=0.005). However, Kruskal-Wallis test showed no 
significant difference in the average amount of tobacco smoked per day and different grades 
of dysplasia (p=0.183).  
 
Patients with mild and moderate dysplasia smoked the same average cigarettes per day (23), 
whilst severe dysplasia patients smoked a higher average number (26). Patients with CIS 
reported the least tobacco intake (17). 
No significant correlation was found between number of cigarettes smoked per day and 
degree of dysplasia (r=0.116; n=63; p>0.01). 
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Table 4.7: Number of cigarettes smoked per day and degree of dysplasia. 
Smoking intensity 
(cigarettes /day) 
Oral epithelia dysplasia 
(consensus diagnosis WHO system) 
Total 
Mild Moderate Severe CIS 
 
< 10 1 - - 1 2 
10-20 20 9 6 3 38 
> 20 6 7 9 1 23 
Total 
27 
43% 
16 
25% 
15 
24% 
5 
8% 
63 
100% 
 
 
 
 
Figure 4.18: Association between numbers of cigarettes smoked per day and degree of 
dysplasia. 
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Smoking History and Sex 
Smoking history was recorded for 36 patients (28 males and 8 females), whilst no reliable 
data were found for the remaining 27 current smokers.  
Duration of smoking was divided into 3 categories: 10-30 years, 31-50 years and > 50 years; 
Figure 4.19. 
Overall, 58% (20/36) of current smokers reported a long history (31-50 years), followed by 
39% (14/36) of relatively long (10-30 years), with only one patient more than 50 years 
smoking history. 
 
Male smokers had longer smoking histories (31-50 years) compared to females (64%; 17/28 
vs. 38%; 3/8). Females mainly had relatively long histories (10-30 years) compared to males 
(63%; 5/8 vs. 32%; 9/28). No significant relation was found between the length of smoking 
history and sex (p=0.310; Chi-Square test). 
A significant difference was found between males and females in mean smoking history 
(p=0.034; Mann-Whitney U test), with males showing a longer mean history (37.11 vs. 28.13 
years). 
 
 
Figure 4.19: Sex distribution in relation to the length of smoking history.
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Smoking History and Number of Cigarettes  
A negative correlation was found between the number of cigarettes smoked per day and 
length of smoking history (years), although it did not reach statistical significance (r=-0.317, 
n=36, p>0.01).  
Patients with a history of 10-30 years consumed a higher number of cigarettes/day compared 
to those who had smoked for 31-50 years (28 vs. 22).  
 
Patients who smoked < 10 cigarettes/day had the highest average smoking history (46.4 
years), followed by patients smoking 10 to 20 (35.05 years) and those smoking > 20/day 
(33.57 years); Figure 4.20. 
The majority of heavy 57% (8/14) and intermediate smokers 55% (11/20) had a long smoking 
history (31-50 years), although Chi-Square test was not significant (p=0.254); Figure 4.21. 
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Figure 4.20: Correlation between number of cigarettes and history of smoking. 
 
 
 
Figure 4.21: Length of smoking history according to the number of cigarettes. 
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Smoking History and Anatomical Site of PMDs 
Overall, patients with long smoking histories (31-50 years) showed higher numbers of PMDs 
(21/36) compared to those with shorter histories (10-30 years) (14/36); Table 4.8. 
 
A significant relationship was found between smoking history and PMD site (p=0.043; Chi-
Square test). The FOM was the main site for PMDs with long histories (11/19), followed by 
ventral tongue and soft palate equally (3/4), whilst buccal mucosa and fauces were mainly 
affected in patients with shorter histories. 
 
High-risk sites showed higher frequencies of PMDs compared to low-risk sites for both long 
and relatively long smoking histories, although patients with a longer history developed more 
PMDs in high risk sites than those with a shorter duration of smoking (16/26 vs. 9/26); Table 
4.9. Chi-Square testing, however, showed no significant relation between smoking history 
and high/low-risk sites (p=0.438). 
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Table 4.8: Length of smoking history in relation to PMD anatomical site. 
PMD anatomical sites 
Smoking history (years) 
Total 
10-30 31-50 > 50 
 
FOM 8 11 - 
19 
53% 
Lateral tongue 1 2 - 
3 
8% 
Ventral tongue - 3 1 
4 
11% 
Buccal mucosa 2 1 - 
3 
8% 
Soft palate 1 3 - 
4 
11% 
Fauces 2 1 - 
3 
8% 
Total 14 21 1 
36 
100% 
 
 
 
 
Table 4.9: Length of smoking history in relation to high/low risk sites. 
PMD anatomical sites 
History of smoking 
(years) 
Total 
10-30 31-50 > 50 
High risk  9 16 1 26 
Low risk  5 5 - 10 
Total 14 21 1 36 
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Smoking History and Clinical Appearance of PMD  
As shown in Figure 4.22, homogenous leukoplakia was the main clinical appearance in 
patients with a long smoking history, followed by those with a shorter history (67% vs. 57%). 
The one patient with a history > 50 years also had homogenous leukoplakia. 
 
Chi-Square test showed no significant relationship between smoking history and the clinical 
type of PMDs: leukoplakia and erythroplakia (p=0.522), homogenous and non-homogenous 
leukoplakia (p=0.498) or non-homogenous leukoplakia subtypes (p=0.455). However, the 
relation was significant when all clinical types were combined (p=0.049).  
 
 
 
 
Figure 4.22: Clinical type of PMDs according to smoking history. 
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Smoking History and Size of Dysplastic PMDs  
All major sized (2/2), 60% (9/15) of minor and 53% (10/19) of intermediate sized PMDs 
were observed in patients with a long smoking history (31-50 years); Figure 4.23. 
 
Patients with a short history (10-30 years) showed 47% (9/19) intermediate, followed by 33% 
(5/15) minor size. However, no significant relation was found between smoking history and 
size of PMDs (p=0.233; Chi-Square test). 
 
A negative, albeit, non-significant, correlation was found between PMD size and smoking 
history (r=-0.050; n=98; p>0.01); patients with a longer history were liable to develop smaller 
sized PMDs. 
 
 
 
Figure 4.23: PMD size (mm
2
) in relation to smoking history. 
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Smoking History and Dysplasia Grading 
Overall, patients with long smoking histories were likely to develop more dysplastic lesions 
(21/36) compared to those with a short history (14/36). 
In this study, the one patient with a history > 50 years developed moderate dysplasia; Table 
4.10. 
No significant relationship was found between smoking history and degree of dysplasia 
(p=0.141; Chi-Square test). 
 
Table 4.11 shows mean smoking history in relation to degree of dysplasia. A positive, though 
non-significant, correlation was found between length of smoking history and degree of 
dysplasia (r=0.117, n=48, p>0.01); a longer smoking history was associated with increased 
severity of dysplasia. Patients with mild dysplasia showed the shortest duration of smoking 
(32.7 years), whilst patients with CIS exhibited the longest history of smoking (41 years).  
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Table 4.10: Oral epithelial dysplasia in relation to smoking history. 
Smoking history 
(years) 
Oral epithelial dysplasia 
(consensus diagnosis WHO system) Total 
Mild Moderate Severe CIS 
 
10-30 
7 4 3 - 14 
50% 29% 21%  100% 
31-50 
9 6 3 3 21 
43% 29% 14% 14% 100% 
> 50 
- 1 - - 1 
 100%   100% 
Total 
16 
44% 
11 
31% 
6 
17% 
3 
8% 
36 
100% 
 
 
 
 
Table 4.11: Mean smoking history in relation to degree of dysplasia. 
Oral epithelial dysplasia N 
Mean smoking history 
(years) 
SD 
Mild 23 32.65 9.708 
Moderate 14 32.93 13.170 
Severe 8 33.75 8.763 
CIS 3 41.00 6.557 
Total 48 33.44 10.459 
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Pack-years Score 
In this analysis, the effect of both intensity and duration of tobacco smoking was investigated. 
The lifetime (cumulative tobacco smoking) or pack-years score was calculated by 
multiplying the number of cigarettes smoked per day by history of smoking, divided by 20 
cigarettes (one pack) (Prignot, 1987). The mean pack-year score was 40.78 with a range of 10 
to 150 (SD: 20.61). 
 
Males showed a higher mean pack-years score than females (43.23 vs. 32.18), however, the 
differences were not significant (p=0.200; Mann-Whitney U test). A negative, non-significant, 
correlation was found between pack-years score and both age of patients (r=-0.210, n=36, 
p>0.01) and size of dysplasia (r=-0.0127, n=36, p>0.01).  
 
Smoking Trends in PMD Patients 
Figure 4.24 shows the percentage of smokers versus the percentage stopping smoking during 
their clinical management time. Higher percentages of smokers were seen up until 108 
months. 
 
 
 
Figure 4.24: Percentage of smokers and quitters during the clinical management time. 
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Figure 4.25 compares smoking status at initial presentation and at most recent follow-up.  
A highly significant difference was found between initial presentation and most recent clinic 
follow-up in the number of patients in different smoking status groups (p=0.0001, Sign test).  
Sixty-three current smokers at first presentation decreased to 36 at the most recent follow-up, 
whilst 22 ex-smokers increased to 49 at most recent clinic review. 
 
A significant decrease in the number of cigarettes smoked per day was seen at the most recent 
clinical follow-up compared to first presentation (p=0.0001, Sign test). The number of light 
smokers increased from 2 to 20, intermediate smokers decreased from 38 to 14, and heavy 
smokers reduced from 23 to 2; Figure 4.26. 
 
 
Figure 4.25: Smoking status at first and most recent follow-up time. 
 
 
Figure 4.26: Smoking behaviour (cigarettes/day) at first and most recent follow-up. 
  
219 
 
Table 4.12 compares smoking behaviour between males and females at first presentation and 
at most recent clinic follow-up.  
 
No heavy smoking female patients were seen at most recent clinic follow-up, whilst 
intermediate female smokers decreased from 12 to 2. In males, heavy smokers decreased 
from 18 to 2, whilst the 2 light smokers increased to 17. 
 
 
 
Table 4.12: Smoking behaviour at first and most recent follow-up according to sex. 
Smoking status 
1st presentation Most recent time 
Male Female Total Male Female Total 
Non-smoker 5 10 15 5 10 15 
C
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 < 10 
Light 
2 - 2 17 3 20 
10-20 
Intermediate 
26 12 38 12 2 14 
> 20 
Heavy 
18 5 23 2 - 2 
Ex-smoker 15 7 22 30 19 49 
Total 66 34 100 66 34 100 
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4.4.2. Alcohol Consumption amongst PMD Patients 
The majority of patients were current drinkers (83/100), followed by non-drinkers (14/100), 
with the remaining 3 ex-drinkers; Figure 4.27. 
 
Current drinkers consumed alcohol to an average of 30 units/week (SD: 30.59) and a range of 
1-140 units/week. Alcohol consumption was divided into 3 categories: 39 light drinkers (1-14 
units/week), 10 intermediate (15-28 units/week) and 34 heavy drinkers (> 28 units/week); 
Figure 4.28. 
 
 
 
 
Figure 4.27: Drinking status of 100 PMD patients at first presentation. 
  
221 
 
 
Figure 4.28: Alcohol consumption (units per week) at first presentation. 
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Age, Sex and Drinking Status  
Figure 4.29 shows that the majority of current drinkers were middle aged (57%; 47/83), 
followed by old (31%; 26/83) and young patients (12%; 10/83). 
Chi-Square testing showed a significant association between drinking status and age 
(p=0.031). Young patients were all current drinkers, with ex-drinkers only seen in middle age. 
One elderly patient (> 85 years) was a non-drinker. 
 
A significant relationship was found between drinking status at first presentation and sex 
(p=0.001; Chi-Square test), with the majority of current drinkers male 71% (59/83), and most 
non-drinkers female 71% (10/14). No females were observed in the ex-drinker category 
which comprised 3 males; Figure 4.30. 
 
 
 
  
223 
 
 
Figure 4.29: Drinking status according to age. 
 
 
 
Figure 4.30: Sex distribution and drinking status at first presentation. 
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Age, Sex and Number of Alcohol units/week  
A highly significant relation was found between age and alcohol intake (units/week) 
(p=0.002; Chi-Square test). Fifty-percent (5/10) of young and 53% (25/47) of middle age 
patients were heavy drinkers, whilst the majority of old age 77% (20//26) were light drinkers; 
Table 4.13 and Figure 4.31. 
 
Table 4.14 shows mean alcohol intake (units/week) in relation to age. Using Kruskal-Wallis 
testing, a significant difference was found between age groups and the amount of alcohol 
consumed per week (p=0.003). Subsequently, a Mann-Whitney U test was performed and 
showed a highly significant difference between middle age and old age (p=0.001), with old 
age patients consuming the lowest amount of alcohol compared to both young and middle age 
patients (15.9 vs. 34.7 and 36.87 units/week). 
 
A negative, significant correlation was found between amount of alcohol intake (units/week) 
and age (r=-0.240, n=83, p=0.029), with increasing age associated with a decreased alcohol 
intake. 
 
Out of 83 current drinkers (59 males and 24 females), males were more frequently heavy 
drinkers 97% (33/34), followed by 92% (9/10) intermediate and 44% (17/39) light drinkers. 
The majority of light drinkers were females 56% (22/39), followed by 10% (1/10) 
intermediate and 3% (1/34) heavy drinkers; Figure 4.32. 
 
Females drank a range of 1-70 units/week with a mean of 9.50 (SD: 13.58), whilst males 
ranged from 4-140 units/week with a mean of 38.4 (SD: 31.692). 
Chi-Square test showed a highly significant relation between sex and amount of alcohol 
consumed (p=0.001). Subsequently, a Mann-Whitney U test confirmed that males consumed 
a higher average amount of alcohol per week compared to females (p=0.0001).  
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Current drinkers were further classified into two groups: those who consumed > 28 and < 28 
units/week. Males formed the majority consuming > 28 units/week (97%; 33/34), whilst 
females mainly drank < 28 units/week (96%; 23/24). 
In this study, 58% (38/66) of males and 9% (3/34) of females exceeded the recommended UK 
department of health alcohol intake guidelines. 
 
Figure 4.33 and Table 4.15 summarise drinking behaviour at first presentation and most 
recent clinic follow-up.  
Significant changes in the amount of alcohol intake by both males and females were seen at 
the most recent clinical follow-up, with a Mann-Whitney U test confirming a lower mean 
alcohol intake in females compared to males (p=0.0001). Females consumed alcohol between 
1-20 units/week with a mean of 7.42 (SD: 5.055), whilst males drank between 1-147 
units/week with a mean of 35.86 (SD: 35.340). 
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Table 4.13: Amount of alcohol consumed (units/week) according to age. 
Age groups 
(years) 
Alcohol intake  
(units/week) Total 
1-14 15-28 > 28 
 
≤ 40 
4 1 5 10 
40% 10% 50% 100% 
41-62 
15 7 25 47 
32% 15% 53% 100% 
63-84 
20 2 4 26 
77% 8% 15% 100% 
Total 
39 10 34 83 
47% 12% 41% 100% 
 
 
 
 
Figure 4.31: Amount of alcohol consumed (units/week) according to age. 
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Table 4.14: Mean alcohol consumption in relation to age. 
Age groups 
(years) 
Mean alcohol intake 
(units/week) 
N Maximum Minimum SD 
≤ 40 34.70 10 84 2 29.341 
41-62 36.87 47 140 1 33.438 
63-84 15.92 26 80 4 19.978 
Total 30.40 83 140 1 30.584 
 
 
 
 
 
Figure 4.32: Sex distribution and alcohol intake. 
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Figure 4.33: Drinking behaviour at initial and most recent follow-up. 
 
 
 
Table 4.15: Drinking behaviour at initial and most recent follow-up in relation to sex. 
Drinking status 
1st presentation Most recent time 
Male Female Total Male Female Total 
Non-drinker 4 10 14 4 10 14 
C
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1-14 17 22 39 19 22 41 
15-28 9 1 10 16 2 18 
>28 33 1 34 22 0 22 
Ex-drinker 3 0 3 5 0 5 
Total 66 34 100 66 34 100 
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Drinking Status, Amount of Alcohol (units/week) and Anatomical Site of PMDs 
The relationship between drinking status and anatomical site of PMD can be seen in Figure 
4.34. 
Current drinkers were more frequently affected with FOM PMDs 46% (38/83), followed by 
lateral 19% (16) and ventral tongue 15% (12). 
Similarly, non-drinkers mainly showed FOM PMDs (43%), followed by lateral (21%) and 
ventral tongue (14%); buccal mucosa, fauces and alveolar mucosa were not affected in non-
drinkers. The FOM (67%; 2/3) and soft palate (33%; 1/3) were the only affected anatomical 
sites in ex-drinkers. Chi-Square testing showed a significant relation between drinking status 
and anatomical site (p=0.030). 
 
Eighty-percent (66/83) of current drinkers had PMDs at high-risk sites, compared to 20% 
(17/83) at low-risk sites, which was similar for non-drinkers and ex-drinkers, although non-
significant (p=0.709; Chi-Square test); Table 4.16.  
 
Table 4.17 demonstrates PMD site in relation to alcohol intake. The FOM was the principal 
site for PMDs in heavy drinkers 56% (20/36), followed by light 41% (14/34) and 
intermediate drinkers 31% (4/13). All faucial pillar lesions (4/4) and the majority of soft 
palate PMDs (4/5) were seen in heavy drinkers. 
Using Chi-Square test, a highly significant relation was found between amount of alcohol 
intake (units/week) and all anatomical sites (p=0.0001), 5 sites (p=0.001) or high/low-risk 
sites (p=0.025). All heavy, light and intermediate drinkers developed PMDs more frequently 
in high-risk compared to low-risk sites; Table 4.18. 
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Figure 4.34: PMD anatomical site in relation to drinking status. 
 
 
 
Table 4.16: PMD high and low-risk sites according to alcohol status. 
Alcohol status 
PMDs anatomical site 
Total 
High risk Low risk 
 
Non-drinker 
11 
79% 
3 
21% 
14 
100% 
Current drinker 
66 
80% 
17 
20% 
83 
100% 
Ex-drinker 
2 
67% 
1 
33% 
3 
100% 
Total 
79 21 100 
79% 21% 100% 
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Table 4.17: Anatomical site of PMD according to the amount of alcohol drinking. 
PMD anatomical sites 
Alcohol intake  
(units/week) Total 
1-14 15-28 > 28 
 
FOM 14 4 20 
38 
46% 
Lateral tongue 11 3 2 
16 
19% 
Ventral tongue 7 2 3 
12 
15% 
Buccal mucosa 2 1 2 
5 
6% 
Soft palate - 1 5 
6 
7% 
Fauces - - 4 
4 
3% 
 
Alveolar mucosa - 2 - 
2 
2% 
Total 34 13 36 
83 
100% 
 
 
 
 
Table 4.18: Alcohol intake in relation to high/low-risk sites. 
Alcohol intake 
(units/week) 
PMD anatomical sites 
Total 
High risk Low risk 
 
1-14 
32 2 34 
94% 6% 100% 
15-28 
9 4 13 
69% 31% 100% 
> 28 
25 11 36 
69% 31% 100% 
Total 
66 17 83 
80% 20% 100% 
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Drinking Status, Amount of Alcohol (units/week) and Clinical Appearance of PMD 
Table 4.19 shows the relationship between drinking status and clinical appearance of PMDs. 
Homogenous leukoplakias and specked non-homogenous leukoplakias were the most 
common clinical types in all groups. 
 
In current drinkers, homogenous leukoplakia, followed by the specked subtype, erythroplakia, 
exophytic subtypes and an equal distribution of ulcerated and nodular subtypes were seen. 
Out of 8 erythroplakias, 7 were reported in current drinkers with the remaining a non-drinker. 
All ulcerated PMDs were observed in current drinkers. 
Using Chi-Square testing, no significant relation was found between clinical type of PMD 
and drinking status (p=0.318). 
 
Table 4.20 summarises the relationship between amount of alcohol intake and type of 
leukoplakia; most homogenous leukoplakias were seen in light drinkers (52%; 28/54) 
compared to 37% (20/54) in heavy drinkers. Fifty-percent (11/22) of non-homogenous 
leukoplakias were reported in heavy drinkers compared to 36% (8/22) in light drinkers. 
 
Figure 4.35 shows the distribution of alcohol intake (units/week) according to the clinical 
appearance of PMDs, which showed a significant association (p=0.013; Chi-Square test). 
Erythroplakias were observed equally in heavy and light drinkers (43% each), specked non-
homogenous subtypes were most common in heavy drinkers compared to light drinkers (62% 
vs. 30%). Similarly, exophytic subtypes were more frequently seen in heavy drinkers 
compared to light drinkers (60% vs. 40%).  
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Table 4.19: Clinical type of PMD in relation to drinking status. 
Clinical appearance of 
PMDs 
Drinking status 
Total 
Non-drinker 
Current 
drinker 
Ex-drinker 
 
Homogenous leukoplakia 11 54 2 67 
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Speckled 2 13 1 16 
Nodular - 2 - 2 
Exophytic - 5 - 5 
Ulcerated - 2 - 2 
Erythroplakia 1 7 - 8 
 
Total 14 83 3 100 
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Table 4.20: Alcohol intake in relation to type of leukoplakia. 
Types of leukoplakia 
Amount of alcohol intake 
(units/week) Total 
1-14 15-28 > 28 
 
Homogenous 
28 6 20 54 
52% 11% 37% 100% 
Non-homogenous 
8 3 11 22 
36% 14% 50% 100% 
Total 
36 9 31 76 
47% 12% 41% 100% 
 
 
 
 
 
Figure 4.35: Alcohol intake (units/week) in relation to clinical appearance of  
PMDs. 
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Drinking Status, Amount of Alcohol (units/week) and Dysplasia Grading 
Table 4.21 and Figure 4.36 show the relationship between drinking status and oral epithelial 
dysplasia. In current drinkers, mild dysplasia (40%; 33/83) was most common, followed by 
moderate (25%; 21/83), severe dysplasia (23%; 19/83) and CIS (12% (10/83). Similarly, non-
drinker patients were mainly diagnosed with mild dysplasia 64% (7/11), followed by 
moderate and severe (18%; 2/11) equally; no CIS was diagnosed in this group. Ex-drinkers 
were mainly affected with mild (2/3), followed by severe (1/3), whilst no moderate dysplasia 
or CIS were seen. Using Chi-Square testing, no significant relation was found between 
drinking status and degree of dysplasia (p=0.059). 
 
A lower mean alcohol intake was seen in patients with mild dysplasia (22) compared to 
moderate (37), severe (29) and CIS (43); however, the differences were not significant 
(p=0.449; Kruskal-Wallis test); Table 4.22. No significant correlation was found between 
alcohol intake and degree of dysplasia (r=0.097, n=83, p>0.01). 
 
Table 4.23 shows alcohol intake in relation to the grade of dysplasia. The majority of mild 
and severe dysplasias were observed in light drinkers, whilst the majority of moderate 
dysplasia and CIS were seen in heavy drinkers. However, no significant relation was found 
between alcohol intake and degree of dysplasia (p=0.067; Chi-Square test). 
 
Overall, at the most recent follow-up, average alcohol intake was lower than at first 
presentation (27.5 vs. 30 units/week), albeit non-significant (p=0.541; Sign test). Ex-drinkers 
increased from 3% to 5%, intermediate drinkers increased from 12% to 21%, whilst heavy 
drinkers decreased from 34% to 23%; Figure 4.37. 
 
Chi-Square test showed a highly significant relation between sex and both drinking status 
(p=0.001) and number of alcohol units consumed per week (p=0.0001) at most recent follow-
up. Although there were no clear changes in female drinking behaviour, males showed 
noticeable changes at most recent follow-up, with heavy drinkers decreasing from 33 to 22, 
intermediate drinkers increasing from 9 to 16, and light drinkers increasing from 17 to 19; 
Table 4.24. 
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Table 4.21: Drinking status and epithelial dysplasia grading. 
Drinking status 
Oral epithelial dysplasia  
(consensus WHO scoring) 
Total 
Mild Moderate Severe CIS 
 Non-drinker 7 2 2 - 11 
Current drinker 33 21 19 10 83 
Ex-drinker 2 - 1 - 3 
Total 
42 23 22 10 97 
43% 24% 23% 10% 100% 
 
 
 
 
Figure 4.36: Drinking status and epithelial dysplasia grading. 
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Table 4.22: Average alcohol intake in relation to the degree of epithelial dysplasia. 
Dysplasia grade 
Mean 
(units/week) 
N Minimum Maximum SD 
Mild 22.06 33 1 60 17.960 
Moderate 37.00 21 2 120 37.199 
Severe 29.37 19 4 140 35.603 
CIS 43.10 10 4 112 35.127 
Total 30.05 83 1 140 30.594 
 
 
 
 
Table 4.23: Alcohol intake in relation to degree of dysplasia. 
Alcohol 
(units/week) 
Oral epithelial dysplasia 
Total 
Mild Moderate Severe CIS 
 
1-14 16 8 10 3 37 
15-28 6 4 2 - 12 
> 28 11 9 7 7 34 
Total 
33 21 19 10 83 
40% 25% 23% 12% 100% 
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Figure 4.37: Drinking status at first presentation and most recent follow-up. 
(u/w=units/week) 
 
 
 
Table 4.24: Drinking status at first presentation and most recent follow-up, according to 
sex. 
Drinking status 
1st presentation Most recent follow-up time 
Male Female Total Male Female Total 
Non-drinker 4 10 14 4 10 14 
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) 1-14 17 22 39 19 22 41 
15-28 9 1 10 16 2 18 
> 28 33 1 34 22 - 22 
Ex- drinker 3 - 3 5 - 5 
Total 66 34 100 66 34 100 
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The Association between Tobacco Smoking and Alcohol Drinking 
Overall, Chi-Square testing showed a significant relationship between smoking and alcohol 
behaviour in the study population both at first presentation (p=0.003) and most recent follow-
up (p=0.039); Figure 4.38.  
 
At initial presentation, current drinkers were mainly also current smokers (92%), followed by 
non-smokers (73%) and ex-smokers (64%). Fifty-percent (7/14) of non-drinkers were also 
ex-smokers, followed by non-smokers (29%; 4/14) and current smokers (21%; 3/14). 
In this study, there were only 3 ex-drinkers, 2 (67%) were current smokers and the remaining 
one (33%) an ex-smoker. 
 
No significant correlation was found between the number of cigarettes smoked per day or 
tobacco grams per week and the amount of alcohol intake at the time of presentation (r=0.053, 
n=63 p>0.01), (r=0.045, n=63, p>0.01), respectively. 
 
 
 
 
Figure 4.38: The relation between drinking and smoking status at first presentation.
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4.4.3. Medical History of Patients with PMDs 
In this study, five medical problems were investigated: immunodeficiency, anaemia, oral 
candida infection, diabetes mellitus and hypertension. 
 
Eighty-eight patients reported a positive medical history with one or more active, systemic 
diseases. Hypertension (60%) was the most common, followed by diabetes mellitus (15%), 
candida infection (8%), anaemia (4%) and immunodeficiency (1%); Figure 4.39. 
 
Figure 4.40 shows the distribution of systemic disease in relation to male and female patients; 
55% of males and 33% of females were affected. Males were primarily affected by 
hypertension, candida infection and anaemia, whilst females more frequently had diabetes 
mellitus. 
 
Using Fisher’s Exact testing, no significant association was found between systemic health 
status and sex (p=0.536). Seventy-percent of PMD patients also reported other medical 
conditions such as those related to the cardiovascular (28%), respiratory (19% and 
musculoskeletal systems (18%), liver disease (15%), psychological disorders (10%), nervous 
system (8%), digestive system (7%), endocrine (6%), skin (4%) and renal problems (3%); 
Figure 4.41 and Table 4.25. 
 
No significant association was found between the occurrence of other medical problems and 
sex, although males were more likely to be affected than females (46/70 vs. 24/70) (p=1.000; 
Fisher’s Exact test). 
 
A significant association was found between age group and systemic health status (p=0.045; 
Chi-Square test). Patients with a positive medical history were mainly in middle age (53%; 
47/88), followed by old (38%; 33/88) and young age groups (8%; 7/88).  
All patients in old age (33/33), 84% (47/56) of middle age and 70% (7/10) of young age had 
a positive medical history; Table 4.26 and Figure 4.42. 
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Table 4.27 shows a significant relationship between systemic health and degree of dysplasia  
(p=0.021; Chi-Square test). In general, higher dysplastic features were seen in patients with a 
positive medical history: 40% (34/85) mild, 26% (22/85) severe, 22% (19/85) moderate 
dysplasia and 12% (10/85) CIS. Patients with negative medical histories had no severe 
dysplasia or CIS, with mild the main dysplastic feature (67%; 8/12), followed by moderate 
(33%; 4/12). 
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Figure 4.39: Distribution of systemic disease amongst 100 PMD patients. 
 
 
 
Figure 4.40: Distribution of systemic disease according to sex. 
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Figure 4.41: Other medical conditions recorded in 100 PMD patients. 
 
 
 
Table 4.25: Details of the other associated medical conditions. 
System Associated medical problems 
Cardiovascular 
Myocardial Infarction, Cerebrovascular accident (CVA) 
Cardiac failure, Ischemic heart disease, Rheumatic fever 
Respiratory 
Asthma, Chronic cough, Recurrent chest infection, TB, 
Partially collapsed lung 
Skeleton-muscular 
Asymmetric cervical myelopathy, Osteoarthritis, 
Rheumatoid arthritis, Spondylosis, Autoimmune 
dermatomyositis 
Liver Hepatitis, Alcoholic related jaundice, Liver cirrhosis 
Psychological Anxiety, Depression 
Nervous system Multiple sclerosis, Peripheral neuropathy, Epilepsy 
Digestive Esophagitis, Stomach and duodenal ulcer, Celiac disease 
Endocrine Hyperthyroidism, Hypothyroidism 
Skin Psoriasis, Eczema 
Renal Kidney problem, Prostate  
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Table 4.26: Systemic health status in relation to age.  
Age group 
(years) 
Systemic health status 
Total No systemic 
disease 
Positive systemic 
disease 
 
≤ 40 
3 7 10 
25% 8% 10% 
41-62 
9 47 56 
75% 53% 56% 
63-84 
- 33 33 
 38% 33% 
≥ 85 
- 1 1 
 1% 1% 
Total 
12 88 100 
100% 100% 100% 
 
 
 
 
Figure 4.42: Systemic health status in relation to age. 
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Table 4.27: Systemic health status in relation to the degree of dysplasia. 
Degree of dysplasia 
Systemic health status 
Total No systemic 
disease 
Positive systemic 
disease 
 
Mild 
8 34 42 
67% 40% 43% 
Moderate 
4 19 23 
33% 22% 24% 
Severe 
- 22 22 
 26% 23% 
CIS 
- 10 10 
 12% 10% 
Total 
12 85 97 
100% 100% 100% 
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Immunodeficiency 
Out of the 100 patients, one 48 years old male was immune-suppressed resulting from 
cyclosporine and prednisolone use for autoimmune dermatomyositis. This patient had severe 
dysplasia and had significant comorbidity at the time of diagnosis, including thyroid 
problems, epilepsy, psoriasis and celiac disease. 
 
 
Anaemia 
Four patients reported anaemia diagnosed 1-2 years before initial PMD diagnosis; three males 
(42, 65 and 71 years) and one female (55 years). Two patients had moderate, one severe and 
one mild dysplasia. 
 
 
Oral Candida Infection 
Eight cases of oral candida infection were reported, two in females and six in males. Four 
cases were seen in tongue, three in buccal mucosa and one in soft palate. Two cases exhibited 
homogenous leukoplakia, five with non-homogenous leukoplakia and only one with 
erythroplakia. Four patients had mild dysplasia, two moderate and similar numbers with 
severe dysplasia. 
 
The majority of patients in this group were current drinkers (88%) and smokers (75%). 
Candida infection was diagnosed at initial presentation in six patients, whilst the remaining 
two were identified after laser intervention during follow-up. 
Five patients with candida infection used dental prostheses, (2 crowns and bridges and 3 
dentures). 
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Diabetes Mellitus (DM) 
In this study, 15 patients had DM; ten type II and five type I. A significant relation was found 
between DM status and sex (p=0.036; Fisher’s Exact test); 60% (9/15) were reported in 
females compared to 40% (6/15) in males. 
 
An equal distribution of diabetic patients was seen in middle and old age groups (7/15), 
whilst only one patient was in the young age group (≤ 40 years); Chi-Square test was non-
significant (p=0.483); Figure 4.43. 
 
Figure 4.44 shows the relation between PMD clinical appearance and DM. No significant 
association was found between DM and leukoplakia or erythroplakia (p=0.602; Fisher’s 
Exact test), homogenous or non-homogenous lesions (p=1.000; Fisher’s Exact test) or 
between non-homogenous subtypes (p=0.521; Chi-Square test). 
A significant association was found between DM and clinical appearance, however, when all 
clinical types were considered together (0.035; Chi-Square test). 
 
Chi-Square testing showed no significant relationship between PMD anatomical site and DM 
status, considering all sites (p=0.151) or high/low-risk sites (p=0.731; Fisher’s Exact test). 
However, PMDs were more frequently seen in high-risk sites in DM patients (87%; 13/15) 
compared to low-risk sites (13%; 2/15).  
 
Figure 4.45 shows no significant relationship between DM and degree of dysplasia (p=0.219; 
Chi-Square test). In diabetic patients, mild (5/15) was most common, followed by severe 
(4/15) and moderate dysplasia and CIS equally (3/15 for each). 
 
The majority of diabetics were diagnosed with high grade dysplasia compared with non-
diabetics (9/15; 60% vs. 44/85; 52%), although no significant association was found (p=0.589; 
Fisher’s Exact test). 
 
Most diabetic patients were current smokers (8/15), followed by ex-smokers (4/15) and non-
smoker (3/15); Figure 4.46. Amongst current smoker, 5 were intermediate, whilst 3 were 
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heavy smokers. No significant relation was found between diabetic status and intensity of 
smoking (cigarettes/day) (p=0.469; Chi-Square test). 
 
Similarly, Chi-Square testing was non-significant between DM and drinking status (p=0.579), 
although most diabetic patients were current drinkers (13/15).  
Light drinkers (77%; 10/13) were most common, followed by heavy drinkers (3/13) in 
diabetic patients, whilst the majority of non-diabetic patients were heavy drinkers (44%; 
31/70); Figure 4.47.  
A borderline significant association was seen between DM and intensity of alcohol intake 
(units/week) (p=0.050; Chi-square test). 
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Figure 4.43: Diabetes mellitus in relation to age. 
 
 
Figure 4.44: Diabetes mellitus in relation to PMD clinical appearance. 
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Figure 4.45: Diabetes mellitus in relation to degree of dysplasia. 
 
 
Figure 4.46: Diabetes mellitus in relation to smoking behaviour of PMD patients. 
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Figure 4.47: Diabetes mellitus in relation to drinking behaviour of PMD 
patients. 
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Hypertension 
Hypertension was the most common systemic disease, affecting 60% of PMD patients, who 
used a variety of medical treatments. 
Although males (39/60) were more common than females (21/60), no significant relationship 
was found between hypertension status and sex (p=0.832; Fisher’s Exact test); Figure 4.48. 
 
A significant difference was found in mean age between hypertensive and normotensive 
patients (p=0.02; Independent t-test), with hypertensive patients (60.05 years) older than 
normotensive ones (54.23 years). 
 
Females with hypertension showed a higher mean age than hypertensive males (63.33 years 
vs. 58.38 years), although this was not significant (p=0.14; Independent t-test).  
 
 
 
 
Figure 4.48: Sex distribution according to hypertension status. 
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Hypertension and PMD Clinical Appearance  
Table 4.28 shows that out of 60 patients with hypertension, 54 had leukoplakia and 6 
erythroplakia. 
Homogenous leukoplakia was the main clinical type in both normotensive (70%; 28/40) and 
hypertensive patients (65% (39/60). 
Erythroplakia was more frequently seen in hypertensive patients (6/8) compared with 
normotensive patients (2/8), although no significant relation was found between hypertension 
status and leukoplakia or erythroplakia (p=0.471; Fisher’s Exact test). 
 
Non-homogenous leukoplakia was more often seen in hypertensive patients (60%; 15/25) 
compared to normotensive (40%; 10/25), albeit non-significant (p=1.000, Fisher’s Exact test). 
A significant association was found between hypertension and non-homogenous leukoplakia 
subtypes (p=0.028; Chi-Square test). Speckled, non-homogenous leukoplakias were 
predominantly seen in hypertensive patients (75%; 12/16) compared to normotensive (25%; 
4/16). All nodular and 60% (3/5) of exophytic were more likely to appear in normotensive 
patients, whilst ulcerated was seen equally in hypertensive and normotensive patients. 
 
 
Table 4.28: Association between hypertension status and PMD clinical appearance. 
Clinical appearance of 
PMDs 
Hypertension status 
Total 
Normotensive Hypertensive 
 
Homogenous leukoplakia 28 39 67 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 Speckled 4 12 16 
Nodular 2 - 2 
Exophytic 3 2 5 
Ulcerated 1 1 2 
Erythroplakia 2 6 8 
 Total 40 60 100 
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Hypertension and PMD Anatomical Site 
Figure 4.49 displays PMD anatomical site in relation to hypertension status. A significant 
relation was found (p=0.0001; Chi-Square test), with FOM, lateral and ventral tongue, and 
soft palate the main sites for PMDs in patients with hypertension. The faucial pillars were 
equally seen in normotensive and hypertensive patients, and buccal mucosa was most 
common in normotensive patients. 
 
In hypertensive patients most PMDs were seen at high-risk sites (63%; 50/79), compared to 
normotensive patients (37%; 29/79); Fisher’s Exact test was not significant, however 
(p=0.217); Figure 4.50. 
 
 
 
 
 
 
 
 
 
  
255 
 
 
Figure 4.49: PMD anatomical site in relation to hypertension status. 
 
 
 
Figure 4.50: High and low-risk sites in relation to hypertension status. 
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Hypertension and PMD Size  
Patients with hypertension showed predominantly minor sized PMDs, followed by 
intermediate and major size, whilst normotensive patients mainly showed intermediate sized 
lesions; Figure 4.51. 
Although a lower mean size was seen in hypertensive compared to normotensive patients 
(291.93 vs. 312.13 mm
2
), a Mann-Whitney U test was not significant (p=0.523), and 
Chi-Square testing showed no significant relationship between hypertension and PMD size 
(p=0.629). 
 
 
 
 
Figure 4.51: Size of PMD (mm
2
) according to hypertension status. 
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Hypertension Status and Dysplasia Grading 
Table 4.29 and Figure 4.52 summarise a significant association between hypertension status 
and degree of dysplasia (p=0.001; Chi-Square test). 
Mild dysplasia was seen equally in both hypertensive and normotensive patients, whereas 90% 
of CIS, 73% of severe and 48% of moderate dysplasia were reported in patients with 
hypertension.  
 
Table 4.29: Oral epithelial dysplasia in relation to hypertension status. 
Hypertension status 
Degree of dysplasia 
Total 
Mild Moderate Severe CIS 
 
Normotensive 
21 12 6 1 40 
50% 52% 27% 10% 41% 
Hypertensive 
21 11 16 9 57 
50% 48% 73% 90% 59% 
Total 
42 23 22 10 97 
100% 100% 100% 100% 100% 
 
 
 
Figure 4.52: Oral epithelial dysplasia according to hypertension status.
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Hypertension Status, Tobacco and Alcohol Use 
Using Chi-Square testing, no significant relationship was found between hypertension and 
smoking status (p=0.921) or alcohol drinking status (p=0.061), although all smoking and 
drinking status subgroups were more frequently seen in hypertensive patients. 
 
 
Family Cancer History  
Full and detailed information related to family cancer history in medical records was limited 
to 15 patients in this study; 10 had a negative family history and 5 were positive. In the 5 
positive histories, a first degree relative was involved; 4 fathers (prostate, throat, bowel and 
oral cancer) and one maternal history of breast and stomach cancer. 
 
Patients with a positive familial history were all alcohol drinkers and tobacco smokers; 3 
males (1< 40 years and 2 between 41-62 years old) and 2 females younger than 40 years. 
Four smoked less than 20 cigarettes per day and one was an ex-smoker; 2 males drank more 
than the recommended units of alcohol (> 21 units) per week. 
 
Out of the ten patients with a negative family cancer history, seven were male (two < 40 
years and five between 41-62 years) and 3 female (41-62 years); five drank more than the 
recommended units, 3 were non-smokers, 4 smoked < 20 cigarettes/day, 2 smoked > 20 and 
one was an ex-smoker. 
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Dental Prosthesis Wear 
The majority (53%) of PMD patients wore dental prostheses; 25% complete dentures, 17% 
crowns and bridges and 11% either upper or lower dentures; Figure 4.53. 
 
No significant relation was found between PMD size and dental prosthesis wear (p=0.684; 
Chi-Square test), although patients wearing prostheses were more likely to have intermediate 
sized dysplasia, followed by minor and major lesions. Non-wearers showed a higher 
prevalence of minor sized lesions; Table 4.30 and Table 4.31. 
 
Table 4.32 shows the average size of PMDs in relation to intraoral dental prostheses types. 
Overall, patients with prostheses exhibited larger mean sizes than non-wearers (332.5 vs. 
269.5 mm
2
). Patients with crowns and bridges had larger sized PMDs compared to denture 
wearers (345 vs. 330.5 mm
2
), although in both cases Mann-Whitney U tests were not 
significant (p=0.557, p=0.647, respectively). 
 
In dental prostheses wearers, the majority of PMDs were seen at high-risk sites; 77% (41/53) 
compared with 23% (12/53) low-risk sites.  
 
Patients with FOM dysplasia were mainly dentures wearers 40% (14/35) compared to 31% 
for tongue. Whilst crowns and bridges were more frequently associated with tongue lesions 
(47%) compared to FOM (41%), the relation was non-significant (p=0.338; Chi-Square test). 
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Figure 4.53: Dental prostheses in PMD patients. 
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Table 4.30: Dental prostheses wear and PMD size. 
PMD size categories 
(mm
2
) 
Dental prosthesis 
wear 
Total 
Yes No 
 
 
Minor < 200 19 23 42 
Intermediate (200-600) 26 19 45 
Major > 600 5 5 10 
Total 
50 
52% 
47 
48% 
97 
100% 
 
 
Table 4.31: Types of dental prosthesis according to PMD size. 
PMD size categories 
(mm
2
) 
Types of dental prosthesis 
Total 
Full 
denture 
Upper/lower 
denture 
Crowns and 
bridges 
Non-wearer 
 Minor 9 4 6 23 42 
Intermediate 12 6 8 19 45 
Major 2 1 2 5 10 
Total 
23 11 16 47 97 
24% 11% 17% 48% 100% 
 
 
Table 4.32: Mean PMD size according to dental prosthesis wear. 
Types of dental  prosthesis Mean N Maximum Minimum SD 
Full denture 330.5 23 1,800 36 377.566 
Upper/lower denture 319 11 1,050 40 307.349 
Crowns and bridges 345 16 945 21 267.198 
Non-wearer 269.5 47 884 36 217.439 
Total 301.98 97 1,800 21 279.166 
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Oral Health Status and Mouthwash Use  
In this study, a deficiency in recording oral hygiene status and mouthwash use was noted in 
PMD patient files. 
Out of 100 patients, data retrieved from the medical records showed information for only 12 
patients; 9 were mouthwash users, although no detailed information was available. Also, no 
specific information was recorded in relation to oral hygiene status. 
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4.4.4. Logistic Regression Analysis 
Non-homogenous Leukoplakia 
In order to investigate predictors of developing non-homogenous leukoplakia, logistic 
regression analysis was performed. Several independent risk factors were initially considered 
separately, and then -2 log likelihood ratios were applied to assess the statistical significance 
of these variables. Multivariable logistic regression analysis was then used to explore the 
possible effects of these risk factors. 
 
Table 4.33 presents Odds-Ratios (OR) and 95% confidence intervals (CI) of the univariable 
and multivariable predictor model for non-homogenous leukoplakia development. 
 
Regression analysis showed that patient age had no effect (OR=1.012, 95% CI, 0.977-1.048) 
(p=0.516), whilst the risk for non-homogenous leukoplakia to occur in males was 1.631 times 
higher than females (95% CI, 0.599-4.441), although this was not significant (p=0.339). 
 
The analysis supported that the majority of homogenous leukoplakias were associated with 
smoking. A reduction in risk of non-homogenous leukoplakia development by 65% was seen 
in ex-smokers, 80% for smoking > 20 cigarettes/day and 71% for smoking ≤ 20, compared to 
non-smokers, however these were non-significant (p=0.773, p=0.641, p=0.478, respectively). 
This observation indicates that non-homogeneous leukoplakias were more common in non-
smokers or in patients with lower smoking activity, emphasising the inherent high-risk in 
these patients. 
 
Drinking > 28 units/week increased the risk for non-homogenous leukoplakia by 3-times 
compared to non-drinkers (95% CI, 0.566- 16.177), whilst drinking ≤ 28 units/week caused a 
1.78-times higher risk compared to non-drinkers (95% CI, 0.341-9.293), although both were 
non-significant (p=0.196, p=0.494, respectively). 
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Patients with a history of systemic disease had an increased risk of non-homogenous 
leukoplakia 4.2-times higher than those without (95% CI, 0.510- 34.737), although this was 
not significant (p=0.182). 
In the final regression model, when smoking and drinking were entered together, the 
reduction in risk for non-homogenous leukoplakia development was also seen among current 
smokers, with a 38% and 47% reduction risk was observed in patients who smoked ≤ 20 and 
> 20 cigarettes/day, respectively. 
 
Drinkers exceeding 28 units/week exhibited a 6.27 times increased risk of non-homogenous 
leukoplakia development compared to non-drinkers, however, this did not reach statistical 
significance (95% CI, 0.717- 42.796) (p=0.061). 
 
 
  
 
 
2
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Table 4.33: Logistic regression models for non-homogenous leukoplakia. 
Clinical appearance Risk Factors 
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds (95% CI) p-value 
Non-homogenous 
leukoplakia 
 
 
 
Age 1.012 (0.977-1.048) 0.516   
Sex 
Females 
Males 
 
Reference category 
1.631 (0.599-4.441) 
 
 
0.339 
  
Smoking status 
Non-smokers 
Smoking ≤ 20 cig/day 
Smoking > 20 cig/day 
Ex-smokers 
 
Reference category 
0.800 (0.175-3.651) 
0.645 (0.192-2.167) 
0.714 (0.173-2.941) 
 
 
0.773 
0.478 
0.641 
 
 
0.381 (0.080-1.811) 
0.467 (0.080-2.716) 
1.232 (0.0250-6.083) 
 
 
0.225 
0.396 
0.798 
Drinking status 
Non-drinker 
≤ 28 units/week 
> 28 units/week 
 
Reference category 
1.779 (0.341-9.293) 
3.025 (0.566-16.177) 
 
 
0.494 
0.196 
 
 
2.652 (0.469-14.977) 
6.265 (0.917-42.769) 
 
 
0.270 
0.061 
Medical history  
Negative 
positive 
 
Reference category 
4.211 (0.510-34.737) 
 
 
0.182 
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High Grade Dysplasia 
Age of patient, sex, clinical types of leukoplakia, anatomical site and size of dysplasia, 
medical history, smoking and drinking behaviours were entered as independent variables to 
try to predict the most important factor (s) associated with high grade dysplasia. 
 
Table 4.34 summarises logistic regression analysis of univariable and multivariable predictor 
models for high grade dysplasia. 
 
The analysis showed that patient age did not significantly influence the development of high 
grade dysplasia (OR=1.017, 95% CI, 0.985-1.049) (p=0.312).  
Males had a 1.338 times higher risk than females for developing high grade dysplasia (95% 
CI, 0.572-3.128), although this was not significant (p=0.502). 
 
Non-homogenous leukoplakia was a significant predictor of high grade dysplasia 
development (p=0.020), increasing the risk 3.3-times compared to homogenous lesions (95% 
CI, 1.205-9.018). 
 
Lesion size > 600 mm
2
 was a significant predictor of high grade dysplasia development 
(p=0.026), with an 11.5-times higher risk than minor sized lesions (< 200 mm
2
) (95% CI, 
1.331-99.329). 
 
Alcohol drinking > 28 units/week was a significant predictor for high grade dysplasia 
(p=0.038), with a 4.89-times higher risk compared to non-drinkers (95% CI, 1.089-21.950). 
Drinking ≤ 28 showed 2.78-times the risk of non-drinkers (95% CI, 0.658-11.727), although 
non-significant (p=0.164).  
 
A history of systemic disease was found to be a significant predictor of high grade dysplasia 
development (p=0.047), with a 4-times increased risk compared to patients with no systemic 
disease (95% CI, 1.016-15.981). 
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The multivariate logistic regression final model utilized the goodness of fit statistic -2 log 
likelihood ratio, including leukoplakia type, PMD size, medical history, smoking and 
drinking behaviours.  
A positive history of systemic disease remained the only significant predictor in the 
multivariable model for high grade dysplasia occurrence (p=0.026), with an increased risk of 
7.45-times compared to patients with no systemic disease (95% CI, 1.269- 43.721). 
 
In the final model, lesion size > 600 mm
2
 showed a 7.635-times higher risk for high grade 
dysplasia development compared to small lesions, but this was non-significant (p=0.090). 
Drinking > 28 units/week showed a 4.760-times higher risk for high grade dysplasia 
compared to non-drinker, however, this was not significant (p=0.105). 
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Table 4.34: Logistic regression analysis for high grade dysplasia. 
Histopathology Risk Factors  
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds(95% CI) p-value 
 
Binary grading 
system 
High grade dysplasia 
Age 1.017 (0.985-1.049) 0.312 
  
Sex 
Females 
Males 
 
reference category 
1.381 (0.572-3.128) 
 
 
0.502 
  
Leukoplakia types 
Homogenous 
Non- homogenous 
 
Reference category 
3.296 (1.205-9.018) 
 
 
0.020 
 
2.481 (0.745-8.261) 
 
 
0.139 
PMDs site 
FOM 
Tongue 
Remaining sites 
 
Reference category 
1.825 (0.721-4.620) 
1.095 (0.366-3.281) 
 
 
0.204 
0.871 
  
PMDs size (mm2) 
Minor < 200 
Intermediate 200-600 
Major > 600 
 
Reference category 
1.460 (0.624-3.418) 
11.500 (1.331-99.329) 
 
 
0.383 
0.026 
 
 
0.756 (0.257-2.225) 
7.635 (0.727-80.179) 
 
 
0.612 
0.090 
Medical history  
No 
Yes 
 
Reference category 
4.029 (1.016--15.981) 
 
 
0.047 
 
 
7.449 (1.269-43.721) 
 
 
0.026 
Smoking status 
Non-smokers 
Smoking ≤ 20 cig/day 
Smoking > 20 cig/day 
Ex-smokers 
 
Reference category 
0.576 (0.173-1.915) 
1.429 (0.364-6.6127) 
0.485 (0.122-1.922) 
 
 
0.368 
0.609 
0.303 
 
 
0.427 (0.085-2.156) 
1.638 (0.253-10.588) 
0.212 (0.033-1.354) 
 
 
0.303 
0.604 
0.101 
Drinking status 
Non- drinker 
≤ 28 u/w 
> 28 u/w 
 
Reference category 
2.778 (0.658-11.727) 
4.889 (1.089-21.950) 
 
 
0.164 
0.038 
 
 
2.329 (0.425-12.747) 
4.760 (0.721-31.414) 
 
 
0.330 
0.105 
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4.5. Discussion 
Assessment of risk factors in PMD patients may facilitate treatment planning and identify 
patients at higher risk of developing OSCC and/or further disease who require extended 
follow-up. 
Patients in this study formed a homogenous cohort, since all were diagnosed with dysplastic 
PMD, all underwent standardised laser intervention and were then followed-up by the same 
clinical team. 
 
The current study investigated possible effects from the two most widely recognised risk 
factors of tobacco and alcohol use, in addition to systemic disease and dental factors, on 
demographic, clinical and histopatholgical features of dysplastic PMDs. 
 
 
4.5.1. Tobacco Smoking Behaviour in PMD Patients 
Three measurements of tobacco exposure were used: number of cigarettes smoked per day, 
duration of smoking (years) and pack-years score which captures both dose and duration of 
exposure (Dietrich et al., 2004). For each smoker, the status and intensity of smoking were 
reported at each clinic follow-up, in addition to first presentation and most recent follow-up, 
because smoking behaviour changes from one point to another during the clinical 
management time. 
 
At initial presentation, the majority of patients were active smokers (63%), with 22% ex-
smokers and only 15% non-smokers. This is in accordance with other studies: Hamadah 
(2007) found that 70% of leukoplakias were associated with current smokers, 20% with ex-
smokers and 10% with non-smokers, Freitas et al. (2006) reported a higher proportion of 
leukoplakias in current smokers (79%) and Hogewind and van der Waal (1988) found that 64% 
of leukoplakias occurred in smokers compared to 36% idiopathic or smoking-unrelated 
leukoplakia. 
In this study, amongst current smokers, a higher percentage of males (73%) compared to 
females (27%) was seen and the proportion of male smokers was higher than non-smokers 
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(73% vs. 33%). Female patients were more likely to be non-smokers than smokers (67% vs. 
27%). This sex difference is in agreement with most of the previous studies (Freitas et al., 
2006; Hamadah, 2007) and may be explained by social habits, more responsibility and stress 
on males who need a coping mechanism for the stress or may reflect women’s low economic 
resources with more health awareness.  
 
Current smokers were significantly younger than both non-smokers and ex-smokers for both 
male (52 vs. 64, 68 years) and female patients (52 vs. 68, 65 years), which agrees with Freitas 
et al. (2006) who found a significantly lower mean age of smokers compared to non-smokers 
with PMDs (49 vs. 59 years). 
 
Males smoked for a significantly longer time (mean 37 years) compared to females (28 years) 
although, interestingly, male and female current smokers were of similar mean age (52.20 vs. 
52.47 years). Males presumably started smoking earlier than females with increased risk 
arising from long-standing exposure. 
 
Patients consuming < 10 cigarettes per day had the highest mean smoking history (46 years), 
compared to those smoking 10-20 cigarettes per day (35 years) and those smoked > 20 per 
day (33.6 years); however, the correlation was not significant. It is clear that both the number 
of cigarettes smoked per day and the length of smoking history needs to be recorded, 
therefore, for every PMD patient. 
 
Females were more often non-smokers than males (67% compared to 33%), which is similar 
to the findings of other studies (Muscat et al., 1996; Schepman et al., 1998; Freitas et al., 
2006).  
Similar to Muscat et al. (1996), who found a greater percentage of non-smoking females over 
the age of 50 years, our non-smoker females had a mean age of 68 years. 
 
Although males consumed a higher amount of tobacco than females, no significant 
differences were seen between males and females in the average number of cigarettes smoked 
per day.  
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The study showed that patients in middle age (41-62 years) smoked a significantly higher 
average number of cigarettes per day compared to those older than 63 years (25 vs. 16 
cigarettes/day); 88% of heavy smokers and 66% of intermediate smokers were middle-aged. 
One reason for the lower average number of cigarettes intake in older ages may be the health 
problems caused by smoking, which are more likely to appear later in life, compared to 
younger age who have not yet developed many secondary diseases. As smokers get older, 
many forced by health problems to either reduce or quite smoking.  
 
It has been reported that unemployment individuals smoke more (Lin, 2010), which may be 
related to the stress from low income (Greenwood et al., 2003). Smoking in this group of 
patients has been described as a coping mechanism for the stress associated with deprivation 
and low income (Marmot, 1997; Stead et al., 2001). 
The current study supports this view: 88% of unemployed patients smoked tobacco in the 
range 10 to 60 cigarettes/day, compared to 74% employed and 44% retired who smoked 10-
50 and 7-30 cigarettes/day, respectively. Smoking fall in retired individuals may be one of the 
substantial changes in lifestyle accompanied occupational retirement (Nooyens et al., 2005). 
Individuals who undergo the transition into retirement are more likely to reduce or quit 
smoking than those who do not (Lang et al., 2007), which may be explained by the fact that 
retired patients are usually old age with systemic diseases compared to younger patients. In 
addition, a change in economic resources after retirement may influence the smoking habit. 
 
The role of tobacco as a principal risk factor for oral leukoplakia development is well 
documented (Axell, 1987; Schepman et al., 2001). Baric et al. (1982) found that leukoplakia 
was 6-times more likely to affect smokers compared to non-smokers.  
 
It is known that the type, quality and quantity of tobacco smoking affects localization of 
leukoplakia in the oral cavity (Schepman et al., 2001). In this study, compared to all other 
oral subsites, FOM leukoplakias were significantly more common in current smokers than 
non-smokers. In contrast, leukoplakias on lateral and ventral tongue surfaces were 
significantly more frequent in non-smokers. The preferential localization of FOM PMDs in 
current smokers may relate to the accumulation of tobacco-related toxins in saliva which act 
as a reservoire for carcinogens in tobacco products (Lederman, 1964). In addition, a lower 
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degree of keratinization and higher permeability of oral mucosa at this location may also 
influence carcinogenesis of tobacco-related toxins (Mashberg and Meyers, 1976; Lesch et al., 
1989). 
This is similar to Freitas et al.’s (2006) study, which found that FOM and buccal mucosa 
were more frequent sites amongst smokers, whilst tongue leukoplakia was the main location 
amongst non-smokers. 
Furthermore, a correlation between cigarette smoking and cell proliferative activity was 
reported in oral anatomic sites exposed to smoking (Cancado et al., 2001; Paiva et al., 2004). 
This correlation was investigated using cytological analysis conducted by Cancado et al. 
(2004), who found a significant larger number of argyrophilic nucleolar organizer regions 
(AgNORs) per nucleus among FOM smokers compared to lateral tongue smears with a 
significant correlation between number of cigarettes smoked per day in FOM cases but not 
lateral tongue. This suggests that oral mucosa is susceptible to alterations in the genetic 
patterns of the cellular regulation in cigarette smokers and in less keratinized regions 
(Cancado et al., 2001), reflected by a cell proliferative activity and may explain the more 
frequent FOM PMDs in smokers and lateral tongue in non-smokers. 
 
Patients younger than 40 years more frequently presented with FOM PMDs, with no tongue 
lesions, whilst patients older than 41 years showed both FOM and tongue PMDs, but with 
more FOM cases. This further supports FOM as the preferential localization in smokers, 
because all young patients were tobacco users (90% current and 10% ex-smokers) compared 
to patients > 41 years who were a mixture of current, non- and ex-smokers. 
 
In both male and female patients, FOM was the main affected subsite in current smokers, 52% 
and 82%, respectively. However, this finding disagrees with Schepman et al. (2001) who 
found buccal mucosa significantly more common in male smokers and FOM more frequent 
in female smokers. They suggested that different ways of placing cigarettes during smoking, 
more centred between the lips in females and to the side in males, may account for the 
difference. 
 
In non-smokers, the tongue was the only affected oral site in females compared to 80% in 
non-smoker males, which is in agreement with other studies (Schepman et al., 2001; Freitas 
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et al., 2006). There is no clear reason why lateral tongue is the only affected site in non-
smoking females and was the predominant site in non-smoker males. However, this indicates 
that non-smokers who develop PMDs in lateral tongue surface may be subjected to other 
more potent carcinogenic factors such as nutritional deficiency, viral infection and chronic 
irritation, but this did not detract from the well-established role of tobacco in oral 
carcinogenesis (Neville and Day, 2002) in the most dependent part of oral cavity (FOM). 
Further studies are needed to confirm this finding and investigate the potential associated 
factors. 
 
The soft palate was not affected in non-smokers and was more involved in current than ex-
smokers (78% vs. 22%). To the best of our knowledge, this finding is reported for the first 
time and suggests that the soft palate is a specific, smoking-related site, although further 
studies with larger sample sizes are required to confirm and investigate this finding. This 
finding supports the hypothesis of carcinogenic effect of tobacco smoke on the oral 
epithelium through a direct contact to this high-risk site with a thin unprotected epithelium 
that devoid of keratin (Schwartz, 2008). This is supported by a study conducted by Boffetta et 
al. (1992) who found that tobacco smoking was more strongly associated with soft palate 
cancer than with lesions in more anterior sites. In addition, soft palate is a less accessible site 
for a mechanical cleansing action with prolonged tobacco-related carcinogens contact, 
compared to anterior parts of the oral cavity. 
 
FOM, ventral tongue and soft palate were the most significantly affected sites in patients with 
long smoking histories. This study has shown that the duration of smoking was more 
significant than its intensity in relation to site distribution. This suggests that long-term 
continuous exposure is more harmful than the amount of tobacco smoked at any one time-
point. This may reflect intensity-duration molecular mechanisms in the FOM, tongue and soft 
palate from prolonged and continuous contact to tobacco-related carcinogens. This is 
supported by a study on lung cancer conducted by Lubin et al. (2008) who indicated that 
smoking duration is much more important than the intensity in causing lung cancer and they 
indicated that for fixed pack-years, smoking at a lower intensity for a longer duration was 
more harmful compared to a higher intensity for a shorter duration. This was explained by the 
behavioural factors, with heavy smokers inhaling less deeply while maintaining addiction-
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sufficient nicotine levels, decreasing the carcinogenic effect per cigarette and decreasing risks 
at higher intensities (Lubin et al., 2008) with saturation activation pathways (Lutz, 1998). 
 
In this study the joint effect of intensity and duration of tobacco smoking was investigated 
using lifetime tobacco exposure (pack-years). The negative correlation between tobacco 
cumulative effect and age of patients did not reach significance. When smokers get older, 
they were found to consume a lower number of cigarettes per day, which may be due to the 
health problems that are more likely to appear at older ages, forcing them to reduce smoking 
intensity. Although the mean pack-years score for males was higher than females (43 vs. 32), 
which was expected due to longer smoking history and higher mean number of cigarettes 
smoked per day, the difference was not significant. This may be due to the small number of 
females relative to males (8 vs. 28), which may be inadequate to detect statistical significance. 
 
This study showed a significant relation between numbers of cigarettes smoked per day and 
the clinical type of PMDs. Erythroplakias were only seen in heavy smokers, with the highest 
number of cigarettes smoked per day (38). Exophytic non-homogenous leukoplakias were 
more frequently observed in light-smokers (18). 
 
Homogenous leukoplakias in this study were seen in patients with a long smoking history 
(mean 34.8 years), but with no significant relation, which may be due to the small number of 
cases in each clinical type. 
To the best of our knowledge, this is the first study to consider the relation between smoking 
status, intensity of smoking and PMD clinical appearance.  
 
Significantly, current smokers exhibited the smallest mean size of PMD compared to non-
smokers (241.5 vs. 473 mm
2
). Minor sized PMDs were most common in heavy smokers who 
showed the smallest mean size compared to light smokers (247.5 vs. 316 mm
2
). A negative 
correlation, albeit non-significant, was found between smoking intensity (cigarettes/day) and 
PMD size; the higher the intensity, the smaller the size. A longer smoking history was also 
associated with smaller sized PMDs. While there is no clear biological explanation for this 
phenomenon, it may be that non-smokers have intrinsically wider field changes within the 
oral cavity as opposed to more localized tobacco initiated lesions. 
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Freitas et al. (2006) found no significant difference between lesion size in smokers and non-
smokers. These authors measured lesion size clinically at the time of diagnosis, however, 
whilst this study used accurate measurements from pathology reports following lesion 
excision. Freitas et al. (2006) did show a higher percentage of smaller sized lesions in 
smokers compared to non-smokers (66% vs. 55%), with only 8% of larger size lesions found 
in smokers. 
 
This study showed a higher presentation of dysplastic lesions in current smokers compared to 
both ex-smokers and non-smokers (65% vs. 20% and 15%, respectively). 
A significant relationship was found between smoking intensity and degree of dysplasia; 
heavy smokers showed primarily severe dysplasia, whilst light smokers showed the least 
dysplastic features (1 mild dysplasia and 1 CIS). 
 
A positive correlation was found between smoking history and degree of dysplasia, with a 
longer history associated with higher dysplasia severity. These findings suggest that 
increasing dysplasia is associated with longer exposure to risk factors (Napier and Speight, 
2008; Warnakulasuriya et al., 2008). Previous studies on oral cancer and epithelia dysplasia 
have reported increased risk with higher levels of smoking which may decrease following 
smoking cessation (Blot et al., 1988; Morse et al., 1996; Morse et al., 2007). 
 
 
4.5.2. Alcohol Consumption in PMD Patients 
Existing studies show controversial data on the role of alcohol as an independent risk factor 
for oral PMDs. Recently, more evidence to support alcohol as an independent risk factor for 
leukoplakia and erythroplakia has been found. 
 
In a hospital-based, cross-sectional study of 2017 patients, oral leukoplakias were seen in 
those who were drinking but not smoking (Saraswathi et al., 2006). This is supported by a 
prospective cohort study in US males, which found that alcohol consumption was an 
independent risk factor for the incidence of PMDs (Maserejian et al., 2006a). In an Indian 
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study conducted by Hashibe et al. (2000a), alcohol was a significant factor for oral 
leukoplakia even after adjusting for tobacco habits.  
 
The relationship between drinking alcohol and erythroplakia was also demonstrated in a case-
control study of 100 erythroplakia patients and 47,773 controls with a dose-response 
relationship for both frequency and duration after adjusting for age, sex and smoking habits 
(Hashibe et al., 2000b). 
 
Case control studies on the risk of oral epithelial dysplasia in Great Britain have considered 
alcohol to be important only in conjunction with tobacco, suggesting a synergistic effect 
(Jaber et al., 1998; Jaber et al., 1999). A more recent study in Taiwan supports the notion that 
alcohol intake was not a risk factor for the development of oral leukoplakia (Lee et al., 2003). 
 
The current study found 83% of patients were current drinkers at initial presentation. Light 
drinkers (1-14 units/week) were the most common, followed by heavy drinkers (> 28), whilst 
intermediate drinkers (15-28) were least common. A significant association was found 
between drinking status and patients’ sex and age: males were predominantly current drinkers, 
whilst females were often non-drinkers. All young patients were current drinkers whereas 
middle age patients were usually ex-drinkers. Common reasons for non-drinking in females 
may be due to cultural or family traditions, pregnancy or maternal responsibility, whilst 
males drink due to social pressures and may have greater disposable income. Middle aged 
patients with more health problems may quit drinking compared to younger patients who 
have not yet developed drinking-associated diseases. 
 
Higher levels of alcohol intake in males are reported in studies from all over the world. The 
present study found that males formed 97% of heavy drinkers with an average alcohol intake 
of 38 units/week (compared to females 9.5 units/week). Data from the Office for National 
Statistics in 2006 showed men to be drinking twice as much alcohol as women, with an 
average 18.7 units a week, compared to 9.0 for women. Males in our PMD cohort consumed 
twice the National Statistics average, emphasising the difference between general population 
and high risk hospital-based studies. 
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In the United Kingdom, safe levels for alcohol drinking are less than 21 units per week for 
men and 14 units per week for women, with a high risk of developing several health 
problems associated with > 50 units/week for men and 35 for women. In this study, 58% of 
males consumed > 21 units/week and 9% of women consumed > 14 units per week, both 
exceeding the guidelines established by the Department of Health, and emphasising that our 
patients were at higher risk of alcohol misuse. 
 
Furthermore, the study showed that 29% of males reported drinking over 50 units/week and 3% 
of females over 35 units/week. In England, in 2008, 7% of men reported drinking over 50 
units per week with 5% of women drinking over 35 units. This study showed a higher 
percentage of male drinkers at higher risk than the general population (29% vs. 7%), whilst 
female drinkers reported a lower percentage (3% vs. 5%). This suggests underreporting of 
alcohol intake in female patients and emphasises the need for more objective bioassays for 
alcohol risk assessment in addition to self-reporting. The reasons for inaccuracy of self-
reporting may be to deny problem drinking, avoid personal criticism or the inability to 
remember drinking patterns because of alcohol intoxication itself (Sommers et al., 2002). 
This may reflect complex physiological, psychological, and social differences between males 
and females (Sommers et al., 2002). 
 
All exposures were measured by self-reporting and some degree of exposure 
misclassification may occur as a result of underreporting. Unreliability of self-reporting of 
alcohol consumption has been reported previously by Babor et al. (1987). The validity of 
reporting alcohol intake in heavy drinkers in females who tend to underreport heavy drinking 
of alcohol may be problematic and also this may occur among males (Muscat et al., 1996). 
However, since relatively few heavy drinker females in this study, the misclassification of 
heavy drinkers as intermediate may result in slightly spurious effects associated with 
intermediate drinkers, but also may lead to substantial underestimation of risk in heavy 
drinkers group. 
 
Similarly, it is difficult to obtain a reliable information about the amount of tobacco intake 
and type of the product (van der Waal and Axell, 2002); thus study limitation should be 
considered when interpretate the findings related to both alcohol and tobacco. This 
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emphasises the need for more objective and reliable way of measurement, in addition to self-
reporting. Laboratory test modalities for more accurate and useful risk assessment have been 
used; cotinine which is a nicotine metabolite with a long half-life in the circulation has been 
used to confirm the dose and duration of tobacco exposure (Atkin et al., 2002; Sinha et al., 
2012) and mean corpuscular volume (MCV) or other biomarkers for alcohol use (Neumann 
and Spies, 2003; Goodson et al., 2010). 
 
This study showed a significant correlation between patient age and number of alcohol units 
consumed per week: old age drinkers consumed the lowest level of alcohol compared to both 
young and middle aged. This agrees with the Office for National Statistics (2008), which 
reported lower alcohol consumption in the oldest age groups in both males and females. 
Alcohol consumption declining with age may be connected to changes in life circumstances 
and attitudes such as ill health, less ability to process alcohol, increased interaction with 
medications and a reduced income in retirement. 
 
Whilst no significant relationship was found between drinking status and PMD site, the FOM 
was the most frequent site in heavy drinkers (> 28 units/week). This supports the hypothesis 
of the carcinogenic effect of alcoholic beverages on the oral mucosa through direct contact 
(Boffetta et al., 1992). 
 
Alcohol may be an independent risk factor for oral PMDs regardless of frequency, drinking 
pattern, type of beverage or smoking history, and the association has been seen in non-
smokers (Maserejian et al., 2006a). Alcohol intake of more than 30 g/day increased the risk 
of developing oral PMDs by 2.5-times, with one additional drink per day increasing risk by 
22% (Maserejian et al., 2006a). 
 
The relation between amount of alcohol intake and PMD clinical appearance was significant. 
Homogenous leukoplakias were more commonly seen in light drinkers, with a higher 
presentation of speckled and exophytic subtypes in heavy drinkers. Seven out of eight 
patients with erythroplakia were current drinkers. Heavy exposure to alcohol-related 
carcinogens, associated with genetic profile factors, may be responsible for certain clinical 
types of PMDs development. 
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Patients with mild dysplasia had the lowest average alcohol intake (22), whilst those with CIS 
had the highest average alcohol intake (43), albeit non-significant.  
 
This study demonstrated a significant relationship between the two major risk factors, 
tobacco and alcohol at first presentation and most recent follow-up. Whilst 92% of current 
drinkers at initial presentation were also current smokers, half of non-drinkers were ex-
smokers. This is similar to Bien and Burge (1990) who reported that over 90% of alcoholic 
inpatients were smokers. Smoking and alcohol consumption can be seen as complementary 
behaviours, occurring at social, psychological and physiological levels, with a factor which 
increases or decreases one behaviour will also tend to increase or decrease the other (Room, 
2004). Nicotine appears to facilitate ethanol consumption by reducing the intoxicating effects 
of alcohol, enhancing more drinking (Johnson et al., 1991; Chen et al., 2001). 
 
 
4.5.3. Medical History of PMD patients 
Medical problems such as hypertension, diabetes mellitus, oral candida infection, anaemia 
and immunodeficiency were seen in 88% of the study population (55% males and 33% 
females). 
 
In this study, a significant relationship was found between patient age and medical history. 
All PMD patients older than 63 years, 84% of middle aged and 70% < 40 years, had one or 
more systemic disorders. This agrees with a considerable body of opinion that suggests as 
human lifespan increases, there is an increased prevalence of disease. Elderly patients often 
suffer from medical problems which may be due to complex physiological, biochemical and 
molecular changes (Malaguarnera et al., 2010). In addition, there is a decreased efficiency of 
both host defense mechanisms and healing (Soames and Southam, 2005). 
 
Regular medication intake was reported by PMD patients with systemic disease in this study; 
however, investigating the interaction of these medications and the behaviour of PMDs was 
unachievable because most patients took multiple medications of varying dose and duration.  
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Investigating systemic disease in this study cohort revealed that hypertension was most 
common, followed by diabetes mellitus; this distribution agrees with a study on the 
prevalence of oral mucosal lesions in alcohol misusers in India, conducted by Rooban et al. 
(2009). In this study, 60% of PMD patients were hypertensive and usually older than 
normotensive ones, in particular females were older than males, but differences did not reach 
significance. 
 
Associations between systemic diseases and oral PMDs have not been examined or reported 
widely. In this study, non-homogenous leukoplakias were more frequently seen in 
hypertensive patients, albeit non-significant. A significant association was found between 
hypertension and non-homogenous subtypes; 75% of speckled lesions were seen in 
hypertensive patients, whilst all nodular and 60% of exophytic subtypes were seen in 
normotensive patients. The higher prevalence of non-homogenous leukoplakia in 
hypertensive patients and the significant association between certain clinical non-
homogenous subtypes and hypertension may be due to an effect from anti-hypertensive 
medications which may influence the clinical appearance of PMDs. 
 
FOM, lateral and ventral tongue surfaces as well as soft palate were the most common 
affected sites in hypertensive patients, whereas buccal mucosa was most frequent in 
normotensive. In this study, 70% of major sized lesions were seen in hypertensive patients. 
 
A higher frequency of CIS and severe dysplasia were seen in hypertensive patients and it is 
possible that anti-hypertensive drugs may play an enhancing role. According to 
Tangjarturonrasme et al. (2007), medications such as Atenolol cause oral lichenoid reactions 
which can undergo dysplastic change, and malignant transformation (Fatahzadeh et al., 2004), 
although the pathogenesis of this adverse reaction is still unclear. 
 
To the best of our knowledge, this is the first study to investigate the relation between oral 
PMD behaviour and systemic hypertension, but it is clear further research is warranted in this 
area. 
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Similar to Saini et al. (2010) diabetic patients in this study were mainly affected with type II 
diabetes mellitus, with females significantly more commonly affected. This is consistent with 
an Indian study conducted by Dikshit et al. (2006) who found that diabetes mellitus was 
mainly associated with PMDs in females. 
 
Leukoplakia was the only clinical type of PMD seen in our diabetic patients. It has been 
reported that diabetes mellitus is a risk factor for oral cancer and oral leukoplakia, with 
diabetic patients 3-times more likely to develop oral leukoplakias than non-diabetics 
(Dietrich et al., 2004; Ujpal et al., 2004). A similar association was found by Albrecht et al. 
(1992) who noted a 6.2% prevalence of oral leukoplakias amongst diabetic patients, 
compared with 2.2% in controls. However, Saini et al. (2010) found no association between 
diabetes mellitus and oral PMDs and suggested that adjustment for confounders such as 
tobacco and alcohol may be an important factor to consider.  
Erythroplakias and speckled leukoplakias were only seen in non-diabetic patients. Dikshit et 
al. (2006), however, reported diabetes as an independent risk factor for oral leukoplakia and 
also erythroplakia in women. 
 
The majority of diabetic patients in this study were current smokers and drinkers, with 
intermediate smokers and light drinkers most common. Oral PMDs in diabetic patients were 
often seen in high-risk sites (FOM and tongue). However, no relationship between diabetic 
mellitus and PMD behaviour was significant, probably because of the small number of 
patients. 
 
Diabetes mellitus may lead to metabolic and immunological changes along with 
inflammatory and atrophic changes affecting oral mucosa (Ponte et al., 2001). The atrophic 
changes may promote development of oral PMDs (Albrecht et al., 1992; Ujpal et al., 2004). 
 
The precise role of candida infection in oral carcinogenesis remains unclear. Cawson (1966) 
suggested that fungal infection may be superimposed upon pre-existing disorders rather than 
initiating them. This is supported by Holmstrup and Bessermann (1983) who found that a 
non-homogenous candidal leukoplakia converted into homogenous leukoplakia following 
candida infection control. 
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Barrett et al. (1998), however, found a significant correlation between dysplasia severity and 
infection with candida; 22% of dysplasias infected with fungi showed more severe dysplastic 
features compared with 8% of non-infected ones. The same group concluded that, following 
histological confirmation of dysplasia, anti-fungal therapy should be part of clinical 
management.  
 
Evidence supports the role of candida species in oral carcinogenesis based on the fact that 
certain species have a higher production of nitrosamine compounds which play a role in 
initiation of carcinogenesis (Sanjaya et al., 2011). 
 
In this study, eight cases were diagnosed with oral candida infection; six were seen at initial 
presentation and affected equally with mild, moderate and severe dysplasia, whilst two with 
mild dysplasia were diagnosed after laser intervention during follow-up. 
Candida infection was diagnosed in five non-homogenous leukoplakias which agrees with 
Krogh et al. (1987) who evaluated various strains of candida in leukoplakia and found that 
rarely occurring candida albicans were increasingly isolated from non-homogenous 
leukoplakia. All cases with candida albicans in this study were tobacco users, with the 
majority heavy smokers. This agrees with the hypothesis of epithelial alteration caused by 
cigarette smoking (increased keratinization) allowing candida colonization and enhanced 
adherence (Sanjaya et al., 2011). In this study, it is unclear whether candida infection 
diagnosed at first presentation was secondary to dysplastic changes (co-incidental) or had led 
uncontrolled epithelial growth initiating change (Sanjaya et al., 2011). Further understanding 
of the biological effects of candida and oral epithelial dysplasia is warranted. 
 
In this study, detailed information relating to family cancer history in medical records was 
limited, leading to a reduced ability to evaluate the importance of this factor for PMD patients. 
The medical background of our patients with a positive family history of cancer did not 
reveal any predisposing factors and the number of young patients was not large enough to 
provide conclusive information in respect of familial antecedents as a risk factor for this 
group. Three out of five patients with a familial cancer history were < 40 years. A familial 
cancer history may be an increased risk for young patients, since tobacco and alcohol use 
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require relatively long durations of exposure and these factors may be less implicated in 
OSCC development in younger patients (Hirota et al., 2008). 
 
 
4.5.4. Dental Prosthesis Wear 
More than half of PMD patients in this study wore dental prostheses, mainly removable 
appliances, which were either complete or upper/lower dentures. The need for dentures is not 
surprising since more than 90% of patients were older than 40 years and 35% older than 62 
years. 
 
Overall, patients wearing dental prosthesis had larger sized PMDs, with FOM lesions more 
commonly seen in denture wearers. PMDs affecting the tongue were more frequently seen in 
patients with crowns and bridges, although this was not significant. It has been said that 
denture wear is not associated with an increased risk of oral cancer (Zheng et al., 1990; 
Marshall et al., 1992; Fisher et al., 2005); however, large sized PMDs in wearers may be 
associated with chronic physical irritation, particularly to FOM and tongue epithelium 
(Piemonte et al., 2010). Further, well-designed studies in this respect with more information 
about dental prosthesis wear in relation to oral anatomical sites are required. 
 
Since the current study is a retrospective investigation using data recorded in patients’ 
medical records for diagnosis and follow-up, information concerning mouthwash use was 
limited to 12 patients, with nine who did not use mouth wash and only 3 mouthwash users, 
which did not allow for statistical analysis. 
 
In many available mouthwashes, the presence of ethanol has raised concern regarding safety. 
It has been suggested that a heavy alcoholic-mouthwash may expose oral mucosa to the level 
of alcoholic beverages that induce oral cancer (Winn et al., 2001). Therefore, it has been 
recommended that the use of alcohol-containing mouth rinses in high-risk populations should 
be restricted (Reidy et al., 2011). 
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Although some substantial evidence may support the relationship between ethanol and oral 
cancer, the assumed relation is inconsistent and lacks scientific evidence (Badran et al., 
2010). Well-designed studies are needed in future to determine any causal relationships 
between alcohol-containing mouthwashes and oral cancer and require larger sample sizes, 
detailed parameters and assessment of residual confounders such as alcohol and tobacco use. 
 
Similarly, limited information about oral hygiene status prevented statistical evaluation in this 
respect and our study was not specifically designed to address the relationship between PMD 
behaviour and oral health. It has been reported that a poor periodontal condition was 
associated with a small but statistically significant increase in risk of cancer in non-smokers 
(Michaud et al., 2008). The periodontal status in our patients was not formally assessed but 
further studies are warranted to investigate possible associations between dysplastic PMDs 
and oral hygiene parameters such as chronic periodontitis. Routine dental visits as a predictor 
for favourable oral hygiene status are recognised and may be associated with a decreased risk 
of oral cancer and early diagnosis of PMDs. 
 
Likewise, limited information about dietary habits in this study did not allow statistical 
analysis. Associations between nutritional deficiencies and SCC remain possible and a 
number of case-control studies have consistently shown patients with oral cancer have poor 
dietary habits (Rossing et al., 1989). Also, it has been reported that increased consumption of 
citrus fruits reduce the risk of oral PMDs by 30-40% using multivariate-adjusted relative 
risks, whilst no consistent associations were apparent for vegetable intake (Maserejian et al., 
2006a). 
 
The relationship between diet and the risk of oral cancer and PMDs is not fully understood 
and may be related to the fact that not all chemical constituents of food are identifiable and 
the role of different micronutrients is not entirely clear (Petti, 2009). However, the protective 
effects of diet may be explained by mechanical cleansing effects, a dilution action and anti-
oxidant and anti-carcinogenic properties (Potter and Steinmetz, 1996; Lucenteforte et al., 
2009). 
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By analysing hospital records and finding omissions in data collection for information such 
as diet, familial cancer history, oral health status and mouthwash usage, we recommend the 
use of a standardized case sheet to ensure both consistency and reliability in data collection 
(Appendix 1-E). 
 
 
4.5.5. Logistic Regression Analysis  
This analysis revealed that various factors previously believed to be important predictors of 
non-homogenous leukoplakia development, such as patient age, smoking and drinking 
intensity as well as a history of systemic disease were non-significant. However, males were 
at increased risk for non-homogenous leukoplakia 1.6-times compared to females. It may be 
the high prevalence of tobacco and alcohol habits in males that explain this, although further 
studies on a biomolecular basis are required. 
 
Compared to non-drinkers, drinking alcohol > 28 units/week increased the risk for non-
homogenous leukoplakia 3-times whilst drinking < 28 (units/week) increased the risk 1.8-
times. The higher risk of developing non-homogenous leukoplakia in such patients was 
reported for the first time in this study, although in general, alcohol has been suggested as an 
independent risk factor for oral leukoplakia (Hashibe et al., 2000a; Maserejian et al., 2006a; 
Saraswathi et al., 2006). 
 
The final regression model showed that simultaneous exposure to tobacco and alcohol 
increased the risk for non-homogenous leukoplakia to develop by 6.3-times compared to non-
drinkers. This reflects the synergistic effects of both risk factors (Castellsague et al., 2004) 
and is supported by previous studies (Franco et al., 1989; Garrote et al., 2001) which 
suggested that the combination of smoking and drinking has supra-multiplicative effects. 
 
Homogenous leukoplakia appears to be more common in smokers, whilst non-homogenous 
lesions are less closely related to tobacco use. In this study, current and past tobacco smoking 
reduced the risk of non-homogenous leukoplakia development by 65% for smoking > 20 
cigarettes/day, 80% for < 20 and 71% in ex-smokers. The reduction in the risk of non-
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homogenous leukoplakia was further supported by final regression model, which showed a 
further reduction in the risk of smoking > 20 and < 20 cigarettes/day (47% and 38%, 
respectively). This finding clearly supports the well-known relationship between tobacco 
smoking and the development of homogenous leukoplakia. Previous studies showed that 
tobacco smoking was the strongest independent risk factor for oral leukoplakia (Gupta, 1984; 
Morse et al., 1996; Reichart, 2001) and since homogenous leukoplakia is the most common 
clinical type and consistent with these findings, smoking may be associated with a reduction 
in the risk of non-homogenous leukoplakia, however, further studies are required to 
investigate this finding. 
 
Regression analysis showed that non-homogenous leukoplakia was a significant predictor for 
high grade dysplasia, with a 3.3 times increased risk than homogenous lesions. This finding is 
consistent with a previous study by Lee et al. (2006) who reported a 5.7-times higher 
potential for dysplasia in non-homogenous leukoplakias. This is further supported by earlier 
studies which showed an association between non-homogenous leukoplakia and epithelial 
dysplasia (Mincer et al., 1972; Banoczy and Csiba, 1976). This may be explained by 
accumulated of more genetic changes with subsequent more severe dysplastic features in 
non-homogenous leukoplakia compared to homogenous due to a longer presentation time and 
different biomolecular conformations. 
 
The size of dysplastic PMD was a significant predictor for high grade dysplasia, with sizes 
exceeding 600 mm
2 
showing an 11.5-times increased risk compared to sizes < 200 mm
2
. This 
is supported by the final regression model which confirmed sizes > 600 mm
2 
increased the 
risk for high grade dysplasia by 7.6-times, albeit non-significant. This may be due to a longer 
presentation time of larger lesions with accumulation of more genetic alteration and resultant 
higher dysplastic grading (Napier and Speight, 2008; Warnakulasuriya et al., 2008).  
 
Regression analysis showed that alcohol drinking was a significant predictor of high grade 
dysplasia, with > 28 units/week showing 4.9-times the risk of non-drinkers. This is consistent 
with multivariate data analysis of Lee et al.(2006) which showed a 1.48 fold risk of dysplasia 
development in drinkers compared to no-drinkers, and is supported by other studies which 
found increased alcohol consumption associated with an increased risk of dysplasia, 
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particularly in heavy drinkers (Jokelainen et al., 1996a; Morse et al., 1996; Howie et al., 
2001).  
 
In the present study, a positive history of systemic disease was identified as a significant 
predictor of high grade dysplasia development and showed a 4-times higher risk than patients 
with clear medical histories. This is supported by the significant relationship between the 
degree of dysplasia and systemic disease found in this study, whereby no severe dysplasia or 
CIS was seen in patients without systemic disease, whilst high grade dysplasia was seen in 
those with systemic disorders. This may be due to PMD patients with systemic disorders 
being of an older age and taking a variety of medications which may play an enhancing role. 
 
In the final multivariate regression model, the only significant predictor of high grade 
dysplasia development was a positive medical history, which increased the risk by 7.5-times. 
This was a higher risk than that identified by the univariable regression model (4-times), 
reflecting the enhancing effects of other factors incorporated into the multivariate analysis 
such as PMD size, type of leukoplakia and smoking and drinking behaviour. This finding 
further emphasises the importance of a systemic history of patients with PMDs as an 
important prognostic factor for high grade dysplasia and unfavourable prognosis. 
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4.6. Conclusions 
The results of the present study provide a solid ground for additional research and emphasise 
the importance of risk factor assessment in association with clinical and pathological features 
to identify patients at high risk. 
 
4.6.1. Tobacco Smoking 
1. The majority of PMD patients were active smokers. 
2. Male smokers (73%) were more common than non-smoking males (33%). 
3. Males were significantly more common in the current smokers group (73%), compared 
to females (27%).  
4. Males were most often heavy and intermediate smokers, compared to females. 
5. Female non-smokers (67%) were more predominant than male non-smokers (33%). 
6. Significantly, females formed the majority of non-smokers (67%). 
7. In both male and female patients, current smokers were significantly younger than 
non-smokers or ex-smokers.  
8. Males smoked for a significantly longer duration of time compared to females (37.11 
vs. 28.13 years). 
9. The majority of heavy and intermediate smokers were middle aged. 
10. Light smokers showed the longest smoking history compared with both intermediate 
and heavy smokers.  
11. Males started smoking earlier than females, subjecting themselves to increased risk 
from long-standing exposure to tobacco smoke.  
12. Unemployed patients consumed the largest amounts of tobacco compared to employed 
or retired patients. 
13. Significantly, in both males and females, FOM leukoplakias (60%) arose more 
frequently in current smokers than non-smokers. 
14.  Leukoplakias in the lateral and ventral tongue surfaces (93%) were significantly more 
common in non-smokers compared to current smokers. 
15. All patients younger than 40 years were tobacco users and mainly presented with FOM 
lesions. 
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16. Patients older than 41 years comprised tobacco users and non-users and developed 
both FOM and tongue PMDs. 
17. In non-smokers, the tongue was the only affected site in females and in 80% of males. 
18. The soft palate only developed PMDs in tobacco users, most commonly in current 
rather than ex-smokers. 
19. Patients with FOM leukoplakias were mainly intermediate and heavy smokers.  
20. The joint effect of intensity and duration of tobacco smoking was negatively correlated 
with patient age and PMD size. 
21.  The mean pack-years score was higher in males (43.23) than females (32.18). 
22. Erythroplakias only affected heavy smokers. 
23.  Exophytic subtypes were more commonly seen in light-smokers.  
24. Patients with homogenous leukoplakias exhibited long smoking histories. 
25. Current smokers showed smaller mean PMD sizes compared to non-smokers (241.5 vs. 
473 mm
2
); heavy smokers exhibited smallest mean size compared with light smokers 
(247.5 vs. 316 mm
2
). 
26. Patients with longer smoking histories more often presented with smaller sized PMDs. 
27. A higher presentation of all dysplastic features was seen in current smokers compared 
to both ex-smokers and non-smokers. 
28. Heavy smokers were significantly more likely to exhibit severe dysplasia compared 
with light smokers. 
29. The longer the smoking history, the higher the dysplasia severity seen.  
 
4.6.2. Alcohol Use 
1. The majority of the study population were current drinkers, light drinkers were most 
common, followed by heavy and intermediate drinkers. 
2. All patients younger than 40 years were current drinkers. 
3. Males were predominantly current drinkers (71%), with females mainly non-drinkers 
(71%). 
4. Significant sex differences in alcohol consumption were seen, with 97% of males 
consuming > 28 units/week compared with 96% of females consuming < 28 
units/week. 
5. Males showed twice the average UK recommended alcohol consumption. 
 290 
 
6.  PMD patients are a high-risk group, with 58% of males and 9% of women routinely 
exceeding recommended alcohol intake. 
7. In both males and females, a lower level of alcohol consumption was seen in elderly 
patients. 
8. The FOM was the most common site for PMDs in heavy drinkers (56%).  
9.  A higher number of homogenous leukoplakias occurred in light drinkers compared to 
heavy drinkers (52% vs. 37%). 
10.  A higher number of non-homogenous leukoplakias was observed in heavy drinkers 
compared to light drinkers (50% vs. 36%). 
11. A higher presentation of speckled (62%) and exophytic subtypes (60%) were seen in 
heavy drinkers compared to light drinkers (30% and 40%). 
12. Almost all erythroplakias were seen in current drinkers. 
13. The majority of patients with mild dysplasia were light drinkers, whereas the majority 
of CIS cases were heavy drinkers. 
14. Half of non-drinkers were ex-smokers. 
15. 92% of current drinkers were also current smokers. 
 
4.6.3. Systemic Health Disorders 
1. 88% of the study populations had a positive medical history. 
2. Hypertension followed by diabetes mellitus was the most common systemic diseases. 
3. Hypertensive patients mainly presented with speckled subtypes. 
4. Higher grade dysplasias were more frequently seen in hypertensive patients compared 
to normotensive; CIS (90% vs. 10%), severe dysplasia (73% vs. 27%) and moderate 
dysplasia (52% vs. 48%). 
5. Females were more commonly affected with diabetes mellitus than males (60% vs. 
40%). 
6. All PMDs in diabetic patients were leukoplakias. 
7.  The majority of diabetic patients were intermediate smokers and light drinkers. 
8. PMDs in diabetic patients were seen mainly in high-risk sites (87%).  
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4.6.4. Dental Factors 
1. Dental prosthesis wearers mainly presented with large sized PMDs.  
2. Patients wearing dentures commonly presented with FOM PMDs, whilst those with 
crowns and bridges mainly developed tongue lesions. 
 
4.6.5. Logistic Regression Analysis 
1. Logistic regression analysis emphasised the inherent high-risk of non-smokers and 
showed that non-homogeneous leukoplakias were more frequently seen in these 
patients or in patients with lower tobacco intake. 
2. Heavy drinking (> 28 units/week) had 3-times greater risk for developing non-
homogenous leukoplakia than non-drinkers, whilst drinking ≤ 28 (units/week) had 
1.78-times higher risk.  
3. Patients with systemic health disorders showed 4.2-times higher risk for developing 
non-homogenous leukoplakia than those without. 
4. Males showed a 1.338-time greater risk than females for developing high grade 
dysplasia.  
5. Non-homogenous leukoplakia was a significant predictor of high grade dysplasia, 
increasing the risk by 3.3-times compared to homogenous lesions. 
6. Lesion size exceeding 600 mm2 was a significant predictor of high grade dysplasia, 
increasing the risk 11.5-times. 
7. Heavy drinking (> 28 units/week) was a significant predictor for developing high 
grade dysplasia, increasing the risk 4.89-times greater than non-drinkers. 
8. A history of systemic health disorders was a significant predictor of high grade 
dysplasia occurrence, increasing the risk 4-times. 
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Chapter Five: Clinical Outcome 
 
Study 3 
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5.1. Aims  
The aim was to investigate the long-term follow-up outcome of a cohort of patients with 
single dysplastic oral PMDs who had been treated with laser surgery and to identify 
significant risk factors for recurrent or new PMD disease formation and for the development 
of OSCC and malignant transformation. 
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5.2. Methods 
Clinical outcome for the 100 PMD patients was determined as either disease-free (clinical 
resolution) or disease-active. Disease active (DA) included: persistent disease (same site), 
recurrent disease (same site), further disease (new-site), malignant transformation (MT) 
(same site) and development of oral squamous cell carcinoma (OSCC) at sites distant from 
the primary dysplasia and proven histologically.  
 
For each patient, times were calculated from the first presentation of the patient to the time of 
incisional biopsy, excisional biopsy (laser surgery) and the most recent clinical contact with 
patients.  
After laser intervention, time to event and number of each event such as recurrences, further 
disease formation, MT and OSCC were recorded for each patient and at each clinical review 
time, as proven histologically. 
Also, the number of observational biopsies (prior to laser surgery) and follow-up biopsies 
(after laser surgery), the number of laser interventions, the length of follow-up period and the 
frequency of clinical review were also recorded.  
All patients in this study attended regular follow-up appointments in dedicated oral dysplasia 
clinics. 
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5.2.1. Statistical Analysis 
Statistical calculations were performed using SPSS, version 17.0 and 19.0 (Statistical 
Package for the Social Sciences, Chicago, IL, USA).  
The outcome of the categorical variables for the whole group of oral PMDs such as 
recurrence, malignant development and new disease formation were summarized as 
frequencies and percentages. The Chi-Square test or Fisher’s Exact test were used to evaluate 
the relationship between the categorical variables. Continuous variables were expressed as 
mean ± SD and were compared using Independent student t-test or Mann-Whitney U test for 
pair-wise comparison. ANOVA or Kruskal-Wills tests were used for group comparison. 
Spearman’s and Pearson's correlations were used to find and evaluate the correlation between 
variables. 
 
The Kaplan-Meier survival analysis method with Log-Rank test was used to assess the 
differences between the outcome groups and to calculate the overall cumulative survival rate 
for the total cohort and stratified by baseline tobacco smoking, alcohol consumption and 
consensus histopathological diagnosis for both the binary and the WHO grading systems. 
 
Further statistical analysis was performed using univariate and multivariate logistic 
regression analysis to determine the independent predictors of recurrent, further disease, MT 
and cancer development, using the factors primarily found to be significant by univariate 
analysis. Odds ratios (OR) and corresponding confidence intervals (CI) were calculated at an 
ordinary level of significance (p=0.05). 
The factors were incorporated as independent variables in the analysis if they had an 
association with the outcome variables at a p-value < 0.15. 
 
Patient age, size of dysplasia, number of cigarettes/day, length of smoking history, pack 
score, tobacco grams/week and the number of alcohol units/week were used as covariate 
whilst sex, clinical appearance, anatomical site of PMD, oral prosthesis wear, smoking status, 
drinking status and histopathological diagnosis (WHO and binary grading system) were 
entered as independent variables to predict the most important factors for clinical outcome.  
For single factor analysis, age was entered as a continuous variable to perform a trend test. 
 296 
 
Considering the localization of PMDs, oral subsites were stratified into 3 locations to 
facilitate the regression analysis (FOM, tongue and other remaining sites).  
 
Logistic regression model selection utilised the goodness of fit statistic -2 log likelihood ratio. 
Firstly, all one predictor and all combinations of two predictor models were used. The two 
predictor model with the smallest value of the log likelihood ratio was used as a basis for 
fitting three predictor models; each of the remaining predictors was added, one at a time, to 
the best two predictor model and the log likelihoods assessed. The three predictor model with 
the smallest value of-2 log likelihood was used as a basis for fitting 4 predictor models; each 
of the remaining predictors was added to that model to see if fit was significantly increased. 
If the criterion of the first analysis was not fulfilled for any factor, the factor was excluded 
from the regression analysis.  
For all statistical tests, p-values ≤ 0.05 were considered statistically significant. 
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5.3. Results 
5.3.1. Analysis by Clinical Outcome 
In this study, at the most recent patient follow-up appointment, 5 groups of treatment 
outcomes were defined and subsequently studied: 
1. Disease-free (DF) (clinical resolution). 
2. Recurrent disease (recurrence of dysplasia at the same site as the primary dysplasia). 
3. Further disease (development of new-site dysplasia). 
4. Malignant transformation (MT) (development of OSSC in the same site as the primary 
dysplasia). 
5. OSCC Development in which OSCC was diagnosed arising at a site distant from the 
primary dysplasia. 
The latter 4 categories were considered to be disease active (DA). 
 
Following laser intervention and at the most recent follow-up time, 62 out of the 100 patients 
(39 males and 23 females) of the study population remained DF, whilst 38 were DA, 
developing recurrent, further disease, MT and OSCC development. 
Out of the 38 DA patients (27 males and 11 females), same site recurrence was reported in 17 
patients, further (new-site) disease in 14, 5 underwent MT (same site) and 2 developed OSSC 
at new sites distant from the primary dysplasia; Figure 5.1. 
 
Figure 5.2 shows the relation between age groups and the clinical outcome. Middle age 
patients were predominant in all outcome groups, although patients younger than 40 years 
exhibited no cancer development; they were equally affected by recurrent and further 
dysplasia formation. 
Using Chi-Square test, no significant relation was found between patient age and clinical 
outcome (p=0.118). 
 
Males were usually the most common in all clinical outcome groups; Figure 5.3. However, 
no significant association was found between sex and treatment outcome (p=0.811; Chi-
Square test). 
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Figure 5.1: Clinical outcome of 100 patients with dysplastic PMDs treated with laser 
surgery.  
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Figure 5.2: Distribution of age group according to clinical outcomes. 
 
 300 
 
 
Figure 5.3: Sex distribution in relation to clinical outcomes. 
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Time to Treatment Considerations 
To investigate the influence of time on the diagnosis and management of patients with oral 
epithelial dysplasia, time intervals were calculated from the point of presentation to the 
clinical event of interest. 
 
Figure 5.4 illustrates a flowchart of defined time points during sequential diagnosis and 
management of patients with PMDs. 
 
 
 
 
Figure 5.4: Different time points in relation to management of PMD patients. 
 
 
In general, the time between the first presentation of patients (zero point) and the most recent 
follow-up appointment was defined as the total clinical management time, which ranged from 
5-189 months in this study with a mean of 71.86 months (SD: 45.077). 
 
Prior to laser intervention, the number of observational biopsies taken from patients ranged 
between 0 to 7, whilst the number of follow-up biopsies following laser surgery varied 
between 0-13. Patients in this study underwent between 1 to 6 laser interventions and 5-78 
follow-up appointments depending on the clinical course of the patient. 
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A negative significant correlation was found between number of observational biopsies and 
the degree of dysplasia (r=-0.291, n=100, p=0.003), with higher number of observational 
biopsies were reported in patients with mild dysplasia (73%; 16/22) compared to 27% (6/22) 
in higher grades of dysplasia. 
 
The time between the first presentation and initial diagnostic biopsy (incisional biopsy) was 
defined as the provisional diagnostic time (PDT). 
In this study, the provisional diagnostic time ranged from 0-24 months with a mean of 1.74 
months (SD: 4.089). Incisional biopsies were taken on the same day as first presentation in 
52% of patients, from 39% of patients within the first 3 months of initial presentation and 
from 6% between 4-12 months. A delay of more than 12 months in taking the initial 
diagnostic biopsies was reported for only 3 cases due to patients’ delays; Figure 5.5. 
 
 
 
 
 
Figure 5.5: The provisional diagnostic time (PDT) for 100 PMD patients. 
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As can be seen in Table 5.1, cases experiencing a delay in incisional biopsy included one 
mild, one moderate and one severe dysplasia, however all of them were DF at the most recent 
patients follow-up. 
 
Using Kruskal-Wallis testing, no significant differences were found in the mean provisional 
diagnosis time (first presentation to incisional biopsy) amongst different grades of dysplasia 
(p=0.758) and clinical outcomes (p=0.177). 
 
Also, no correlation was found between the provisional diagnostic time and the degree of 
dysplasia for both WHO and binary grading systems (r=-0.019, n=100, p=0.855), (r=-0.009, 
n=100, p=0.926), respectively. 
 
 
 
Table 5.1: Degree of dysplasia in relation to provisional diagnostic time. 
Degree of dysplasia 
Time between first presentation and 
incisional biopsy (months) 
Total 
Same day  
biopsy 
1-3 4-12 > 12 
 
Mild 
20 20 1 1 42 
48% 48% 2% 2% 100% 
Moderate 
14 6 3 1 24 
58% 25% 13% 4% 100% 
Severe-CIS 
18 13 2 1 34 
53% 38% 6% 3% 100% 
Total 52 39 6 3 100 
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There was no significant association between the clinical appearance of PMDs and the time 
between first presentation and undertaking incisional biopsy (p=0.062; Chi-Square test), 
although 63% of erythroplakias and 50% of speckled non-homogenous leukoplakias 
underwent same day incisional biopsies; Table 5.2. 
 
 
 
Table 5.2: Clinical appearance of PMDs in relation to provisional diagnostic time. 
Clinical type of PMDs 
Time between first presentation and 
incisional biopsy (months) 
Total 
Same day 
biopsy 
1-3 4-12 > 12 
 
Homogenous 
leukoplakia 
34 28 4 1 67 
51% 42% 6% 1% 100% 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 
8 5 1 2 16 
50% 31% 6% 13% 100% 
Nodular 
- 1 1 - 2 
 50% 50%  100% 
Exophytic 
4 1 - - 5 
80% 20%   100% 
Ulcerated 
1 1 - - 2 
50% 50%   100% 
Erythroplakia 
5 3 - - 8 
63% 38%   100% 
Total 52 39 6 3 100 
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The time between the first presentation of the patient and laser treatment or the diagnosis and 
management time was similarly investigated and classified into 3 groups: 1-3 months, 4-12 
and > 12 months. In this study, this time ranged from 1-163 months with a mean of 16.96 
months (SD: 26.262). Thirty-three percent of patients waited 4-12 months for the laser 
intervention after initial presentation, with a similar percentage of patients experienced the 
shortest time for laser to take place 1-3 months, followed by > 12 months waiting time 
(34%); Figure 5.6. 
 
 
 
 
Figure 5.6: First presentation to laser surgery time among 100 PMD patients. 
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A significant relation was found between first presentation to laser time and the degree of 
dysplasia (p=0.0001; Chi-Square test), with the longest wait for laser intervention (> 12 
months) seen in mild dysplasia cases 57% (24/42), followed by 4-12 months wait for 38% 
(9/24) of moderate dysplasia cases, and the shortest waiting time (1-3 months) in 59% 
(20/34) of patients with severe dysplasia-CIS; Table 5.3. 
 
 
Table 5.3: Degree of dysplasia in relation to first presentation to laser time. 
 
Degree of dysplasia 
Time between first presentation 
and laser intervention (PDT) 
(months) Total 
1-3 4-12 > 12 
 
Mild 
5 13 24 42 
12% 31% 57% 100% 
Moderate 
8 9 7 24 
33% 38% 29% 100% 
Severe-CIS 
20 11 3 34 
59% 32% 9% 100% 
Total 33 33 34 100 
 
 
 
Table 5.4 and Table 5.5 show the mean total clinical management time intervals (mean time 
of the provisional diagnostic time, first presentation to laser surgery, definitive diagnosis and 
follow-up time) in relation to the degree of dysplasia and the clinical outcome, respectively. 
 
In general, Kruskal-Wallis testing showed no significant differences in clinical outcome with 
varying time from first presentation to laser intervention (p=0.175). However, pair-wise 
comparison using Mann-Whitney U test showed a significant differences in time to laser 
from the first presentation between DF and DA patients (p=0.034), with DA cases 
experienced a shorter mean time to laser surgery than DF patients. Similarly, patients with 
further disease showed significantly a shorter mean time for the laser to take place after first 
presentation than further disease-free patients (p=0.030); Table 5.5. 
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Table 5.4: Mean total clinical management time intervals in relation to the grades of 
dysplasia. 
Degree 
of dysplasia 
Provisional 
diagnostic 
First 
presentation 
to laser 
Definitive 
diagnostic 
Follow-up Total 
Mild 1.57 25.55 23.69 50.50 42 
Moderate 2.29 18.21 10.96 46.42 24 
Severe 1.57 6.65 4.78 66.91 23 
CIS 1.55 3 1.18 66.36 11 
Total mean 1.74 16.96 13.81 55.04 100 
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Table 5.5: Time to treatment consideration in relation to clinical outcome with p-value of Mann-Whitney U test. 
Treatment outcome N 
Provisional 
diagnostic  
mean time 
p-value 
First  presentation  
to laser 
mean time 
p-value 
Definitive 
diagnostic  
mean time 
p-value 
Follow-up 
mean time 
p-value 
Disease-active 38 1.11 
0.479 
14.26 
0.034 
10 
0.004 
81.42 
0.0001 
Disease-free 62 2.13 18.61 16.15 38.87 
Recurrent disease 17 0.88 
0.076 
22.41 
0.740 
15 
0.428 
86.94 
0.002 
Recurrence-free 83 1.92 15.84 13.7 48.51 
Further disease 14 1.36 
0.143 
6.43 
0.030 
4.57 
0.004 
87.21 
0.001 
Further disease-free 86 1.80 18.67 15.31 49.80 
OSCC (new site) 2 3 
0.630 
6.50 
1.000 
4 
0.663 
79.50 
0.328 
OSCC-free 98 1.71 17.17 14.01 54.54 
MT (same site) 5 0.40 
0.230 
11.60 
0.480 
10.60 
0.848 
47.20 
0.937 
MT-free 95 1.81 17.24 13.98 55.45 
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The time between incisional biopsy and laser excision was defined as the definitive diagnosis 
time (DDT), and ranged from 3 weeks-163 months with a mean of 13.81 months (SD: 25.81).  
 
The majority of patients in this study (44%) waited between 1-3 months for laser 
interventions, 26% waited 4-12 months and a further 25% waited for more than 12 months; 
5% of patients actually waited less than one month to undergo laser surgery. 
Thirty-three percent and 45% of mild dysplasia cases waited for 4-12 and more than 12 
months, respectively. In contrast, 68% of severe dysplasia-CIS and 50% of moderate 
dysplasia only waited between 1-3 months for laser excision; Table 5.6. 
 
A highly significant difference in the mean time for definitive diagnosis (incisional to 
excisional time) between different grades of dysplasia was found (p=0.001; Kruskal-Wallis 
test). Subsequently, a Mann-Whitney U test was performed which showed a highly 
significant difference between mild and CIS (p=0.0001), mild and severe dysplasia 
(p=0.0001), mild and moderate (p=0.002) and moderate-CIS (p=0.042). The milder the 
dysplasia, the longer the waiting time for laser treatment. Mild dysplasia exhibited the longest 
mean time between incisional biopsy and excisional laser treatment compared to moderate, 
severe dysplasia and CIS. 
 
Further statistical analysis showed a negative significant correlation between the time of 
definitive diagnosis and degree of dysplasia (r=-0.554, n=100, p=0.0001). The higher the 
degree of dysplasia, the shorter the waiting time for laser treatment after incisional biopsy 
was reported; Figure 5.7. Similarly, for the binary grading system (r=-0.466, n=100, 
p=0.0001), low grade dysplasia was associated with a longer waiting time from incisional 
biopsy to laser treatment. 
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Table 5.6: Degree of dysplasia in relation to definitive diagnostic time (DDT). 
Degree of dysplasia 
Time between incisional biopsy and 
laser intervention (months) Total 
< 1 1-3 4-12 > 12 
 
Mild 
- 9 14 19 42 
 21% 33% 45% 100% 
Moderate 
1 12 7 4 24 
4% 50% 29% 17% 100% 
Severe-CIS 
4 23 5 2 34 
12% 68% 15% 6% 100% 
Total 5 44 26 25 100 
 
 
 
 
Figure 5.7: Mean time between incisional biopsy and laser intervention (DDT) and 
degree of dysplasia. 
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Kruskal-Wallis testing showed a significant difference in the DDT (incisional to excisional 
time) among clinical outcome groups (p=0.026). Subsequently, a Mann-Whitney U test 
showed a highly significant difference in the mean time to laser intervention after incisional 
biopsy (DDT) between DF patients and DA patients (p=0.004) who had a shorter mean time 
to laser intervention, compared to DF patients (10 vs. 16.15 months).  
 
Patients developing further disease showed a significantly shorter mean time to laser 
treatment following incisional biopsy (DDT) compared to those who did not (4.57 vs. 15.31 
months, p=0.004). However, no significant differences were seen in the mean time to laser 
intervention after incisional biopsy between patients who developed recurrent disease or 
those who did not, patients who developed OSCC (new-site) or did not, patients undergoing 
MT or who did not, and between patients who had recurrence and those who developed 
further (new-site) dysplasia (p=0.173). 
 
With respect to sex, male patients experienced a shorter mean time to laser intervention after 
incisional biopsy (DDT) compared to female patients (12.48 vs. 16.38 months), however the 
differences did not reach significance (p=0.107; Mann-Whitney U test). 
 
The time between laser intervention and the most recent follow-up was defined as the follow-
up time, and was measured from the date of definitive diagnosis to the most recent clinical 
contact with the patient. 
In this study, patients were followed-up after laser treatment from between 6-183 months, 
with a mean period of 55.49 months (SD: 41.667). 
Using a Kruskal-Wallis test, no significant differences in the mean follow-up time (laser to 
last visit) was found among different grades of dysplasia (p=0.438), which was similar for 
high and low grade dysplasia grading (p=0.868; Mann-Whitney U test). However, a highly 
significant difference in the mean follow-up time was found for treatment outcomes 
(p=0.0001). DF patients showed the shortest mean follow-up time, followed by MT (same 
site), OSCC (new-site), recurrent dysplasia (same site) and further dysplasia formation (new-
site) (38.87, 47.20, 79.5, 86.94 and 87.21 months); Table 5.5. 
 
Subsequently, Mann-Whitney U testing showed a significant difference in mean follow-up 
times between patients who developed recurrence (same site) and those who were recurrence-
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free (p=0.002), and between patients developing further dysplasia and those who did not 
(p=0.001).  
Patients with recurrence were followed-up for a longer time than recurrence-free patients 
(86.94 vs. 48.51 month) and this was similar for patients with further disease compared to 
further disease-free patients (87.21 vs. 49.80 months). However, no significant differences 
were seen between patients who developed OSCC (new-site) or those who underwent MT 
(same site) and those who were OSCC-free or MT-free. 
 
Considering the clinical appearance of oral dysplastic PMDs, no significant difference was 
seen in the mean follow-up time between homogenous and non-homogenous leukoplakia 
(p=0.0648; Mann-Whitney U test), although non-homogenous type did exhibit longer follow-
up time compared with homogenous leukoplakia (62.32 vs. 54.06 months). 
 
Table 5.7 shows the mean follow-up time for homogenous and non-homogenous leukoplakia 
subtypes. Although a Kruskal-Wallis test was not significant (p=0.395), the longest mean 
follow-up time was reported for exophytic subtypes (90.40 months; range 46-133), followed 
by speckled (57.19 months; range 4-183), ulcerated (53.00 months; range 24-82) and nodular 
PMDs (42.50 months; range 16-69). 
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Table 5.7: Mean follow-up time in relation to clinical appearance of leukoplakia. 
Leukoplakia 
clinical appearance 
Mean 
Follow-up time 
(month) 
N Range SD 
Homogenous 54.06 67 3-168 39.432 
Non-homogenous 62.32 25 4-183 48.487 
Total mean 56.30 92 3-183 41.969 
Non-homogenous 
        subtypes 
Speckled 57.19 16 4-183 53.755 
Nodular 42.50 2 16-69 37.477 
Exophytic 90.40 5 46-133 34.166 
Ulcerated 53.00 2 24-82 41.012 
Total mean 62.32 25 4-183 48.487 
 
 
 
 
.
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With respect to total clinical management time, which was calculated from the first 
presentation to the most recent follow-up time, a significant difference in clinical outcome 
was found (p=0.0001; Kruskal-Wallis test). Subsequently, using a Mann-Whitney U test, a 
significant difference in the mean total clinical management time was found between DF and 
recurrent disease groups (p=0.0001), with a significantly shorter total clinical management 
time for DF patients compared to those undergoing recurrence (57.95 vs. 108.25 months). 
Similarly, a significant shorter mean management time for DF patients was observed 
compared to patients developing further disease (57.95 vs. 94.21 months, p=0.002). 
No significant differences in total management time were seen, however between the 
remaining clinical outcome groups. 
Table 5.8 presents the mean total clinical management time for all five clinical outcomes; DF 
showed the shortest mean time compared to the others. 
 
 
 
Table 5.8: Mean total clinical management time in relation to clinical outcomes. 
Total clinical management time  
(First presentation to the most recent follow-up) 
(months) 
Clinical outcome Mean N Range SD 
DF 57.95 62 5-189 42.045 
Recurrent disease 108.25 17 17-184 47.460 
Further disease 94.21 14 31-135 31.232 
MT (same site) 59.20 5 26-103 29.064 
OSCC (new site) 87.00 2 84-90 4.243 
Total mean 71.86 100 5-189 45.077 
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Disease-Free (Clinical resolution) 
Disease-free (DF) cases were defined as such by clinical examinations and/or pathological 
evidence, with the time between definitive diagnosis and the confirmation of any disease 
active state defined as disease-free time. 
 
After laser treatment and at the most recent follow-up, 62/100 patients were DF (39 males 
and 23 females); these had been followed-up from 4 to 122 months (mean of 38.87 months), 
with 5-42 follow-up appointments. 
The total clinical management time of patients in this group was between 5-189 months, with 
a mean of 57.95 months (SD: 42.045). 
 
All patients in this group underwent one laser intervention and between 0 to 4 observational 
biopsies before laser surgery and between 0 to 2 follow-up biopsies after laser intervention.  
 
Fifty-two percent (32/62) of DF patients were middle age (41-62 years), followed by 34% 
(21/62) old age (63-84 years), 12% (8/62) young age (≤ 40) with only one patient older than 
85 years; Figure 5.2. No significant association was found between clinical outcome and age 
group (p=0.316; Chi-Square test). 
 
Disease-free survival was the time between the diagnosis and confirmation of the DF event. 
Kaplan-Meier survival analysis method showed that overall disease-free survival rates for the 
total PMDs cohort at 1-year, 2, 3, 5 and 10-years were 88%, 75%, 68%, 47% and 42% 
postoperatively; Figure 5.8. 
 
Table 5.9 summarises the clinicopathological characteristics of the 62 DF patients. 
 
 
 
 
 316 
 
 
 
Figure 5.8: Overall disease-free survival curve by Kaplan-Meier analysis. 
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Table 5.9: Clinicopathological features of 62 disease-free patients. 
Case Age Sex Site 
Clinical  
types 
Hpath 
WHO 
Hpath 
Binary 
Size 
(mm2) 
Resection 
Margins 
Smoking  
(cig./day) 
Drinking 
(u/w) 
Follow-up  
(months) 
Medical conditions 
1 36 F FOM Non-homogenous speckled  Md LG <200 Normal Ex-smoker 1-14 15 Hypertension, DM II 
2 62 M FOM Homogenous leukoplakia Modd HG 200-600 Modd >20 >28 74 Hypertension, DM  
3 33 F FOM Homogenous leukoplakia Md LG <200 Md 10-20 1-14 4   
4 66 F FOM Homogenous leukoplakia Modd HG <200 Normal >20 1-14 21 Hypertension 
5 52 M FOM Homogenous leukoplakia CIS HG >600 Normal >20 >28 48 Hypertension, DM  
6 59 F FOM Homogenous leukoplakia Md LG <200 Normal 10-20 1-14 16   
7 67 M FOM Non-homogenous speckled  Modd HG 200-600 Normal Ex-smoker 1-14 6   
8 35 M FOM Homogenous leukoplakia Md LG 200-600 Md 10-20 >28 81   
9 42 M FOM Homogenous leukoplakia Modd HG 200-600 Md >20 >28 116 Hypertension 
10 59 M FOM Homogenous leukoplakia CIS HG 200-600 Md 10-20 >28 12 Hypertension 
11 64 F FOM Homogenous leukoplakia Md LG 200-600 Md 10-20 1-14 14 Hypertension, DM II 
12 48 M FOM Homogenous leukoplakia Md LG <200 
 
10-20 1-14 122   
13 54 F FOM Homogenous leukoplakia Md LG <200 Md >20 
Non-
drinker 
15 Hypertension, DM II 
14 48 F FOM Homogenous leukoplakia Md LG 200-600 
 
10-20 1-14 68   
15 45 F FOM Homogenous leukoplakia Md LG 200-600 Md 10-20 1-14 30 Hypertension, DM  
16 56 F FOM Homogenous leukoplakia Md LG <200 Normal Ex-smoker 
Non-
drinker 
89   
17 64 M FOM Homogenous leukoplakia Md LG <200 Normal 10-20 1-14 26 Hypertension 
18 71 F FOM Homogenous leukoplakia Md LG 200-600 
 
Ex-smoker 
Non-
drinker 
56   
19 55 F FOM Homogenous leukoplakia Md LG <200 Normal 10-20 
Non-
drinker 
18 Hypertension 
20 49 M FOM Homogenous leukoplakia Md LG <200 Normal >20 Ex-drinker 8 Hypertension 
 
F=female; M=males; FOM=Floor of the mouth; Hpath=histopathology; Md=mild dysplasia; Modd=moderate dysplasia; Sd=severe dysplasia; CIS=carcinoma in situ; LG=low grade dysphasia; 
HG=high grade dysphasia; DM II=diabetes mellitus type 2, DM=diabetes mellitus. 
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Continued 
Case Age Sex Site 
Clinical  
types 
Hpath 
WHO 
Hpath 
 Binary 
Size 
(mm2) 
Margin 
Smoking  
(Cig./day) 
Drinking  
(U/W) 
Follow-up  
(months) 
Medical 
conditions 
21 40 F FOM Homogenous leukoplakia Md LG <200 Md 10-20 1-14 112 
 
22 71 M FOM Erythroplakia CIS HG <200 CIS Ex-smoker >28 13 Hypertension 
23 37 M FOM Homogenous leukoplakia Md LG <200 Normal >20 >28 12 
 
24 45 M FOM Homogenous leukoplakia Md LG <200 Md 10-20 15-28 108 
 
25 30 M FOM Homogenous leukoplakia Md LG <200 Normal 10-20 >28 95 
 
26 58 M FOM Non-homogenous speckled Sd HG 200-600 
 
10-20 >28 38 
 
27 65 M FOM Homogenous leukoplakia Modd LG 200-600 Md 10-20 15-28 60 Anaemia 
28 58 F FOM Homogenous leukoplakia Modd HG <200 Md >20 1-14 72 Hypertension 
29 71 M FOM Homogenous leukoplakia Mdd LG <200 Modd >20 1-14 80 
Hypertension, 
anaemia 
30 55 F FOM Homogenous leukoplakia Sd HG <200 Md 10-20 1-14 108 
Hypertension, 
DM II, anaemia 
31 61 M FOM Homogenous leukoplakia Md LG <200 Normal Ex-smoker >28 14 Hypertension 
32 58 F FOM Homogenous leukoplakia Modd HG <200 Md 10-20 Non-drinker 24 Hypertension 
33 65 M FOM Homogenous leukoplakia Md LG <200 Normal 10-20 >28 28 Hypertension 
34 57 M FOM Homogenous leukoplakia Md LG <200 Mild Ex-smoker Ex-drinker 26 Hypertension 
35 42 M FOM Homogenous leukoplakia Md LG 200-600 Normal >20 1-14 26 
 
36 42 F 
Lateral 
tongue 
Homogenous leukoplakia Md LG <200 Normal Non-smoker 1-14 15 
 
37 75 M 
Lateral 
tongue 
Homogenous leukoplakia Md LG <200 Md Ex-smoker 1-14 25 Hypertension 
38 69 M 
Lateral 
tongue 
Erythroplakia Modd HG 200-600 Modd Ex-smoker 1-14 21 Hypertension 
39 94 F 
Lateral 
tongue 
Non-homogenous speckled Md LG 200-600 Normal Non-smoker Non-drinker 30 Hypertension 
40 50 M 
Lateral 
tongue 
Homogenous leukoplakia Modd HG 200-600 Normal 10-20 1-14 10 
 
41 69 M 
Lateral 
tongue 
Homogenous leukoplakia Sd HG >600 Normal Non-smoker 1-14 8 
Hypertension, 
DM 
  
 
3
1
9
 
Continued 
Case Age Sex Site 
Clinical  
types 
Hpath 
WHO 
Hpath 
Binary  
Size 
(mm2)  
Margin 
 
Smoking  
(Cig./day) 
Drinking  
(U/W) 
Follow-up  
(months)  
Medical 
conditions 
42 54 F Lateral tongue Homogenous leukoplakia Md LG 200-600 Sd Non-smoker 1-14 49 
 
43 69 F Lateral tongue Homogenous leukoplakia Modd HG >600 Modd Non-smoker 1-14 75 Hypertension 
44 51 F Lateral tongue 
Non-homogenous 
speckled 
Modd HG 200-600 Normal >20 15-28 4 Hypertension 
45 47 M Lateral tongue Homogenous leukoplakia Md LG 200-600 Normal Non-smoker Non-drinker 16 
 
46 68 F Lateral tongue Erythroplakia Sd HG 200-600 Normal Ex-smoker 1-14 25 
 
47 79 F Ventral tongue Homogenous leukoplakia Modd HG <200 Normal Ex-smoker 1-14 26 DM II 
48 76 M Ventral tongue Non-homogenous/nodular Sd HG >600 Normal Non-smoker 1-14 12 
 
49 51 M Ventral tongue Homogenous leukoplakia Md LG 200-600 Normal 10-20 1-14 24 Hypertension 
50 60 M Ventral tongue Homogenous leukoplakia Sd HG <200 Normal >20 15-28 38 
Hypertension, 
Oral Candida 
51 77 M Ventral tongue Homogenous leukoplakia Modd HG <200 Normal 10-20 1-14 9 
 
52 47 M Soft palate Erythroplakia Modd HG <200 Sd >20 >28 9 
 
53 39 M Soft palate Homogenous leukoplakia Modd HG <200 Modd 10-20 >28 46 
 
54 70 M Soft palate Homogenous leukoplakia Modd LG <200 Normal Ex-smoker Non-drinker 18 Hypertension 
55 47 M Soft palate Homogenous leukoplakia Md LG <200 Normal 10-20 >28 57 
Hypertension, 
DM 
56 46 M Soft palate 
Non-homogenous 
speckled 
Sd HG <200 Sd 10-20 Ex-drinker 10 Hypertension 
57 56 M Fauces 
Non-homogenous 
speckled 
Modd HG <200 Modd 10-20 >28 13 
 
58 58 M Fauces Homogenous leukoplakia CIS HG <200 Sd 10-20 >28 7 Hypertension 
59 81 M Alveolar mucosa 
Non-homogenous 
exophytic 
Modd LG <200 Normal Ex-smoker 1-14 91 DM II 
60 79 M Alveolar mucosa Homogenous leukoplakia Md LG Vaporization Normal Ex-smoker 15-28 22 
 
61 81 M Buccal mucosa 
Non-homogenous 
speckled 
Sd HG 200-600 Modd Non-smoker 1-14 9 Hypertension 
62 37 M Buccal mucosa 
Non-homogenous 
nodular 
Md LG 200-600 Md 10-20 15-28 69 Oral Candida 
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Clinical Appearance 
Clinically, 93% (58/62) of PMDs seen in DF patients were leukoplakias, whilst the remaining 
7% (4/62) were erythroplakias. Of the leukoplakia cases, 70% (47/67) seen in DF patients 
were homogenous leukoplakia compared to only 44% (11/25) of non-homogenous 
leukoplakias; Table 5.10. 
Considering non-homogenous categories, speckled was the main reported subtype in the DF 
group 73% (8/11), followed by nodular 18% (2/11) and exophytic 9% (1/11); Table 5.11 and 
Figure 5.9. 
 
The relation between the clinical appearance of PMDs and treatment outcomes was found to 
be significant (p=0.042; Chi-Square test).  
In this study, homogenous leukoplakia was predominant in all clinical outcome groups. 
While 50% (4/8) of erythroplakias, 50% (8/16) of speckled leukoplakias, and all nodular 
subtypes were reported as DF at the most recent patient follow-up, the majority of exophytic 
non-homogenous leukoplakias exhibited recurrent disease 60% (3/5). 
 
 
 
Table 5.10: Type of leukoplakia in relation to clinical outcomes. 
Leukoplakia 
type 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
Homogenous 
47 10 7 2 1 67 
70% 15% 10% 3% 1% 100% 
Non-homogenous 
11 6 6 2 - 25 
44% 24% 24% 8%  100% 
Total 
58 16 13 4 1 92 
63% 17% 14% 4% 1% 100% 
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Table 5.11: Clinical outcome in relation to clinical appearance of PMDs. 
Clinical type of 
PMDs 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 Homogenous 
leukoplakia 
47 10 7 2 1 67 
70% 15% 10% 3% 1% 100% 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 
8 2 4 2 - 16 
50% 13% 25% 13%  100% 
Nodular 
2 - - - - 2 
100%     100% 
Exophytic 
1 3 1 - - 5 
20% 60% 20%   100% 
Ulcerated 
- 1 1 - - 2 
 50% 50%   100% 
Erythroplakia 
4 1 1 1 1 8 
50% 13% 13% 13% 13% 100% 
Total 62 17 14 5 2 100 
 
 
 
Figure 5.9: Clinical outcome in relation to clinical appearance of PMDs. 
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Anatomical Site 
Seventy-six percent (35/46) of patients with FOM dysplasia were reported as DF, followed 
by 58% (11/19) with lateral tongue, 56% (5/9) soft palate, 50% (2/4) faucial of pillars, 40% 
(2/5) buccal mucosa and 36% (5/14) with ventral tongue.  
All cases of alveolar mucosa 100% (2/2) were DF at the most recent follow-up of patients; 
Table 5.12 and Figure 5.10. 
 
The relation between clinical outcome and anatomical site of dysplastic PMDs was 
significant (p=0.020; Chi-Square test).  
The majority of both DF (57%; 35/62) and recurrent cases (29%; 5/17) were observed in the 
FOM. Both FOM and ventral tongue were equally affected by further disease formation 
(29%; 4/14). In this study, the case of retromolar area was affected with MT and OSCC 
developments distant from the primary dysplasia (2/2) were only seen in the tongue. 
 
 
Size of Dysplasia 
The size of dysplasia in DF patients ranged from 36 to 1,040 mm
2
 with a mean size of 251.22 
mm
2
. 74% (31/42) of minor sized cases were DF, followed by 56% (25/45) intermediate and 
40% (4/10) major size.  
 
Table 5.13 and Figure 5.11 summarise the clinical outcome in relation to PMD size 
categories. 
 
A significant relation was found between clinical outcome and size (p=0.010; Chi-Square 
test). 
DF (52%; 31/60) and recurrent cases (44%; 7/16) were mainly minor sized dysplasia, whilst 
both patients with MT (80%; 4/5) and those developing new site dysplasias (64%; 9/14) were 
mainly intermediate size. OSCC development distant from the primary dysplasia was only 
seen in intermediate or major sized dysplasias (100%; 2/2). 
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Table 5.12: Clinical outcome in relation to PMD anatomical site. 
Anatomical site 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
FOM 
35 5 4 2 - 46 
76% 11% 9% 4%  100% 
Lateral tongue 
11 4 1 2 1 19 
58% 21% 5% 11% 5% 100% 
Ventral tongue 
5 4 4 - 1 14 
36% 29% 29%  7% 100% 
Buccal mucosa 
2 1 2 - - 5 
40% 20% 40%   100% 
Soft palate 
5 3 1 - - 9 
56% 33% 11%   100% 
Fauces 
2 - 2 - - 4 
50%  50%   100% 
Retromolar area 
- - - 
1 
- 1 
    100% 
Alveolar mucosa 2 
- - - - 2 
    100% 
Total 62 17 14 5 2 100 
 
 
Figure 5.10: Clinical outcome in relation to PMD anatomical site. 
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Table 5.13: Clinical outcome in relation to PMD size (mm
2
). 
PMD size category 
(mm
2
) 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
Minor < 200 
31 7 3 1 - 42 
74% 17% 7% 2%  100% 
Intermediate 
(200-600) 
25 6 9 4 1 45 
56% 13% 20% 9% 2% 100% 
Major > 600 
4 3 2 - 1 10 
40% 30% 20%  10% 100% 
Total 
60 16 14 5 2 97 
62% 16% 14% 5% 2% 100% 
 
 
 
 
Figure 5.11: Clinical outcome in relation to PMD size category (mm
2
). 
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Dysplasia Grading 
Considering the histopathological diagnosis of laser excised tissue, the majority of mild 
dysplasia 76% (32/42) was seen in DF patients, followed by 71% (17/24) of moderate, 39% 
(9/23) of severe dysplasia and 36% (4/11) of CIS; Table 5.14 and Figure 5.12. 
 
A significant relation was found between the degree of dysplasia and clinical outcome 
(p=0.003; Chi-Square test). DF (32/62) and further disease (6/14) were mainly reported in 
patients affected with mild dysplasia. Recurrent cases were predominantly and equally 
observed in moderate-severe dysplasia (6/17, for each). MT was equally seen in mild and 
severe dysplasia cases (2/4, for each), with one case of CIS, whilst developing OSCC (new 
site) was only reported in severe dysplasia-CIS (2/2). 
 
Similarly, a significant relation was found between clinical outcome and high/low grade 
dysplasia (p=0.004; Chi-Square test). The majority of low grade dysplasias were seen in DF 
patients, compared to the high grade dysplasias (74%; 35/47 vs. 50%; 27/53), respectively. In 
contrast, high grade dysplasias were predominantly observed in cases which underwent 
recurrences, further dysplasia and MT, with OSCCs (new-site) were only reported in patients 
affected with high grade dysplasia; Table 5.15 and Figure 5.13. 
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Table 5.14: Clinical outcome in relation to degree of dysplasia. 
Dysplasia 
WHO system 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
Mild 
32 2 6 2 - 42 
76% 5% 14% 5%  100% 
Moderate 
17 6 1 - - 24 
71% 25% 4%   100% 
Severe 
9 6 5 2 1 23 
39% 26% 22% 9% 4% 100% 
CIS 
4 3 2 1 1 11 
36% 27% 18% 9% 9% 100% 
Total 62 17 14 5 2 
100 
100% 
 
 
 
 
Figure 5.12: Grade of epithelial dysplasia in relation to clinical outcome. 
 
 327 
 
Table 5.15: Clinical outcome in relation to binary grading system. 
Dysplasia 
Binary grading 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
  
High grade 
27 13 8 3 2 53 
50% 25% 15% 6% 4% 100% 
Low grade 
35 4 6 2 - 47 
74% 9% 13% 4%  100% 
Total 
62 17 14 5 2 100 
63% 16% 14% 5% 2% 100% 
 
 
 
 
 
Figure 5.13: High/low grade dysplasia in relation to clinical outcome. 
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Smoking Behaviour 
With respect to smoking behaviour, the majority of DF patients were current smokers 64% 
(40/62), followed by ex-smokers 21% (13/62) and non-smokers 15% (9/62). 
DF current tobacco smokers were mainly intermediate smokers who smoked between 10-20 
cigarettes/day (43%; 27/62), followed by heavy smokers who smoked more than 20 
cigarettes/day (21%; 13/62), however no light smokers were seen in this group; Table 5.16 
and Figure 5.14. 
 
A significant relation was found between smoking status and clinical outcome (p=0.014; Chi-
Square test). All OSCC patients 100% (2/2) were non-smokers. Seventy-one percent of 
patients who developed further disease (10/14), 59% (10/17) of patients with recurrence and 
56% (40/62) of DF patients were reported as current tobacco smokers. 
 
With respect to the extent of smoking, Chi-Square test showed no significant relation 
between clinical outcome and the number of cigarettes smoked per day (p=0.139). 
 
Regarding smoking history, no significant relation was found between patients’ smoking 
history in term of years as a smoker and clinical outcome (p=0.565; Chi-Square test).  
Fifty-nine percent of DF patients had a smoking history of 31-50 years, followed by 36% 
who smoked for 10-30 years, with only one case in our patient series who smoked for more 
than 50 years and this patient was DF at the most recent follow-up; Table 5.17 and Figure 
5.15. 
 
The current smoking behaviour of patients who were DF showed a significant change at the 
most recent follow-up (p=0.0001; Sign test). Ex-smokers increased from 13 (21%) to 32 
(52%), current smokers decreased from 40 (65%) to 21 (34%), light smokers increased from 
0 to 12 cases, intermediate smokers decreased from 27 to 8 cases and heavy smokers 
decreased dramatically from 13 cases to only one case at the most recent follow-up time; 
Figure 5.16. 
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Table 5.16: Clinical outcome in relation to smoking behaviour. 
Smoking behaviour 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
  
Non-smoker 
9 2 1 1 2 
15 
15% 12% 7% 20% 100% 
 
C
u
rr
en
t 
sm
o
k
e
r 
(c
ig
a
re
tt
es
/d
a
y
) 
< 10 
- 1 1 - - 
2 
 6% 7%   
10-20 
27 
43% 
4 
24% 
5 
36% 
2 
40% 
- 38 
> 20 13 
21% 
5 
29% 
4 
29% 
1 
20% 
- 23 
Ex-smoker 
13 5 3 1 - 
22 
21% 29% 21% 20%  
Total 
62 
100% 
17 
100% 
14 
100% 
5 
100% 
2 
100% 
100 
 
 
 
 
Figure 5.14: Clinical outcome in relation to smoking behaviour. 
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Table 5.17: Clinical outcome in relation to smoking history. 
Smoking history 
(years) 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT 
 
10-30 
8 3 2 1 14 
36% 50% 33% 50% 39% 
31-50 
13 3 4 1 21 
59% 50% 67% 50% 58% 
> 50 
1 - - - 1 
5%    3% 
Total 
22 6 6 2 36 
100% 100% 100% 100% 100% 
 
 
 
 
Figure 5.15: Clinical outcome in relation to smoking history. 
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Figure 5.16: Comparison between smoking status at initial presentation and at most 
recent follow-up for 62 DF patients (p=0.0001; Sign test). 
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Alcohol Use 
Table 5.18 and Figure 5.17 show the association between alcohol drinking and clinical 
outcome. DF cases were predominant in all groups of drinking behaviour. 
The majority of DF patients were current alcohol drinkers 83% (51/62), followed by non-
drinkers 13% (8/62) and ex-drinkers 4% (3/62). 
Of the current drinkers, the highest rate of DF was reported in the light drinkers 44% (27/62), 
followed by heavy 26% (16/62) and intermediate drinkers 13% (8/62), whilst all ex-drinkers 
100% (3/3) were DF at the most recent follow-up. 
 
Using Chi-Square test, no significant relation was found between clinical outcomes and 
drinking status (p=0.080); however, a significant association was found with the amount of 
alcohol consumed in term of units per week (p=0.013). The majority of DF patients (44%; 
27/62) and 100% (2/2) of patients who developed OSSC at distant site were light drinkers. 
The majority of patients who underwent recurrences (53%; 9/17), further disease (50%; 7/14) 
and those who underwent MT (40%; 2/5) were all reported as heavy drinkers. 
 
At the most recent follow-up appointment, alcohol drinking behaviour showed no significant 
change (p=0.161; Sign test). Whilst non-drinkers and ex-drinkers remained the same, heavy 
drinkers decreased from 16 to 11 cases, intermediate drinkers increased from 6 to 10 and light 
drinkers increased from 29 to 30 cases; Figure 5.18. 
 
 
Dental Prosthesis Wear 
Regarding the relationship between clinical outcome and the presence of a dental prosthesis 
or not, the majority of non-wearers 70% (33/47) were DF compared to 55% (29/53) of 
wearers who were DF; Table 5.19 and Figure 5.19. 
 
Using Chi-Square test, a significant relation was found between the presence of a dental 
prosthesis and clinical outcome (p=0.004). 100% (5/5) of patients underwent MT and 71% 
(12/17) of those who had recurrent dysplasia were dental prosthesis wearers. In contrast, 57% 
(8/14) of patients who developed further dysplasia and 53% (33/62) of DF patients did not 
wear dental prostheses. 
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Table 5.18: Clinical outcome in relation to alcohol drinking behaviour. 
Drinking behaviour 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
  
Non-drinker 
8 3 1 2 - 
14 
13% 18% 7% 40%  
C
u
rr
en
t 
d
ri
n
k
er
 
(u
n
it
s/
w
ee
k
) 1-14 
27 3 4 1 
2 37 
44% 18% 29% 20% 
15-28 
8 2 2 - - 
12 
13% 11% 14%   
> 28 
16 9 7 2 - 
34 
26% 53% 50% 40%  
Ex-drinker 
3 - - - - 
3 
4%     
Total 
62 17 14 5 2 
100 
100% 100% 100% 100% 100% 
 
 
 
 
 
Figure 5.17: Clinical outcome in relation to alcohol drinking behaviour. 
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Figure 5.18: Comparison between alcohol drinking status at initial presentation and at 
most recent follow-up for 62 DF patients (p=0.161; Sign test). 
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Table 5.19: Clinical outcome in relation to dental prostheses wear. 
Dental prosthesis 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
Wearer 
29 12 6 5 1 53 
55% 23% 11% 9% 2% 100% 
Non-wearer 
33 5 8 - 1 47 
70% 11% 17%  2% 100% 
Total 62 17 14 5 2 100 
 
 
 
 
 
Figure 5.19: Clinical outcome in relation to dental prostheses wear. 
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Disease Active (DA) 
This group involves all patients with unfavourable events following laser treatment including 
recurrence, new site dysplasia, MT and OSCC development at sites distant from primary 
dysplasia. 
 
 
Dysplasia Grading 
The degree of dysplasia had a significant effect on patients developing an unfavourable 
outcome (DA). Severe dysplasia-CIS showed a significantly shorter mean time to develop 
active disease state compared with patients with moderate or mild dysplasia respectively (40 
vs. 78.8, 87.83 months). Also, lower 2- and 5-year disease-free survival rates were seen for 
severe dysplasia-CIS than for moderate and mild dysplasia (63% vs. 76%, 85%) and (14% vs. 
59%, 62%), respectively (p=0.006; Log-Rank test); Figure 5.20. 
 
 
 
 
Figure 5.20: Disease-free survival according to the WHO grading of dysplasia 
(p=0.006; Log-Rank test). 
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With respect to binary grading of histopathological diagnosis, patients with high grade 
dysplasia had significantly a shorter mean time to develop an unfavourable outcome (DA), 
compared to patients with low grade dysplasia (64 vs. 88.7 months). Also, lower 2- and 5-
year disease-free survival rates for high grade than low grade dysplasia was found (68% vs. 
83%) and (29% vs. 63%), respectively (p=0.013; Log-Rank test); Figure 5.21. 
 
 
 
 
Figure 5.21: Disease-free survival according to high and low grade dysplasia 
(p=0.013; Log-Rank test). 
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Smoking Behaviour 
Figure 5.22 shows the cumulative survival analysis of smoking status subgroups. Disease-
free survival rate in relation to smoking status 1-year post laser surgery was 71% for ex-
smokers, 86% for non-smokers and 91% for current smokers. The percentage dropped to 
36% for ex-smokers at 4 years post laser treatment and to 49% for current and 18% for non-
smokers at 5 years post laser treatment. 
 
Survival analysis showed that ex-smokers presented the shortest estimated mean time to 
develop unfavourable outcome (DA) (49.4 months), followed by non-smokers (50.7 months), 
whilst current smokers exhibited the longest estimated mean time for DA state to develop 
(87.7 months), however, Log-Rank testing was not significant (p=0.511). 
 
 
 
 
Figure 5.22: Disease-free survival in relation to smoking status. 
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Alcohol Use 
Considering drinking behaviour, Figure 5.23 shows the Kaplan-Meier analysis for alcohol 
drinkers and non-drinkers. 
Disease-free survival rate 1-year post laser surgery was 78% for non-drinkers and 89% for 
drinkers. The rate dropped to 49% and 55% for non-drinkers and drinkers at 4 years post 
laser treatment, and to 33% for non-drinker and 44% for drinkers at 5 years post laser 
surgery. 
Non-drinkers of alcohol showed a shorter estimated mean time to develop unfavourable 
outcome (DA) (50.62 months) compared with alcohol drinkers (82.2 months), however, Log-
Rank testing was not significant (p=0.552).  
 
 
 
 
Figure 5.23: Disease-free survival in relation to alcohol drinking status. 
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Logistic Regression Analysis 
Further statistical analysis was performed using logistic regression analysis to try to predict 
significant factors determining clinical outcome.  
Age of patients, size of dysplasia, number of cigarettes/day, length of smoking history, pack 
score, tobacco grams/week and number of alcohol units/week were used as covariates. Sex, 
clinical appearance, anatomical site of PMD, wearing of dental prostheses, smoking status, 
drinking status and histopathological diagnosis (WHO and binary grading system) were 
entered as independent variables to try to predict the most important factor (s) determining 
treatment outcome. 
 
For single factor analysis, age was entered as a continuous variable to perform a trend test. 
Considering the anatomical site of dysplasia, oral subsites were stratified into 3 subgroups to 
facilitate the regression analysis: FOM, tongue and “other remaining sites”. 
 
The role of several independent factors for unfavourable outcome (DA) including recurrence, 
new site dysplasia, MT and OSCC development were estimated by means of univariate and 
multivariate logistic regression analysis. 
 
Table 5.20 shows OR and 95% CI, with significant levels for single variables and 
multivariable final model. 
Factors included in the univariate regression analysis were: age, sex, PMD clinical types, 
anatomical site of disease, histopathological diagnosis (WHO and binary grading system), 
resection margins status (dysplastic/clear), size of dysplasia and medical history (having 
systemic disease or not). 
 
The analysis showed that patients’ age showed no effect on disease active status (OR=1.007, 
95% CI, 0.976-1.040) (p=0.646). 
Males were at increased risk for disease active status being 1.448 times more likely to occur, 
compared with females (95% CI, 0.806-3.455), but this did not reach significance (p=0.405). 
Non-homogenous leukoplakia was identified as a significant predictor for disease active 
status (p=0.023); this increased the risk by 2.991 times, compared with homogenous 
leukoplakia (95% CI, 1.160-7.713). 
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Logistic regression analysis showed that tongue, as an anatomical site of origin, was a 
significant predictor for disease active status to develop (p=0.013), increasing risk by 3.381-
time compared to the FOM as a reference category (95% CI, 1.292-8.845).  
 
The analysis showed that severe dysplasia was a highly significant predictor for DA status to 
develop (p=0.007); severe dysplasia showing 4.622 times the risk of mild dysplasia (95% CI, 
1.527-13.990). CIS exhibited 4.8 times the risk of mild dysplasia for disease active (95% CI, 
1.123-20.479) (p=0.034), however moderate dysplasia was a non-significant predictor for DA 
status to develop (OR=1.129) (95% CI, 0.350-3.641) (p=0.839). 
 
Also, high grade dysplasia was found to be a significant predictor for the DA state (p=0.020), 
increasing the risk by 2.828 times compared with low grade dysplasia (95% CI, 1.182-6.768). 
 
Regarding the status of surgical resection margins, dysplasia present in margins was 
identified as a significant prognostic factor for the disease active state (p=0.035), dysplastic 
margins increasing risk by 2.812 times compared with clear-margins (95% CI, 1.073-7.371). 
The major sized dysplasia (> 600 mm
2
) appeared as a significant predictor (p=0.045) for 
disease active status; major size increasing risk by 4.464 times compared to minor sizes (< 
200 mm
2
) (95% CI, 1.035-18.394). Whilst intermediate size (200-600 mm
2
) was 2.327 times 
the risk of minor size for disease active events to occur (95% CI, 0.944-5.740), but did not 
reach significance (p=0.067). 
 
A 7.980 times increased risk for a disease active state to develop in patients with systemic 
disease (positive medical history) was found compared to patients with no medical problems 
(95% CI, 0.987-64.547), but this had border line significance (p=0.051). 
 
The final model to try to predict disease active events included margin status, clinical type of 
leukoplakia, degree and anatomical site of dysplasia, although only dysplastic margins 
(p=0.011), severe dysplasia (p=0.023) and CIS (p=0.004) were identified as significant 
predictors. Dysplastic margins showed 6.562 times the risk for clear margins (95% CI, 1.545-
27.878); severe dysplasia 5.994 times the risk of mild dysplasia (95% CI, 1.282-128.018), 
whilst CIS exhibited 17.104 times increased risk compared to mild dysplasia (95% CI, 2.427-
120.561). 
  
 
3
4
2
 
Table 5.20: Logistic regression models for disease active status. 
Outcome Risk Factors 
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds (95% CI) p-value 
Disease active: 
 
Recurrence, 
New-site dysplasia, 
MT and OSCC  
Age 1.007 (0.976-1.040) 0.646   
Sex 
Females 
Males 
 
Reference category 
1.448 (0.806-3.455) 
 
 
0.405 
  
Leukoplakia types 
Homogenous 
Non-homogenous 
 
Reference category 
2.991 (1.160-7.713) 
 
 
0.023 
 
 
3.319 (0.799-13.779) 
 
 
0.099 
PMDs site 
FOM 
Tongue 
Other remaining site 
 
Reference category 
3.381 (1.292-8.845) 
2.893 (0.971-8.620) 
 
 
0.013 
0.057 
 
 
3.323 (0.775-14.241) 
0.944 (0.171-5.218) 
 
 
0.106 
0.947 
Histopathology (WHO grading) 
Mid dysphasia 
Moderate  
Severe 
CIS 
 
Reference category 
1.129 (0.350- 3.641) 
4.622 (1.527- 13.990) 
4.800 (1.123-20.479) 
 
 
0.839 
0.007 
0.034 
 
 
1.960 (0.419- 9.167) 
5.994 (1.282- 28.018) 
17.104 (2.427-120.561) 
 
 
0.393 
0.023 
0.004 
Binary grading 
Low grade 
High grade 
 
Reference category 
2.828 (1.182-6.678) 
 
 
0.020 
  
Resection margin 
Free-margins 
Dysplastic-margins  
 
Reference category 
2.812 (1.073-7.371) 
 
 
0.035 
 
 
6.562 (1.545- 27.878) 
 
 
0.011 
PMDs size (mm
2
) 
Minor < 200 
Intermediate 200-600 
Major > 600 
 
Reference category 
2.327 (0.944- 5.740) 
4.464 (1.035- 18.394)  
 
 
0.067 
0.045 
  
Medical history 
Negative history 
Positive history 
 
Reference category 
7.980 (0.987-64.547) 
 
 
0.051 
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Recurrent (same site) Disease 
The overall incidence of same site recurrent PMD disease in this study was 17/100; 13 males 
and 4 females. Patients with recurrence were followed- up from 14-183 months (mean 83.75 
months). 
The mean age of patients who underwent recurrence was 58.06 years (SD: 12.044) but ranged 
from 40-77 years. As can be seen in Figure 5.2, 59% (10/17) of patients who developed 
recurrent PMD were middle age, followed by 35% (6/17) old age and only one patient 6% 
was younger than 40 years. In this group of patients, 77% (13/17) were married and 47% 
(8/17) were retired. 
 
The mean time between primary treatment and first recurrence was 28.47 months, ranging 
from 6-148 months (SD: 33.88), whilst a second recurrence occurred at a mean time of 
40.875 months ranged from 18-96 months (SD: 27.80).  
In this study, out of the 17 patients with recurrent dysplasia, 8 had 2 or more recurrences. 
 
Recurrence of dysplasia after laser treatment had a male predilection, 76% (13/17) of males 
underwent recurrences compared to 24% (4/17) of females; Figure 5.3. However, the 
association between having a recurrence or not and sex was not significant (p=0.406; Fisher’s 
Exact test). Females showed a shorter mean time to recurrence than males (26.25 vs. 29.15 
months), but statistically the difference was not significant (p=0.88; Independent t-test). 
Males who experienced recurrences were younger than females (56.08 vs. 64.50 years), but 
the difference did not reach significance (p=0.233; Independent t-test). 
 
The total clinical management time for patients developing recurrent disease was between 17-
184 months (SD: 45.931) with a mean of 110.47 months.  
A significantly longer mean management time of patient with recurrence compared to that of 
DF patients was found (110.47 vs. 60.63 months) (p=0.0001; Mann-Whitney U test). 
 
During their clinical management time, patients in this group experienced 0 to 7 
observational biopsies, underwent 1 to 4 laser interventions, between 1 to 7 recurrences and  
0 to 10 follow-up biopsies after laser surgery.  
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Sixty-five percent (11/17) of patients in this group underwent between 2 to 4 further laser 
interventions, whilst the remaining 35% (6/17) underwent only one further laser surgery. 
Patients developing recurrent disease experienced a higher number of follow-up visits 
compared with other outcome groups, between 9 to 78 appointments.  
 
Kaplan-Meier survival analysis showed that, 1-year, 2, 3 and 5-years recurrence-free survival 
rates were 92%, 86%, 80% and 73%, respectively; Figure 5.24. 
Recurrence and recurrence-free cumulative survival function were compared in Figure 5.25; 
the majority of recurrences 65% (11/17) were more likely to take place in the first 2 years 
following laser treatment, whilst the remaining 35% (6/17) occurred after 2-years. 
A significantly lower disease-free survival rate of patients underwent recurrences 1-year, 2-, 
and 4-years after laser treatment compared to the recurrence-free patients (71% vs. 93%), 
(35% vs. 86%) and (12% vs. 68%), respectively (p=0.0001; Log-Rank test). 
 
The clinicopathological features of recurrent cases are summarized in Table 5.21. 
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Figure 5.24: Recurrence–free survival functions by Kaplan–Meier analysis. 
 
 
 
Figure 5.25: Kaplan-Meier survival functions of recurrence and recurrence-free 
patients (p=0.0001; Log-Rank test). 
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Table 5.21: Clinicopathological features of patients developing recurrent disease. 
Case 
Age 
(year) 
Sex Site Clinical types 
Hpath 
WHO 
Hpath 
Binary  
Size 
(mm2)  
Margin 
status  
1st 
RT 
2nd 
RT 
Smoking Drinking  
Follow-up 
(months) 
Medical 
conditions 
1 40 F FOM 
Homogenous 
leukoplakia 
Modd HG <200 Normal 15 20 
10-20 
(cig./day) 
1-14 (u/w)  35 Hypertension 
2 48 M FOM 
Homogenous 
leukoplakia 
Sd HG 200-600 Sd 148 - >20 (cig./day) >28 (u/w)  168 Hypertension 
3 53 M FOM 
Homogenous 
leukoplakia 
CIS HG 200-600 Sd 10 - 
10-20 
(cig./day) 
>28(u/w)  109 Hypertension 
4 47 M FOM Erythroplakia Sd HG <200 
Laser 
damaged 
30 96 >20 (cig./day) >28(u/w)  110 Hypertension 
5 63 M FOM 
Non-homogenous 
exophytic 
CIS HG 200-600 Normal 14 - <10 (cig./day)  >28 (u/w) 70 Hypertension 
6 68 F 
Lateral 
tongue 
Non-homogenous 
exophytic 
Md LG <200 Md 6 18 Non-smoker 1-14(u/w)  46 Hypertension 
7 56 M 
Lateral 
tongue 
Non-homogenous 
ulcerated 
Modd HG >600 Modd 7 22 Ex-smoker 15-28(u/w)  24 Digestive system 
8 62 M 
Lateral 
tongue 
Homogenous 
leukoplakia 
Md LG 200-600 Normal 10 39 Ex-smoker >28(u/w)  81 Hypertension 
9 74 M 
Lateral 
tongue 
Homogenous 
leukoplakia 
CIS HG >600 CIS 12 - Ex-smoker 1-14(u/w)  112 Hypertension-DM 
10 77 F 
Ventral 
tongue 
Homogenous 
leukoplakia 
Sd HG <200 Modd 54 - Non-smoker Non-drinker 124 Hypertension 
11 48 M 
Ventral 
tongue 
Homogenous 
leukoplakia 
Sd HG >600 Sd 10 - 
10-20 
(cig./day) 
15-28(u/w)  13 Hypertension 
12 73 F 
Ventral 
tongue 
Non-homogenous 
speckled 
Sd HG <200 Sd 30 68 Ex-smoker Non-drinker 183 
Hypertension, DM 
oral candida 
13 60 M 
Ventral 
tongue 
Homogenous 
leukoplakia 
Sd HG 200-600 Modd 12 23 >20 (cig./day) >28 (u/w) 88 CVS, liver problem 
14 56 M 
Soft 
palate 
Non-homogenous 
speckled 
Modd HG 200-600 Modd 34 - 
10-20 
(cig./day)  
>28(u/w)  73 Hypertension 
15 46 M 
Soft 
palate 
Homogenous 
leukoplakia 
Modd LG <200 Normal 24 - >20 (cig./day) >28 (u/w) 26 - 
16 74 M 
Soft 
palate 
Homogenous 
leukoplakia 
Vaporization Normal 48 41 Ex-smoker Non-drinker 104 Hypertension 
17 48 M 
Buccal 
mucosa 
Non-homogenous 
exophytic 
Modd HG <200 Md 20 - >20 (cig./day)  >28(u/w)  112 
Oral candida, 
anaemia 
 
F=female; M=males; FOM=Floor of the mouth; Hpath=histopathology; Md=mild dysplasia; Modd=moderate dysplasia; Sd=severe dysplasia; CIS=carcinoma in situ; 
LG=low grade; HG=high grade; DM=diabetes mellitus; 1
st
 RT=1
st
 recurrence time; 2nd RT=2
nd
 recurrence time. 
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Clinical Appearance 
Table 5.10 and Table 5.11, together with Figure 5.9 summarise the clinical outcome in 
relation to the clinical appearance of PMDs. Ninety-four percent (16/17) of recurrent cases 
were leukoplakias (10 homogenous and 6 non-homogenous), with only 6% (1/17) 
erythroplakia. Half of the cases of non-homogenous leukoplakia (3/6) were exophytic 
subtypes. 
A significant relation was found between recurrence status and PMDs clinical appearance 
(p=0.028; Chi-Square test). Non-homogenous leukoplakia showed a higher rate of recurrence 
than homogenous leukoplakia 24% (6/25) vs. 15% (10/67), with the risk estimate showed that 
non-homogenous leukoplakia was 1.6 times higher risk to develop recurrence after laser 
surgery than homogenous leukoplakia (95% CI, 0.653-3.963). 
 
Also, Kaplan-Meier survival analysis showed that non-homogenous leukoplakia cases 
exhibited a shorter estimated mean time to develop recurrences compared with homogenous 
leukoplakia (63.643 vs. 123.008 months), but this was non-significant (p=0.094; Log-Rank 
test); Figure 5.26. 
 
 
Figure 5.26: Kaplan-Meier analysis of recurrence in relation to homogenous and non-
homogenous leukoplakia.
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Anatomical Site 
The FOM showed the highest recurrence rate 29% (5/17), followed equally by lateral and 
ventral surfaces of the tongue 24% (4/17), soft palate 17% (3/17) and buccal mucosa which 
showed the least recurrence rate 6% (1/17). However, no recurrences were seen in the pillar 
of fauces, retromolar area and alveolar mucosa; Table 5.12 and Figure 5.10. The relation 
between recurrence status (yes, no) and the primary affected anatomical site approached 
significance (p=0.051; Chi-Square test). 
 
Size of Dysplasia 
Recurrent disease developed in cases with a mean size of 393.63 mm
2 
and a range from 32-
1,800 mm
2
. Forty-four percent (7/16) of recurrent cases were seen in sites primarily affected 
by minor sized PMDs, followed by those affected with intermediate 37% (6/16) and major 
size 19% (3/16); Table 5.13 and Figure 5.11. 
 
A comparison between recurrence and recurrence-free cases showed a higher recurrence rate 
in patients affected with major size dysplasias compared to recurrence-free patients 19% 
(3/16) vs. 9% (7/82). However, the association between recurrence status and the size of 
dysplastic PMDs was not significant (p=0.241; Chi-Square test); Figure 5.27. 
A higher mean size of dysplasia in patients with recurrence (393.63 mm
2
) compared to those 
who were recurrence-free (281.70 mm
2
) was seen, but also the difference did not reach 
statistical significant (p=0.356; Independent t-test). 
 
 
Figure 5.27: Recurrence and recurrence-free in relation to PMD size (mm
2
). 
 349 
 
Dysplasia Grading 
A significant association was found between recurrence status (yes, no) and the grade of 
dysplasia (p=0.008; Chi-Square test), with CIS showing the highest recurrence rates 27% 
(3/11), followed by severe 26% (6/23) and moderate dysplasia 25% (6/24), with mild 
dysplasia exhibiting the least recurrence rates 5% (2/42).  
 
Recurrence-free patients exhibited primarily mild dysplasia 48% (40/83), followed by 
moderate 22% (18/83), severe 21% (17/83) and CIS 10% (8/83); Figure 5.28. 
 
 
 
 
Figure 5.28: Degree of dysplasia in relation to recurrence status. 
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Similarly, the highest recurrence rate 77% (13/17) was seen in cases with high grade 
dysplasias compared with low grade dysplasias 23% (4/17). Patients with high grade 
dysplasia had a significantly higher recurrence incidence than low grade dysplasia, reflected 
by the significant relation found between high/low grade dysplasia and recurrence status 
(p=0.025; Fisher’s Exact test). 
Recurrence-free cases were slightly more commonly seen in patients with low grade 
dysplasia 52% (43/83) compared to high grade dysplasia 48% (40/83); Figure 5.29. 
 
Of those patients who developed recurrence, 3 (18%) developed recurrent PMD with an 
increased grade of dysplasia, 8 (47%) developed recurrences with less severe dysplasia, 
whilst 6 cases (35%) recurred with the same degree of dysplasia as the initially presenting 
disease. 
 
 
 
 
Figure 5.29: High/low grade dysplasia in relation to recurrence status. 
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Comparing the recurrence-free survival rates of patients with mild, moderate, severe 
dysplasia, and CIS, Kaplan Meier survival analysis showed that patients with CIS showed the 
shortest estimated mean time for recurrence to develop, followed by moderate, severe and 
mild dysplasia (38.84, 85.39, 102.20 and 116.06 months), respectively; however the 
differences did not reach significance (p=0.085; Log-Rank test); Figure 5.30. Patients with 
severe dysplasia showed lower recurrence-free survival rates at 1, 3 and 5-year 
postoperatively (88%, 78% and 59%). Similarly, for patients with moderate dysplasia, a 
lower recurrence–free survival rate 2-and 5-year post-laser surgery was seen (76% and 68%). 
Also, moderate dysplasia cases showed a higher recurrence-free survival rate at 1-year 
compared to patients with both severe dysplasia and CIS (95% vs. 88%, 77%). 
 
 
 
 
Figure 5.30: Kaplan-Meier analysis of patients with recurrence in relation to grade of 
dysplasia. 
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Considering the binary grading system, Figure 5.31 compares recurrence-free survival for 
high and low grade dysplasia. Patients who underwent recurrences primarily affected by high 
grade dysplasia had significantly lower 2-and 5–year recurrence-free survival rates than those 
with low grade dysplasia (79% vs. 91%), (63% vs. 91%), respectively.  
Also, the estimated mean time for recurrence to occur in high grade dysplasia was 
significantly shorter than those with low grade dysplasia (103.13 vs. 113.16 months) 
(p=0.023; Log-Rank test).  
 
 
 
 
Figure 5.31: Kaplan-Meier analysis of patients with recurrence in relation to high/low 
grade dysplasia (p=0.023; Log-Rank test). 
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Recurrence and Resection Margin Status 
Table 5.22 and Table 5.23 show the recurrence status in relation to the surgical margins status 
and margins histopathology, respectively. 
Histopathological reports showed that 44% (38/87) of cases showed clear resection margins, 
whilst 56% (49/87) displayed residual dysplasia. Out of the cases with clear-margins, 11% 
(4/38) developed recurrences, but this increased to 20% (10/49) in cases with dysplastic 
margins. However, there was no significant relation between recurrence status 
(recurrence/recurrence free) and resection margins status (clear/dysplastic) (p=0.252; Fisher’s 
Exact test). 
 
There was a significant relation between recurrence status and the histopathology diagnosis 
of residual dysplasia in the resection margins (p=0.004; Chi-Square test). Four (29%) of 
recurrent cases showed moderate residual dysplasia in the margins with a similar number of 
severe residual dysplasia, and only one case with CIS and one case with mild residual 
dysplasia. Whilst the majority of patients who were recurrence-free (89%; 34/38) showed 
clear resection margins, compared to only 11% (4/38) of those who underwent recurrence but 
with clear margins. 
 
 
 
Table 5.22: Recurrence status in relation to surgical margin status. 
Resection margin  
status 
Recurrence status 
Total 
Recurrence-free Recurrence 
 
Clear-margin 
34 4 38 
89% 11% 100% 
Dysplastic margins 
39 10 49 
80% 20% 100% 
Total 
73 14 87 
84% 16% 100% 
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Table 5.23: Recurrence status in relation to surgical margin histopathology. 
Histopathology 
of surgical margin 
Recurrence status 
Total 
Recurrence-free Recurrence 
 
Clear-margin 
34 4 38 
47% 29% 44% 
Mild 
19 1 20 
26% 7% 23% 
Moderate 
9 4 13 
12% 29% 15% 
Severe 
9 4 13 
12% 29% 15% 
CIS 
2 1 3 
3% 7% 3% 
Total 
73 
100% 
14 
100% 
87 
100% 
 
 
With respect to the anatomical sites of the recurrent cases in relation to resection margins, 
Table 5.24, out of the 4 cases with clear resection margins, 2 were in the FOM and 2 in the 
soft palate. Seven cases with residual dysplasias in the margins were observed in the tongue 
(3 in the lateral and 4 in the ventral tongue), followed by 2 in the FOM and one in the soft 
palate.  
 
 
Table 5.24: Recurrent cases in relation to anatomical site. 
Histopathology 
of surgical margin 
Anatomical site of the recurrent cases 
Total 
FOM 
Lateral 
tongue 
Ventral 
tongue 
Soft 
palate 
  Clear-margin 2 - - 2 4 
Mild - 1 - - 1 
Moderate - 1 2 1 4 
Severe 2 - 2 - 4 
CIS - 1 - - 1 
Total 4 3 4 3 14 
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Smoking Behaviour 
Regarding smoking behaviour and recurrence of dysplasia, 88% (15/17) of patients who 
underwent recurrence were tobacco users, whilst the remaining 12% (2/17) were non-
smokers. Of the 15 tobacco users, 67% (10) were current smokers and 33% (5) were ex-
smokers. Current smokers with recurrences smoked between 7- 40 cigarettes/day (mean of 
23.60). Of the current tobacco smokers, 50% (5/10) were heavy smokers, 40% (4/10) 
intermediate and only one patient was a light smoker 10% (1/10); Table 5.16 and Figure 5.14. 
 
Using Chi-Square test, no significant association was found between recurrent status and 
either smoking status (p=0.509) or number of cigarettes smoked per day (p=0.062). However, 
heavy smokers showed a higher recurrence rate 50% (5/10), whilst intermediate smokers 
represented the majority of the recurrence-free group; Figure 5.32. 
 
 
 
 
Figure 5.32: Recurrence status in relation to the number of cigarettes smoked per day. 
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Patients with recurrence had a smoking history between 10- 48 years with a mean of 32.50 
years. Recurrence rate was the same for both groups of patients who smoked for either a long 
duration of time (31-50 years) or a relatively long duration (10-30 years). However, 60% 
(18/30) of recurrence-free cases were associated with a long smoking history (31-50) 
compared with those who smoked for 10-30 years, but the relation between smoking history 
and recurrence status was not significant (p=0.415; Chi-Square test); Figure 5.33. 
 
 
 
 
Figure 5.33: Recurrence status in relation to smoking history. 
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Taking into consideration the smoking status in patients who underwent recurrences, Kaplan-
Meier analysis showed that recurrence-free survival rates of patients with recurrences 1-year 
postoperatively was 94%, 93% 84% for current smokers, non-smokers and ex-smokers, 
respectively. Two-years after treatment, the percentage for current smokers decreased to 85% 
but remained the same for both non-smokers and ex-smokers. The 3-year recurrence-free 
survival rate of current smokers dropped to 80%, whilst the 5-year rate was the same, but 
dropped to 70% and 52% for non-smokers and ex-smokers, respectively; Figure 5.34. 
Also, ex-smokers experienced the shortest estimated mean time for recurrence to occur 
(61.82 months) compared to both non-smokers (65.19 months) and current smokers (121.67 
months), however, a Log-Rank test was not significant (p=0.396). 
 
 
 
 
Figure 5.34: Kaplan-Meier analysis of patients with recurrence in relation to smoking 
status. 
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In general, Chi-Square testing showed no significant relation between clinical outcome and 
smoking status, both at the first presentation and the most recent follow-up (p=0.509, 
p=0.516, respectively). Whilst non-smokers remained the same, current smokers who 
underwent recurrence decreased from 10 to 7 cases, ex-smokers increased from 5 to 8 cases; 
Figure 5.35 and Figure 5.36. 
 
Similarly, no significant association was found between clinical outcome and smoking 
intensity (cigarettes/day) either at the first or most recent follow-up (p=0.06, p=0.252, 
respectively). However, light smokers with recurrences increased from one patient at initial 
presentation to 5 at the most recent follow-up, whilst intermediate smokers decreased from 4 
to 2 patients and no heavy smokers were seen at the most recent follow-up from the 5 cases at 
first presentation. 
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Figure 5.35: Smoking status at first presentation in relation to clinical outcome. 
 
 
Figure 5.36: Smoking status at most recent follow-up in relation to clinical outcome. 
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Alcohol Use  
Out of the 17 patients with recurrence, 82% (14/17) were current drinkers and the remaining 
18% (3/17) were non-drinkers, though no ex-drinkers were seen in this group; Table 5.25. 
Patients who developed recurrent disease drank between 2 and 80 units/week with a mean of 
36.2 (units/week). 
 
 
 
Table 5.25: Recurrence status in relation to drinking status. 
Recurrence status 
Drinking status at initial presentation 
Total 
Non-drinker 
Current 
drinker 
Ex-drinker 
 
Recurrence-free 
11 69 3 83 
13% 83% 4% 100% 
Recurrence 
3 14 - 17 
18% 82%  100% 
Total 14 83 3 100 
 
 
 
A significant relation was found between recurrence status and the amount of alcohol 
consumed in terms of units per week (light, moderate, heavy drinkers) (p=0.019; Chi-Square 
test). Heavy drinkers exhibited the highest recurrences rates 64% (9/14), whilst recurrence-
free patients were light drinkers 52% (36/69); Figure 5.37. 
 
Patients consuming > 28 units/week experienced higher recurrence rates 64% (9/14) after 
laser treatment compared to those who consumed ≤ 28 units/week 36% (5/14). However, no 
significant relation was found between the amount of alcohol consumed in terms of 
units/week and recurrence (p=0.074; Fisher’s Exact test). However, risk estimate showed that 
consumption of more than 28 units/week was a 2.594 times higher risk for recurrence to 
develop post-laser intervention than in those consuming ≤ 28 units/week (95% CI, 0.953-
0.7065). 
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Figure 5.37: Recurrence and recurrence-free in relation to alcohol intake. 
 
 
 
Although the majority of patients who underwent recurrence were drinkers, a higher 
recurrence rate was seen among non-drinkers 21% (3/14) compared with 17% (14/83) in 
drinkers; the relation, however, was not significant (p=0.707; Fisher’s Exact test). 
Risk estimate showed that non-drinkers had an increased risk of 1.27 times of developing 
recurrence compared to current drinkers (95% CI, 0.418-3.859).  
 
Furthermore, Kaplan-Meier analysis showed that non-drinkers had a shorter estimated mean 
time to develop recurrence compared to drinkers (63.33 vs. 120.39 months), but Log-Rank 
testing was not significant (p=0.566). Recurrence-free survival rate of non-drinkers who 
underwent recurrence was 80% at 30 months (2.5 years) after laser surgery, which dropped to 
53% at 54 months (4.5 years); Figure 5.38. 
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Figure 5.38: Kaplan-Meier analysis of patients with recurrence in relation to alcohol 
drinker and non-drinker. 
 
 
 
Patients consuming > 28 and ≤ 28 units/week had the same recurrence-free survival rates 1-
year after laser treatment (90%), but at 2-years the rate dropped to 78% for patients 
consuming more than 28 units/week compared to those consuming ≤ 28 (88%).  
At 5-years post-laser intervention the survival rate was the same for patients consuming ≤ 28 
units/week, but decreased to 69% for those who drank more than 28 units/week; however the 
Log-Rank test was not significant (p=0.206); Figure 5.39. 
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Figure 5.39: Kaplan-Meier analysis of patients with recurrence in relation to drinking 
behaviour. 
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Dental Prosthesis Wear 
Overall, the majority of patients who underwent recurrence (71%; 12/17) were dental 
prostheses wearers, whilst the majority of recurrence-free patients were non-wearers (51%; 
42/83). Out of the 17 recurrent cases, 12 were dental prosthesis wearers (6 wore full dentures, 
4 with crowns & bridges and 2 with upper or lower set of denture) and 5 were non-wearers; 
Figure 5.40 and Table 5.26. Fisher’s Exact test showed no significant association between 
recurrence status and the wearing of a dental prosthesis (p=0.181). 
 
 
 
Figure 5.40: Recurrence status in relation to dental prostheses wear. 
 
Table 5.26: Recurrence status in relation to dental prostheses wear. 
Recurrence status 
Dental prosthesis 
Total 
Wearer Non-wearer 
  
Recurrence-free 
41 42 83 
49% 51% 100% 
Recurrence 
12 5 17 
71% 29% 100% 
Total 
53 47 100 
53% 47% 100% 
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Logistic Regression Analysis 
To explore the most important significant predictors (independent risk factors) associated 
with same site recurrence of dysplasia after laser surgery, age, sex, clinical types of 
leukoplakia, anatomical site, size, degree of epithelial dysplasia, resection margin 
histopathology, smoking and drinking status, dental prosthesis wearer and a history of 
systemic disease were incorporated into the regression analysis separately. The -2 log 
likelihood ratio test statistic was used to reach the best fit for the final model. 
 
Table 5.27 shows the final logistic regression models for recurrence of dysplasia after laser 
treatment of dysplastic PMDs. 
The age of the patient had no effect on recurrence of dysplasia (OR=1.002, 95% CI, 0.963-
1.044) (p=0.905). Males exhibited 1.840 times the risk of females for recurrence (95% CI, 
0.550-6.149), but this was not significant (p=0.322). 
 
The clinical type of leukoplakia seems to influence recurrence, so that non-homogenous 
leukoplakia was 1.8 times more likely to recur than homogenous leukoplakia (95% CI, 0.577-
5.614), but did not reach significance (p=0.311). 
 
Major size PMDs were 2.204 times more likely to recur than minor size PMDs (95% CI, 
0.456-10.661), but this was non-significant (p=0.326). 
 
Using mild dysplasia as a reference category, moderate dysplasia increased the risk of 
recurrence by 5.556 times (95% CI, 0.983-31.387) but with a border line significant 
(p=0.052). Severe dysplasia increased the risk of recurrence 5.882 times (95% CI, 1.037-
33.354); and was a significant predictor for recurrence to develop (p=0.045). Similarly, CIS 
increased the risk for recurrence to occur by 8.571 times compared to mild dysplasia (95% 
CI, 1.206-60.920); and was as a significant predictor of recurrence (p=0.032). 
 
With respect to histopathology of resection margins, those displaying severe dysplasia-CIS 
increased the risk of recurrence by 3.864 times compared to the risk for clear-margins (95% 
CI, 0.879-16.975) (p=0.073). Margins with moderate dysplasia were 3.778 times more likely 
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to develop recurrence than clear-margins (95% CI, 0.787-18.133), but was non-significant 
(p=0.097).  
 
Using non-smoker and non-drinker as reference categories, smoking ≤ 20 cigarettes/day 
produced 1.114 times the risk of non-smokers for recurrence (95% CI, 0.199-6.237) 
(p=0.902), whilst smoking > 20 cigarettes/day caused 1.444 times the risk of non-smokers 
(95% CI, 0.229-9.106) (p=0.695). For ex-smokers, the risk was 1.912 times higher of 
recurrence compared with non-smokers (95% CI, 0.319-11.471) (p=0.478). 
Patients who drank > 28 units/week were 1.320 times more likely to develop recurrence than 
non-drinkers (95% CI, 0.298-5.838) (p=0.714). 
 
The lateral and ventral surfaces of the tongue have an increased risk of recurrence by 2.624 
times compared with the recurrence risk for the FOM (95% CI, 0.772-8.915), although this 
was non-significant (p=0.122). 
Wearing a dental prosthesis showed an increased risk by 2.459 times for recurrence compared 
with non-wearers (95% CI, 0.795-7.600), but this was not significant (p=0.118). 
 
Chronic medical problems increased the risk for recurrence by 2.444 times compared with 
patients who had no systemic disease (95% CI, 0.294-20.316), but this was non-significant 
(p=0.408). 
 
After the model-fitting technique, final model selection utilized the goodness of fit statistic -2 
log likelihood ratio and revealed that the histopathology of the margins, degree of epithelial 
dysplasia, clinical type of leukoplakia and site of dysplasia were the most important 
predictors of recurrent disease, although no one was a significant predictor. 
CIS showed an 11.902 times increased risk for recurrence compared to mild dysplasia. 
Dysplastic margins with severe dysplasia-CIS exhibited a 4.312 times risk of recurrence.  
The tongue showed a 6.4 times increased risk compared to the FOM and drinking an excess 
of 28 units per week increased the risk of recurrence 2.327 times compared to non-drinkers. 
 
  
 
3
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Table 5.27: Logistic regression models of local recurrence of dysplasia. 
Clinical outcome Risk Factors 
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds (95% CI) p-value 
Recurrence 
(same site) 
 
Age 1.002 (0.963- 1.044) 0.905 
  
Sex 
Females 
Males 
 
Reference category 
1.840 (0.550-6.149) 
 
 
0.322 
  
leukoplakia types 
Homogenous 
Non-homogenous 
 
Reference category 
1.8 (0.577-5.614) 
 
 
0.311 
 
 
1.627 (0.315- 8.407) 
 
 
0.561 
PMDs site 
FOM 
Tongue 
Other remaining sites 
 
Reference category 
2.624 (0.772-8.915) 
1.929 (0.461-8.072) 
 
 
0.122 
0.368 
 
 
6.400 (0.434- 94.305) 
0.543 (0.056-5.237) 
 
 
0.176 
0.598 
Histopathology (WHO grading) 
Mid dysphasia 
Moderate  
Severe 
CIS 
 
Reference category 
5.556 (0.983- 31.387) 
5.882 (1.037-33.354) 
8.571 (1.206- 60.920) 
 
 
0.052 
0.045 
0.032 
 
 
6.726 (0.538-84.109) 
3.892 (0.302-50.217) 
11.902 (0.817- 173.431) 
 
 
0.139 
0.298 
0.070 
Resection margins histopathology 
Free-margins 
Mild dysplasia 
Moderate 
Severe-CI 
 
Reference category 
0.45 (0.047- 4.296) 
3.778 (0.787- 18.133) 
3.864 (0.879- 16.975) 
 
 
0.486 
0.097 
0.073 
 
 
1.056 (0.074-15.023) 
3.954 (0.421-37.146) 
4.312 (0.518- 35.911) 
 
 
0.968 
0.229 
0.177 
PMDs size (mm2) 
Minor < 200 
Intermediate 200-600 
Major > 600 
 
Reference category 
0.791 (0.242-2.577) 
2.204 (0.456-10.661) 
 
 
0.697 
0.326 
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Continued 
Clinical outcome Risk Factors 
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds (95% CI) p-value 
Recurrence 
(same site) 
 
Smoking status 
Non-smokers 
Smoking ≤ 20 cigarettes/day 
Smoking > 20 cigarettes/day 
Ex-smokers 
 
Reference category 
1.114 (0.199- 6.237) 
1.444 (0.229- 9.106) 
1.912 (0.319-11.471) 
 
 
0.902 
0.695 
0.478 
  
Drinking status 
Non- drinker 
≤ 28 units/week 
> 28 unite/week 
 
Reference category 
0.417 (0.86-2.016) 
1.320 (0.298-5.838) 
 
 
0.276 
0.714 
 
 
0.459 (0.024-8.757) 
2.327 (0.112-48.475) 
 
 
0.605 
0.586 
Medical history 
Negative  
positive 
 
Reference category 
2.444 (0.294-20.316) 
 
 
0.408 
  
Oral dental prosthesis 
Non-wearer 
Wearer 
 
Reference category 
2.459 (0.795-7.600) 
 
 
0.118 
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Further Disease (new-site PMDs) 
Further disease was defined as new dysplastic lesions developing at oral sites, distant from 
the primary dysplasia. 
At the most recent follow-up of patients, 14/100 of the study cohort patients had undergone 
new-site dysplasia formation. 
 
The total clinical management time of patients in this group was between 33-139 months, 
with 15-68 follow-up appointments. The mean follow-up time was 93 months, with a range 
from 25-133 months. Patients in this group developed between 1 to 3 new dysplasias during 
their clinical course and experienced between 0 to 3 observational biopsies.  
Overall, patients in this group underwent between 1 to 6 further lasers interventions, with the 
majority of them 64% (9/14) undergoing 2 to 6 laser surgeries; the remaining 36% (5/14) 
underwent only one additional laser surgery. Patients in this group experienced between 0 to 
13 follow-up biopsies post-laser surgery. 
 
After laser treatment, the first new-site dysplasia appeared at an average time of 30.35 
months with a range of 7-60 months, whilst the second new dysplasia occurred after an 
average time of 48.25 months and a range of 41-63 month. 
 
The mean age of patients with further disease was 58.93 years (SD: 11.579), with a range 
from 39-76 years. Patients were predominantly in their middle age 64% (9/14), followed by 
old age 29% (4/14), whilst patients ≤ 40 years showed the least tendency for new-site disease 
formation 7% (1/14); Figure 5.2. However, no significant relation was found between 
developing new-site dysplasia and patient age groups (p=0.210; Chi-Square test). 
 
Development of new-site dysplasia had a male predilection: 71% (10/14) compared to 29% 
(4/14) in females; as shown in Figure 5.3. However, a Chi-Square test showed no significant 
relation between sex and developing new-site dysplasia (p=0.767). Females showed a shorter 
mean time to develop new disease compared with males (25.50 vs. 32.30 months), but this 
difference was not significant (p=0.549; Independent t- test). 
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Also, no significant difference was found in the mean age between males and females who 
underwent new-site dysplasia (p=0.399; Independent t-test), although females presented at a 
higher mean age than males (63.25 vs. 57.20 years).  
 
Kaplan-Meier survival analysis showed that new-site dysplasia-free survival rates of patients 
1-, 2-, 3 and 5-years after laser treatment were 97%, 92%, 89% and 69%, respectively.  
Patients were more likely to develop new-site dysplasia 3-years after laser treatment (8/14), 
compared with first and second post-operative years; Figure 5.41. 
 
Figure 5.42 compares the disease-free survival rates of new-site dysplasia and new-site 
dysplasia-free group of patients, significantly a lower disease-free survival rates of patients 
experienced new-site dysplasia formation compared to those who were new-site dysplasia-
free at 1-year and~3 years (38 months) post-laser surgery (50% vs. 94%), (36% vs. 72%), 
respectively (p=0.0001; Log-Rank test).  
 
The clinicopathological features of this group of patients are summarized in Table 5.28. 
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Figure 5.41: Overall new site dysplasia-free survival functions by Kaplan–Meier 
analysis. 
 
 
Figure 5.42: Kaplan-Meier analysis of patients with further disease and further disease-
free (p=0.0001; Log-Rank test). 
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Table 5.28: Clinicopathological features of patients developing further (new site) PMDs. 
Case Age Sex Primary site Clinical types 
1st new 
dysplasia 
1st NT 
months 
Hpath 
WHO 
Hpath 
Binary 
Margin Smoking Drinking 
Follow-up 
months 
Medical 
 conditions 
1 53 M R.FOM Homogenous leukoplakia L.FOM 38 Modd HG Md 
10-20 
cig./day 
>28 (u/w) 82 Hypertension 
2 39 M L.FOM Non-homogenous/speckled 
L.Ventral 
tongue 
18 Sd HG CIS >20 cig./day >28 (u/w) 119 Hypertension 
3 76 M FOM Homogenous leukoplakia 
L.Buccal 
mucosa 
8 Sd HG Sd Ex-smoker Non-drinker 27 Hypertension 
4 61 M FOM Homogenous leukoplakia 
R.Lateral 
tongue 
56 Md LG Modd 
10-20 
cig./day 
>28 (u/w) 77 Hypertension 
5 59 M Ventral tongue Homogenous leukoplakia 
L.Ventral 
tongue 
7 Md LG Md 
10-20 
cig./day 
15-28 (u/w) 107 
Cervical myelopathy 
Bladder cancer 
6 74 M Ventral tongue Homogenous leukoplakia 
L.Lateral 
tongue 
7 Md LG 
Laser 
damaged 
Ex-smoker 1-14 (u/w) 69 Oral Candida 
7 76 F Ventral tongue Homogenous leukoplakia 
L.Lateral 
tongue 
42 CIS HG Normal Non-smoker 1-14 (u/w) 124 Hypertension 
8 68 M Ventral tongue Non-homogenous/speckled 
L.Lateral 
tongue 
45 CIS HG Sd Ex-smoker >28 (u/w) 114 Hypertension 
9 52 M Lateral tongue Non-homogenous/ulcerated L.FOM 36 Sd HG Sd >20 cig./day 1-14 (u/w) 24 Hypertension 
10 60 M 
R. Buccal 
mucosa 
Non-homogenous/exophytic 
L.Buccal 
mucosa 
60 Md LG Md <10 cig./day >28 (u/w) 133 Oral Candida 
11 59 F 
L. Buccal 
mucosa 
Homogenous leukoplakia 
R.Buccal 
mucosa 
39 Sd HG Sd 
10-20 
cig./day 
1-14 (u/w) 77 
Skeletomuscular 
Rheumatoid arthritis 
12 55 M Fauces Non-homogenous/speckled 
Anterior 
FOM 
38 Md LG Modd 
10-20 
cig./day 
>28 (u/w) 104 Hypertension 
13 42 F Fauces non-homogenous/speckled L.FOM 13 Sd HG Md >20 cig./day >28 (u/w) 106 CVS, Respiratory 
14 68 M Soft palate Erythroplakia 
L.Labial 
mucosa 
18 Md LG Normal >20 cig./day 15-28 (u/w) 25 
Hypertension 
Oral candida 
 
R=right side, L=left side; FOM=floor of mouth; 1st NT=1st new dysplasia time; Hpath=histopathology; cig =cigarettes; u/w=units of alcohol per week 
Modd=moderate dysplasia; Sd=severe dysplasia; Md=mild dysplasia; CIS=carcinoma in situ; HG=high grade dysplasia; LG=low grade dysplasia. 
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Clinical Appearance 
Out of the 14 patients who developed new-site dysplasia, 13 were leukoplakias with 1 
erythroplakia. Of the 13 leukoplakias, 7 were homogenous and 6 non-homogenous, in which 
the majority were speckled (4/6), one exophytic and one ulcerated; Table 5.11 and Figure 5.9. 
No significant relation was found between new-site dysplasia formation and leukoplakia type 
either homogenous or non-homogenous (p=0.174; Fisher’s Exact test), although a significant 
relation was found overall between clinical appearance of PMDs and the development of new 
dysplasia (p=0.021; Chi-Square test).  
 
Ninety-percent (60/67) of patients with homogenous leukoplakia were free from new 
dysplasia compared to 10% (7/67) that developed new-site dysplasia. New-site dysplasia 
formation rate of homogenous leukoplakia was 54% (7/13) compared to 46% (6/13) of non-
homogenous type. Among other non-homogenous leukoplakia, patients with the speckled 
subtype showed the highest rate of new dysplasia formation 31% (4/13); Table 5.29. 
Risk estimate showed that patients with non-homogenous leukoplakia had 2.297 times the 
risk to develop new-site dysplasia compared to those with homogenous leukoplakia (95% CI, 
0.854-6.176). 
 
Table 5.29: New site dysplasia status in relation to clinical appearance of PMDs. 
PMDs appearance 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
Homogenous 
leukoplakia 
60 7 67 
90% 10% 100% 
N
o
n
-h
o
m
o
g
en
o
u
s 
le
u
k
o
p
la
k
ia
 
Speckled 
12 4 16 
75% 25% 100% 
Nodular 
2 - 2 
100% - 100% 
Exophytic 
4 1 5 
80% 20% 100% 
Ulcerated 
1 1 2 
50% 50% 100% 
Erythroplakia 
7 1 8 
88% 12% 100% 
Total 86 14 100 
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Anatomical Site 
A significant relationship was found between developing new-site dysplasia and the primary 
affected oral subsites (p=0.002; Chi-Square test). New-site dysplasia formation was mainly 
seen in patients with FOM and ventral tongue lesions equally at 29% (4/14), followed by 
buccal mucosa and fauces 14% (2/14), lateral tongue and soft palate in equal distribution 
(1/14), whilst no new dysplasia was seen in patients initially affected at retromolar area or 
alveolar mucosa sites; Table 5.30. 
 
 
 
Table 5.30: New site dysplasia status in relation to PMD anatomical site. 
PMDs  
anatomical site 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
FOM 
42 4 46 
91% 9% 100% 
Lateral tongue 
18 1 19 
95% 5% 100% 
Ventral tongue 
10 4 14 
71% 29% 100% 
Buccal mucosa 
3 2 5 
60% 40% 100% 
Soft palate 
8 1 9 
89% 11% 100% 
Fauces 
2 2 4 
50% 50% 100% 
Retromolar area 
1 - 1 
100%  100% 
Alveolar mucosa 
2 - 2 
100%  100% 
Total 
86 14 100 
86% 14% 100% 
 
 
 
 375 
 
Size of Dysplasia 
Patients developing new-site dysplasia primarily presented with lesions of a mean size of 
342.79 mm
2
 (SD: 217.493) with a range of 21-704 mm
2
.  
A significant relation was found between developing new-site dysplasia and the size of the 
primary dysplastic PMDs affecting the patients (p=0.049; Chi-Square test); patients with 
dysplasia sized between 200-600 mm
2
 showing the highest rate of new dysplasia formation 
64% (9/14); Table 5.31. 
 
 
 
Table 5.31: New site dysplasia status in relation to the primary PMD size category. 
PMD size category 
(mm
2
) 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
Minor < 200 
40 3 43 
48% 21% 44% 
Intermediate 
(200-600) 
36 9 45 
43% 64% 46% 
Major > 600 
8 2 10 
10% 14% 10% 
Total 
84 14 98 
100% 100% 100% 
 
 
 
Dysplasia Grading 
Regarding histopathology diagnosis, the relation between the degree of epithelial dysplasia 
and developing new-site dysplasia was significant (p=0.040; Chi-Square test). 
A higher rate of new dysplasia formation was observed in patients exhibiting mild dysplasia 
43% (6/14), followed by severe 36% (5/14) and CIS 14% (2/14), with patients with moderate 
dysplasia showing the least rate of new-site dysplasia formation 7% (1/14); Table 5.32. 
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Considering the binary grading system, high grade dysplasia showed the highest rate of new-
site dysplasia formation compared with low grade dysplasia (57%; 8/14 vs. 43%; 6/14), 
however, Fisher’s Exact test was not significant (p=0.778); Table 5.33. 
For patients who developed new-site dysplasia, 57% (8/14) developed new-site disease with 
the same degree of initial dysplasia, 36% (5/14) showed a decreased degree of dysplasia and 
only one case (7%) of new-site dysplasia showed an increased grade of dysplasia. 
 
 
 
Table 5.32: New site dysplasia status in relation to degree of primary dysplasia. 
Degree of dysplasia 
(WHO grading) 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
Mild 
36 6 42 
43% 43% 43% 
Moderate 
22 1 23 
27% 7% 24% 
Severe 
17 5 22 
20% 36% 23% 
CIS 
8 2 10 
10% 14% 10% 
Total 
83 
100% 
14 
100% 
97 
100% 
 
 
 
Table 5.33: New site dysplasia status in relation to high/low grade dysplasia. 
Binary grading 
dysplasia 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
Low grade 
40 6 46 
48% 43% 47% 
High grade 
43 8 51 
52% 57% 53% 
Total 
83 14 97 
100% 100% 100% 
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Smoking Behaviour 
Patients showing new-site dysplasia smoked between 8-50 cigarettes/day with a mean of 
26.80. A higher rate of new dysplasia formation was seen in tobacco users; 71% (10/14) in 
current smokers and 21% (3/14) in ex-smokers, whilst only one case (7%) of a non-smoker 
developing new-site dysplasia was seen; Table 5.34. 
No significant association was found between the development of new-site dysplasia and 
smoking status (p=0.284; Chi-Square test). 
 
 
Table 5.34: New site dysplasia status in relation to smoking status. 
Smoking status 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
  
Non-smoker 
14 1 15 
16% 7% 15% 
Current smoker 
53 10 63 
62% 71% 63% 
Ex-smoker 
19 3 22 
22% 21% 22% 
Total 
86 14 100 
100% 100% 100% 
 
 
 
No significant relation was found between the development of new-site dysplasia and 
smoking intensity in term of cigarettes per day (p=0.093; Chi-Square test). However, the 
highest rates of new dysplasia formation were seen in patients who smoked intermediate and 
heavy amounts of tobacco 50% (5/10) and 40% (4/10), respectively, followed by those who 
consumed small numbers of cigarettes per day 10% (1/10) who showed the lowest rate of 
new-site dysplasia; Table 5.35. 
 
A higher rate of new dysplastic PMD presentation was seen amongst patients with a long 
smoking history (31-50) years (67%; 4/6) compared to those who had smoked for a relatively 
shorter duration of time (10-30) years (33%; 2/6), however this relation was not significant 
(p=0.446; Chi-Square test); Table 5.36. 
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Table 5.35: New site dysplasia status in relation to number of cigarettes per day. 
Smoking intensity 
(cigarettes/day) 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
< 10 
1 1 2 
2% 10% 3% 
10-20 
33 5 38 
62% 50% 60% 
> 20 
19 4 23 
36% 40% 37% 
Total 
53 10 63 
100% 100% 100% 
 
 
 
Table 5.36: New site dysplasia status in relation to smoking history. 
Smoking history  
(years) 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
10-30 
12 2 14 
40% 33% 39% 
31-50 
17 4 21 
57% 67% 58% 
> 50 
1 - 1 
3%  3% 
Total 
30 6 36 
100% 100% 100% 
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Kaplan-Meier survival function regarding smoking status in relation to new-site dysplasia 
formation showed that ex-smokers demonstrated a shorter estimated mean time to develop 
new-site dysplasia compared with current smokers (74.17 vs. 112.3 months). Lower new-site 
dysplasia-free survival rates were seen amongst ex-smokers 1-and 4-year post-laser 
intervention compared to current smokers (89% vs. 98%) and (71% vs. 77%), respectively, 
although Log-Rank testing was non-significant (p=0.687); Figure 5.43. 
 
 
 
 
Figure 5.43: Kaplan-Meier analysis of patients with new site dysplasia according to 
smoking status. 
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Alcohol Use 
The majority of patients who developed new-site dysplasia were current drinkers 93% 
(13/14), with only one non-drinker (7%) reported in this group; Table 5.37. No significant 
relation was found, however, between developing new dysplasia and drinking status 
(p=0.218; Chi-Square test).  
 
Also, no significant association was found between new dysplasia formation and the number 
of alcohol units consumed per week (p=0.387; Chi-Square test). However, heavy drinkers 
who consumed > 28 units/week showed higher rates of new dysplasia formation (54%; 7/13), 
followed by light drinkers (31%; 4/13) and intermediate drinkers (15%; 2/14). 
Patients who were new-site dysplasia-free were mainly light drinkers who consumed between 
1-14 units/week (50%; 35/70); Table 5.38. 
 
Table 5.37: New site dysplasia status in relation to drinking status. 
Drinking status 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
Non-drinker 
13 1 14 
15% 7% 14% 
Current drinker 
70 13 83 
81% 93% 83% 
Ex-drinker 
3 - 3 
3%  3% 
Total 
86 14 100 
100% 100% 100% 
 
Table 5.38: New site dysplasia status in relation to alcohol intake. 
Alcohol 
(units/week) 
New site 
dysplasia-free 
New site 
dysplasia 
Total 
 
1-14 
35 4 39 
50% 31% 47% 
15-28 
8 2 10 
11% 15% 12% 
> 28 
27 7 34 
39% 54% 41% 
Total 
70 13 83 
100% 100% 100% 
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With respect to drinking status and new-site dysplasia formation, Kaplan-Meier survival 
analysis showed that current drinkers showed a clear fall in disease-free survival rates 1-, 2-, 
3-, 4- and 5-years after laser treatment (97%, 92%, 89%, 74% and 67%, respectively), 
compared to non-drinkers. A fall in disease-free survival rate of current drinkers compared to 
non-drinkers 4 years and 5 years post-laser surgery was found (74% vs.92%), (67% vs. 92%) 
respectively, although Log-Rank testing was not significant (p=0.773); Figure 5.44. 
 
 
 
 
Figure 5.44: Kaplan-Meier analysis of patients with new site dysplasia in relation to 
drinking status. 
 
 
 382 
 
Dental Prosthesis Wear 
A higher proportion of new-site dysplasia formation was seen amongst patients not wearing 
dental prostheses (57%; 8/14) compared to wearers (43%; 6/14); however, Fisher’s Exact test 
showed no significant association between wearing a dental prosthesis and new-site dysplasia 
formation (p=0.565); Table 5.19 and Figure 5.19. 
 
 
Logistic Regression Analysis 
To explore the most important predictors for new-site dysplasia formation, a logistic 
regression analysis was performed. Age, sex, binary histopathological diagnosis, clinical type 
of leukoplakia, smoking and drinking behaviour, anatomical site of dysplasia and history of 
medical problems were included in the analysis separately, then the goodness of fit statistic -2 
log likelihood ratio was utilized to select the final regression model. 
Table 5.39 shows the logistic regression models of new-site dysplasia formation. 
 
Whilst no effect of patients’ age on new-site dysplasia formation was found (OR=1.009, 95% 
CI, 0.965-1.054) (p=0.704), males displayed 1.339 times the risk of females for new-site 
dysplasia development (95% CI, 0.387-4.635), but this was non-significant (p=0.645). 
 
Non-homogenous leukoplakia showed a 2.707 times increased risk for new dysplasia to occur 
compared with homogenous leukoplakia (95% CI, 0.810-9.044); statistically, this was non-
significant (p=0.106).  
 
High grade dysplasia was at 1.240 times the risk of low grade dysplasia for new-site PMDs to 
develop (95% CI, 0.396- 3.889), but again this was not significant (p=0.712). 
 
Smoking ≤ 20 cigarettes/day increased the risk for new-site dysplasia to occur 2.4 times more 
compared with the risk of non-smokers (95% CI, 0.264-21.787), whereas smoking > 20 
cigarettes/day showed a 3.111 times increased risk compared with non-smokers (95% CI, 
0.312-31.028); both were non-significant (p=0.333, p=0.437, respectively). Ex-smokers 
increased the risk for new-site dysplasia to occur by 2.211 compared with non-smokers (95% 
CI, 0.207-23.555), but again this was not significant (p=0.511). 
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Drinking alcohol ≤ 28 units/week posed a 1.814 times higher risk for new-site dysplasia to 
occur compared with non-drinkers (95% CI, 0.200-16.470), but this was not significant 
(p=0.597), whilst drinking > 28 units/week increased the risk for new-site dysplasia to 
develop by 3.370 compared with non-drinkers (95% CI, 0.374-30.335), but again non-
significant (p=0.278). 
 
The best fit for the final model for multivariable regression analysis that utilized the goodness 
of fit statistic -2 log likelihood ratio was for leukoplakia type, anatomical site, binary 
histopathological diagnosis, smoking and drinking, all of which may be considered as 
important predictors, although none reach statistical significance. 
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Table 5.39: Logistic regression models of new site dysplasia formation. 
Outcome Risk factors  
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds(95% CI) p-value 
 
Further Disease 
New site PMD 
 
Age 1.009 (0.965-1.054)  0.704 
  
Sex 
Females 
Males 
 
Reference category 
1.339 (0.387- 4.635) 
 
 
0.645 
  
Leukoplakia type 
Homogenous 
Non-homogenous 
 
Reference category 
2.707(0.810- 9.044) 
 
 
0.106 
 
 
2.212 (0.538-9.098) 
 
 
0.271 
 
Histopathology -binary system 
Low grade  
High grade 
 
 
Reference category 
1.240 (0.396- 3.889) 
 
 
 
0.712 
 
 
 
1.281 (0.317-5.180) 
 
 
 
0.728 
PMD site 
FOM 
Tongue  
Remaining sites 
 
Reference category 
1.875 (0.463-7.596) 
3.281 (0.781-13.785) 
 
 
0.379 
0.105 
 
 
3.564 (0.652-19.483) 
2.181 (0.398- 11.934) 
 
 
0.143 
0.369 
Smoking status 
Non-smokers 
Smoking ≤ 20 cig/day 
Smoking > 20 cig/day 
Ex-smokers 
 
Reference category 
2.400 (0.264- 21.787) 
3.111 (0.312- 31.028) 
2.211 (0.207- 23.555) 
 
 
0.437 
0.333 
0.511 
 
 
3.638 (0.240-55.203) 
3.530 (0.209- 59.512) 
4.589 (0.349-60.355) 
 
 
0.240 
0.209 
0.349 
Drinking status 
Non-drinker 
≤ 28 u/w 
> 28 u/w 
 
Reference category 
1.814 (0.200- 16.470) 
3.370 (0.374- 30.335) 
 
 
0.597 
0.278 
 
 
0.658 (0.054- 8.052) 
1.506(0.110-20.656) 
 
 
0.743 
0.759 
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Comparison between the Recurrent Disease and the Development of Further Dysplasia 
Male patients developed more recurrent disease 57% (13/23) than further disease at sites 
distant from their primary dysplasia 43% (10/23), whereas females developed recurrences 
and new-site dysplasia equally; the relation was not significant, however (p=1.000; Fisher’s 
Exact test); Figure 5.45. 
 
 
 
 
Figure 5.45: Sex in relation to recurrent (same site) disease and new site dysplasia 
formation. 
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In middle age patients, a higher recurrence rate compared to new-site dysplasia formation 
was seen (10/17 vs. 9/14). Similarly, in old age a higher rate of recurrence (6/17) was seen 
compared to new dysplasia formation (4/14). Patients ≤ 40 years showed an equal rate of both 
recurrence and new-site dysplasia formation, although the relation was not significant 
(p=0.634; Chi-Square test); Figure 5.46. 
 
 
 
 
Figure 5.46: Age in relation to recurrent (same site) disease and new site dysplasia 
formation. 
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A significant relationship was found between the degree of dysplasia and whether same site 
or new-site dysplasia occurred (p=0.048; Chi-Square test).  
Cases that were diagnosed initially as mild dysplasia, showed a higher rate of new-site 
dysplasia compared to recurrence (75%; 6/8 vs. 25%; 2/8), whereas moderate dysplasia 
showed a higher recurrence rate compared to new-site dysplasia (86%; 6/7 vs. 14%; 1/7). 
Both CIS and severe dysplasia showed higher rates of recurrence compared with new-site 
dysplasia (60%; 3/5 vs. 40%; 2/5), (55%; 6/11 vs. 45%; 5/11), respectively; Table 5.40.  
 
 
 
Table 5.40: Recurrent and new site disease formation in relation to degree of dysplasia. 
Degree of dysplasia 
Recurrent 
disease 
Further 
disease 
Total 
  
Mild 
2 6 8 
25% 75% 100% 
Moderate 
6 1 7 
86% 14% 100% 
Severe 
6 5 11 
55% 45% 100% 
CIS 
3 2 5 
60% 40% 100% 
Total 
17 14 31 
55% 45% 100% 
 
 
 
 
 
 388 
 
Current smokers showed equal rates for both recurrence and new-site dysplasia formation 
(10/20). Recurrence rates were higher than new-site disease in both non-smokers (2/3 vs.1/3) 
and ex-smokers (5/8 vs. 3/8), but Chi-Square testing was not significant (p=0.693); Figure 
5.47 and Table 5.41. 
 
 
 
Figure 5.47: Recurrent and new dysplasia in relation to smoking status. 
 
 
Table 5.41: Recurrent and new dysplasia in relation to smoking status. 
Smoking status 
Recurrent 
disease 
Further 
disease 
Total 
 
Non-smoker 
2 1 3 
67% 33% 100% 
Current smoker 
10 10 20 
50% 50% 100% 
Ex-smoker 
5 3 8 
63% 38% 100% 
Total 
17 14 31 
55% 45% 100% 
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A higher mean tobacco consumption in terms of both cigarettes smoked per day (26.80 vs. 
23.60) and grams of tobacco per week in patients developing new-site dysplasia compared to 
recurrent disease cases was seen (189.09 vs. 165.20), however the differences did not reach 
significance (p=0.614, p=0.561; Mann-Whitney U test). 
 
Patients who smoked for a long duration of time (31-50 years) showed a higher rate of new-
site dysplasia formation compared to recurrence (4/7 vs. 3/7), whilst patients with a shorter 
smoking history (10-30 years) showed higher recurrence rates (3/5) than new-site disease 
(2/5); Fisher’s Exact test was not significant (p=1.000); Table 5.42. 
 
Considering the intensity and duration of smoking, pack-years score was higher in patients 
developing new-site dysplasia than those with recurrent disease (44.17 vs. 36.7), but the 
differences did not reach significance (p=0.532; Independent t-test). 
 
 
 
Table 5.42: Recurrent and new dysplasia in relation to smoking history. 
Smoking history 
(years) 
Recurrent 
disease 
Further 
disease 
Total 
 
10-30 
 3 2 5 
 60% 40% 100% 
31-50 
 3 4 7 
 43% 57% 100% 
Total 
 6 6 12 
 50% 50% 100% 
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The majority of patients who underwent both recurrences (14/17) and new-site dysplasia 
formation (13/14) were current drinkers, but the relation was not significant (p=0.607; 
Fisher’s Exact test); Table 5.43. 
 
Also, patients with new-site dysplasia showed a higher mean of alcohol consumed in terms of 
units per week (38.92) compared to patients who suffered recurrent disease (36.21); however 
these differences did not reach significance (p=1.000; Mann-Whitney U test). 
 
 
Table 5.43: Recurrent and new dysplasia in relation to drinking status. 
Drinking status 
Recurrent 
disease 
Further 
disease 
Total 
  
Non-drinker 
3 1 4 
18% 7%  
Current drinker 
14 13 27 
82% 93%  
Total 
17 14 31 
100% 100% 100% 
 
 
Seventy-one percent of patients (12/17) who developed recurrence wore dental prostheses, 
whilst the majority of patients with new-site dysplasia were non-dental prosthesis wearers 
(57%; 8/14); Table 5.44. However, no significant relation was found between the presence of 
a dental prosthesis and the occurrence of active disease; (p=0.157 Fisher’s Exact test). 
 
 
Table 5.44: Recurrent and new dysplasia in relation to dental prosthesis wear. 
Dental prosthesis 
Recurrent 
disease 
Further 
disease 
Total 
 
Wearer 
 12 6 18 
 71% 43% 58% 
Non-wearer 
 5 8 13 
 29% 57% 42% 
Total 
 17 14 31 
 100% 100% 100% 
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Malignant Transformation (same site) 
MT was defined as OSCC arising at a site of pre-existing epithelial dysplasia and which was 
proven histologically. In our hospital-based population, MT was only seen in 5/100 patients 
(3 males and 2 females). 
The total clinical management time for this group of patients was between 35 and 115 months 
with a mean follow-up time of 47.2 months (range, 24-65 months), and between 10-35 
follow-up appointments. 
 
After laser intervention, MT occurred between 1 to 41 months post-surgery (mean, 12.4 
months). Patients in this group experienced between 0 to 3 observational biopsies before laser 
surgery and between 1 to 3 laser interventions, with 1 to 7 follow-up biopsies after laser 
treatment. 
 
The mean age of patients in this group was 63 years (range, 58-76 years). Out of the 5 
transformed cases, 3 (60%) were middle aged (41-62 years) and 2 (40%) old age (63-84 
years), but no MT was identified in patients ≤ 40 years of old; Figure 5.2. All males were 
middle aged (3/3), whilst all females were old age (2/2). Males undergoing MT (mean age 58 
years) were younger than females (mean age 70.50 years), with Independent t-test 
approaching a significant difference (p=0.055). 
 
Females showed a higher percentage of MT (5.9%; 2/34) compared to males (4.5; 3/66), with 
a risk estimate that showed females were 1.294 times more likely to develop MT compared 
with males (95% CI, 0.227-7.378); Table 5.45. 
 
 
Table 5.45: Sex and malignant transformation (MT). 
Sex MT-free MT Total 
 
Male 
63 3 66 
95.5% 4.5% 100% 
Female 
32 2 34 
94.1% 5.9% 100% 
Total 
95 5 
100 
95% 5% 
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Kaplan-Meier survival analysis showed that the MT-free survival rates, 1-, 2 and 5-years 
following laser intervention were 97%, 96% and 93%, respectively; Figure 5.48. 
 
 
 
 
Figure 5.48: Overall disease-free survival functions of patients with MT by Kaplan–
Meier analysis. 
 
 
 
Figure 5.49 compares the survival function of patients underwent MT and those who were 
MT-free. A significantly lower disease-free survival rate of patients underwent MT after laser 
treatment than patients free from MT. At 15-months post-laser surgery, the disease-free 
survival rate was 20% for patient underwent MT compared to 85% for patients free from MT 
(p=0.0001; Log-Rank test). 
 
Clinicopathological characteristics of this group of patients are summarized in Table 5.46. 
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Figure 5.49: Kaplan-Meier analysis of patients with MT and MT-free  
(p=0.0001; Log-Rank test). 
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Table 5.46: Clinicopathological features of patients developing OSCC at same site (MT) and new distant site. 
Case Age Sex 
Primary 
 site 
Cancer  
outcome 
Clinical types 
Size 
(mm2) 
Time 
(months) 
Hpath 
incision 
Hpath 
excision 
Margin 
status 
Smoking 
(cig./day) 
Drinking 
(u/w) 
Follow-up 
months 
Medical 
conditions 
1 58 M FOM MT 
Non-homogenous 
speckled 
200-600 15 Sd Sd Sd > 20 > 28 24 Hypertension 
2 58 M 
Lateral 
tongue 
MT 
Homogenous 
leukoplakia 
200-600 41 Md SCC - 10-20 > 28 62 Depression 
3 76 F 
Lateral 
tongue 
MT 
Homogenous 
leukoplakia 
200-600 3 Md SCC - Non-smoker 
Non-
drinker 
44 Hypertension 
4 65 F FOM MT 
Non-homogenous 
speckled 
200-600 2 Sd SCC - 10-20 1-14 65 
Hypertension 
DM 
5 58 M 
Retromolar 
area 
MT Erythroplakia < 200 1 CIS CIS Normal Ex-smoker 
Non-
drinker 
41 Hypertension 
6 47 F 
Ventral 
tongue 
OSCC 
(new site) 
Homogenous 
leukoplakia 
200-600 55 CIS CIS Normal Non-smoker 1-14 87 DM 
7 48 M 
Lateral 
tongue 
OSCC 
(new site) 
Erythroplakia > 600 60 Modd Sd - Non-smoker 1-15 82 
Immunodeficiency 
Hypertension 
 
F=female; M=male; FOM=Floor of the mouth; MT=malignant transformation; H path=histopathology; Md=mild dysplasia; Modd=moderate dysplasia 
Sd=severe dysplasia; CIS=carcinoma in situ; cig=cigarettes; u/w=units per week; DM=diabetes mellitus. 
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Clinical Appearance 
The clinical type of PMDs associated with MT was 80% (4/5) leukoplakia (2 homogenous, 2 
non-homogenous speckled) and 20% (1/5) erythroplakia; Table 5.11 and Figure 5.9. 
A higher proportion of non-homogenous leukoplakia 8% (2/25) was seen in transformed 
cases compared to homogenous ones 3% (2/67); Table 5.47. Risk estimate showed that non-
homogenous leukoplakia had 2.680 times the risk of homogenous leukoplakia for MT to 
occur (95% CI, 0.399-18.015). 
 
 
 
Table 5.47: Malignant transformation (MT) in relation to leukoplakia type. 
Leukoplakia type MT-free MT Total 
 
Non-homogenous 
23 2 25 
92% 8% 100% 
Homogenous 
65 2 67 
97% 3% 100% 
Total 
88 4 92 
96% 4% 100% 
 
 
 
Anatomical Site 
MT occurred in 40% (2/5) of FOM cases, 40% (2/5) of lateral tongue and 20% (1/5) of the 
retromolar area, but no transformed cases were seen in the remaining oral subsites. 
The lateral border of the tongue showed a higher rate of MT compared to the FOM (11%; 
2/19 vs. 4%; 2/46); Table 5.12 and Figure 5.10. 
 
Although MT was mainly seen in high risk oral sites (FOM and tongue) (80%; 4/5), the high 
risk sites exhibited no increased risk for MT compared to low risk sites (OR=1.063; 95% CI, 
0.125-9.018).  
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Size of Dysplasia 
Eighty-percent (4/5) of the transformed dysplasias were intermediate in size (200-600 mm
2
) 
and one was minor, with a range from 60-570 mm
2
 (mean size of 316 mm
2
); Table 5.13 and 
Figure 5.11. 
 
Although no significant association was found between MT and the size of PMD (p=0.593; 
Chi-Square test), risk estimate showed that if the size of dysplasia exceeded or equalled to 
425 mm
2
 (equivalent to the third quartile), the OR for MT was 2.056 times higher than for 
smaller sizes (95% CI, 0.365-11.582). 
 
 
Dysplasia Grading 
Out of the 5 cases that underwent MT, 2 (40%) were severe dysplasia, 2 (40%) mild 
dysplasia and 1 (20%) CIS. 
Severe dysplasia 9% (2/23) and CIS 9% (1/11) were the histological features associated with 
the highest percentages of MT, whilst mild dysplasia accounted for 5% (2/42) of MT cases; 
Table 5.48. This reflects a tendency for more severe dysplastic features to develop 
malignancies, compared to mildly dysplastic ones, however, the relation between MT and 
degree of dysplasia was not significant (p=0.124; Chi-Square test). 
 
 
Table 5.48: Malignant transformation (MT) in relation to degree of dysplasia. 
Degree of dysplasia MT-free MT Total 
  
Mild 
40 2 42 
95% 5% 100% 
Moderate 
24 - 24 
100%  100% 
Severe 
21 2 23 
91% 9% 100% 
CIS 
10 1 11 
91% 9% 100% 
Total 95 5 100 
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MT was higher in high grade dysplasia compared to low grade lesions (60%; 3/5 vs. 40% 
2/5). High grade dysplasia accounted for 6% (3/53) of transformed cases, which was higher 
than low grade transformed cases 4% (2/47), but the relation between binary grading and MT 
was not significant (p=1.000; Fisher’s Exact test); Table 5.15 and Figure 5.13. 
 
 
Smoking Behaviour 
Sixty-percent (3/5) of transformed cases were current smokers consuming an intermediate 
amount of tobacco (15-28 cigarettes/day), followed by ex-smokers and non-smokers equally, 
one case for each (20%); Table 5.16 and Figure 5.14. 
 
Non-smokers showed a higher percentage of MT 7% (1/15) compared to both current 
smokers 5% (3/63) and ex-smokers 5% (1/22). However, the relation between smoking status 
and MT was not significant (p=0.771; Chi-Square test); Table 5.49. 
 
The rate of MT in females was seen equally in both current and non-smokers, whilst in males, 
MT was higher in current smokers, but MT was not seen in one male non-smoker.  
 
 
 
Table 5.49: Malignant transformation (MT) in relation to smoking status. 
MT status 
Smoking status 
Total 
Non-smoker 
Current 
smoker 
Ex-smoker 
 
MT-free 
14 60 21 95 
93% 95% 95% 95% 
MT 
1 3 1 5 
7% 5% 5% 5% 
Total 
15 63 22 
100 
100% 100% 100% 
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Alcohol Use 
Patients undergoing MT were mainly current drinkers 60% (2 heavy drinkers and 1 light 
drinker), with the remaining 2 cases (40%) non-drinkers; Table 5.18 and Figure 5.17. 
 
Non-drinkers demonstrated a higher rate of MT 14% (2/14) compared to current drinkers 4% 
(3/83), but the relation between drinking status and MT was not significant (p=0.255; Chi-
Square test); Table 5.50. 
 
 
 
Table 5.50: Malignant transformation (MT) in relation to drinking status. 
MT status 
Drinking status 
Total 
Non-drinker 
Current 
drinker 
Ex-drinker 
 
MT-free 
12 80 3 95 
86% 96% 100% 95% 
MT 
2 3 - 5 
14% 4%  5% 
Total 
14 83 3 
100 
100% 100% 100% 
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OSCC Development (new site from primary dysplasia)  
Development of OSCC at new sites distant from the primary dysplasia was reported in only 
2/100 of our study population (47 years female and 48 years male) at 55 months and 60 
months following laser intervention. 
Table 5.46 summarises the clinicopathological characteristics of the two patients in this 
group. 
 
The total clinical management time was 84 and 90 months, whilst follow-up after laser 
intervention was 82 and 87 months. Patients in this group underwent only one observational 
biopsy, but between 5 to 13 follow-up biopsies after laser surgery which followed 2 to 6 laser 
interventions, with 23-39 follow-up appointments. 
 
Both cases of OSCC occurred in the tongue, the ventral and lateral surfaces. Development of 
OSCC at sites distant from the primary dysplasia was only seen in patients affected with high 
grade dysplasia. One was seen in a patient who presented with a severe major sized dysplasia 
(945 mm
2
), whilst the other one was an intermediate sized CIS (450 mm
2
). 
 
In addition to developing OSCC, these patients also suffered from recurrence and new-site 
dysplasia. One patient displayed 1 recurrence and 3 new-site dysplasias whilst the other 
patient developed 5 recurrences and 1 new dysplasia formation. Both patients were non-
smokers and light drinkers (social drinkers) who consumed 4 units per week. The female 
patient was diabetic and the male was hypertensive with an immunodeficiency syndrome. 
 
For statistical purposes and because of the small number of samples, cases with MT (n=5) 
and those who developed OSCC at distant sites from the primary dysplasia (n=2), were 
combined into one group for analysis. 
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Clinical Appearance 
Risk estimate showed that non-homogenous leukoplakia increased the risk of developing oral 
cancer by 1.787 times compared with that for homogenous leukoplakia (95% CI, 0.317-
10.07). 
 
 
Smoking Behaviour 
Patients who developed oral cancer smoked small amounts of tobacco compared to OSCC-
free patients, in terms of both cigarettes per day (21.67 vs. 23.32) and also grams of tobacco 
per week (151.67 vs. 165.37), however the differences were not significant (p=0.881, 
p=0.987; Mann-Whitney U test, respectively). 
 
Also, patients who developed oral cancer had a shorter smoking history compared with 
OSCC-free patients (27.50 vs. 34.04 months), with a lower pack-year score (27.50 vs. 41.56), 
but differences did not reach significance for either history of smoking (p=0.399) or pack-
year score (p=0.356; Independent t-test).  
 
Kaplan-Meier survival analysis showed that oral cancer-free survival rate 1-, 2 and 5-year 
after laser treatment were 97%, 95% and 83%, respectively; Figure 5.50. 
 
Non-smokers experienced the shortest mean time to develop oral cancer (59.31 months) 
compared to both ex-smokers (86.90 months) and current smokers (137.56 months). Non-
smokers who developed oral cancer showed a lower oral cancer-free survival rate 5-year 
post-laser surgery compared to the first-year (31% vs. 93%). Also, non-smokers with oral 
cancer showed a lower 5-years survival rates compared with current smokers (31% vs. 91%), 
however Log-Rank test was not significant (p=0.108); Figure 5.51. 
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Figure 5.50: Oral cancer-free survival functions for patients by Kaplan–Meier analysis. 
 
 
 
Figure 5.51: Kaplan-Meier analysis of patients with oral cancer in relation to smoking 
status. 
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Alcohol Use 
Patients developing oral cancer consumed a higher amount of alcohol in terms of units per 
week compared with OSCC-free patients (38 vs. 29.54), although Mann-Whitney U testing 
was not significant (p=0.715). 
 
Kaplan-Meier survival analysis showed that non-alcohol drinkers demonstrated a shorter 
mean time to develop oral cancer, compared with current drinkers but Log-Rank test was not 
significant (p=0.382); Figure 5.52. 
 
 
 
 
Figure 5.52: Kaplan Meier analysis of patients with oral cancer in relation to drinking 
status. 
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Logistic Regression Analysis 
Logistic regression analysis was performed to explore important and significant predictors for 
oral cancer development. Because of the small number of samples and to facilitate regression 
analysis the size of dysplasia was entered as < 425 mm
2
 and ≥ 425 mm2 (equivalent to the 
third quartile), smoking habit was entered as either smokers (past and current tobacco users) 
or non-smokers, drinking was entered as drinkers (past and current alcohol drinkers) and non-
drinkers, sites was entered as high risk (FOM and tongue) or low risk (the remaining oral 
sites). 
 
Table 5.51 presents the included independent variables for oral cancer development in the 
logistic regression models. 
 
Considering univariate statistical analysis, tobacco smoking was found to be the most 
significant prognostic factor for oral cancer to develop (p=0.049), whilst clinical type 
(erythroplakia) and size of PMDs (425 mm
2
) were identified as marginally significant 
predictors (p=0.053). No other significant predictors were identified.  
 
The best fit for the final model for multivariable regression depending on the -2 log 
likelihood ratio included: clinical type of PMD, resection margin status and smoking status. 
Although no significant predictors were identified from the multivariable models, non-
homogenous leukoplakia was 3.147 times more likely than homogenous leukoplakia to 
develop oral cancer (95% CI, 0.174-56.659). Erythroplakia increased the risk for oral cancer 
to develop by 18.625 times compared with homogenous leukoplakia (95% CI, 0.733-
473.301), although both were non-significant (p=0.438, p=0.076, respectively). 
 
 
  
 
4
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Table 5.51: Logistic regression models of oral cancer development. 
Outcome Risk factors  
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds (95% CI) p-value 
Cancer development 
(MT and OSCC) 
Age 1.006 (0.947-1.067) 0.856  
 
Sex 
Females 
Males 
 
Reference category 
0.667 (0.140-3.166) 
 
 
0.610 
  
Clinical types 
Homogenous 
Non-homogenous 
Erythroplakia 
 
Reference category 
1.855 (0.291-11.816) 
7.111 (0.987-51.258) 
 
 
0.513 
0.053 
 
 
3.147 (0.174-56.959) 
18.625 (0.733-473.301) 
 
 
0.438 
0.076 
PMD site 
Low risk site 
High risk site 
 
Reference category 
1.644 (0.187-14.455) 
 
 
0.654 
  
Size of PMDs (mm
2
) 
< 425 
≥ 425 
 
Reference category 
4.733 (0.978-22.912) 
 
 
0.053 
  
Histopathology 
Low grade 
High grade 
 
Reference category 
1.872 (0.327-10.737) 
 
 
0.482 
  
Margin status 
Free-margin 
Dysplastic 
 
Reference category 
0.375 (0.033-4.298) 
 
 
0.431 
 
 
0.414 (0.032-5.348) 
 
 
0.499 
Smoking status 
Non-smokers 
Smoker (past & present) 
 
Reference category 
0.198 (0.039-0.993) 
 
 
0.049 
 
 
0.225 (0.012-4.100) 
 
 
0.314 
Drinking status 
Non-drinker 
Drinkers 
 
Reference category 
0.385 (0.067-2.211) 
 
 
0.284 
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5.3.2. Analysis by Clinicopathological Profiling 
Age and Sex 
No significant association was found between clinical outcome and patient age (p=0.316; 
Chi-Square test), although middle age patients were predominant in all outcome groups and 
no OSCC development at distant sites was seen in patients younger than 40 years. Similarly, 
no significant association was found between the clinical outcome and sex (p=0.118; Chi-
Square test), although males were most common in DF, recurrence, new-site dysplasia and 
MT categories. 
 
 
Clinical Appearance 
A significant relation was found between the clinical type of leukoplakia (homogenous and 
non-homogenous) and clinical outcome (p=0.016; Chi-Square test); non-homogenous 
leukoplakia showed a higher rate of recurrence 24% (6/25) compared to homogenous 
leukoplakia 15% (10/67), which was similar for new-site dysplasia formation 24%; 6/25 vs. 
10%; 7/67 and MT 8%; 2/25 vs. 3%; 2/67; Table 5.10. 
 
 
Anatomical Site 
Table 5.12 and Figure 5.10 summarise the relation between anatomical site and clinical 
outcome, which was significant (p=0.020; Chi-Square test). At the most recent clinical 
follow-up, the majority of FOM cases 76% (35/46) were DF. However, FOM also showed an 
equal rate for recurrent disease of 29% (5/17) and new-site disease formation 29% (4/14).  
 
Whilst no OSCC developed at distant sites in FOM cases, an equal MT rate was seen in the 
FOM and lateral tongue surface (2/5), followed by the retromolar region (1/5). 
 
The ventral and lateral surfaces of the tongue were the only sites for the development of 
OSCC at distant site from the primary dysplasia. The lateral surface of the tongue showed a 
 406 
 
MT rate of 11% (2/19), which also showed a 21% (4/19) recurrent disease and 5% (1/19) 
new-site dysplasia formation. 
 
Half of the cases in the pillars of fauces were DF (2/4) with the other half developing new-
site dysplasia formation (2/4); however, this site showed no recurrent disease or oral cancer 
development. 
 
The soft palate showed the highest rate of DF cases 56% (5/9), with 33% (3/9) recurrence 
rate followed by new-site dysplasia formation 11% (1/9), but no cancer development was 
observed at this site. Buccal mucosa showed equal rates of DF and new-site dysplasia 
formation 40% (2/5), with a recurrence rate of only 20% (1/5).  
 
In this study, the only reported case of retromolar area underwent MT, with the two cases of 
the alveolar mucosa were reported as a DF (2/2). No cancer development was seen in the 
buccal or alveolar mucosa. 
 
 
Size of Dysplasia 
A significant relation was found between clinical outcome and the size of presenting 
dysplastic PMD (p=0.009; Chi-Square test). The majority of DF cases were reported as minor 
size 52% (32/61). Also, minor size dysplasias showed the highest recurrence rate 44% (7/16). 
Dysplasia with intermediate size exhibited the highest rate in both MT 80% (4/5) and new-
site dysplasia formation 64% (9/14). 
The two dysplasia cases that developed OSCC at sites distant from primary dysplasia were 
major and intermediate in size; Table 5.13 and Figure 5.11. 
 
 
Dysplasia Grading 
A significant association was found between clinical outcome and the degree of dysplasia 
(p=0.004; Chi-Square test); Table 5.14 and Figure 5.12. Whilst mild and moderate dysplasia 
showed no development of OSCC at distant sites, severe dysplasia and CIS both showed 
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OSCC development with a higher percentage in CIS 9% (1/11), compared to 4% (1/23) in 
severe dysplasia. Mild dysplastic PMDs showed a higher rate of new-site dysplasia formation 
14% (6/42) compared with the development of recurrent disease and MT rates, which were 
both seen in only 5% of cases (2/42). Moderate dysplasia showed a higher recurrence rate 
25% (6/24) compared with new-site dysplasia formation 4% (1/24). Similarly, severe 
dysplasia showed a higher rate of recurrence 26% (6/23), followed by new-site dysplasia 22% 
(5/23), MT 9% (2/23) and OSCC development 4% (1/23). CIS cases showed a higher rate of 
recurrence 27% (3/11), followed by new-site dysplasia 18% (2/11), with MT and OSCC both 
occurring in 9% of cases (1/11). 
 
Considering the binary grading system, a similar, significant relationship was found between 
clinical outcome and high/low grade dysplasia (p=0.004; Chi-Square test). 
A higher rate of DF status was seen in patients with low grade dysplastic PMD compared to 
those with high grade dysplasia, 75% (35/47) vs. 51% (27/53). 
High grade dysplasia showed a higher rate of recurrence 25% (13/53) compared with low 
grade dysplasia 9% (4/47). Similarly, new-site dysplasia was more common in high grade 
dysplasia 15% (8/53) compared with low grade dysplasia 13% (6/47).  
Also, a higher rate of MT was seen in high grade dysplasia 6% (3/53) compared to low grade 
dysplasia 4% (2/47). Whilst no OSCC development at distant sites was seen in low grade 
dysplasia cases, the two OSCCs in this study arose in patients previously showing high grade 
dysplasia. 
 
 
Smoking Behaviour 
Table 5.16 and Figure 5.14 show the relation between smoking behaviour and clinical 
outcome. In this study, the two patients who developed OSCC were both non-smokers, but 
ex-smokers showed a higher rate of recurrence 23% (5/22) compared to new-site dysplasia 
formation 14% (3/22). 
 
The two light smokers in this study exhibited recurrence and new-site dysplasia. Heavy 
smokers showed a lower rate of DF status compared with intermediate smokers, 57% (13/23) 
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vs. 71% (27/38). Heavy smokers also showed a higher recurrence rate (22%; 5/23) compared 
with intermediate smokers (11%; 4/38).  
The majority of MT 40% (2/5) and new-site dysplasia formation 36% (5/14) were seen in 
intermediate smokers. A Chi-Square test showed no significant relation between clinical 
outcome and number of cigarettes smoked per day, however (p=0.139). 
 
Regarding the length of smoking history, an equal distribution of both recurrence and MT 
was seen in patients with a long smoking history (31-50 years) and a relatively shorter 
smoking history (10-30 years). Increased smoking history was associated with a higher rate 
of new-site dysplasia compared to those with shorter smoking histories (67%; 4/6 vs. 33%; 
2/6); Table 5.17. No significant relation was found, however, between smoking history and 
clinical outcome (p=0.565; Chi-Square test). 
 
 
Alcohol Use 
Table 5.18 and Figure 5.17 summarise the relation between alcohol drinking and clinical 
outcome. Ex-drinkers were all DF, but whilst non-drinkers showed no OSCC, a higher rate of 
recurrence 22% (3/14) compared to new-site dysplasia formation was seen 7% (1/14). 
 
DF status was predominant in all groups of drinking, with the highest rate seen in light 
drinkers 44% (27/62), who also showed a higher rate of new-site dysplasia compared with 
recurrence (11%; 4/37 vs. 8%; 3/37). Intermediate drinkers also showed no OSCC 
development, although both recurrent and new-site dysplasias were observed equally in this 
group (17%; 2/12). 
 
In contrast, a higher recurrence rate compared to new-site disease was observed in heavy 
drinkers (26%; 9/34 vs. 21%; 7/34). Also, heavy drinkers showed a much higher recurrence 
rate 26% (9/34) compared with light drinkers 8% (3/37). However, no significant association 
was found between clinical outcome and the amount of alcohol consumed, both at first 
presentation and at most recent clinical follow-up (p=0.267, p=0.277; Chi-Square test, 
respectively). 
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Dental Prosthesis Wear 
A significant relation was found between wearing dental prosthesis and clinical outcome 
(p=0.004; Chi-Square test). The majority of non-dental prosthesis wearers 70% (33/47) were 
DF. Although OSCC was equally seen in both wearers and non-wearers (1/2), MT was only 
reported in dental prostheses wearers (5/5). 
 
Whilst the recurrence rate was much higher in dental prostheses wearers 71% (12/17) 
compared to non-wearers 29% (5/17), the rate of new-site dysplasia formation was higher in 
non-wearers 57% (8/14) compared with wearers 43% (6/14); Table 5.19 and Figure 5.19. 
 
 
Resection Margin Status and Clinical Outcome 
Table 5.52 and Figure 5.53 display the resection margin status in relation to treatment 
outcome which was found to be statistically significant (p=0.001; Chi-Square test). DF was 
mainly seen in patients with clear, non-dysplastic margins 52% (30/58), whilst new-site 
dysplasia and recurrences were predominantly seen in cases with dysplasia present in 
excision margins (83%; 10/12) and (71%; 10/14), respectively.  
MT was seen equally in both dysplasia-free and positive margins (1 for each), whereas OSCC 
development at distant sites was only seen in patients with clear margins. 
 
Using Fisher’s Exact test, no significant relation between margin status and recurrence status 
was seen (p=0.252), although the majority of recurrent cases (71%; 10/14) were seen in 
patients with dysplastic margins compared to 29% (4/14) in patients with clear resection 
margins. Similarly, 83% (10/12) of patients who developed new-site dysplasia showed 
dysplasia in resection margins, compared to 17% (2/12) with non-dysplastic margins, but this 
was not significant (p=0.060). 
 
With respect to sex and resection margin status, males showed a higher rate of dysplastic 
margins compared to females (65%; 32/49 vs. 35%; 17/49), however the association was not 
significant (p=1.000; Fisher’s Exact test). 
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Table 5.52: Resection margin status in relation to clinical outcomes. 
Clinical Outcome 
Resection margin status 
Total 
Free-margin Dysplastic 
DF 
30 28 58 
52% 48% 100% 
Recurrent disease 
4 10 14 
29% 71% 100% 
Further disease 
2 10 12 
17% 83% 100% 
MT 
1 1 2 
50% 50% 100% 
OSCC 
1 - 1 
100%  100% 
Total 
38 49 87 
44% 56% 100% 
 
 
 
 
Figure 5.53: Resection margin status in relation to clinical outcomes. 
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Although dysplastic margins were equally reported for recurrent and new-site disease (10/20 
for each), patients with dysplastic margins showed a higher proportion of new-site dysplasia 
formation compared with those exhibiting recurrence (83%; 10/12 vs. 71%; 10/14); but Chi-
Square test was not significant, however (p=0.652); Table 5.53. 
 
A significant association was found between the histopathological diagnosis of resection 
margin status and recurrence (p=0.004; Chi-Square test). Patients with recurrent disease were 
equally diagnosed with clear margins, or margins with moderate and severe dysplasia (29%; 
4/14). Recurrence was equally seen in margins with mild dysplasia and CIS (7%; 1/14). 
The majority of recurrence-free patients were diagnosed with clear margins, followed by 
margins with mild, moderate-severe dysplasia and CIS, respectively; Table 5.54. 
 
Table 5.53: Recurrent and new site dysplasia in relation to margin status. 
Margin status 
Recurrent 
disease 
Further 
disease 
Total 
 
Clear-margin 
4 2 6 
29% 17% 23% 
Dysplastic margin 
10 10 20 
71% 83% 77% 
Total 
14 12 26 
100% 100% 100% 
 
 
Table 5.54: Histopathology of surgical margin in relation to recurrence status. 
Resection margin 
histopathological diagnosis 
Recurrence status 
Total 
Recurrence-free Recurrence 
 
Clear-margin 
34 
47% 
4 
29% 
38 
44% 
Mild  
19 
26% 
1 
7% 
20 
23% 
Moderate  
9 
12% 
4 
29% 
13 
15% 
Severe  
9 
12% 
4 
29% 
13 
15% 
CIS 
2 
3% 
1 
7% 
3 
3% 
Total 
73 
100% 
14 
100% 
87 
100% 
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A significant relation was found between new-site dysplasia and the histopathology of 
resection margins (p=0.050; Chi-Square test). A higher rate of new-site dysplasia were 
reported in cases which showed severe dysplasia in excision margins (33%; 4/12), whilst 
patient free from new-site dysplasia had predominantly clear-surgical margins (48%; 36/75); 
Table 5.55. 
 
 
 
Table 5.55: Histopathology of surgical margin in relation to the new site dysplasia 
status. 
Resection margin 
histopathological diagnosis 
New site dysplasia status 
Total 
New 
dysplasia-free 
New 
dysplasia 
 
Clear-margin 
36 2 38 
48% 17% 44% 
Mild 
17 3 20 
23% 25% 23% 
Moderate 
11 2 13 
15% 17% 15% 
Severe 
9 4 13 
12% 33% 15% 
CIS 
2 1 3 
3% 8% 3% 
Total 
75 12 87 
100% 100% 100% 
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Table 5.56 compares recurrent (same site) disease and further (new-site) dysplasia formation 
in relation to histopathology of resection margins; a higher rate of new-site dysplasia 
formation was reported in patients with severe dysplasia in the margins 33% (4/12), whilst a 
higher recurrence rate was seen equally frequently in moderate and severely dysplastic 
margins 29% (4/14). 
 
Lesions with surgical margins showing mild dysplasia were more at risk of developing new-
site dysplasia formation than having recurrences (25%; 3/4 vs. 7%; 1/4), whereas clear 
margins showed a higher recurrence rate than new dysplasia formation (29%; 4/6 vs. 17%; 
2/6); but Chi-Square test was not significant, however (p=0.216). 
 
 
Table 5.56: Histopathology of surgical margin in relation to recurrent and new site 
dysplasia formation. 
Resection margin 
histopathological diagnosis 
Recurrent 
disease 
Further 
disease 
Total 
 
Clear-margin 
4 2 6 
29% 17% 23% 
Mild 
1 3 4 
7% 25% 15% 
Moderate 
4 2 6 
29% 17% 23% 
Severe 
4 4 8 
29% 33% 31% 
CIS 
1 1 2 
7% 8% 8% 
Total 
14 12 26 
100% 100% 100% 
 
 
 
Further statistical analysis was performed considering the association between clinical 
outcome and the extent of residual dysplasia in resection margins. One margin involvement 
was the most common (30/49), followed by four margins (8/49); an equal presentation of one 
margin involvement was seen in cases with DF and DA status; Table 5.57. One margin 
involvement was equally seen in patients with recurrent and new-site dysplasia formation; 
Table 5.58. 
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No significant association was found between extent of dysplasia in the margins and the 
clinical outcome (DF/DA) (p=0.163) and as DF, recurrent disease, further disease and MT 
(p=0.388; Chi-Square test). This suggests that the extent of resection margin involvement has 
no influence on the clinical outcome of patients. 
 
 
Table 5.57: Disease-free and disease active in relation to the extent of dysplasia in 
margins. 
Resection margins 
involvement status 
Clinical outcome 
Total 
DF DA 
 
One/margin 
15 15 30 
50% 50% 100% 
Two/margins 
5 1 6 
83% 17% 100% 
Three/margins 
3 2 5 
60% 40% 100% 
Four/margins 
5 3 8 
63% 38% 100% 
Total 
28 21 49 
57% 43% 100% 
 
 
 
Table 5.58: Clinical outcomes in relation to the extent of dysplasia in margins. 
Resection margins 
involvement status 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT 
 
One/margin 
15 7 7 1 30 
50% 23% 23% 3% 100% 
Two/margins 
5 1 - - 6 
83% 17%   100% 
Three/margins 
3 - 2 - 5 
60%  40%  100% 
Four/margins 
5 2 1 - 8 
63% 25% 13%  100% 
Total 
28 10 10 1 49 
57% 20% 20% 2% 100% 
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Logistic Regression Analysis 
In order to investigate important predictors of positive dysplastic resection margins, logistic 
regression analysis was performed; Table 5.59. Univariate analysis showed that age 
(OR=0.987, 95% CI, 0.955-1.020) (p=0.429) and sex had no influence on dysplastic margins 
to occur (OR=1.022, 95%, CI 0.401-2.388) (p=0.962). 
 
The appearance of non-homogenous leukoplakia increased the risk for dysplastic margins to 
occur by 1.750 times compared with homogenous PMDs (95% CI, 0.619-4.948), but this was 
not significant (p=0.291). 
 
A reduced risk of approximately 38% was observed in tongue PMDs compared to the FOM 
(OR=0.619, 95% CI, 0.231-1.658), but this was not significant (p=0.340).  
Size of dysplastic PMDs, between 200 to 600 mm
2
, was a significant predictor for dysplastic 
margins to occur compared with smaller sizes (< 200 mm
2
) (p=0.010), with an increased risk 
of dysplastic margin 3.518 times  higher than smaller sizes (95% CI, 1.345-9.203). Dysplasia 
> 600 mm
2 
had a 2.706 times higher risk than minor sized PMDs (95% CI, 0.591-12.385), but 
this was not significant (p=0.200). 
 
Regarding degree of dysplasia, severe dysplasia-CIS showed a 2.118 times increased risk for 
dysplastic margins occurrence, compared with mild dysplasia (95% CI, 0.749-5.986), but this 
was not significant (p=0.157). Moderate dysplasia exhibited a 1.529 times higher risk for 
dysplastic margins to occur compared with mild dysplasia (95% CI, 0.521-4.494), but this 
was also not significant (p=0.440). 
 
The multivariate logistic regression final model selection included the clinical type of 
leukoplakia, anatomical site, size, degree of dysplasia and sex. These factors were considered 
the most important to be associated with the presence of residual dysplasia in surgical 
margins. However, size was the only significant predictor identified in both univariable and 
multivariable regression analyses. Size of dysplasia exceeding 600 mm
2
 increased the risk for 
dysplastic margins to occur by 12.247 times, compared with minor sizes (< 200 mm
2
) 
(p=0.026). Also, sizes between 200 to 600 mm
2 
exhibited an increased risk for dysplastic 
margins to occur by 5.875 times compared with minor sizes (p=0.006). 
  
 
4
1
6
 
Table 5.59: Logistic regression models for resection margin with dysplasia. 
Outcome Risk Factors 
Uni-variable analysis Multi-variable analysis 
Odds (95% CI) p-value Odds(95% CI) p-value 
Resection margin 
status 
Dysplastic margin 
 
Age 0.987 (0.955-1.020) 0.429  
 
Sex 
Females 
Males 
 
Reference category 
0.979 (0.401-2.383) 
 
 
0.962 
 
 
0.362 (0.102-1.281) 
 
 
0.115 
Leukoplakia types 
Homogenous 
Non-homogenous 
 
Reference category 
1.750 (0.619-4.948) 
 
 
0.291 
 
 
0.649 (0.176-2.400) 
 
 
0.517 
PMDs site 
FOM 
Tongue  
Remaining sites 
 
Reference category 
0.619 (0.231-1.658) 
1.000 (0.334-2.991) 
 
 
0.340 
1.000 
 
 
0.302 (0.080-1.138) 
2.813 (0.541-14.618) 
 
 
0.077 
0.219 
Size of PMDs (mm
2
) 
Minor < 200 
Intermediate (200-600) 
Major > 600 
 
Reference category 
3.518 (1.345- 9.203) 
2.706 (0.591- 12.385) 
 
 
0.010 
0.200 
 
 
5.875 (1.668-20.701) 
12.247 (1.350-111.090) 
 
 
0.006 
0.026 
WHO histopathological diagnosis 
Mid 
Moderate  
Severe-CIS 
 
Reference category 
1.529 (0.521-4.494) 
2.118 (0.749- 5.986) 
 
 
0.440 
0.157 
 
 
1.246 (0.348- 4.458) 
1.408 (0.388- 5.106) 
 
 
0.735 
0.603 
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Medical History and Clinical Outcome 
A significant relation was found between systemic health status (having a systemic disease or 
not) and clinical outcome (p=0.022; Chi-Square test). At the most recent follow-up, the 
majority of patients with a clear medical history (92%; 11/12) were reported as DF, compared 
to 58% (51/88) of patients with a positive medical history. 
All patients who developed oral cancer (7/7), new-site dysplasia (14/14) and 94% (16/17) of 
recurrent cases and 82% (51/62) of DF patients, were seen to have a positive medical history, 
having one or more chronic, systemic diseases; Table 5.60. 
 
Table 5.60: Clinical outcome in relation to medical history. 
Medical history 
status  
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
  
Negative 
11 1 - - - 12 
92% 8%    100% 
Positive 
51 16 14 5 2 88 
58% 18% 16% 6% 2% 100% 
Total 62 17 14 5 2 100 
 
 
A much higher recurrence rate was observed in patients with a positive medical history (94%; 
16/17), compared to systemic disease-free patients (6%; 1/17). However, no significant 
association was found between the presence of a systemic disease and recurrence status 
(p=0.472; Fisher’s Exact test); Table 5.61. 
 
 
Table 5.61: Medical history in relation to recurrence status. 
Medical history 
 status 
Recurrence status 
Total 
Recurrence-free Recurrence 
  
Negative 
11 
13% 
1 
6% 
12 
12% 
Positive 
72 
87% 
16 
94% 
88 
88% 
Total 
83 
100% 
17 
100% 
100 
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Table 5.62 shows the distribution of the systemic diseases according to clinical outcome. 
Out of the 60 hypertensive patients, 33 (55%) were DF, 13 (21%) underwent recurrence, 9 
(15%) showed new-site dysplasia, 4 (7%) underwent MT and only one case (2%) developed 
OSCC at a site distant from the primary dysplasia. 
 
 
Table 5.62: Systemic disease in relation to the clinical outcome. 
Medical disease 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 Immunodeficiency - - - - 1 1 
 
Anaemia 3 1 - - - 4 
Diabetes mellitus 11 2 - 1 1 15 
 Candida infection 3 2 3 - - 8 
Hypertension 
33 
55% 
13 
21% 
9 
15% 
4 
7% 
1 
2% 
60 
100% 
 
 
Comparing hypertensive with normotensive patients, a higher rate of MT, recurrence and 
new-site dysplasia formation were all found in hypertensive patients, whilst OSCC 
development was seen equally in both hypertensive and normotensive patients; Table 5.63. 
However, no significant association was found between clinical outcome and hypertension 
status (presence or absence of hypertension) (p=0.060; Chi-Square test). 
 
 
Table 5.63: Clinical outcome in relation to hypertension. 
Hypertension 
status 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
  
Normotensive 
29 4 5 1 1 40 
73% 10% 13% 3% 3% 100% 
Hypertensive 
33 13 9 4 1 60 
55% 22% 15% 7% 2% 100% 
Total 62 17 14 5 2 100 
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Considering diabetes mellitus (DM), a significant relation was found between having DM or 
not and clinical outcome (p=0.024; Chi-Square test).  
A higher rate of DF was seen in diabetics; out of 15 diabetics, 73% (11) were reported as DF. 
Recurrence was seen in 13% (2/15) of diabetics at 12 and 30 months following laser 
treatment, whilst MT and OSCC development were seen equally (7%; 1/15) at 2 months and 
55 months after laser treatment, respectively. Diabetics showed no new-site dysplasia 
formation. 
 
Comparing diabetic and diabetic-free patients, higher proportions of MT and OSCC 
development were observed in diabetics compared to non-diabetics (7% vs. 5%), (7% vs. 1%) 
respectively, whereas a lower recurrence rate was seen in diabetics compared to non-diabetic 
patients (13% vs. 18%); Table 5.64. 
 
No further statistical analysis was performed because of the small numbers of cases in the 
related subgroups. 
 
 
 
Table 5.64: Clinical outcome in relation to diabetes mellitus. 
Diabetes mellitus 
status 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
Diabetes-free 
51 15 14 4 1 85 
60% 18% 16% 5% 1% 100% 
Diabetic 
11 2 - 1 1 15 
73% 13%  7% 7% 100% 
Total 62 17 14 5 2 100 
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With respect to candida infection, in this study, amongst 8 patients with positive candida 
infection, no MT or OSCC development was seen. 
 
At the most recent follow-up, 3 out of the 8 patients were DF, whilst 3 developed new-site 
dysplasia at 7.45, 60 and 18 months post-laser intervention, and the remaining 2 exhibited 
recurrent disease at 20 and 30 months postoperatively. 
 
Patients with candida infection exhibited a higher rate of new-site dysplasia (3/8) compared 
to recurrence (2/8). However, no significant relationship was found between candida 
infection and clinical outcome (p=0.164; Chi-Square test); Table 5.65. 
 
 
 
Table 5.65: Clinical outcome in relation to candida infection. 
Candida infection 
status 
Clinical outcome 
Total 
DF 
Recurrent 
disease 
Further 
disease 
MT OSCC 
 
Candida infection-free 
59 15 11 
5 2 
92 
95% 88% 79% 92% 
Candida infection 
3 2 3 - - 8 
5% 12% 21%   8% 
Total 
62 17 14 5 2 
100 
100% 100% 100% 100% 100% 
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In this study, anaemia was seen in 4 cases, 3 of them were DF at the most recent follow-up 
and 1 (a 48 year old male) underwent recurrence at 20 months after laser surgery. This patient 
was diagnosed with minor size (150 mm
2
) moderate dysplasia which presented as an 
exophytic leukoplakia in the buccal mucosa. The patient was a heavy smoker (40 
cigarettes/day), and a heavy drinker (70 units/week) and was also affected by candida 
infection. 
No significant relation was found between the presence of anaemia and clinical outcome 
(p=0.243; Chi-Square test). 
 
Regarding family cancer history, out of 10 patients who reported a negative familial history, 
seven were DF, 2 had recurrence and 1 developed new-site dysplasia, whilst no cancer 
development was seen. 
 
On the other hand, out of 5 patients with a positive cancer history, 2 were DF, 2 developed 
recurrence and 1 exhibited new-site dysplasia formation. However, no significant relation 
between familial cancer history status (negative or positive) and clinical outcome was found 
(p=0.668, Chi-Square test). 
 
No further statistical analysis was conducted because of the small number in these related 
subgroups. 
 
In the current study there was only one patient who suffered from immunodeficiency who 
developed OSCC at a site distant from the primary dysplasia, at 60 months following laser 
intervention. This patient presented with a 945 mm
2
 sized erythroplakia, diagnosed initially 
with moderate dysplasia in the incisional biopsy and severe dysplasia in the excisional 
biopsy. Although suffering from hypertension, this patient was a non-smoker and a light 
drinker (4 units/week). In addition, this patient underwent 5 recurrences and one new-site 
dysplasia formation. 
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5.4. Discussion 
Investigating treatment outcomes requires standardisation of the length of follow-up time and 
a defined study population (van der Waal and Axell, 2002; Holmstrup et al., 2006). 
 
In this study, our hospital-based 100 patients were diagnosed with single oral epithelial 
dysplastic lesions, underwent laser intervention, and were followed-up by the same team in 
Newcastle Oncology and Dysplasia Clinics.  
 
 
5.4.1. Analysis by Clinical Outcome 
Time Considerations 
The overall clinical management time in this study was 189 months (15.75 years) with an 
average of 71.86 months (5.98 years). 
The average time between the initial presentation and incisional biopsy was 1.74 months with 
a maximum time of 24 months (2 years). In this study, 52% of patient undergoing same day 
incisional biopsies as first presentation and 39% within the first 3 months of presentation, 
however a delay of more than one year was reported in 3 cases, which was mainly due to 
patients’ delays.  
This may suggest a greater degree of suspicious appearance of the majority of cases attended 
the Oncology/Dysplasia Clinics at their first presentation and/or the efficient management 
protocol used in this clinic for patients with PMDs. 
 
The time from first presentation to incisional biopsy showed no significant differences among 
different grades of dysplasia. Of the 3 cases who underwent initial diagnostic delay, one 
showed mild dysplasia, one moderate and one severe dysplasia.  
The time from the first presentation to incisional biopsy showed no influence on treatment 
outcomes (no significant differences between the different treatment outcomes) which was 
supported by the fact that a DF state was seen in all cases that had experienced delay in their 
incisional biopsies. 
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The time between the initial diagnostic biopsy and laser excision (definitive diagnosis) was 
significantly associated and correlated with the degree of dysplasia; the higher the severity of 
dysplasia confirmed histopathologically the shorter the waiting time for laser intervention. 
The majority of moderate, severe dysplasia and CIS patients had a short waiting time 
compared with the majority of mild dysplasia cases which had a delay of more than one year 
to have their laser interventions. Despite the attempts to modify risk factors behaviour in 
these apparently low risk cases, continued to tobacco and alcohol consumption and the 
resultant persistent of oral lesions ultimately led to formal laser excision. During these 
periods of observation it was also observed that a much higher number of observational 
biopsies, which found to have a negative significant correlation with degree of dysplasia; 
with the majority of observational biopsies were reported in cases of mild dysplasia (73%), 
compared to higher grades dysplasias (27%). 
 
Since epithelial dysplasia is considered one of the most important predictors of MT (Reibel, 
2003), and the association between MT and the presence of dysplasia is significant (Schaaij-
Visser et al., 2010), early removal of dysplasia is the fundamental aim to prevent MT. It is 
increasingly accepted that the higher the severity of epithelia dysplasia, the more tendency for 
MT and this explains the short waiting time to laser surgery after initial diagnosis for cases 
with high grade dysplasias.  
 
In general, the study showed that patients with disease active state showed a significantly 
shorter mean time to have laser surgery after incisional biopsy as compared to disease-free 
patients. In particular, new-site dysplasia formation experienced a significantly shorter mean 
time to laser intervention compared to patients free from new-site dysplasia. This may be due 
to the fact that 50% of patients with new dysplasia formation were diagnosed primarily with 
high grade dysplasia: severe dysplasia 36% (5/14) and CIS 14% (2/14) which obviously 
require early laser intervention than lower grade dysplasia depending on the general accepted 
rule of more dysplasia severity more MT rate. Also, 64% of these cases were relatively large 
sized disorders (200-600 mm
2
) which require early treatment. 
 
With respect to sex, males experienced a shorter mean time to have their laser surgery 
compared to females, but this was not significant. This may be due to the fact that 55% of 
males were diagnosed with high grade dysplasia compared to females, and thus suggesting 
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higher risk of disease active state compared to females (OR=1.45). Males were also more 
likely to develop both recurrences and new-site dysplasia (76% and 71%), respectively. In 
light of these findings male patients may need to have their laser surgery arranged in a shorter 
time period compared to females. 
 
Follow-up was measured from the time of definitive diagnosis to the most recent clinic 
follow-up of patients (Jaber, 2010). Although no universally accepted guidelines are available 
with respect to duration and period of intervals of follow-up appointments, lifelong follow-up 
is generally advised for PMD patients both for surgically treated and non-treated cases 
(supervised) (van der Waal and Axell, 2002; Weijers et al., 2008; Jaber, 2010). 
 
In the current study all patients were reviewed on a regular basis post-laser intervention, at 
varying intervals of 2, 3, 4, 6 or 12 months based upon both clinical and pathological 
features, to monitor the clinical course of disease and patients’ outcome. 
At each follow-up appointment, updating of the medical history of patients and review of risk 
factors, disease status determined clinically and via follow-up biopsy if appropriate was 
confirmed. 
 
Patients in this study were followed-up for up to 183 months (15.25 years) after laser 
intervention with a mean of 55.49 months (4.62 years). Patients who developed recurrences 
demonstrated a significantly longer average follow-up time compared to those who were 
recurrence-free which was similar for patients suffering from new-site dysplasia compared to 
those who were new-site dysplasia-free. The extended surveillance duration for DA patients 
(recurrence and new-site dysplasia) suggests a more complicated clinical course in these 
patients. 
 
Although development of OSCC at sites distant from the primary dysplasia experienced a 
longer follow-up time compared to OSCC-free patients (79.50 vs. 54.54 months), the 
differences did not reach statistical significance, probably because of the very small number 
of patient in this group (2/100).  
 
MT cases showed a shorter mean follow-up time as opposed to MT-free patients, however 
this was non-significant. There is no clear reason why the transformed cases demonstrated a 
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shorter follow-up time compared to patients free from MT, unless this observation highlight 
inherent instability of the oral mucosa in patients at high risk of neoplastic transformation. 
 
 
Clinical Outcome  
Considering treatment outcomes, time intervals were calculated from the time of laser 
intervention to the subsequent event of interest, such as recurrent (same site) disease, further 
(new-site) dysplasia, MT or development of OSCC at a site distant from the primary 
dysplasia.  
 
After laser intervention and at the most recent follow-up appointment there were 62 disease-
free patients with complete clinical resolution, with a mean follow-up time of 38.87 months 
(3.24 years) (range, 4-122 months) (0.4-10.16 years). This finding is quite similar to a 
previous study performed by Thomson et al. (2008) on 40 patients with single dysplastic 
PMDs treated by laser excision, in which 24 patients (60%) were disease-free after laser 
intervention. 
 
A large retrospective study used the CO2 laser to treat 282 leukoplakias in 200 patients and 
achieved a cure rate of 89% during a mean follow-up period of 52 months (4.3 years, range 
1-219 months). This high “cure” rate, however, was related to the fact that approximately 
64% of cases in this study were actually non-dysplastic with only 36% showing dysplasia 
(van der Hem et al., 2005). 
 
In the present study, 75% of patients were disease-free 2-years after laser treatment which 
dropped to 63% and 47%, at 3-years and 5-years postoperatively. In an Australian study, with 
a mean follow-up time of 47 months (3.91 years), disease-free survival 3-year postoperatively 
was 55.4% which dropped to 33.9%, 5 years after treatment (Chandu and Smith, 2005).  
The marked fall in disease-free survival after 5-years in this study was associated with long-
term recurrence, the longest of which occurred at 183 months (15.25 years, with a range of 
13-183 months). This emphasises the need for long-term follow-up of patients and this has 
been noted in several previous studies (Chu et al., 1988; Roodenburg et al., 1991; Schoelch et 
al., 1999; Thomson and Wylie, 2002; Chandu and Smith, 2005). 
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In a systematic review with meta-analysis of treatment and follow-up of oral dysplasia, 
Mehanna et al. (2009) suggested that after diagnosis, patients should be kept under 
surveillance for up to 20 years. It may be feasible to tailor the duration and frequency of this 
surveillance, depending on clinicopathological factors including the grade of dysplasia and 
the type of management. 
 
In this study, significantly lower disease-free survival status was seen in high grade dysplasia 
compared to low grade dysplasia at 2 years (68% vs. 83%) and 5 years (29% vs. 63%) 
postoperatively. This was supported by a significantly shorter mean time for high grade 
dysplasia to develop further disease compared to low grade dysplasia (5.33 vs. 7.39 years). 
This clearly reflects an association between dysplasia severity and the time to develop disease 
active state, with a much shorter the time for disease active state development with more 
severely dysplastic tissue. 
 
Logistic regression analysis was employed to predict the significant factors for disease active 
status. Univariate analysis revealed that high grade dysplasia, localization in the tongue, the 
clinical appearance of non-homogenous leukoplakia, dysplasia present in resection margins, 
size of dysplasia exceeding 600 mm
2
 and patients with a positive history of systemic disease 
were strongly associated with active disease. Subsequently, the final model of multivariate 
regression analysis identified CIS-severe dysplasia and dysplastic margins as the most 
significant predictors of further disease. 
This may reflect the importance of these parameters in the prediction of unsuccessful 
treatment outcome and emphasises urgent intervention and close follow-up of patients with 
high grade dysplasia and dysplasia in resection margins. 
 
 
Recurrent (same site) Disease 
One of this study’s aims was to investigate the recurrence prevalence and to identify 
significant clinicopathological predictors associated with an increased risk for local failure or 
recurrence in a cohort of patients with PMDs.  
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Local recurrence was defined as reappearance of dysplasia in the same site of the primary 
dysplasia which has been previously successfully treated by laser and whose recurrence was 
then confirmed by a follow-up biopsy. 
 
Follow-up data were obtained, including pathologically proven recurrence and time to first 
recurrence, which was defined as the time period between the date of laser surgery and the 
date of recurrence. After surgical excision, recurrences may occur at the same site of the 
primary dysplasia, regardless of the duration of time between laser excision and the 
recurrence (van der Waal and Axell, 2002). The overall recurrence rate in this study was 
17%, 14-183 months (1.16-15.25 years) after laser intervention, with a mean follow-up of 
83.75 months (~7 years). This is similar to a study conducted by Yang et al. (2011) to 
evaluate factors associated with recurrence in patients who received laser surgery for 
dysplastic leukoplakia who found a recurrence rate of 17.5%, 1.75-9.1 years (21-109.2 
months) after treatment with a mean follow-up time of 3.4 years (40.8 months). 
Also, this finding is similar to another recent study conducted by Jerjes et al. (2012) on the 
CO2 laser of oral dysplasia with a recurrence rate of 19.5% after laser surgery and with 
patients followed-up for a mean of 6.4 years (76.8 months). This emphasises the long-term 
nature of recurrences in oral PMDs and necessitates close and long term follow-up to manage 
early recurrent disease. 
 
The rate of recurrence is different between different studies. These variations may be 
attributed to different surgical techniques, such as the precise modality of laser beams, 
different follow-up times, patient factors (Frame, 1985; Ishii et al., 2004), differences in 
reporting recurrence per patient or per lesion, and different definitions of recurrent disease. 
Thus, comparing the recurrence rates between different studies is problematic, difficult and 
sometimes unfeasible (Yang et al., 2011). 
 
Reporting recurrence per patient may result in higher rates of recurrences than might be 
expected as one patient may be affected by multiple PMDs, only one of which may actually 
undergo recurrence (Chandu and Smith, 2005). However, this study investigation was 
presented to single PMD disease so that recurrence was reported per patient not per lesion, to 
avoid any controversy regarding patient/lesion numbers and recurrence rates. 
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A comparable study was conducted by Thomson et al. (2008) in 40 patients with single 
dysplastic PMDs treated by laser excision. Outcome was classified as no recurrence or further 
disease which included recurrences at the same site or new disease at distinct intraoral sites.  
24 patients had no recurrence after laser intervention, while 16 developed further disease, 7 
(18%) at new intra oral sites and 9 with same site recurrence (23%). The most episodes of 
further disease occurred during the first 18 months following treatment. 
 
To assess the clinical usefulness of CO2 laser surgery for OL, Ishii et al. (2004), stated that 
the rate of recurrence in laser surgery was 29.3% over a mean time period of 3.4 years (0.6-
11.3 years). The higher recurrence rate compared to the present study may be due to the use 
of laser vaporization technique for the majority of cases (98/154) restricting laser excision to 
only 14 cases. The author concluded that vaporization technique is very suitable for non-
dysplastic homogenous leukoplakia on the gingiva which is anatomically coved by 1-1.5 mm 
thick gingiva with a low risk of MT, whilst laser excision was indicated for non-keratinized 
sites. 
 
In this study, with the exception of three cases, all dysplastic PMDs were excised using CO2 
laser with additional 5 mm margins outside the obvious clinical edge of each lesion. By 
defocusing the laser beam, laser vaporization can be used to treat some dysplasia which 
cannot be excised or accessed easily, such as those in the gingiva or hard palate (Thomson 
and Wylie, 2002). However, the risk of laser vaporization is that pathological tissue may not 
be completely removed (Pinheiro and Frame, 1996) and also it prevents acquisition of a 
postoperative specimen for histopathological assessment leaving the decision about complete 
resection and more definitive diagnosis uncertain. 
 
A large retrospective study conducted by van der Hem et al. (2005) who studied a group of 
200 patients with 282 OLs reported a 10% local recurrence rate in a mean period of 87 
months (5-168 months) post-laser treatment which were confirmed by biopsy, but 63% of 
specimens were originally non-dysplastic. This finding is quite similar to previous studies, 
such as a study conducted by Chu et al. (1988) with an initial recurrence rate of 10.8% (4/37) 
of leukoplakias varied from hyperkeratosis to CIS in an average time of 5 years and a follow-
up ranged from 3 to 10 years. Roodenburg et al.’s (1991) study with a recurrence rate of 10% 
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in 70 patients with 103 OLs followed for an average of 3.9 years after operation but again 
68% of treated cases were non-dysplastic. 
However, a recent study conducted by Lim et al. (2010) showed a higher crude recurrence 
rate of 39.5% in an average time of 26.16 months (2-80 months) in CO2 laser treated patients 
with different dysplastic grades, lichenoid changes and hyperplasia and actinic changes. The 
higher recurrence rate may possibly due to the wide range of different oral disorders that 
were included.  
Different explanations for local recurrences have been suggested: recurrence may occur, 
according to Lim et al. (2010) if deep nests are left in place after any surgical treatment, so it 
is important to remove the full thickness of epithelium during laser surgery (Cantarelli 
Morosolli et al., 2006).  
Frame et al. (1985) hypothesized that recurrence of leukoplakia following excision might be 
due to migration of new epithelium from the periphery of the wound originating from 
surrounding, potentially unstable oral mucosa explaining the recurrence of dysplastic 
leukoplakia via the concept of field change cancerization (Lim et al., 2010). 
Clinically, oral epithelium within the area of field change might appear morphologically 
normal and in such patients, recurrence may be inevitable, regardless of treatment methods, 
because the surgical margins might be located within a wider area of field change (Thomson 
and Wylie, 2002; Chandu and Smith, 2005). 
Genetically altered epithelial cells uncovered by routine histopathological examination and 
even in areas with normal histology (Tabor et al., 2003) might explain why recurrence is 
almost unavoidable (Yang et al., 2011). 
 
Some investigators have advocated the use of vital staining, such as toluidine blue (Martin et 
al., 1998; Onofre et al., 2001) or iodine (Nakanishi et al., 1997) before laser intervention to 
ensure clear resection margins and to reduce local recurrences and MT, but little benefit of 
these vital staining techniques has been reported (Kerawala et al., 2000) as well as alterations 
in the amount of the energy absorbed from the laser in dyed tissue which may reduce its 
effectiveness (Ishii et al., 2003). 
 
This study showed that the mean time to the first recurrence was 28.47 months (2.37 years), 
whilst the mean time to the second recurrence was 40.875 months (3.4 years). Sixty-five 
percent (11/17) of recurrent cases developed within the first 2 years (24 months) following 
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laser interventions, with the remaining 35% (6/17) arising after 2 years. These findings are 
consistent with Thomson et al.’s (2008) study which found that most episodes of further 
disease occurred during the first 18 months following laser treatment. 
These observations are also quite similar to the findings of a study conducted by Chandu and 
Smith (2005) who reported a mean time to first recurrence/new lesion of 19.1 months (~1.6 
year) and the mean time for a second recurrence of 22.5 months (~1.88 year). 
 
The average total clinical management time (1st presentation to the most recent follow-up) of 
patients with recurrence was 108.25 months (9 years), which was significantly longer than 
that in the DF group (57.95 months), with more frequent follow-up appointments (9-78) vs. 
(5-42). 
Compared to DF patients who underwent only one laser surgery and one-fifth of the follow-
up biopsies, only 35% of patients in this group underwent one laser surgery, whilst the 
remaining 65% experienced up to 4 laser interventions and up to10 follow-up biopsies. 
This may suggest the problematical clinical course of this group of patients and the need of 
longer and close follow-up protocol. This is supported by what has been previously reported 
by Chiesa et al. (1990) that recurrence rate of leukoplakia increased as time passed with 
higher risk of malignant potential. 
 
In this study, males suffered from a higher rate of recurrent disease (76%; 13/17) compared 
with females. This finding was further supported by univariate regression analysis, which 
demonstrated an increased the risk of 1.8 times in males compared to females, although this 
was not statistically significant. Similarly, in a study conducted by Jerjes et al. (2012) out of 
15 patients who underwent recurrence, 13 (86%) were males with only 2 females. 
There is no obvious reason why males have a higher rate of recurrence compared to females, 
but it may be influenced by the fact that the 65% of male cases exhibited dysplasia in 
resection margins. Although recurrence of oral epithelial dysplasia had a male predominance, 
females did exhibit a shorter (albeit non-significant) mean time to develop recurrence. 
 
Overall, a significant relation was found between the site of origin of dysplasia and clinical 
outcome classified as DF, recurrence, new-site dysplasia, MT and OSCC, although only 
borderline significance was found when considering recurrent disease and anatomical site. 
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The FOM and tongue showed the higher rate of recurrences, whilst buccal mucosa showed 
the least number of recurrences. 
These findings are consistent with a study conducted by Thomson et al. (2008) who found no 
significant association between clinical outcome, and site of presenting lesion. Also, Jerjes et 
al. (2012) in a prospective study of 123 oral dysplasias from 77 consecutive patients treated 
with CO2 laser resection and/or ablation found no association between the rate of recurrence 
and the location of dysplasia affecting ventral tongue, buccal mucosa or retromolar sites. The 
difference in oral sites affected by recurrence of dysplasia may be related to different study 
populations and varying risk factor and lifestyle habits. 
 
Non-homogenous leukoplakia showed a higher recurrence rate compared to homogenous 
(24%; 6/25 vs. 15%; 10/67). This was supported by a higher risk of recurrence (OR=1.8 
times) in non-homogenous compared to homogenous leukoplakia, which was further 
supported by the results of a Kaplan-Meier survival analysis that showed a shorter mean time 
to recurrence of non-homogenous leukoplakia cases compared to homogenous ones (63.6 vs. 
123 months), although this did not reach significance. The higher recurrence rate in non-
homogenous leukoplakia is in agreement with other recent studies. Yang et al. (2011) 
investigated treatment outcomes for dysplastic OL and found that non-homogenous 
leukoplakia was a significant risk factor for recurrence. Jerjes et al. (2012) also reported that 
recurrence of oral dysplasia was mainly seen in non-homogenous leukoplakias. The reason 
behind the higher tendency for non-homogenous leukoplakia to recur is not clear, but is 
probably due to the fact that this type of leukoplakia is mainly associated with higher grades 
of dysplasia and larger sized PMDs. 
 
The high recurrence rate seen in patients with major sized dysplastic PMDs compared to 
recurrence-free patients (19% vs. 9%) was also supported by the finding of a larger mean size 
of dysplasia affecting patients with recurrence compared to those free from recurrence (393.6 
vs. 281.7 mm
2
). Also, univariate statistical analysis showed that dysplasia of a major size  
(> 600 mm
2
) increased the risk for recurrence 2.2 times more than minor size (< 200 mm
2
), 
although this did not reach significance. This may underline the link between the clinical 
extent of PMD and the development of recurrence. A larger sized dysplasia may be subjected 
to the risk of incomplete removal allowing the residual diseased tissue to grow from the 
border of the wound, perhaps accounting for treatment failure (Napier et al., 2003).  
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Recognising the extent of mucosal involvement by PMDs might help in identifying patients 
at high risk of unsuccessful treatment, such as developing recurrent disease and who thus 
require close clinical follow-up in conjunction with the assessment of other important 
clinicopathological parameters such as site, clinical appearance, extent of dysplasia and 
lifestyle risk factors. 
 
In the present study, a significant association was found between recurrence status and the 
degree of dysplasia. Interestingly, CIS showed the highest recurrence rate, followed by severe 
and moderate dysplasia, with mild dysplasia showing the least recurrence rate (30%, 23%, 
22% and 5%, respectively) compared to recurrence-free patients who showed a higher 
proportion of mild, followed by moderate, severe dysplasia and CIS (49%, 22%, 21% and 
9%, respectively). 
 
Kaplan-Meier survival analysis showed a clear fall in disease-free survival rate in patients 
with recurrence associated with an increased dysplasia severity: 1-year survival rate after 
initial intervention for patients with CIS was 77%, compared to 88%, 95% and 94% of 
severe, moderate and mild dysplasia, respectively. Further, CIS was found to have the 
shortest mean time to develop recurrence compared with other grades of dysplasia, albeit 
non-significant. 
 
Univariate statistical analysis showed that CIS, followed by severe dysplasia, were identified 
as significant predictors for recurrence to develop (p=0.032) and (p=0.045), respectively, and 
increased the risk of recurrence 8.6 and 5.88 times compared to mild dysplasia. Moderate 
dysplasia was 5.56 times more likely to develop recurrence compared to mild dysplasia, but 
with only borderline significance (p=0.052).  
These findings were further confirmed by multivariate regression analysis which showed that 
CIS had a 12 times higher risk for recurrence to develop compared with mild dysplasia. 
 
With respect to binary grading, a similar significant association was found between 
recurrence status and high/low grade dysplasia (p=0.025); 80% of recurrence cases were 
diagnosed initially as high grade dysplasia. 
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Survival analysis showed that patients with high grade dysplasia experienced a significantly 
lower disease-free survival rate at 2 and 5-years post-operatively (79% and 63%, 
respectively) compared with low grade dysplasia and also experienced a shorter mean time to 
develop recurrence than low grade dysplasia (p=0.023). Similar findings were noted in other 
studies: Yang et al. (2011) reported that OL showing high grade dysplasia was significantly 
associated with increased post-operative recurrence compared with intermediate and low 
grade dysplasia. Chandu and Smith (2005) found that recurrent disease occurred with all 
grades of dysplasia but particularly so when severe dysplasia and CIS were involved, 
although this was not significant and they explained this in light of an inadequate number of 
cases to analyse. Hamadah and Thomson’s (2009) study showed similar findings, notably that 
recurrence was seen in all dysplasia categories but was especially frequent in severe 
dysplasia, albeit statistically non-significant.  
 
A recent prospective study carried out by Jerjes et al. (2012), analysing 123 oral dysplasias 
treated with CO2 laser, showed a significant association between the severity of dysplasia and 
recurrence after treatment; recurrence was doubled when severely dysplastic PMDs were 
compared with moderate dysplasia. The same group also observed that complete response to 
treatment was significantly lower in severe dysplasia compared to mild or moderate dysplasia 
cohorts. These results compare favourably with our findings of lower DF rates found in CIS, 
severe and moderate dysplasia compared to mild dysplasia. These findings reflect the 
association between development of recurrence and the severity of presenting dysplasia and 
clearly confirm the importance of epithelial dysplasia, in particular high grade dysplasia, in 
the prediction of postoperative recurrence. Thus, patients with high grade dysplasia should be 
considered as high risk patients requiring careful intervention with close follow-up and life-
long surveillance. 
 
In this study, one of our aims was to investigate the importance of laser resection margin 
status on both local recurrence and overall disease-free survival for PMD patients.  
Complete removal of all dysplastic tissue is of fundamental importance in any planed surgical 
intervention for PMD treatment. The histopathology of resection margins was found to be 
significantly associated with recurrence status. Of the 14 recurrent cases, 4 were reported 
with clear resection margins (2 in the FOM and 2 in the soft palate), whereas the remaining 
10 cases showed foci of dysplasia within excision margins. The majority were in the tongue 
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(7/14), 2 in the FOM and one in the soft palate (1 mild, 4 moderate, 4 severe dysplasias and 1 
CIS). We found that the degree of residual dysplasia seen in the resection margins was 
significantly associated with definitive histopathological diagnosis. Mild dysplasia cases thus 
showed mainly clear margins whilst more severe dysplasia was more likely to exhibit 
dysplasia in resection margins which was usually the same grade as the excised dysplasia. 
This almost certainly reflects incomplete removal of the presenting dysplasia in these cases. 
 
Furthermore, in this study, a significant association was found between the clinical extent of 
the excised dysplastic lesion and resection margin status and grades of residual dysplasia. 
Minor sized lesions usually had clear margins, whilst intermediate and major sizes often 
showed dysplasia in the margins. Also, minor size lesions with dysplastic margins were 
predominantly seen in mild dysplasias, whereas severe dysplasia-CIS and moderate dysplasia 
in margins were more frequently seen in major and intermediate sized PMDs. This clearly 
underlines the association between the clinical extent of dysplasia and the margins status; 
higher dysplastic features in excision margins are associated with larger sized dysplasia. 
 
The extent of dysplasia in the resection margins and the clinical outcome was also 
investigated; whilst one margin involvement was most common in DF patients, it was equally 
seen in patients who developed recurrent and new-site dysplasia. 24% of cases with four 
margin involvement developed recurrent disease, although the relation was not significant. 
This suggests that the number of margins involved by residual dysplasia does not 
significantly influence patients’ clinical outcome. However, further study with a larger 
sample size is required. 
 
Histopathological data confirmed that 44% of cases had dysplasia-free-margins. 
Subsequently, 11% developed same site recurrences, but this increased to 25% when excision 
margins exhibited residual dysplasia, although the difference did not approach significance. 
These findings were confirmed by both univariate and multivariate analysis which 
emphasised that resection margins with severe-CIS residual dysplasia increased the risk for 
recurrence 3.9 times compared with margins with mild dysplasia; this remained statistically 
non-significant, however. 
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These data appear to reflect incomplete removal of the presenting focal dysplasia in 10/14 
cases as compared to entirely removed dysplasia from the remaining 4 cases. Thus, same site 
recurrence in this study may be explained in two ways: firstly, field change cancerization in 
cases with clear resection margins with migration of new epithelium from surrounding 
unstable mucosa (Lim et al., 2010), in which case margin status means clearly very little; this 
is supported by mounting evidence that suggests that complete resection of dysplasia may 
have little impact on recurrences or cancer development (Lippman and Hong, 2001). 
Secondly, recurrence may be due to incomplete removal of focal dysplasia with the 
possibility of residual dysplasia extending from the border of the wound to develop a 
recurrence (Frame et al., 1984).  
 
Recurrence in the presence of clear excision margins may thus be inevitable regardless of the 
effectiveness of the treatment modality if resection margins are in an area of field change 
(Thomson and Wylie, 2002; Chandu and Smith, 2005). Margins with residual dysplasia, 
however, may reflect both inadequate surgical excision and difficulties in removing the entire 
focal dysplasia which may be influenced by biological or anatomical factors in the affected 
region. There are also no accepted guidelines for the amount of normal tissue to be removed 
to achieve clear excision margins which may have a substantive influence on both disease-
free and patient survival. 
 
Single variable statistical analysis in the present study showed that the recurrence rate 
following laser surgery was higher in tobacco users; 67% of patients undergoing recurrences 
were current smokers and 33% were ex-smokers, whilst only 12% were non-smokers.  
Heavy smokers were the most common subgroup amongst current smokers to exhibit 
recurrent disease. Using survival analysis, a decrease in disease-free survival rate of current 
smokers from 94% to 80%, 1-year and 3 years post-treatment was seen. 
 
Interestingly, ex-smokers who experienced same site recurrence showed a clear fall in 
disease-free survival 5-years post-laser treatment compared to 1-year (84% vs. 52%); this 
was also supported by the shortest mean time to develop recurrence compared to other 
smoking subgroups, albeit non-significant. Also, univariate regression analysis showed that 
ex-smokers and heavy smokers showed a higher risk to develop recurrence, 1.9 and 1.4 times 
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higher, respectively compared with the risk for non-smokers, although this was not 
statistically significant. 
 
These data confirm a strong relation between smoking behaviour and recurrence of dysplasia 
after treatment. This may be explained by chronic mucosal irritation by tobacco agents that 
may affect the entire oral mucosa well before the clinical appearance of any disease 
(Tepperman and Fitzpatrick, 1981). This concept was investigated by van Oijen et al. (1998) 
who showed that cell proliferation indices of oral epithelium from histopatholgically normal 
mucosa taken from smokers and non-smokers, were significantly higher in smokers than non-
smokers. 
 
In the current study, the higher rate and risk of recurrence in ex-smokers is not surprising 
since the accumulation of irreversible biological damage may be seen in oral mucosa even 
after long-term quitting (van Oijen et al., 1998). Thus tobacco smoking behaviour both past 
and current was found to be closely associated with recurrence of dysplasia after laser 
treatment. It has been previously estimated that quitting of tobacco smoking may take 10–15 
years before risks lessen significantly (Jaber et al., 1999). This is also in line with a recent 
study conducted by Warnakulasuriya et al. (2010) who showed that the risk of oral cancer in 
former smokers almost matched that of never smokers but only after 10 years cessation.  
 
In the current study, the confirmed higher potential for current smokers to develop recurrence 
is in agreement with the findings of several other studies. For example, Jerjes et al. (2012) 
found that heavy long-life smoking (> 20 cigarettes/day) was significantly likely to lead to 
recurrence of dysplasia following laser surgery. Yang et al. (2011) emphasised that 
recurrence is of higher clinical importance than simple treatment failure. Although it may 
reflect inadequate surgical excision, it may also indicate continuous exposure to risk factors 
after treatment and an enhanced malignant potential. They also found that recurrence rates 
after laser surgery were significantly higher in patients who continued to smoke or chew betel 
quid and continuation of smoking was identified in multivariate logistic regression as an 
independent prognostic factor for disease recurrence. 
These observations were supported by Chandu and Smith’s (2005) study in which a 
significant effect of continued smoking on recurrence was found, treatment failure probably 
because of oral mucosa field changes due to oral habits. It was concluded by the same group 
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that during overall treatment of oral PMDs, removal of risk factors such as smoking and 
alcohol must be given a strong emphasis as well as surgical removal of individual lesions.  
According to Arduino et al. (2009), patients who have continued exposure to risk factors after 
treatment are more likely to have recurrence during the follow-up period.  
 
Smoking cessation is associated with a decrease in tobacco-related leukoplakia (Jaber et al., 
1999; Roosaar et al., 2007). However, no controlled studies are available to assess the impact 
of cessation of risk habits on the recurrence of dysplasia or induced malignant transformation 
(Lodi and Porter, 2008). A number of studies have investigated the effectiveness of tobacco 
cessation in patients with PMDs: Roed-Petersen (1982) reported a resolution of OL following 
smoking cessation, whilst another study conducted in a dysplasia clinic in London provided a 
brief cessation advice and achieved a 30% cessation rate, with ultimately three patients out of 
180 managed cases developed invasive carcinoma in a mean follow up time of 4.2 years 
(Poate and Warnakulasuriya, 2006). Thus, recommendations to reduce alcohol intake and 
smoking cessation may have the potential to reduce the incidence of recurrence. Encouraging 
tobacco cessation is an effective modality in achieving better outcomes and this requires 
informational exchange between specialist smoking cessation services and dental/oral 
clinicians which will be of high importance during patient follow-up (Warnakulasuriya, 
2011). However, whether recurrence is related to continued exposure to risk factors or due to 
an underlying disease predisposition that initiated the original presentation remains unclear. 
Patients, however, should be closely monitored for recurrent disease regardless (Jaber, 2010). 
 
A growing body of evidence has thus shown that disease-free survival rate, risk of recurrence, 
susceptibility to new-site disease and overall treatment outcomes are affected by persistent 
smoking. However, a considerable number of patients continue to smoke both during and 
after interventional treatment. 
 
Overall, 85% of our study population were tobacco users (63% current and 22% ex-smokers) 
and only 15% were non-smokers. Out of the 63% current smokers, 36% were still tobacco 
smokers at their most recent follow-up. It is difficult to know what else can be done to 
encourage smoking cessation, but it does seem to be the case that ready access to smoking 
cessation services helps improve quit rates (Hamadah et al., 2007). 
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Considering alcohol drinking, 82% of patients who developed dysplasia recurrence were 
regular drinkers. A significant relation was found between drinking intensity in term of units 
of alcohol per week and recurrent status; heavy drinkers (> 28 units/week) showed the 
highest rate of recurrence (64%) and increased their risk of recurrence 2.6 times compared to 
those who consumed ≤ 28 units/week. 
 
Further, Kaplan-Meier survival analysis showed that current drinkers who consumed > 28 
units/week displayed a fall in their recurrent-free survival rate from 90% to 69%, 1-and 5 
years post-laser treatment. A similar trend for a fall in recurrence-free survival in non-
drinkers was also observed, 2.5 and 4.5 years post-treatment, at 80% and 53%, respectively.  
Univariate analysis showed that heavy drinkers increased their risk of recurrence by 1.3 times 
the risk of non-drinkers, whilst in multivariate analysis, where multiple risk factors were 
entered in the model, heavy drinkers showed an even stronger risk of 2.3 times for 
recurrence, but this was not significant. 
 
The increased risk of heavy drinkers to develop recurrence was confirmed in multivariate 
analysis, probably associated with the well-known synergistic and multiplicative effects of 
combining both tobacco smoking and alcohol drinking (Salaspuro and Salaspuro, 2004; 
Salaspuro, 2007). These findings are consistent with other studies, for example Chandu and 
Smith (2005), who investigated factors affecting recurrence and found that alcohol 
consumption was associated with significant adverse effects on disease-free survival post-
laser treatment. Similarly, Goodson et al. (2010) observed that a heavy alcohol intake of 
more than 28 units/week was significantly associated with an increased risk of further 
dysplastic disease particularly recurrence at the same site of primary disease after treatment; 
continued exposure to alcohol may thus have encouraged further dysplastic change in 
susceptible healing oral mucosa. A recent study carried out by Jerjes et al. (2012) found that 
heavy long-life drinking (> 21 units/week) was significant and likely to lead to recurrence of 
dysplasia. 
 
An eighty-three percent of our study cohort was active drinkers, 14 were non-drinkers and 
3% were ex-drinkers. At the most recent contact with patients, no significant changes in 
drinking behaviour were noticed. Although heavy drinkers had decreased from 34 to 23%, 
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intermediate drinkers actually increased from 12 to 21% whilst ex-drinkers increased from 3 
to 5%. 
 
Unfortunately, the population of North-East England has one of the worst health deprivation 
indicators in the UK, with 71% of men and 56% of women (aged 16 and over) reported as 
drinking an alcoholic drink on at least one day in the week, with 21% of men and 20% of 
women also reporting cigarette smoking (The NHS Information Centre, 2010). 
 
With respect to oral health, a significant association was found between clinical outcome and 
the wearing of a dental prosthesis or not. Seventy-percent of DF patients did not wear dental 
prostheses. More than fifty-percent of recurrence-free patients did not wear dental prostheses 
and a higher rate of recurrent disease was seen in patients who wore dental prostheses 
compared to non-wearers (71% vs. 29%), but this was non-significant. Further, univariate 
analysis confirmed that wearing a dental prosthesis increased the risk of recurrence 2.5 times 
compared with non-wearers, but again this was non-significant. 
 
To the best of our knowledge, this is the first study to investigate the relation between dental 
prosthesis wear and recurrence of dysplasia after laser treatment. 
There is no direct explanation of the higher risk of recurrence of dysplasia in patients wearing 
dental prosthesis, including complete/partial denture or crowns and bridges, and further 
detailed investigations are required to confirm this finding. It may be the presence of 
prosthetic dental appliance reflects a poor, pre-existing oral health status with loss of the 
natural dentition or perhaps cause local mucosal trauma irritation and/ or infection rendering 
the oral mucosa vulnerable to further dysplastic change. 
 
Considering systemic health, univariate statistical analysis showed that patients with systemic 
disease had an increased risk of recurrence 2.4 times higher than patients without systemic 
diseases, albeit non-significant. Ninety-four percent of patients who developed recurrences 
exhibited systemic disease, although the relation between having systemic disease and 
recurrent disease remained not significant. 
 
To the best of our knowledge this is the first study that has investigated the relationship 
between recurrence of dysplasia after laser treatment and systemic disease status. 
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The higher risk for recurrence in patients with systemic disease may be explained in two local 
ways: firstly, patients with positive systemic diseases were initially affected with high grade 
dysplasia compared to patients without systemic diseases, which may make recurrence more 
likely, and secondly, the higher risk of recurrence may be due to the fact that more patients in 
this group had dysplastic margins (88%; 43/49) compared to only 12% (6/49) of patients 
without systemic diseases. However, the relevance of general patients’ fitness, well-being and 
possible immunosuppression consequent upon long-term chronic illness may also be an 
important systemic mechanism rendering patients with systemic disease susceptible to 
unforeseen clinical outcome and progression of dysplasia. 
 
 
Further (new site) Disease 
Further disease was defined as the development of new dysplastic changes at sites distant 
from the primary dysplasia. 
The overall rate of new-site dysplasia formation in this study was 14/100, 25-133 months (2-
11 years) after laser intervention, with a mean follow-up of 93 months (7.75 years).  
The mean time for the first new-site dysplasia was 30.4 months (2.5 years), with the second 
new dysplasia 48.3 months (4 years) after laser. During their clinical course, patients in this 
group developed from 1 to 3 new-site dysplasias, 64% underwent 2-6 laser surgeries, with up 
to 13 follow-up biopsies. These data reflect the complicated clinical course experienced by 
this group of patients, emphasising an inherent instability in their oral mucosa.  
 
Survival analysis showed a clear fall in disease-free survival rate of patients who underwent 
new-site dysplasia compared to patients free from further disease, 1 year and ~3 years post-
laser intervention (50% vs. 94%), (36% vs. 72%), respectively. Most episodes of new-site 
dysplasia formation were seen at 3-years post-laser treatment (57%; 8/14) compared to first 
(3/14) and second years (3/14) after laser. 
 
Patients younger than 40 years showed the least tendency to develop new-site dysplasia, but 
the relation between age groups and further disease formation was not significant, and this 
was confirmed by univariate analysis. 
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This study showed that development of new-site dysplasia had a male predilection compared 
to females (71% vs. 29%), which was confirmed by a higher risk estimate of 1.3 times for 
new-site dysplasia in males compared with females. 
This higher tendency for further disease in males may be explained by the association that 
higher grade dysplasia occurs 1.13 times more commonly in males and that new-site 
dysplasia was seen mainly in patients with high grade dysplasia. Females, however, exhibited 
a shorter mean time for new-site dysplasia to develop compared with their male counterparts 
(25.5 vs. 32.3 months), but this was non-significant. It may be that disease progression in 
susceptible females is much quicker, although there are no clear reasons to explain this. 
 
Significantly, FOM and ventral tongue showed the highest rates of new-site dysplasia 
compared to other oral subsites. This may be due to the fact that high grade dysplasias were 
mainly seen in those high-risk sites (FOM and tongue); severe dysplasia and CIS were thus 
seen more frequently in the FOM (41%, 50%), followed by the ventral tongue (23%, 30%). 
This is supported by Waldron and Shafer’s (1975) study who found a higher prevalence of 
severe dysplasia or CIS in the FOM and tongue reflecting the higher risk of these regions.  
 
A significant association was found in this study between the development of new-site 
dysplasia and high grade lesions with new-site dysplasia more frequently affecting patients 
with high grade dysplasia. It has been shown that dysplasia arising in high-risk sites (FOM, 
ventro-lateral tongue and the soft palate complex) contain a significantly higher frequency of 
loss of heterozygosity at chromosomes 3 p, 9 p, and 17 p, compared with low-risk sites 
(Zhang et al., 2001b).  
 
Widespread field cancerization in the oral cavity was originally proposed by Slaughter in 
1953 to explain the occurrence of multiple dysplastic lesions both synchronously and 
metachronously. Field carcinogenesis suggests that dysplastic change may occur in any area 
of mucous membrane exposed to a carcinogen, so patients with dysplasia are at risk of 
developing multiple primary lesions within the upper aerodigestive tract due to the 
accumulation of genetic alterations of oncogenes and tumour suppressor genes (Choi and 
Myers, 2008). Thus, development of new disease at new-sites remains a problem resulting in 
both complex and difficult clinical management situations (Thomson, 2002; Thomas et al., 
2003; Thomson and Hamadah, 2007). 
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Overall, 93% (13/14) of PMDs that developed further (new-site) dysphasia were leukoplakias 
(7 homogenous and 6 non-homogenous) with only one erythroplakia. 
 
Although numerically there were more cases of homogenous leukoplakia that subsequently 
developed new-site lesions, non-homogenous leukoplakia was statistically more significant 
exhibiting 2.3 times increasing risk of further disease development compared to homogenous 
ones. A higher risk for non-homogenous leukoplakia to develop new-site dysplasia was 
supported by univariate regression analysis, which demonstrated that non-homogenous 
leukoplakia had a 2.7 times increased risk for further disease development compared to 
homogenous leukoplakia, albeit non-significant. 
 
The higher risk for new-site dysplasia formation in non-homogenous leukoplakia in general 
and in the speckled subtype in particular observed in this study is supported by the findings of 
other studies. Lee et al. (2006) showed that non-homogenous leukoplakia increased the risk 
for dysplasia 5.69 times compared with homogenous leukoplakia. Arduino et al. (2009) 
reported that the speckled subtype was a significant predictor for high grade dysplasia to 
occur. More recently, Vazquez-Alvarez et al. (2010) conducted a study to establish 
correlation between clinical and pathological diagnosis for OL and found that non-
homogenous leukoplakia was significantly associated with an increased degree of dysplasia. 
The relation between dysplastic non-homogenous leukoplakia and new-site dysplasia 
formation is clearly important and of clinical value and may be related to field change 
concept discussed previously. Since non-homogenous leukoplakias were frequently 
associated with more extensive dysplastic changes which may subsequently subject patients 
to the field cancerization from unstable oral mucosa and ultimately developing of a new-site 
disease.  
 
Patients initially affected with dysplastic PMDs sized 200-600 mm
2
 showed a significantly 
higher rate of new-site dysplasia formation. Out of the 14 cases affected with further disease, 
9 cases were (64%) intermediate in size. 
To the best of our knowledge, this is the first study to investigate the relation between the size 
of dysplastic PMDs and new-site dysplasia formation and it seems clear that PMD size is one 
of the important clinical parameters that helps identify high risk patients who require close 
follow-up. 
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The current study showed a higher rate of new-site dysplasia formation in patients who were 
initially diagnosed with high grade dysplasia compared to low grade dysplasia (57% vs. 
43%). This was further confirmed by univariate analysis which showed that high grade 
dysplasia increased the risk for new-site dysplasia formation by 1.2 times compared with low 
grade dysplasia, this was non-significant, however. This higher tendency for new-site 
dysplasia to occur in high grade dysplasia cases is, however in agreement with the concept of 
field change carcinogenesis. 
 
Considering subgroup analysis, mild dysplasia showed a significantly higher rate for new-site 
dysplasia formation. This unpredictable association, however, may simply reflect the higher 
frequency of mild dysplasia in our study population (43%). 
 
Overall, tobacco users were more likely to develop new-site dysplasia, with the majority of 
cases being current smokers (71%). Intermediate and heavy smokers showed the highest rates 
of new-site dysplasia especially in patients who had smoked for a long duration of time, 
although this was non-significant. These data were further supported by univariate regression 
analysis which showed that patients who smoked more than 20 cigarettes/day increased their 
risk for new-site dysplasia by 3 times, followed by an increased risk for those who smoked 
less than 20 cigarettes/day (2.4 times) and then ex-smokers (2.2 times) compared with non-
smokers, although this was non-significant. 
 
It has been suggested that second primary malignancies in tobacco users may reflect the 
chronic mucosal irritation by carcinogens which subjects the entire oral epithelial tissue to the 
risk of neoplastic change even before the morphological appearance of disease (Tepperman 
and Fitzpatrick, 1981). This may explain the higher risk of tobacco users to develop new-site 
dysplasia compared to non-users observed in the current study.  
 
Interestingly, Jaber (2010) found that the rates of development of second dysplastic lesions 
was more common in non-smokers compared to smokers (13.5% vs.7.7%), although this was 
not significant. Perhaps the non-smokers in Jaber’s study possessed other aetiological factors 
responsible for the higher rate of new-site dysplasia seen in this group compared with tobacco 
users. Alternatively, patients who develop oral dysplasia in the absence of identifiable risk 
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factors may exhibit substantial pre-existing molecular and genetic abnormalities resulting in 
field cancerization. 
 
A clear fall in the disease-free survival rate of current drinkers compared to non-drinkers was 
observed, but this was non-significant. Similar to smoking behaviour, current drinkers 
showed the highest rate of new-site dysplasia formation, with patients who drank > 28 
units/week exhibiting the highest rate of new-site dysplasia compared to light and 
intermediate drinkers. These findings were further supported by univariate analysis: high 
alcohol intake increased the risk for new-site dysplasia formation by 3.4 times compared to 
non-drinkers whilst, patients who drank < 28 units/week increased their risk for new-site 
dysplasia by 1.8 times, but the difference was non-significant. 
 
These data are in agreement with other studies, for example Maserejian et al. (2006a) who 
found that an alcohol intake of more than 4 units per day was associated with a 2.5 times 
increased risk of developing PMDs. Goodson et al. (2010) investigated the role of alcohol in 
oral precancer in a North-East England population and found that an alcohol consumption of 
more than 28 units/week was significantly associated with an increased risk of further 
disease. This may be explained by the chronic irritation of carcinogens subjecting the oral 
mucosa to the risk of new-site dysplasia by the effect of field change phenomenon. 
 
Comparing recurrent (same site) and further (new-site) dysplasia, showed that males were 
more likely to develop recurrences, whilst females were equally affected by recurrence and 
new-site dysplasia, although this was not statistically significant. This may be explained in 
light of this study findings, that males more commonly showed dysplasia in the margins than 
females (32/49 vs. 17/49) and they also exhibited higher grades of dysplasia in excision 
margins with more margin involvement. These observations may explain why males had 
more recurrences than females. 
 
Patients developing new-site dysplasia showed a higher mean number of cigarettes smoked 
per day, a longer history of smoking and a higher pack-year score with a higher amount of 
alcohol consumed in terms of units/week compared to patients who underwent same-site 
recurrence. Whilst recurrent disease was more commonly seen in non-smokers and ex-
smokers compared to new-site dysplasia, this was non-significant. 
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Dental prostheses wearers were most often affected by recurrent dysplasia, whereby new-site 
dysplasia formation was mainly seen in non-prosthesis wearers. 
Interestingly, and at a statistically significant level, patients who developed new-site 
dysplasia were mainly those showing mild dysplasia on initial presentation, whilst patients 
with severe dysplasia were affected equally by recurrence or new-site dysplasia. 
These observations are difficult to explain in the current study analysis and probably further 
investigation is required utilizing molecular investigations to obtain precise genetic profiling 
for different grades of dysplasia in relation to treatment outcome. 
 
 
Malignant Transformation (same site) and OSCC Development (new site) 
The main clinical significance of PMDs is their ability to undergo MT which was defined in 
this study as the appearance of OSCC at the same site as pre-existing PMD. 
The time to MT was defined as the time between definitive diagnosis and progression to 
OSCC, confirmed histologically. 
MT rates of PMDs vary from population to population and from study to study probably due 
to both individual disease and population differences. It is likely that MT rates of hospital-
based study are consistently higher than those of community-based ones because of sampling 
bias (Napier and Speight, 2008). However, identified risk factors remain useful in patient 
assessment, whatever the patient base, to help alert clinicians to patients at increased risk. 
 
In the present study the overall MT rate was 5/100, approximately 12.4 months (~1 year) (1-
41 months) after laser intervention, with a mean follow-up of 47.2 months (3.93 years) (24-
65 months) (2-5.41 years). This is similar to a retrospective laboratory-based study conducted 
by Cowan et al. (2001) who investigated the malignant potential of oral mucosal disorders in 
Northern Ireland and found an overall MT of 3% which although lower than in our study 
probably reflects the wide range of both dysplastic and non-dysplastic oral disorders 
included. However, if dysplasia only patients were considered, MT occurred in 6% of cases 
at an average interval of 48 months following diagnosis, which is quite similar to our study 
findings. 
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In a study from Taiwan conducted by Hsue et al. (2007) a 3% MT rate was reported at an 
average interval of 42.64 months post-diagnosis. However, the same group suggested that at 
least 6 months latency time should be given for transformation to exclude the possibility of a 
concomitant presentation of oral cancer. However, 6 months for MT may be a long time for 
consideration as rapid progression of some dysplastic cases may take place. 
 
It was reported by Cowan et al. (2001) that in a number of cases a dysplastic lesions was 
associated with an adjacent invasive tumour, there was a short clinical history of less than 12 
months (often only 1 or 2 months before transformation). Interestingly, this is supported by 
earlier studies (Pindborg et al., 1968; Silverman et al., 1984; Lind, 1987; Schepman et al., 
1998) who found that a significant number of leukoplakias progress to oral cancer during the 
first year of follow-up of early cancer diagnosis following laser excision of precancerous 
lesions.  
 
In their study, Goodson and Thomson (2011) reported that the longest time interval between 
incisional biopsy and laser excision was 6 weeks, which suggested that foci of oral SCC seen 
in 9% of cases were present but missed at incisional biopsy, probably because of sampling 
errors during initial diagnostic biopsies. It has been reported previously that 3% of 
leukoplakias might already be carcinomas at the time of biopsy (Waldron and Shafer, 1975). 
These cases may represent either unrepresentative tissue sampling during biopsy or perhaps 
long-standing disorders in the last stages of MT (Cowan et al., 2001). 
 
It is possible that areas of dysplasia or early carcinoma are missed at initial biopsy due to the 
inhomogeneity of dysplastic lesions or that some biopsies are not representative of the worst 
areas of the lesion especially when small specimens are taken (Cowan et al., 2001). Biopsy 
samples should be representative, of course, and it has been recommended that biopsies 
should be taken from the most suspicious area, such as erosions or verrucus areas, with larger 
lesions requiring more than one biopsy (van der Hem et al., 2005; Sloan, 2011). Moreover, 
assessment of the histopathological features of dysplasia can be relatively subjective and may 
not always be reliable (Pindborg et al., 1985; Abbey et al., 1995). 
 
In the current study, there were 3 cases in which oral cancer became evident on surgical laser 
excision of the dysplastic lesions, respectively 1, 2 and 3 months after incisional biopsies 
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showing mild, severe and mild dysplasia. Two of these cases underwent same day incisional 
biopsy of clinically suspicious lesions with the remaining biopsy 2 months after first 
presentation.  
 
The time between incisional and excisional biopsy was 3 weeks, 2 months and 11 months, 
respectively. The time between 1
st
 presentations to laser was 1, 3 and 13 months, 
respectively. These observations suggested the presence of foci of oral cancer in the first 2 
cases which were missed at incisional biopsies (non-representative sample), whilst long 
waiting time for laser surgery from the time of initial diagnostic biopsy in the third case 
explained the progression to oral cancer. 
 
Patients exhibiting MT experienced 1-3 laser interventions and 1-7 follow-up biopsies, 
reflecting the difficult clinical course followed by those patients. Also, this group of patients 
showed a significantly lower disease-free survival rate compared to MT-free patients, 15 
months (1.25 years) after laser treatment the survival rate dropped to 20% in patients with 
MT compared to 85% in patients free from MT. 
 
Interestingly, MT was not seen in patients younger than 40 years, but males who suffered MT 
were younger than females (58 vs. 70.5 years; p=0.055). 
This is supported by other studies: a higher MT rate in patients aged over 50 years was 
reported by Amagasa et al. (2006), Banoczy (1977) and Chiesa et al. (1993) also reported a 
higher risk of MT among 60-70 years old patients. 
 
Our study showed that females were at an increased risk of 1.3 times for MT compared to 
males. This is similar to a study conducted by Lind (1987) who reported that females were 
more prone to MT than males. Amagasa et al. (2006) also reported a higher MT rate in 
females than males (11.2% vs. 6.2%), but the difference was not significant. It remains 
unclear why the risk for MT is higher in females compared to males. Female patients in spite 
of less exposure to the risk of tobacco and alcohol may have an increased susceptibility to 
carcinogenic effects with different genetic and hormonal factors; further studies in molecular 
biology and genetic susceptibility are required.  
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Our results are in contrast to other studies which found a male predilection for MT in India 
and Taiwan (Silverman et al., 1976; Gupta et al., 1980; Hsue et al., 2007). This may be 
explained in the light of populational, environmental, disease and oral habits differences. 
Males in these studies may be more frequently subjected to the risk from smokeless tobacco, 
betel-quid, areca nut, in addition to cigarette smoking and alcohol drinking, compared to 
females. 
 
Schepman et al. (1999) suggested that almost 50% of oral cancers were associated with or 
preceded by OL. Similarly, Bouquot et al. (1988) in a retrospective laboratory-based study of 
oral and oropharyngeal cancers in the USA reported that leukoplakia and erythroplakia were 
associated with 41% of intra-oral carcinomas.  
 
In this study, leukoplakia was the most common clinical type accounting for MT; 80% 
compared with 20% for erythroplakia. Although MT was equally seen in homogenous and 
non-homogenous leukoplakia, a higher percentage of non-homogenous leukoplakias 
underwent MT compared to the homogenous type (8%; 2/25 vs. 3%; 2/67) was seen. A 
higher risk of MT for non-homogenous leukoplakia by 2.7 times was seen compared with 
homogenous leukoplakia. 
 
The higher risk associated with non-homogenous leukoplakia is consistent with other 
previous studies (Pindborg et al., 1968; Banoczy, 1977; Silverman et al., 1984; Lind, 1987; 
Gupta et al., 1989; Schepman et al., 1998). Also, our findings agree with a more recent study 
conducted by Holmstrup et al. (2006) who found that the clinical type of leukoplakia was a 
significant predictor for MT; non-homogenous leukoplakia increased the risk for oral cancer 
7 times compared to homogenous leukoplakia. They showed that the clinical type accounting 
for most MT was non-homogenous leukoplakia (20%) compared to homogenous leukoplakia 
(3%).  
 
The current study also showed that MT was more predominant in high risk sites (FOM and 
tongue) compared to low risk ones (80%; 4/5 vs. 20%; 1/5). The lateral border of the tongue 
(11%; 2/19) showed a higher rate of MT compared to the FOM (4%; 2/46). This is supported 
by a previous study conducted by Flynn et al. (1988) who reported that the lateral tongue 
surface is characterised by a high risk of MT. 
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It has been reported previously that the anatomical site of origin of PMDs has great influence 
on MT, with the chance of carcinoma 2.72 times higher in tongue and FOM leukoplakias 
compared to the buccal mucosa (Lee et al., 2006). This is supported by other studies which 
showed that these locations were liable to exhibit severe dysplasia (Jaber et al., 1999) and 
that PMDs at these locations have a higher potential for MT (Mashberg and Meyers, 1976; 
Silverman et al., 1984; Gupta et al., 1989).  
 
Also, in a cross-sectional study of dysplasia and OSCC in the USA, the highest prevalence of 
severe dysplasia or CIS was seen in the FOM (13.5%) and tongue (5%) emphasising the high 
risk nature of these locations (Waldron and Shafer, 1975). 
 
The higher tendency of tongue and FOM to undergo MT may be related to the thinner, non-
keratinized oral mucosa covering these sites which offers less protection and higher 
permeability (Mashberg and Meyers, 1976; Lesch et al., 1989) enhancing the effects of local 
carcinogens pooling in saliva (Lederman, 1964). As adjacent epithelia in early cancer or OL 
cases may alter to promote cell migration and molecular alteration of basal cells, it has been 
suggested that tongue leukoplakia should be completely excised with confirmation of 
histopathology diagnosis and subsequent close and long-term follow-up (Ishii et al., 2004). 
Further, Zhang et al. (2001a) performed a genetic study and analysed 127 oral dysplasias for 
loss of heterozygosity on 3 chromosome arms. They found that loss of heterozygosity 
frequencies were elevated at high risk sites among both sexes and amongst both smokers and 
non-smokers and they concluded that the anatomic location of mild and moderate oral 
dysplasias in Western populations may be an important diagnostic indicator because lesions 
at high risk sites have a greater tendency to include genetic alterations associated with an 
elevated risk of progression. 
 
In this study, the lack of a higher risk for MT at high risk sites is consistent with the findings 
of Holmstrup et al. (2006) who reported that sites considered to be at risk such as the lateral 
and ventral tongue and the FOM exhibited no increased risk of MT compared with other oral 
sites. This was supported by Schepman et al. (1998) who investigated MT of OL in a 
hospital-based population from Netherlands and found that no oral subsites were associated 
with an increased risk of MT and that malignant potential was independent of dysplasia site. 
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However, in this study the high risk sites seems to carry a higher tendency for malignant 
progression as cancer development was mainly seen in these anatomical sites (FOM and 
tongue), thus a careful thorough and regular examination of high risk site is mandatory. 
 
The size of the majority of cases that underwent MT were between 200-600 mm
2
 with a mean 
of 380 mm
2
; dysplasia size greater than or equal to the third quartile (425 mm
2
) increased the 
risk for MT two times compared to smaller sizes. This is in agreement with Holmstrup et al. 
(2006), who found that if lesion size exceeded 200 mm
2
, the risk of having oral cancer was 
5.4 times the risk of smaller lesions. In another study following 331 PMDs for more than 1 
year, Roed-Petersen (1971) reported that 8 out of 9 leukoplakias that developed cancer were 
greater than a mean size of 5.5 cm
2
. 
 
It is generally accepted that dysplastic disorders carry a greater risk of MT than non-
dysplastic ones, and the more dysplasia the greater the risk (Banoczy and Csiba, 1976). 
Nevertheless, it should be recognized that not all dysplasias will eventually transform to 
cancer and some may even spontaneously regress particularly after discontinuation of 
smoking and drinking and changes in life style habits (Axell et al., 1996). 
MT may also arise in non-dysplastic lesions (Pindborg et al., 1977; Gupta et al., 1980; 
Silverman et al., 1984; Schepman et al., 1998) and OSCC can occur without preceding 
dysplasia (Schoelch et al., 1999). 
 
The present study demonstrated that patients diagnosed with high grade dysplasia tended to 
have greater transformation rates than those with low grade dysplasia: 6% (3/51) of high 
grade dysplasia underwent MT compared to 4% (2/46) of low grade dysplasia, although this 
was non-significant. This is in agreement with the findings of several other studies, which 
showed that high grade dysplasia carried a greater risk of progression to carcinoma 
(Schepman et al., 1998; Neville and Day, 2002; Kujan et al., 2006; Rosin et al., 2007). 
 
In this study, MT occurred often in severe dysplasia and CIS (9%) compared to mild 
dysplasia (5%); but no cancer development was seen in moderate dysplasia. It has been 
reported that severe epithelial dysplasia can show a wide range of MT, from 7%–50% 
(Silverman et al., 1984; Lumerman et al., 1995; Schepman et al., 1998; Jaber et al., 2003); 
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our findings are comparable to this, with severe dysplasia cases exhibiting a 9% 
transformation rate. 
 
Similar to our findings, Chandu and Smith (2005) found that the majority of MT cases 
occurred in severe dysplasia-CIS and Mehanna et al. (2009) in a meta-analysis reported a MT 
rate for mild-moderate lesions of 10.3% compared to 24.1% for severe dysplasia and CIS. 
A hospital-based study conducted by Holmstrup et al. (2006) showed that the histological 
features most associated with the highest percentage of MT following surgical treatment was 
CIS 33%, compared to 9% moderate/severe or 11% mild dysplasia. However, the degree of 
dysplasia did not correlate precisely with MT and it was suggested that the lack of correlation 
may be explained by biopsy techniques being unrepresentative of the affected area. They 
reported that mild dysplasia exhibited a MT rate similar to severe dysplasia, which challenges 
previous assumptions that mild dysplasia can be considered harmless. This is in agreement 
with our findings that 2 out of 5 cases undergoing MT were mild dysplastic. Thus, mild 
dysplasia should be considered important and should be managed similarly to other grades of 
dysplasia. 
 
At the present time, it is generally accepted that the more severe the dysplasia, the higher the 
tendency is for malignant change; however, MT rates based upon grade of dysplasia are 
difficult to establish (Brennan et al., 2007) because of the inherent subjectivity of the 
histopathological grading system and inter-observer disagreement. The latter is one of the 
main restrictions in using existing histological criteria to predict transformation of dysplasia 
(de Vet et al., 1995). Nevertheless, histopathological dysplasia grading remains a 
fundamental guide to relative risk of malignant change in individual lesions (Lumerman et 
al., 1995; Cowan et al., 2001; Reibel, 2003). The presence of significantly dysplastic areas in 
oral epithelium is believed to be associated with progression to cancer (van der Waal et al., 
1997; Arduino et al., 2009; Schaaij-Visser et al., 2010), possibly because of accumulation of 
chromosomal, genomic and molecular alterations (Warnakulasuriya et al., 2008; Garnis et al., 
2009). 
 
In the current study, patients undergoing MT were mainly tobacco users (3 current smokers 
and 1 ex-smoker) with only 1 non-smoker. However, non-smokers showed a higher rate of 
MT (7%; 1/15) compared to both current smokers (5%; 3/63) and ex-smokers (5%; 1/22). 
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While smoking tobacco is associated with an increased risk of OL (Hashibe et al., 2000a; 
Banoczy et al., 2001; Lee et al., 2003; Dietrich et al., 2004), follow-up studies have reported 
that the risk of MT of oral PMDs is higher in non-smokers compared to smokers. It is, 
however, often difficult to obtain reliable information about the exact quantity of tobacco 
intake, the type of tobacco product used, and the number of pack years for individual patients 
(van der Waal and Axell, 2002).  
 
Lower rates of MT in smokers compared with non-smokers is supported by previous studies 
(Gupta et al., 1980; Silverman et al., 1984; Lind, 1987; Schepman et al., 1998; Reibel, 2003). 
In a study of 257 patients with OL, 12% of 183 smokers developed carcinoma, whereas 32% 
of 74 non-smokers developed carcinoma (Silverman et al., 1984). In another study of 166 
patients with OL, non-smoking women had a significantly higher risk of MT than female 
smokers (Schepman et al., 1998). In a study performed by Jaber (2010), 4% of tobacco users 
and 10.8% of non-users transformed to malignancy after a mean follow-up of 4 years. 
The reasons of why non-smokers at increased risk of MT remain unclear and further studies 
are required to investigate why oral mucosa remains prone to further disease and oral cancer 
development in the absence of known carcinogens. 
 
The present study showed that out of 5 patients undergoing MT, 3 were current drinkers (2 
heavy, 1 light) and 2 were non-drinkers. Non-drinkers exhibited a higher rate of MT (14%; 
2/14) than current drinkers (4%; 3/83), but not significantly. 
 
All alcohol use was assessed by self-reporting, however, and this may not always be reliable. 
Controversy about the role of alcohol alone in PMD transformation exists (Andre et al., 1995; 
La Vecchia et al., 1997). The non-significant relation between MT and drinking status agrees 
with a study conducted by Schepman et al. (1998) who found no association between alcohol 
consumption and MT. 
 
It has been reported previously that in heavy drinkers (over 30 gram ethanol/day), alcohol 
increases the relative risk for MT of oral PMDs after controlling for tobacco smoking by 2.5 
times compared with non-drinkers and is independent of the drink or drinking pattern (La 
Vecchia et al., 1997). In our study we found a higher rate of MT in non-drinkers compared to 
alcohol drinkers.  
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Further studies are thus required with larger sample sizes to investigate this to provide more 
accurate alcohol measurements other than self-reporting. 
In the current study, in 2 patients, cancer developed at distant sites to the primary dysplasia, 
at 4.58 and 5 years after laser intervention with means of 6.83 years and 7.75 years, 
respectively. The 2 OSCC cases were seen in patients affected with ventral tongue severely 
dysplastic erythroplakia (945 mm
2
) and lateral tongue homogenous leukoplakia with CIS 
(450 mm
2
). 
 
These patients underwent 2 to 6 laser interventions, 5 to 13 follow-up biopsies and 23-39 
follow-up visits. They also exhibited multiple recurrences and new-site dysplasias both 
synchronously and metachronously, suggesting a complicated clinical course and highly 
unstable oral mucosa. Both of these patients were non-smokers and social drinkers 
consuming only 1-4 units/week; one showed clear excision margins and the other only mild 
dysplasia in the margin. 
 
Developing OSCC at sites distant from the primary dysplasia supports the concept of field 
change cancerization which is important in oral carcinogenesis (Chiesa et al., 1990; Thomson 
and Wylie, 2002) and reflects an inherently unstable nature of these patients’ oral mucosa and 
emphasises the need for close and long term clinical follow-up. 
 
For statistical purposes, cancer development at both same site (5) and new sites (2) were 
combined into one group and compared to cancer-free patients. 
 
Patients developing oral cancer had lower tobacco intake, shorter smoking histories and 
lower pack-year scores compared to oral cancer-free patients and non-smokers exhibited the 
shortest time to develop oral cancer compared to both ex-smokers and current smokers. 
 
Although patients developing oral cancer consumed a higher amount of alcohol in terms of 
units per week compared to cancer-free patients, this did not reach the significance and non-
drinkers who developed cancer exhibited a shorter time to cancer presentation with a lower 2-
year disease-free survival rate compared to current drinkers (85% vs. 97%); but this did not 
reach significance. 
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Single variable statistics showed that non-homogenous leukoplakia had a 1.8 times increased 
risk for oral cancer compared to homogenous leukoplakia. 
To predict the most significant factor(s) for oral cancer development, univariate regression 
analysis was performed and showed that tobacco smoking was a significant predictor, with 
size and clinical type of PMDs only marginally significant. A multivariate model showed no 
significant predictors, although non-homogenous leukoplakia increased the risk for oral 
cancer by 3 times and erythroplakia a stronger risk of 18.6 times. It is possible that 
erythroplakia rather than leukoplakia is a truly pre-invasive disorder, and this is supported by 
an earlier study conducted by Mashberg et al. (1973) who found 96% of asymptomatic 
OSCCs were erythroplastic in appearance. This is supported by a study conducted by Shafer 
and Waldron (1975) who found a higher rate of dysplasia in erythroplakia: 91% of 65 
erythroplakic biopsies showed invasive carcinoma, CIS or severe dysplasia.  
 
The multi-step process of oral cancer development is well developed, with progression from 
hyperplasia, through increasing grades of dysplasia to CIS and ultimately invasive OSCC 
attributed to a series of genetic abnormalities. The main difficulty in early diagnosis of high 
risk tissue is our limited ability to differentiate lesions at risk of progressing into cancer from 
those at low risk (Guillaud et al., 2008). 
 
In the light of the present study findings, there is a need for improved management of 
dysplastic PMDs to prevent MT and recurrence after treatment. This may be through 
identification of significant predictors of local failure (recurrence), new-site dysplasia, MT 
and oral cancer formation, and implementation of these in the assessment of patients at high 
risk. Further, there is a real need to develop understanding of these mechanisms at a 
bimolecular level.  
 
 
5.4.2. Analysis by Clinicopathological Profiling 
The relation between clinical outcome and location of dysplasia was significant. Whilst most 
FOM lesions were DF following laser, the FOM also showed the highest proportion of 
recurrent, new-site and MT cases. Although FOM lesions were affected by MT, no distant 
site OSCC development as a result of field cancerization was seen. The number of cases was 
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small, but this is an important clinical observation suggesting the FOM is subjected to direct 
effects of local carcinogens from tobacco smoking and alcohol drinking at the site where the 
greatest dose is supplied pooled in saliva. 
 
The ventral and lateral surfaces of the tongue were the only sites to develop OSCC, whilst 
buccal mucosa showed a high rate of new-site dysplasia formation. The faucial of pillars 
showed no recurrence or cancer development whilst the soft palate showed a higher rate of 
recurrence compared to new-site dysplasia formation with no cancer development. The 2 
cases arising on alveolar mucosa were DF following treatment. 
 
The tongue was the only site affected by OSCC development as a distant site phenomenon 
presumably due to field change. There is no reason why the tongue influenced by the field 
cancerization phenomenon rather than MT, however, this clearly demonstrated and in a very 
small number of cases that the tongue is a high risk site for cancer development.  
 
The relation between the size of dysplasia and the treatment outcome was significant; the 
majority of DF patients originally had minor sized PMDs. Unexpectedly, minor sized 
dysplasias underwent the highest rate of MT among all size groups. 
Interestingly, out of the 7 minor size dysplasias that underwent recurrence 4 had dysplastic 
margins which suggest that biological activity rather than size and zone is important in local 
control of disease. 
 
Non-homogenous leukoplakias showed significantly higher recurrence, new-site and MT 
rates which may be because most non-homogenous lesions showed severe dysplasia and were 
larger in size. Larger dysplasias may be at risk of incomplete removal allowing residual 
disease to remain active, undergo clonal expansion and replace adjacent morphologically 
normal oral epithelium (Napier et al., 2003). 
 
A significant relationship was found between clinical outcome and epithelial dysplasia. 
Higher rates of DF status were seen in low grade dysplasias, whilst much higher recurrence 
and new-site dysplasia rates were observed in high grade dysplasias. A higher MT rate was 
seen in high than low grade dysplasia, whilst 2 cases of OSCC development were only seen 
in high grade dysplasia. 
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MT, however, was seen in low grade dysplasia and this emphasises that removal of mildly 
dysplastic tissue together with close and long follow-up is also relevant in planning treatment 
protocols. 
 
Ex-smokers exhibited a higher incidence of recurrent disease compared to new-site dysplasia, 
so that past users of tobacco may also suffer from treatment failure. Although no controlled 
studies are available to assess the impact of cessation of tobacco on recurrence of dysplasia or 
MT (Lodi and Porter, 2008), recommendation to stop smoking does have potential to reduce 
the incidence of recurrence and may decrease the risk of new PMD formation (Poate and 
Warnakulasuriya, 2006). However, it has been estimated that a significant decrease in risk 
after smoking cessation may take 10-15 years (Jaber et al., 1999). 
 
Light smokers may also be affected by recurrence and new-site dysplasia and this is in 
agreement with a study performed by Castellsague et al. (2004) who reported an increased 
risk for oral carcinogenesis amongst both light smokers (1-10 cigarettes/day) and short-term 
smokers (1-10 years). So, all smokers and recent ex-smokers require close and careful 
follow-up. 
 
All MT and the majority of recurrent disease were seen in dental prostheses wearers, whilst 
new-site dysplasia and OSCC were more commonly seen in non-wearers. This may be due to 
the fact that the mean size of dysplasia in patients with dental prosthesis was larger than in 
patients without prosthesis (328 vs. 269.5 mm
2
), subjecting patients with prosthesis to the risk 
of incomplete lesions removal and subsequent recurrence of dysplasia and/or MT. 
 
 
Resection Margin Status and Clinical Outcome 
The study showed a significant relation between surgical margins status and treatment 
outcome. The majority of DF patients exhibited clear surgical margins, whilst the majority of 
patients who remained DA showed dysplastic margins. 
 
The relation between histopathological diagnosis of resection margins and recurrence status 
was significant. Patients who were recurrence-free were more frequently reported to have 
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clear surgical margins, followed by those with mild dysplasia in the margins, and then 
moderate, severe and CIS, respectively with cases of moderate-severe residual dysplasia in 
the margins showing a higher recurrence rate (29%). Of interest in this study is the 
observation of a significant relation between residual dysplasia in excision margins and 
definitive histopathological diagnosis of dysplasia. Clear margins were mainly seen in cases 
of mild dysplasia, whilst higher grades of dysplasia were more likely to exhibit dysplastic 
margins. 
 
Higher recurrence rates in cases with clear surgical margins compared to new-site dysplasia 
formation was an interesting finding which may suggest that in spite of apparent complete 
removal of dysplasia, biomolecularly altered fields may remain nearby to the original 
presenting lesions (Choi and Myers, 2008). 
 
The most significant predictor(s) for dysplastic margins was investigated using regression 
analysis: the presence of non-homogenous leukoplakia was found to increase the risk for 
dysplastic margins by 1.8 times compared with that of homogenous leukoplakia. It is unclear 
why non-homogenous leukoplakia was associated with a higher risk of recurrence; however, 
this may be because non-homogenous leukoplakias are mainly high grade dysplasias and 
major size, both of which are associated with high rates of recurrent disease.  
 
A 38% reduction in risk for dysplastic margins to occur was seen in the tongue compared to 
the FOM. There is no clear reason why the positive margins were lower in the tongue 
compared to the FOM. 
 
Severe dysplasia-CIS increased the risk of dysplastic margin to occur 2 times more than mild 
dysplasia, whilst moderate dysplasia increased the risk 1.5 times. Severe dysplasias were 
mainly associated with major sized PMDs which may increase the risk of incomplete removal 
with a subsequent higher risk of recurrence. 
 
The only significant predictor for the presence of dysplasia in excision margins in both 
univariate and multivariate analysis was the size of the treated dysplastic lesion. 
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Univariate analysis showed that if the size of the dysplasia was 200-600 mm
2
 the risk for 
dysplastic margins to occur was 3.5 times compared to minor sizes, and when the size 
exceeded 600 mm
2
 the risk was 2.7 times.  
 
The final multivariate model showed that size exceeding 600 mm
2 
strongly increased the risk 
for dysplastic margins by 12 times compared to the risk for minor sized dysplasia (p=0.026), 
and those between 200-600 mm
2
 increased the risk 5.8 times compared to minor sizes 
(p=0.006). This clearly emphasises the close relationship between the extent of focal 
dysplasia and the risk of dysplastic margins. This suggests either incomplete removal of 
dysplastic tissue or that large sized dysplasias are biologically different from smaller lesions 
due to clonal expansion and replacement of adjacent’ normal’ oral epithelium (Napier et al., 
2003). 
 
Regression analysis revealed that the clinical type of leukoplakia, the site of oral lesion and 
the degree of dysplasia may be important factors in determining the likelihood of dysplastic 
margins, but was not statistically significant. 
 
Removal of local dysplasia with clear surgical margins greatly benefits disease-free patient 
survival. However, ensuring clear surgical margins depends on innate biological features 
such as the clinical type of leukoplakia, the degree of dysplasia and the anatomical site 
affected. Although there is no accepted, standard excision margin for oral PMDs, 3-5 mm is 
most widely used by surgeons. 
 459 
 
Systemic Health and Clinical Out come 
The systemic health of patients was significantly associated with treatment outcome. DF was 
mainly seen in patients without systemic disease, whilst all cancer development and new-site 
dysplasia and the majority of recurrent PMD cases were seen in patients with a history of one 
or more systemic diseases. 
This may reflect an association between oral and systemic health and emphasises that patients 
with a history of systemic disease should be considered potentially high risk requiring a 
careful management protocol with close and life-long follow-up. 
 
Hypertension and diabetes mellitus were the most common systemic diseases in our series. 
The higher frequency of patients with hypertension and diabetic mellitus might simply be 
coincidental due to the relatively advanced ages of the patients in this study as many of these 
disorders tend to occur in the later decades of life. 
 
A higher rate of MT, recurrences and new-site dysplasia formation were reported in 
hypertensive patients compared to the normotensive, but this was non-significant.  
There is no clear reason why hypertensive patients underwent both MT and further disease 
development more than the normotensive patients, although our study showed that 
hypertensive patients were significantly associated with more dysplastic lesions (moderate, 
severe dysplasia and CIS) compared to normotensive individuals which may explain the 
higher rates of MT and further disease formation. 
 
A significant relation was found between diabetes mellitus and clinical outcome, with the 
majority of diabetic patients reported as DF (73%; 11/15) with only 2 recurrent cases and 2 
cancer development (MT and OSCC at new-site). 
 
A lower recurrence and a higher cancer development rate were thus observed in diabetic 
patients compared with non-diabetics, but for no obvious reason. However, the 2 diabetic 
patients who suffered from recurrent disease exhibited residual dysplasia in resection margins 
which may explain the higher recurrence rate. Further investigations are required, however, 
with larger number of patients to establish any detailed inter-relationships. 
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5.5. Conclusions 
5.5.1. Time Considerations  
1. More than half of patients had their incisional biopsies on the same day as first 
presentation. 
2. Clinical appearance of PMDs did not influence the waiting time to have the incisional 
biopsy. 
3. Degree of dysplasia did not influence the time between the 1st presentation and incisional 
biopsy. 
4. Time between the 1st presentation and incisional biopsy did not influence the treatment 
outcome. 
5. Degree of dysplasia significantly influenced the time between incisional biopsy and laser 
excision, the higher the severity the shorter the waiting time for laser surgery. 
6.  Patients with DA demonstrated a significantly shorter time to have laser surgery after 
incisional biopsy compared to DF patients.  
7. Males experienced a shorter waiting time to undergo laser surgery than females. 
8. An extended follow-up time was seen for patients who suffered from recurrences, further 
disease and oral cancer compared to disease-free patients. 
9. PMD patients should be kept under long-term surveillance taking into consideration 
clinicopathological features and the method of treatment.  
10. High grade dysplasia was significantly associated with a shorter time to develop DA 
state. 
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5.5.2. Disease-Free (clinical resolution) 
1. Seventy-percent of patients with homogenous leukoplakias were DF compared to 44% of 
non-homogenous leukoplakias. 
2. The majority of DF cases were with FOM PMDs. 
3. More than 50% of DF cases were minor sized dysplasias. 
4. Seventy-six percent of patients with mild dysplasias were reported as DF at the most 
recent patients follow-up. 
5. High grade dysplasias were associated with lower rate of DF. 
6. The majority of DF patients were intermediate smokers and light drinkers. 
7. DF patients changed their smoking behaviour significantly at the most recent clinical 
contact, with current smokers decreased from 40 to 21 patients and ex-smokers increased 
from 13 to 32 patients. 
8. Seventy-percent of non–dental prosthesis wearers were DF patients. 
 
 
5.5.3. Disease Active  
1. Logistic regression analysis revealed that high grade dysplasia (severe dysplasia-CIS), 
lateral-ventral aspect of the tongue, non-homogenous leukoplakia, dysplasia in resection 
margins, size exceeding 600 mm
2 
and a positive medical history were all significant 
predictors for DA states to develop. The final model of multivariate analysis confirmed 
that CIS, severe dysplasia and dysplasia in the margins were still significant predictors 
for DA to develop after laser surgery. Severe dysplasia was 6 times the risk of mild 
dysplasia; dysplasia at the resection margins was approximately 7-time the risk of clear 
margins, with CIS showing 17-time increased risk for DA to occur compared to the risk 
of mild dysplasia. 
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Recurrent (same site) Disease  
1. Residual dysplasias in resection margin and field change phenomenon may account for 
recurrence of dysplasia after removal. 
2. Approximately two-thirds of recurrences developed within the first two years after laser 
treatment, with the remaining one-third developing after that time. 
3. Approximately two-thirds of recurrent cases underwent multiple laser interventions and 
multiple follow-up biopsies. 
4.  Male sex increases the risk of recurrences after laser treatment compared to females. 
5. Females experienced a shorter time to recurrence after laser treatment than males. 
6. The FOM and tongue were significantly more common oral sites to be affected by 
dysplasia recurrence after removal. 
7. Non-homogenous leukoplakias showed a shorter time and the greatest risk for recurrence 
(1.8 times) compared to homogenous leukoplakias. 
8. Size of dysplasia exceeding 600 mm2 increased the risk for recurrence by more than 2 
fold. 
9. Significantly, CIS presented the shortest time and the highest recurrence rate, followed 
by severe, moderate and mild dysplasia, respectively. CIS increased the risk for 
recurrence by more than 12-fold, severe dysplasia increase the risk by approximately 6-
fold and moderate dysplasia increased the risk by more than 5-fold. 
10. Severe dysplasia or CIS at the resection margins increased the risk for recurrence by 
approximately 4-fold compared to clear margins. 
11. Current tobacco smokers, in particular heavy smokers, showed a higher rate of 
recurrence with increased risk (1.4 fold) compared to non-smokers. 
12. Ex-smokers exhibited the shortest time to undergo recurrences with a 1.9 fold increased 
risk of recurrence compared to non-smokers. 
13. More than half of current smokers continued to smoke after laser surgery. 
14. Ninety-eight percent of current drinkers continued to drink after laser surgery. 
15. Heavy drinking significantly showed the highest recurrence rate with a 2.6 times 
increased risk. 
16. The joint effect of tobacco and alcohol presented a strong intensifier risk factor for 
recurrence. 
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17. A higher rate of recurrence was seen in patients wearing dental prostheses; 2.5 times 
higher risk compared to non-wearers. 
18. Ninety-four percent of patients who suffered from recurrence also had systemic disease 
which increased the risk of recurrence by 2.4 times compared to patients without 
systemic disease. 
 
 
Further (new site) Disease 
1. Patients who suffered from new-site dysplasia formation experienced a more 
complicated clinical course compared to those with recurrences, reflected by more laser 
interventions and more follow-up biopsies. 
2. Most episodes of new-site dysplasia formation were reported 3-years post-laser 
intervention. 
3. Males showed a higher tendency for new-site dysplasia formation than females. 
4.  Females developed new-site dysplasia in a shorter time than males. 
5. The FOM and ventral tongue significantly showed the highest rate of new-site dysplasia 
formation. 
6. Non-homogenous leukoplakias increase the risk of new-site dysplasia formation by more 
than 2.7 fold compared to homogenous leukoplakias. 
7. Size of dysplasia was an important prognostic parameter, significantly associated with 
high rates of new-site dysplasia formation. 
8. High grade dysplasias carry both higher rates and higher risk for new-site dysplasia to 
develop compared to low grade dysplasias. 
9. Current tobacco smokers with long smoking history, in particular heavy smokers (> 20 
cigarettes/day) were associated with a higher rate of new-site dysplasia formation and an 
increased risk of 3 fold compared to non-smokers. 
10. Current drinkers and in particular heavy drinkers have the highest rate of new-site 
dysplasia with an increased risk of more than 3-fold compared to non-drinkers. 
11. Males were more likely to have recurrences, whilst females were affected equally by 
recurrence and new-site dysplasia formation. 
12. Wearing dental prostheses was associated with recurrent disease, but not with new-site 
dysplasia formation. 
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13. Patients affected with mild dysplasia were significantly associated with a higher rate of 
new-site dysplasia compared to recurrences. 
14. Patients affected with severe dysplasia exhibited equal rates of recurrences and new-site 
dysplasia formation. 
 
 
Malignant Transformation  
1. Patients with MT showed significantly a lower disease-free survival rate compared to 
patients free from MT. 
2. No MT in patients younger than 40 years. 
3. Males with MT were younger than females (58 vs. 70.5 years). 
4. Female sex increased the risk for MT by 1.3-fold compared to males. 
5. Non-homogenous leukoplakias increased the risk for MT by 2.7-fold compared with 
homogenous leukoplakias. 
6. The FOM and lateral tongue exhibited a higher tendency for MT, with the lateral aspect 
of the tongue demonstrating the highest rate. 
7. Size of dysplasia ≥ 425 mm2 increased the risk for MT by 2-fold compared to smaller 
sizes. 
8. Mild and severe dysplasias exhibited equal rates of MT. 
9. High grade dysplasias (severe-CIS) have a greater tendency for MT than low grade 
dysplasias (mild dysplasia).  
10. No MT reported in moderate dysplasia. 
11. Non-smokers have a higher rate of MT compared to current and ex-smokers. 
12. Non-drinkers have a higher rate of MT compared to current drinkers. 
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OSCC (new site) Development 
1. Patients developing oral cancers at distant sites were non-smokers and social drinkers. 
2. Non-homogenous leukoplakia increased the risk of oral cancer by 3-fold compared to 
homogenous leukoplakia. 
3. Erythroplakias increased risk of oral cancer to develop by 19-times.  
4. Size of dysplasia was an important predictor for oral cancer development. 
5. The FOM is only affected with MT, but not oral cancer at new-site. 
6. Cancer development in the lateral and ventral tongue surfaces were not from MT of 
dysplasia, but resulted from field change. 
7. Non-smokers have the shortest time to develop oral cancer compared to current and ex-
smokers. 
8. Smokers who developed oral cancer were those reporting low tobacco intake, shorter 
smoking histories and lower pack-year scores.  
9. Tobacco smoking is a significant predictor for oral cancer development. 
10. Drinkers who develop oral cancer were associated with a higher intake of alcohol. 
11. Non-drinkers have the shortest time to develop oral cancer. 
 
 
5.5.4. Resection Margin 
1. Margin status and outcome were significantly related; with the majority of DF cases 
were associated with clear margins, whilst the majority of DA states were associated 
with dysplastic margins. 
2. Recurrence-free patients showed significant relationship with clear resection margins 
3. A higher rate of recurrence was associated with moderate-severe dysplasia in the 
margins. 
4. Patients with clear resection margins showed a higher rate of recurrence compared to 
new-site dysplasia formation. 
5. Severe-CIS and moderately dysplastic PMDs were 2 and 1.5 times, respectively, more 
likely to exhibit dysplasia in their resection margins compared to mildly dysplastic ones. 
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6. Size of dysplasia was the only significant predictor for dysplastic margins to occur, with 
size exceeding 600 mm
2
 increasing the risk of dysplastic margins by 12 times and those 
200-600 mm
2
 increasing the risk by approximately 6-times. 
7. Degree of dysplasia, sites and clinical type of leukoplakia were all important in 
predicting dysplasia in resection margins. 
 
 
5.5.5. Medical History  
1. Hypertension and diabetes mellitus were the most common systemic disease in PMD 
patients. 
2. Hypertensive patients were affected with higher rates of recurrences and MT compared 
to normotensive patients. 
3. Diabetic patients were predominantly DF. 
 
 
5.5.6. Dental Prosthesis 
1. All patients with MT and the majority of patients who underwent recurrence were dental 
prostheses wearers. 
2. Developing further dysplasia and oral cancer were not statistically associated with 
wearing dental prostheses. 
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6.1. Introduction  
The major aim in cancer research is the early detection and management of oral cancer and 
precancer to improve quality of life, and to increase the survival rate of patients. There is real 
clinical need for a diagnostic technique that can detect early changes, and to fully understand 
the biological process associated with carcinogenesis. 
 
The conventional method for tissue diagnosis is through histopathological evaluation of 
morphological abnormalities based on hematoxylin and eosin (H&E) staining after tissue 
fixation and sectioning. Histopathology is somewhat subjective, and associated with inter-
observer variations. It is both costly and unable to provide biochemical information on 
cellular tissue structure, in addition to its lack of immediate results (Manoharan et al., 1996). 
 
Tissue undergoing transformation towards dysplasia and subsequently toward malignancies 
undergoes structural and metabolic changes which change their light interaction properties 
(Gobinet et al., 2007). Substantial changes in cellular biochemistry in all stages of tissue 
cancer is often driven by underlying genetic changes, these changes may either initiate 
disease or occur as the result of the disease process (Swain et al., 2008). Qualitative and 
quantitative analysis of these changes may provide important information about specific 
diagnosis and/or the grade of disease process (Manoharan et al., 1996). 
 
Raman spectroscopy (RS) is a potentially powerful diagnostic technique known for its high 
sensitivity to subtle molecular and biochemical changes associated with the process of 
carcinogenesis (Shafer-Peltier et al., 2002b; Lieber and Mahadevan-Jansen, 2003; Swain et 
al., 2008). It has the ability to detect early biochemical changes associated with 
carcinogenesis before the morphological clinical manifestation (Papamarkakis et al., 2010) 
and this may greatly improve early diagnosis of cancers (Harris et al. 2010). 
 
RS is a laser based system applied to a wide range of biological applications (Lambert et al. 
2006). This system is able to provide chemical characterisation of tissue molecules under 
examination, providing detailed information about tissue constituents including proteins, 
nucleic acids and lipids (Chan et al., 2006). Biological molecules, in general, exhibit their 
own characteristic spectral features (Bakker Schut et al., 2000; Huang et al., 2003b; 
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Koljenovic et al., 2004; Stone et al., 2004). The Raman spectrum represents molecular 
information about all cellular components, including DNA, RNA, proteins, lipids, and 
carbohydrates (Swain et al., 2008). In this spectrum of bands, each Raman band is 
characteristic of specific molecular motion within an investigated area of the sample (Krafft, 
2004; Yu et al., 2006). RS is a useful tool to analyse the molecular composition and the 
structure of a sample on the basis of unique Raman signatures specific to each molecular 
constituent. Therefore, the positions, relative intensities and shapes of the bands in a Raman 
spectrum carry detailed information about the molecular composition of the sample (Oliveira 
et al., 2006; Gobinet et al., 2007; Gobinet et al., 2009). 
 
Analysing the differences between the acquired Raman spectra from morphologically normal 
and pathological tissues may be used for real-time clinical diagnosis (Gniadecka et al., 1997; 
Bakker Schut et al., 2000; Stone et al., 2000; Venkatakrishna et al., 2001; Stone et al., 2002b; 
Krishna et al., 2004; Romeo et al., 2006). This allows the differentiation of cancerous from 
normal tissue and may allow the detection of precancerous changes at early stages. RS has 
been successfully used for distinguishing tissue pathologies in various tissues including 
cervical (Mahadevan-Jansen et al., 1998), oesophageal (Stone et al., 2002a) and oral tissue 
(Venkatakrishna et al., 2001; Malini et al., 2006). 
 
Recent years have seen a great interest in the use of RS for clinical applications. Additionally, 
it has been shown to be a promising method for the classification of tissue samples based on 
spectral biochemical information, rather than on the distribution of stains and cellular or 
nuclear morphology for diagnosis. The spectroscopic measurements identify the changes in 
spectral patterns of the tissue, and are analysed using multivariate statistical data analysis 
methods (Kendall et al., 2011). Unlike conventional histopathology, this does not necessarily 
require fixation, labelling and staining of tissue. It can provide real-time biochemical tissue 
analysis, automated information, an objective, reproducible diagnosis and is independent of 
inter-observer variability and morphological changes (Viehoever et al., 2003; Swain and 
Stevens, 2007; Papamarkakis et al., 2010). 
 
In this study, RS has been assessed as an objective potential diagnostic system due to its 
ability to detect subtle biochemical tissue changes at a cellular level objectively and 
reproducibly (Baena and Lendl, 2004).  
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This system may improve the already existing gold standard of histopathological analysis 
being utilised alternatively or conjointly with conventional histopathology. 
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6.2. Current Diagnostic Method/Limitations 
Presently, the current diagnosis of cancer is through histopathological assessment which 
includes removal of a tissue biopsy from a suspicious area, subjecting it to many steps of 
tissue processing (fixation, sectioning and staining) followed by pathologist examination. 
This is largely based on the measurement of structural and morphological changes to detect 
cancer cells which are mainly due to biochemical changes within the diseased tissue (Stone et 
al., 2004). Currently, histopathology is often subjective, suffering from both inter- and intra-
observer variability (Kujan et al., 2007). Further, it requires sample preparation, associated 
with cost, and delay of both diagnosis and treatment accordingly (de Veld et al., 2005a; Upile 
et al., 2007; Kendall et al., 2009). Finally, sampling errors which cause unnecessary 
repetition of biopsies (Kendall et al., 2003; Muller et al., 2003) are often associated with 
patient morbidity and discomfort (Lau et al., 2003). 
 
Successful treatment increases the survival rate and improves the life quality of patients. This 
can be obtained by early detection of the PMDs and early diagnosis of malignant lesions 
which are often diagnosed at advanced stages (de Veld et al., 2005a; Ahmed et al., 2009). In 
fact, there is real need for an objective, real-time, accurate, reliable diagnostic method 
without prior tissue processing that it is either complementary or alternative to the 
conventional histopathology. Further, it should efficiently and rapidly diagnose malignant 
and PMDs even before their clinico-morphological detection. 
 
 472 
 
6.3. New Diagnostic Techniques: Optical Spectroscopy 
Recently, optical spectroscopy techniques have been used to enable the identification of early 
neoplastic changes by probing the tissue biochemically, providing detailed information about 
biochemical tissue components. Optical diagnostic techniques have shown a considerable 
promise as complementary and possible alternatives to the current diagnostic technique 
(Hutchings, 2009). These techniques could potentially complement the conventional 
histopathology by guiding the biopsy and assessing the resection margins during surgery. 
Alternatively, they may be used as a non-invasive, real time in situ tool for tissue diagnosis 
through a fibre optic device.  
Essentially, all spectroscopy techniques have the same mode of action, based on the 
interaction of light with matter and dependent on the fact that the optical spectrum displays 
biochemical constitutes of tissue under examination by measuring the signals of fluorescence, 
absorption, and scattering (Bigio and Bown, 2004; Schwarz et al., 2008). Qualitative and 
quantitative analysis of the biochemical changes can be performed by studying spectral 
features and measuring their intensities over the spectral range providing important 
information about disease diagnosis and disease stages (Manoharan et al., 1996; Mourant et 
al., 2005). 
The advantages of optical spectroscopy as an intended objective diagnostic technique have 
been demonstrated by many authors (Ingrams et al., 1997; Bigio and Bown, 2004; Stone et 
al., 2004; Upile et al., 2007; Bagan and Scully, 2008). In summary, they potentially could: 
 Reduce pathological observers’ disagreement by providing reliable biochemical tissue 
measurements used as standard for diagnosis of dysplasia and cancer stages.  
 Reduce missed lesions (sampling errors) by guiding biopsy location. 
 Reduce the number of multiple biopsies required for patient follow-up which will 
probably reduce both costs and patient anxiety.  
 Provide a simple portable tool with a reduced need for skilled interpretation. 
 Increase the ability to assess resection margins during surgical operation.  
 Provide diagnosis for lesions in higher risk areas such as the central nervous system and 
vascular system, in which surgical biopsy is dangerous.  
In addition to diagnosis, optical spectroscopy could be useful in disease management through 
adaptation of chemodynamic and photodynamic therapy dosage (Upile et al., 2007) as well as 
monitoring the response of the patient to treatment (dosage customisation) (Bigio and Bown, 
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2004). There are many types of optical spectroscopy systems which have been used in cancer 
research, such as fluorescent spectroscopy, infrared spectroscopy, elastic scattering 
spectroscopy and Raman inelastic scattering spectroscopy (Muller et al., 2003; Swinson et al., 
2006; Harris et al., 2010).  
 
 
6.3.1. Fluorescence Spectroscopy (FS) 
Fluorescence happens by excitation of a biological molecule (fluorophores) by a light at a 
wavelength that is located within the absorption spectrum of that molecule causing molecular 
excitation from the ground to an excited state, and returning back to the first position with an 
associated emitted fluorescence (Ramanujam, 2000). Basically, the fluorescent features of a 
tissue may occur either naturally by light stimulation, or by topical or systemic application of 
exogenous photosensitiser such as 5-aminolevulinic acids (ALA) (Upile et al., 2007). Since 
different tissues have different biochemical components and different naturally occurring 
endogenous fluorophores, FS has the ability to detect these fluorophores by providing 
distinctive spectra, which represent biochemical changes characteristic of dysplastic or 
cancerous conditions (Swinson et al., 2006; Upile et al., 2007). The endogenous fluorophores 
which are expected to change in the malignant transformation include: amino acids 
(tryptophan, tyrosine) structural proteins, collagens, elastin, porphyrins and co-enzymes, such 
as nicotinamide adenine dinucleotide hydrate and flavins (Ramanujam, 2000; Bigio and 
Bown, 2004). This concept was initially used for detection of cancer by Alfano and co-
workers (1984) using normal and cancerous animal tissues. The spectral profiles of normal 
and cancerous tissue showed substantial differences related to flavins and porphyrins 
fluorphorse. Following, several researchers have studied the use of FS using various 
experimental techniques in differentiating normal from malignant and pre-malignant tissues 
of different human organs. Ingrams et al. (1997) studied the fluorescence characteristics 
features of twelve histologically normal and ten dysplastic and malignant oral mucosa 
samples and found that using a 410 nm excitation wavelength and spectral range of 250–500 
nm was most significant. They correctly discriminated 20 of 22 samples and indicated that 
the emissions in this region may be generally attributed to porphyrins and particularly to 
protoporphyrin IX.  
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Although FS seems to be accurate for differentiating healthy from pathological oral mucosa, 
this method is less specific when discriminating between different types of pathologies and is 
limited by false positive results (Pfefer et al., 2003; De Veld et al., 2005c). 
 
 
6.3.2. Elastic Scattering Spectroscopy (ESS) 
This technique is based on backscattered photons which have the same wavelength as the 
incident photons. When the scattering light has the same frequency as the incident light, it is 
called elastic or Rayleigh scattering (Sharwani et al., 2006; Swinson et al., 2006; Upile et al., 
2007). According to Swinson et al. (2006), nucleus, chromatin concentration and subcellular 
organelles are the main scattering centres in the tissue. Additional scattering centres include 
structural proteins, lipids and erythrocytes (Sharwani et al., 2006). ESS provides a 
wavelength dependant spectrum which reflects morphological and structural alterations in the 
examined tissue (Sharwani et al., 2006; Swinson et al., 2006; Upile et al., 2007). It is 
sensitive to cellular crowding, nuclear cytoplasmic ratio, nuclear size and the chromatin 
content of the nucleus (Upile et al., 2007) which in fact is similar to criteria used by 
pathologists in the diagnosis of malignant cells (Mourant et al., 1998; Mourant et al., 2000; 
Lovat et al., 2006; Swinson et al., 2006; Upile et al., 2007). This technique is limited by both 
sampling volume and morphologically probing tissue. Specifically, it can examine only 1 
mm
3
 of tissue volume (Lovat et al., 2006) and probe only the morphology of the tissue not 
their biochemical changes (Hutchings, 2009). 
 
 
6.3.3. Infrared Spectroscopy  
Infrared spectroscopy (IRS) is an absorption analytical tool for detecting biomedical 
constituents such as nucleic acids, proteins, lipids and carbohydrates in cells, tissues, and 
biological fluids in diseases or disease progression states (Wang and Mizaikoff, 2008). IRS 
uses a polychromatic source of radiation (Hutchings, 2009). The frequency of the IRS 
absorption provides information relating to structure/conformation and intermolecular 
interaction (Krishnakumar et al., 2008).  
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This technique has been applied by a variety of research groups and in different fields such as 
cancer detection. However, it is hindered by water absorption which disturbs the resulting 
spectra and prevents in vivo application for clinical implementation (Hutchings, 2009). 
 
IRS has been utilized to study a number of normal and pathological tissues. For example, 
detection of epithelial dysplasia and neoplasia in cervical tissue (Wood et al., 2004), 
distinction and grading of malignant brain tumours tissues (Krafft et al., 2004) and analysis of 
normal and malignant oral epithelial tissue (Romeo et al., 2006; Krishnakumar et al., 2008). 
With multivariate statistical analysis, IRS has the ability to provide information on individual 
cell type, level of maturity and the state of disease which can be exploited for diagnostic 
purposes (Romeo et al., 2006). 
 
Studies on oral epithelial tissue have shown that peaks associated with lipids dominate 
normal epithelial tissue spectra (Krishnakumar et al., 2008), while proteins and nucleic acids 
dominate the malignant tissue spectra, confirming the increase in protein content in the 
cancerous tissues, compared to the normal tissues (Krishnakumar et al., 2008). This was 
proposed to be due to the production of large amounts of surface proteins, like receptor 
proteins, enzymes, antigens and antibodies (Malini et al., 2006). Also, the increased cell 
proliferation and decreased apoptotic activity of malignant cells may lead to an increase in 
number and size of the differentiated oral malignant cells, due to enlargement of the cellular 
nuclei and increased nuclear-cytoplasm ratio. These changes result in higher concentrations 
of proteins in the cells and increased thickness of the epithelium. This is reflected by an 
intense absorption of the nucleic acid bands at 1240, 1338 and 1715 cm
-1
 (Krishnakumar et 
al., 2008). 
 
In a recent study, a spectral cytopathological approach has been applied using IRS as a novel 
approach for diagnosis of disease in individual exfoliated cells by collecting spectral 
biochemical information, followed by multivariate data analysis. In this approach, cellular 
deviations from the natural composition produces specific spectral features of a disease state 
that are reproducible and can be used to identify cells compromised at the molecular level by 
dysplasia, neoplasia, drug metabolites or viral infection (Papamarkakis et al., 2010).  
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6.3.4. Raman Spectroscopy  
Among other optical diagnostic techniques, Raman spectroscopy (RS) in particular is well 
suited to probe the cellular biochemical changes when comparing between numerous healthy 
and diseased samples (Lambert et al., 2006). It has the ability to explore many specific 
chemical bonds present within tissue, providing detailed biochemical information with 
molecular specificity, hence providing a highly specific spectral fingerprint (Viehoever et al., 
2003). Although RS has weak signals, with recent technological advances this problem may 
no longer be considered as a limitation for its use (Hutchings, 2009). 
 
RS is a laser-based system using a monochromatic source of excitation and relying on 
molecular vibration frequencies (Hutchings, 2009). Raman system can provide detailed 
qualitative and quantitative information about a sample being studied (Shafer-Peltier et al., 
2002a). Basically, different tissues have individual molecular structures and accordingly they 
have specific Raman spectra, pathologic conditions associated with chemical and structural 
tissue changes will also have particular vibrational spectra (Koljenovic et al., 2005; Krafft et 
al., 2009). RS is an objective diagnostic system providing accurate and very detailed 
biochemical analysis of the target materials. Additionally, it requires very little sample 
preparation (Harris et al., 2010).  
 
 
A Brief History of Raman Spectroscopy  
The Raman effect was first observed experimentally in 1928 by Sir Chandrasekhara Venkata 
Raman and is due to the interaction between light and matter (Smith and Dent, 2005). Raman, 
along with K.S. Krishnan found that when a beam of light crosses a transparent chemical 
compound, a small fraction of that light is scattered at right angles and different wavelengths 
from the original beam (Raman and Krishnan, 1928-in Smith and Dent, 2005). In the original 
experiment, sunlight was focused by telescope onto a sample which was either a purified 
liquid or a dust-free vapour, with a second lens placed to collect the scattered radiation 
(Smith and Dent, 2005). However, the modern era of RS began in 1960s along with the 
development of commercial lasers and detectors (Manoharan et al., 1996). 
 477 
 
Biological applications of RS started with first report of proteins and amino acids performed 
by Tobin (1968), while the first cellular spectra were reported in early 1980s to study 
antibiotic interactions with nucleic acid (Manfait et al., 1982). In the early 1990s several 
research groups used RS to study normal and malignant tissues. Subsequently, with the 
development of instrumentation and multivariate spectral data analysis techniques, RS has 
been increasingly used to investigate biological systems including cells (Shafer-Peltier et al., 
2002a; Krishna et al., 2005b; Taleb et al., 2006; Harris et al., 2009b), complex tissues (Stone 
et al., 2000; Venkatakrishna et al., 2001; Krishna et al., 2004; Stone et al., 2004) and body 
fluids (Harris et al., 2009a; Sikirzhytski et al., 2010). 
 
There are four types of Raman system, each detailed in the following sections: 
 
 
Surfaces Enhance Raman Spectroscopy (SERS) 
In spite of the effective diagnostic ability of RS to provides quantitative and qualitative 
biochemical tissue information, it is considered as a low efficacy system with a limited ability 
to detect very low molecular concentrations (Petry et al., 2003). Therefore, using special 
resonators, the magnitude of the Raman cross-section can be significantly increased to about 
15 times that of the primary RS, thus enabling measurement of very low concentrations, even 
a single molecular spectrum (Kudelski, 2008). In this system, a molecule is placed on 
resonators of rough surfaces of gold, silver or copper and the enhancement is either 
performed by formation of electromagnetic field at the metal surface or by charge transfer 
between the metal and the adsorbed molecules (Petry et al., 2003; Kudelski, 2008). 
 
The potential applications of SERS such as the recognition of bacteria, bacteria spores, 
viruses and fungi (Kudelski, 2008) might provide an accurate and rapid identification of the 
biological agents in cases of disease diagnosis. In addition, SERS is able to offer a highly 
sensitive and rich information for trace analysis (Petry et al., 2003). The heavy metal surface 
used in this system may lead to damage of sensitive biological specimens; however, this can 
be managed by using a metal-coated glass fibre tip which also has the benefit of accurately 
positioning the device (Kiefer et al., 2003). Recently, this system has been developed and 
modified to a small probe-head attached to an optical fibre connected to a portable Raman 
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device (tip-enhanced RS) (Kudelski, 2008). This can be implanted as sensor inside a human 
and animal body such as a glucose sensor to analyse glucose level in the body directly by 
measuring the spectra of the compound under investigation (Lyandres et al., 2005). 
 
 
Resonance Raman Spectroscopy (RRS) 
This system uses the benefit of emission from the excited molecules at a wavelength near 
their transition positions and is occasionally hampered by fluorescence interference (Baena 
and Lendl, 2004). This technique is widely used in the analysis of a variety of chromophoric 
biological samples such as enzymes. It is mostly due to increased electronic excitation of the 
vibrational mode in the area surrounding the chromophores leading to signal enhancement 
(Kudelski, 2008). RRS has been used to determine the haemoglobin oxygen saturation in 
living tissue by measuring the ratio of intensities due to oxygenated and de-oxygenated 
haemoglobin (Ward et al., 2007). Also, a combination of both SERS and RRS can reduce 
fluorescence contamination and provide significantly sharp spectrographs which are highly 
useful for detection of DNA (Faulds et al., 2005).  
 
 
Coherent Anti-Stokes Raman Scattering System (CASRS) 
This system has widely used the non-linear Raman technique in which the incident radiation 
has either one monochromatic wave of frequencies (the scattered radiation may involve other 
frequencies) or two or more coherent monochromatic beams. It is rarely used because of the 
complexity of instrumentation (Kudelski, 2008). The incident radiation of a typical coherent 
anti-Stokes Raman scattering consist of two overlapping coherent monochromatic beams of 
frequencies, F1, F2 when F1 is greater than F2 and F1 minus F2 is equal to the frequency of 
the molecule. According to Kudelski (2008), this system has two important benefits: strong 
signal level and significant spatial resolution, in which laser light is focused into a sample and 
the signal is produced in a small excitation volume less than 1 μm3 (Baena and Lendl, 2004). 
The advantages of this technique over the conventional Raman are well documented in its 
important recent application in cell analysis such as embryonic stem cells. For example, 
Konorov et al. (2007) reported that coherent anti-Stokes Raman scattering microscopy is a 
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sensitive and non-destructive method that can provide spectroscopic markers to discriminate 
between differentiated and undifferentiated cells. Further, CASRS reduces the fluorescence 
interference by creating a highly strong single laser beam obtained by a combination of 
beams from two laser sources, so that Raman spectra can be detected over background 
fluorescence. However, the most important limitation of this system is its failure to 
discriminate between small equally sized molecules (Holtom et al., 2001). 
 
 
Confocal Raman Microscopy/Raman Micro-spectroscopy 
With classic RS, the entire sample area is evenly illuminated, while combining Raman 
spectrometry with confocal microscopy, the objective of the microscope focuses the incident 
laser light onto only a small point of the specimen depending on the objective used (Petry et 
al., 2003). The Raman scatter is collected by the objective which is coupled to a spectrometer 
by a pinhole to separate the light releases from the excited spot and in the same time prevents 
the light from the surrounded zones, similar results can be achieved by using a CCD detector 
(Petry et al., 2003). Since the laser is focused on a very small area of sample, it is very 
difficult to reduce the fluorescence in a shorter period of time, compared with the 
conventional RS. This system allows femtolitre volume (10
-15
 litre) and very high spatial 
resolution of >1 µm (Chan et al., 2006) allowing single cell analysis (Holtom et al., 2001) 
and three dimensions (Zhang et al., 2008). It is worth mentioning that in spite of high ability 
in detecting small biological molecules, which may be difficult to be detected by other 
methods (Lambert et al., 2006), the main limitation of this system is the long time needed to 
obtain a Raman image (Schafer et al., 2003). 
 
CASRS and confocal Raman microscopy are the main systems used for biological tissue 
analysis. 
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Basic Concept and Raman System Description 
Raman spectroscopy is an optical technique based on the interaction of light with matter. 
When incident photons from monochromatic laser light are directed towards target matter, 
while most will pass through unchanged, some photons will come into contact with 
molecules in the matter. Most of the photons that contact the molecules will interact with 
these molecules by exciting the particles, which are reemitted at the same frequency as the 
incident photon, named Rayleigh scattering or elastic scattering (Smith and Dent, 2005). 
However, a smaller number of these photons will undergo inelastic scattering which is called 
the Raman effect or Raman inelastic scattering (Swain and Stevens, 2007). The Raman effect 
is an inelastic light scattering process whereby a very small proportion of incident photons 
are scattered, comprising approximately 1 in 10
6
 to 1 in 10
9
 of those scattered elastically 
(Huang et al., 2003b; Lau et al., 2003; Bigio and Bown, 2004; Stone et al., 2004; Koljenovic 
et al., 2005; Ellis and Goodacre, 2006; Swinson et al., 2006; Swain and Stevens, 2007; 
Kudelski, 2008; Guze et al., 2009; Kendall et al., 2009). These photons are scattered at 
differing wavelengths to the incident photons, with the energy difference between the 
incoming and scattered photons referred to as the ‘Raman shift’ (Kendall et al., 2009). This 
corresponds to the vibrational modes of molecules contributing in the interaction (Swain and 
Stevens, 2007; Kendall et al., 2009) and corresponds to specific vibrational energies of 
chemical bonds of the scattering molecules (Ellis and Goodacre, 2006). The shift or position 
of the Raman peaks is independent of the wavelength of excitation and it is specific for 
particular molecular bonds responsible for the scattering (Harris et al., 2009b) enabling the 
chemical characterisation of molecules within a sample (Kendall et al., 2009). The scattered 
photon is either red-shifted by providing energy to the bond vibration and re-emitted with 
smaller energy than the incident photons, named Stokes-Raman scattering or blue-shifted by 
receiving energy from the bond and released with higher energy, the event here is referred to 
anti-Stokes Raman scattering (Petry et al., 2003; Lambert et al., 2006; Wachsmann-Hogiu et 
al., 2009). Because the anti-Stokes effect is weaker than the Stokes at room temperature, the 
Stokes scattering is recorded (Gobinet et al., 2009).  
 
The exact energy required to excite a molecular vibration depends on the masses of the atoms 
involved in the vibration, the type of chemical bonds between these atoms and may be 
influenced by molecular structure, interactions and the chemical microenvironment of the 
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molecule (Lyng et al., 2007). Using the fact that every chemical bond in a molecule has a 
characteristic vibrational energy, the interaction of the photons with a substance provides 
detailed biochemical information about sample constituent chemical bonds (Wachsmann-
Hogiu et al., 2009). Detection of these scattering photons produces a spectrum of Raman 
peaks. Each peak represents a specific molecular bond, together these peaks deliver an 
intrinsic molecular characterisation of the sample, resulting in rich information about the 
chemical bonds relating to nucleic acids, proteins, lipids, carbohydrates and other biological 
molecules present in the tissue or in a single cell (Chan et al., 2006; Wachsmann-Hogiu et al., 
2009). In addition, RS provides information about the interaction between macromolecules, 
such as DNA-protein or protein-lipid interactions (Wachsmann-Hogiu et al., 2009).  
 
Any physiological or pathological process associated with biochemical tissue changes would 
therefore lead to changes in Raman spectra (Harris et al., 2009a), where a wide range of 
chemical bonds and functional groups can be attributed to every single peak (Movasaghi et 
al., 2007). Raman spectrum is a direct function between the intensity of an individual peak 
and the concentration of the sum of molecular constituents of the investigated area within the 
tissue (Kendall et al., 2009). Therefore, it is mainly based on molecular concentrations rather 
than on architectural variations, hence the most important characteristic feature is the peak 
intensities which are positively proportionate to the concentration of molecular material 
within the examined tissue (Stone et al., 2004). So, one can understand that RS provides both 
qualitative and quantitative information through shapes and positions of the bands in a 
Raman spectrum and relative peak intensities respectively, all carry detailed information 
about the molecular composition of the sample.  
 
RS can detect and record information from specific molecular species from very small 
sections and may be applied to samples over a wide size range from single cells through to 
intact tissue (Huang et al., 2003b; Jess et al., 2006; Swain and Stevens, 2007). Accordingly, a 
Raman system is able to provide a library of spectra that can be utilised for identification and 
analysis of molecules in a variety of biological specimens (Lambert et al., 2006).  
Raman systems require a monochromatic high intensity light; typically a laser source is used 
for the excitation of the specimen which is delivered to the sample often using an optical 
microscope. Depending on the objective used, the microscope focuses the laser to a 0.5–10 
µm diameter spot; the analysis region on the sample matches this spot size. The Raman signal 
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is collected back through the microscope objective and through the confocal optics. Raman 
spectrometers use edge filters to cut out the signal from a spot corresponding to the laser 
radiation on the sample. Coupling a Raman spectrometer with a confocal microscope allows 
the acquisition of full spectral information with a high spatial resolution (<1 μm), a high 
biochemical sensitivity (da Silva Martins et al., 2010) and in three dimensions (Zhang et al., 
2008).  
 
Figure 6.1 shows the schematic diagram of the experimental Raman system. This diagram 
showing the laser light which comes from the sample passes back through the microscope 
optics into the spectrometer. An edge filter (sharp cut-off high pass filter) is used to reject the 
elastically scattered light prior to entering the spectrometer allowing only Raman inelastic 
scattered light to pass. Consequently, the Raman shifted radiation is detected with a charge-
coupled device (CCD). An entrance slit is used to block all light except that which is in the 
focal plane, with data acquisition performed by a computer. These factors have helped RS to 
become a very sensitive and accurate technique. The final Raman spectrum is a plot of the 
Raman intensity at each wavelength shift, recorded in wavenumbers (cm
-1
) which are the 
units that represent the number of wavelengths in a centimetre (Shim, 1996).  
 
 
Figure 6.1: Schematic diagram of Raman experimental system set-up. 
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Important Practical Considerations 
According to da Silva Martins and colleagues (2010) the available spectroscopic 
instrumentations (detectors, gratings, lasers) have better performance in the visible-light 
spectral region (400–700 nm). However, Raman excitation in this range may interfere with 
strong auto-fluorescence for nearly all human biological samples (Manoharan et al., 1996; 
Petry et al., 2003; Krafft, 2004; Gobinet et al., 2007; Harris et al., 2009b; da Silva Martins et 
al., 2010). A high noise to signal ratio compromises the accuracy of the acquired spectra and 
affects the spectroscopic measurement of tissue changes (Stone, 2001). Noise occurs due to 
the random motion of electrons which sometimes can totally obscure the Raman signal, so 
this ratio refers to the magnitude of measured Raman signal alone describing the quality of 
spectrum (Stone, 2001). To overcome this problem, many strategies have been proposed such 
as using different sources of excitation and more accurate tools (Lau et al., 2003). Two light 
excitations have been established both of them are far from the visible region: ultraviolet 
radiation (UV) (Manoharan et al., 1996; Lambert et al., 2006) and near-IR (NIR) excitation 
wavelengths (Krafft, 2004; Andrade et al., 2007; Guze et al., 2009; Kendall et al., 2011). 
Although UV excitation (10–400 nm) has a better avoidance of the fluorescence found with 
visible and NIR excitation (Ager et al., 2005), the instrumentation is limited, expensive and 
causes damage to biological tissues particularly affecting in vivo applications (da Silva 
Martins et al., 2010). NIR (750–1200 nm) has a relatively small extinction coefficient (a 
parameter related to how strongly a substance absorbs light) in human biological tissue, and 
therefore penetrates deeply (>1 mm), probing a relatively larger tissue volume (Manoharan et 
al., 1996). Also, this small absorption coefficient prevents tissue photo-degradation 
commonly associated with UV excitation, and reduces the fluorescence interference 
generated with visible-wavelength excitation. Furthermore, NIR wavelengths are simply 
transmitted along optical fibres for in situ or remote Raman spectral diagnosis (Manoharan et 
al., 1996).  
 
Several techniques have been developed to overcome high fluorescent backgrounds using 
visible light excitation in biological tissue samples. One of these methods is photo-bleaching 
(Manoharan et al., 1996). Since the fluorescence and Raman signals are located in the same 
spectral region and the fluorescence is due to the intrinsic tissue fluorophores, elimination of 
the fluorescence is difficult without altering the sample composition (Mahadevan-Jansen and 
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Richards-Kortum, 1997). Therefore, the tissue sample is subjected to a laser light for a 
considerable length of time, before acquiring any spectra (pre-laser irradiation) to reduce the 
fluorescence background contamination (Manoharan et al., 1996). Basically, fluorescent 
molecules in the ground state absorbed light and fluoresce, but with photo-bleaching, laser 
light progressively excites these molecules from the ground state losing their ability to emit 
light under prolonged exposure time (Glawdel et al., 2009). 
 
Another techniques to overcome the fluorescent background for biomedical applications is 
the use of computational algorithms for automated subtraction of the fluorescent background 
(Lieber and Mahadevan-Jansen, 2003; Zhao et al., 2007; Beier and Berger, 2009). Thus a 
combination of both photo-bleaching and automated fluorescent background subtraction for 
the treatment of the fluorescent problem using visible light excitation may be regarded as a 
suitable strategy to remove the intrinsic autofluorescent background signals, which are 
usually a few orders of magnitude stronger than those arising from Raman inelastic scattering 
(Zhao et al., 2007). 
 
RS has been widely used in the biomedical sciences applied over a wide range of samples 
from single cells to tissues (Jess et al., 2006). One important limitation of RS is the low 
Raman intensity signal from biological molecules which requires long acquisition time and 
high laser power for tissue excitation (Notingher et al., 2003b). However, prolonged laser 
light illumination or increased laser power to acquire high spectral quality might lead to 
undesirable sample degradation and damage to living cells due to local heating on sample 
from long acquisition times or extended radiation (Omberg et al., 2002; Jess et al., 2006). 
Therefore, carefully choosing an established optical technique can be one of the important 
steps in a spectroscopic tissue analysis. 
 
In spite of the large amount of biochemical information provided by RS which is regarded as 
the main strength, it is in the same time the greatest associated difficulty. The volume of 
information often makes the extraction of the required information difficult. Consequently, 
researchers usually select a defined spectral range for data analysis to exploit the relative and 
important information (Movasaghi et al., 2007). Furthermore, the main vibrational modes of 
most proteins that are probed due to C–C, C–N, C–H and other similar organic bonds, are 
very similar (Wachsmann-Hogiu et al., 2009). This fact makes it very difficult for RS to 
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measure differences between different isoforms of proteins or protein mutants, particularly 
against a background of other proteins (Wachsmann-Hogiu et al., 2009). 
 
Components used in Raman studies are important and can contribute to Raman signal if they 
are Raman active. So for spectral acquisition, the choice of a substrate for specimen mounting 
is of particular importance (Romeo et al., 2006) and it is vital that the substrate should not 
have a strong Raman signature within the studied spectral range, to eliminate any spectral 
contamination from the mounting agent. Although many types of substrate are available for 
spectroscopic studies, barium fluoride is one of the commonly used and the most suitable 
substrate for Raman tissue measurements. This mounting material has no Raman signature 
within the spectral range of biological tissue components named the fingerprint region (800–
1700 cm
-1
) (Gobinet et al., 2009), with only one known Raman peak at ~ 242 cm
-1
 (Chen and 
Shen, 2006). 
 
 
6.3.5. Comparisons between Raman and Infrared spectroscopy  
In general, both statistical data analysis and information evaluation are the same for both 
Raman inelastic scattering and IR absorption techniques (Manoharan et al., 1996; Mourant et 
al., 2005). IR spectroscopy is able to provide biochemical information about the main cellular 
components such as proteins, lipids and nucleic acids (Mourant et al., 2003), whilst RS 
provides similar information in addition to much more information about specific species in 
the main tissue components such as phenylalanine, tyrosine and adenine, which is not 
available from IR (Short et al., 2005).  
 
RS is an inelastic scattering technique of monochromatic laser excitation based on changes in 
polarisability (relative tendency of charge distribution), whereas IR is a light absorption of a 
polychromatic light source which is based on changes on dipole moment (relative tendency 
of the separation of positive and negative electrical charges in a system due to non-uniform 
distributions on the various atoms) (Smith and Dent, 2005). It has been shown that RS can 
provide spectra from thick sections (> 15 μm) with superior spatial resolution ~ 1 μm 
(Kendall et al., 2009), whereas IRS has been shown not to provide spectra from thick 
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sections, as these samples may lead to spectral saturation with lower spatial resolution (~ 10 
μm) compared to RS (Kendall et al., 2009).  
 
Generally, Raman spectra of biological samples often show narrow bands with a better 
understanding and better assignment of Raman peaks (Mahadevan-Jansen and Richards-
Kortum, 1996). Whereas, IR spectra of cells and tissue often show broader spectral features 
(Naumann, 2001). The IR signal is greater compared to Raman scatter, but in general there 
are fewer spectral peaks compared to RS indicating less detailed information (Krafft and 
Sergo, 2006). 
 
The most important application difference between the two systems is related to the strong 
absorption of water in IR which disturbs the spectral measurement (Kendall et al., 2009) and 
compromises the analysis of hydrated biological tissue. RS using UV, visible or NIR is more 
suitable for cellular based biological systems since the strong asymmetric nature of water 
molecules results in very weak Raman scattering bands, with very little or no interference 
with the Raman spectra (Notingher et al., 2003a; Short et al., 2005; Oshima et al., 2009; da 
Silva Martins et al., 2010). This greatly supports the suitability of in vivo spectral collection 
via fibre optic probe (Oshima et al., 2009; da Silva Martins et al., 2010). 
 
 
6.3.6. Biochemical Tissue Components 
Biological tissue is a heterogeneous mixture of four major components: proteins, lipids, 
carbohydrates and nucleic acids with the concentrations of these constituents varying within 
cells, between the same types and different types of the cells and in different 
physiopathlogical states (Malini et al., 2006; Harris et al., 2009b). Proteins are the major 
constituent of the human body (~ 20% of total body weight). They are responsible for 
structural support and are involved in all metabolic processes, with different types of proteins 
being constructed from 20 types of amino acids (Martini and Ober, 2001). Lipids form 
between 12%-24% of the total body weight, providing structural support and acting as an 
energy source, while carbohydrates such as sugars and starches form less than 1% of total 
body weight and are considered the most important source of energy (Martini and Ober, 
2001). Nucleic acids which store and possess genetic information are of two types 
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specifically, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Both nucleic acids 
consist of chains of repeating units called nucleotides and each have three components: a 
sugar molecule (deoxyribose or ribose), a purine or pyrimidine nitrogen base and a phosphate 
group (Martini and Ober, 2001). RNA molecules are predominantly single stranded with the 
branches consisting of the nitrogen bases adenine, cytosine, guanine and uracil, while DNA 
molecules are double-stranded helices of the nitrogen bases adenine, cytosine, guanine and 
thymine (Martini and Ober, 2001).  
 
Detecting such a wide variety of cellular components gives complex tissue spectra for tissue 
discrimination (Harris et al., 2009a). This complexity is mostly related to the fact that more 
Raman bands correspond to a functional group identifying a class of molecules rather than to 
one particular compound. Additionally, the spectral variations occur in a number of different 
Raman bands (Beljebbar et al., 2009). Morphological and/or biochemical cellular changes 
may result in different Raman spectra and could be identified by investigating the spectral 
differences acquired from normal and pathological tissues (Bakker Schut et al., 2000; Stone 
et al., 2000; Venkatakrishna et al., 2001; Stone et al., 2002b; Krishna et al., 2004). This may 
provide a disease marker(s) for tissue discrimination with the aid of multivariate statistical 
analysis.  
Figure 6.2 demonstrates a typical Raman spectrum with the assignment of the key features 
labelled. 
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Figure 6.2: Example of a Raman spectrum of oral epithelial tissue with assignment of 
the key features. 
 
 
 
Before developing a diagnostic approach for the purpose of comparison, it is important to 
understand both the spectral features of individual tissue components and changes in 
molecular species in the Raman spectra which are important for identifying and 
differentiating different proteins in different pathological states (Malini et al., 2006). Previous 
studies conducted by Venkatakrishna et al. (2001), Krishna et al. (2004) and Malini et al. 
(2006) showed that the normal tissue spectrum is similar to the lipid spectrum, while 
malignant and pre-malignant tissue spectra are similar to proteins spectra; amide I (N-C=O, 
C-N, C-C-N, N-H), amide III (N-H, C-N, CH3-C) and phenylalanine. As a result, 
standardised models of normal, premalignant and malignant spectra could be used as a 
comparable model for classifying and then diagnosing suspicious tissues.  
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6.3.7. Tissue Preparation for Raman Analysis 
Different types of biological tissues with different methods of sample preparation have been 
studied using RS. Fresh tissue section, fresh-frozen, air-dried, formalin-fixed and formalin-
fixed paraffin embedded (FFPE) tissues and de-waxed FFPE. Although fresh tissue is the 
ideal type of tissue for optical spectroscopy (Krishna et al., 2005a) because it is very close to 
the in vivo optimal conditions, paucity, sample handling difficulties, rapid deterioration and 
unsuitability for retrospective analysis are the major limitations for it being widely used (Ó 
Faoláin et al., 2005c). However, fresh tissue specimens may be placed in saline and spectra 
measured within 30 minutes of biopsy (Huang et al., 2003b) or in ice-cold saline (Chowdary 
et al., 2009). 
 
In general, spectroscopic analysis is commonly performed on fresh-frozen tissue sections 
with the advantage of lipid preservation that might be used as differentiation markers 
between normal and cancerous tissues (Tfayli et al., 2005). However, a freezing effect on 
cells has been documented in the cryogenics field. Specifically, a reduction in temperature 
cause depolymerisation of the cellular cytoskeleton which is formed from different types of 
protein fibres (Watson and Morris, 1987). This depolymerisation leads to an unravelling of 
protein secondary structures leading to increase amino group (NH3
+
) deformation (Ó Faoláin 
et al., 2004). Thus, researchers using frozen tissue should be aware of the appearance of a 
Raman band at (1485–1550 cm-1) due to increased vibration of this molecule because of the 
freezing effect which should not be used for diagnostic marker purposes (Ó Faoláin et al., 
2004). 
 
Regarding formalin-fixed tissue, it is important to mention that formaldehyde, which is the 
most commonly used fixative agent in pathology, might cause protein cross-linking 
(methylene bridging) which might cause structural alterations in secondary proteins (Mason 
and O'Leary, 1991). However, Shim and Wilson (1996) showed no changes in the position or 
the intensity of the amide bands, which are mainly used to study protein changes. This was 
supported by a study conducted by Mason and O'Leary (1991) who showed that the IR 
spectra of both fixed and unfixed proteins are similar. This indicates that formaldehyde 
fixation results in little or no protein secondary structure changes. Huang et al. (2003a) 
investigated the effect of formalin fixation in detecting lung cancer. Raman spectra were 
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collected from fresh normal and tumour bronchial tissue samples from six patients, compared 
to formalin-fixed normal and tumour tissue spectra. Formalin fixed tissues spectra showed 
decrease in overall intensities of the Raman peaks in addition to spectral contaminations of 
formalin at peaks 1041 cm
-1
 and 1492 cm
-1
 noticed in the both tissues. They indicated that the 
diagnostic markers derived from fixed tissues was not applicable for in vivo lung cancer 
detection and they recommended the use of fresh tissue for Raman studies, or if not available, 
a thorough rinsing of tissue specimens using phosphate-buffered saline before spectral 
measurements may help reduce the formalin contamination. Recent studies have shown that 
this type of tissue provided considerable discriminant features between normal and malignant 
tissues in ovarian tissue (Krishna et al., 2005a) and cervical tissue (Krishna et al., 2007b).  
 
To summarize, formalin fixed tissue samples can be used for Raman spectroscopic study after 
thorough washing in phosphate-buffered saline, and understanding that formalin peaks at 
907, 1040, 1492 cm
-1
 region will not be used as a diagnostic markers (Shim and Wilson, 
1996; Huang et al., 2003b; Krishna et al., 2004; Krishna et al., 2005a; Krishna et al., 2007b). 
 
Microscopic examination of a tissue needs a thin section of the tissue which is usually 
between 3–20 µm thick to transmit light. However, preparation of such thin slices requires 
pre-processing steps using embedding medium to support the specimen and for easy 
sectioning (Ó Faoláin et al., 2005a). Paraffin wax is the most commonly used embedding 
medium for both normal and pathological histology, allowing not only diagnostic but also 
retrospective studies with good cutting qualities and long term storing without any 
deterioration (Ó Faoláin et al., 2005a). FFPE ex vivo tissue samples have been used by many 
spectroscopic research groups due to availability, ability to enable larger sample studies to 
validate a technique and to provide retrospective information on patients outcome for spectral 
correlation (Kendall et al., 2009). Additionally, they benefit from better morphological details 
and easily handling compared to the shortage, rapid decay and handling difficulties of fresh 
tissue (Ó Faoláin et al., 2005c; Krishna et al., 2007b). Although biochemical information 
might be endangered (Krishna et al., 2005a), the suitability of this type of tissue for 
spectroscopic studies has been investigated and found to be appropriate for tissue 
classification, carrying sufficient discriminant information and reasonable classification 
between benign and malignant after excluding paraffin bands (Krishna et al., 2005a; Tfayli et 
al., 2005) at 1062, 1296 and 1441 cm
-1
 (Ó Faoláin et al., 2005b).  
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For the FFPE tissue samples to be as close to its in vivo state as possible and to minimize the 
paraffin wax contributions in the resultant spectra that might overlap or mask the important 
biochemical spectral information, tissue de-waxing has been used in spectroscopic studies to 
remove paraffin wax (Ó Faoláin et al., 2005a). There are many types of de-waxing agents, 
however, the currently used de-waxing agents such as xylene, Histoclear and other types are 
not completely effective in wax removal. A study conducted by Ó Faoláin et al. (2005b) on 
the efficacy of the de-waxing agents, showed that hexane has a superior de-waxing properties 
compared to the currently used solvents and they have recommended the use of hexane for 
tissue de-waxing for the spectroscopic tissue analysis.  
 
Due to the unavailability of fresh tissue for spectroscopic tissue analysis, it has been well 
accepted that the effect of any tissue processing method such as fixation or paraffin 
embedding has similar effects on both normal and diseased tissue specimens under 
examination. With the effects on both normal and malignant tissues more or less the same, 
tissue discrimination may not be greatly affected (Krishna et al., 2004), providing there is 
sufficient understanding of the effect of each particular processing method on the tissue 
specimens used. 
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6.3.8. Raman Peaks Assignments 
Raman assignments may be considered the most difficult part of Raman data analysis 
because of the complicated structures of biological tissue, generating complex tissue spectra 
and comprising of overlapping bands that might be seen in many cases (Stone et al., 2004). In 
biological tissue studies, a wide range of chemical bands and functional groups can be 
attributed to every single peak which can provide information about the presence and the 
concentration of biochemical constituents. Peak assignments show many inconsistencies in 
the literature because they depend on the scattering of many biological molecules co-added, 
providing the Raman peak with variations in shape and position (Stone et al., 2004). So 
finding appropriate meanings for the clinical importance of these constituents is considered 
one of the most important steps to achieve results and to complete any spectroscopic 
research.  
 
Although different techniques have been used by RS researchers, the spectral interpretation 
of comparable areas of the collected Raman spectra, show a noticeable similarity (Movasaghi 
et al., 2007). Table 6.1 lists some biological tissue Raman peak assignments from previously 
published works and have been identified in oral and other tissue studies. 
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Table 6.1: Tentative Raman peak assignments. 
Peak Assignment Reference 
824-840 
Out of plane breathing Tyrosine, O-P-O stretching of nucleic 
acids  
(Stone et al., 2002b) 
(Puppels et al., 1991) 
856-857 Amino acid side chain vibrations of proline & hydroxyproline 
(Stone et al., 2002b) 
(Hayashi et al., 1986) 
(Cheng et al., 2005) 
859 
Molecular  vibration mode of proteins mainly Tyrosine and  
C-C stretch  
(Oliveira et al., 2006) 
861 Phosphate group (Krafft et al., 2005) 
872-879 Hydroxyproline(C-C), tryptophan 
(Cheng et al., 2005)  
(Gniadecka et al., 1997) 
(Krishna et al., 2004) 
881-886 Tryptophan (protein) (Shetty et al., 2006) 
890 Protein bands 
(Hanlon et al., 2000) 
(Utzinger et al., 2001) 
(Dukor, 2002) 
(Maiti et al., 2004) 
(Krafft et al., 2005) 
892-896 Backbone, C-C skeletal (Chan et al., 2006) 
898 Monosaccharides  (β-glucose), (C-O-C) skeletal mode (Shetty et al., 2006) 
921-924 C-C stretch of proline ring/glucose/lactic acid 
(Benevides et al., 1997) 
(Stone et al., 2002b)  
(Stone et al., 2004)  
(Krishna et al., 2004) 
(Kendall et al., 2011) 
927-929 
C-C, stretching-probably in amino acids ,proline & valine 
(protein band) 
(Lau et al., 2003) 
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Continued 
Peak Assignment Reference 
934-937 
C-C stretching mode of proline, valine and 
protein backbone (α-helix conformation) 
/collagen 
(Stone et al., 2004) 
(Cheng et al., 2005) 
944-946 C-C protein (Venkatakrishna et al., 2001) 
949 CH3 rock, olefinic CCH deformation,  CH3 α-helix 
(Krishna et al., 2004)  
(Chrit et al., 2005) 
954 
Hydroxyapatite /carotenoid/cholesterol CH3 α-
helix 
(957) (Stone et al. 2004) 
(952)(Krishna et al., 2004)  
961-962 Symmetric stretching vibration of PO4- 
(Silveira et al., 2002) 
(Cheng et al., 2005) 
963-964 Unassigned in protein assignments Huang, 2003) 
967-968 Lipids (Dukor, 2002) 
972-977 CH3, CCH olefinic (protein assignment) (Katainen et al., 2007) 
981 
C-C stretching β-sheet (proteins), CH bending 
(lipids) 
(Notingher et al., 2003b) 
1003-1014 
Symmetric ring breathing mode of phenylalanine 
(proteins) 
(Puppels et al., 1991) 
(Mahadevan-Jansen and 
Richards-Kortum, 1997) 
(Venkatakrishna et al., 2001) 
(Stone et al., 2002b) 
(Stone et al., 2004) 
(Krishna et al., 2004) 
(Malini et al., 2006) 
(Chan et al., 2006) 
(Jess et al., 2006) 
(Zhang et al., 2008) 
1021-1023 Glycogen (Dukor, 2002) 
1035 
C-H in- plane breathing mode of phenylalanine 
/collagen 
(Stone et al., 2002b) 
(Stone et al., 2004) 
(Cheng et al., 2005) 
1037 Phenylalanine of collagen (Cheng et al., 2005) 
1048 
C-C stretch In deoxyribose, C-O stretching 
carbohydrate (Puppels et al. 1991) 
(Jess et al., 2006) 
(Hutchings, 2009) Glycogen 
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Continued 
Peak Assignment Reference 
1050-1050 Glycogen (Krishna et al., 2007b) 
1066-1068 
C-C stretch protein, C–C stretch lipids, 
C-O DNA/RNA, phospholipids,  
O-P-O stretch (nucleic acids),  
C–N stretching mode of proteins. 
(Puppels et al., 1991) 
(Mahadevan-Jansen and 
Richards-Kortum, 1997) 
(Borchman et al., 1999) 
(Naumann, 2001) 
(Krafft et al., 2005) 
(Krishna et al., 2004) 
(Chrit et al., 2005) 
1080 Typical phospholipids (Malini et al., 2006) 
1084 
C-N protein Phosphodiester groups in nucleic 
acids, C-N stretching mode of proteins (lipids 
mode to lesser degree). 
(Stone et al., 2002b) 
(Dukor, 2002) 
(Stone et al., 2004) 
(Krishna et al., 2004) 
1087-1089 
C–C stretch, 
C-C stretch lipid,  
O-P-O nucleic acid 
(Benevides et al., 1997) 
(Puppels et al., 1991) 
(Shafer-Peltier et al., 2002b) 
(Stone et al., 2004) 
(Krishna et al., 2004) 
(Chrit et al., 2005) 
(Short et al., 2005) 
(Jess et al., 2006) 
(Taleb et al., 2006) 
1099 C-N proteins (Cheng et al., 2005) 
1101-1103 
Collagen C–C stretch, O-P-O-stretching  
DNA/RNA, 
C-C stretch lipid 
(Benevides et al., 1997) 
(Puppels et al., 1991) 
(Shafer-Peltier et al., 2002b) 
(Stone et al., 2004) 
(Krishna et al., 2004) 
(Chrit et al., 2005) 
(Short et al., 2005) 
(Jess et al., 2006) 
(Taleb et al., 2006) 
1104 Phenylalanine (proteins) (Lakshimi et al., 2002) 
1135 C-N protein (1129), CO,CH3 (lactic acid) 
(Venkatakrishna et al., 2001) 
(Hutchings, 2009) 
1166 C-H in plane bending  Tyrosine 
(Krishna et al., 2004) 
(Cheng et al., 2005) 
1174 Tyrosine, phenylalanine, C-H bend (protein) (Chan et al., 2006) 
1176 C-H bending Tyrosine (proteins) (Stone et al., 2002b) 
1177 Cytosine, Guanine 
(Ruiz-Chica et al., 2004) 
(Jess et al., 2006) 
1213-1214 
Amide III, Tryptophan and phenylalanine, 
Tyrosine, Thymine, Cytosine, Adenine 
(Puppels et al., 1991) 
(Stone et al., 2002b) 
(Huang et al., 2003b) 
(Stone et al., 2004) 
(Krishna et al., 2004) 
(Krafft et al., 2005) 
(Taleb et al., 2006) 
(Jess et al., 2006) 
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Continued 
Peak Assignment Reference 
1230-1234 
Amide III (β-sheet), antisymmetric 
stretching of phosphate groups of the 
polynucleotide chain (DNA) 
(Shetty et al., 2006) 
(Dukor 2002) 
1237-1239-1250 Amide III 
(Dukor, 2002) 
(Ó Faoláin et al., 2005c) 
(Shetty et al., 2006) 
1243 
Amide III, asymmetric phosphate 
stretching modes (phosphate  stretching  
modes originated from the 
phosphodiester groups of nucleic acids 
and suggest an increase the in nucleic 
acids in the malignant tissues)  
(Dukor, 2002) 
(Cheng et al., 2005) 
C-O aromatic stretch  or amide III 
collagen (CH2 wagging, C-N stretch 
/pyrimidine bases (Cytosine, Thymine)  
(Stone et al., 2002b) 
(Stone et al., 2004) 
1245 
Amide III disorder  structure of proteins, 
collagen 
(Krishna et al., 2004) 
(Shetty et al., 2006) 
(Chowdary et al., 2009) 
1250 Guanine, cytosine (NH2) (Movasaghi et al., 2007) 
1235-1270 
Amide III C-N stretch, N-H in plane 
bending unordered 
(Mahadevan-Jansen et al., 
1998) 
1272 C=C phenylalanine, Tyrosine 
(Venkatakrishna et al., 2001) 
(Chowdary et al., 2009) 
1288 
Amide III, α-helix CH bend  
(Krishna et al., 2004) 
(Zenone et al., 2006) 
Phosphodiester groups in nucleic acids (Dukor, 2002) 
1299 CH2 deformation (lipid) (Stone et al., 2004) 
(Malini et al., 2006) 
(Chowdary et al., 2009) 
(Hartman et al., 1973) 1301 Adenine, cytosine (1300) 
1315 
Guanine ring breathing modes of the 
DNA/RNA bases, C-H deformation (Ruiz-Chica et al., 2004) 
(Chan et al., 2006) 
(Chowdary et al., 2009) 
Protein, Amide III, (α–helix) 
1317 
Guanine ring breathing modes of 
DNA/RNA bases, C-H deformation 
(protein) 
(Benevides et al., 1997) 
(Ruiz-Chica et al., 2004) 
(Chan et al., 2006) 
1318 
(Benevides et al., 1997) 
(Ruiz-Chica et al., 2004) 
(Chan et al., 2006) 
1320 Guanine, DNA/RNA CH deformation 
(Puppels et al., 1991) 
(Ruiz-Chica et al., 2004) 
(Chan et al., 2006) 
1322 
CH3 CH2 deforming modes of collagen 
and nucleic acids 
(Huang et al., 2003b) 
1323 Guanine (Ruiz-Chica et al., 2004) 
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Continued 
peak Assignment Reference 
1325 
CH3 CH2 wagging mode in purine bases of 
nucleic acids 
(Viehoever et al., 2003) 
1344 CH3 CH2 wagging  mode protein of collagen  (Stone et al., 2004) 
1345-1349 
CH2 twisting &bending (protein, lipids), nucleic 
acids 
(Short, 2005) 
1373 
Thymine, Guanine,  Adenine amino acids 
breathing modes of nucleic acids 
(Chan et al., 2006) 
1375-1377 
Thymine, Guanine,  Adenine amino acids CH3 
deformation  
(Short et al., 2005) 
(Jess et al., 2006) 
1378-1379 
CH3 glycosamineglycans/ COO, CH3 
hyaluronic acid 
(Krishna et al., 2004) 
Thymine nucleic acid (Krafft et al., 2005) 
1389 CH2 deformation  (Short et al., 2005) 
1407-1411 
A symmetric stretching carboxylate (IgG) (Lakshimi et al., 2002) 
(Hayashi et al., 1986) 
(Puppels et al., 1991) Adenine, Guanine  
1422 
Backbone CH2  (Krafft et al. 2005) 
COO- of protein  (Chowdary et al., 2009) 
1420-1450 CH2 scissoring vibration of lipids (Gniadecka et al., 1997) 
1423-1424 Deoxyribose, (Ruiz-Chica et al. 2004) 
1442 Fatty acids, CH2 bending mode  
(Mahadevan-Jansen and 
Richards-Kortum, 1997) 
(Hanlon et al., 2000) 
(Dukor, 2002) 
1443 CH2 deformation (lipids and protein) (Stone et al., 2004) 
1445 CH2 deformation (protein) (Venkatakrishna et al., 2001) 
1448 
CH2 CH3 deformation lipids, proteins  (Cheng et al., 2005) 
Collagen  (Kaminaka et al., 2002) 
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Continued 
Peak Assignment Reference 
1450 
Methylene deformation in biomolecules  (Dukor, 2002) 
CH2 bending  (Malini et al., 2006) 
1451 
Lipids/proteins CH deformation  (Jess et al., 2006) 
CH2 CH3 deformation (Lakshimi et al., 2002) 
1453 
Protein bands   
(Hanlon et al., 2000) 
(Dukor, 2002) 
Proline  (Zhu et al., 2011) 
Structural protein modes of tumours  (Utzinger et al., 2001) 
1454 Collagen & phospholipids  
(Mahadevan-Jansen et al., 1998) 
(Utzinger et al., 2001) 
(Lau et al., 2003) 
1457 Nucleic acid (Feld et al., 1995) 
1460 CH2 CH3 deformation of lipids & collagen  (Cheng et al., 2005) 
1462 CH2, Disaccharides, sucrose  (Shetty et al., 2006) 
1469-1471 C=N stretching (Naumann, 2001) 
1507 
C=N stretching   (Naumann, 1998) 
Cytosine  (Ruiz-Chica et al., 2004) 
1522-1537 C=C carotenoid (Stone et al., 2004) 
1589-1592 C=C stretch olefinic (Chrit et al., 2005) 
1600 
C=C stretching mode of  phenylalanine and 
Tyrosine 
(Stone et al., 2002b) 
1607 Cytosine (NH2)  
(Puppels et al., 1991) 
(Lakshimi et al., 2002) 
(Ruiz-Chica et al., 2004) 
1608-1609 Aromatic amino acid (protein) (Venkatakrishna et al., 2001) 
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Continued 
Peak Assignment Reference 
1619 C=C bending of proteins Tryptophan (Cheng et al. 2005) 
1621 
Tryptophan (Ig G) (Lakshimi et al., 2002) 
Tryptophan (Ig G), phenylalanine, Tyrosine (Chowdary et al., 2009) 
1623 Tryptophan and /or β-sheet (Cheng et al. 2005) 
1658-1660 Amide I (protein) 
(Naumann, 1998) 
(Jess et al., 2006) 
1661 Amide I/collagen (Krishna et al., 2004) 
1673 Amide I (Ó Faoláin et al., 2005c) 
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6.4. Data Pre-Processing 
Following spectral data acquisition a significant spectral processing is essential because the 
collected Raman spectra represented a combination of intrinsic tissue fluorescence, weak 
tissue Raman scattering signals, cosmic ray and noise (Huang et al., 2003b; Teh et al., 2008). 
Pre-processing steps aimed to remove any contaminations to the real tissue spectrum 
(Mahadevan-Jansen et al., 1998). Data pre-processing may be generally categorised into 
baseline correction, calibration shifts, cosmic ray removal, averaging and normalisation, with 
the baseline correction and normalisation are the most important steps. 
 
 
6.4.1. Baselines Correction  
Baseline correction can be conducted using either fully or semi-automated techniques. Fully 
automated techniques although more convenient to use, tends to be less accurate than semi-
automated techniques (Prakash and Wei, 2011). In many spectroscopic techniques, it is not 
uncommon to have baseline offsets from spectrum to spectrum; this type of effects creates an 
additional confounding effect on principal component analysis (PCA) models. High or broad 
and weak baselines may result from instrument drifting or fluorescent background signals. 
This is referred to a non-Raman background (Taleb et al., 2006).  
 
Although several baseline correction techniques exist which can be performed using different 
software, according to Gan et al. (2006), it is difficult to develop a theoretically perfect 
method for baseline correction when an approximate estimation of baseline has been the 
general method. A straight line to connect the two ends of a signal peak may be used and 
taken as the baseline for further calculation of peak area or peak height. However, if the 
straight line does not fit the real baseline, a polynomial fitting approach for baseline 
calculation by a sequential step-wise process will be implemented (Gan et al., 2006). For 
each step, the information from signal peaks is reduced and the baseline information takes the 
control position, which finally reaches the best estimation of the baseline (Gan et al., 2006). 
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6.4.2. Normalisation  
The absolute signal intensity is not very reproducible in RS and is dependant on many 
experimental factors, such as the intensity of laser light source used for sample excitation, 
accumulation time, sample tissue orientation, as well as constituent and temperature 
variations (Skoulika et al., 1999; Gemperline, 2006; Taleb et al., 2006). For the purpose of 
quantitative measurements, and to compensate for any fluctuations in the intensity, a 
normalisation procedure is used (Skoulika et al., 1999).  
 
Depending on the needs of an application, many normalisation schemes can be used, such as 
normalisation to a well defend peak, total area or centred and normalised to a given variance 
(normally unity) (Hutchings, 2009). The last normalisation procedure which is also referred 
to standard normal variate (SNV) normalises the spectrum, so the standard deviation of all 
intensities in a spectrum is 1. 
 
 
6.4.3. Smoothing  
Smoothing is the elimination of noise from the signal with the lowest possible signal 
distortion (Vivo-Truyols and Schoenmakers, 2006). Basically, smoothing reduces the pixel to 
pixel variance of the signal, but does not eliminate the noise from the signal. However, it is 
difficult to find a method that is able to eliminate all the noise without losing any valuable 
information. Therefore, a balance must be found between removal of noise and signal 
distortion. This balance depends on both the features of the signal and on the noise (signal 
frequency, noise variance, or the peak-shape) which are changeable from sample to sample 
(Vivo-Truyols and Schoenmakers, 2006). 
 
Several smoothing methods such as Savitzky–Golay, mean filtering, exponential smoothing, 
and Fourier transfer, have been used in managing noise problems (Gan et al., 2006). 
According to Gobinet et al. (2009), polynomial smoothing is the most commonly used 
technique which is also called Savitzky-Golay (SG) smoothing after the names of the two 
authors who described the technique in 1964 (Savitzky and Golay, 1964). In the SG 
algorithm, the smoothing can be controlled with two parameters, the window size and the 
polynomial degree. With small window sizes and high polynomial degrees yielding noisy 
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signals (light smoothing), while large window sizes and low polynomial degrees may yield 
distorted signals (strong smoothing) (Vivo-Truyols and Schoenmakers, 2006). The window 
size allows for better fine-tuning of the smoothing. Therefore, the polynomial degree is kept 
constant and the smoothing process is optimised by varying only the window size (Vivo-
Truyols and Schoenmakers, 2006). Smoothing fits a polynomial function of a specified 
‘degree’ through a range ‘size’ of adjacent pixels, and replaces those with the polynomial 
curve which is applied across the entire spectrum.  
 
One can understand that smoothing of the spectra should be done with considerable caution 
(Smith and Dent, 2005; Gemperline, 2006). The strong smoothing programme provides better 
signal-to-noise ratios than weak smoothing. However, this may result in the loss of 
significant spectral information for interpretation (Smith and Dent, 2005). For example, sharp 
peaks or shoulders are smoothed in a similar way to noise (Gemperline, 2006) and that will 
mix the source of variation in spectral data. To improve the Raman signal, it is important to 
reduce the amplitude of the noise, leaving the signal unaffected (Gemperline, 2006). For that 
reason, heavy spectral smoothing should be avoided. 
 
 
6.5. Data Analysis  
Statistical data analysis following pre-processing of raw spectral data which is a very 
important step prior to data analysis obtains successful and adequate data classification. By 
data classification, a representative spectrum of each group can be recognised and then 
features of spatial allocation of each biochemical constituent can be examined (Lee et al., 
2007a).  
 
There are two main approaches for spectral data analysis: univariate and multivariate 
analyses. 
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6.5.1. Univariate Data Analysis 
Spectroscopic data are very complex and large for visual analysis and although variations in 
spectral data are often visible, subtle differences may be missed and can be difficult to 
identify (Kelly et al., 2011). Univariate statistical techniques based on peak intensities or 
peak-ratios have been widely used by many research groups to identify potential biochemical 
markers from spectral data (Mahadevan-Jansen et al., 1998; Stone et al., 2004; Teh et al., 
2008). For comparison purposes, a representative spectrum of each group has been 
constructed by calculating the mean spectrum of the collected spectra. Univariate statistical 
analysis such as, t-test and ANOVA for normally distributed and non-parametric tests for 
non-normally distributed data, such as Mann-Whitney U and Kruskal-Wallis tests for pair-
wise and groups differences determination, respectively, were used for selected important 
particular peaks. 
 
Relative peak intensity and peak ratio intensity may be considered as a simple and useful 
calculation for group comparisons. Many research groups have developed classification 
models based on these methods. However, a significant amount of spectral information is still 
not exploited using such methods. While a univariate approach only considers a specific 
region of the spectra (Hutchings, 2009), complicated biochemical changes might affect the 
entire spectrum rather than just a particular spectral band. Although using single peak 
intensity and ratios are found to be useful to identify diagnostic markers, this approach may 
be of limited value compared to multivariate techniques (Hutchings, 2009). 
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Potential Biochemical Tissue Markers in Dysplastic Epithelium 
Understanding the carcinogenesis process greatly assists the improvement of diagnostic 
techniques (Beljebbar et al., 2009). The process of tissue transformation to cancer is 
associated with fundamental changes in cellular morphology and biochemistry (molecular 
tissue composition) which can be detected by RS at early stages even before the 
morphological appearance (Beljebbar et al., 2009). In general, a dysplastic tissue shows 
increased cellular crowding with disorganization, increased nuclear material, increased 
nuclear cytoplasmic ratio, increased cells proliferation (mitotic activity) and abnormal 
distribution of chromatin (Pindborg et al., 1997). These changes are associated with increased 
metabolic activity (Mahadevan-Jansen and Richards-Kortum, 1997) and lead to increased 
relative amounts of nucleic acids and proteins (Short et al., 2005). These features result in 
specific changes in nucleic acid, protein, lipid and carbohydrate quantities and/or 
conformations (Robbins et al., 1994). 
 
A lipid-dominated spectrum of normal epithelium and protein-DNA dominated spectra in 
malignant tissue have been reported by previous studies (Venkatakrishna et al., 2001; Krishna 
et al., 2004; Malini et al., 2006). The normal tissue lipid-like spectrum is mainly due to the 
fact that the epithelial surface consists of a closely packed layer of cells with their lipid 
bilayer cell membranes subjected to the laser beam excitation (Krishna et al., 2004). While in 
inflammatory, dysplasia, and malignant tissues, protein and DNA dominated spectra are 
largely related to the increased amounts of surface proteins such as signalling agents, receptor 
proteins, enzymes, antigens, antibodies, immunoglobulins and DNA from the fast growing 
and proliferating cells in cancer tissue (Krishna et al., 2004; Malini et al., 2006). This is also 
supported by DNA studies which indicate that increased cellular nucleic acid content is one 
of the more prominent changes in cancer and pre-cancer which can be investigated by RS 
(Robbins et al., 1994).  
 
For instance, Figure 6.3 shows typical mean Raman spectra for normal and malignant oral 
tissue (Malini et al., 2006). The normal tissue spectrum (a) which can show sufficient 
differences, shows prominent peaks at the 1301 cm
-1
 (CH2 lipids) and 1745 cm
-1
 
(phospholipids) bands. While the malignant tissue spectrum (b) exhibits more distinct peaks 
between 951 and 1337 cm
-1
 relating to nucleic acids and proteins. 
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Figure 6.3: Mean Raman spectra of oral tissue: (a) normal and (b) malignant. 
(Malini et al., 2006) 
 
 
 
The morphological and biochemical tissue changes associated with cancer development are 
numerous and depend on the type and location of the cancer. These changes may be located 
in the cell membrane, cytoplasm, nucleus and extracellular space (Mahadevan-Jansen and 
Richards-Kortum, 1997). The progression of epithelial tissue towards cancer is associated 
with biochemical changes including increased nucleic acids, protein conformation and a 
reduction in glycogen and carotenoids (Stone et al., 2004). In epithelial tissue, such as 
oesophagus, colon and prostate tissue, it has been shown that benign tissue spectra exhibited 
increased levels of amino acids, such as tryptophan, tyrosine, proline and α-helix proteins, 
while neoplastic tissue spectra showed higher concentrations of nucleobases such as guanine, 
adenine, cytosine, uracil, O-P-O, β-sheet and unordered proteins (Stone et al., 2004). These 
general features have led to the development of a number of ratios between peak intensities 
being suggested as potential markers. For instance, Teh et al. (2008) reported that the 
differentiation between normal and dysplastic stomach tissue, could be achieved with a 
diagnostic sensitivity and a specificity of 86% and 80% respectively, if the intensity ratio of 
the hydroxyprolin peak (875 cm
-1
) to the intensity of the CH2 mode for protein/lipids (1450 
cm
-1
) was calculated. These features of biochemical tissue changes have, in a number of 
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cases, been found to agree with histological criteria used for cancer grading (Huang et al., 
2003b; Mourant et al., 2005).  
 
Studies on spectroscopic tissue markers for oral cancer are very limited and currently no 
specific spectroscopic marker is found for tissue diagnosis. However, a previous study on 
oral epithelium conducted by Isacsson and Shear (1981), found a lower concentration of 
glycogen in oral epithelial dysplasia including mild dysplasia compared with non-dysplastic 
epithelium. This decrease in glycogen content was found to be enhanced with increased 
severity of dysplasia. The reason for the decrease of glycogen was proposed to be due to 
consumption due to increased metabolic activity or decreased synthesis. 
 
Diagnostic algorithms have been identified by Mahadevan-Jansen et al. (1998) which may 
have the potential for diagnosis of cervical pre-cancer. This was based on the decrease in the 
intensities of collagen at 1656 and 1070 cm
-1
 and increased intensity of peaks attributed to 
phospholipids, DAN and glucose 1-phosphate (a glucose molecule with a phosphate group on 
the 1-carbon) at 1454, 1330 and 978 cm
-1
 in squamous intraepithelial lesions of cervical 
tissue. These results are consistent with the histopathology of the neoplastic process, where 
the number of proliferating cells increases as dysplasia progresses (Mahadevan-Jansen et al., 
1998). Furthermore, Mahadevan-Jansen et al. (1998) and Utzinger et al. (2001) identified 
similar algorithms related to the intensities at 1330, 1454 and 1656 cm
-1
 attributed to 
collagen, phospholipids and DNA and used to differentiate high grade squamous dysplasia 
from all other cervical samples with minimal classification errors. These peaks exhibited a 
consistent increase in intensity as disease progressed from normal to high-grade squamous 
dysplasia in an in vivo study. The intensity ratio of 1657 cm
-1
 to 1445 cm
-1
 may be used for 
differentiation in all gynaecologic tissue; the intensity is greater in normal than malignant in 
uterine and cervical samples. The intensity of 1070 cm
-1
 and 1656 cm
-1
 may be used to 
discriminate dysplasia from other tissues, with sensitivity and specificity of 88% and 92% 
(Mahadevan-Jansen and Richards-Kortum, 1997). 
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6.5.2. Multivariate Data Analysis Techniques 
Multivariate techniques use mathematical, statistical and computer sciences to extract useful 
information from data set (Wang and Mizaikoff, 2008) and it is either ‘unsupervised’ which 
has no prior information about the samples or ‘supervised’ which requires a prior knowledge 
about the sample groups such as normal or pathological classification (Wang and Mizaikoff, 
2008; Martin and Pollock, 2009). For both types, sufficient number of samples are required 
for robust model generation (Wang and Mizaikoff, 2008). For example, one third of the 
sample size may be taken for the test set, however, that is not always possible and may be 
difficult to generate such test sets due to insufficient number of spectra (Hu et al., 2009). 
 
 
Unsupervised Procedures 
Principal Component Analysis (PCA) 
Many research groups working with different tissues have successfully used PCA for Raman 
data analysis (Mahadevan-Jansen et al., 1998; Krishna et al., 2004; Stone et al., 2004; Malini 
et al., 2006; Teh et al., 2008; Teh et al., 2010a). PCA is a widely used multivariate statistical 
tool for Raman data analysis to identify spectral changes that might be related to the 
pathological state of the biological tissue. 
 
Usually there are many different sources of variation in a spectral data set related to a 
particular spectrum. Including, differences in constituents, instrument variation, sample 
handling error and others, and all can affect the appearance of the resulting spectrum. 
However, only few independent variables in the sample constitution are usually responsible 
for spectral differences (Nogueira et al., 2005). Raman spectra include information about 
peak intensity for a very large number of wavelengths. However, only a small number of 
variables might be responsible for variation in the data. PCA is a data compression 
multivariate technique (Krishna et al., 2007b) that removes irrelevant variations in spectral 
features, while preserving spectral features with independent variations. It is an unsupervised 
model with no prior knowledge of group classification.  
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Basically, PCA is able to extract the relevant information from the raw data and create a new 
set of variables named principal components (PCs) (factors) and scores (S). The PCs are 
related to the most important variation of the spectral data (Gemperline, 2006) and appear in 
order, with the first PC usually accounting for the most variation in the spectral data set, the 
second PC representing the next highest variance. This continues until the principal 
components represent only noise. Usually the first 8–10 PCs may be used (Martin and 
Pollock, 2009). Scores are related to the weight of each PC to reconstruct the original data 
(Geladi and Kowalski, 1986). PCA may be used under different conditions, entire spectra, 
selected regions and derivative spectra (Krishna et al., 2005a). Thus, it is important to find 
which principal components carry most of the information (Gemperline, 2006). The most 
significant principal components can then be used for group separation by plotting the scores 
in principal component space, each spectrum represented by a single point or score (Martin 
and Pollock, 2009). 
 
PCA is the analysis of choice followed by classification, cluster analysis or other multivariate 
methods. It is able to reduce both the dimensionality of complex data and the influence of the 
measurement error by eliminating the principal component associated with noise 
(Gemperline, 2006). Also, PCA can identify an overall variance over the entire data set, 
although it is unable to detect within-groups and among-groups variations. 
 
 
Cluster Analysis 
Clustering techniques are unsupervised methods for grouping data into classes (Wang and 
Mizaikoff, 2008). Clustering may be applied when information about data classes is not 
available, or to see the trend of data grouping without using the data classes (Kelly et al., 
2011). Many clustering techniques are used that do not need prior knowledge about the 
number of data groups, such as hierarchical clustering analysis (HCA), whereas other 
clustering techniques such as k-mean cluster analysis (KMCA) and fussy c-means cluster 
analysis (FCA) need such information for data input as a basic requirement. Cluster analysis 
has the same principle that in a measurement space, the distances between pairs of cases is 
inversely associated with degree of similarity (Gemperline, 2006). All these techniques group 
spectra according to the similarity between them, however, FCA has an additional advantage 
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over others by providing information about the relationship of each spectrum to each cluster 
(Wang and Mizaikoff, 2008). FCA is similar to KMCA, but FCA is able to determine the 
possibility of the fitness of each case to a specific cluster and also the association with other 
clusters, so one case may be assigned to more than one cluster which may provide valuable 
information for disease progression such as MT (Wang and Mizaikoff, 2008). 
 
However, a major disadvantage of cluster analysis techniques which limits their practicality 
is that there is no validity measurement for quality of data clustering. Thus, these techniques 
mostly depend on the data set criteria and on the problem itself (Gemperline, 2006), not on a 
mathematical analysis. For that reason, it is important to have previous information about the 
study problem before using such methods (Wang and Mizaikoff, 2008). 
 
 
Supervised Classification Procedures 
The aim of the classification or discriminant analysis or supervised learning is to obtain bases 
that describe the separation between known groups of observations (Gemperline, 2006). A 
simple example of that is a binary classifier when data space is divided into two areas; with 
cases sharing the same properties are seen on one side of the decision line, whereas those 
possessing the other features are observed on the other side. 
 
 
Soft Independent Modeling of Class Analogy (SIMCA) 
SIMCA is a classification model capable of classifying high-dimensional data set 
observations (Branden and Hubert, 2005) and using separate PC models for different classes 
(Wang and Mizaikoff, 2008). This method is also useful when small datasets are analysed 
(more variables than objects) since it performs a substantial dimensionality reduction 
(Marengo et al., 2007). It is normally used for identifying local models for defined groups 
and to predict a possible class membership for new observations (Sikirzhytski et al., 2010). 
Hotelling’s T2 and Q statistics is used for group membership decisions (Sikirzhytski et al., 
2010). The significance of the classification is assessed using the default of parameter of 
Quality of model fit (Q
2
). The Q
2
 statistic employed by SIMCA refers to:   ∏ 
     
  
 ; 
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where PRESS is the prediction error sum of squares (measure of the classification error) and 
SS is the sum of squares. A probability used that a value of Q
2
 greater than 0.097 arose by 
random chance is equivalent to p <0.05; (SIMCA P-manual guide). 
 
The classification in SIMCA is made by comparing the residual variance of a sample with the 
average residual variance distances of those samples that make up the class. This comparison 
provides a direct measure of the similarity of a sample to a particular class and can be 
considered as a measure of goodness of fit of a sample for a particular class model. Good 
classification of the data is greatly affected by irrelevant features (noise), thus removal of 
these features is essential to provide a clear separation of class structure (Gemperline, 2006).  
 
There are several advantages of using SIMCA. Firstly, the unknown sample is not assigned to 
any class if its residual variance exceeds the upper limit of every class because it is either an 
outlier or not represented in the training set. Secondly, if the residual distance of a sample is 
below the statistical limit, other classification methods assign the sample to a single class 
forcibly leading to misclassification, while SIMCA assigns such a sample to multiple classes 
(overlapping between classes). Thirdly, to generate classification models, SIMCA is known 
to be sensitive to the data quality, so variables having low power for both modelling and 
discriminant are usually deleted from the analysis, because they mainly contribute to noise 
(Gemperline, 2006; Wang and Mizaikoff, 2008). Due to the aforementioned, SIMCA is 
considered the first successful approach for the discriminant analysis for datasets. 
 
 
Linear Discriminant Analysis 
Linear discriminant analysis (LDA) is a supervised technique which forms linear 
combinations of variables depending on differences between classes in the data set and 
determining the directions of the variable in the spectral space (German et al., 2006). An 
important feature in LDA is the establishment of discriminant functions which maximize the 
variations between groups and minimize them within group. Mahalanobis distance (MD) is 
the standard measure of distance between two cases when the observed data are quantitative 
(Bedrick et al., 2000). It is based on correlations between variables by which different 
patterns can be identified and analysed. Usually MD is used for classification of unknown 
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samples depending on the distance of the new sample to the centre of each class (Wang and 
Mizaikoff, 2008). For the validation of the LDA model, the leave-one-out cross-validation 
has been often used in which all spectra except one were used and then to classify the left out 
spectrum, this method is repeated so that each spectrum is predicted once (German et al., 
2006). For its reliability, LDA needs the number of objects to be higher than the number of 
variables (Wang and Mizaikoff, 2008).  
 
 
Partial Least Squares Discriminant Analysis (PLS-DA) 
PLS-DA is an analytical technique that has been successfully applied to laser Raman spectral 
analysis derived from PLS regression models (Barker and Rayens, 2003). It is basically the 
inverse-least squares approach to LDA, which produces essentially the same result but with 
the noise reduction and variable selection advantages of partial least square (PLS) (Barker 
and Rayens, 2003). PLS-DA is more suitable for spectral data analysis when both data 
reduction and discrimination are needed (Barker and Rayens, 2003). While PCA is an 
unsupervised technique employed to reduce dimensionality and generate a visualisation of 
data based on total variances, PLS-DA is used to create ‘scores’ summarising the main 
variation among–group within the spectral data set (Taleb et al., 2006; Wang and Mizaikoff, 
2008). Basically, PLS-DA constructs a set of linear combinations of the wavenumbers the 
same way as PCA, but uses the data classes at the same time, so it identifies and ranks of the 
basic signals based on their simultaneous ability to account for the variation in both group 
assignment and the spectral data. This means that variation between groups is emphasised 
and ranked higher, making the analysis more sensitive and accurate in the face of 
confounding variation. PLS-DA model is used successfully to group classification and it is 
preferred over PCA when both discrimination and dimension reduction is required (Barker 
and Rayens, 2003).  
 
 
Artificial Neural Networks (ANNs) 
It is a non-linear multivariate data analysis technique composed of several layers of 
connected processing units. Every processing unit transforms input data into an output by a 
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non-linear transferring function after assigning a weighting function for each node input 
(Wang and Mizaikoff, 2008). Although ANNs have the advantages of handling a very large 
amount of datasets and differentiate groups by subtle changes, it requires an extensive 
training and sufficient number of training samples to cover all the possible variations in the 
data set. ANNs is an inflexible technique in organising the number of units, neurons or layers, 
so it is time consuming, however, it is a useful application for biomedical samples with 
different disease stages or severities (Wang and Mizaikoff, 2008). 
 
In conclusion, all the approaches described previously are available from commercial 
software packages including Matlab, Unscrambler and SIMCA. The existing multivariate 
methods of spectroscopic data analysis can extract useful information from the acquired 
complex data; however, novel solutions to the spectroscopic data analysis problem are always 
mandatory. Multivariate data analysis plays an increasingly important role for extraction of 
biomarkers, which are used for clustering and classification of samples from spectral datasets. 
The extraction of such markers is one of the important steps in the interpretation of group 
differences to detect the presence of certain diseases or identify their stages (Kelly et al., 
2011). 
 
 
6.5.3. Sensitivity and Specificity 
In medical practice, to measure the power of a diagnostic test for correctly prediction a 
particular medical condition, sensitivity and specificity are commonly used (Stone et al., 
2004). According to Van Belle et al. (2004), the sensitivity of a diagnostic test is the 
percentage of subjects with a disease who are classified positively with that disease. A 
diagnostic test is considered to be sensitive when the majority of subjects are positively 
classified with a disease. Specificity is the percentage of subjects having no disease, who are 
correctly classified as such. A highly specific test is when a small percentage of subjects are 
diagnosed positively with disease and most of them are without a disease (Stone et al., 2004). 
Using conventional histopathology as the standard for testing the ability of RS in tissue 
classifications, Raman assignment is classified as true positive or true negative when the is an 
agreement between both the diagnostic test and the spectral prediction; or Raman assignment 
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is classified as false positive or false negative when there is no agreement between them 
(Mahadevan-Jansen et al., 1998). 
 
 
6.3.9. Biological Tissue Applications of Raman Spectroscopy 
Since the early 1990s many research groups have used RS as a biospectroscopic diagnostic 
tool to differentiate normal from malignant cells in several different tissues (Kendall et al., 
2009). Recently, with the development of instrumentation and analytical technologies, much 
progress has been made and researchers have started to consider changes at very early stages 
of dysplasia, moving toward early detection and classification of different stages of dysplastic 
features. RS may be regarded as a system of choice with a diversity of applications. This is 
mostly due to its high sensitivity to subtle molecular alterations, minimal sample preparations 
with no need for tissue fixation, labelling or staining as well as easily used for in situ, remote 
examination via fibre optic probe (Baena and Lendl, 2004). It has the ability to provide an 
enormous amount of information on many specific chemical bonds present in the investigated 
tissue (Wachsmann-Hogiu et al., 2009).  
 
Studying biological tissues using RS is quite different from other types of samples. The 
reasons for that have been addressed by Manoharan and colleagues (1996) as follow: 
1) Due to inhomogeneity in tissue composition and high scattering (tissue fluorphorse). 
2) Because Raman signals are inherently weak and detection of early stage of disease that 
might be associated with low concentration of molecular constituents, requiring high intensity 
laser light excitation to acquire weak signals with high possibility of sample degradation. 
3) The complexity of biological tissue with absorption of light throughout the visible 
spectrum causes auto-fluorescence emission which strongly interferes with Raman spectra.  
 
However, such problems have been recognised and treated with new technology and 
instrumentations such as sensitive detectors, spectrographs, laser light sources and automated 
fluorescence subtraction with multivariate statistical data analysis. 
 
Thus, RS is shown to be a promising diagnostic tool for discriminating normal from 
dysplastic or cancerous tissue, in both in vivo or in vitro samples analysis of cellular 
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constituents and metabolites of epithelial cell changes in different anatomical sites (Stone et 
al., 2002b) providing a great patient benefit for an early, rapid and accurate diagnosis with the 
most important clinical implementation being in vivo application via optical fibres. From this 
a great deal has been learned and extensive spectral library datasets now exist. 
 
Table 6.2 summarises key Raman assignments within various biological tissues to help 
discriminate pathological from morphologically normal tissue spectra. 
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Table 6.2: Key Raman assignments of different biological tissues. 
Type of tissue Key Raman assignments References 
Skin 
800–1000 cm
-1
 (amino acids proline, valine and 
polysaccharides) were observed with marked loss of 
intensities in basal cell carcinoma (BCC) compared to 
normal skin; 1220–1360 cm
-1 
(secondary proteins structure) 
showed higher intensity in BCC 
(Gniadecka et al., 1997) 
1660 cm
-1
 (amide I of protein) can differentiate melanoma 
from the other types of tissue  
(Gniadecka et al., 2004) 
Lung  
Amide I (~1670 cm
-1
) and CH2 bend mode of (1450 cm
-1
) 
differentiate between normal and cancerous tissues; 1490 
and 1449 cm
-1
 (CH2 bend mode) differentiate between 
squamous cell carcinoma and adenocarcinoma  
(Kaminaka et al., 2002) 
Higher percentage signals for nucleic acids, tryptophan, and 
phenylalanine, and lower percentage signals for 
phospholipids, proline, and valine in tumours compared to 
normal tissues 
(Huang et al., 2003b) 
Oesophagus  
Increased levels of glycogen in normal tissue compared with 
increased DNA and protein levels in the dysplastic tissue 
areas 
(Shetty et al., 2006) 
Breast  
Diseased breast tissue showed spectra similar to collagen 
with weaker lipid bands compared to normal 
(Frank et al., 1995) 
(Frank et al., 1994) 
Normal breast tissue is primarily composed of lipid, while the 
amount of collagen increased in all abnormal breast tissues 
(Haka et al., 2005) 
A strong presence of lipids in normal, collagen in benign and 
DNA in malignant breast tissues 
(Chowdary et al., 2009) 
Stomach 
1200–1500 cm
-1
 (amide III and amide I of proteins) and 
1600–1800 cm
-1
 (CH3 CH2 twisting of proteins nucleic acids, 
and the C=C stretching mode of phospholipids) can 
differentiate between normal and dysplastic tissues  
(Teh et al., 2008) 
848–917, 960–1015, 1088–1133, 1206–1213, 1277–1313, 
1395–1445, 1517–1549, 1607-1690, and 1714-1767 cm
-1
, 
which are mainly assigned to proteins, lipids and porphyrin 
can differentiate between different gastric tissues 
(Teh et al., 2010b) 
850-1150 cm
-1
 (proteins), 1200-1500 cm
-1
 (nucleic acids) 
and 1600-1750 cm
-1
 (lipids) bands identified between 
normal tissue and the two gastric adenocarcinoma subtypes 
(Teh et al., 2010a) 
Cervical/ovarian 
1070 cm
-1
 (collagen) and 1656 cm
-1
 (amide I) can 
differentiate non-precancerous from precancerous, both 
were found to be greater in non-precancerous compared to 
precancerous; 1454 cm
-1
 (phospholipids), 1330 cm
-1
 (DNA) 
and 978 cm
-1
 (glucose-1 phosphate) were found to be 
increased in cervical precancerous 
(Mahadevan-Jansen et 
al., 1998) 
1330, 1454 and 1650 cm
-1
 average intensities increase as 
tissue progressed from normal to high-grade dysplasia 
(Utzinger et al., 2001) 
Normal and benign tissues dominated by proteins and lower 
concentrations of DNA and lipids compared to malignant 
tissue  
(Krishna et al., 2007a) 
Laryngeal  
850-950 cm
-1
 and 1200-1350 cm
-1
 assigned to protein 
conformation and C-H bond stretch in nucleic acid bases 
can differentiate normal, dysplastic and squamous cell 
carcinoma 
(Stone et al., 2000) 
Oral  
Normal tissue spectra originated from the lipid bi-layer 
cellular membrane, while inflammatory or cancerous cells 
dominated with protein spectra, related mainly to antigens, 
antibodies and DNA from the proliferating cells with large 
amount of surface proteins 
(Malini et al., 2006) 
(Venkatakrishna et al., 
2001) 
(Krishna et al., 2004) 
 
 516 
 
Oral Tissue 
The efficacy and potential application of RS technique in oral cancer and PMDs has been 
well demonstrated using various statistical approaches to exploit the subtle differences for 
diagnosis (Ghanate et al., 2011). Malini et al. (2006) applied RS to discriminate among 216 
oral tissue spectra from 10 premalignant, 90 malignant, 37 inflammatory and 79 normal 
tissue samples. Specimens were placed in ice-cold saline and stored at -80 ºC. Spectra were 
collected after samples were passively thawed. Noticeable differences in spectral profiles 
were observed; normal tissue spectra originated from the lipid bi-layer cellular membrane, 
while inflammatory or cancerous cells dominated with protein spectra which are mainly 
related to several proteins on the cell surface. Although PCA scores discriminated normal 
from all other pathologies, poor discrimination was observed among the three disease sates. 
While combining PCA with multiparameter tests, all four tissue groups could be 
differentiated and diagnosed. Venkatakrishana et al. (2001) analysed oral tissue samples 
obtained from biopsy or surgical resection. Tissue from normal and squamous cell 
carcinomas were kept in saline and spectra were measured within half an hour of tissue 
removal. More than 140 spectra were acquired from different tissue sites and classified into 
normal and malignant sets and then subjected to PCA. The results showed that spectra could 
be classified into normal and malignant groups, with sensitivity and specificity of 90 test 
spectra were greater than 85% and 90%, respectively. Further spectroscopic work on oral 
tissue has been performed by Krishna and co-workers (2004). Oral tissues from normal and 
carcinoma were taken from biopsies fixed in formalin and stored at room temperature for two 
months. Spectra were collected from epithelial and subepithelial regions. The results showed 
significant differences between normal and malignant epithelial tissues, with no 
subepithelium spectral differences. The major differences between normal and malignant 
tissue spectra related to conformational changes in proteins that related mainly to 
contributions of antigens, antibodies and DNA from the proliferating cells with large amount 
of surface proteins. PCA showed very good discrimination between malignant and normal 
tissue spectra indicating the suitability of formalin-fixed tissues for optical pathology in oral 
oncology. 
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6.3.10. Fibre Optic Probe 
As the Raman spectrum is not affected by water in biological tissue, it is considered as an 
appropriate possible future tool for portable equipment for in situ optical diagnosis (Santos et 
al., 2005; Beljebbar et al., 2009). Raman optical fibre is quite useful to measure the spectra in 
an optimal natural tissue condition providing valuable diagnostic information in a very short 
time (seconds) (Bakker Schut et al., 2000), not only from the surface, but also several 
microns deep (Zenone et al., 2006). The oral cavity is easily accessible for clinical 
examination and may be considered as ideal for the use of a Raman fibre optic probe for the 
purpose of early detection and diagnosis of oral pathologies.  
 
With technical improvement, such as efficient lasers, detectors and advanced statistical 
multivariate data analysis, RS combined with data algorithms can be used routinely and 
objectively for optical diagnosis of oral pre-cancer and cancer through application of small 
portable optical fibre probes which can accurately collect tissue spectra in situ (Motz et al., 
2005; Guze et al., 2009). The first promising in situ application was conducted on rat oral 
palatal mucosa by Bakker Schut et al. (2000) who reported a sensitivity of 93% and a 
specificity of 78% in detection of low grade dysplasia and sensitivity and specificity of 100% 
for detection of high grade-dysplasia and CIS. 
 
Since fibre optic probe materials have high Raman signal in the fingerprint region of Raman 
(800-1800 cm
-1
), in which many molecular vibrations scatter and produce Raman spectra, it 
may hinder the fingerprint spectra causing difficulties in differentiating Raman tissue spectra 
from background spectra (Utzinger et al., 2001; Koljenovic et al., 2005; Santos et al., 2005). 
To overcome such a problem, separate excitation and collection paths were designed (Santos 
et al., 2005). Also, materials used for optical probe construction should be considered for 
their fluorescence and optical properties (Utzinger and Richards-Kortum, 2003). Many 
optical fibres have been tested commercially for the best suitability for in situ use considering 
the time and irradiation powers for safety and practicality (Utzinger et al., 2001). Due to low 
hydroxyl groups (OH) in its core material (Santos et al., 2005), silica core-silica clad fibres, 
an acrylate coating and a black nylon jacket probe is found to be the most applicable for in 
vivo application. Although the noise problem persists in the fingerprint area, researchers tried 
to use high frequency region 2400–3800 cm-1 where there is only small background signal 
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contribution (Santos et al., 2005). This region has less Raman spectra; however, a significant 
achievement has been obtained utilizing C-H stretching bands close to 3000 cm
-1
 to 
differentiate between various tissue types (Guze et al., 2009). Different optical probes have 
been used with the Raman spectrometer using filters placed at or near the distal end of the 
optical fibre to reduce the contribution of the background signals (Koljenovic et al., 2005). 
Regarding the laser excitation used and according to Hutchings (2009), with NIR 
wavelengths thermal damage is possible, however, UV irradiation should be avoided because 
it breaks DNA strands. 
 
Fibre optic probe can serve effectively as an adjunct to clinical examination may be of great 
benefit in clinic as a non-invasive, objective real-time diagnostic tool and for patient follow-
up. This may include biopsy targeting by identifying the high risk area to eliminate random 
biopsies and reducing sampling errors (Beljebbar et al., 2009) as well as assessment of 
surgical margins during surgery. 
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6.6. Materials and Methods 
6.6.1. Preparation of Oral Tissue Samples 
All of the samples used in this study (n=32) were taken from the FOM; the most common 
oral sub-site affected by PMDs. The samples were selected from previously FFPE laser 
excised samples housed in the Royal Victoria Infirmary (RVI) histopathology archive. These 
blocks had been stored in the archive between 1999 and 2009. 
 
Using haematoxylin and eosin (H and E) stained sections taken at diagnosis of samples that 
showed epithelial dysplasia with adjacent normal epithelium were selected. The FFPE blocks 
were then retrieved and 10 m thick specimens were cut using a microtome (Olympus 
microtome) in the pathology department of the RVI. For every case, two adjacent sections 
were cut. The first section, to be used for the Raman analysis, was mounted onto a 20 mm x 
20 mm x 0.5 mm barium fluoride (BaF2, Photox Optical Systems Ltd, Sheffield, UK) window 
which was then dried overnight. The second section was mounted onto a glass slide and 
stained with H and E. Typical examples of the two sections are shown in Figure 6.4. 
The purpose of this second H and E stained section was two-fold. Firstly, at least two oral 
pathologists independently assessed the tissue to grade the epithelial dysplasia using two 
separate classification systems; namely the WHO classification system (Gale et al., 2005) 
(mild, moderate, severe dysplasia and CIS) and a novel binary grading system; (high and low 
grade dysplasia) (Kujan et al., 2006); Figure 6.5. Where disparity between classifications was 
found between the pathologists, both pathologists reviewed the sections together a second 
time and a consensus grade agreed. Once this grade had been decided for all sections, the 
areas on the H and E slides relating to epithelial dysplasia and morphologically normal 
epithelium were marked by one of the pathologists, so that the areas for Raman analysis 
could be identified on the parallel BaF2-mounted section. 
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Figure 6.4: Typical examples of (A) a H & E stained section and (B) BaF2 mounted 
specimens as used in this study. 
 
 
 
Figure 6.5: Tissue samples details. 
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The paraffin used to mount the archived samples has a characteristic Raman spectrum, which 
has been shown to affect the spectra of tissue samples (Manoharan et al., 1996; Glawdel et 
al., 2009). Consequently, before Raman analysis all tissue sections on the BaF2 windows 
were de-waxed using the following protocol: 
1. Immersed in a sealed glass bath containing 60 ml of n-hexane (3 pg/ml impurities, 
Merck, Germany) for 5 minutes. 
2. Immersed in a sealed glass bath containing 60 ml ethanol (99.8%, Fisher Scientific, 
UK) for 5 minutes. 
3. Placed overnight in an oven (25 °C) to allow to fully dry. 
4. Stored in a sealed desiccator containing silica gel beads until analysis.  
 
 
6.6.2. Spectroscopic Instrumentation  
All of the Raman analyses were conducted using a LabRam HR Raman spectrometer 
(HORIBA Scientific, France), shown in Figure 6.6. The spectrometer was equipped with a 
coherent diode pumped solid-state continuous wave-frequency doubled Nd:YAG laser 
(neodymium-doped yttrium aluminium garnet; Nd:Y3Al5O12) operating at 532 nm. The 
intensity of the Raman signal with respect to the frequency (wavenumber) was detected with 
a CCD detector. A diffraction grating of 600 grooves per mm and confocal-hole diameter of 
250 µm was selected as measuring parameters for the experiments. The Raman microscope 
was equipped with a motorized (xyz) sample stage for automatic scanning of tissue mapping 
points. The instrument was controlled using Lab Spec 5 control software (HORIBA 
Scientific, France). 
 
The wavelength calibration of the Raman spectrometer was performed using the centre 
frequency of the silicon band from silicon wafer sample 520.7 cm
-1 
with a signal 
accumulation of 1 second. 
 
With the H and E stained specimen placed in one light microscope (VWRI, ML 200) used to 
identify the correct experimental, each unstained BaF2-mounted specimen was mounted in a 
specifically manufactured holder (Figure 6.7) and positioned in the Raman spectrometer, 
using a 10x lens (Olympus) so that the area of interest was in the centre of the visual field. 
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Once in place, a series of locations on the basal epithelium were selected, using the attached 
software, for each area (10-12 per location) as the locations from which spectra would be 
measured. Once this was complete, the lens was swapped for a 50x lens (Leica with 
numerical aperture (NA) of 0.55) to focus the laser onto the specimen (spot size 
approximately 1.5 m in diameter, with an approximate laser power at the sample surface of 
2.5 mW).  
 
Preliminary investigation revealed that some specimens exhibited strong fluorescence 
background signals. As has been previously shown (Mahadevan-Jansen and Richards-
Kortum, 1996; Petry et al., 2003; Krafft, 2004; Gobinet et al., 2007; Harris et al., 2009b) 
these can result in a reduced spectral quality. Consequently, a standard protocol, to be used 
for each specimen, was developed to reduce this fluorescence contamination by exposing the 
specimen to the laser light before acquiring spectra; a process previously termed photo-
bleaching (Mahadevan-Jansen and Richards-Kortum, 1996). For the present study, an 
exposure time of 120 seconds was found, in a preliminary study, to reduce this fluorescence 
signal sufficiently to allow no obvious contribution in the spectrum. Consequently, this 
photo-bleaching procedure was used for all specimens in the study. 
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Figure 6.6: (A) The Raman system set up used for all experiments, (B) the confocal 
microscope unite with a close-up of a specimen in place with the laser focussed on the 
specimen. 
 
 
 
 
 
 
 
Figure 6.7: Specifically designed holder for BaF2 windows. 
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6.6.3. Collection of Spectra 
Upon completion of the bleaching period, the specimen was orientated under the optical 
microscope so that the relevant region (either dysplastic or morphologically normal) could be 
identified. Next, a series of points (10 ≤ n ≤ 30) along the basal epithelial layer, within the 
boundaries indicated by the pathologists for each region, was selected using the spectrometer 
software (Lab Spec), a typical example of which is shown in Figure 6.8. These points marked 
the locations from which spectra were obtained. For dysplastic regions, the spectra were 
recorded from the central region within the boundaries indicated by the pathologists in the 
relevant adjacent section for dysplasia. For the morphologically normal epithelium, spectra 
were recorded at the excision margins. 
 
Once the points had been selected, spectral acquisition was commenced with each point 
analysed automatically using the software. All spectra were measured over the spectral range 
of 800 to 1800 cm
-1
. At each point two co-added spectra were measured, each collected over 
30 seconds. 
 
 
 
 
Figure 6.8: Typical optical image with points for measuring spectra marked by blue 
triangles. 
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Table 6.3 and Table 6.4 summarise the tissue samples classified according to WHO and 
binary grading systems, number of patient in each group, demography and number of Raman 
spectra used in the analysis. 
 
 
 
Table 6.3: Histopathological diagnosis according to WHO (2005) with number of 
spectra used in the data analysis. 
Histopathology 
group 
N 
Sex Mean 
age/range 
(years) 
Number of spectra 
Total 
M F Dysplastic 
Morphologically 
normal 
Mild 12 3 9 51 (33-71) 134 110 244 
Moderate 10 5 5 58 (40-77) 79 93 172 
Severe 6 4 2 57 (39-76) 83 107 190 
CIS 4 1 3 58 (52-63) 90 82 172 
Total 32 13 19 55 (33-77) 386 392 778 
 
 
 
Table 6.4: Histopathological diagnosis according to the binary system with number of 
spectra used in the data analysis. 
Histopathology 
group 
N 
Sex Mean age 
in years 
(range) 
Number of spectra 
Total 
M F Dysplastic 
Morphologically 
normal 
High grade 18 11 7 58 (39-77) 253 255 508 
Low grade 14 4 10 51 (33-71) 147 123 270 
Total 32 15 17 55 (33-77) 400 378 778 
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6.6.4. Data Processing  
Once the spectra had been collected it was necessary to process them to remove a series of 
environmental components common to all Raman spectra but not related directly to the real 
tissue spectra. Consequently, a number of procedures were used after acquisition before the 
spectra could be analysed, summarised in Figure 6.9 and detailed below. 
 
First, all spectra were assessed visually for detector saturation. Those spectra found to have a 
flat line in all, or part of, the spectral range were excluded from the data set. A typical 
example of a spectrum with and a spectrum without detector saturation are shown in Figure 
6.10. Next all the remaining spectra were loaded into one file (Excel 2007, Microsoft) and the 
mean spectrum calculated. This mean spectrum was then subtracted from each individual 
spectrum to eliminate the majority of the variation between the spectra. 
 
Careful observation of the spectra after mean centring revealed that a number of spectra 
exhibited systematic shifts in the locations of all of the peaks, a typical example of spectra 
exhibiting this are shown in Figure 6.11. Using the CH2 scissoring peak at 1450 cm
-1
 as a 
datum, the spectra were edited in Excel so that the peaks lined up with the correct 
wavenumber. Those spectra that were corrected in this manner were noted down in case this 
process was subsequently found to affect the data. 
 
All Raman spectra measured from biological tissue are affected by a background spectrum, 
mostly due to tissue fluorescence and the laboratory environment, which can be several 
orders of magnitude more intense than the actual tissue spectrum. Consequently, after the 
spectra were aligned the data file was loaded in MatLab (v R2008a, Mathworks, Cambridge, 
UK) to allow the removal of this background. The correction was done by selecting local 
minima in the spectra by eye and then conducting linear interpolation between these points. 
Figure 6.12 (A) shows the original spectrum collected from the resection margins of mild 
dysplasia (morphologically normal) and (B) baseline corrected.  
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Figure 6.9: Data processing. 
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Figure 6.10: Example of unprocessed spectra showing (A) saturation and (B) without 
saturation. 
 
 
 
Figure 6.11: Example of calibration shift in spectra; as determined by a consistent x-
axis offset compared to majority of the spectra. 
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Figure 6.12: Raman spectra acquired from morphologically normal tissue at the 
resection margins of mild dysplasia sample; (A) original spectra (B) background 
corrected spectra. 
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After baseline correction it was clear that there were spectra in which the signal to noise ratio 
was low, with many of the spectral features obscured by noise. Using PCA, the average 
intensity of the CH2 scissor mode (1450 cm
-1
) was used to define three threshold intensity 
values: 250, 500, and 750 counts; Figure 6.13 (A), (B) and (C). 
 
Only data above the threshold of 750 counts which eliminates all the noisiest signals that 
affect the performance of the data set (masking the features of the real Raman spectra) were 
included in further data analysis. 
 
After that the data were assessed for outliers, using Hotelling’s T2 test in PCA (Unscrambler, 
v 9.7 Camo, Oslo, Norway) to identify potential strong outliers (outliers that are the most 
different from the rest of the data set) and the use of sample leverage (distance from model 
centre) and residual variance (distance to model plane) to identify weak outliers (outliers that 
having the biggest undue influence on the model generation).  
 
These data were then normalised against the mean intensity, between 1435 cm
-1
 and 1480 cm
-
1
, corresponding to the full width at half maximum for the CH2 scissoring mode, centred at 
approximately 1450 cm
-1
. The next step in data processing was to average the spectra by 
patient and by tissue type, as dysplastic and morphologically normal tissue groups. 
 
The spectra were reviewed blind to the case so that no bias would be caused during these 
selection procedures. This was true of all processing steps and that is why the full raw data 
set was inserted into one file for the processing. After all spectral exclusion, the total number 
of spectra was reduced to 778 spectra, from an initial collected 1045 spectra. 
 
Regarding tissue classification, once the data processing was complete, the fully processed 
data were analysed with PLS-DA using SIMCA (SIMCA P 8.0, Umetrics, Umea, Sweden) 
and a series of models were generated to discriminate between different groupings. Partial 
least square analysis components (PLSCs) were calculated to maximise the co-variance 
between the data and the groupings, so that the models simultaneously described information 
contained in both the spectra and the group assignments. The significance of the classification 
by each PLS component was assessed using “Quality of model fit” (Q2). 
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To highlight the differences between spectra, a representative average spectrum of each 
group of dysplastic and morphologically normal tissue with their subtraction spectrum was 
plotted using Lab Spec spectroscopy suite (HORIBA Scientific, France). To improve the 
spectral clarity and for presentation purposes only, spectra were lightly smoothed by fitting a 
fourth order polynomial through adjacent 9 pixel segments of the spectra; care was taken to 
ensure that no spectral information was lost during this processing. 
 
 
 
 
Figure 6.13: Three threshold intensity values overlaid from PCA loading (PC1): (A) 250 
counts, (B) 500 counts, (C) 750 counts which eliminates all the noisiest signals. 
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6.6.5. Raman Data Analysis  
A representative spectrum of each patient and each group of patient was obtained by 
calculating the mean spectrum of the collected spectra. To compare between the groups, peak 
relative intensity, peak position and other spectral features were considered. 
 
Normality tests were performed using the Shapiro-Wilk test to check the distribution of 
spectral data. Spectral data were found to be not normally distributed, as the Shapiro-Wilk p-
value was less than the chosen alpha level (0.05). Therefore, a nonparametric test, which does 
not assume that the data are normally distributed was used. The Mann-Whitney U test; to 
determine the statistical significance of differences on the mean value in relative peak 
intensities for each pair of groups (pairs-wise comparisons) and Kruskal-Wallis test to test for 
significance of groups separation were used. 
 
To quantify the intensity differences between the study groups at the identified peaks, 
univariate statistical techniques based on single-peak intensities were used in this study. 
SPSS (Statistical Package for Social Sciences) version 19.0 software package (SPSS Inc.; 
Chicago, IL, US) was used in this study. The probability (p-value) of less 0.05 was used to 
represent real significant structural differences. 
 
Regarding Raman tissue classification, the performance was quantified using a sensitivity and 
specificity test (Mahadevan-Jansen et al., 1998). Using histopathological diagnosis as a gold 
standard, Raman assignment was classified as true positive or true negative when there is an 
agreement between both the diagnostic test and the spectral prediction or classified as false 
positive or false negative when there is no agreement (Mahadevan-Jansen et al., 1998; Stone 
et al., 2004). These can be calculated as below: 
            
  
     
 
TP is the number of true positives 
FN is the number of false negatives 
 
            
  
     
 
TN is the number of true negatives 
FP is the number of false positives 
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6.7. Raman Results  
Two grading systems were used to group the tissue specimens, the WHO classification 
system (Gale et al., 2005) of mild, moderate, severe dysplasia and CIS, and the binary scoring 
system of high/low grade dysplasia (Kujan et al., 2006). 
 
No spectral contamination from formalin was observed, confirmed by the absence of very 
strong formalin bands at 907, 1041 and 1492, cm
-1 
(Shim and Wilson, 1996; Huang et al., 
2003a; Krishna et al., 2004; Krishna et al., 2007a). Also, no strong paraffin contribution was 
observed in Raman spectra at 1062, 1296 and 1441 cm
-1 
(Ó Faoláin et al., 2005b), indicating 
an effective de-waxing protocol used in this study. Mean spectra were calculated for each 
group to allow the identification of the important Raman peaks for each tissue type.  
 
 
6.7.1. Practical Considerations for Sample Mounting 
Two potential specimen substrates were considered, conventional silicate glass and BaF2. The 
former routinely used in histopathology labs, the latter are routinely used by IR and Raman 
spectroscopists for tissue analysis. Tissue specimens mounted on glass slides were not 
suitable for Raman study due to the relatively strong Raman signal of glass which masked 
any contribution from tissue components; Figure 6.14. Consequently, BaF2 was chosen for 
use as a substrate for the Raman tissue measurements. This material has no Raman signature 
within spectral range of the biological tissue samples (800-1700 cm
-1
) (Gobinet et al., 2009) 
and has only one Raman peak at approximately 242 cm
-1
 (Chen and Shen, 2006) minimising 
the contamination of the tissue spectrum by the slide; Figure 6.15. 
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Figure 6.14: Typical spectrum for (A) bare glass and (B) an oral tissue spectrum 
mounted on a glass slide. 
 
 
Figure 6.15: Typical oral tissue spectrum mounted on barium fluoride substrate. 
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6.7.2. Raman Spectra 
Mild Dysplasia Tissue Specimens 
The mean spectra for morphologically normal and mild dysplastic tissue specimens are 
shown in Figure 6.16 and Figure 6.17, respectively. In general, the spectra for the two tissue 
types exhibited the same shape, with the key peaks for each tissue type with their relative 
intensities summarised in Table 6.5 using the peak identification routine in Lab Spec. 
 
Careful analysis of the spectra showed clear intensity differences in some regions indicating a 
biochemical tissue changes between the two types of tissue. To better show these key 
differences, spectra overlaid and the difference spectrum was constructed, where the 
morphological normal mean spectrum was subtracted from the mild dysplastic mean 
spectrum; Figure 6.18. The morphologically normal tissue spectrum exhibited more intense 
peaks in the region at 859-967 cm
-1
 (amino acids), 1022-1105 cm
-1
 (glycogen, proteins and 
nucleic acids), 1301 cm
-1
 (CH2 deformation lipids) and 1423 cm
-1
 (nucleic acids). Whereas, 
the mild dysplastic tissue specimens showed a higher intensity of phenylalanine protein at 
1009 cm
-1
 and in the peaks of the region at 1135-1661 cm
-1
. In this region, differences 
between the two tissue types were seen at 1317 and 1347 cm
-1
 (nucleic acids bases and C-H 
deformation proteins), 1377 cm
-1
 (amino acids CH3 deformation), 1591 cm
-1
 (C=C olefinic 
stretch of lipids), 1609 cm
-1
 (aromatic amino acid of proteins) and 1661 cm
-1
 (amide I of 
protein). However, only the difference in intensity of the symmetric ring breathing mode of 
phenylalanine at 1009 cm
-1
 was found to be significantly more intense in mild dysplastic 
tissue specimens compared to morphologically normal tissue (0.642 vs. 0.557) (p=0.001; 
Mann-Whiney U test); Table 6.6. This indicates a major contribution from proteins in 
dysplastic tissue spectra. 
Peaks such as 1251 cm
-1
 and 1272 cm
-1
 (amide III of protein), 1288 cm
-1
 (phosphodiester 
groups in nucleic acids) and 1600 cm
-1
 (proteins assignment of phenylalanine and tyrosine) 
occurred in morphologically normal tissue, but were absent or very weak in the mild 
dysplastic tissue specimens indicating a degradation or disordering of these cellular 
components in mild dysplasia compared to normal tissue specimens. 
 
An average spectrum of morphologically normal and mildly dysplastic tissue from each 
patient in this group (n=12) can be seen in the Appendix (2-A). 
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Figure 6.16: Mean Raman spectrum of morphologically normal tissue of mild dysplasia 
specimens (n=110 spectra). 
 
 
 
Figure 6.17: Mean Raman spectrum of mild dysplastic tissue (n=134). 
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Table 6.5: Peak position and relative intensity for mild dysplasia and morphologically 
normal tissue mean spectra. 
Morphologically normal tissue spectra 
(Mn) 
Mild dysplastic tissue spectra  
(Md) 
Spectral features 
Peak position 
(cm-1) 
Intensity 
(a.u) 
Peak position 
(cm-1) 
Intensity 
(a.u) 
839 0.040 834 0.047 Higher intensity in Md 
859 0.215 859 0.180 Higher intensity in Mn 
872 0.100 874 0.088 Higher intensity in Mn 
882 0.082 886 0.087 Higher intensity in Md 
901 0.069 902 0.076 Higher intensity in Md 
920 0.029 925 0.019 Higher intensity in Mn 
937 0.044 938 0.026 Higher intensity in Mn 
948 0.029 944 0.010 Higher intensity in Mn 
967 0.030 968 0.013 Higher intensity in Mn 
1009 0.557 1009 0.642 Higher intensity in Md 
1022 0.279 1020 0.269 Higher intensity in Mn 
1039 0.446 1039 0.417 Higher intensity in Mn 
1048 0.393 1050 0.365 Higher intensity in Mn 
1068 0.530 1066 0.472 Higher intensity in Mn 
1084 0.337 1086 0.310 Higher intensity in Mn 
1105 0.244 1103 0.216 Higher intensity in Mn 
1137 0.375 1135 0.381 Higher intensity in Md 
1177 0.202 1177 0.263 Higher intensity in Md 
1213 0.338 1214 0.364 Higher intensity in Md 
1235 0.409 1237 0.443 Higher intensity in Md 
1243 0.429 1245 0.447 Higher intensity in Md 
1251 0.379 - - Missing in Md 
1272 0.148 - - Missing in Md 
1288 0.021 - - Very weak in Md 
1301 0.294 1301 0.267 Higher intensity in Mn 
1320 0.180 1317 0.243 Higher intensity in Md 
1347 0.292 1347 0.399 Higher intensity in Md 
1378 0.323 1377 0.375 Higher intensity in Md 
1407 0.425 1407 0.443 Higher intensity in Md 
1423 0.554 1423 0.552 Higher intensity in Mn 
1454 1.220 1454 1.231 Higher intensity in Md 
1536 0.070 1536 0.098 Higher intensity in Md 
1592 0.654 1591 0.883 Higher intensity in Md 
1600 0.654 - - Missing in Md 
1609 0.663 1609 0.766 Higher intensity in Md 
1660 0.988 1661 1.080 Higher intensity in Md 
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Figure 6.18: Overlaid normalised mean spectra for morphologically normal and mild 
dysplastic tissue with the difference spectrum beneath. 
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Table 6.6: Main Raman bands and assignments in mild dysplasia and morphologically 
normal tissue with p-value resulting from Mann-Whitney test comparison of the relative 
peak intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
834- 839 
Out of plane breathing 
Tyrosine, O-P-O 
stretching of nucleic 
acids 
0.974 1135-1137 
C-N protein 
CO, CH3 (lactic acid) 
0.818 
859 
Molecular vibration mode 
of proteins mainly 
Tyrosine and C-C stretch 
0.224 
 
1177 Cytosine, Guanine 0.082 
872-874 
Hydroxyproline, 
tryptophan 
0.158 
 
1213-1114 
Amide III, Tryptophan 
and phenylalanine, 
Tyrosine, Thymine, 
Cytosine, Adenine. 
0.768 
882-886 Tryptophan (protein) 0.375 
 
1243-1245 
Amide III, disorder 
structure of proteins, 
collagen 
0.922 
920-925 
C-C stretch of proline 
ring, glucose, lactic acid 
0.375 
 
1301 
CH2 deformation 
(lipids) 
0.818 
937-938 
C-C stretching mode of 
proline, valine, protein 
backbone (α-helix 
conformation), collagen 
0.491 
 
1317-1320 
Guanine ring breathing 
modes of DNA/RNA 
bases, protein C-H 
deformation 
0.450 
944-948 
CH3 rock, olefinic CCH 
deformation, CH3 α-helix 
0.491 
 
1347 
CH2 twisting and 
bending in protein, 
lipids, nucleic acids 
0.533 
967-968 Lipids 0.158 
 
1377-1378 
Thymine, Guanine, 
Adenine amino acids 
CH3 deformation 
0.974 
1009 
Symmetric ring breathing 
mode of phenylalanine 
(proteins) 
0.001 
 
1407 
A symmetric stretching 
carboxylate (IgG) 
0.922 
1020-1022 Glycogen 0.818 
 
1423 
Adenine, Guanine, 
backbone CH2 
0.974 
1039 Phenylalanine of collagen 0.412 
 
1454 
Collagen & 
phospholipids 
0.922 
1048-1050 Glycogen 0.450 
 
1536 C=C carotenoid 0.200 
1066-1068 
C-C, C–N stretching 
mode of proteins; C–C 
stretch lipids; O-P-O 
stretch nucleic acids;  
C-O DNA/RNA 
0.491 
1591-1592 
C=C stretch olefinic of 
lipids 
0.341 
 
1609 
Aromatic amino acid 
(proteins) 
0.450 
1103-1105 
Collagen C–C stretch, 
O-P-O-stretching 
DNA/RNA, 
C-C stretch lipid 
0.974 
 
 
1660-1661 Amide I protein 0.577 
 540 
 
Moderate Dysplasia Tissue Specimens 
The mean spectra for morphologically normal and moderate dysplastic tissue specimens are 
shown in Figure 6.19 and Figure 6.20. Overall, the spectra for the two tissue types were quite 
similar, however relative intensity differences between the morphologically normal and 
moderate dysplastic tissue were observed, with the key peaks for each type of tissue 
summarised in Table 6.7. 
To clearly demonstrate the key differences between the two types of tissue, the spectra were 
overlaid and the difference spectrum was plotted in Figure 6.21. Although the majority of 
Raman peaks were more intense in morphologically normal tissue spectrum, the differences 
were only statistically significant at 1087 cm
-1
, which can be attributed to C-C stretch lipids 
(0.289 vs. 0.252) (p=0.001; Mann-Whitney U test); Table 6.8. 
 
The moderate dysplastic tissue specimens exhibited more prominent peaks particularly at 
1137 cm
-1
 (C-N stretching modes of protein), 1301 cm
-1
 (CH2 deformation lipids), 1322 cm
-1
 
(CH3CH2 deforming modes of collagen and nucleic acids), 1345 cm
-1
 (CH2 twisting and 
bending modes of proteins), 1448 cm
-1
 (lipids and nucleic acids) and 1658 cm
-1
 (CH2 
deformation proteins and amide I of protein). Notably, peaks such as 1315 cm
-1
 and 1457 cm
-
1
 (nucleic acids modes), 1623 cm
-1
 (tryptophan, phenylalanine) and 1673 cm
-1
 (tyrosine and 
amide I of protein) which are present in morphologically normal tissue were absent or very 
weak in moderate dysplastic tissue. 
 
An average spectrum of morphologically normal and moderate dysplastic tissue from each 
patient in this group (n=10) can be found in the Appendix (2-B). 
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Figure 6.19: Mean Raman spectrum of morphologically normal tissue of moderate 
dysplasia specimens (n=93). 
 
 
 
Figure 6.20: Mean Raman spectrum of moderate dysplastic tissue (n=79). 
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Table 6.7: Peak position and relative intensity of moderate dysplasia and 
morphologically normal tissue mean spectra. 
Morphologically normal tissue spectra 
(Modn) 
Moderate dysplastic tissue spectra 
(Modd) 
Spectral features 
Peak position 
    (cm-1) 
Intensity 
    (a.u) 
Peak position 
    (cm-1) 
Intensity 
    (a.u) 
835 0.065 835 0.082 Higher intensity in Modd 
862 0.207 859 0.181 Higher intensity in Modn 
879 0.156 - - Missing or very weak in Modd 
890 0.091 896 0.106 higher intensity in Modd 
924 0.028 929 0.052 Higher intensity in Modd 
936 0.0156 931 0.0317 Higher intensity in Modd 
946 0.0317 945 0.0009 Higher intensity in Modn 
974 0.007 971 0.024 Higher intensity in Modd 
1009  0.583 1009 0.552 Higher intensity in Modn 
1024 0.287 1023 0.189 Higher intensity in Modn 
1039 0.404 1037 0.326 Higher intensity in Modn 
1066 0.521 1068 0.480 Higher intensity in Modn 
1087 0.289 1084 0.252 Higher intensity in Modn 
1104 0.264 1101 0.214 Higher intensity in Modn 
1135 0.306 1137 0.378 Higher intensity in Modd 
1166 0.163 1166 0.158 Higher intensity in Modn 
1176 0.225 1174 0.223 Higher intensity in Modn 
1213 0.332 1214 0.283 Higher intensity in Modn 
1245 0.412 1243 0.393 Higher intensity in Modn 
1299 0.277 1301 0.364 Higher intensity in Modd 
1315 0.143 - - Missing in Modd 
1323 0.143 1322 0.220 Higher intensity in Modd 
1349 0.261 1345 0.336 Higher intensity in Modd 
1374 0.287 1375 0.282 Higher intensity in Modn 
1408 0.373 1403 0.314 Higher intensity in Modn 
1422 0.556 1424 0.499 Higher intensity in Modn 
1449 1.192 1448 1.244 Higher intensity in Modd 
1457 1.165 - - Missing in Modd 
1591 0.618 1591 0.656 Higher intensity in Modd 
1609 0.691 1609 0.628 Higher intensity in Modn 
1623 0.684 - - Missing in Modd 
1661 0.971 1658 0.977 Higher intensity in Modd 
1673 0.922 - - Missing in Modd 
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Figure 6.21: Overlaid normalised mean spectra for morphologically normal and 
moderate dysplastic tissue specimens with the difference spectrum beneath. 
 
 
 
 
 
 
 
1087 
C-C stretch lipids  
p=0.001 
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Table 6.8: Main Raman bands and assignments in moderate dysplasia and 
morphologically normal tissue with p-value resulting from Mann-Whitney test 
comparison of the relative peak intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
835 
Out of plane breathing 
Tyrosine, O-P-O 
stretching of nucleic 
acids 
0.974 1174-1176 Cytosine, Guanine 0.450 
859-861 
Molecular vibration 
mode of proteins mainly 
Tyrosine and 
C-C stretch 
0.224 
 
1213-1214 
Amide III, Tryptophan, 
phenylalanine, Tyrosine, 
Thymine, Cytosine, 
Adenine. 
0.491 
890-896 Backbone, C-C skeletal 0.158 1243-1245 
Amide III, disorder 
structure of proteins, 
collagen 
0.972 
 
924-929 
C-C stretch probably in 
amino acids, proline and 
valine  protein band 
0.375 1299-1301 CH2 deformation (lipids) 0.818 
 
971-974 
CH3, CCH olefinic 
(protein assignment) 
0.375 
 
1322-1323 
CH3 CH2 deforming 
modes of collagen, 
Guanine and nucleic 
acids 
0.082 
1009 
Symmetric ring 
breathing mode of 
phenylalanine (proteins) 
0.491 
 
1345-1349 
CH2 twisting-bending 
(protein, lipids) and  
nucleic acids 
0.768 
1023-1024 Glycogen 0.491 
 
1374-1375 
Thymine, Guanine, 
Adenine amino acids 
CH3 deformation 
0.922 
1037-1039 
Phenylalanine of 
collagen 
0.158 
 
1422-1423 
Adenine, Guanine, 
backbone CH2,, 
deoxyribose 
0.818 
1066-1068 
C-C and C–N stretching 
mode of proteins; C–C 
stretch lipids, O-P-O 
stretch (nucleic acids) 
C-O (nucleic acids) 
0.922 
 
1448-1449 CH2 CH3 deformation 0.450 
1084-1086 
C–C stretch, C-C stretch 
lipid, O-P-O nucleic acid 
0.001  1591 C=C stretch olefinic 0.922 
1101-1104 
Collagen C–C stretch, 
O-P-O-stretching 
(nucleic acids), C-C 
stretch lipid 
0.818 
 
1609 
Aromatic amino acid 
(proteins) 
0.974 
1135-1137 
C-N protein, CO, 
CH3 (lactic acid) 
0.412 
 
1661 Amide I protein 0.922 
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Severe Dysplasia 
Figure 6.22 and Figure 6.23 show the mean spectra of morphologically normal and severe 
dysplastic tissue specimens. In general, the two types of tissue showed the same shape with 
the identified key peaks for each type of tissue with their relative intensities summarised in 
Table 6.9. 
 
To carefully identify the differences between the two types of tissue, overlaid and the 
difference spectra were constructed; Figure 6.24. Although severe dysplastic tissue specimens 
exhibited higher relative intensity in the region between 1299 cm
-1
 and 1658 cm
-1
, which is 
mainly assigned to proteins and nucleic acids, the differences were only significant at 1344 
cm
-1
 (CH2 twisting/bending modes of proteins and nucleic acids) (0.333 vs.0.236) (p=0.011; 
Mann-Whitney U test); Table 6.10. In the same spectral region, the severe dysplastic tissue 
spectrum showed a lower intensity at 1421 cm
-1
 which is mainly attributed to CH2 scissoring 
vibration of lipids. The morphologically normal tissue specimens showed higher relative 
intensity in the majority of peaks between 859 cm
-1
 and 1243 cm
-1
, which can mainly give 
information about amino acids, proteins and nucleic acids; however, Mann-Whitney U test 
showed significant differences in relative peak intensity only at 1243 cm
-1
 (amide III β-sheet) 
(0.449 vs. 0.384) (p=0.018); Table 6.10. 
In the same spectral region, the morphologically normal tissue spectrum showed a lower 
intensity at 824, 963, 1009, and 1135 cm
-1
 mainly corresponding to proteins and amino acids. 
 
Further, peaks in morphologically normal tissue spectrum such as 1102 cm
-1
 (C-C stretching 
modes of lipids) and 1326 cm
-1
 (nucleic acids) were either absent or very weak in the severe 
dysplastic tissue spectrum. 
 
An average spectrum of each pair of morphologically normal and severe dysplastic tissue 
spectra of each patient in this group can be seen in the Appendix (2-C). 
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Figure 6.22: Mean Raman spectrum of morphologically normal tissue of severe 
dysplasia specimens (n=107 spectra). 
 
 
 
Figure 6.23: Mean Raman spectrum of severe dysplasia tissue specimens (n=83 spectra). 
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Table 6.9: Peak position and relative intensity of morphologically normal and severe 
dysplastic tissue mean spectra. 
Morphologically normal tissue spectra 
(Sn) 
Severe dysplastic tissue spectra 
(Sd) 
Spectral features 
Peak position 
     (cm
-1
) 
Intensity 
    (a.u) 
Peak position 
     (cm
-1
) 
Intensity 
    (a.u) 
824 0.021 829 0.048 Higher intensity in Sd 
859 0.177 859 0.124 Higher intensity in Sn 
963 0.001 961 0.016 Higher intensity in Sd 
1009 0.551 1007 0.594 Higher intensity in Sd 
1037 0.455 1035 0.376 Higher intensity in Sn 
- - 1045 0.337 Missing in Sn 
1052 0.415 1052 0.378 Higher intensity in Sn 
1066 0.560 1065 0.526 Higher intensity in Sn 
- - 1078 0.302 Missing in Sn 
1091 0.299 1085 0.280 Higher intensity in Sn 
1102 0.246 - - Missing in Sd 
1135 0.282 1135 0.348 Higher intensity in Sd 
1174 0.252 1174 0.255 Higher intensity in Sd 
- - 1190 0.128 Missing in Sn 
1213 0.356 1213 0.342 Higher intensity in Sn 
1243 0.449 1235 0.384 Higher intensity in Sn 
- - 1245 0.350 Missing in Sn 
1299 0.286 1299 0.293 Higher intensity in Sd 
1317 0.072 1315 0.195 Higher intensity in Sd 
1326 0.082 - - Missing in Sd 
1345 0.236 1344 0.333 Higher intensity in Sd 
1375 0.243 1375 0.312 Higher intensity in Sd 
1423 0.597 1421 0.499 Higher intensity in Sn 
1448 1.250 1446 1.260 Higher intensity in Sd 
1457 1.177 1458 1.201 Higher intensity in Sd 
1589 0.548 1589 0.617 Higher intensity in Sd 
1608 0.616 1609 0.636 Higher intensity in Sd 
1619 0.605 1620 0.611 Higher intensity in Sd 
1660 0.920 1658 0.925 Higher intensity in Sd 
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Figure 6.24: Overlaid normalised mean spectra for morphologically normal and severe 
dysplastic tissue with the difference spectrum beneath. 
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Table 6.10: Main Raman bands and assignments in severe dysplasia and 
morphologically normal tissue with p-value resulting from Mann-Whitney test 
comparison of the relative peak intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
824-829 
Out of plane breathing 
Tyrosine/ O-P-O stretching of 
nucleic acids 
0.100 
1213 
Amide III, Tryptophan, 
phenylalanine, 
Tyrosine, Thymine, 
Cytosine, Adenine. 
0.855 
859 
Molecular vibration mode of 
proteins mainly Tyrosine and  
C-C stretch 
0.144 
 1243-1245 
Amide III, disorder 
structure of proteins, 
collagen 
0.018 
892-898 Backbone, C-C skeletal 0.100 
 
1299-1301 
CH2 deformation 
(lipids) 
0.201 
923-927 
C-C stretch probably in 
amino acids ,proline & valine 
protein band 
0.361 1315-1317 
Guanine ring breathing 
modes of DNA/RNA 
bases, C-H 
deformation protein  
0.068 
 
945-946 C-C protein assignment 0.715  1344-1345 
CH2 twisting-bending 
(protein, lipids) and 
nucleic acids 
0.011 
961-963 
Symmetric stretching 
vibration of PO4- 
0.855  1375 
Thymine, Guanine, 
Adenine amino acids  
CH3 deformation 
0.068 
1007-1009 
Symmetric ring breathing 
mode of phenylalanine 
(proteins) 
0.273  1421-1423 
CH2 scissoring 
vibration of lipids 
0.584 
1037-1035 Phenylalanine of collagen 0.201  1446-1448 CH2 CH3 deformation 0.465 
1052 Glycogen 0.273  
1457-1458 
Collagen and 
phospholipids 
1.000 
1065-1066 
C-C and C–N stretching 
mode of proteins; 
C–C stretch lipids, 
O-P-O stretch (nucleic acids)  
C-O (nucleic acids) 
0.715 
 
 
1589 
C=C olefinic stretch of 
lipids 
0.361 
1608-1609 
Aromatic amino acid 
(proteins) 
0.201 
1085-1091 
C–C stretch proteins, 
C-C stretch lipid, 
O-P-O nucleic acids 
0.855  
1135 C-N protein 0.361 
 
1619-1620 
C=C bending of 
proteins Tryptophan  
(Ig G), phenylalanine, 
Tyrosine 
0.465 
1174 
Tyrosine, phenylalanine, 
C-H bend (protein) 
0.584 
1658-1661 Amide I protein 0.465 
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Carcinoma in situ (CIS) 
Figure 6.25 and Figure 6.26 display the mean spectra of morphologically normal and CIS 
tissue specimens. The spectral shape of the two types of tissue is very similar with key 
Raman peaks for each tissue type with their relative intensities summarised in Table 6.11. 
 
To clearly observe the variations between the two types of tissue; overlaid and the difference 
spectra were plotted in Figure 6.27. The intensity differences between the two types of tissue 
were small, with the morphologically normal tissue demonstrating higher peak intensity 
mainly at 1374 cm
-1
 (amino acids breathing modes of nucleic acids), 1589 cm
-1
 (C=C olefinic 
stretch of lipids), 1609 cm
-1
 (aromatic amino acid of proteins) and 1621 cm
-1
 (C=C bending 
modes tryptophan of proteins); however, the differences were not significant. 
Although the differences between the two types of tissue is subtle, CIS tissue specimens 
showed a significantly higher relative peak intensity at 1007 cm
-1
 (symmetric ring breathing 
mode of phenylalanine proteins) (0.654 vs. 0.627) (p=0.021) and at 1091 cm
-1
 (O-P-O 
stretching mode of nucleic acids, C–C stretching modes of proteins) (0.267 vs. 0.250) 
(p=0.043). Also, the peak at 1037 cm
-1
 corresponding to
 
O-P-O stretching mode of nucleic 
acids was more intense in CIS tissue spectra, but was non-significant; Table 6.12.  
 
An average spectrum of each pair of morphologically normal and CIS of each patient in this 
group can be seen in the Appendix (2-D). 
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Figure 6.25: Mean spectrum of morphologically normal tissue of carcinoma in situ 
(CIS) tissue specimen (n=82 spectra). 
 
 
 
Figure 6.26: Mean spectrum of CIS tissue specimen (n=90 spectra). 
 
 552 
 
Table 6.11: Peak position and relative intensity of CIS and morphologically normal 
tissue mean spectra. 
Morphologically normal tissue spectrum 
(CISn) 
Carcinoma in situ tissue spectrum 
(CIS) 
Spectral features  
Peak position 
   (cm
-1
) 
 
Intensity 
 (a.u) 
Peak position 
    (cm
-1
) 
Intensity 
 (a.u) 
832 0.092 833 0.069 Higher intensity in CISn 
857 0.157 859 0.173 Higher intensity in CIS 
880 0.063 882 0.067 Higher intensity in CIS 
898 0.066 892 0.075 Higher intensity in CIS 
925 0.017 926 0.023 Higher intensity in CIS 
936 0.031 936 0.039 Higher intensity in CIS 
944 0.040 945 0.008 Higher intensity in CISn 
952 0.007 - - Missing or very weak in CIS 
964 0.035 961 0.019 Higher intensity in CISn 
1007 0.627 1007 0.654 Higher intensity in CIS 
1037 0.336 1037 0.345 Higher intensity in CIS 
- - 1047 0.312 Very weak in CISn 
1066 0.442 1066 0.425 Higher intensity in CISn 
1082 0.265 - - Missing or very weak in CIS 
1091 0.250 1091 0.267 Higher intensity in CIS 
1104 0.244 1103 0.238 Higher intensity in CISn 
1135 0.372 1135 0.358 Higher intensity in CISn 
1177 0.221 1176 0.186 Higher intensity in CISn 
1214 0.294 1214 0.293 Higher intensity in CISn 
1243 0.379 1238 0.375 Higher intensity in CISn 
1301 0.361 1299 0.310 Higher intensity in CISn 
1318 0.233 1317 0.208 Higher intensity in CISn 
- - 1323 0.233 Missing or very weak in CISn 
1344 0.385 1344 0.337 Higher intensity in CISn 
1374 0.270 1375 0.216 Higher intensity in CISn 
1422 0.477 1423 0.475 Higher intensity in CISn 
1449 1.215 1451 1.238 Higher intensity in CIS 
1589 0.617 1591 0.549 Higher intensity in CISn 
1609 0.629 1609 0.602 Higher intensity in CISn 
1621 0.668 1621 0.603 Higher intensity in CISn 
1660 1.063 1661 1.059 Higher intensity in CISn 
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Figure 6.27: Overlaid normalised mean spectra of morphologically normal and CIS 
tissue with the subtraction spectrum beneath. 
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Table 6.12: Main Raman bands and assignments in CIS and morphologically normal 
tissue with p-value resulted from Mann-Whitney test comparison of the relative peak 
intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
832-833 
Out of plane breathing 
Tyrosine/ O-P-O stretching 
of nucleic acids 
0.083 1214 
Amide III, Tryptophan, 
phenylalanine, 
Tyrosine, Thymine, 
Cytosine, Adenine. 
0.564 
857-859 
Molecular vibration mode 
of proteins mainly 
Tyrosine and C-C stretch 
0.386  1238-1243 
Amide III, disorder 
structure of proteins, 
collagen 
1.000 
880-882 Tryptophan (proteins) 0.564  1299-1301 CH2 deformation (lipids) 0.773 
892-898 Backbone, C-C skeletal  0.564 
 
1317-1318 
Guanine ring breathing 
modes of DNA/RNA 
bases, C-H deformation  
protein  
0.083 
936 
C-C stretching mode of 
proline, valine and protein 
backbone, (α-helix 
conformation) /collagen 
0.248 
1344 
CH3 CH2 wagging  
mode protein of 
collagen 
0.773 
 
944-945 C-C protein 0.564 1374-1375 
Thymine, Guanine, 
Adenine amino acids 
CH3 deformation 
0.564 
 
961-964 Symmetric stretching 
vibration of PO4- 
0.564  1422-1423 
Adenine, Guanine, 
backbone CH2,, 
deoxyribose 
0.564 
1007 
Symmetric ring breathing 
mode of phenylalanine 
(proteins) 
0.021  1449-1451 CH2 CH3 deformation 0.564 
1037 Phenylalanine of collagen 0.149 
 
1589-1591 C=C stretch olefinic of 
lipids 
0.248 
1066 
C-C and C–N stretching 
mode of proteins; 
C–C stretch lipids, 
O-P-O stretch (nucleic 
acids), C-O (nucleic acids) 
0.248 
1609 Aromatic amino acid 
(proteins) 
0.564 
 
1621 
C=C bending of 
proteins Tryptophan 
(Ig G), phenylalanine, 
Tyrosine 
0.564 
1091 
C–C stretch proteins, 
C-C stretch lipid, 
O-P-O nucleic acid 
0.043  
1135 C-N protein 0.083 
 1660-1661 Amide I protein 0.386 
1176-1177 Cytosine, Guanine 0.248 
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Low Grade Dysplasia  
The mean spectra for morphologically normal tissue and low grade dysplastic tissue 
specimens are presented in Figure 6.28 and Figure 6.29, respectively. Overall, the two types 
of tissue specimens exhibited similar spectral shape, with the main peaks for each tissue type 
with their relative intensities summarised in Table 6.13. 
Careful analysis of the two types of tissue revealed intensity differences and to better show 
these differences, overlaid and difference spectra were constructed in Figure 6.30. 
Low grade dysplastic tissue compared with morphologically normal tissue exhibited more 
intense peaks in the spectral region at 1591-1661 cm
-1
, (lipids, proteins, amino acids), 1301-
1379 cm
-1
 (proteins, amino acids, CH3 hyaluronic acid), 1135 cm
-1
, 1177 cm
-1
 and 1009 cm
-1 
which mainly corresponds to amino acids and proteins. The morphologically normal tissue 
spectrum showed more intense peaks in the regions at 1039-1104 cm
-1
 (proteins, amino acids, 
nucleic acids) and at 859-967 cm
-1
 (amino acids); however, the differences were not 
significant. The most significant intensity differences demonstrated higher levels of 
phenylalanine proteins at 1009 cm
-1
 in low grade dysplasia tissue specimens compared with 
morphologically normal tissue (0.600 vs. 0.579) and at 1661 cm
-1
 (amide I of protein) (1.056 
vs. 1.028) (p=0.010, p=0.0001; Mann-Whitney U test, respectively); Table 6.14. 
 
Further, contribution of new peaks such as 886 cm
-1
 (tryptophan-protein) and 984 cm
-1
 (C-C 
stretching β-sheet proteins) were identified in low grade dysplastic tissue specimens that were 
absent in morphologically normal tissue. Similarly, peaks in the morphologically normal 
tissue spectrum at 1624 and 1632 cm
-1
 which
 
may be assigned to proteins, were absent or 
very weak in low grade dysplastic tissue specimens.  
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Figure 6.28: Mean spectrum of morphologically normal tissue of low grade dysplasia 
specimens (n=123 spectra). 
 
 
 
Figure 6.29: Mean spectrum of low grade dysplastic tissue specimens (n=147 spectra). 
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Table 6.13: Peak position and relative intensity of the average spectra of low grade 
dysplasia and morphologically normal tissue specimens. 
Morphologically normal tissue spectrum 
(LGN) 
Low grade dysplastic tissue spectrum 
(LGD) 
Spectral features  
Peak position 
(cm-1) 
Intensity 
(a.u) 
Peak position 
(cm-1)  
Intensity 
(a.u) 
830 0.063 834 0.063 
 859 0.192 859 0.157 Higher intensity in LGN 
- - 886 0.048 Missing in LGN 
894 0.084 896 0.072 Higher intensity in LGN 
903 0.085 904 0.072 Higher intensity in LGN 
920 0.056 924 0.022 Higher intensity in LGN 
938 0.070 936 0.027 Higher intensity in LGN 
946 0.015 946 0.002 Higher intensity in LGN 
967 0.025 967 0.008 Higher intensity in LGN 
- - 984 0.019 Missing in LGN 
1009  0.579 1009 0.600 Higher intensity in LGD 
1024 0.252 1023 0.206 Higher intensity in LGN 
1039 0.435 1039 0.384 Higher intensity in LGN 
1048 0.387 1048 0.358 Higher intensity in LGN 
1068 0.499 1066 0.463 Higher intensity in LGN 
1086 0.328 1083 0.278 Higher intensity in LGN 
1104 0.262 1104 0.231 Higher intensity in LGN 
1137 0.344 1135 0.361 Higher intensity in LGD 
1177 0.194 1177 0.242 Higher intensity in LGD 
1213 0.338 1213 0.318 Higher intensity in LGN 
1243 0.424 1245 0.420 Higher intensity in LGD 
1301 0.285 1301 0.305 Higher intensity in LGD 
1321 0.199 1317 0.259 Higher intensity in LGD 
1347 0.316 1345 0.367 Higher intensity in LGD 
1379 0.289 1379 0.373 Higher intensity in LGD 
1408 0.389 1408 0.409 Higher intensity in LGD 
1426 0.536 1423 0.532 Higher intensity in LGN 
1454 0.233 1449 1.211 Higher intensity in LGN 
1592 0.611 1591 0.773 Higher intensity in LGD 
1609 0.617 1609 0.689 Higher intensity in LGD 
1624 0.642 - - Missing or very weak in LGD 
1632 0.710 - - Missing or very weak in LGD 
1660 1.028 1661 1.056 Higher intensity in LGD 
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Figure 6.30: Overlaid normalised mean spectra for morphologically normal and low 
grade dysplastic tissue specimens with the difference spectrum beneath. 
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Table 6.14: Main Raman bands and assignments of low grade dysplasia and 
morphologically normal tissue with p-value resulted from Mann-Whitney test 
comparison on the relative peak intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
830-834 
Out of plane breathing 
Tyrosine, O-P-O 
stretch of nucleic acids 
0.951 1177 Cytosine, Guanine 0.074 
859 
Molecular vibration 
mode of proteins 
mainly Tyrosine  
and C-C stretch 
0.157  1213 
Amide III, Tryptophan, 
phenylalanine, 
Tyrosine, Thymine, 
Cytosine, Adenine. 
1.000 
894-896 
Backbone, C-C 
skeletal  
0.902 
 
1243-1245 
Amide III, disorder 
structure of proteins, 
collagen 
0.712 
920-924 
C-C stretch of proline 
ring/glucose/lactic acid 
0.424 1301 CH2 deformation lipids 0.580 
 
936-938 
C-C stretching mode 
of proline, valine and 
protein backbone, 
(α-helix conformation) 
/collagen 
0.268 1317-1321 
Guanine ring breathing 
modes nucleic acids 
bases, C-H deformation  
protein 
0.295 
 
946 C-C protein  0.460 
 
1345-1347 
CH3 CH2 twisting and 
bending  mode of 
protein lipids, nucleic 
acids 
0.667 
967 Lipid 0.242 1379 Thymine nucleic acid 0.854 
 
1009 
Symmetric ring 
breathing mode of 
phenylalanine 
(proteins) 
0.010 1408 
A symmetric stretching 
carboxylate (IgG) 
1.000 
 
1039 
Phenylalanine of 
collagen 
0.295 1423-1426 
Adenine, Guanine, 
backbone CH2 
deoxyribose 
0.806 
 
1066-1068 
C-C and C–N 
stretching mode of 
proteins, C–C stretch 
lipids, O-P-O stretch 
nucleic acids, C-O 
nucleic acids 
0.667  1449-1454 CH2 CH3 deformation 0.758 
1083-1086 
C–C stretch proteins, 
C-C stretch lipid, 
O-P-O nucleic acid 
0.622  1591-592 
C=C stretch olefinic of 
lipids 
0.424 
1104 Phenylalanine proteins 0.712  1609 
Aromatic amino acid 
(proteins) 
0.622 
1135-1137 C-N protein 0.951  1660-1661 Amide I protein 0.0001 
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High Grade Dysplasia  
The mean spectra of morphologically normal (HGN) and high grade dysplastic tissue 
specimens (HGD) are shown in Figure 6.31 and Figure 6.32, respectively. At first glance, the 
spectra of the two tissue types appear similar, with the identified key peaks and their 
intensities for each type of tissue summarised in Table 6.15. 
 
For a closer study of the spectral differences, the two types of tissue spectra were overlaid 
and their difference spectrum constructed (Figure 6.33) in which the morphologically normal 
tissue mean spectrum was subtracted from the high grade dysplastic mean spectrum. 
Variations in the relative peak intensities between the two types of tissue exist; high grade 
dysplasia specimens showed more intense peaks in three main spectral regions: at 837-971 
cm
-1
 which is mainly attributed to amino acids and proteins; 1301-1377 cm
-1
 (protein, lipid 
and nucleic acids) and 1591-1661 cm
-1
 corresponding mainly to proteins and to lesser extent 
lipids. The morphologically normal tissue specimens exhibited more intense peaks in the 
region between 1037-1104 cm
-1
 which can give information on proteins, lipids and nucleic 
acids, and 1176-1243 cm
-1
 which may be assigned to proteins and amino acids.  
 
To test the significant differences in relative intensities between the two types of tissue, 
Mann-Whitney U test was used. As can be seen in Table 6.16, the most significant intensity 
differences demonstrated higher levels in high grade dysplasia tissue specimens at 934 cm
-1
 
(C-C stretching mode of proline, valine and protein backbone), 1137 cm
-1
 (C-N protein), 
1301 cm
-1
 (CH2 deformation lipids), 1322 cm
-1
 (CH3 CH2 deformation modes of the nucleic 
acids), 1345 cm
-1
 (CH3 CH2 twisting and bending  mode of protein, lipids, nucleic acids), 
1377 cm
-1
 (amino acids CH2 deformation), 1591 cm
-1
 (C=C olefinic stretch of lipids) and 
1622 cm
-1
 (C=C bending modes of tryptophan, phenylalanine, tyrosine, β-sheet of proteins). 
In morphologically normal tissue specimens, the most significant intensity variations 
revealed higher intensity levels at 1037 cm
-1
 (phenylalanine proteins), 1081 cm
-1
 
(phospholipids), 1104 cm
-1
 (phenylalanine proteins), 1176 cm
-1
 (C-H bending amino acids 
proteins), 1213 cm
-1
 (amino acids proteins) and amide III of protein at 1243 cm
-1
. 
 
In high grade dysplastic tissue specimens, an additional contribution of a new peak 
corresponding to protein assignment was observed at 971 cm
-1
 which was not seen in the 
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morphologically normal tissue specimens. While the peak attributed to O-P-O-stretching in 
nucleic acids at 1099 cm
-1
 was very weak in morphologically normal tissue specimens, peaks 
such as 880 cm
-1
 (tryptophan-proteins) and 1326 cm
-1
 (purine bases of nucleic acids) were 
very weak or absent in high grade dysplastic tissue specimens. 
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Figure 6.31: Normalized mean spectrum of morphologically normal tissue from high 
grade dysplasia (n=255). 
 
 
 
Figure 6.32: Normalized mean spectrum of high grade dysplastic tissue specimens 
(n=253). 
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Table 6.15: Peak position and relative intensity of the average spectra of high grade 
dysplasia and morphologically normal tissue specimens. 
Morphologically normal tissue spectrum 
(HGN) 
High grade dysplastic tissue spectrum 
(HGD) 
Spectral features 
Peak position 
   (cm
-1
) 
Intensity 
(a.u) 
Peak position 
    (cm-1)  
Intensity 
(a.u) 
832 0.040 837 0.065 Higher intensity in HGD 
859 0.174 859 0.177 Higher intensity in HGD 
880 0.050 - - Weak in HGD 
893 0.065 894 0.094 Higher intensity in HGD 
936 0.007 934 0.016 Higher intensity in HGD 
946 0.009 946 0.001 Higher intensity in HGD 
964 0.007 961 0.009 Higher intensity in HGD 
- - 971 0.019 Missing in HGN 
1007 0.561 1009 0.577 Higher intensity in HGD 
1037 0.364 1037 0.344 Higher intensity in HGN 
1068 0.537 1068 0.470 Higher intensity in HGN 
1081 0.290 1086 0.251 Higher intensity in HGN 
- - 1099 0.149 Weak in HGN 
1104 0.229 1104 0.182 Higher intensity in HGN 
1135 0.319 1137 0.326 Higher intensity in HGD 
1176 0.241 1174 0.211 Higher intensity in HGN 
1213 0.331 1214 0.285 Higher intensity in HGN 
1243 0.412 1242 0.378 Higher intensity in HGN 
1299 0.347 1301 0.366 Higher intensity in HGD 
1317 0.150 1322 0.211 Higher intensity in HGD 
1326 0.144 - - Missing or very weak in HGD 
1345 0.289 1345 0.340 Higher intensity in HGD 
1375 0.228 1377 0.271 Higher intensity in HGD 
1423 0.554 1422 0.494 Higher intensity in HGN 
1448 1.238 1448 1.132 Higher intensity in HGN 
1589 0.510 1591 0.553 Higher intensity in HGD 
1608 0.574 1609 0.584 Higher intensity in HGD 
1620 0.596 1622 0.623 Higher intensity in HGD 
1661 0.955 1661 0.964 Higher intensity in HGD 
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Figure 6.33: Overlaid normalised mean spectra for morphologically normal and high 
grade dysplastic tissue with the difference spectrum beneath. 
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Table 6.16: Main Raman bands and assignments in high grade dysplasia and 
morphologically normal tissue with p-value resulting from Mann-Whitney test 
comparison of the relative peak intensity between the two tissue types. 
Peak 
position 
(cm
-1
) 
Raman 
Assignment p-value 
 
 
 
Peak  
position 
(cm
-1
) 
Raman 
Assignment p-value 
832-837 
Out of plane breathing 
Tyrosine, O-P-O 
stretching of nucleic 
acids 
0.254 1213-1214 
Amide III, Tryptophan, 
phenylalanine, 
Tyrosine, Thymine, 
Cytosine, Adenine. 
0.0001 
857-859 
Molecular vibration mode 
of proteins mainly 
Tyrosine and 
C-C stretch 
0.419 1242-1243 
Amide III, disorder 
structure of proteins, 
collagen 
0.004 
 
893-894 Backbone, C-C skeletal  0.373 1299-1301 
CH2 deformation 
(lipids) 
0.049 
 
934-936 
C-C stretching mode of 
proline, valine and 
protein backbone,  
(α-helix conformation) 
/collagen 
0.007  1317-1322 
CH3 CH2 deforming 
modes of collagen 
and nucleic acids, C-H 
deformation protein  
0.003 
946 C-C protein 0.443  
1345 
CH3 CH2 twisting and 
bending  mode of 
protein lipids,  nucleic 
acids 
0.001 
961-964 Symmetric stretching 
vibration of PO4- 
0.885 
 
 1375-1377 
Thymine, Guanine, 
Adenine amino acids 
CH3 deformation 
0.0001 
1007-1009 
Symmetric ring breathing 
mode of phenylalanine 
(proteins) 
0.950 
 1422-1423 
Adenine, Guanine, 
backbone CH2, 
deoxyribose 
0.604 
1037 Phenylalanine of 
collagen 
0.0001 
 1448 CH2 CH3 deformation 0.290 
1068 
C-C and C–N stretching 
mode of proteins, 
C–C stretch lipids, 
O-P-O stretch (nucleic 
acids) 
0.520 
 
1589-1591 C=C stretch olefinic 0.0001 
1609 Aromatic amino acid 
(proteins) 
0.290 
1081-1086 
C-O (nucleic acids) 
C–C stretch proteins, 
C-C stretch lipid, 
O-P-O nucleic acid 
 
0.007  
1621-1622 
C=C bending modes 
of Tryptophan, 
phenylalanine, 
Tyrosine, β-sheet of 
proteins  
0.0001 
1104 Phenylalanine (proteins) 0.0001 
 
1135-1137 C-N protein 0.001 
1660-1661 Amide I protein 0.694 
 
1174-1176 
C-H bending Cytosine, 
Guanine, Tyrosine, 
phenylalanine proteins 
0.0001 
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6.7.3. Dysplasia Severity in Relation to the Peak Relative Intensity 
To study the association between relative peak intensity and the severity of epithelial 
dysplasia, the intensities of the identified peaks were measured from the mean spectrum of 
each grade of dysplasia (mild, moderate, severe dysplasia and CIS) along the spectral range 
from 800-1800 cm
-1
; Table 6.17. To clearly demonstrate the relation between peak intensities 
and dysplasia severity, a histogram in Figure 6.34 was used. In general, no clear relation was 
found for the majority of the identified Raman peaks. However, for two peaks an apparent 
relationship was seen, at 1235-1243 cm
-1
 (amide III of protein) and 1589-1591 cm
-1
 (C=C 
olefinic stretch of lipids). These two Raman bands showed a decreased intensity with 
increased dysplasia severity from the mild through moderate and severe dysplasia to the CIS. 
 
Five spectral regions 1007-1009 cm
-1
, 1084-1091 cm
-1
, 1235-1243 cm
-1
, 1344-1347 cm
-1
 and 
1589-1591 cm
-1
 were selected to investigate the relation between their relative peak 
intensities and the severity of dysplasia. This selection was based on the significant 
differences found between morphologically normal and dysplastic tissue groups (pair-wise 
comparison) in these spectral regions and also on the consistent relation found; Figure 6.35 
and Table 6.18. In general, an increased dysplasia severity from mild through to CIS was 
associated with a decrease in relative intensity at 1235-1243 cm
-1
 and 1589-1591 cm
-1
, 
although this trend was not found to be significant for any of the 5 selected peaks (p=0.329, 
0.657, 0.640, 0.532, 0.736; Kruskal-Wallis test), respectively. 
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Table 6.17: Mean relative intensity of the identified Raman peaks in dysplastic groups. 
Spectral Range 
(cm
-1
) 
Mean Relative Intensity (a.u) 
Md Modd Sd CIS 
829-835 0.047 0.082 0.048 0.069 
859 0.18 0.181 0.124 0.173 
1007-1009 0.642 0.552 0.594 0.654 
1035-1039 0.417 0.326 0.376 0.345 
1065-1068 0.472 0.158 0.526 0.425 
1084-1091 0.31 0.252 0.28 0.267 
1135-1137 0.381 0.378 0.348 0.358 
1174-1177 0.263 0.223 0.255 0.186 
1213-1214 0.364 0.283 0.342 0.293 
1235-1243 0.443 0.393 0.384 0.375 
1299-1301 0.267 0.364 0.293 0.31 
1315-1322 0.243 0.22 0.195 0.208 
1344-1347 0.399 0.336 0.333 0.337 
1375-1377 0.375 0.282 0.312 0.216 
1403 0.443 0.314 0.318 0.25 
1421-1424 0.552 0.499 0.499 0.475 
1446-1454 1.22 1.244 1.26 1.238 
1589-1591 0.883 0.656 0.617 0.549 
1609 0.766 0.628 0.636 0.602 
1658-1661 1.08 0.977 0.925 1.059 
 
Md=mild dysplasia, Modd=moderate dysplasia, Sd=severe dysplasia, CIS=carcinoma in situ, 
a.u =arbitrary unit. 
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Figure 6.34: The association between the relative peaks intensities and the severity of 
oral epithelial dysplasia. 
 
 
 
 
 
0
0.3
0.6
0.9
1.2
1.5
In
te
n
si
ty
 (
a
.u
)
cm-1
Md Modd Sd CIS
 569 
 
 
Figure 6.35: The relation between peaks relative intensities and degree of oral epithelial 
dysplasia at 5 selected Raman peaks. 
 
 
 
 
Table 6.18: Mean relative intensity of the dysplastic tissue groups of the 5 selected 
Raman bands. 
Spectral range 
(cm
-1
) 
Mean relative intensity (a.u) 
Md Modd Sd CIS 
1007-1009 0.642 0.552 0.594 0.654 
1084-1091 0.31 0.252 0.28 0.267 
1235-1243 0.443 0.393 0.384 0.375 
1344-1347 0.399 0.336 0.333 0.337 
1589-1591 0.883 0.656 0.617 0.549 
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Considering high/low grade dysplasia groups, Figure 6.36 compares the relative intensities of 
the identified peaks in both types of tissue. Overall, the differences were small between the 
two types of tissue. High grade dysplasia tissue specimens showed more intense peaks at 
1066-1068 cm
-1 
(proteins and nucleic acids), 1301 cm
-1 
(CH2 deformation lipids) and 1448-
1449 cm
-1 
(CH2 CH3 deformation proteins). Low grade dysplasia exhibited more intense 
peaks in the majority of the identified peaks, with a more pronounced difference was seen at 
1591 cm
-1
. No significant differences between low and high grade dysplasia tissue spectra in 
the relative peak intensity for almost all the identified peaks; however, one peak at 1242-1245 
cm
-1
 (amide III of proteins) approaching the significance difference (p=0.051; Mann Whitney 
U test); Table 6.19. 
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Figure 6.36: The relation between peak relative intensities and severity of oral epithelial 
dysplasia between low and high grade dysplasia. 
 
 
Table 6.19: Mann-Whitney U test on relative peak intensity between low and high grade 
dysplastic tissue groups. 
Peak position (cm
-1
) p-value 
834-837 0.884 
859 0.435 
1009 0.354 
1037-1039 0.435 
1066-1068 0.696 
1083-1086 0.961 
1135-1137 0.922 
1174-1177 0.222 
1213-1214 0.494 
1242-1245 0.051 
1301 0.241 
1317-1322 0.188 
1345 0.223 
1377-1379 0.495 
1422-1423 0.407 
1448-1449 0.143 
1591 0.380 
1609 0.329 
1661 0.071 
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6.7.4. Spectral Features of Dysplastic Tissue 
To carefully investigate the spectral features among the dysplastic groups labelled as mild, 
moderate, severe dysplasia and CIS, the mean spectra of the four dysplastic groups were 
plotted and overlaid in Figure 6.37. Also, for clarity the four dysplastic tissue spectra were 
offset in Figure 6.38 to show the differences in the main spectral features among the 
dysplastic groups. The areas showing the greatest visual spectral distinctions were enclosed 
in boxes. The area enclosed in the box A at 829–838 cm-1 corresponding to the out of plane 
breathing mode of tyrosine protein assignments/O-P-O stretching mode of nucleic acids, is 
broad in mild dysplastic tissue specimens and starts to develop and become more prominent 
with increased degree of dysplasia indicating more tissue activity with increased dysplasia 
severity and greater biochemical changes in proteins and nucleic acids.  
 
Box B encloses the area attributed to the symmetric ring breathing mode of phenylalanine 
proteins at 1007–1009 cm-1 which is prominent in all grades of dysplasia, becoming more 
intense and sharper with increased dysplasia severity, reflecting the progressive increase in 
proteins tissue components with higher degrees of dysplasia. The peak at 1315–1322 cm-1 
enclosed in box C is assigned to the guanine ring breathing modes of the nucleic acids bases, 
C-H deformation protein. It is prominent in mild dysplasia but starts to weaken and appears 
less prominent with increased grades of dysplasia. Similarly, the box labelled D encloses the 
band at 1375–1377 cm-1 (thymine, guanine, adenine amino acids), is more prominent in mild 
dysplasia and becomes weaker and less prominent with increased dysplasia severity. The 
Raman peaks broaden as the molecular complexity increases.  
 
Box E shows that there is a small shoulder seen in the spectrum for severe dysplastic tissue 
specimens at 1458 cm
-1
 corresponding to nucleic acid, but absent in the spectra of mild, 
moderate dysplasia and CIS tissue specimens, indicating increased cellular nucleic acid 
content (nuclear material) in dysplastic tissue from the proliferation cells. 
 
At 1589–1591 cm-1 (C=C stretch olefinic of lipids), a mild dysplastic tissue spectrum 
exhibited a sharp peak which starts to broaden gradually with increased dysplasia grade 
severity (Box F). This suggests disturbances in the lipids content with increased dysplasia 
severity during the carcinogenesis process. 
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The shoulder enclosed in box G at 1620–1624 cm-1 that can be assigned to C=C bending 
modes of tryptophan, phenylalanine, tyrosine, β-sheet of proteins is very weak or absent in 
mild dysplastic tissue specimens starts to develop in moderate and become more prominent in 
severe and CIS. This indicates the substantial changes in spectral profiles from normal to CIS 
tissue arising from expression of new and different proteins from progressive cell 
proliferation and cellular response to disease. 
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Figure 6.37: Mean spectra of the four dysplastic tissue groups; mild (n=134) moderate 
(n=79), severe dysplasia (n=83) and CIS (n=90). 
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Figure 6.38: The main spectral characterizations in the four grades of oral epithelial dysplasia. 
A= (829-838), B= (1007-1009), C= (1315-1322), D= (1375-1377), E=1458, F= (1589-1591) and G= (1620-1624) 
 
 
B 
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Considering the spectral features in high and low grade dysplastic tissue specimens, the 
overlaid mean spectra of both types of tissue specimens can be seen in Figure 6.39. To better 
clarify the spectral differences between the two groups of tissue, the spectra were offset and 
the main spectral features were enclosed in boxes; Figure 6.40. In the plot of the high grade 
dysplasia, the shoulder enclosed in box A at 1166 cm
-1
 (C–H in-plane bending modes of 
tyrosine proteins) appears very weak in low grade dysplastic tissue specimens, indicates the 
formation of more proteins from the proliferated cells.  
 
The peak labelled B at 1317–1322 cm-1 (guanine ring breathing modes of the nucleic acid 
base, C-H deformation proteins) for low grade dysplastic tissue showed sharp peak which 
becomes broader in the high grade dysplasia. This broad peak in high grade dysplasia reflects 
increased cellular proteins and nucleic acid content. 
 
The small peak at 1407 cm
-1
 corresponding to a symmetric stretching carboxylate IgG, 
labelled C, is more prominent in low grade dysplasia, appearing broader in high grade 
dysplasia, indicating high levels of immunoglobulins in the disease condition which increases 
with high grade dysplasia.  
 
Box D enclosed the shoulder at 1623 cm
-1
 for the high grade dysplastic tissue specimens 
corresponding to C=C bending modes of tryptophan, phenylalanine, tyrosine, β-sheet of 
proteins, appears very weak or absent in low grade dysplastic tissue spectrum. This represents 
the formation of new proteins from progressive cell proliferation and cellular response to 
disease. 
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Figure 6.39: Mean spectra of high grade dysplasia (n=253 spectra) and low grade 
dysplasia (n=147 spectra). 
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Figure 6.40: The main spectral characterizations of high grade and low grade dysplastic tissue specimens. 
A=1166, B= (1317-1322), C= (1405-1407) and D=1623 
A 
D 
C 
B 
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6.7.5. Spectral Features of Morphologically Normal Tissue 
Figure 6.41 shows the mean spectra of morphologically normal epithelial tissue from the 
resection margins of mild, moderate, severe dysplasia and CIS tissue specimens. To better 
understand the differences among morphologically normal tissue groups, the spectra were 
offset and the greatest visual differences were enclosed in boxes shown in Figure 6.42. 
 
The peak enclosed in box A at 1009 cm
-1
 corresponds to the symmetric ring breathing mode 
of phenylalanine protein and appears in all cases of morphologically normal tissue 
specimens. It showed intensity increases as dysplasia severity increased from mild dysplasia 
through to CIS indicating the similarity between morphologically normal and dysplastic 
tissue with more proteins formation with increased dysplasia severity from the proliferation 
cells. 
 
The morphologically normal tissue from the resection margins of mild and moderate 
dysplasia exhibited a more prominent feature at 1022 cm
-1
 corresponding to glycogen (box A, 
arrows), but absent in severe dysplasia and CIS tissue spectra. This reflects a reduction in the 
glycogen content in morphologically normal tissue from severe-CIS tissue specimens, 
indicating close similarity of these morphologically normal with dysplastic tissue with high 
metabolic activity. 
 
The peak labelled B at 1347 cm
-1
 (CH2 twisting and bending modes of lipids) appears in all 
morphologically normal tissues, with notably increased sharpness, respectively, in the 
morphologically normal tissue from mild, moderate, severe dysplasia and CIS. This 
represents disturbances in the lipid content of morphologically normal tissue adjacent to 
severe dysplasia and CIS during the carcinogenesis. 
 
At box C, the region for morphologically normal epithelium from moderate, severe dysplasia 
and CIS show prominent shoulders at 1619–1623 cm-1 (C=C bending modes of tryptophan, 
phenylalanine, tyrosine, β-sheet of proteins) which may be absent or very weak in the 
morphologically normal from mild dysplastic tissue. This indicates the formation of new 
proteins and reflects the similarity of the morphologically normal tissue from moderate, 
severe dysplasia and CIS to their dysplastic tissues. 
 580 
 
In morphologically normal tissue from moderate dysplasia labelled D, there is a shoulder at 
1673 cm
-1
 corresponding to unordered protein secondary structure, but absent in all other 
morphologically normal tissue from mild, severe dysplasia and CIS, indicating the formation 
of new proteins in morphologically normal looking cells from moderate dysplasia and 
supports the concept of field change of malignancy-associated changes throughout the entire 
oral mucosa. 
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Figure 6.41: Mean spectra of the four morphologically normal tissue groups from the 
resection margins of mild (n=110), moderate (n=93), severe dysplasia (n=107) and CIS 
(n=82). 
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Figure 6.42: The main spectral characterizations of the 4 morphologically normal tissue groups. 
A= (1009, 1022), B=1347, C= (1619-1623) and D=1673 
A B 
C D 
 583 
 
With respect to the binary grading system, Figure 6.43 shows the mean spectra of the 
morphologically normal tissue from the resection margins of both high and low grade 
dysplasia overlaid. To better compare the two tissue types, the spectra were offset and the 
main distinction features were enclosed in boxes; Figure 6.44. 
 
The peak enclosed in box A at 1048 cm
-1
 (glycogen) appears prominent in morphologically 
normal from low grade dysplastic tissue, but very weak or may be absent in morphologically 
normal from high grade dysplasia. This reflects a reduction in the glycogen content in tissues 
of morphologically normal from high grade dysplasia indicating close similarity with the 
dysplastic tissue in lower glycogen content due to increase metabolic activity. 
 
The morphologically normal tissue from low grade dysplastic tissue specimens labelled B, 
shows two small shoulders at 1235 and 1251 cm
-1
 corresponding to amide III C-N stretch, N-
H in plane bending unordered proteins, it is absent in morphologically normal samples from 
high grade dysplasia. This represents degradation or disordering of protein components in 
morphologically normal tissue from high grade which becomes similar to dysplastic tissue by 
the phenomenon of field change cancerization. 
 
The peak at 1322 cm
-1
 (guanine ring breathing modes of the nucleic acid base, C-H 
deformation proteins) enclosed in box C, appears to be more prominent in morphologically 
normal from low grade dysplastic tissue specimens becoming weaker and broader in 
morphologically normal tissue from high grade dysplasia. These features represent 
degradation or disordering of protein components in morphologically normal tissue from high 
grade which becomes similar to dysplastic tissue by the phenomenon of field cancerization.  
 
The area labelled D at 1423 cm
-1
 (adenine, guanine, backbone nucleic acids) is more 
prominent in morphologically normal tissue from high grade dysplasia specimens, appearing 
broader in morphologically normal from low grade dysplasia. This reflects increased nucleic 
acid content in morphologically normal from high grade dysplasia indicating a similarity with 
high grade dysplastic tissue features. 
 
In the morphologically normal tissue from high grade dysplasia tissue specimens labelled E, 
the small peak at 1620 cm
-1
 (C=C bending modes of tryptophan, phenylalanine, tyrosine, β-
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sheet of proteins) appears more prominent compared to that in the morphologically normal 
tissue from low grade dysplasia. This represents additional protein formation in 
morphologically normal from high grade dysplasia, a tissue which becomes similar to high 
grade dysplastic tissue. 
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Figure 6.43: Mean spectra of morphologically normal tissue from the resection margins 
of high grade dysplasia (n=255) and low grade dysplasia (n=123). 
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Figure 6.44: The main spectral characterizations of morphologically normal tissue from high and low grade dysplastic tissue. 
A= (1048) B= (1235, 1251), C= 1322, D= 1423 and E= 1620 
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D 
E 
C 
 587 
 
6.7.6. Tissue Classifications 
Using histopathology diagnosis as a standard of tissue diagnosis, the potential of RS for 
tissue classification to provide diagnostic information for the early detection of dysplastic 
changes (Raman classification/prediction) was investigated. PLS-DA was employed on the 
data matrix consisting of the fully processed data of tissue Raman spectra. 12 significant 
partial least squares components (PLSCs) were identified, which best described the original 
variance in the data between groups. 
 
The histopathological diagnosis was compared to the Raman tissue prediction. Different 
classification models which showed important clinical implementations were generated 
using both WHO and binary classification systems of epithelial dysplasia. A diagnostic 
model combining all dysplastic against all morphologically normal tissue samples was 
generated. Pair-wise comparisons between dysplasia and morphologically normal tissue 
cases for each grade of dysplasia were used: Mn vs. Md, Modn vs. Modd, Sn vs. Sd and 
CISn vs. CIS. Further, discrimination of high grade and low grade dysplasia from their 
morphologically normal tissue samples and a model to discriminate low grade dysplasia 
from high grade dysplasia cases were also performed. 
 
The significant loadings obtained from PLS-DA for each group of tissues were plotted 
(Appendix 2-E), in which Q
2
 is higher than 0.097 (equivalent to the p-value ≤ 0.05). These 
significant loadings were used to plot the scatter plots of the discriminant functions. 
Considering the discrimination of all dysplastic from all morphologically normal tissue, 
Figure 6.45 shows the scatter plots that discriminate all dysplastic from all morphologically 
normal tissues, in which three morphologically normal were misclassified as dysplastic 
tissue, while five dysplasia cases were misclassified as morphologically normal tissues. 
Figure 6.46 shows the details of these misclassified cases; two of them were Modd, one Md, 
one Sd, one CIS, one Mn and two Sn. To quantify the performance of this model, sensitivity 
and specificity tests were performed and showed 80.77% sensitivity and 81.48% specificity; 
Table 6.20. 
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Figure 6.45: Scatter plots of the significant discriminant scores between all dysplastic 
and all morphologically normal tissue samples. 
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Figure 6.46: Samples details of the scatter plots of the significant discriminant scores 
between all dysplastic and all morphologically normal tissue samples. 
 
Md= mild dysplasia; Mn=morphologically normal from mild dysplasia; Modn=morphologically normal 
from moderate dysplasia; Modd=moderate dysplasia; Sn=morphologically normal from severe 
dysplasia, Sd=severe dysplasia; CIS=carcinoma in situ; CISn=morphologically normal from CIS. 
 
 
 
 
Table 6.20: Sensitivity and specificity of Raman classification for all dysplastic tissue 
samples and all morphologically normal. 
Pathology Diagnosis 
(groups) 
Raman prediction 
Total 
Ds Ns 
All dysplastic tissues  
(Ds) 
26 21 5 26 
All morphologically normal tissues 
(Ns) 
27 3 24 27 
Sensitivity  80.77% 
  Specificity  81.48% 
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Based on the pathological diagnosis of WHO system and spectroscopic Raman predictions, 
Figure 6.47 displays the scatter plots of the discriminant functions of each pair-wise grade 
of dysplasia comparisons. The two groups’ classification was found to be promising. 
Looking to the decision line (zero-line) of the scatter plot, there is complete agreement 
between pathologist and Raman prediction regarding the discrimination of Sd from Sn (no 
misclassification). While there is just one Mn was misclassified as Md and one Md 
misclassified as Mn, two Modd were misclassified as Modn and one Modn was 
misclassified as Modd, two CIS samples were misclassified as CISn. 
 
The performances of these classification models were tested using sensitivity and specificity 
tests. Using histopathology diagnosis, Raman prediction achieved a sensitivity and 
specificity of 100% in distinguishing Sd from Sn and 90.9% in differentiating Md from Mn. 
For distinguishing Modd from Modn a sensitivity of 71.4% and specificity of 80% were 
achieved. While CIS separation from CISn showed a sensitivity of 60% and specificity of 
100%; Table 6.21. 
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Figure 6.47: Scatter plot of the discriminant scores for the morphologically normal and dysplastic tissue of each grade of dysplasia. 
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Table 6.21: Sensitivity and specificity of the Raman classifications of the pair-wise 
groups (WHO classification system). 
Pathology Diagnosis 
Raman Classifications 
Total 
Md Mn Modd Modn Sd Sn CIS CISn 
Mild dysplasia (Md) 11 10 1       11 
Morphologically normal 
from mild dysplasia (Mn) 
11 1 10       11 
Moderate dysplasia (Modd) 7   5 2     7 
Morphologically normal 
from moderate dysplasia 
(Modn) 
5   1 4     5 
Severe dysplasia (Sd) 5     5    5 
Morphologically normal 
from severe dysplasia (Sn) 
6      6   6 
Carcinoma in situ 5       3 2 5 
Morphologically normal 
from CIS (CISn) 
4        4 4 
Sensitivity 
 
90.9% 71.4% 100% 60% 
 
Specificity 90.9% 80% 100% 100% 
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Regarding the binary classification system models, Figure 6.48 shows scatter plot of the 
discriminant functions of high grade dysplasia (HGD) and morphologically normal from high 
grade dysplasia (HGN), in which two HGD were misclassified spectroscopically as HGN, 
while one HGN was misclassified as HGD.  
 
 
 
 
 
 
Figure 6.48: Scatter plots of the discriminant scores of pair-wise of high grade dysplasia 
(HGD) and morphologically normal tissue (HGN). 
 
 
 
 
 594 
 
Considering low grade dysplasia, Figure 6.49 displays scatter plot of the discriminant 
functions of low grade dysplasia (LGD) and morphologically normal from low grade 
dysplasia (LGN). Looking to the decision line of the scatter plot, similarly two LGD cases 
were misclassified as LGN, whereas one LGN was misclassified as LGD.  
 
The performance of these models was tested by sensitivity and specificity tests which are 
shown in Table 6.22. A sensitivity and specificity of 86.7% and 93.3% respectively, was 
achieved to distinguish HGD from HGN; whilst a sensitivity of 83.3% and specificity of 
90.9% to discriminate between LGD from LGN were recorded. 
 
 
 
 
 
Figure 6.49: Scatter plots of the discriminant scores of pair-wise of low grade dysplasia 
(LGD) and morphologically normal tissue group (LGN). 
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Table 6.22: Sensitivity and specificity of Raman classifications of pair-wise of high and 
low grade dysplasia. 
Pathology Diagnosis 
Raman Assignment 
Total 
LGD LGN HGD HGN 
Low grade  dysplasia (LGD) 12 10 2   12 
Low grade morphologically 
normal (LGN) 
11 1 10   11 
High grade  dysplasia (HGD) 15   13 2 15 
High grade morphologically 
normal (HGN) 
15   1 14 15 
Sensitivity 
 
83.3% 86.7% 
 
Specificity 90.9% 93.3% 
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Discriminating between dysplastic tissue as low grade and high grade dysplasia, the scatter 
plots that discriminates the two types of tissue samples are shown in Figure 6.50, in which 
five cases of LGD were misclassified as HGD, whilst four HGD samples were misclassified 
as LGD. This indicats a poor performance of this model associated with lower levels of 
sensitivity (58.3%) and specificity (73.3%); Table 6.23. 
 
 
 
Figure 6.50: Scatter plots of the significant discriminant scores between low grade 
dysplasia (LGD) and high grade dysplasia (HGD). 
 
Table 6.23: Sensitivity and specificity test of Raman classification between low and high 
grade dysplasia. 
Pathology Diagnosis 
Raman Assignment 
Total 
LGD HGD 
Low grade dysplasia (LGD) 12 7 5 12 
High grade dysplasia (HGD) 15 4 11 15 
Sensitivity 
 
58.3% 
 
Specificity 73.3% 
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6.7.7. Clinical Relations of the Raman Misclassified Cases 
Table 6.24 presents the main clinical features of cases used for the present Raman study. 
Tissue specimens used for current spectroscopic analysis were from 32 patients affected with 
different grades of the FOM epithelial dysplasia. Those patients were of an age range from 
33–77 years (mean, 55.28 years) and all patients were treated with laser surgery and followed 
up from 11 to 122 months (mean 48.5 months). Males and females were equally distributed 
in the Raman investigated cases (16 males and 16 females). 
 
In general, the majority of Raman misclassified cases were presented primarily as 
homogenous leukoplakias (7/9), whilst the remaining 2/9 were non-homogenous speckled. 
Also, all the misclassified cases were tobacco users and alcohol drinkers and the majority 
being males. The details of the clinical characterisations of the Raman misclassified cases, 
dysplastic and morphologically normal tissue samples were summarised in Table 6.25. 
Overall, five dysplastic cases were spectroscopy misclassified as morphologically normal 
tissues indicating the presence of normal constituents within the dysplastic tissue 
components. While four morphologically normal tissues were misclassified as dysplastic 
tissues representing the presence of dysplasia in the resection margins, since the 
morphologically normal tissue controls were taken from the resection margins. However, out 
of the four morphologically normal misclassified cases only one was with dysplastic margins 
and the remaining three cases were with clear excision margins. This indicates that these 
morphologically normal tissues with clear margins were subjected to field cancerization 
phenomenon and they were no longer considered as normal. Also, all the misclassified cases 
were disease-free, except the one with dysplastic margins, and underwent new site dysplasia 
formation at the most recent follow-up. 
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Table 6.24: The main clinical characterisations of all Raman cases. 
N
o
 
A
g
e
 
y
e
a
rs
 
S
e
x
 
Clinical  
types 
S
m
o
k
in
g
 
D
ri
n
k
in
g
 
H
p
a
th
 
W
H
O
 
R
a
m
a
n
  
p
re
d
ic
ti
o
n
 
H
p
a
th
 
B
in
a
ry
 
R
a
m
a
n
 
p
re
d
ic
ti
o
n
 
F
o
ll
o
w
-u
p
  
m
o
n
th
s
 
C
li
n
ic
a
l 
 
o
u
tc
o
m
e
 
1 36 F Non-homogenous/Speckled Yes Yes Md Md LGD LGD 15 DF 
2 64 F Homogenous leukoplakia Yes Yes Md Md LGD LGD 14 DF 
3 48 M Homogenous leukoplakia Yes Yes Md Md LGD LGD 122 DF 
4 54 F Homogenous leukoplakia Yes No Md Md LGD LGD 15 DF 
5 48 F Homogenous leukoplakia Yes Yes Md Md LGD LGD 68 DF 
6 45 F Homogenous leukoplakia Yes Yes Md Md LGD LGD 30 DF 
7 56 F Homogenous leukoplakia Yes No Md Md LGD LGD 89 DF 
8 64 M Homogenous leukoplakia Yes Yes Md Md LGD LGN 26 DF 
9 71 F Homogenous leukoplakia Yes No Md Md LGD LGD 56 DF 
10 33 F Homogenous leukoplakia Yes Yes Md Mn LGD LGN 12 DF 
11 59 F Homogenous leukoplakia Yes Yes Md Md LGD LGD 16 DF 
12 35 M Homogenous leukoplakia Yes Yes Md Md LGD LGD 81 DF 
13 62 M Homogenous leukoplakia Yes Yes Modd Modn HGD HGD 74 DF 
14 67 M Non-homogenous/Speckled Yes Yes Modd Modd HGD HGD 11 DF 
15 42 M Homogenous leukoplakia Yes Yes Modd Modd HGD HGD 116 DF 
16 40 F Homogenous leukoplakia Yes Yes Modd Modd HGD HGD 35 R 
17 77 M Homogenous leukoplakia Yes Yes Modd Modd HGD HGD 12 DF 
18 56 F Homogenous leukoplakia Yes Yes Modd Modn HGD HGD 26 DF 
19 54 F Homogenous leukoplakia Yes Yes Mod d Modd LGD LGD 72 DF 
20 65 M Homogenous leukoplakia Yes Yes Modd Modd LGD LGD 60 DF 
21 58 F Homogenous leukoplakia Yes Yes Modd Modd HGD HGN 73 DF 
22 58 F Homogenous leukoplakia Yes No Modd Modd HGD HGN 24 DF 
23 66 F Homogenous leukoplakia Yes Yes Sd Sd HGD HGD 21 DF 
24 39 M Non-homogenous/Speckled Yes Yes Sd Sd HGD HGD 119 NSD 
25 76 F Homogenous leukoplakia Yes No Sd Sd HGD HGD 27 NSD 
26 58 M Non-homogenous/Speckled Yes Yes Sd Sd HGD HGD 38 DF 
27 47 M Erythroplakia Yes Yes Sd Sd HGD HGD 110 R 
28 58 M Non-homogenous/Speckled Yes Yes Sd Sd HGD HGD 24 MT 
29 52 M Homogenous leukoplakia Yes Yes CIS CISn HGD HGD 48 DF 
30 59 M Non-homogenous/Speckled Yes Yes CIS CIS HGD HGD 35 MT 
31 59 M Homogenous leukoplakia Yes Yes CIS CISn HGD HGD 12 DF 
32 63 M Non-homogenous/Exophytic Yes Yes CIS CIS HGD HGD 70 R 
 
F=female; M=male; Md=mild dysplasia;Mn=morphologically normal from Md; Modd=moderate 
dysplasia; Modn=morphologically normal from Modd; Sd=severe dysplasia; Sn=morphologically normal 
from Sd; CIS=carcinoma in situ; CISn=morphologically normal from CIS; HGD=high grade dysplasia; 
HGN=morphologically normal  from HGD; LGD=low grade dysplasia; LGN=morphologically normal 
from LGD; DF=disease-free; R=recurrence; MT=malignant transformation; NSD=new–site dysplasia. 
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Table 6.25: Details of the Raman misclassified cases based on dysplastic tissue 
against morphologically normal tissue. 
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59 F 
Homogenous 
leukoplakia 
Intermediate  
20 cig./day 
Mild  
1 u/w 
Dysplasia MorphN Clear 16 DF 
62 M 
Homogenous 
leukoplakia 
Heavy  
30 cig/day 
Heavy  
42 u/w 
Dysplasia MorphN Modd 74 DF 
65 M 
Homogenous 
leukoplakia 
Intermediate  
15 cig/day 
Intermediate 
25 u/w 
Dysplasia MorphN Md 60 DF 
59 M 
Homogenous 
leukoplakia 
Intermediate  
15 cig/day 
Heavy  
50 u/w 
Dysplasia MorphN Md 10 DF 
52 M 
Homogenous 
leukoplakia 
Heavy  
25 cig/day 
Heavy  
40 u/w 
Dysplasia MorphN Clear 48 DF 
48 M 
Homogenous 
leukoplakia 
Intermediate  
20 cig/day 
Mild  
14 u/w 
MorphN Dysplasia Clear 121 DF 
66 F 
Homogenous 
leukoplakia 
Heavy  
25 cig/day 
Mild  
10 u/w 
MorphN Dysplasia Clear 20 DF 
39 M 
Non-homogenous 
Speckled 
Heavy  
40 cig/day 
Heavy  
70 u/w 
MorphN Dysplasia CIS 119 NSD 
58 M 
Non-homogenous 
Speckled 
Intermediate  
20 cig/day 
Heavy  
50 u/w 
MorphN Dysplasia Clear 38 DF 
 
F=female; M=male; Hpath=histopathology; morphN=morphologically normal; Modd=moderate 
dysplasia; Md=mild dysplasia; CIS=carcinoma in situ; DF=disease-free; cig=cigarettes; 
u/w=units/week; NSD=new–site dysplasia. 
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6.8. Discussion 
6.8.1. Practical Considerations 
The present study was conducted to investigate the suitability of confocal Raman 
microspectroscopy to differentiate between morphologically normal and dysplastic tissue 
spectra, and also to examine the ability of this technique to detect dysplastic changes at early 
stages. This work differs from that previously published in that the present study used a 
single oral subsite, with different grades of dysplasia and morphologically normal tissue from 
their resection margins, using two grading systems (WHO and binary). 
 
Only laser excision biopsy samples were used in this study, as they provided sufficient tissue 
material, optimal orientation, adjacent to morphologically normal epithelium at the excision 
margins, representative of the clinical lesion and these biopsies were the standard approach 
for the final diagnosis. Sixty-four tissue locations within 32 FOM tissue specimens (the most 
common affected oral site) from 32 patients were studied. Based on consensus 
histopathological diagnosis of the two efficient oral pathologists, tissues were classified 
according to the current WHO classification systems: mild, moderate, severe dysplasia and 
CIS (Gale et al., 2005) and novel binary system: high and low grade dysplasia (Kujan et al., 
2006). The current study used only one oral site (FOM) to reduce the variations that might be 
related to different anatomical sites. This study was different from Malini et al.’s (2006) 
study which used mixed oral tissue (gingiva and FOM). In addition, all patients in this study 
were from one ethnic group (caucasian) recruited from the North-East of the England at 
Newcastle General Hospital. 
 
Recently, it has been demonstrated by Guze et al. (2009) that Raman spectra were consistent 
among individuals of different ethnicity and sex and they depend largely on the type of oral 
mucosa being investigated. Raman signal varied between gingival tissue and cheek mucosa 
and similarly between dorsal and ventral tongue surfaces. They explained that under the basis 
of differences or similarities in the molecular composition of lipids, proteins, carbohydrates 
of different oral subsites quantitatively and/or qualitatively (Guze et al., 2009). This was also 
supported by a study conducted by Krishna et al. (2004) who reported that Raman spectrum 
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is site dependent and the location of spectral measurement should be mentioned for the 
purpose of differentiation between normal and pathological tissue spectra. 
 
The current gold standard of diagnosis of oral epithelial dysplasia is through clinical 
examination, biopsy taking and histopathological evaluation of cytological and architectural 
abnormalities (Muller et al., 2003). However, histopathological assessment of tissue is based 
mainly on cellular and nuclear morphology, heavily relying on the pathologist’s experience 
with unsatisfactory levels of inter- and intra-observer variability. It remains a time consuming 
technique requiring  a preparatory process and is unable to provide immediate diagnostic 
feedback (Bird et al., 2008). Therefore, there is a real need for an objective real time 
diagnostic system able to overcome the observer variability and independent of 
morphological changes (Papamarkakis et al., 2010), requiring no tissue preparation (staining 
and labelling) and amenable to multivariate statistical techniques. 
 
The choice of substrate is a vital issue and important step in experimental design of a 
microspectroscopic study (Romeo et al., 2006). In a preliminary validation study, ordinary 
glass slides that were routinely used in histopathology were used for FFPE tissue mounting 
with subsequent de-waxing and spectral measurements. However, no Raman signal was 
identified from the investigated area and that might be due to strong absorbance property of 
glass slides as reported previously by Romeo et al. (2006). In the current study, tissue 
samples were mounted on BaF2 substrate (10 µm thick sections). BaF2 window has been 
chosen based on the fact that it has no Raman signature within the selected spectral range 
(800–1800 cm-1) of the biological samples (Gobinet et al., 2009), with only one Raman peak 
at ~242 cm
-1
 (Chen and Shen, 2006) eliminating any spectral tissue contamination from the 
mounting materials, and also has been successfully used in similar studies.  
 
Fresh tissue in saline may be an ideal tissue for optical spectroscopy because biochemically, 
it is the best simulation for in vivo conditions. However, quick decay, handling difficulties 
and unavailability (Krishna et al., 2005a) necessitated the evaluation of suitability of other 
types of tissue for Raman study, such as formalin fixed (Krishna et al., 2004) and FFPE tissue 
samples (Krishna et al., 2005a). FFPE tissues were used in this study due to the availability 
from the pathology archive for larger sample study (Krishna et al., 2007b) and suitability for 
retrospective studies providing valuable information about patients outcomes which can be 
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correlated with Raman spectral data (Kendall et al., 2009) for a robust spectroscopic 
diagnostic technique.  
 
As with any microscopic tissue examination, Raman microspectroscopic tissue analysis 
requires a thin homogenous tissue section (similar thickness) which transmits light. This 
necessitates a preparatory process of embedding medium for supporting and easily sectioning 
of the specimen (Ó Faoláin et al., 2005b), with the advantage of easily dissolving away from 
tissue. Therefore, the investigation of tissue that has been chemically treated is unavoidable 
in this situation, and it is likely to have small affects upon the biochemistry of the tissue, with 
these modifications affecting the comparable tissues (normal and dysplastic) more or less 
similarly (Krishna et al., 2004). For example, during the paraffin-wax embedding procedure, 
which is an efficient procedure for conserving tissue biopsies for several years, tissue sections 
were subjected to a series of solvents that may dissolve lipids and consequently remove them 
from the tissue sections. Therefore, such tissue preparation is not recommended for the 
investigation of adipose rich tissues (Shim and Wilson, 1996; Bird et al., 2008) and fresh or 
fresh frozen tissues samples that can preserve lipids, was recommended to discriminate 
normal from diseased tissues (Tfayli et al., 2005). Additionally, using FFPE sections directly 
are very restricting due to highly intense paraffin signals which are able to mask Raman 
spectra (Haka et al., 2002; Bird et al., 2008; Tfayli et al., 2009). Therefore, de-paraffinisation 
and rehydration of tissue is recommended for spectroscopic tissue analyses. 
 
In this study after tissue mounting and prior to tissue analysis, all samples were 
deparaffinised using n-hexane as a de-waxing agent followed by alcohol wash. Previously, it 
has been assumed that after formalin fixation there will be no further alteration of the 
secondary protein structures in the tissue due to the de-waxing process (Mason and O'Leary, 
1991). The same group also indicated that formalin fixation does not cause noticeable 
changes in proteins and they supported that by similarity of both fixed and unfixed tissue 
spectra acquired. However, previous work in ovarian tissue conducted by Krishna et al. 
(2005a) showed severe tissue alterations following tissue de-waxing spatially to the protein 
structures.  
 
In light of the current study, some of the previously reported problems associated with de-
waxing procedures, such as the remnant of a residual layer of paraffin wax have been shown 
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to be related to the choice of inefficient routine de-waxing agents (solvents). In the present 
study, n-hexane followed by ethanol was used to remove the wax. This type of solvent has 
been shown to be an effective and a superior de-waxing agent in the removal of paraffin and 
eliminating the contamination of Raman tissue spectra (Ó Faoláin et al., 2005b). Since all 
specimens used in this study were processed using an identical protocol, the type of 
alterations that might have occurred to the proteins after processing is consistent amongst all 
specimens and was unlikely to cause any major effect to the tissues under investigation, and 
leading to no overall reduction in the precision of this study.  
 
The present study is the first spectroscopic study, to the best of our knowledge, that used de-
paraffinised FFPE oral tissues; however, similar studies were conducted using the same 
processing but on different types of tissue, such as breast (Haka et al., 2002), ovarian 
(Krishna et al., 2005a) and cervical tissue (Ó Faoláin et al., 2005a; Lyng et al., 2007).  
 
In spite of sufficient discriminant information for spectroscopic pathology to discriminate 
normal from abnormal tissue, obtained from chemically de-waxed tissues (Ó Faoláin et al., 
2005a), another study conducted by Tfayli et al. (2009) reported that the de-waxing process is 
both time and reagent consuming and causes alteration in the protein tissue structure, in 
addition to the remnants of some residual paraffin. 
 
Recently, attempts have been made to remove the paraffin-wax contamination to the Raman 
spectrum; a process termed digital de-waxing (Vrabie et al., 2007; Tfayli et al., 2009). In 
these studies and as part of the pre-processing steps, the spectrum of paraffin is subtracted 
from the spectrum taken from the tissue sample and from the mounting substrate. However, 
this technique relies on complicated mathematical processing of the spectra, with 
consequential increases in processing time. It also is not clear if the digital removal procedure 
actual removes only the contribution from the paraffin or may affect other information, or if it 
is possible that extra information, not actually present in the spectrum, may be added to the 
processed data. 
 
In pathological diagnosis, since a particular disease state is the same for all patients’ age 
group and sex, the same should be for the spectroscopic tissue diagnosis (Viehoever et al., 
2003), with an ultimate aim of developing an accurate and objective optical tissue diagnosis 
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regardless of inherent patients’ diversity in both demography and genetic state. Furthermore, 
the similarity between histopathological and Raman measurements is that the histopathology 
examines several tissue sites under the microscope, some of these sites may not show any 
abnormality; however, if one site is found to be abnormal the diagnosis will be abnormal 
(dysplasia or cancer). Similarly, Raman spectra can be recorded at several sites and spectra 
from each site subjected to PCA to check if any site is abnormal (Krishna et al., 2005a). Since 
histopathological changes involve morphological and biochemical alterations within 
cells/tissue (Huang et al., 2003b; Lau et al., 2005), RS has the ability to provide highly 
specific detailed information about these biochemical changes qualitatively and 
quantitatively. This technique may be a promising objective diagnostic tool for discriminating 
dysplastic from morphologically normal tissue by early detection of molecular dysplastic 
changes at a cellular level.  
 
In this study, Raman spectra acquisition along the selected wavelength 800–1800 cm-1 which 
is well known to encode the most important information of biochemical tissue changes (Li et 
al., 2010), the so-called “fingerprint” (Teh et al., 2008) commonly used by research groups 
working within oral tissues (Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 
2006). Spectra were collected from multiple points per mapping area along the basal cell 
layer. The advantages were to cover most of the constituents in the area for the benefit of 
searching for the largest differences and to minimise the intra-sample variability by avoiding 
mispositioning of the points in the investigated area if point-by-point scanning was used (de 
Veld et al., 2005b). Also, the mapping technique allows time-efficient automated spectral 
acquisition from a defined area of a tissue (Venkatakrishna et al., 2001). Further, in epithelial 
cancer, the abnormal cells proliferation start near the basal lamina and then advance into the 
epithelial cell layers (Malini et al., 2006). Thus, in this study, the spectral measurements were 
taken along the basement membrane. 
 
The Raman spectra of biological tissue specimens are very complex and they are usually 
combination of Raman spectra with noise signals, and known to be affected by a broad 
fluorescence background (Huang et al., 2003b; Gobinet et al., 2007; Teh et al., 2008). The 
CCD detector in Raman system records a noise signal, named dark current even without 
sample and laser light, so there is unfortunately unavoidable contamination to Raman 
spectrum. The fluorescence background which is mainly due to intrinsic tissue fluorophors 
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(Mahadevan-Jansen and Richards-Kortum, 1997; Gobinet et al., 2007), is often several orders 
of magnitude more intense than the Raman spectrum, and if untreated, can dominate the 
Raman spectra and make data analysis impractical.  
 
In the current study, in order to eliminate the influence of the aforementioned contaminations 
on Raman tissue spectra and other sources of variation that may be related to instrumentation 
imperfection (calibration shift) (Gemperline, 2006); data pre-processing prior to data analysis 
has been accomplished through sequential steps to achieve a successful data analysis (Lieber 
and Mahadevan-Jansen, 2003; Taleb et al., 2006; Lee et al., 2007a). Thus, in this study 
altering sample composition (Mahadevan-Jansen and Richards-Kortum, 1997) through a 
photo-physical bleaching of 120 seconds was used to excite the fluorescent molecules within 
the tissue from ground state to higher energy levels to eliminate their fluorescent properties. 
Under the foregoing conditions, no sample degradation was observed during the 
measurements, as confirmed by the morphological appearance of the white light image, 
indicating the temporary effect of the photo-bleaching on tissue rather than permanent 
damage. 
 
In the current study, similar to a previous study on skin cell line conducted by Donfack et al. 
(2010), the majority of the excluded bad spectra were found to be from the morphologically 
normal tissue compared to dysplastic tissue spectra. This may be due to simple physical 
distortions, bending or twisting of the normal tissue which is usually located at the distal end 
of the resection margins of the dysplastic tissue mounted on the barium fluoride near the 
substrate margins. Also, the absolute signal intensity is not very reproducible in the measured 
Raman spectra and has different intensity ranges depending on many experimental conditions 
(laser intensity, accumulation time, temperature variations and tissue constituents) (Skoulika 
et al., 1999). In the present study, for the purpose of groups comparison and to compensate 
for such variations in spectral shape and peak intensities (Huang et al., 2003b; Teh et al., 
2008), Raman spectra were normalised against the mean intensity between 1435 and 1480 
cm
-1
 band corresponding to the full width at half maximum for CH2 scissor mode centred at 
~1450 cm
-1
 to minimise the impact of variation of peak position and reduce the effect of 
noise. The choice of CH2
 
band for normalisation is based on both commonly used and the 
most stable in all biochemical constituents of the cells, for example Le Bihan et al. (1996), 
Notingher et al. (2003b) and Notingher et al. (2004). 
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There are hundreds, to more than thousands, of Raman spectra with each spectrum ranging 
from 800–1800 cm-1 and containing 629 intensity values. Manual investigation of such a high 
dimensional data sets proves difficult to achieve efficient data analysis (Lee et al., 2007a), 
hence multivariate data analysis was used to reduce the high dimensional data set by 
condensing the spectral information into completely new variables, describing the key 
information from the original data for groups classification, using the established techniques, 
such as PCA fed to PLS-DA. However, a univariate approach of data analysis was also used 
to investigate the diagnostic capability of Raman by using an individual spectral feature, such 
as peak relative intensity and position, which was also found to be useful in identifying 
spectral diagnostic markers in previous studies (Mahadevan-Jansen et al., 1998; Krishna et 
al., 2004; Stone et al., 2004; Lyng et al., 2007; Huang et al., 2010; Teh et al., 2010a). 
 
For diagnostic purposes and to compare spectral differences between groups of tissue, all the 
scanning parameters, such as time, accumulation number, laser power and wavelength were 
kept constant during the experiment for all samples. Changing any of these conditions may 
result in intensity differences not related to the disease state, but to the experimental 
environment. 
 
In this study, a small pilot study was designed to investigate the effect of different scanning 
times and accumulate numbers on spectral quality, 30 second acquisition times with 2 
accumulations were found to be suitable and providing a good spectral quality. That was 
supported by a study conducted by Lyng et al. (2007) who used the same accumulation time 
on cervical tissue spectral analysis. Also, it has been reported earlier that spectral intensity 
differences may be related to variations in tissue section densities (Ó Faoláin et al., 2005c). 
However, that is not applicable in this study, because all tissue sections were with the same 
thickness (10 µm) and the differences in the relative peak intensity observed between groups 
are due to biochemical changes related to disease state and not to the effect of specimen size. 
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6.8.2. Spectral Feature and Peak Assignments  
The primary aim of this work was to develop a spectroscopic tissue diagnosis based on 
overall spectral differences. Thus, it was necessary to obtain an average spectrum from 
different points in the tissue to be used as a representative spectrum of the investigated site 
(Krishna et al., 2004; Tfayli et al., 2005). These mean spectra from several sites in both 
dysplastic and morphologically normal tissue were used for spectroscopic data analysis to 
eliminate the variation of single spectrum and maintain commonality (Li et al., 2010). 
 
A set of Raman peaks of each representative spectrum of dysplastic and morphologically 
normal tissues were identified and a direct visual comparison was carried out. The observed 
differences between spectra are generally based on the associated changes in chemical bonds 
vibrations identified at particular wavenumbers (Wang and Mizaikoff, 2008) and reflect the 
biochemical tissue changes related to the disease state. Increases or decreases in the 
concentration of a certain type of biomolecule in dysplastic tissue is reflected by an intensity 
difference from morphologically normal tissue. In this study, a difference spectrum was also 
calculated by subtracting one spectrum from another to emphasise the main differences 
between the two spectra for comparison purposes (Hutchings, 2009). 
 
A similar biochemical tissue changes between the dysplastic and the malignant tissues were 
reported and confirmed by the presence of the same spectral features at some wavelengths in 
both carcinoma and dysplasia in cervical tissue spectra (Lyng et al., 2007). Shim et al. (2000) 
reported the same differences between normal and dysplasia in oesophageal epithelial tissue 
in the same bands which was observed between normal and cancer tissues in the nasopharynx 
that was found by Lau et al. (2003). 
 
 
Mild Dysplasia 
In general, this has shown that the dysplastic spectrum showed a predominant protein pattern 
with contributions from nucleic acids, amino acids, such as phenylalanine, tryptophan and 
tyrosine. Although no significant intensity differences between mild dysplasia (Md) and 
morphologically normal tissue from mild dysplasia (Mn) for the majority of the identified 
peaks, a significantly higher relative intensity of phenylalanine protein at 1009 cm
-1
 was 
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observed in Md. This reflects increased protein content associated with dysplastic changes. 
This is an expected finding due to the fact that mild dysplasia is a first step in the progression 
from normal, with most of the components of normal tissue still found in this early stage of 
dysplasia and the changes in biochemical tissue constituents may be in low or undetectable 
concentrations (Kendall et al., 2011). The significantly higher intensity of phenylalanine 
protein in mild dysplasia reflects the ability of the Raman system to detect early biochemical 
tissue changes at early stages. In addition, the relative intensity of the small bands at 834, 886 
and 902 cm
-1
 in Md, are more intense than in Mn. These bands may be attributed to nucleic 
acids, proteins and amino acids, respectively, which is in agreement with the concept of 
protein predominant patterns in dysplastic tissue with contributions from amino acids and 
nucleic acids from the proliferating cells and from surface proteins, signalling, antibody, 
antigens and enzymes associated with transformational changes (Venkatakrishna et al., 2001; 
Krishna et al., 2004; Malini et al., 2006).  
 
The wavenumber at 1039 cm
-1
 corresponding to phenylalanine (protein) showed a lower 
intensity in Md compared to Mn with no obvious reason. This is consistent with a study 
conducted by Teh et al. (2008) who reported a lower intensity of phenylalanine proteins in 
dysplasia of gastric mucosa compared to normal tissue, with no clear explanation. Also, a 
higher intensity of glycogen at 1022 and 1048 cm
-1
 in Mn compared with Md was found. The 
decreased intensity of glycogen in dysplastic oral tissue even in mild dysplasia has been 
reported previously by Isacsson and Shear (1981) who studied the content and distribution of 
glycogen in oral epithelial dysplasia and found to be decreased in dysplasia. This has been 
explained under the basis of either increases in metabolic activity, for more energy 
consumption from cellular proliferation during the transitional process from normal to 
dysplastic (Stone et al., 2002b), or may be due to a decrease in glycogen synthesis in oral 
epithelial dysplasia; however, the difference was not statistically significant in this study. 
 
The band at 1301 cm
-1 
(CH2 deformation lipids) is more intense in Mn, which is in agreement 
with the fact of lipids dominated the spectra of normal epithelial tissue. This is mainly due to 
the fact that normal tissue consists of a closely packed layer of surface epithelial cells, with 
their lipid bilayer membranes expose to the laser excitation, resulting in the membrane lipid 
dominated spectrum for normal tissue (Krishna et al., 2004). In addition to their small nuclei 
with less contribution from nucleic acids of non-proliferating cell (Krishna et al., 2004). 
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Similarly, Mn showed a higher relative intensity at 1423 cm
-1
 (nucleic acids), but for no clear 
reason. 
 
Raman peaks only seen in the spectrum of Mn at 1251 cm
-1
 (amino acids), 1272 cm
-1
 (amide 
III of protein) and 1600 cm
-1
 (phenylalanine, tyrosine). This may be due to the degradation of 
these constituents in Md as a part of the disease process and no longer can be detected 
because of low concentrations (Kendall et al., 2011).  
 
A noticeably higher relative intensity at 1317 cm
-1
 (guanine ring breathing mode of nucleic 
acids bases), 1347 cm
-1
 (CH2 protein, nucleic acids) and 1377 cm
-1
 (thymine, guanine, 
adenine amino acids) in Md was found. This suggests an increased amount of nucleic acids 
and proteins in proliferating cells (Short et al., 2005) and also increased nuclear/cytoplasmic 
ratio as a part of cellular transformation in dysplastic changes (Stone et al., 2002b). This 
agrees with the knowledge of histopathology in grading of epithelial dysplasia depending 
upon nucleic acid to cytoplasmic ratio (Huang et al., 2003b). The results of the spectroscopic 
study are in agreement with histopathological study of biopsy as a typical standard for the 
biospectroscopic identification. 
 
Also, in Md, a higher intensity at 1591 cm
-1
 assigned to olefinic stretch of lipids was seen, but 
the difference was not statistically significant. This is an unexpected finding, since lipids 
mainly dominate the spectra of normal tissue and this may be due to the presence of normal 
constituents within the Md spectrum. Similarly, Md showed a higher relative intensity at 
1609 cm
-1
 (aromatic amino acids) which is consistent with the development of new surface 
proteins, amino acids formation, and contribution from the proliferating epithelial cells in 
dysplasia (Krishna et al., 2004). Also, Md showed a higher relative intensity of amide I of 
proteins at 1661 cm
-1
 which suggests an increase in the relative amount of protein in 
dysplastic tissue (Mahadevan-Jansen and Richards-Kortum, 1996). 
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Moderate Dysplasia  
A significant higher intensity at 1087 cm
-1
 (C-C stretching mode of lipids) in 
morphologically normal tissue from moderate dysplasia (Modn) was observed, compared 
with moderate dysplasia (Modd). This is supported by the observations of lipid dominated 
spectra of normal epithelium previously reported (Venkatakrishna et al., 2001; Krishna et al., 
2004; Malini et al., 2006). 
 
Peaks or shoulders seen in Modn were either very weak or absent in Modd including 879 cm
-
1
 (hydroxyproline, tryptophan), 1315 cm
-1
 and 1457 cm
-1
 (guanine ring breathing mode of 
nucleic acids base), 1623 cm
-1
 (tryptophan, phenylalanine protein) and 1673 cm
-1
 (tyrosine 
and amide I of protein). Similar to mild dysplasia, this may suggest degradation or 
disordering in the related tissue components associated with the dysplastic transformation 
process. These biochemical changes are more likely reflective of the progression from normal 
to moderate dysplasia supported by the histopathological base of knowledge. 
 
In this study, in Modd, higher relative intensity at 896 cm
-1
 (backbone of nucleic acids), 929–
931 cm
-1
 (amino acids proline, valine), 971 cm
-1 
and 1137 cm
-1
 assigned to proteins, 1322 cm
-
1
 (guanine of nucleic acids), 1345 cm
-1
 (CH2 proteins thymine, guanine, adenine amino acids) 
and amide I of proteins at 1658 cm
-1
. This suggests the progressive increase in proteins, 
amino acids and nucleic acid components reflecting the progress of the disease from normal 
towards dysplasia. It is in agreement with what was reported by Krishna et al. (2004) and 
Stone et al. (2002b). 
 
The band at 1301 cm
-1
, 1448 cm
-1
 (CH2 deformation lipids) and 1591 cm
-1
 attributed to C=C 
olefinic stretch of lipids were unexpectedly more intense in Modd, similar to Md, although 
this was not significant. This may be due to the presence of normal tissue constituents within 
the dysplastic region of Modd (Krishna et al., 2004), which may lead subsequently to 
misclassification.  
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Severe Dysplasia 
Two significant peaks were identified: one at 1243 cm
-1
 assigned to amide III of protein 
which was more intense in morphologically normal from severe dysplasia (Sn) compared to 
severe dysplasia (Sd). This unexpected decreased in amide III of protein intensity in Sd 
suggests degradation and/or disordering of proteins accompanying the disease process and is 
supported by the study conducted by Donfack et al. (2010) who reported disordered and 
degraded protein structures in neoplastic skin cells compared to normal cells. This finding is 
in contrast with the earlier finding of a laryngeal tissue study conducted by Stone et al. 
(2000) who found a higher intensity of amide III based on protein secondary structures with 
progression from normal to precancerous to carcinoma, indicating an increased protein 
cellular contents in precancerous lesions compared to normal tissue. 
 
The second significant peak was found in severe dysplastic tissue specimens at 1344 cm
-1 
(CH2 CH3 proteins), which suggests increased protein content in Sd from the proliferating 
cells, surface proteins, antigens, antibody, and enzymes associated with transformation 
process from normal to dysplastic (Venkatakrishna et al., 2001; Krishna et al., 2004; Malini 
et al., 2006), or may be due to the synthesis of new protein contributions in Sd from the 
proliferated cells (Notingher et al., 2003b).  
 
In Sn and similar to Mn and Modn, a higher relative intensity of phenylalanine at 1037 cm
-1 
was observed; however, there is no direct cause for the higher phenylalanine level in Sn 
tissue sample compared to Sd, but probably, as previously mentioned, is due to degradation 
and disorientation of proteins in severe dysplastic tissue. 
 
The wavenumber corresponding to 1052 cm
-1
 attributed to glycogen was more intense in Sn 
compared to Sd, this is in agreement with the finding of Isacsson and Shear (1981) who 
reported a decrease in glycogen content in oral epithelial dysplasia due to increased metabolic 
activity that needs the glycogen source of energy or may be due to a decrease in glycogen 
synthesis in dysplastic tissue. 
 
The bands at 1052 cm
-1
 (glycogen), 1066 cm
-1
 and 1091 cm
-1
 (lipids) were more intense in 
Sn. This is supported by both higher level of glycogen (Isacsson and Shear, 1981) and lipid 
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dominated spectra (Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 2006) in 
normal tissue spectra. 
 
Another unexpected finding in Sn is the higher relative intensity of 1213, 1243 and 1423 cm
-1
 
attributed to proteins and nucleic acid backbone. Although there is no clear reason for more 
intense levels of these components in Sn, this may reflect the ability of RS for early detection 
of dysplastic features at a molecular level before their morphological appearance (Keller et 
al., 2008), or may be due to the presence of dysplasia in the resection margin, which was 
considered as histologically normal. 
 
Severe dysplasia showed higher relative intensities at 829 cm
-1
 (tyrosine of nucleic acids), 
961 cm
-1
 (symmetric stretching of PO4
-
), 1007 cm
-1
 (phenylalanine), 1135 cm
-1
 (C-N 
proteins), 1174 cm
-1
 (tyrosine, phenylalanine, proteins), 1315 cm
-1
 (guanine, nucleic acids), 
1344 cm
-1
 (CH2 protein), 1375 cm
-1
 (thymine, guanine, adenine amino acids), 1609 cm
-1
 
(aromatic amino acids), 1620 cm
-1
 (tryptophan, proteins) and 1658 cm
-1
 (amide I of proteins). 
These suggest higher content of proteins, amino acids and nucleic acids in dysplastic tissue 
spectra which was also reported previously (Stone et al., 2002b).  
 
Peaks such as 1299 cm
-1
 and 1446–1458 cm-1 attributed to CH2 deformation lipids, and peak 
at 1589 cm
-1
 assigned to oleifinc stretching mode of lipid showed higher intensity in Sd 
compared to Sn. These unexpected findings may further support the concept of normal tissue 
constituents within the dysplastic tissue components and is in agreement with a previous 
study conducted by Krishna et al. (2004) who indicated that most of the normal tissue 
components are still found in the malignant tissue. 
 
Furthermore, in Sn, a peak such as at 1102 cm
-1
 assigned to lipids was either absent or very 
weak in Sd. This agrees with lipid-dominated spectra of normal tissue compared with protein-
dominated spectra in dysplastic tissue. Also, the peak assigned to nucleic acids at 1326 cm
-1
 
was seen in Sn, while absent or weak in Sd. This is an unexpected finding and may be due 
again to degradation of proteins as cells respond to the disease (Papamarkakis et al., 2010) 
with subsequent lower concentration for detection (Kendall et al., 2011). 
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Carcinoma in situ 
Although the differences in the majority of Raman peaks between CIS and morphologically 
normal from CIS (CISn) were subtle, there were two peaks in CIS tissue specimens with 
significantly higher intensity compared to CISn spectrum: 1007 cm
-1
 and 1091 cm
-1
 
corresponding to phenylalanine proteins and O-P-O stretching mode of nucleic acids, C-C 
proteins, respectively. The peak at 1037 cm
-1
 attributed to phenylalanine proteins was more 
intense in CIS, but was not significant. As reported previously by Krishna et al. (2004), in 
CIS, cells in all layers of stratified epithelium are proliferating and are more likely to express 
many surface proteins from signalling agents, antigens, antibodies and enzymes. This may 
explain the higher proteins and nucleic acid content in this type of tissue, which is in 
complete agreement with histopathology. 
 
Clearly, a decrease in relative intensities was observed in CIS at 1135 cm
-1
 (C-N protein), 
1176 cm
-1
 (tyrosine, phenylalanine, proteins), 1238 cm
-1
 (amide III of proteins), 1299 cm
-1
 
(CH2 deformation lipids), 1344 cm
-1
 (CH2 protein), 1375 cm
-1
 (thymine, guanine, adenine 
amino acids), 1589 cm
-1
 (C=C stretch olefinic of lipid), 1608 cm
-1
 (aromatic amino acids), 
1621 cm
-1
 (tryptophan proteins) and 1661 cm
-1
 (amide I of proteins). The lower intensity of 
amide III of proteins and amino acids in CIS tissue specimens compared to CISn was similar 
to what were seen in severe and moderate dysplasia, indicating disturbances of protein 
structures from ordered to unordered proteins with progression of dysplasia severity 
compared to normal (Gniadecka et al., 1997). Or may be due to degradation of proteins as 
cells respond to the disease (Papamarkakis et al., 2010), with subsequent lower concentration 
for detection (Kendall et al., 2011). 
 
Contrary, in this study, mild dysplasia demonstrates higher intensity of amide III of protein 
compared to normal tissue, suggesting increased relative amount of proteins (Mahadevan-
Jansen and Richards-Kortum, 1996). Similar to amide III of protein, the intensity of amide I 
is less intense in CIS compared to CISn, which is more likely due to lower proteins contents 
in CIS tissue reflecting protein degradation and/or disordering, or may be due to highly 
ordered protein content in CISn. This was confirmed by a prominent or strong peak in CISn 
compared to degraded unordered protein conformations in CIS confirmed by a lower 
intensity, weak or missing peaks. 
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Considering the lower intensity of 1299 cm
-1
 and 1589 cm
-1
 band in CIS compared to CISn 
which suggests lower contents of lipid in CIS. This agrees with the concept of biological 
transformation process from normal to CIS in which lower contents of lipid and higher 
content of proteins/nucleic acids. However, the same wavelengths (1299 cm
-1
 and 1589 cm
-1
) 
were found to be more intense in Md, Modd and Sd, compared to CIS tissue spectra.  
 
In addition, small band such as 859, 882, 892, 926 and 936 cm
-1
 which were generally 
attributed to amino acids proteins and nucleic acids, were seen more intense in CIS. This was 
in agreement with the histopathological findings of dysplastic tissue changes of more proteins 
and nucleic acids with dysplastic transformation process from cellular proliferation 
(Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 2006). 
 
 
Low Grade Dysplasia (LGD) 
The significant intensity differences between LGD and morphologically normal from LGD 
(LGN) were identified at two Raman peaks. The first one is the higher relative intensity of 
amide I of proteins at 1660 cm
-1
 in LGD, suggesting an increase in protein content from 
proliferating cells, compared to LGN. This is in agreement with the concept of protein-
dominated spectra in malignant tissue and supported by the findings of Malini et al. (2006) 
who reported a broad and strong amide I of proteins (±5 cm
-1
) in oral tissue spectra of 
inflamed, premalignant and malignant tissues. Also, this is consistent with the findings of 
Lyng et al. (2007) who reported an increased intensity of amide I of proteins (±5 cm
-1
) in 
spectra of cervical carcinoma compared to normal tissue. However, this finding is 
inconsistent with the findings of Hu et al. (2009) who found a decreased relative intensity of 
amide I of proteins at 1660 cm
-1
 in oral cancer compared to normal tissue. 
 
The second significant peak corresponding to higher phenylalanine proteins level at 1009 cm
-
1
 in LGD compared to LGN. This may be due to more protein formation in dysplastic tissue. 
This is inconsistent with Teh et al. (2008) who reported lower intensity of phenylalanine 
proteins in dysplasia of gastric mucosa compared to normal tissue, but with no clear 
explanation.  
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In this study, a noticeably lower relative intensity was observed in LGD at 859 cm
-1
 (tyrosine 
protein), 1039 cm
-1
 (phenylalanine proteins), 1066 cm
-1
, 1083 cm
-1
 (C-C stretch lipids) and 
1104 cm
-1
 (phenylalanine proteins). The lower proteins contents in LGD suggests again 
degradation or disturbing of these constituents in dysplastic cells, while lower lipids content 
in LGD is consistent with the concept of lower lipids/higher protein content in dysplasia 
compared to morphologically normal. Generally, these spectroscopic changes further support 
protein-dominated spectra in malignant tissue and lipid-dominated spectra in normal tissue.  
 
The current study demonstrated more intense peaks in LGD, compared to LGN at 1135 cm
-1
 
(C-N protein), 1177 cm
-1
 (tyrosine, phenylalanine proteins), 1317 cm
-1
 (guanine ring 
breathing mode of nucleic acids bases), 1345 cm
-1
 (CH2 protein), 1379 cm
-1
 (CH3 hyaluronic 
acids), 1591 cm
-1
 (C=C stretch olefinic of lipids) and 1609 cm
-1
 (aromatic amino acids). This 
suggests more proteins, amino acids and nucleic acids associated with transformation process 
from normal to dysplastic and is supported by previous spectroscopic studies on oral tissues 
(Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 2006). While higher intensity 
of hyaluronic acids at 1379 cm
-1
 contributes significantly to cell proliferation and progression 
to malignancy (Krishna et al., 2004). A higher intensity of lipids at 1591 cm
-1
 in LGD is 
inconsistent with the knowledge of protein-dominated spectra in malignancy and lipid-
dominated spectra in normal tissue. However, this may further support the idea of normal 
tissue constituents still found within the dysplastic tissue components and it is in agreement 
with previous study indicated that most of the normal tissue components are still found in the 
malignant tissue (Krishna et al., 2004).  
 
New peaks in LGD were observed at 886 cm
-1
 and 983 cm
-1
 assigned to tryptophan and 
phenylalanine proteins respectively, suggesting new protein formation as disease progresses 
from normal to dysplasia, which is consistent with knowledge of disease process. 
 
In this study, in LGN, bands such as 1624 cm
-1
 and 1632 cm
-1
 assigned to proteins were very 
weak or absent in LGD. This again suggests degradation and/or disordering of these proteins 
associated with tissue transformation and reflected by weak or absent peaks in LGD, with 
subsequent lower or undetectable concentrations for spectroscopic detection (Kendall et al., 
2011). 
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High Grade Dysplasia (HGD) 
Significant differences in relative peak intensities were identified between HGD and 
morphologically normal from HGD (HGN) in 15 wavenumbers. In HGD, a significant higher 
relative intensity was found at 934 cm
-1
 (amino acids proline, valine), 1137 cm
-1
 (C-N 
proteins), 1322 cm
-1
 (guanine of nucleic acids), 1345 cm
-1
 (CH2 protein), 1377 cm
-1
 (thymine, 
guanine, adenine amino acids), and 1622 cm
-1
 (tryptophan, proteins). This suggests higher 
amount of proteins, amino acids and nucleic acids in HGD specimens associated with 
biological tissue transformation and seems to be consistent with other studies (Stone et al., 
2002b; Krishna et al., 2004; Lyng et al., 2007). In addition, the peaks at 1301 cm
-1
 and 1591 
cm
-1
 corresponding to CH2 deformation lipid and C=C olefinic stretch of lipid, respectively 
were also significantly more intense in HGD. These unexpected findings are not supported by 
the concept of protein-dominated spectra in dysplasia and cancer tissue. However, the higher 
intensity of 1301 cm
-1
 in HGD was similarly reported in dysplasia of gastric mucosa in a 
study conducted by Teh et al. (2008). The higher intensity of olefinic/lipid at 1591 cm
-1
 in 
HGD compared to HGN suggests the presence of normal tissue constituents within the 
dysplastic tissue spectra; however, it is inconsistent with the finding of Hu et al. (2009) who 
reported more intense C=C stretch olefinic of lipids (±4 cm
-1
) in normal oral tissue than in 
malignant tissue which is in agreement with the concept of lipid-dominated spectra in normal 
tissue. 
 
In this study, other significant bands were seen with lower relative intensity in HGD 
compared to HGN, at 1037 cm
-1
 (phenylalanine proteins), 1081 cm
-1
 (C-C stretch lipids), 
1104 cm
-1
 (phenylalanine proteins), 1176 cm
-1
 (tyrosine, phenylalanine, proteins), 1213–1243 
cm
-1
 (amide III of proteins) and 1448 cm
-1
 (CH2 deformation lipids). The lower intensity of 
phenylalanine protein in HGD may suggest degradation or disordering of proteins in 
dysplasia compared to morphologically normal tissue. This is consistent with Teh et al. 
(2008) who reported a lower intensity of phenylalanine at 1004 cm
-1
 in dysplasia of gastric 
mucosa, compared to normal tissue. They explained that in light of higher or lower amounts 
of a certain types of biomolecules in relation to the total Raman active component in 
dysplastic tissue. Also, a decreased intensity of 1081 cm
-1
 (phospholipids) in HGD is more 
likely supported by the previously mentioned concept of protein-dominated spectra in 
malignancy and lipid-dominated spectra in normal tissue. The lower relative intensity of 
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proteins and amino acids bands in HGD due to degradation and/or disturbances of theses 
structures, compared to HGN with subsequent low concentration and lower spectral intensity 
(Papamarkakis et al., 2010).  
 
In addition, the contribution of new peaks in the spectrum of HGD at 971 cm
-1
 and 1099 cm
-1
 
suggests new protein formation from cellular proliferation and other associated 
transformation processes. In HGN, the bands at 880 cm
-1
 and 1326 cm
-1
 corresponding to 
tryptophan proteins and purine bases of nucleic acids, respectively were absent in HGD. This 
may suggest degradation or disturbances of these components in dysplastic tissue, compared 
to normal tissue associated with disease progression. This is in agreement with the findings of 
Papamarkakis et al. (2010) who reported that with disease progression, degradation of 
common proteins and expression of different proteins as cells respond to the disease. 
 
 
6.8.3. Spectral Intensity and Dysplasia Severity 
By investigating the relationship between relative peak intensity and degree of dysplasia 
severity from the mild through moderate and severe to CIS, only two peaks were found with 
a consistent relation. The first one was attributed to amide III of protein at 1235–1243 cm-1 in 
which the intensity decreased with increased grade of dysplasia. This suggests lower protein 
content in relation to the total Raman active components, which disagrees with knowledge of 
the disease process that should reflect the progression from mild through moderate to severe 
and CIS. Also, this was unable to support the previous studies which indicated progressive 
increases of proteins with transformation from normal to dysplasia and malignancy due to 
more surface proteins, signalling, antibodies, antigens, and enzymes from the increased 
number of proliferating cells (Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 
2006).  
 
The second consistent band corresponding to C=C olefinic stretching of lipids at 1589–
1591cm
-1
 where the relative intensity decreased with increased dysplasia severity. This is 
strongly supported by the concept of protein-dominated spectra in malignant tissue 
(Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 2006). Since the number of 
proliferating cells increases progressively with higher grades of dysplasia and with more 
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energy consumption for their biological transformation process, this may results in low lipid 
content and be associated with more protein formation as the disease progresses. 
 
In this study, the potential diagnostic ability of a Raman peak(s) to differentiate between 
different grades of dysplasia was not investigated. Since the identification of a significant 
potential diagnostic peak (marker) that can differentiate between different grades of dysplasia 
needs larger number of samples to overcome the large inter-sample variations of the 
individual peak intensities between different grades, which may mask the group differences. 
Thus, further work using the identified peaks with significant relation to try to find diagnostic 
markers among groups of dysplasia is required. 
 
 
6.8.4. Spectral Features of Dysplastic Tissue Groups 
The bands at 829–838 cm-1 assigned to tyrosine, O-P-O nucleic acids and the shoulder at 
1621 cm
-1
 attributed to tryptophan, phenylalanine and tyrosine amino acids are broad and 
weak in the spectrum of mild dysplasia, but became more prominent with progression of 
dysplasia from mild through moderate and severe dysplasia to CIS. This suggests higher 
percentages of nucleic acids and proteins relative to total Raman active components and 
supported by the histopathological criteria used for biopsy diagnosis, such as nuclear 
cytoplasmic ratio (Huang et al., 2003b) and also formation of new proteins from the 
proliferating cells and other transformation process. Similarly, for the phenylalanine proteins 
at 1007–1009 cm-1 which appears to be more pronounced with higher grades of dysplasia. 
 
The wavenumbers 1315–1322 cm-1 and 1375–1377 cm-1 corresponding to nucleic acids and 
amino acids, became broad, less prominent and weak with progression of dysplasia from mild 
to CIS. A possible explanation is more degradation or disturbing of tissue proteins 
accompanying the disease progression which was no longer detected because of low 
concentrations (Kendall et al., 2011). This is confirmed by lower intensity, weak or absent in 
high grade dysplasia compared to highly ordered proteins contents in normal and low grade 
dysplasia which confirmed by a prominent peak. This is supported by a study conducted by 
Donfack et al. (2010) who reported disordered and degraded proteins structures in neoplastic 
skin cells compared to normal cells.  
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The band of C=C olefinic stretching of lipids at (1589–1591) cm-1 became broad and weak 
with increased severity of dysplasia, suggesting lower concentration of lipids with higher 
grades dysplasia which is in line of lipid-dominated spectra in normal tissue (Venkatakrishna 
et al., 2001; Krishna et al., 2004; Malini et al., 2006). 
 
A small peak at 1458 cm
-1
 which corresponds to CH2 deformation lipids was observed only 
in severe dysplasia, which is more likely due to the presence of normal constituents within 
dysplastic tissue reported by (Krishna et al., 2004). 
 
Considering the spectral features of high and low grade dysplasia, in HGD the bands at 1166 
cm
-1
 (C-H in plan tyrosine modes of amino acids) and 1623 cm
-1
 (tryptophan, phenylalanine 
proteins) appeared very weak or absent in LGD. This suggests a progressively larger 
contribution of amino acids and proteins from the proliferating cells in HGD, compared to 
LGD and is supported by knowledge of the histopathology of disease progression and has 
been previously reported (Venkatakrishna et al., 2001; Krishna et al., 2004; Malini et al., 
2006). 
 
The band at 1317 cm
-1
 (guanine ring breathing mode of nucleic acids bases) was sharp in 
LGD, but became broad in HGD. Similarly, the small peak at 1407 cm
-1
 (a symmetric 
stretching carboxylate, IgG) was more prominent in LGD, but became broader in HGD. This 
may suggest the synthesis of more unordered proteins in HGD compared to LGD with 
disease progression, which can be identified at different peak positions and consequently 
overlapped to provide a broad peak compared to LGD.  
 
Corroborating the basic concept of vibration spectroscopy; vibration of bonds in biological 
Raman spectrum is very complex with different environment and energy (Smith and Dent, 
2005). Proteins structure found with different types of bonds in molecules which may give 
different peak positions overlapped to appear as a broad peak. 
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6.8.5. Spectral Features of Morphologically Normal Tissue Groups 
In the current study, the histologically normal tissues from the laser resection margins were 
used as control group. This is more likely to control the influence of individual variations on 
spectral data analysis such as patients’ demography and risk factors. This is consistent with 
pervious studies conducted by Malini et al. (2006) who used the uninvolved areas from the 
same subjects as a control and Li et al. (2010) who used the sample of normal oral mucosa 
from the surgical margin of patients with oral cancer. 
 
Interestingly, phenylalanine proteins peak at 1007–1009 cm-1 appear in all groups of 
morphologically normal tissue groups, became more prominent with increased grades of 
dysplasia. This suggests that normal tissue from mild dysplasia as a first step in progression 
process may be considered as a real normal tissue with no spectroscopic changes, with the 
histologically normal tissue from moderate, severe dysplasia and CIS start to change 
biochemically by the effect of field change cancerization (Slaughter et al., 1953). This is 
supported by the findings of a small study conducted by Keller et al. (2008) who compared 
the spectra from true normal cervical tissue taken from healthy subjects to the spectra of 
histologically normal from cervical dysplasia specimens. They reported that histologically 
both tissues were similar, but the differences between them can be identified 
spectroscopically, reflecting the biochemical tissue changes at early stage and even before the 
appearance of dysplasia clinically. Similarly, the shoulder at 1619–1623 cm-1 (tryptophan, 
phenylalanine proteins) was very weak or absent in morphologically normal from mild 
dysplasia, becoming prominent in morphologically normal from moderate, severe dysplasia 
and CIS. It is expected that as a tissue starts to become more active, with more biochemical 
changes, more protein from cellular proliferation is seen in dysplasia. These changes seem to 
affect on the surrounding normal tissue evidencing spectroscopically, but not 
histopathologically based on field change cancerization (Keller et al., 2008). Also, the 
morphologically normal from mild and moderate dysplasia exhibited a more prominent peak 
at 1022 cm
-1
 (glycogen), which was absent in both morphologically normal from severe 
dysplasia and CIS. This further support the field change concept on the surrounding normal 
tissue and suggesting less glycogen content in morphologically normal from severe dysplasia 
and CIS similar to that in dysplastic tissue which reflect the need for more energy 
consumption by the proliferating cells. 
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The peak at 1347 cm
-1
 (CH2 protein, nucleic acids) was seen in all morphologically normal 
from all grades of dysplasia. It became more prominent with increased dysplasia severity 
reflecting the progressive increase in proteins and nucleic acid contents in these tissues of the 
dysplastic tissue specimens. 
 
Considering the binary grading system, LGN exhibited a more prominent peak at 1048 cm
-1
 
(glycogen) which was very weak or absent in HGN. This further supports the field change 
concept on the surrounding normal tissue with less glycogen content in high grade dysplasia 
suggesting more energy consumption by the proliferating cells in this tissue.  
 
LGN showed a small peak at 1235–1251 cm-1 (amide III of proteins), which was absent in 
HGN suggesting unordered or degradation of proteins in HGN simulating HGD. Similarly, 
the peak at 1322 cm
-1
 (guanine of nucleic acids) appeared more prominent in LGN, but 
became weaker and broader in HGN, suggesting lower nucleic acids in HGN compared to 
LGN, but for no clear reason. 
 
In HGN, the peaks at 1423 cm
-1
 (nucleic acids), and 1620 cm
-1
 (tryptophan, proteins) 
demonstrated the contribution of nucleic acids and proteins; however, these peaks became 
broad and very weak compared to LGN. This suggests higher contributions from these 
constituents simulating to HGD and reflects the effect of field changes cancerization in 
morphologically normal adjacent to dysplastic tissue. 
 
In this study, the biochemical changes identified by RS reflecting the ability of Raman 
system to detect subtle molecular changes in certain tissue constituent at an early stage and 
even before the morphological/histological changes. This further supports the true normal 
control of morphologically normal form mild dysplasia or LGD, but not from the 
morphologically normal from moderate, severe dysplasia and CIS or HGD. 
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6.8.6. Tissue Classification 
Based on the success of previous studies on discriminating morphologically normal from 
different grades of dysplasia on non-oral tissues, such as cervical (Mahadevan-Jansen et al., 
1998; Lyng et al., 2007), oesophagus (Kendall et al., 2003), stomach (Teh et al., 2008), 
larynx (Stone et al., 2000) or mixed epithelial tissues; larynx, oesophagus, bladder, colon, 
breast, and prostate (Stone et al., 2002b; Stone et al., 2004) and oral tissue (Malini et al., 
2006). In general, the majority of earlier spectroscopic studies on human oral tissues were 
based on the discrimination between normal and malignant oral tissues (Venkatakrishna et 
al., 2001; Krishna et al., 2004; Hu et al., 2009). However, one study conducted by Malini et 
al. (2006) extended further and evaluated the efficacy of the technique to discriminate 
between normal, inflammatory, premalignant, and malignant conditions. They showed that 
PCA discriminated between normal and all pathological tissue groups, but with poor 
separation ability among the pathological conditions. While PCA combined with 
multiparameter limit tests allowing match/mismatch criteria to be applied, all tissue types 
were shown to be discriminated with sensitivity and specificity of 100% for the diagnosis of 
malignancy. 
 
Conventional histopathology (consensus diagnosis) was used as standard for testing the 
ability of RS for tissue classification. PCA fed to PLS-DA was used and was able to 
emphasis the variation between different groups of dysplasia from their morphologically 
normal tissue making the analysis more accurate (Wang and Mizaikoff, 2008). PLS-DA 
specifically looks for common patterns of variations in both histopathological groups and the 
spectra, identifying the spectral features that can correlate most strongly with group 
distribution.  
 
In the present study, the Raman system was able to separate dysplastic from morphologically 
normal tissue with more than 80% specificity and sensitivity rates. This demonstrated the 
ability of Raman to classify dysplastic tissue from morphologically normal tissue efficiently. 
Raman prediction was found to be promising with small misclassification and larger 
percentage of correctly classified pair-wise cases. For example, Raman was able to identify 
severe dysplasia from the corresponding morphologically normal tissue with 100% sensitivity 
and specificity. Also, RS assigned mild dysplasia from morphologically normal tissue with 
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more than 90% specificity and sensitivity. However, a drop in the classification rate of 
moderate dysplasia from morphologically normal tissue with more than 71% sensitivity and 
80% specificity was reported in this study. This suggests more false negative and false 
positive cases, compared to the ability of Raman in discriminating mild and severe dysplasia 
from their morphologically normal tissues. Although RS showed a low sensitivity rate of 
60% in separation of CIS from CISn suggesting higher rate of false negative, RS was able to 
discriminate CISn from CIS with 100% specificity indicating the ability of Raman to identify 
CISn without any false positive. 
 
With respect to the binary grading system, Raman classification of HGD from HGN and 
LGD from LGN was also promising, with sensitivity of more than 83% and specificity of 
more than 90%. Raman classification seems to be better in cases of high grade dysplasia 
(HGD vs. HGN), compared to low grade dysplasia (LGD vs. LGN) by more than 3%. This 
was supported by the univariate statistical analysis that identified multiple significant peaks 
between HGD from HGN, compared to only two peaks in case of LGD vs. LGN. 
 
In this study, the misclassification can be explained under the basis of the consensus 
histopathological diagnosis. If dysplastic tissues were misclassified as morphological normal, 
a possible explanation might be the presence of normal tissue constituents within the 
dysplastic area under examination, or spectra were measured from a clear resection margin, 
not from the dysplastic region (points mispositioning). However, this option was not 
applicable in this study because of two reasons: firstly, normal and dysplastic regions were 
selected and marked under pathological guidance and secondly, the spectral measurements 
were performed within the boundaries of the pathologist selection using mapping technique, 
not point-by-point measurement. Further, the dysplastic tissue changes undergo gradual 
biochemical changes from normal to dysplastic and no one can expect to see a line between 
dysplasia and normal tissue (Stone et al., 2004). While if morphologically normal tissues 
were spectroscopically misclassified as dysplastic tissues, Raman spectra might be collected 
from margins which were regarded as histologically normal. However, in this case they were 
probably not normal and had residual dysplastic components which subsequently lead to the 
misclassifications. Another possible explanation is that if the resection margins were free 
from dysplasia (clear-margins), the measurement may be taken from the dysplastic area and 
not from the morphologically normal tissue; however, this was not applicable in this study 
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because of the pathological guidance. Furthermore, Raman misclassification of 
morphologically normal tissue as a dysplastic tissue, may be related to the presence of 
malignancy associated changes or field changes cancerization phenomenon (Slaughter et al., 
1953), in which oral epithelium within the area of field change (unstable oral mucosa) could 
appear clinically normal, but carry biochemical tissue changes identified spectroscopically 
(Keller et al., 2008). 
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6.9. Strength of the Study  
 The current study was the first spectroscopic study that used de-paraffinised FFPE oral 
tissue samples from different grades of dysplasia to validate an objective-automated 
technique for dysplastic oral tissue diagnosis, toward more valuable in vivo Raman probe for 
clinical application.  
 
 This study is the first to demonstrate the feasibility of using RS to investigate and 
differentiate different grades of oral epithelial dysplasia from their counterpart 
morphologically normal tissues, using both WHO and binary grading systems. 
 
 The current study used only laser excision specimens with consensus histopathological 
diagnosis of two expert oral pathologists, which was at least minimising the histopathological 
discrepancies.  
 
  Morphologically normal tissue from an unaffected area at the resection margins from the 
same patient was used as control to minimise the individual source of variation that might 
relate to patient demography, risk factors, medical history and medications used, which may 
cause other source of variations not related to the disease itself. 
 
 All samples used in this spectroscopic study were taking from patients affected with 
PMDs in one oral subsite, the FOM, eliminating the effect of anatomical site variation. 
 
 All patients were selected from a cohort of patients diagnosed, treated and followed up 
by the same team with a similar management protocol, with known outcomes for further 
advantage correlated with spectroscopic data. 
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6.10. Limitation of the Study  
The need for specific types of substrates for tissue mounting was one of the main limitations 
in this study, which are usually small in size, expensive and brittle requiring careful handing. 
However, the poor quality spectra obtained when normal glass slides were used, suggests that 
either these BaF2 slides must be used or further analysis of a range of potential substrates is 
needed. 
 
Although the number of the collected spectra (1045) was sufficient for data analysis, Raman 
tissue spectra contaminated with detector saturation, noise and high fluorescent background 
reduced the number of spectra by excluding these contaminated spectra (267). Subsequently, 
this limits the employment of a test subset prior the application of multivariate data analysis. 
Therefore, the measurement of more points per sample area are required to facilitate both 
data testing and also to decrease the sampling errors related to spectral variations not related 
to the disease state, which may affect the group separation. Thus, increased the number of 
sample will enhance the information upon which the classification models can be built and 
should provide significantly more robust performance.  
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6.11. Conclusion 
2. In this study, the consensus histopathological diagnosis of two grading systems were 
used to group the tissue specimens; the WHO classification system of mild, moderate, 
severe dysplasia and CIS, and the binary system of high/low grade dysplasia.  
3. All of the 32 samples used in this study were from the most common affected oral 
subsite (FOM). 
4. Out of 1045 collected spectra, a total of 778 spectra (386 dysplastic, 392 
morphologically normal) were used for spectroscopic data analysis. 
5. Practical consideration revealed the unsuitability of glass slides and recommended the 
used of BaF2 substrate for tissue mounting. 
6. This study recommended the use of a standard protocol for photo-bleaching of 120 
seconds to reduce the strong fluorescence background signals contamination to improve 
Raman spectral quality. 
7. Spectroscopic tissue analysis confirmed the ability Raman system to identify 
biochemical tissue changes associated with tissue progression from normal to dysplastic.  
8. The mean spectrum of Md significantly exhibited a higher phenylalanine protein 
concentration reflected by a higher intensity peak at 1009 cm
-1
 indicating a major 
contribution of proteins in Md compared to Mn. 
9. The mean spectrum of Modd exhibited mainly a higher intensity of proteins and nucleic 
acids, although the difference was not significant.  
10. The Modn showed a significantly higher intensity level of lipid at 1087 cm-1 compared to 
Modd spectrum.  
11. The Sd spectrum showed a significantly higher concentration of proteins and nucleic 
acids reflected by higher relative intensity at 1344 cm
-1
, compared to Sn. 
12. The Sn exhibited a significantly higher relative intensity of amide III of protein at 1243 
cm
-1
. 
13. The mean spectrum of CIS which was similar to Md, showed a significantly higher 
concentration of phenylalanine protein at 1007 cm
-1
, in addition to a significantly higher 
relative intensity of 1091 cm
-1
 (proteins and nucleic acids), compared to CISn. 
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14. The mean spectrum of HGD compared to HGN showed a number of significant peaks 
corresponding to amino acids and protein back bone at 934 cm
-1
, C-N proteins at 1137 
cm
-1
, nucleic acids at 1322 cm
-1
and protein with nucleic acids at 1345 cm
-1
. Based on our 
understanding of the molecular origin of the Raman bands, the study findings suggested 
that the relative intensity of these Raman bands increased with progression of dysplasia, 
indicating increased cellular proteins and nuclear content in dysplastic compared to 
normal. 
15. The HGN exhibited a significantly higher concentration of lipids reflected by higher 
relative peak intensity at 1081 cm
-1
, phenylalanine protein at 1037 cm
-1 
and 1104 cm
-1
, 
amide III of protein at 1243 cm
-1
, amino acids at 1176 cm
-1
 and 1213 cm
-1
. 
16. The mean spectrum of HGD exhibited a significantly higher concentration of 
phenylalanine protein and amide I of protein demonstrated by higher relative intensities 
at 1009 cm
-1
 and 1661 cm
-1
, compared to HGN.  
17. The current study supported the ability of RS to provide a single peak for diagnostic 
purposes; however, further studies with larger sample size to test the validity of the 
identified significant peaks for diagnostic purposes are required.  
18. The relative intensity of olefinic stretch of lipids at 1589-1591 cm-1 was consistently 
decreased with increased dysplasia severity supporting the lower lipids content in 
dysplastic tissues (disease progressing). This peak may be used to differentiate between 
different grades of dysplasia; however, further studies are required to confirm and 
validate this finding. 
19.  The higher concentration of nucleic acids and proteins relative to the total Raman active 
components and formation of new proteins from the proliferating cells were supported by 
the histopathological criteria used for biopsy diagnosis. Whilst degradation and/or 
disturbing of tissue proteins accompany the dysplastic tissue progression with lower 
concentrations, may be no longer detected spectroscopically. 
20. This study supported that Mn is a true normal tissue, but higher grades dysplasia (Modd, 
Sd and CIS) that associated with more biochemical changes affected on the surrounding 
normal tissue by the field change, evidencing spectroscopically but not histologically, 
Modn, Sn and CISn were no longer considered as normal.  
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21. The study supported less glycogen content in morphologically normal tissue associated 
with increased grades of dysplasia, apart from morphologically normal from mild 
dysplasia, reflecting the need for more energy consumption by the proliferating cells and 
simulating the dysplastic tissues changes.  
22. The absence of shoulder corresponding to proteins in Mn, which was prominent in 
Modn, Sn and CISn. Similarly, the peaks corresponding to nucleic acids and proteins in 
HGN were broad and very weak compared to LGN, all these suggesting higher 
contributions from these constituents simulating to dysplasia and reflecting the effect of 
field change in morphologically normal tissue adjacent to dysplastic tissue. These 
findings showed that RS has the ability to identify neoplastic change in these tissues 
before their histological appearance. The clinical implementation of this finding is the 
use of Raman system to assess biopsy targeting during surveillance and to assess resection 
margins in the operating theatre. In many cases early cellular changes are invisible and the 
detection will rely upon a random biopsy procedure, with a chance of missing abnormal 
tissue with large numbers of unnecessary biopsy samples. 
23. This study demonstrated the potential ability of RS, combined with multivariate 
statistical techniques, as an objective tissue classifier to successfully distinguish between 
morphologically normal and dysplastic tissue samples. 
24. An excellent separation between severe dysplasia and their morphologically normal 
tissue, with 100% sensitivity and specificity was achieved.  
25. The Md was differentiated from normal tissue with more than 90% sensitivity and 
specificity, which further supporting the ability of Raman to detect early dysplastic 
changes at a cellular level. 
26. The Modd was differentiated from normal tissue with more than 71% specificity and 
80% specificity. 
27. The CIS was differentiated from morphologically normal tissue with 60% sensitivity and 
100% specificity. 
28. Raman classification was promising for separating high and low grade dysplasia from 
their morphologically normal tissue achieving a sensitivity of more than 83% and 
specificity of more than 91%. 
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6.12. Recommendations for Future Raman Work 
It is necessary to identify and control as many sources of irrelevant variation as possible in 
order to inherently maximise the desired variation by carrying out a controlled experiments 
including specific form of variation to detect the subtle biochemical tissue changes. In the 
biomedical application and according the wide physiological ranges, cell characteristics may 
vary markedly, so larger numbers of samples are required to overcome these variations for a 
robust study.  
 
To assess the desired variations and to improve the groups’ discrimination, more 
measurement points per sample area are recommended to cover the whole area under 
investigation; otherwise spectral variations not related to the disease state may contribute to, 
and affect tissue classification. 
 
It may be desirable to select representative samples from a spectroscopic data set as a 
completely independent test subset. This technique was previously used by using 
approximately one-third of the total data set (Hu et al., 2009) and found to be useful for the 
validation of the model (Shaw et al., 2000). 
 
In this study, regarding the noise contamination, three datasets of spectral intensity were 
identified, a signal accumulated to 750 counts across the CH2 scissoring mode gave the best 
results by showing an adequate signal to noise ratio. Thus, it is highly recommended to use 
such intensity threshold for similar type of tissue analysis for high spectral quality and 
subsequent efficient data analysis. 
 
Further studies are required to confirm these preliminary results and also a multi-centric 
research to validate these findings. The work in this area may address experimental issues, 
such as exploring the use of red lasers to minimise fluorescence background for better 
spectral quality. 
Finally, it is recommended to develop standard protocols for tissue sampling, spectral 
collection and data analysis for diagnostic spectral purposes to achieve a standard set of 
spectra transferable between the research groups and subsequently from clinic to clinic for 
great patient benefit. 
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Chapter Seven: Conclusions and Suggestions for Future Studies 
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7.1. Introduction 
The present study was designed to identify and follow a cohort of patients affected with new, 
single PMDs in the North-East of England from initial presentation, through laser 
interventional treatment to long-term follow-up and confirmed clinical outcome. Profiling of 
associated risk factors and the factors affecting clinical outcome following laser treatment 
were also investigated. In addition, the efficacy of Raman spectroscopy as an effective and 
objective tool for discriminating morphologically normal from dysplastic tissue, the early 
detection of dysplastic tissue changes and tissue classification were also studied. 
 
The findings of the current study emphasise the importance of both clinical and pathological 
characteristics of dysplastic PMDs, in addition to patients’ lifestyle risk factors, in identifying 
high risk patients, predicting treatment outcome and directing clinical management protocols.  
 
The study has shown that Raman spectroscopy is able to identify biochemical tissue changes 
associated with early dysplastic changes seen in oral PMDs and can detect field change 
before morphological (histopathological) appearance. Also, the Raman system is able to 
differentiate between dysplastic and morphologically normal tissue using de-waxed formalin 
fixed paraffin embedded oral tissue samples. 
 
 
7.1.1. Study One:  
Potentially Malignant Disorders: Demographic, clinical and histopathological 
features of a cohort of 100 patients, who were diagnosed, treated and reviewed at 
Newcastle Upon Tyne Hospitals. 
100 patients with single dysplastic PMD (66 males, 34 females) with a mean age of 57.72 
years (30-94 years) participated in this study. The FOM, followed by lateral and ventral 
surfaces of the tongue, were the most commonly affected anatomical sites. The majority of 
PMDs presented as leukoplakia (92%), with only 8% erythroplakia; erythroplakia was mainly 
seen in patients over 40 years old, with 88% (7/8) identified in males. Mild dysplasia (43%) 
was the main histopathological diagnosis of laser excision specimens, followed by moderate 
(24%) severe dysplasia (23%) and CIS 10%. The majority of homogenous leukoplakias 
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(58%) were diagnosed as low grade dysplasia, whilst most non-homogenous lesions (71%) 
were high grade; erythroplakia often showed severe dysplasia 37% (3/8). Clear surgical 
margins were primarily seen in mild dysplasia cases (60%), whilst dysplastic margins were 
more frequently associated with higher degrees of dysplasia. Higher dysplastic features were 
associated with larger sized PMDs which were both also associated with advancing age. Male 
patients exhibited greater excision margin involvement with higher grades of dysplasia in the 
affected margins compared to females’ resection margins. 
 
 
7.1.2. Study Two:  
Risk factors of patients with PMDs in the North-East of England 
At initial presentation, the majority of PMD patients were current smokers 63% (46 males 
and 17 females); with 22% (15 males and 7 females) ex-smokers and 15% (5 males and 10 
females) non-smokers. Females were primarily non-smokers (67%), whilst males were 
mainly smokers (73%) who also started smoking earlier than females, and had significantly 
longer smoking histories (37.11 vs. 28.13 years). The FOM was the main affected site in 
smokers (60%), whilst lateral and ventral tongue surfaces were the principal sites in non-
smokers (93%). All patients ≤ 40 years were tobacco users mainly presenting as FOM PMDs, 
whereas patients older than 41 years were a mixture of tobacco users and non-users, with 
both FOM and tongue affected. The tongue was the only affected site in female non-smokers 
and in 80% of male non-smokers. Erythroplakias were only seen in heavy smokers. Severe 
dysplastic features were associated with both heavy smoking and a longer smoking history. 
 
Patients in this study were mainly current drinkers (83%), followed by non-drinkers (14%) 
and ex-drinkers (3%). All patients ≤ 40 years were regular drinkers. The majority of males 
were regular drinkers (71%), whilst the majority of females were non-drinkers (71%). Fifty-
eight percent of males and 9% of females exceeded maximum recommended consumption 
levels (21 units/week for male, 14 units/week for female). The FOM was the main affected 
site in heavy drinkers. Fifty-two percent of homogenous leukoplakias affected light drinkers, 
50% of non-homogenous leukoplakias were observed in heavy drinkers, whilst erythroplakias 
presented equally in heavy and light drinkers. Mild dysplasia was frequently diagnosed in 
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light drinkers, whilst CIS was usually seen in heavy drinkers. Ninety-two percent of current 
drinkers were also current smokers, whilst 50% of non-drinkers were also reported as ex-
smokers. Eighty-eight percent of our study cohort reported a history of a systemic disorder, 
with hypertension the most common followed by diabetes mellitus, which was mainly seen in 
females. Hypertensive patients mainly presented with severe dysplasia-CIS, which may have 
a link with anti-hypertensive medication-induced lichenoid reactions with subsequent 
dysplastic change. Large sized dysplastic PMDs were frequently associated with denture 
wearers in FOM cases and with crowns and bridges in tongue lesions suggesting repeated 
mechanical irritation from intraoral appliances may play a role on pathogenesis. 
 
 
7.1.3. Study Three:  
Clinical Outcome 
This study showed that 62% of patients were DF (39 males and 23 females), 17% had 
recurrent disease (13 males, 4 females), 14% new site dysplasia (10 males, 4 females), 5% 
underwent MT (3 males, 2 females), and 2% developed oral cancer at a site distant from the 
primary dysplasia (1 male, 1 female). Univariate logistic regression analysis revealed that 
high grade dysplasia (severe dysplasia-CIS), the ventro-lateral tongue, non-homogenous 
leukoplakia, the presence of dysplasia in resection margins, dysplasia size exceeding 600 
mm
2 
and an active systemic medical condition were all significant predictors of a disease 
active state. However, prediction of an individual patient’s clinical course remains difficult 
and all patients with dysplastic PMDs should be kept under long-term surveillance regardless 
of clinicopathological features and method of treatment.  
 
 
Recurrent (same site) Disease 
Recurrent disease usually presents within the first two years following laser treatment. 
Regression analysis showed that the presence of severe dysplasia-CIS in surgical margins 
increased the risk of recurrence by 4 times. Although females exhibited a shorter mean time 
to recurrence, males were at increased risk. The FOM and tongue were the main anatomical 
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sites affected. Non-homogenous leukoplakia exhibited both increased risk and a shorter mean 
time to development. Lesion size exceeding 600 mm
2
 increased recurrence risk by 2 times. 
Recurrence risk was increased in higher grades of dysplasia, with CIS 12 times, severe 
dysplasia 6 times and moderate dysplasia 5 times higher. 
 
Both heavy smokers and drinkers were at increased risk of recurrent disease by 2 and 3 times, 
respectively; more than half of the patients continued to smoke and 98% continued to drink 
following laser treatment. The majority of patients who underwent recurrent disease (94%) 
had an active systemic medical disorder, which was found to increase the risk of recurrence 
by 2 times. Intraoral dental prosthesis wear was also found to increase the risk of recurrence 
by 2.5 times. 
 
 
Further Disease (new site PMDs) 
Patients who developed new site dysplasia exhibited a complex clinical course characterised 
by multiple laser interventions and follow-up biopsies, with most disease episodes reported 
by 3 years post-treatment. Although males exhibited a higher rate for new-site dysplasia, 
females showed a shorter mean time for this to develop. The FOM and ventral tongue were 
the main anatomical sites for new-site dysplasia to develop, and non-homogenous 
leukoplakias showed a 3 times increased risk. Lesions sized between 200-600 mm
2
 showed 
the highest rate of new site disease (64%). 
 
Patients with high grade dysplasia exhibited a higher risk of new-site disease, with heavy 
smokers and drinkers at a 3 times increased risk. 
Whilst males were more likely to develop recurrent disease, females were affected equally by 
recurrent and new-site dysplasia. Patients with severe dysplasia exhibited an equal rate of 
recurrent and further disease, whereas those with mild dysplasia primarily showed new-site 
dysplasia. 
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Malignant Transformation and OSCC Development 
No MT was reported in patients younger than 40 years. Males with MT were younger than 
females. The FOM and lateral tongue were affected equally by MT, whilst new site OSCC 
only affected the tongue. Non-homogenous leukoplakia showed a 3 times increased risk of 
oral cancer, whilst erythroplakia was found to increase the risk of oral cancer by 19 times. 
Lesion size exceeding 425 mm
2
 increased the risk of MT by 2 times. Severe dysplasia-CIS 
was found to have a greater tendency for MT, whilst no MT was seen in moderate dysplasia 
cases. Non-users of tobacco and alcohol had higher rates of MT and patients with new site 
OSCC were non-smokers and light drinkers.  
 
 
Resection Margin Status 
Disease-free patients were significantly more likely to have had clear surgical margins, whilst 
the majority of disease active cases showed dysplasia in excision margins. Severe dysplasia-
CIS and moderate dysplasia were found to increase the risk of dysplastic margins by 2 and 
1.5 times. Lesion size exceeding 600 mm
2
 significantly increased the risk for dysplastic 
margins by 12 times and those between 200-600 mm
2
 6 times. Moderate-severe dysplasia in 
the margins was associated with a higher recurrence rate, whilst recurrence-free patients 
usually had clear margins.  
 
 
7.1.4. Study Four:  
Raman Spectroscopy 
The Raman system, combined with confocal micro-spectroscopy, is a promising tool for oral 
tissue diagnosis and has the ability to identify biochemical tissue changes associated with 
progression from normal to dysplastic tissue.  
The study showed a higher relative intensity of proteins and nucleic acids in dysplastic tissue 
indicating increased protein and nuclear content in proliferating cells.  
 
Raman, combined with multivariate statistical techniques, has the ability to objectively 
distinguish between morphologically normal and dysplastic tissue using de-waxed FFPE 
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samples. These particular findings are encouraging since these tissue specimens are easily 
available and carry enough discriminant information to be used in optical oral pathology 
techniques. 
 
This study adds to the growing body of evidence that Raman spectroscopy can detect subtle 
or undetectable histopathological changes in tissue and may make a significant contribution 
to our understanding of the mechanisms of neoplastic transformation. This study 
demonstrated that morphologically normal tissue from mild dysplasia excision margins is 
true normal tissue, but in higher grades of dysplasia, biochemical changes affect surrounding 
tissue with the result that morphologically normal tissue taken from moderate, severe 
dysplasia and CIS samples could no longer be considered normal. These spatial effects have 
an impact on choosing the type of tissue to use as a normal reference in classification studies, 
and may thus have an impact on the development of screening techniques to benefit patients 
in clinical practice. 
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7.2. Suggestions for Future Studies 
This project investigated in depth the clinical and pathological presentations of dysplastic 
PMDs; however, further research might explore the site preference for specific clinical types 
in particular non-homogenous subtypes, providing more information on their biological 
behaviours which will help in treatment protocols. 
 
More information on the relation between lesion size and anatomical site of PMD, in 
particular those affecting the tongue and the FOM, would help us to establish a greater degree 
of understanding of their biological behaviours. 
 
An important finding in our study is that the lateral tongue was identified as a non-smoking-
related site, whilst the soft palate was a specific smoking-related site; further investigations 
should concentrate on risk assessment in relation to specific anatomical sites.  
 
To avoid the substantial underestimation of risk in alcohol and tobacco users, further work 
needs to be done using more accurate and objective methods of assessment in addition to self-
reporting. 
 
The presence of systemic disease is one of the important predictors for high grade dysplasia 
to develop; future research should be undertaken to understand potential inter relationships in 
these patients. 
 
Investigating potential interactions between systemic medications and the behaviour of PMDs 
in patients with chronic medical conditions may be a useful future study.  
 
A further study is required to establish whether intra-oral dental prostheses wear may 
influence the characterisation of dysplastic PMDs in relation to particular anatomical sites 
and their impact on subsequent clinical outcome. 
 
Large size dysplastic PMDs as significant predictors of high risk disease should be further 
investigated with more focus on the biomolecular basis.  
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Non-homogenous leukoplakias are often associated with large size, high grade dysplasias and 
a higher tendency for recurrence after removal; further investigations are required to support 
these findings for the benefit of patients’ classification and treatment planning for this high 
risk group. 
 
The presence of residual dysplasia in an excision margin, and the extent and grade of 
dysplasia are important parameters for patient prognosis, associated with both recurrence and 
MT; therefore, a further detailed study with a larger number of cases is required. 
 
Excised FOM lesions displayed higher rates of residual dysplasia in resection margin, 
contrary to the tongue for example and further investigations are needed to explore the 
reasons behind this and to identify associated factors. 
 
The susceptibility of oral mucosa to develop further disease and new site oral cancer 
development, especially in the absence of known carcinogens, require further studies using 
molecular and biochemical approaches to elucidate biomarker(s) to aid in early detection of 
field change. 
 
Further Raman studies using the same experimental set up with more sample numbers are 
required to confirm these study findings for clinical use in the future. Also, a group of 
patients who developed oral cancer may be involved to provide a complete spectroscopic data 
set for oral optical tissue diagnosis.  
 
From a practical point of view and for future studies, it is recommended to use the signal 
accumulated to 750 counts across the CH2 scissoring mode for oral tissue analysis. Such 
intensity gave the best results by showing an adequate signal to noise ratio for high spectral 
quality and subsequent efficient data analysis. 
 
Also, to improve tissue classification and group discrimination, more measurement points per 
sample area are recommended to cover the whole area under investigation and to reduce 
spectral variations not related to the disease state.  
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1.2. Appendix (1-B): Patient Information Sheet 
 
 
 
 
Patient Information sheet 
 
Studies in the diagnosis and management of unstable mouth lining 
 
You are being invited to take part in a research study. This information sheet explains why 
the research study is being undertaken and what it will involve. Please read it carefully and 
ask questions about anything you do not understand. This form is for you to keep and 
refer to as required. 
 
 
Professor Peter Thomson is the head of the team in this study. 
 
 
Why I have been chosen? 
 
In the recent past you were diagnosed as suffering from a patch of “unstable” mouth lining. 
These patches contain “unstable” cells which if left untreated or unmonitored can change 
to precancer or cancer cells.  We are conducting a study to try to improve our 
understanding of the behaviour of these cells and are inviting you to take part and help us 
with the study.  This investigation will not require you to undergo any additional treatment 
and will not influence your current care. At all times      you will remain under the care of 
Professor P.J.Thomson (Consultant in Oral Maxillofacial Surgery). 
In this study we wish to find new and better ways to predict outcomes for patients with 
unstable patches in their mouths. In order to do this we plan to review the progress of 
patients we have previously treated to try to identify the reasons why some patients do 
well and others have more problems with their mouth lining. 
 
 
Study details 
 
In this study we will review the details about your mouth lining already recorded in 
your medical records to confidentially build a database of unstable mouth lining 
conditions affecting people in the North East of England. We will also re-examine 
your biopsy tissue specimens, previously taken for diagnosis and routinely stored 
in the pathology department at the RVI, using new and additional laboratory 
techniques to try to learn more about your condition.  
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This re-examination will not affect your treatment and normal planned clinic follow-
up in any way, but will hopefully provide new information and better understanding 
of the nature of unstable mouth lining to help future patients. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and will be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
 
 
What will happen if I take part in this study? 
 
If you agree to be in this study, you will be asked to sign a consent form to allow us to use 
medical information held in your normal medical records along with a re-examination of 
tissue biopsy specimens already held in the pathology department following your 
treatment.  
 
 
Will my taking part in this study be kept confidential? 
 
Information collected during the research will be kept strictly confidential, and no one 
outside the research team will have access to your information.  Any information about 
your name, date of birth and address will be removed so that you cannot be recognized. 
With your permission, we will inform your GP that you are taking part in this study. 
 
 
Who is organising and funding the research? 
 
This study is being organised by the School of Dental Sciences /Newcastle University. 
 
 
Who has reviewed the study? 
 
This study has been reviewed by NHS Research Ethics Committee. The Ethics Committee 
is made up of doctors, nurses, scientists, non-scientists and people from the community. 
 
 
 
What if there is a problem? 
 
If you have any concerns about any aspect of this study, you should speak to the 
researcher who will do her best to answer your questions. 
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Contact for further information 
 
If you have questions about this study, please contact Professor Peter Thomson, or the 
study doctor (researcher) Dr. Ameena Diajil. 
 
 
 
Professor Peter James Thomson                      
Oral and Maxillofacial Surgery      
School of Dental sciences 
Newcastle University  
Framlington Place 
Newcastle upon Tyne 
NE2 4BW                                                       
Tel.  0191-222-8290 
Email address: peter.thomson@ncl.ac.uk 
 
 
 
Dr. Ameena Ryhan Diajil 
Oral and Maxillofacial Surgery      
School of Dental sciences 
Newcastle University  
Framlington Place 
Newcastle upon Tyne 
NE2 4BW   
Tel.   0191-222-7888  
Email address: ameena.diajil1@ncl.ac.uk 
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1.3. Appendix (1-C): Patient Informed Consent 
 
 
 
Studies in Diagnosis and Management of Unstable Mouth Lining 
Patient Consent Form 
1. I confirm that I have read and understood the information sheet for the above study 
and have had the opportunity to ask questions and have had these answered 
satisfactorily. I have been given a copy of the patient’s information sheet to keep. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time. 
 
3. I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals and I give permission 
for these individuals to have access to my records. 
 
4.  I understand that my personal data will be processed and stored securely in 
agreement with the 1998 Data Protection Act. 
 
5.  I give permission for the researchers to inform my GP of my taking part in this 
study. 
 
6. I freely agree to take part in the above study. 
 
Patient’s name................................................................................................................ 
Patient’s signature.......................................................................................................... 
     Date................................................................................................................................. 
    Members of the research team: 
    Professor PJ Thomson       
    Dr Max Robinson          
    Dr Matthew German  
 
 
Researcher Dr Ameena Diajil                                    Professor Peter Thomson 
Signature....................................                                Signature.................................... 
Date................................                                            Date.................................... 
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1.4. Appendix (1-D): General Practice Information Letter 
 
 
GP Information Letter 
 
Dear Dr 
 
Research Project 
 
Studies in Diagnosis and Management of Unstable Mouth Lining 
 
I am writing to inform you that your patient ………………………   d.o.b ……..  
of ……………………………….. ……………………………………………………... 
has kindly agreed to take part in the above study, which is designed to build up a data base 
for potentially malignant disorders of oral mucosal tissue. 
Your patient is currently under the care of Professor PJ Thomson (Professor of Oral & 
Maxillofacial Surgery) at Newcastle General Hospital. 
 
As part of this study your patients have agreed that their medical records can be reviewed to 
build up a database and to find methods to help predict lesion behaviour and patient outcomes 
in the future. We will also review biopsy material (archived in the Department of Cellular 
Pathology, RVI) to try to find biological markers in oral epithelial tissue which may predict 
clinical outcome.  
I hope this information is helpful. 
 
Please do not hesitate to contact me if you require any further information. 
Kind regards, 
Yours sincerely 
 
Professor PJ Thomson 
Professor of Oral & Maxillofacial Surgery 
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1.5. Appendix (1-E): Standardized Case Sheet 
Data Collection Sheet 
Patient hospital NO. 
Patient study NO.  
First presentation time 
Sex 
Female  
Male 
Date of Birth 
Occupation 
Civil status  
Married 
Single  
Divorced  
Widowed 
Medical history 
1) Immunodeficiency 
2) Diabetes 
3) Hypertension 
4) Anaemia 
5) Candidal infection 
Other medical conditions 
Risk factors 
Tobacco smoking 
1) Current smoking  
2) Ex-smoking  
3) Non-smoker 
History of smoking (years)  
Cigarettes per day 
Alcohol Drinking 
1) Current drinker 
2) Ex-drinker 
3) Non-drinker 
History of drinking 
Units per week 
Diet 
1) Prepared food 
2) Fresh food/vegetables 
 
 
/  / 
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Familial cancer history 
Father  
Mother 
1
st
 relative 
2
nd
 relative 
Oral hygiene  
Good 
Bad 
Mouth wash use 
User 
Non-user 
Oral prosthesis  
None 
Full denture 
Crown and bridge 
Upper or lower denture 
PMD clinical appearance 
 Leukoplakia  
Homogenous leukoplakia 
Non-Homogenous leukoplakia 
o Speckled  
o Nodular  
o Exophytic  
o Ulcer 
 Erythroplakia 
PMD anatomical site 
1) Floor of the mouth  
2) Ventral tongue 
3) Lateral tongue  
4) Dorsal tongue  
5) Buccal mucosa  
6) Soft palate  
7) Fauces 
8) Hard palate 
9) Retromolar area 
10) Alveolar mucosa  
11) Lower lip 
12) Upper lip 
Histopathology Diagnosis 
Incisional biopsy 
1) Mild dysplasia 
2) Moderate dysplasia 
3) Severe dysplasia 
4) Carcinoma in situ 
Date                                          Lab No. 
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Excision biopsy 
1) Mild dysplasia 
2) Moderate dysplasia 
3) Severe dysplasia 
4) Carcinoma in situ 
Date                                         Lab No. 
Size            mm
2
 
Surgical margin status  
 Free margins 
 Dysplastic margins 
o Mild dysplasia 
o Moderate dysplasia 
o Severe dysplasia 
o Carcinoma in situ 
Follow-up biopsy 
1) Mild dysplasia 
2) Moderate dysplasia 
3) Severe dysplasia 
4) Carcinoma in situ 
Date                                         Lab No.     
Number of observational biopsies 
Number of laser interventions 
Number of follow-up biopsies 
Number of follow-up visits 
Treatment 
Laser surgery 
Observation 
Clinical outcome at the most recent clinic follow-up 
1. Clinical resolution (Disease-free) 
2. Persistent (same site, same disorder) 
3. Recurrence after treatment (same site of primary disease) 
o Time of recurrence 
o Number of recurrences 
4. Development of new disease (new site, further disease)  
o Time 
o New site 
5. Malignant transformation (same site OSCC) 
o Time 
6. OSCC development(new site, new disease)  
o Time  
o location 
7. Malignant events outside the oral cavity  
o Time  
o location 
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1.6. Appendix (1-F): International Standard classification of Occupations (ISCO-08) 
(http://www.ilo.org/public/english/bureau/stat/isco/press1.htm) 
1. Manager  
2. Professional  
3. Technicians and associate professionals 
4. Clerical support workers 
5. Service and sales worker 
6. Skilled agricultural, forestry and fishery workers 
7. Craft and related trades workers 
8. Plant and machine operators and assemblers 
9. Elementary occupations (simple) 
10. Armed forces 
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1.7 Appendix (1-G): PhD Related Poster Presentations  
1) Presented at 4th European Conference on Head and Neck Oncology-Athens 4-6th March 
2010 Oto-Rhino-Laryngology and Head and Neck; Volume 267.Supp. 1 March 2010 
 
PP054 Risk Factors  and  Oral  Precancer
Development of  a High/ Low Risk Profiling  System
Ameena Diajil, Michaela Goodson, Peter Thomson
Oral & Maxillofacial Surgery, School of  Dental Sciences, Newcastle University                                               
ameena.diajil1@ncl.ac.uk
Oral squamous cell carcinoma (OSCC) remains
a lethal and deforming disease, with
significant mortality and a rising incidence in
younger and female patients. Recent studies
suggest up to 50% of OSCC cases may not
have been exposed to the major identifiable
carcinogens tobacco and alcohol (1). It is thus
imperative to determine the significance of
other potential risk factors for oral
carcinogenesis.
Introduction
 To identify potential risk factors for oral
squamous cell carcinoma and oral precancer
 To design an accurate data collection tool
to try to identify patients at high risk of OSCC
development
Aims
Methods
Using Pub med, Scopus and Medline, more
than 200 papers published between the
period of 1982 and late 2009 on risk factors
for oral cancer (Figure 1) and precancer
(Figure 2), from 35 countries, mainly from
USA, UK and other European countries were
comprehensively reviewed. The identifiable
factors were classified into high and low risk
categories.
Figure 2: lateral tongue  leukoplakiaFigure 1: lateral tongue SCC
References
1. Campo-Trapero et al (2008) Update on molecular pathology in 
oral cancer and precancer. Anticancer Res 28: 2B
Conclusions
 Understanding the significance of various
risk factors in oral carcinogenesis helps stratify
patients, especially those with potentially
malignant disorders, into high and low risk
groups.
 Early recognition of disease susceptibility 
helps to direct interventional treatments and 
greatly improves prognosis of patients.  
Results & Discussion 
14 factors associated with the pathogenesis of
OSCC and oral potentially malignant disorders
were identified. 8 high risk (table 1) and 6 low
risk (table 2) were stratified according to
severity of risk, associated carcinogenicity and
clinicopathological effects, using evidence
obtained from the International Agency for
Research on Cancer (IARC) and other
epidemiological studies linking the degree of
evidence to risk of cancer development.
Reference
1. Tobacco
2. Alcohol
51
3. Betel quid 12
4. Genetic factors / family history/ individual 
susceptibility
14
5. Immunodeficiency 17
6. Dietary factor 17
7. Old age 11
8. Marijuana 18
Reference
1. Socioeconomic 
status 
12
2. Oral health 9
3. Shammah/Toombak 11
4. Human papillomavirus 11
5. Candida albicans 8
6. Diabetes mellitus 12
Table 1:   8 high risk factors
Table 2:   6 low risk factors
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2) Presented at 15th IAOP Biannual Meeting 2010 August 16-20-Seoul, Korea 
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2. Raman Study Appendices 
2.1. Appendix (2-A): Pair-wise average spectra of mild dysplasia tissue group. 
(mn=morphologically normal tissue, md= mild dysplastic tissue) 
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2.2. Appendix (2-B): Pair-wise average spectra of moderate dysplasia tissue group.  
(modn= morphologically normal, modd= moderate dysplastic tissue) 
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2.3. Appendix (2-C): Pair-wise average spectra of severe dysplasia tissue group. 
(sn= morphologically normal, sd= severe dysplastic tissue) 
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2.4. Appendix (2-D): Pair-wise average spectra of CIS tissue group. 
(cisn= morphologically normal tissue, cis= carcinoma in situ) 
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2.5. Appendix (2-E): Partial Least Square Component Loadings. 
The significant partial least square component loadings plots for the dysplasia against 
morphologically normal tissue spectra for WHO grading systems and binary grading system 
with their Q
2
 values. 
 
 
 
Loadings used for group classification between all morphologically normal against all 
dysplastic tissue samples. 
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Loadings used for group classification between mild dysplasia and morphologically 
normal tissue samples. 
 
 
 
Loadings used for group classification between moderate dysplasia and morphologically 
normal tissue samples. 
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Loadings used for group classification between severe dysplasia and morphologically 
normal tissue samples. 
 
 
 
Loadings used for group classification between CIS and morphologically normal tissue 
samples. 
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Loadings used for group classification between high grad dysplasia and morphologically 
normal tissue samples. 
 
 
 
Loadings used for group classification between low grad dysplasia and morphologically 
normal tissue samples. 
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Loadings used for group classification between high grade and low grade dysplasia 
tissue samples. 
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